Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.7.10.2 - non-specific protein-tyrosine kinase and Organism(s) Homo sapiens and UniProt Accession P00519

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Aberrant Crypt Foci
Inhibition by dietary curcumin of azoxymethane-induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon.
Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon.
Abscess
Expression of transforming growth factor-beta1, 2, 3 isoforms and type I and II receptors in acute focal cerebral ischemia: an immunohistochemical study in rat after transient and permanent occlusion of middle cerebral artery.
Acantholysis
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
Pemphigus vulgaris autoimmune globulin induces Src-dependent tyrosine-phosphorylation of plakophilin 3 and its detachment from desmoglein 3.
Acidosis
A central role for Pyk2-Src interaction in coupling diverse stimuli to increased epithelial NBC activity.
Dominant negative c-Src inhibits angiotensin II induced activation of NHE3 in OKP cells.
Acne Vulgaris
Activation of Janus kinase signaling pathway in acne lesions.
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Acquired Hyperostosis Syndrome
Exosomal proteome from the serum, bone marrow, and palm and toe pustular skin tissues of a single patient with SAPHO syndrome.
Acquired Immunodeficiency Syndrome
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms.
HIV envelope-directed signaling aberrancies and cell death of CD4+ T cells in the absence of TCR co-stimulation.
HIV-1 Nef perturbs the function, structure, and signaling of the golgi through the Src kinase Hck.
Identification of an allosteric signaling network within Tec family kinases.
Interaction between Hck and HIV-1 Nef negatively regulates cell surface expression of M-CSF receptor.
Methodological comparison of two anti-ZAP-70 antibodies.
Role of the F-BAR Family Member PSTPIP2 in Autoinflammatory Diseases.
The crystal structure of HIV-1 Nef protein bound to the Fyn kinase SH3 domain suggests a role for this complex in altered T cell receptor signaling.
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
Acromegaly
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
Activated Protein C Resistance
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Acute Coronary Syndrome
Insufficient deactivation of the protein tyrosine kinase lck amplifies T-cell responsiveness in acute coronary syndrome.
The Role of FAK in the Secretion of MMP9 after CD147 Stimulation in Macrophages.
Acute Kidney Injury
Amelioration of sepsis-induced acute kidney injury through inhibition of inflammatory cytokines and oxidative stress in dendritic cells and neutrophils respectively in mice: Role of spleen tyrosine kinase signaling.
Bruton's tyrosine kinase inhibition attenuates oxidative stress in systemic immune cells and renal compartment during sepsis-induced acute kidney injury in mice.
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Focal adhesion kinase signaling mediates acute renal injury induced by ischemia/reperfusion.
Fyn Kinase: A Potential Therapeutic Target in Acute Kidney Injury.
Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer.
M1 macrophage triggered by Mincle leads to a deterioration of acute kidney injury.
Negative Regulation of Tec Kinase Alleviates LPS-Induced Acute Kidney Injury in Mice via theTLR4/NF-?B Signaling Pathway.
Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.
The Bcr-Abl inhibitor GNF-7 inhibits necroptosis and ameliorates acute kidney injury by targeting RIPK1 and RIPK3 kinases.
WITHDRAWN: Spleen tyrosine kinase (SYK) protects renal tubular epithelial cell against hypoxia injury in children with acute kidney injury.
[Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors.]
Acute Lung Injury
Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase.
Induced Pluripotent Stem Cells Attenuate Endothelial Leakage in Acute Lung Injury via Tissue Inhibitor of Metalloproteinases-1 to Reduce Focal Adhesion Kinase Activity.
Inhibiting Bruton's Tyrosine Kinase Rescues Mice from Lethal Influenza Induced Acute Lung Injury.
Inhibition of spleen tyrosine kinase signaling protects against acute lung injury through blockade of NADPH oxidase and IL-17A in neutrophils and ?? T cells respectively in mice.
JAK2/STAT1-mediated HMGB1 translocation increases inflammation and cell death in a ventilator-induced lung injury model.
Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Coninfections: Insights Into 1918 H1N1 Pandemic?
Retrograde perfusion in isolated perfused mouse lungs-Feasibility and effects on cytokine levels and pulmonary oedema formation.
Shockingly: the loss of Lyn leads to leakiness.
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury.
The potential of nanoscale combinations of self-assembling peptides and amino acids of the Src tyrosine kinase inhibitor in acute lung injury therapy.
Transforming growth factor beta1 inhibits cystic fibrosis transmembrane conductance regulator-dependent cAMP-stimulated alveolar epithelial fluid transport via a phosphatidylinositol 3-kinase-dependent mechanism.
[Src protein tyrosine kinase family and acute lung injury]
Adenocarcinoma
3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities.
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors.
An Update on Inherited Colon Cancer and Gastrointestinal Polyposis.
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Association of polymorphisms in transforming growth factor-? receptors with susceptibility to gastric cardia adenocarcinoma.
CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells.
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Constitutive activation of Jak-2 and Tyk-2 in a v-Src-transformed human gallbladder adenocarcinoma cell line.
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Evaluation of the Clinical Significance of Focal Adhesion Kinase and Src Expression in Human Pancreatic Ductal Adenocarcinoma.
Expression and clinical significance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma.
Expression of cortactin and focal adhesion kinase in colorectal adenocarcinoma: correlation with clinicopathologic parameters and their prognostic implication.
Expression of FAK and PTEN in Bronchioloalveolar carcinoma and lung adenocarcinoma.
Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth.
Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.
Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma.
Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis.
Focal Adhesion Kinase: A promising therapeutic target in pancreatic adenocarcinoma.
Genomic alterations of ground-glass nodular lung adenocarcinoma.
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Immunohistochemical expression of TGF beta (TGF-?), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model.
Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin ?3, Focal Adhesion Kinase, and Cofilin.
Molecular cloning and characterization of human WNT11.
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis.
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Oncogenic Ras/Src cooperativity in pancreatic neoplasia.
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma.
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study.
Src activation in malignant and premalignant epithelia of Barrett's esophagus.
Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion.
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
TGFBR1 and cancer susceptibility.
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
The human splice variant ?16HER2 induces rapid tumor onset in a reporter transgenic mouse.
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer.
v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
[Oncogenes in human gastric carcinoma]
Adenocarcinoma of Lung
ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis.
Activation of Focal Adhesion Kinase and Src Mediates Acquired Sorafenib Resistance in A549 Human Lung Adenocarcinoma Xenografts.
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Bosutinib inhibits migration and invasion via ACK1 in KRAS mutant non-small cell lung cancer.
Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNF?-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Dual EGFR and ABL Tyrosine Kinase Inhibitor Treatment in a Patient with Concomitant EGFR-Mutated Lung Adenocarcinoma and BCR-ABL1-Positive CML.
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
High CC chemokine receptor 7 expression improves postoperative prognosis of lung adenocarcinoma patients.
Honokiol Inhibits Proliferation, Invasion and Induces Apoptosis Through Targeting Lyn Kinase in Human Lung Adenocarcinoma Cells.
IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line.
Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells.
Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells.
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
MicroRNA-204 deregulation in lung adenocarcinoma controls the biological behaviors of endothelial cells potentially by modulating Janus kinase 2-signal transducer and activator of transcription 3 pathway.
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.
Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas.
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK.
Therapeutic Targeting of the Premetastatic Stage in Human Lung-to-Brain Metastasis.
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors.
[The possible mechanisms of simvastatin on apoptosis of lung adenocarcinoma cells].
[Tyrosin kinase inhibitors in oncology].
Adenocarcinoma, Follicular
Epidermal growth factor stimulates matrix metalloproteinase-9 expression and invasion in human follicular thyroid carcinoma cells through Focal adhesion kinase.
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
Adenocarcinoma, Mucinous
Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors.
Adenoma
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon.
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Genetic alterations are frequent in APC but rare in the TGF-beta type II receptor gene in cancer in adenomas of the colon.
Genome-wide association studies and meta-analysis reveal novel quantitative trait loci and pleiotropic loci for swine head-related traits.
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Microsatellite instability in the adenoma-carcinoma sequence of the stomach.
Protein western array analysis in human pituitary tumours: insights and limitations.
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis.
[Hereditary nonpolyposis colorectal cancer]
Adenoma, Liver Cell
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
Adenomatous Polyposis Coli
An EphB-Abl signaling pathway is associated with intestinal tumor initiation and growth.
Chibby drives ? catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing.
Genetic testing by cancer site: stomach.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Tanshinone IIA promotes cardiac differentiation and improves cell motility by modulating the Wnt/??catenin signaling pathway.
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Adenomyosis
Expression of focal adhesion kinase in the eutopic endometrium of women with adenomyosis varies with dysmenorrhea and pelvic pain.
FAK regulates epithelial?mesenchymal transition in adenomyosis.
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.
adenosine deaminase deficiency
Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency.
Adenoviridae Infections
Novel model of innate immunity in corneal infection.
Adenovirus Infections, Human
Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase.
Adrenocortical Carcinoma
Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
Agammaglobulinemia
A Btk transgene restores the antiviral TI-2 antibody responses of xid mice in a dose-dependent fashion.
A case of Fabry's disease with congenital agammaglobulinemia.
A case of X-linked agammaglobulinemia diagnosed in adulthood.
A genotype-phenotype correlation study in a group of 54 patients with X-linked agammaglobulinemia.
A mutation in the pleckstrin homology (PH) domain of the FGD1 gene in an Italian family with faciogenital dysplasia (Aarskog-Scott syndrome).
A novel
A novel Bruton tyrosine kinase gene variation was found in an adult with X-linked agammaglobulinemia during blood cross-matching prior to surgical operation.
A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia.
A novel Bruton's tyrosine kinase gene (BTK) missense mutation in a Chinese family with X-linked agammaglobulinemia.
A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.
A novel deletion mutation and structural abnormality in the Bruton's tyrosine kinase gene identified in a Chinese patient with X-linked agammaglobulinemia.
A novel mutation (Cys145-->Stop) in Bruton's tyrosine kinase is associated with newly diagnosed X-linked agammaglobulinemia in a 51-year-old male.
A novel mutation leading to a deletion in the SH3 domain of Bruton's tyrosine kinase.
A novel single basepair insertion in exon 6 of the Bruton's tyrosine kinase (Btk) gene from a Japanese X-linked agammaglobulinemia patient with growth hormone insufficiency.
A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation.
A postmeningitic cochlear implant patient who was postoperatively diagnosed as having X-linked agammaglobulinemia.
A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2.
Absence of memory B cells in patients with common variable immunodeficiency.
Advances in basic and clinical immunology in 2012.
An essential role for Bruton's [corrected] tyrosine kinase in the regulation of B-cell apoptosis.
Analysis of clinical presentations of bruton disease: a review of 20 years of accumulated data from pediatric patients at severance hospital.
Analysis of the Bruton's tyrosine kinase gene promoter reveals critical PU.1 and SP1 sites.
Analysis of the genetic alterations in a case of juvenile multiple colon carcinoma with hypogammaglobulinemia.
Autoimmunity and immunodeficiency.
B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia.
B-cell antigen receptor stimulation activates the human Bruton's tyrosine kinase, which is deficient in X-linked agammaglobulinemia.
Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.
Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA).
Bruton tyrosine kinase gene mutations in Turkish patients with presumed X-linked agammaglobulinemia.
Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells.
Bruton's agammaglobulinemia in an adult male due to a novel mutation: a case report.
Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein.
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Bruton's tyrosine kinase is not essential for LPS-induced activation of human monocytes.
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
Bruton's tyrosine kinase is required for TLR-dependent heme oxygenase-1 gene activation via Nrf2 in macrophages.
Bruton's Tyrosine Kinase Is Required for TLR2 and TLR4-Induced TNF, but Not IL-6, Production.
Bruton's tyrosine kinase mutations in 8 Chinese families with X-linked agammaglobulinemia.
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
BTK gene targeting by homologous recombination using a helper-dependent adenovirus/adeno-associated virus hybrid vector.
BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.
BTK mediated apoptosis, a possible mechanism for failure to generate high titer retroviral producer clones.
BTK Signaling in B Cell Differentiation and Autoimmunity.
BTK, the tyrosine kinase affected in X-linked agammaglobulinemia.
Btk29A-mediated tyrosine phosphorylation of armadillo/?-catenin promotes ring canal growth in Drosophila oogenesis.
BTKbase: the mutation database for X-linked agammaglobulinemia.
Characterization of Bruton's tyrosine kinase mutations in Mexican patients with X-linked agammaglobulinemia.
Characterization of germline mutations of the gene encoding Bruton's tyrosine kinase in families with X-linked agammaglobulinemia.
Characterization of mutations, including a novel regulatory defect in the first intron, in Bruton's tyrosine kinase gene from seven Korean X-linked agammaglobulinemia families.
Characterization of novel Bruton's tyrosine kinase gene mutations in Central European patients with agammaglobulinemia.
Characterization of the pleckstrin homology domain of Btk as an inositol polyphosphate and phosphoinositide binding domain.
Clinical and Genetic Study of X-linked Agammaglobulinemia Patients (The Benefit of Early Diagnosis).
Clinical and mutational characteristics of X-linked agammaglobulinemia and its carrier identified by flow cytometric assessment combined with genetic analysis.
Clinical characteristics and molecular analysis of 21 chinese children with congenital agammaglobulinemia.
Clinical characteristics and prenatal diagnosis for 22 families in Henan Province of China with X-linked agammaglobulinemia (XLA) related to Bruton's tyrosine kinase (BTK) gene mutations.
Clinical findings leading to the diagnosis of X-linked agammaglobulinemia.
Comparison of clinical and immunological features and mortality in common variable immunodeficiency and agammaglobulinemia patients.
Concomitant diagnosis of immune deficiency and Pseudomonas sepsis in a 19 month old with ecthyma gangrenosum by host whole-genome sequencing.
Conservation and covariance in PH domain sequences: physicochemical profile and information theoretical analysis of XLA-causing mutations in the Btk PH domain.
Constitutive membrane association potentiates activation of Bruton tyrosine kinase.
Correction of B-cell development in Btk-deficient mice using lentiviral vectors with codon-optimized human BTK.
Crystal structure of Bruton's tyrosine kinase domain suggests a novel pathway for activation and provides insights into the molecular basis of X-linked agammaglobulinemia.
Cutting edge: lack of peripheral B cells and severe agammaglobulinemia in mice simultaneously lacking Bruton's tyrosine kinase and the B cell-specific transcriptional coactivator OBF-1.
De novo mutation in the BTK gene of atypical X-linked agammaglobulinemia in a patient with recurrent pyoderma.
Debilitating progressive encephalitis in a patient with BTK deficiency.
Defective B cell development and function in Btk-deficient mice.
Deficient expression of Bruton's tyrosine kinase in monocytes from X-linked agammaglobulinemia as evaluated by a flow cytometric analysis and its clinical application to carrier detection.
Deletion within the Src homology domain 3 of Bruton's tyrosine kinase resulting in X-linked agammaglobulinemia (XLA).
Dendritic and T Cell Response to Influenza is Normal in the Patients with X-Linked Agammaglobulinemia.
Detection of a novel mutation in the SRC homology domain 2 (SH2) of Bruton's tyrosine kinase and direct female carrier evaluation in a family with X-linked agammaglobulinemia.
Distinct Clinical Features and Novel Mutations in Taiwanese Patients With X-Linked Agammaglobulinemia.
Disturbed Transcription of TLRs' Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients.
Dynamic Allostery Mediated by a Conserved Tryptophan in the Tec Family Kinases.
Early arrest in B cell development in transgenic mice that express the E41K Bruton's tyrosine kinase mutant under the control of the CD19 promoter region.
Ecthyma gangrenosum due to Pseudomonas aeruginosa sepsis as initial manifestation of X-linked agammaglobulinemia: a case report.
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
Expression of Bruton's tyrosine kinase protein within the B cell lineage.
Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.
G Protein beta gamma subunits act on the catalytic domain to stimulate Bruton's agammaglobulinemia tyrosine kinase.
Genetic analysis of patients with defects in early B-cell development.
Genetic defect in human X-linked agammaglobulinemia impedes a maturational evolution of pro-B cells into a later stage of pre-B cells in the B-cell differentiation pathway.
Genetics in community-acquired pneumonia.
Genomic organization and structure of Bruton agammaglobulinemia tyrosine kinase: localization of mutations associated with varied clinical presentations and course in X chromosome-linked agammaglobulinemia.
Genomic organization of the Btk gene and exon scanning for mutations in patients with X-linked agammaglobulinemia.
HIV-mediated expression of Btk in hematopoietic stem cells is not sufficient to restore B cell function in X-linked immunodeficient mice.
Ibrutinib (PCI-32765), the First BTK (Bruton's Tyrosine Kinase) Inhibitor in Clinical Trials.
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Identification and characterization of a molecule, BAM11, that associates with the pleckstrin homology domain of mouse Btk.
Identification and characterization of a novel SH3-domain binding protein, Sab, which preferentially associates with Bruton's tyrosine kinase (BtK).
Identification of a new Bruton's tyrosine kinase (BTK) mutation associated with a mild phenotype in a child with X-linked agammaglobulinemia (XLA).
Identification of Bruton's tyrosine kinase (Btk) gene mutations and characterization of the derived proteins in 35 X-linked agammaglobulinemia families: a nationwide study of Btk deficiency in Japan.
Identification of mutations in the Bruton's tyrosine kinase gene, including a novel genomic rearrangements resulting in large deletion, in Korean X-linked agammaglobulinemia patients.
Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia.
Identification of nine novel mutations in the Bruton's tyrosine kinase gene in X-linked agammaglobulinaemia patients.
Identification of the bruton tyrosine kinase (BTK) gene mutations in 20 Australian families with X-linked agammaglobulinemia (XLA).
Impact of amino acid substitution in the kinase domain of Bruton tyrosine kinase and its association with X-linked agammaglobulinemia.
Impaired polysaccharide responsiveness without agammaglobulinemia in three patients with hypomorphic mutations in Bruton Tyrosine Kinase - no detection by newborn screening for primary immunodeficiences.
Impaired Toll-like receptor 8-mediated IL-6 and TNF-alpha production in antigen-presenting cells from patients with X-linked agammaglobulinemia.
In vitro Correction of a Novel Splicing Alteration in the BTK Gene by Using Antisense Morpholino Oligonucleotides.
Inflammatory Response: Role of B1 Cell.
Inhibition of IgE-mediated secretion from human basophils with a highly selective Bruton's tyrosine kinase, Btk, inhibitor.
Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.
Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia.
Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report.
Missense mutations affecting a conserved cysteine pair in the TH domain of Btk.
Molecular analysis of Bruton's tyrosine kinase gene in Spain.
Molecular analysis of the pre-BCR complex in a large cohort of patients affected by autosomal-recessive agammaglobulinemia.
Molecular and structural characterization of five novel mutations in the Bruton's tyrosine kinase gene from patients with X-linked agammaglobulinemia.
Molecular characterization of Bruton's tyrosine kinase deficiency in 12 Iranian patients with presumed X-linked agammaglobulinemia.
Multiple colorectal neoplasms in X-linked agammaglobulinemia.
Mutation analysis of the Bruton's tyrosine kinase gene in X-linked agammaglobulinemia: identification of a mutation which affects the same codon as is altered in immunodeficient xid mice.
Mutation analysis of the gene encoding Bruton's tyrosine kinase in a family with a sporadic case of X-linked agammaglobulinemia reveals three female carriers.
Mutation of the BTK gene and clinical feature of X-linked agammaglobulinemia in mainland China.
Mutation pattern in the Bruton's tyrosine kinase gene in 26 unrelated patients with X-linked agammaglobulinemia.
Mutations in Bruton's tyrosine kinase impair IgA responses.
Mutations in the mu heavy-chain gene in patients with agammaglobulinemia.
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Mutations of the Btk gene in 12 unrelated families with X-linked agammaglobulinemia in Japan.
Mutations of the human BTK gene coding for bruton tyrosine kinase in X-linked agammaglobulinemia.
Neutrophil development and function critically depend on Bruton tyrosine kinase in a mouse model of X-linked agammaglobulinemia.
Novel BTK mutation in X-linked agammaglobulinemia: Report of a 17-year-old male.
Novel BTK mutation presenting with vaccine-associated paralytic poliomyelitis.
Novel deletion mutation in Bruton's tyrosine kinase results in X-linked agammaglobulinemia: A case report.
Novel Igalpha (CD79a) gene mutation in a Turkish patient with B cell-deficient agammaglobulinemia.
Novel immunodeficiency data servers.
Novel insertions of Bruton tyrosine kinase in patients with X-linked agammaglobulinemia.
Optimizing Integration and Expression of Transgenic Bruton's Tyrosine Kinase for CRISPR-Cas9-Mediated Gene Editing of X-Linked Agammaglobulinemia.
Ovarian polarity and cell shape determination by Btk29A in Drosophila.
PBMC-derived integration-free iPSCs line SDQLCHi039-A from a patient with X-linked agammaglobulinemia carrying a novel 9-bp in-frame deletion in BTK gene.
Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells.
Phosphorylation of CD19 Y484 and Y515, and linked activation of phosphatidylinositol 3-kinase, are required for B cell antigen receptor-mediated activation of Bruton's tyrosine kinase.
Phosphorylation of two regulatory tyrosine residues in the activation of Bruton's tyrosine kinase via alternative receptors.
Phylogenetic Profiles Reveal Structural and Functional Determinants of Lipid-binding.
PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization.
Point mutation in intron 11 of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia.
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
Predominantly Antibody-Deficient Patients With Non-infectious Complications Have Reduced Naive B, Treg, Th17, and Tfh17 Cells.
Preimplantation genetic diagnosis for X-linked agammaglobulinemia: a case report.
Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Production of monoclonal antibodies to Bruton's tyrosine kinase.
Progressive engineering of a homing endonuclease genome editing reagent for the murine X-linked immunodeficiency locus.
Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.
Recent insights in primary immunodeficiency diseases: the role of T-lymphocytes and innate immunity.
Recent progress in the diagnosis and treatment of patients with defects in early B-cell development.
Reconstitution of Btk signaling by the atypical tec family tyrosine kinases Bmx and Txk.
Recurrent pneumonia with mild hypogammaglobulinemia diagnosed as X-linked agammaglobulinemia in adults.
Regulation and function of WASp in platelets by the collagen receptor, glycoprotein VI.
Regulation of nuclear localization and transcriptional activity of TFII-I by Bruton's tyrosine kinase.
Relapsing Campylobacter jejuni Systemic Infections in a Child with X-Linked Agammaglobulinemia.
Role of Bruton's tyrosine kinase in immunodeficiency.
Role of the PHTH module in protein substrate recognition by Bruton's agammaglobulinemia tyrosine kinase.
Screening of genomic DNA to identify mutations in the gene for Bruton's tyrosine kinase.
Screening of the Bruton Tyrosine Kinase (BTK) Gene Mutations in 13 Iranian Patients with Presumed X-Linked Agammaglobulinemia.
SH3 domain of Bruton's tyrosine kinase can bind to proline-rich peptides of TH domain of the kinase and p120cbl.
Six X-linked agammaglobulinemia-causing missense mutations in the Src homology 2 domain of Bruton's tyrosine kinase: phosphotyrosine-binding and circular dichroism analysis.
Solution structure of the human BTK SH3 domain complexed with a proline-rich peptide from p120cbl.
Solution structure of the SH3 domain from Bruton's tyrosine kinase.
Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model.
Splice-correction strategies for treatment of x-linked agammaglobulinemia.
Stability and peptide binding specificity of Btk SH2 domain: molecular basis for X-linked agammaglobulinemia.
Structural basis for chromosome X-linked agammaglobulinemia: a tyrosine kinase disease.
Structural basis of SH2 domain mutations in X-linked agammaglobulinemia.
Structure of the high affinity complex of inositol trisphosphate with a phospholipase C pleckstrin homology domain.
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
The genomic structure of human BTK, the defective gene in X-linked agammaglobulinemia.
The pleckstrin homology domain of Bruton tyrosine kinase interacts with protein kinase C.
The protein defective in X-linked agammaglobulinemia, Bruton's tyrosine kinase, shows increased autophosphorylation activity in vitro when isolated from cells in which the B cell receptor has been cross-linked.
The protein product of the c-cbl protooncogene is phosphorylated after B cell receptor stimulation and binds the SH3 domain of Bruton's tyrosine kinase.
The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective.
The Role of Bruton's Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity.
The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species.
The tec family tyrosine kinase Btk Regulates RANKL-induced osteoclast maturation.
The X-linked immunodeficiency defect in the mouse is corrected by expression of human Bruton's tyrosine kinase from a yeast artificial chromosome transgene.
Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia.
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase.
Transcriptional regulatory elements within the first intron of Bruton's tyrosine kinase.
Transient myelodysplastic syndrome in X-linked agammaglobulinemia with a novel Btk mutation.
Treosulfan-based reduced toxicity hematopoietic stem cell transplantation in X-linked agammaglobulinemia: A cost-effective alternative to long-term immunoglobulin replacement in developing countries.
Type I and III Interferon Productions Are Impaired in X-Linked Agammaglobulinemia Patients Toward Poliovirus but Not Influenza Virus.
Unimpaired activation of c-Jun NH2-terminal kinase (JNK) 1 upon CD40 stimulation in B cells of patients with X-linked agammaglobulinemia.
Unique mutations of Bruton's tyrosine kinase in fourteen unrelated X-linked agammaglobulinemia families.
Unusual mutations in Btk: an insertion, a duplication, an inversion, and four large deletions.
Unusual patterns of exon skipping in Bruton tyrosine kinase are associated with mutations involving the intron 17 3' splice site.
Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency.
von Recklinghausen disease in a patient with X-linked agammaglobulinemia.
WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice.
X-chromosome inactivation and mutation pattern in the Bruton's tyrosine kinase gene in patients with X-linked agammaglobulinemia. Italian XLA Collaborative Group.
X-linked agammaglobulinemia (XLA): a genetic tyrosine kinase (Btk) disease.
X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
X-linked agammaglobulinemia and Bruton's tyrosine kinase.
X-linked agammaglobulinemia associated with B-precursor acute lymphoblastic leukemia.
X-Linked Agammaglobulinemia Case with TH Domain Missense Mutation in Bruton Tyrosine Kinase.
X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis.
X-linked agammaglobulinemia diagnosed in adulthood: a case report.
X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.
X-linked agammaglobulinemia in northern Thailand.
X-Linked Agammaglobulinemia Presenting as Neutropenia: Case Report and an Overview of Literature.
X-Linked Agammaglobulinemia With Chronic Meningoencephalitis: A Diagnostic Challenge.
X-linked agammaglobulinemia: report on a United States registry of 201 patients.
xid affects events leading to B cell cycle entry.
xid mice reveal the interplay of homeostasis and Bruton's tyrosine kinase-mediated selection at multiple stages of B cell development.
[Clinical features of X-linked agammaglobulinemia: analysis of 8 cases]
[Detection of Bruton's tyrosine kinase gene mutations and clinical analysis of 6 patients with X-linked agammaglobulinemia].
[Gene diagnosis of X-linked agammaglobulinemia]
Albuminuria
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Alopecia
A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia in patients treated with molecularly targeted anticancer therapies.
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors.
Frontal fibrosing alopecia shows robust T helper 1 and Janus kinase 3 skewing.
New Treatments for Hair Loss.
Ruxolitinib found to cause eyelash growth: a case report.
Ruxolitinib-conjugated gold nanoparticles for topical administration: An alternative for treating alopecia?
Tofacitinib for the treatment of lichen planopilaris: A case series.
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
Alopecia Areata
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
Alopecia Areata: New Treatment Options Including Janus Kinase Inhibitors.
Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
At the crossroads of 2 alopecias: Androgenetic alopecia pattern of hair regrowth in patients with alopecia areata treated with oral Janus kinase inhibitors.
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
Evaluation of the alopecia areata patients on tofacitinib treatment during the COVID-19 pandemic.
Inhibiting Janus kinases to treat alopecia areata.
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Janus kinase inhibitors against other biological treatments in alopecia areata.
Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Janus kinase inhibitors for the use of alopecia areata: A promising therapeutic of the future.
Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata.
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Janus kinase inhibitors: An innovative treatment for alopecia areata.
New Treatments for Hair Loss.
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Role of janus kinase inhibitors in the treatment of alopecia areata.
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
The role of Janus kinase inhibitors in the treatment of alopecia areata: A systematic review.
The status and outcomes of registered clinical trials for Janus kinase inhibitors in alopecia areata: are unpublished trials being overlooked?
The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients.
Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
Tofacitinib for the treatment of lichen planopilaris: A case series.
Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases.
Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata.
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis.
Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata.
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
alpha-n-acetylgalactosaminide alpha-2,6-sialyltransferase deficiency
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Alveolar Bone Loss
Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Alzheimer Disease
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Abelson Kinases Mediate the Depression of Spontaneous Synaptic Activity Induced by Amyloid Beta 1-42 Peptides.
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Altered Subcellular Distribution of c-Abl in Alzheimer's Disease.
Alzheimer's disease pathological lesions activate the spleen tyrosine kinase.
Alzheimer's disease risk factor lymphocyte-specific protein tyrosine kinase regulates long-term synaptic strengthening, spatial learning and memory.
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Amyloid-ß induced signaling by cellular prion protein and Fyn kinase in Alzheimer disease.
An isoform-specific role of FynT tyrosine kinase in Alzheimer's disease.
Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer's disease.
Association and interaction effects of Alzheimer's disease-associated genes and lifestyle on cognitive aging in older adults in a Taiwanese population.
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.
c-Abl modulates AICD dependent cellular responses: transcriptional induction and apoptosis.
c-Abl stabilizes HDAC2 levels by tyrosine phosphorylation repressing neuronal gene expression in Alzheimer's disease.
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Canonical JAK-STAT signaling is pivotal for long-term depression at adult hippocampal temporoammonic-CA1 synapses.
Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses.
Corrigendum to "Common variant in PTK2B is associated with late-onset Alzheimer's disease: A replication study and meta-analyses" [Neurosci. Lett. 621 (2016) 83-87].
Defining functional variants associated with Alzheimer's disease in the induced immune response.
Differential expression of transforming growth factor-beta isoforms in human prion diseases.
Exploring the mechanistic insights of Cas scaffolding protein family member 4 with protein tyrosine kinase 2 in Alzheimer's disease by evaluating protein interactions through molecular docking and dynamic simulations.
Frontotemporal dementia mutant Tau promotes aberrant Fyn nanoclustering in hippocampal dendritic spines.
Fyn depletion ameliorates tauP301L-induced neuropathology.
Fyn inhibition rescues established memory and synapse loss in Alzheimer mice.
Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease.
Fyn kinase inhibition as a novel therapy for Alzheimer's disease.
Fyn Tyrosine Kinase Elicits Amyloid Precursor Protein Tyr682 Phosphorylation in Neurons from Alzheimer's Disease Patients.
Gene-based aggregate SNP associations between candidate AD genes and cognitive decline.
Genetic Association of FERMT2, HLA-DRB1, CD2AP, and PTK2B Polymorphisms With Alzheimer's Disease Risk in the Southern Chinese Population.
Glucosylpolyphenols as inhibitors of A?-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.
Hot off the Press.
Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
Inhibition of Bruton's Tyrosine Kinase Modulates Microglial Phagocytosis: Therapeutic Implications for Alzheimer's Disease.
Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer's disease.
Isoform-specific upregulation of FynT kinase expression is associated with tauopathy and glial activation in Alzheimer's disease and Lewy body dementias.
Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease.
Lymphocyte-specific protein tyrosine kinase is a novel risk gene for Alzheimer disease.
Metabotropic glutamate receptor 5 couples cellular prion protein to intracellular signalling in Alzheimer's disease.
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.
No genetic association between Fyn kinase gene polymorphisms (-93A/G, IVS10+37T/C and Ex12+894T/G) and Japanese sporadic Alzheimer's disease.
Oligomers of Amyloid ? Prevent Physiological Activation of the Cellular Prion Protein-Metabotropic Glutamate Receptor 5 Complex by Glutamate in Alzheimer Disease.
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease.
Polymorphism rs11867353 of Tyrosine Kinase Non-Receptor 1 (TNK1) Gene Is a Novel Genetic Marker for Alzheimer's Disease.
PTK2B/Pyk2 overexpression improves a mouse model of Alzheimer's disease.
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Pyk2 overexpression in postsynaptic neurons blocks amyloid ?1-42-induced synaptotoxicity in microfluidic co-cultures.
Reduction of Blood Amyloid-? Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.
Selective induction of alternatively spliced FynT isoform by TNF facilitates persistent inflammatory responses in astrocytes.
STI571 prevents apoptosis, tau phosphorylation and behavioural impairments induced by Alzheimer's beta-amyloid deposits.
Targeting Fyn Kinase in Alzheimer's Disease.
The prion protein constitutively controls neuronal store-operated Ca(2+) entry through Fyn kinase.
The protein tyrosine kinase, fyn, in Alzheimer's disease pathology.
The relationship between four GWAS-identified loci in Alzheimer's disease and the risk of Parkinson's disease, amyotrophic lateral sclerosis, and multiple system atrophy.
Transforming growth factor-beta protects human hNT cells from degeneration induced by beta-amyloid peptide: involvement of the TGF-beta type II receptor.
Treatment With Nilvadipine Mitigates Inflammatory Pathology and Improves Spatial Memory in Aged hTau Mice After Repetitive Mild TBI.
Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau.
[Analysis of the fyn kinase gene in Alzheimer's disease and schizophrenia]
Ameloblastoma
Focal Adhesion Kinase Expression in Ameloblastoma: A Preliminary Observational Study.
Invadopodia proteins, cortactin, N-WASP and WIP differentially promote local invasiveness in ameloblastoma.
Amyloidosis
Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature.
Small-Molecule Screening for Genetic Diseases.
Amyotrophic Lateral Sclerosis
c-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis.
Partial suppression of M1 microglia by Janus kinase 2 inhibitor does not protect against neurodegeneration in animal models of amyotrophic lateral sclerosis.
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Anaphylaxis
4-Chlorotetrazolo[1,5-a]quinoxaline inhibits activation of Syk kinase to suppress mast cells in vitro and mast cell-mediated passive cutaneous anaphylaxis in mice.
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Antiallergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA).
Bruton's tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis.
Bruton's tyrosine kinase-mediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal kinase activation pathway.
Lyn but not Fyn kinase controls IgG-mediated systemic anaphylaxis.
Optimizing drug inhibition of IgE-mediated anaphylaxis in mice.
Structure-activity relationship studies of imidazo[1,2-c]pyrimidine derivatives as potent and orally effective Syk family kinases inhibitors.
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Targeting the Fc?RI Pathway as a Potential Strategy to Prevent Food-Induced Anaphylaxis.
The Fab fragment of anti-IgE C?2 domain prevents allergic reactions through interacting with IgE-Fc?RI? complex on rat mast cells.
The role of Src family kinases in mast cell effector function.
The Src Family Kinase Fgr Is Critical for Activation of Mast Cells and IgE-Mediated Anaphylaxis in Mice.
The vascular endothelial specific IL-4 receptor alpha-ABL1 kinase signaling axis regulates the severity of IgE-mediated anaphylactic reactions.
Anemia
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Anemia and survival in childhood acute lymphoblastic leukemia.
Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
Disappearance of Bone Marrow Fibrosis in a Patient with Chronic Myeloid Leukemia Treated with Dasatinib.
Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
Expression of v-src induces a myeloproliferative disease in bone-marrow-reconstituted mice.
Identification of e6a2 bcr-abl fusion in a Philadelphia-positive cml with marked basophilia: implications for treatment strategy.
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment.
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
[Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia]
Anemia, Aplastic
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
Anemia, Diamond-Blackfan
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Anemia, Hemolytic, Autoimmune
Fostamatinib: First Global Approval.
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Anemia, Refractory
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Anemia, Refractory, with Excess of Blasts
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Anemia, Sickle Cell
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
The platelet NLRP3 inflammasome is upregulated in sickle cell disease via HMGB1/TLR4 and Bruton tyrosine kinase.
Anemia, Sideroblastic
Mixed myelodysplastic and myeloproliferative syndromes.
Aneurysm
Evolution of the face in Loeys-Dietz syndrome type II: longitudinal observations from infancy in seven cases.
First genetic analysis of aneurysm genes in familial and sporadic abdominal aortic aneurysm.
hiPSC Modeling of Lineage-Specific Smooth Muscle Cell Defects Caused by TGFBR1A230T Variant, and its Therapeutic Implications for Loeys-Dietz Syndrome.
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome in a boy with Loeys-Dietz syndrome.
Aneurysm, Dissecting
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Role of c-Abl in Ang II-induced aortic dissection formation: Potential regulatory efficacy on phenotypic transformation and apoptosis of VSMCs.
Angiofibroma
Hypoxia-Inducible Factor-1? (HIF-1?) Expression on Endothelial Cells in Juvenile Nasopharyngeal Angiofibroma: A Review of 70 cases and Tissue Microarray Analysis.
Anorectal Malformations
Involvement of the WNT and FGF signaling pathways in non-isolated anorectal malformations: Sequencing analysis of WNT3A, WNT5A, WNT11, DACT1, FGF10, FGFR2 and the T gene.
The expression analysis of Bmpr1a and Bmp2 during hindgut development in rat embryos with anorectal malformations.
Anti-Glomerular Basement Membrane Disease
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Antiphospholipid Syndrome
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Anus Neoplasms
Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
Aortic Aneurysm
Activation of TGF-? signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1.
An X-linked Myh11-CreER(T2) mouse line resulting from Y to X chromosome-translocation of the Cre allele.
Cyclophilin A contributes to aortopathy induced by postnatal loss of smooth muscle TGFBR1.
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Focal Adhesion Kinase Promotes the Progression of Aortic Aneurysm by Modulating Macrophage Behavior.
Genetic Risk for Aortic Aneurysm in Adolescent Idiopathic Scoliosis.
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
Multiple Facial Milia in Patients With Loeys-Dietz Syndrome.
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Pregnancy after aortic root replacement in Loeys-Dietz syndrome: High risk of aortic dissection.
Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
Aortic Aneurysm, Abdominal
ACE and TGFBR1 genes interact in influencing the susceptibility to abdominal aortic aneurysm.
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Aortic Aneurysm, Thoracic
Analysis of multigenerational families with thoracic aortic aneurysms and dissections due to TGFBR1 or TGFBR2 mutations.
Association of the TGF-beta receptor genes with abdominal aortic aneurysm.
Identification and surgical repair of familial thoracic aortic aneurysm and dissection caused by TGFBR1 mutation.
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.
Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center.
TGFBR1 Rare Variant Associated With Thoracic Aortic Aneurysm, Double Chamber Left Ventricle, Coronary Anomaly, and Inducible Ventricular Tachycardia.
TGFBR2 mutations alter smooth muscle cell phenotype and predispose to thoracic aortic aneurysms and dissections.
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Aortic Diseases
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Arachnodactyly
FBN2, FBN1, TGFBR1, and TGFBR2 analyses in congenital contractural arachnodactyly.
Arrhythmias, Cardiac
Acute Effects of Ibrutinib on Ventricular Arrhythmia in Spontaneously Hypertensive Rats.
c-Src Kinase Inhibition Reduces Arrhythmia Inducibility and Connexin43 Dysregulation After Myocardial Infarction.
Cellular and Molecular Mechanisms of Arrhythmia by Oxidative Stress.
Arteriosclerosis
Prevention of cardiac allograft arteriosclerosis by protein-tyrosine kinase inhibitor selective for platelet-derived growth factor receptor.
Arteriovenous Malformations
EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Notch1 activation in mice causes arteriovenous malformations phenocopied by ephrinB2 and EphB4 mutants.
Arthralgia
Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Arthritis
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy.
Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice.
An allosteric hot spot in the tandem-SH2 domain of ZAP-70 regulates T-cell signaling.
Anti- and non-tumor necrosis factor-?-targeted therapies effects on insulin resistance in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Anti-rheumatoid arthritis effects in adjuvant-induced arthritis in rats and molecular docking studies of Polygonum orientale L. extracts.
B cell subsets in the joint compartments of seropositive and seronegative RA and non-RA arthritides express memory markers and ZAP-70 and characterize the aggregate pattern irrespectively of the autoantibody status.
Beta-glucan triggers spondyloarthropathy and Crohn's-like ileitis in SKG mice.
Bruton's tyrosine kinase deficiency inhibits autoimmune arthritis but fails to block immune complex-mediated inflammatory arthritis.
Btk inhibition suppresses agonist-induced human macrophage activation and inflammatory gene expression in RA synovial tissue explants.
Can rheumatologists stop causing demyelinating disease?
Deletion of Syk in neutrophils prevents immune complex arthritis.
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
EphB4 Expressing Stromal Cells Exhibit an Enhanced Capacity for Hematopoietic Stem Cell Maintenance.
Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis.
Formation of invadopodia-like structures by synovial cells promotes cartilage breakdown in arthritis. Involvement of the protein tyrosine kinase src.
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers.
Mice with the xid B cell defect are less susceptible to developing Staphylococcus aureus-induced arthritis.
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis.
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Novel concepts and treatments for autoimmune disease: ten focal points.
Resveratrol inhibits Src tyrosine kinase, STAT3, and Wnt signaling pathway in collagen induced arthritis model.
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-?B signaling pathways.
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Spontaneous development of autoimmune arthritis due to genetic anomaly of T cell signal transduction: Part 1.
Src and podoplanin forge a path to destruction.
State-of-the-art treatment of systemic lupus erythematosus.
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.
Tec family kinases in inflammation and disease.
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
The inhibition of Src kinase suppresses the production of matrix metalloproteinases in from synovial fibroblasts and inhibits MAPK and STATs pathways
The SKG mutation in ZAP-70 also confers arthritis susceptibility in C57 Black mouse strains.
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis.
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
[Total saponins of Clematis inhibits JAK2/STAT3 signal pathway of adjuvant-induced arthritis rats].
Arthritis, Experimental
5,7,3'-Triacetyl hesperetin suppresses adjuvant-induced arthritis in rats through modulating JAK2/STAT3 pathway.
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice.
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis.
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
SOCS3 participates in cholinergic pathway regulation of synovitis in rheumatoid arthritis.
Tetrandrine attenuates the bone erosion in collagen-induced arthritis rats by inhibiting osteoclastogenesis via spleen tyrosine kinase.
The adaptor molecule SAP is essential in mechanisms involving the Fyn tyrosine kinase for induction and progression of collagen-induced arthritis.
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Arthritis, Juvenile
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Arthritis, Psoriatic
A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Effect of filgotinib on health-related quality of life in active psoriatic arthritis: a randomized phase 2 trial (EQUATOR).
Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
JAK inhibitors and infections risk: focus on herpes zoster.
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Off-label studies on tofacitinib in dermatology: a review.
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Population pharmacokinetics of tofacitinib in patients with psoriatic arthritis?.
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
State of the art: approved and emerging JAK inhibitors for rheumatoid arthritis.
The role of microRNA-146a (miR-146a) and its target IL-1R-associated kinase (IRAK1) in psoriatic arthritis susceptibility.
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives.
Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Tofacitinib: A Review in Psoriatic Arthritis.
Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice.
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Upadacitinib Pharmacokinetics and Exposure-Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients - Analyses of Phase 3 Clinical Trials.
[Modern disease-modifying antirheumatic drugs].
Arthritis, Rheumatoid
'Should we stop or continue conventional synthetic (including glucocorticoids) and targeted DMARDs before surgery in patients with inflammatory rheumatic diseases?'
4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
A budget impact analysis for making treatment decisions based on anti-cyclic citrullinated peptide (anti-CCP) testing in rheumatoid arthritis.
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction.
A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.
A Hydrophilic Interaction Liquid Chromatography-Tandem Mass Spectrometry Quantitative Method for Determination of Baricitinib in Plasma, and Its Application in a Pharmacokinetic Study in Rats.
A JAK inhibitor tofacitinib regulates synovitis through inhibition of IFN-? and IL-17 production by human CD4(+) T cells.
A Matching-Adjusted Indirect Comparison of Upadacitinib Versus Tofacitinib in Adults with Moderate-to-Severe Rheumatoid Arthritis.
A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis.
A Network Meta-Analysis to Compare Effectiveness of Baricitinib and Other Treatments in Rheumatoid Arthritis Patients with Inadequate Response to Methotrexate.
A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834.
A Peptide-Based Biosensor Assay To Detect Intracellular Syk Kinase Activation and Inhibition.
A Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti-TNF Therapy.
A Randomized Phase 2b Study of ABT-494, a Selective JAK1 Inhibitor in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate.
A retrospective comparison of respiratory events with JAK inhibitors or rituximab for rheumatoid arthritis in patients with pulmonary disease.
A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis.
A study on the risk of fungal infection with tofacitinib (CP-690550), a novel oral agent for rheumatoid arthritis.
Absence of Pharmacokinetic Interactions between the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib and Methotrexate.
Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor ? induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis.
ADAM15 in apoptosis resistance of synovial fibroblasts: converting Fas/CD95 death signals into the activation of pro-survival pathways by calmodulin recruitment.
An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States.
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
An oral syk kinase inhibitor in the treatment of rheumatoid arthritis: A 3 month randomized placebo controlled phase 2 study in patients with active RA who had failed biologic agents.
An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.
An Update on Calcineurin Inhibitor-Free Regimens: The Need Persists, but the Landscape has Changed.
Analysis of non-melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme.
Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy.
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
Application of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in Japanese.
Approaching the active conformation of 1,3-diaminopyrimidine based covalent inhibitors of Bruton's tyrosine kinase for treatment of Rheumatoid arthritis.
Arthritis-associated osteoclastogenic macrophages (AtoMs) participate in pathological bone erosion in rheumatoid arthritis.
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis.
Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib.
Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Baricitinib in Patients with Refractory Rheumatoid Arthritis.
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.
Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
Bruton's tyrosine kinase inhibitor BMS-986142 in experimental models of rheumatoid arthritis enhances efficacy of agents representing clinical standard-of-care.
Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
Bruton's Tyrosine Kinase mediates platelet receptor-induced generation of microparticles: A potential mechanism for amplification of inflammatory responses in rheumatoid arthritis synovial joints.
Cardiovascular Safety During Treatment with Baricitinib in Rheumatoid Arthritis.
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor.
Caring for patients in a new pandemic: the necessity and challenges of observational research.
Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis.
Changes in focal adhesion kinase expression in rats with collagen-induced arthritis and efficacy of intervention with disease modifying anti-rheumatic drugs alone or in combination.
Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment.
Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis.
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Clinical Aspects of Janus Kinase (JAK) Inhibitors in the Cardiovascular System in Patients with Rheumatoid Arthritis.
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment.
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.
Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis.
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain.
Cost-Effectiveness of a JAK1/JAK2 Inhibitor vs a Biologic Disease-Modifying Antirheumatic Drug (bDMARD) in a Treat-to-Target Strategy for Rheumatoid Arthritis.
Cost-effectiveness of Tofacitinib in the Treatment of Moderate to Severe Rheumatoid Arthritis in South Korea.
Critical Assessment of Pharmacokinetic Drug-Drug Interaction Potential of Tofacitinib, Baricitinib and Upadacitinib, the Three Approved Janus Kinase Inhibitors for Rheumatoid Arthritis Treatment.
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Design of novel JAK3 Inhibitors towards Rheumatoid Arthritis using molecular docking analysis.
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
Design, synthesis and evaluation of novel 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as potent, selective and reversible Bruton's tyrosine kinase (BTK) inhibitors for the treatment of rheumatoid arthritis.
Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.
Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS.
Development and Characterization of a JAK-2-specific Antibody Suitable for Immunohistochemical Investigative Studies.
Development and validation of an HPLC-MS/MS method for the determination of filgotinib, a selective Janus kinase 1 inhibitor: Application to a metabolic stability study.
Development of a Janus Kinase Inhibitor Prodrug for the Treatment of Rheumatoid Arthritis.
Development of Bruton's tyrosine kinase Inhibitors for Rheumatoid Arthritis.
Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation.
Development of piperidinyl dipyrrrolopyridine-based dual inhibitors of Janus kinase and Bruton's tyrosine kinase: a potential therapeutic probability to deal with rheumatoid arthritis.
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Developments with investigational Janus kinase inhibitors for rheumatoid arthritis.
Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Differential expression of the FAK family kinases in rheumatoid arthritis and osteoarthritis synovial tissues.
Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Discovery of the Macrocycle (9E)-15-(2-(Pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a Potent Inhibitor of Janus Kinase 2/Fms-LikeTyrosine Kinase-3 (JAK2/FLT3) for the Treatment of Rheumatoid Arthritis.
Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.
Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 year-retrospective study from a rheumatology clinic in Japan.
Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats.
Effect of Discontinuation or Initiation of Methotrexate or Glucocorticoids on Tofacitinib Efficacy in Patients with Rheumatoid Arthritis: A Post Hoc Analysis.
Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study.
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Effects of Fostamatinib (R788), an Oral Spleen Tyrosine Kinase Inhibitor, on Health-related Quality of Life in Patients with Active Rheumatoid Arthritis: Analyses of Patient-reported Outcomes from a Randomized, Double-blind, Placebo-controlled Trial.
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Effects of Janus kinase inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for rheumatoid arthritis.
Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis.
Effects of the Janus Kinase Inhibitor, Tofacitinib, on Testicular Leydig Cell Hyperplasia and Adenoma in Rats, and on Prolactin Signaling in Cultured Primary Rat Leydig Cells.
Effects of the oral Janus kinase inhibitor tofacitinib on patient-reported outcomes in patients with active rheumatoid arthritis: results of two Phase 2 randomised controlled trials.
Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study.
Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Efficacy and Safety of Tofacitinib in Chinese Patients with Rheumatoid Arthritis.
Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis.
Efficacy and safety of tofacitinib in patients with active rheumatoid arthritis: review of key Phase 2 studies.
Efficacy and safety of tofacitinib in US and non-US rheumatoid arthritis patients: pooled analyses of phase II and III.
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.
Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group.
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis.
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.
Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials.
Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial.
Exposure vs. response of blood pressure in patients with rheumatoid arthritis following treatment with fostamatinib.
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Extended-release Once-daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared with Immediate-release Tofacitinib and Impact of Food.
Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial (ANDES Study).
Fifty-Two-Week Results of Clinical and Imaging Assessments of a Patient with Rheumatoid Arthritis Complicated by Systemic Sclerosis with Interstitial Pneumonia and Type 1 Diabetes despite Multiple Disease-Modifying Antirheumatic Drug Therapy That Was Successfully Treated with Baricitinib: A Novel Case Report.
Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Filgotinib, a JAK1 Inhibitor, Modulates Disease-Related Biomarkers in Rheumatoid Arthritis: Results from Two Randomized, Controlled Phase 2b Trials.
Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials.
Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US.
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Herpes zoster as a cause of atypical chronic ulcerations associated with tofacitinib.
High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: central to rheumatoid arthritis pathogenesis?
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Identification of distinct disease activity trajectories in methotrexate-naïve patients with rheumatoid arthritis receiving tofacitinib over 24 months.
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Immunologic effects of chronic administration of tofacitinib, a Janus kinase inhibitor, in cynomolgus monkeys and rats - Comparison of juvenile and adult responses.
Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials.
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Improved pain, physical functioning, and health status in rheumatoid arthritis patients treated with CP-690,550, an orally active Janus kinase (JAK)inhibitor: results from a randomized, double-blind, placebo-controlled trial.
In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Incidence Rates of Interstitial Lung Disease Events in Tofacitinib-Treated Rheumatoid Arthritis Patients: Post Hoc Analysis From 21 Clinical Trials.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
Influence of Janus Kinase Inhibition on Interleukin 6-mediated Induction of Acute-phase Serum Amyloid A in Rheumatoid Synovium.
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Inhibition of JAK/STAT signaling pathway in rheumatoid synovial fibroblasts using small molecule compounds.
Inhibition of Spleen Tyrosine Kinase for Rheumatoid Arthritis.
Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis.
Initial Experience With Tofacitinib in Clinical Practice: Treatment Patterns and Costs of Tofacitinib Administered as Monotherapy or in Combination With Conventional Synthetic DMARDs in 2 US Health Care Claims Databases.
Interactions of janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity.
Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs.
Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.
JAK inhibition in inflammatory bowel disease.
JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production.
JAK inhibitors and infections risk: focus on herpes zoster.
JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data.
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
JAK inhibitors: A broadening approach in rheumatoid arthritis.
JAK Inhibitors: What Is New?
JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
Janus kinase inhibitors for rheumatoid arthritis.
Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Janus Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Joint Location-Specific JAK-STAT Signaling in Rheumatoid Arthritis Fibroblast-like Synoviocytes.
Kinase inhibitors in the treatment of immune-mediated disease.
Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies.
Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5?years: integrated analysis of data from the global clinical trials.
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme.
Malignancy and Janus Kinase Inhibition.
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, Osteoblastogenesis, Cardiovascular disease, Malignancies.
Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis.
Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients.
Model-Informed Development and Registration of a Once-Daily Regimen of Extended-Release Tofacitinib.
Modeling Combined Anti-Inflammatory Effects of Dexamethasone and Tofacitinib in Arthritic Rats.
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Molecular modeling studies of pyrrolo[2,3-d]pyrimidin-4-amine derivatives as JAK1 inhibitors based on 3D-QSAR, molecular docking, molecular dynamics (MD) and MM-PBSA calculations.
More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
Nanoparticle-delivered siRNA targeting Bruton's tyrosine kinase for rheumatoid arthritis therapy.
New drug therapies on the horizon for IBD.
New insights into IFN-? in rheumatoid arthritis: role in the era of JAK inhibitors.
Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Novel concepts and treatments for autoimmune disease: ten focal points.
Off-label studies on tofacitinib in dermatology: a review.
Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
Oral janus kinase inhibitor for the treatment of rheumatoid arthritis: tofacitinib.
Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways.
Palmoplantar Pustulosis-like Eruption Induced by Baricitinib for Treatment of Rheumatoid Arthritis.
Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis.
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Peficitinib hydrobromide to treat rheumatoid arthritis.
Peficitinib Inhibits the Chemotactic Activity of Monocytes via Proinflammatory Cytokine Production in Rheumatoid Arthritis Fibroblast-Like Synoviocytes.
Peficitinib: First Global Approval.
Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years.
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Pharmacokinetic Drug Interaction between Tofacitinib and Voriconazole in Rats.
Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
Pharmacokinetics of Fostamatinib, a SYK Inhibitor, in Healthy Human Subjects Following Single and Multiple Oral Dosing In Three Phase I Studies.
Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Placebo and nocebo responses in randomized controlled trials of Janus kinase inhibitor monotherapy for rheumatoid arthritis : A meta-analysis.
Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis [corrected].
Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry.
Potent anti-inflammatory effects of the narrow spectrum kinase inhibitor RV1088 on rheumatoid arthritis synovial membrane cells.
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.
Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis.
Protein kinase small molecule inhibitors for rheumatoid arthritis: Medicinal chemistry/clinical perspectives.
Protein tyrosine phosphatase non-receptor 22 and C-Src tyrosine kinase genes are down-regulated in patients with rheumatoid arthritis.
Quantitative tracking of inflammatory activity at the peak and trough plasma levels of tofacitinib, a Janus kinase inhibitor, via in vivo 18 F-FDG PET.
Rapid Onset of Efficacy of Baricitinib in Chinese Patients with Moderate to Severe Rheumatoid Arthritis: Results from Study RA-BALANCE.
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Rational design of highly selective spleen tyrosine kinase inhibitors.
Re-establishment of efficacy of tofacitinib, an oral JAK inhibitor, after temporary discontinuation in patients with rheumatoid arthritis.
Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib.
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid Arthritis.
Real-world experience with tofacitinib for treatment of rheumatoid arthritis.
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Regulation of inflammatory responses in tumor necrosis factor - activated and rheumatoid arthritis synovial macrophages by Janus kinase inhibitors.
Remission of anti-tumor necrosis factor-? antibody-induced palmoplantar pustulosis with the Janus kinase inhibitor baricitinib in a patient with rheumatoid arthritis.
Repurposed JAK1/JAK2 Inhibitor Reverses Established Autoimmune Insulitis in NOD Mice.
Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.
Response to: 'Impact of Janus kinase inhibitors on the risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials' by Lee and Song.
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
Role of Janus Kinase inhibitors in rheumatoid arthritis treatment.
Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase-Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-Blind, Placebo-Controlled, 2-Part Phase-2 Study.
Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies.
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies.
Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil).
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Safety signal detection and evaluation in clinical development programs: A case study of tofacitinib.
Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis.
Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor.
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.
Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Spectrophotometric method to quantify tofacitinib in lyotropic liquid crystalline nanoparticles and skin layers: Application in ex vivo dermal distribution studies.
Spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.
Spleen tyrosine kinase inhibitors for rheumatoid arthritis: where are we now?
Spleen tyrosine kinase: a novel target for therapeutic intervention of rheumatoid arthritis.
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study.
Structure Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis.
Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Super-enhancers delineate disease-associated regulatory nodes in T cells.
Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis.
Switching from adalimumab to tofacitinib in the treatment of patients with rheumatoid arthritis.
Syk kinase inhibitors for rheumatoid arthritis: trials and tribulations.
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype.
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis.
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials.
Systemic inflammatory responses after orthopedic surgery in patients with rheumatoid arthritis treated with tofacitinib.
Tapering Janus kinase inhibitors in rheumatoid arthritis with low disease activity or remission: reality or dream?
The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development.
The effect of mild and moderate hepatic impairment on the pharmacokinetics of tofacitinib, an orally active Janus kinase inhibitor.
The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis.
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial.
The emerging safety profile of JAK inhibitors in rheumatic disease.
The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon.
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells.
The Janus kinase 1/2 inhibitor baricitinib reduces biomarkers of joint destruction in moderate to severe rheumatoid arthritis.
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
The Pharmacokinetics, Pharmacodynamics and Safety of Baricitinib, an Oral JAK 1/2 Inhibitor, in Healthy Volunteers.
The Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis in Japan.
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety.
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates arthritis in SKG mice.
Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Tofacitinib in Combination with Conventional DMARDs in Patients with Active Rheumatoid Arthritis: PROs from a Phase 3 Randomized Controlled Trial.
Tofacitinib in Combination with Methotrexate in Patients with Rheumatoid Arthritis: Clinical Efficacy, Radiographic and Safety Outcomes from the 24-Month Phase 3 ORAL Scan Study.
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study.
Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: A post hoc analysis of efficacy and safety in Phase 3 and long-term extension studies over 7 years.
Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
Tofacitinib prevents radiographic progression in rheumatoid arthritis.
Tofacitinib restores the balance of ??Treg/??T17 cells in rheumatoid arthritis by inhibiting the NLRP3 inflammasome.
Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever.
Tofacitinib treatment aggravates Staphylococcus aureus septic arthritis, but attenuates sepsis and enterotoxin induced shock in mice.
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis.
Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
Tofacitinib versus methotrexate in rheumatoid arthritis.
Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses.
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Tofacitinib-induced subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis.
Tofacitinib: Real-World Data and Treatment Persistence in Rheumatoid Arthritis.
Tofacitinib: The First Janus Kinase (JAK) inhibitor for the treatment of rheumatoid arthritis.
Tolerogenic Dendritic Cells Generated with Tofacitinib Ameliorate Experimental Autoimmune Encephalomyelitis through Modulation of Th17/Treg Balance.
Treating active rheumatoid arthritis with Janus kinase inhibitors.
Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Two-Year Safety and Effectiveness of Peficitinib in Moderate-To-Severe Rheumatoid Arthritis: A Phase IIb, Open-Label Extension Study.
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Tyrosine kinases regulate chondrocyte hypertrophy: promising drug targets for Osteoarthritis.
Ultrasound efficacy of targeted-synthetic disease-modifying anti-rheumatic drug treatment in rheumatoid arthritis: a multicenter prospective cohort study in Japan.
Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Upadacitinib Pharmacokinetics and Exposure-Response Analyses of Efficacy and Safety in Psoriatic Arthritis Patients - Analyses of Phase 3 Clinical Trials.
Upadacitinib: First Approval.
Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib.
Use of Early Clinical Trial Data to Support Thorough QT Study Waiver for Upadacitinib and Utility of Food Effect to Demonstrate ECG Assay Sensitivity.
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study.
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
VX-509 (Decernotinib)-Mediated CYP3A Time-Dependent Inhibition: An Aldehyde Oxidase Metabolite as a Perpetrator of Drug-Drug Interactions.
Worldwide, 3-Year, Post-Marketing Surveillance Experience with Tofacitinib in Rheumatoid Arthritis.
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
[JAK inhibitors in the management of rheumatoid arthritis].
[JAK inhibitors: Perspectives in internal medicine].
[Modern disease-modifying antirheumatic drugs].
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
[Small molecules treatment in rheumatoid arthritis].
[Tofacitinib].
Aspergillosis
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Neurologic Complications in Patients With Cancer.
Asthenozoospermia
Correlative study on the JAK-STAT/PSM?3 signal transduction pathway in asthenozoospermia.
Asthma
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
A novel Syk kinase inhibitor suitable for inhalation: R-343(?)--WO-2009031011.
Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK.
Banhahubak-Tang Tablet, a Standardized Medicine Attenuates Allergic Asthma via Inhibition of Janus Kinase 1 (JAK1)/ Signal Transducer and Activator of Transcription 6 (STAT6) Signal Pathway.
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis.
Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Effects of a Janus kinase inhibitor, pyridone 6, on airway responses in a murine model of asthma.
Eighty-eight variants highlight the role of T cell regulation and airway remodeling in asthma pathogenesis.
Fragment Molecular Orbital Method Applied to Lead Optimization of Novel Interleukin-2 Inducible T-Cell Kinase (ITK) Inhibitors.
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
Identification of Type-II Inhibitors Using Kinase Structures.
Immunomodulators for allergic respiratory disorders.
Immunomodulators in asthma therapy.
Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Inhibition of spleen tyrosine kinase (SYK) attenuates allergen-mediated airway constriction.
JAK and Src tyrosine kinase signaling in asthma.
JAK-1 rs2780895 C-Related Genotype and Allele but not JAK-1 rs10789166, rs4916008, rs2780885, rs17127114, and rs3806277 Are Associated with Higher Susceptibility to Asthma.
Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma.
Lyn kinase represses mucus hypersecretion by regulating IL-13-induced endoplasmic reticulum stress in asthma.
Lyn-deficient mice develop severe, persistent asthma: Lyn is a critical negative regulator of Th2 immunity.
MicroRNA-203 negatively regulates c-Abl, ERK1/2 phosphorylation, and proliferation in smooth muscle cells.
Rational design of highly selective spleen tyrosine kinase inhibitors.
Role of Tyk-2 in Th9 and Th17 cells in allergic asthma.
Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.
Spleen tyrosine kinase inhibition attenuates airway hyperresponsiveness and pollution-induced enhanced airway response in a chronic mouse model of asthma.
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Status of serine tyrosine kinase at germline and expressional levels in asthma patients.
Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
TGF? receptor mutations impose a strong predisposition for human allergic disease.
The Dynamic Actin Cytoskeleton in Smooth Muscle.
The effect of siRNA-mediated lymphocyte-specific protein tyrosine kinase (Lck) inhibition on pulmonary inflammation in a mouse model of asthma.
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
[The Involvement of Src in Airway Inflammation Induced by Repeated Exposure to Lipopolysaccharide in Mice].
[The transcription levels of linker for activation of T cell and its upstream regulatory factors in T cells of asthmatic patients]
Astrocytoma
Astrocytoma adhesion to extracellular matrix: functional significance of integrin and focal adhesion kinase expression.
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.
Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells.
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Increased expression in human astrocytomas of a 100 kDa protein with sequence homology to the ros tyrosine kinase domain.
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.
No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo.
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Tumour induction in fetal brain transplants exposed to the viral oncogenes polyoma middle T and v-src.
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
Ataxia
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Inhibition of c-Abl tyrosine kinase activity by filamentous actin.
Ataxia Telangiectasia
Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation.
c-Abl mediates high NaCl-induced phosphorylation and activation of the transcription factor TonEBP/OREBP.
c-Abl tyrosine kinase is not essential for ataxia telangiectasia mutated functions in chromosomal maintenance.
Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals.
Determination of cell fate by c-Abl activation in the response to DNA damage.
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Functional role for the c-Abl tyrosine kinase in meiosis I.
Identification of proteins in the hamster DNA end-binding complex.
Identification of small molecule inhibitors of phosphatidylinositol 3-kinase and autophagy.
Mismatch repair and DNA damage signalling.
Werner Syndrome Protein and DNA Replication.
Atherosclerosis
A Disintegrin and Metalloproteinase 15 Contributes to Atherosclerosis by Mediating Endothelial Barrier Dysfunction via Src Family Kinase Activity.
A spleen tyrosine kinase inhibitor attenuates the proliferation and migration of vascular smooth muscle cells.
CircRNA?0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR?107.
Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis.
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Imatinib mesylate stimulates low-density lipoprotein receptor-related protein 1-mediated ERK phosphorylation in insulin-producing cells.
Mulberry water extracts inhibit atherosclerosis through suppression of the integrin-??/focal adhesion kinase complex and downregulation of nuclear factor ?B signaling in vivo and in vitro.
Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells.
Silencing MR-1 attenuates atherosclerosis in ApoE
The critical role of IL-1 receptor-associated kinase 4-mediated NF-kappaB activation in modified low-density lipoprotein-induced inflammatory gene expression and atherosclerosis.
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors.
Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study.
Urantide alleviates the symptoms of atherosclerotic rats in vivo and in vitro models through the JAK2/STAT3 signaling pathway.
Vascular transcellular signaling.
Atrial Fibrillation
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Cardiotoxicity of Novel Targeted Hematological Therapies.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Focal adhesion kinase mediates atrial fibrosis via the AKT/S6K signaling pathway in chronic atrial fibrillation patients with rheumatic mitral valve disease.
Genome-wide linkage scan identifies a novel genetic locus on chromosome 5p13 for neonatal atrial fibrillation associated with sudden death and variable cardiomyopathy.
Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Pharmacological evidence for altered src kinase regulation of I (Ca,L) in patients with chronic atrial fibrillation.
[Involvement of Src kinase in the down-regulation of ultra-rapid delayed rectifier K(+)current induced by tumor necrosis factor-? in cardiomyocytes].
Autoimmune Diseases
A hypomorphic allele of ZAP-70 reveals a distinct thymic threshold for autoimmune disease versus autoimmune reactivity.
A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.
A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
A Supratherapeutic Dose of the Janus Kinase Inhibitor Tasocitinib (CP-690,550) Does Not Prolong QTc Interval in Healthy Participants.
B cell-specific loss of Lyn kinase leads to autoimmunity.
Bayesian Machine Learning to Discover Bruton's Tyrosine Kinase (BTK) Inhibitors.
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.
Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
Btk inhibition treats TLR7/IFN driven murine lupus.
Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Curcumin modulation of the activation of PYK2 in peripheral blood mononuclear cells from patients with lupus nephritis.
Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.
Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Discovery of a potent, selective, and covalent ZAP-70 kinase inhibitor.
Discovery of Affinity-Based Probes for Btk Occupancy Assays.
Discovery of BIIB068: A Selective, Potent, Reversible Bruton's Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases.
Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Discovery of Lanraplenib (GS-9876): A Once-Daily Spleen Tyrosine Kinase Inhibitor for Autoimmune Diseases.
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Discovery of Novel Bruton's Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking.
Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Discovery of Tyrosine Kinase 2 (TYK2) Inhibitor (PF-06826647) for the Treatment of Autoimmune Diseases.
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases.
Effect of CP-690,550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers.
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes of autoimmune disease patients.
Essential Kinases and Transcriptional Regulators and Their Roles in Autoimmunity.
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Fate of lymphocytes after withdrawal of tofacitinib treatment.
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Garden of therapeutic delights: new targets in rheumatic diseases.
Genetic interdependence of lyn and negative regulators of B cell receptor signaling in autoimmune disease development.
GLIS3 and TYK2 Single Nucleotide Polymorphisms Are Not Associated with Dermatomyositis/Polymyositis in Chinese Han Population.
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165.
Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays.
Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Identification of Inhibitors of the Association of ZAP-70 with the T Cell Receptor by High-Throughput Screen.
Identification of metabolites of evobrutinib in rat and human hepatocytes by using ultra-high performance liquid chromatography coupled with diode array detector and Q Exactive Orbitrap tandem mass spectrometry.
Identification of Type-II Inhibitors Using Kinase Structures.
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.
Interleukin-23: A New Atherosclerosis Target.
Interleukin-6 Trans-Signaling Exacerbates Inflammation and Renal Pathology in Lupus-Prone Mice.
JAK-inhibitor tofacitinib suppresses interferon alfa production by plasmacytoid dendritic cells and inhibits arthrogenic and antiviral effects of interferon alfa.
JAK-STAT inhibitors for the treatment of immunomediated diseases.
JAK1, but not JAK2 and STAT3, confers susceptibility to Vogt-Koyanagi-Harada (VKH) syndrome in a Han Chinese population.
JAK2 and STAT3 polymorphisms in a Han Chinese population with Behçet's disease.
Janus kinase inhibitors in autoimmune diseases.
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks immunoglobulin G-mediated cellular responses and autoimmune reactions in vivo.
Kinase inhibitors in the treatment of immune-mediated disease.
Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Measuring atropisomers of BMS-986142 using 2DLC as an enabling technology.
Modification by covalent reaction or oxidation of cysteine residues in the tandem-SH2 domains of ZAP-70 and Syk can block phosphopeptide binding.
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
Network pharmacology of JAK inhibitors.
Novel concepts and treatments for autoimmune disease: ten focal points.
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Orelabrutinib: First Approval.
Pancreatic Effects of a Bruton's Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent.
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Pharmacophore modeling of JAK1: A target infested with activity-cliffs.
Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients.
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
PTPN22 phosphorylation acts as a molecular rheostat for the inhibition of TCR signaling.
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases.
Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Rational design of highly selective spleen tyrosine kinase inhibitors.
Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity.
Role of Tyk-2 in Th9 and Th17 cells in allergic asthma.
Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.
Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
Separation of Bruton's tyrosine kinase inhibitor atropisomers by supercritical fluid chromatography.
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177).
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
Structure-activity relationship studies of 5-benzylaminoimidazo[1,2-c]pyrimidine-8-carboxamide derivatives as potent, highly selective ZAP-70 kinase inhibitors.
Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
SVM Model for Virtual Screening of Lck Inhibitors.
Syk kinase as a treatment target for therapy in autoimmune diseases.
Syk mediates IL-17-induced CCL20 expression by targeting Act1-dependent K63-linked ubiquitination of TRAF6.
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus.
The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice.
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.
Tyrosine Kinase Inhibitor Tyrphostin AG490 Retards Chronic Joint Inflammation in Mice.
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease.
[Everything you ever wanted to know about ZAP-70]
Autoimmune Lymphoproliferative Syndrome
Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Avian Leukosis
Identification of Avian leukosis virus subgroup J associated acutely transforming viruses carrying the v-src oncogene in layer chickens.
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene.
Rescue of avian leukosis subgroup-J-associated acutely transforming viruses carrying different lengths of the v-fps oncogene and analysis of their tumorigenicity.
Axial Spondyloarthritis
Axial spondyloarthritis: emerging drug targets.
Beyond the TNF-? Inhibitors: New and Emerging Targeted Therapies for Patients with Axial Spondyloarthritis and their Relation to Pathophysiology.
Emerging Immunomodulatory Therapies and New Treatment Paradigms for Axial Spondyloarthritis.
Novel Therapeutic Targets in Axial Spondyloarthritis.
Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents.
Treatment of Axial Spondyloarthritis: What Does the Future Hold?
Azoospermia
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Babesiosis
Urinary proteome of dogs with kidney injury during babesiosis.
Bacteremia
MyD88- and Bruton's tyrosine kinase-mediated signals are essential for T cell-independent pathogen-specific IgM responses.
Bacterial Infections
A case report of disseminated histoplasmosis and concurrent cryptococcal meningitis in a patient treated with ruxolitinib.
Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells.
Chlamydial Infection of Monocytes Stimulates IL-1beta Secretion Through Activation of the NLRP3 Inflammasome.
Functional analysis of the porcine USP18 and its role during porcine arterivirus replication.
Identification of mutations of Bruton's tyrosine kinase gene (BTK) in Brazilian patients with X-linked agammaglobulinemia.
Inositol polyphosphates promote T cell-independent humoral immunity via the regulation of Bruton's tyrosine kinase.
Lyn prevents aberrant inflammatory responses to
Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia.
Neutrophil specific deletion of Syk kinase results in reduced host defense to bacterial infection.
Novel Mutation of ZAP-70-related Combined Immunodeficiency: First Case from the National Iranian Registry and Review of the Literature.
Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response.
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Sustained correction of B-cell development and function in a murine model of X-linked agammaglobulinemia (XLA) using retroviral-mediated gene transfer.
Transcriptional regulatory defects in the first intron of Bruton's tyrosine kinase.
Wingless homolog Wnt11 suppresses bacterial invasion and inflammation in intestinal epithelial cells.
[Gene diagnosis of X-linked agammaglobulinemia]
Barrett Esophagus
Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Behcet Syndrome
Janus kinase 2 V617F mutation and thrombotic events in Behcet's disease: The Alexandria experience.
Bicuspid Aortic Valve Disease
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Sequencing of NOTCH1, GATA5, TGFBR1 and TGFBR2 genes in familial cases of bicuspid aortic valve.
Biliary Tract Neoplasms
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line.
Src as a Therapeutic Target in Biliary Tract Cancer.
Blast Crisis
A case of biphenotypic blast crisis of unclassified myeloproliferative disorder.
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.
A novel HDAC inhibitor chidamide combined with imatinib synergistically targets tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia.
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Acquired homozygosity of the rearranged bcr allele during the acute leukemic phase of a patient with Ph-negative chronic myeloid leukemia.
Activation of EVI1 transcription by the LEF1/?-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/?-catenin signaling.
Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Bilineal T lymphoblastic and myeloid blast transformation in chronic myeloid leukemia with TP53 mutation-an uncommon presentation in adults.
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Chronic myelogenous leukemia: mechanisms underlying disease progression.
Chronic myeloid leukemia blast crisis arises from progenitors.
Chronic myeloid leukemia stem cells.
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Clinico-hematological profile in biphenotypic acute leukemia.
Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Coexistence of p190 BCR/ABL Transcript and CALR 52-bp Deletion in Chronic Myeloid Leukemia Blast Crisis: A Case Report.
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Cross-talk between Bcr-Abl tyrosine kinase, protein kinase C and telomerase-a potential reason for resistance to Glivec in chronic myelogenous leukaemia.
Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.
Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukaemia.
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Description of a new BCR-ABL point mutation in a CML patient with evolution to lymphoid blast crisis.
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Differential display analysis of mRNAs in chronic myelogenous leukaemia.
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Elevated Bcr-Abl expression levels are sufficient for a haematopoietic cell line to acquire a drug-resistant phenotype.
EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins.
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Evolutionary Dynamics of Chronic Myeloid Leukemia Progression: the Progression-Inhibitory Effect of Imatinib.
Expression and activity of Fyn mediate proliferation and blastic features of chronic myelogenous leukemia.
Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia.
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Fluorescence in situ hybridization for the BCR-ABL fusion gene in a patient with imatinib mesylate-resistant chronic myelogenous leukaemia in extramedullary blast crisis.
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice.
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML.
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Jak2 is involved in c-Myc induction by Bcr-Abl.
Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Low concentrations of STI571 in the cerebrospinal fluid: a case report.
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Management of chronic myeloid leukemia in blast crisis.
Methylation of the major breakpoint cluster region (M-bcr) in Philadelphia-positive CML.
Molecular biology of chronic myeloid leukemia.
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.
Pathobiology of lymphoid and myeloid blast crisis and management issues.
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Regulation and Targeting of Eg5, a Mitotic Motor Protein in Blast Crisis CML: Overcoming Imatinib Resistance.
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib.
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
The CML stem cell: evolution of the progenitor.
The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model.
The role of methylation in CML.
The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
Transcriptional suppression of BACH2 by the Bcr-Abl oncoprotein is mediated by PAX5.
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Where are we going with CML research?
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
[Erythroleukemic blast crisis of chronic myeloid leukemia.]
[Molecular analysis of bcr-abl mRNA during long-term follow-up of cases of chronic myelogenous leukemia]
[Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]
[STI571: a new dimension in the treatment of chronic myeloid leukemia]
[The prognostic significance of derivative chromosome 9 deletions in chronic myeloid leukemia]
Blindness
An Anti-inflammatory Role of VEGFR2/Src Kinase Inhibitor in HSV-1 Induced Immunopathology.
Blister
Caspase-mediated cleavage of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell apoptosis.
Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology.
GnRH Induces ERK-Dependent Bleb Formation in Gonadotrope Cells, Involving Recruitment of Members of a GnRH Receptor-Associated Signalosome to the Blebs.
LIM-kinase 2 induces formation of stress fibres, focal adhesions and membrane blebs, dependent on its activation by Rho-associated kinase-catalysed phosphorylation at threonine-505.
Localization of TGF-beta type II receptor and ED-A fibronectin in normal conjunctiva and failed filtering blebs.
SH4-domain-induced plasma membrane dynamization promotes bleb-associated cell motility.
Zyxin and vinculin distribution at the cell-extracellular matrix attachment complex (CMAX) in corneal epithelial tissue are actin dependent.
Bloom Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Novel immunodeficiency data servers.
Bone Diseases
Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases.
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease.
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
Targeting protein kinases for bone disease: discovery and development of Src inhibitors.
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Bone Diseases, Metabolic
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Bone Marrow Diseases
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Bone Marrow Failure Disorders
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
The thrombopoietin receptor: revisiting the master regulator of platelet production.
Bone Neoplasms
Blockade of spinal dopamine D1/D2 receptor suppresses activation of NMDA receptor through G?q and Src kinase to attenuate chronic bone cancer pain.
Interleukin-6-mediated functional upregulation of TRPV1 receptors in dorsal root ganglion neurons through the activation of JAK/PI3K signaling pathway: roles in the development of bone cancer pain in a rat model.
JAK1/STAT3 regulatory effect of ?-caryophyllene on MG-63 osteosarcoma cells via ROS-induced apoptotic mitochondrial pathway by DNA fragmentation.
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Bone Resorption
A novel Bruton's tyrosine kinase inhibitor acalabrutinib suppresses osteoclast differentiation and P. gingivalis lipopolysaccharide-induced alveolar bone resorption.
A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma.
Activation of the receptor EphB4 by its specific ligand ephrin B2 in human osteoarthritic subchondral bone osteoblasts.
Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis.
Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis.
BMPRIA is required for osteogenic differentiation and RANKL expression in adult bone marrow mesenchymal stromal cells.
Bone cell interactions through Eph/ephrin: Bone modeling, remodeling and associated diseases.
Bone morphogenetic protein type IA receptor signaling regulates postnatal osteoblast function and bone remodeling.
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption.
c-Src control of chloride channel support for osteoclast HCl transport and bone resorption.
Cbp Recruitment of Csk Into Lipid Rafts is Critical to c-Src Kinase Activity and Bone Resorption in Osteoclasts.
Compressive force regulates ephrinB2 and EphB4 in osteoblasts and osteoclasts contributing to alveolar bone resorption during experimental tooth movement.
Critical role of cortactin in actin ring formation and osteoclastic bone resorption.
Cytokines and growth factors in the regulation of bone remodeling.
Development and characterization of a porcine model to study osteoclast differentiation and activity.
Effects of Porphyromonas gingivalis lipopolysaccharide on osteoblast-osteoclast bidirectional EphB4-EphrinB2 signaling.
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Effects of the Src Kinase Inhibitor Saracatinib (AZD0530) on Bone Turnover in Healthy Men: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Phase I Trial.
Emerging and potential therapies for osteoporosis.
Emerging pharmacologic therapies for osteoporosis.
EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair.
Future anti-catabolic therapeutic targets in bone disease.
Fyn positively regulates the activation of DAP12 and FcR?-mediated costimulatory signals by RANKL during osteoclastogenesis.
Herbal formulation, Yukmi-jihang-tang-Jahage, regulates bone resorption by inhibition of phosphorylation mediated by tyrosine kinase Src and cyclooxygenase expression.
Histone deacetylase 3 supports endochondral bone formation by controlling cytokine signaling and matrix remodeling.
In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene.
Inhibition of protein kinase c-Src as a therapeutic approach for cancer and bone metastases.
Inhibition of the classical NF-kappaB pathway prevents osteoclast bone-resorbing activity.
Inhibitory Effect of Adenovirus-Mediated siRNA-Targeting BMPR-IB on UHMWPE-Induced Bone Destruction in the Murine Air Pouch Model.
Intracellular signal transduction pathways: good therapeutic targets for joint destruction in rheumatoid arthritis.
Lipoic acid increases the expression of genes involved in bone formation in mice fed a high-fat diet.
Loss of BMP signaling mediated by BMPR1A in osteoblasts leads to differential bone phenotypes in mice depending on anatomical location of the bones.
Macrophage-stimulating protein activates STK receptor tyrosine kinase on osteoclasts and facilitates bone resorption by osteoclast-like cells.
Pharmacologic Calcitriol Inhibits Osteoclast Lineage Commitment via the BMP-Smad1- I?B-NF-?B Pathway.
Plectin stabilizes microtubules during osteoclastic bone resorption by acting as a scaffold for Src and Pyk2.
Possible involvement of focal adhesion kinase, p125FAK, in osteoclastic bone resorption.
Prevalent and Emerging Therapies for Osteoporosis.
Prognostic significance of ACP5 expression in patients with lung adenocarcinoma.
PTH battles TGF-beta in bone.
Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation.
Selective inhibition of Src family kinases by SU6656 increases bone mass by uncoupling bone formation from resorption in mice.
Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
SRC inhibitors in metastatic bone disease.
Src kinase activity is essential for osteoclast function.
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
The potential effect of Bruton's tyrosine kinase in refractory periapical periodontitis.
The role of c-Src kinase in the regulation of osteoclast function.
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.
UCS15A, a non-kinase inhibitor of Src signal transduction.
Boutonneuse Fever
Endothelial Cell Proteomic Response to Rickettsia conorii Infection Reveals Activation of the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT)-Inferferon Stimulated Gene (ISG)15 Pathway and Reprogramming Plasma Membrane Integrin/Cadherin Signaling.
Brain Diseases
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
EphB4 Regulates Self-Renewal, Proliferation and Neuronal Differentiation of Human Embryonic Neural Stem Cells in Vitro.
Fyn kinase in brain diseases and cancer: the search for inhibitors.
Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Brain Edema
Blood-brain barrier breakdown and repair by Src after thrombin-induced injury.
Hydrogen Inhalation Ameliorated Mast Cell-Mediated Brain Injury After Intracerebral Hemorrhage in Mice.
Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.
PGE2 receptor agonist misoprostol protects brain against intracerebral hemorrhage in mice.
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
Brain Infarction
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Injuries
Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury.
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.
Dexmedetomidine Exerts Brain-Protective Effects Under Cardiopulmonary Bypass Through Inhibiting the Janus Kinase 2/Signal Transducers and Activators of Transcription 3 Pathway.
Distribution of bone morphogenetic protein and bone morphogenetic protein receptor transcripts in the rodent nervous system and up-regulation of bone morphogenetic protein receptor type II in hippocampal dentate gyrus in a rat model of global cerebral ischemia.
Experimental treatment for focal hyperglycemic ischemic brain injury in the rat.
Inhibition of Src tyrosine kinase and effect on outcomes in a new in vivo model of surgically induced brain injury.
Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.
Neuroprotection of GluR5-containing Kainate Receptor Activation against Ischemic Brain Injury through Decreasing Tyrosine Phosphorylation of N-Methyl-D-aspartate Receptors Mediated by Src Kinase.
Pyk2 inhibition attenuates hypoxic-ischemic brain injury in neonatal mice.
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke.
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
Suppression of etk/bmx protects against ischemic brain injury.
Brain Injuries, Traumatic
Downregulation of Src-kinase and glutamate-receptor phosphorylation after traumatic brain injury.
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Brain Ischemia
A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury.
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Delayed phosphorylation of p38 mitogen-activated protein kinase in the AT1a knock-out mouse striatal neurons during middle cerebral artery occlusion and reperfusion.
Distribution of bone morphogenetic protein and bone morphogenetic protein receptor transcripts in the rodent nervous system and up-regulation of bone morphogenetic protein receptor type II in hippocampal dentate gyrus in a rat model of global cerebral ischemia.
Electroacupuncture effect on neurological behavior and tyrosine kinase-JAK 2 in rats with focal cerebral ischemia.
Electroacupuncture effects on cortical neurons, as well as Janus kinase 2-signal transducer and activator of transcription 3 signal transduction pathway, in a rat model of cerebral ischemia.
Levo-tetrahydropalmatine attenuates mouse blood-brain barrier injury induced by focal cerebral ischemia and reperfusion: Involvement of Src kinase.
N-methyl-D-aspartate receptor and L-type voltage-gated Ca2+ channel activation mediate proline-rich tyrosine kinase 2 phosphorylation during cerebral ischemia in rats.
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Non-receptor tyrosine kinase Src is required for ischemia-stimulated neuronal cell proliferation via Raf/ERK/CREB activation in the dentate gyrus.
Postischemic gene transfer of soluble Flt-1 protects against brain ischemia with marked attenuation of blood-brain barrier permeability.
S-Nitrosylation of proline-rich tyrosine kinase 2 involves its activation induced by oxygen-glucose deprivation.
Spry2-mediated inhibition of the Ras/ERK pathway through interaction with Src kinase following cerebral ischemia.
Src family kinase-inhibitor PP2 reduces focal ischemic brain injury.
Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemia.
STAT3 signaling after traumatic brain injury.
Study on the mechanism of JAK2/STAT3 signaling pathway-mediated inflammatory reaction after cerebral ischemia.
The role of non-receptor protein tyrosine kinases in the excitotoxicity induced by the overactivation of NMDA receptors.
Two types of calcium channels regulating activation of proline-rich tyrosine kinase 2 induced by transient brain ischemia in rat hippocampus.
Brain Neoplasms
Chondroitin Sulphate Proteoglycans in the Tumour Microenvironment.
Differential expression of Csk homologous kinase (CHK) in normal brain and brain tumors.
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.
Genome Medicine for Brain Tumors: Current Status and Future Perspectives.
Kinome profiling in pediatric brain tumors as a new approach for target discovery.
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Breast Neoplasms
(-)-Oleocanthal Combined with Lapatinib Treatment Synergized against HER-2 Positive Breast Cancer In Vitro and In Vivo.
4-Aryl-4H-naphthopyrans derivatives: one-pot synthesis, evaluation of Src kinase inhibitory and anti-proliferative activities.
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells.
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
A molecular mechanism for stress-induced alterations in susceptibility to disease.
A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK.
A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breast cancer. GEICAM/2010-04 study.
A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
A phosphotyrosine switch determines the antitumor activity of ER?.
A rapid and sensitive method for EphB4 identification as a diagnostic and therapeutic biomarker in invasive breast cancer.
A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
A role for the epithelial-cell-specific tyrosine kinase Sik during keratinocyte differentiation.
A silent mutation made possible efficient production of active human Frk tyrosine kinase in Escherichia coli.
Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Activated Src increases adhesion, survival and alpha2-integrin expression in human breast cancer cells.
Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells.
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells.
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Adipocyte activation of cancer stem cell signaling in breast cancer.
Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
AKT1 and AKT2 isoforms play distinct roles during breast cancer progression through the regulation of specific downstream proteins.
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.
An aberrant spliced transcript of focal adhesion kinase is exclusively expressed in human breast cancer.
An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer.
An ErbB2/c-Src axis links bioenergetics with PRC2 translation to drive epigenetic reprogramming and mammary tumorigenesis.
An essential role for Src kinase in ErbB receptor signaling through the MAPK pathway.
An evaluation of focal adhesion kinase in breast cancer by tissue microarrays.
An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.
Analysis of multiple physical parameters for mechanical phenotyping of living cells.
Anti-metastatic effect of jolkinolide B and the mechanism of activity in breast cancer MDA-MB-231 cells.
Anti-oestrogens but not oestrogen deprivation promote cellular invasion in intercellular adhesion-deficient breast cancer cells.
Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.
Anticancer Activity of Tubulosine through Suppression of Interleukin-6-Induced Janus Kinase 2/Signal Transducer and Activation of Transcription 3 Signaling.
Arg/Abl2 promotes invasion and attenuates proliferation of breast cancer in vivo.
Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2/ErbB-2 in breast cancer cells.
Association of estrogen receptor alpha and histone deacetylase 6 causes rapid deacetylation of tubulin in breast cancer cells.
Association of SYK Genetic Variations with Breast Cancer Pathogenesis.
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Atomic force microscopy and graph analysis to study the P-cadherin/SFK mechanotransduction signalling in breast cancer cells.
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.
Benzo-[a]-pyrene induces FAK activation and cell migration in MDA-MB-231 breast cancer cells.
Beyond genomics.
Binding of MMP-9-degraded fibronectin to ?6 integrin promotes invasion via the FAK-Src-related Erk1/2 and PI3K/Akt/Smad-1/5/8 pathways in breast cancer.
Bioinformatics analysis of microarray profiling identifies the mechanism of focal adhesion kinase signalling pathway in proliferation and apoptosis of breast cancer cells modulated by green tea polyphenol epigallocatechin 3-gallate.
Bosutinib: A review of preclinical studies in chronic myelogenous leukaemia.
Breast cancer cell line proliferation blocked by the Src-related Rak tyrosine kinase.
Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.
Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression.
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Breast Cancer Stem Cells with Tumor- versus Metastasis-Initiating Capacities Are Modulated by TGFBR1 Inhibition.
Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.
Breast cancer: the menacing face of Janus kinase.
Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression.
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Breast tumor kinase (Brk/PTK6) plays a role in the differentiation of primary keratinocytes.
Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells.
Breast tumor kinase and extracellular signal-regulated kinase 5 mediate Met receptor signaling to cell migration in breast cancer cells.
Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration.
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Brk activates rac1 and promotes cell migration and invasion by phosphorylating paxillin.
BRK phosphorylates PSF promoting its cytoplasmic localization and cell cycle arrest.
BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential.
BRK targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration.
Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer cell survival and epithelial-to-mesenchymal transition.
Brk/PTK6 signaling in normal and cancer cell models.
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR.
BRK/Sik expression in the gastrointestinal tract and in colon tumors.
Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Building a better understanding of the intracellular tyrosine kinase PTK6 - BRK by BRK.
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
c-Abl regulates estrogen receptor alpha transcription activity through its stabilization by phosphorylation.
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
cAMP Elevation Down-Regulates ?3 Integrin and Focal Adhesion Kinase and Inhibits Leptin-Induced Migration of MDA-MB-231 Breast Cancer Cells.
Carboxyl-terminal Src kinase homologous kinase negatively regulates the chemokine receptor CXCR4 through YY1 and impairs CXCR4/CXCL12 (SDF-1alpha)-mediated breast cancer cell migration.
CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.
CEP-33779 antagonizes ATP-binding cassette subfamily B member 1 mediated multidrug resistance by inhibiting its transport function.
Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
Circulating extracellular vesicles from patients with breast cancer enhance migration and invasion via a Src?dependent pathway in MDA?MB?231 breast cancer cells.
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer.
Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours.
Clustering of monosialyl-Gb5 initiates downstream signalling events leading to invasion of MCF-7 breast cancer cells.
Co-crystal structures of PTK6: With Dasatinib at 2.24 ?, with novel imidazo[1,2-a]pyrazin-8-amine derivative inhibitor at 1.70 ? resolution.
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Co-overexpression of Janus kinase 2 and signal transducer and activator of transcription 5a promotes differentiation of mammary cancer cells through reversal of epithelial-mesenchymal transition.
Combined inhibition of EGFR and c-ABL suppresses the growth of fulvestrant-resistant breast cancer cells through miR-375-autophagy axis.
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Constitutive activation of pp125fak in newly isolated human breast cancer cell lines.
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells.
Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer.
Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Copine-III interacts with ErbB2 and promotes tumor cell migration.
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Correction: Breast Tumor Kinase Phosphorylates p190RhoGAP to Regulate Rho and Ras and Promote Breast Carcinoma Growth, Migration, and Invasion.
Corrigendum: RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Coupling of RAFTK/Pyk2 kinase with c-Abl and their role in the migration of breast cancer cells.
Crystal structure of the kinase domain of human protein tyrosine kinase 6 (PTK6) at 2.33 ? resolution.
Csk homologous kinase (CHK) and ErbB-2 interactions are directly coupled with CHK negative growth regulatory function in breast cancer.
Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration.
Csk homologous kinase, a novel signaling molecule, directly associates with the activated ErbB-2 receptor in breast cancer cells and inhibits their proliferation.
Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Curbing the focal adhesion kinase and its associated signaling events by pentoxifylline in MDA-MB-231 human breast cancer cells.
CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004.
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
Decreased tyrosine phosphorylation of focal adhesion kinase after estradiol treatment of MCF-7 human breast carcinoma cells.
Defining central themes in breast cancer biology by differential proteomics: conserved regulation of cell spreading and focal adhesion kinase.
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Deregulation of the cell cycle by breast tumor kinase (Brk).
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand.
Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance.
Development of radicicol analogues.
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Discordant ERBB2 Status and Genome Wide DNA Copy Number Alterations in Breast Cancer and Synchronous Lymph Node Metastasis: A Case Report and Literature Review.
Discovery of 4-anilino ?-carbolines as novel Brk inhibitors.
Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Doxorubicin induces atypical NF-?B activation through c-Abl kinase activity in breast cancer cells.
Dual inhibition of focal adhesion kinase and epidermal growth factor receptor pathways cooperatively induces death receptor-mediated apoptosis in human breast cancer cells.
Dual Mechanisms of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells.
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells.
Effect of RAD51C expression on the chemosensitivity of E?-Myc p19Arf-/- cells and its clinical significance in breast cancer.
Effect of triptolide on focal adhesion kinase and survival in MCF-7 breast cancer cells.
Effects of hyperactive Janus kinase 2 signaling in mammary epithelial cells.
Effects of simultaneous knockdown of HER2 and PTK6 on malignancy and tumor progression in human breast cancer cells.
EGFR-c-Src-Mediated HDAC3 Phosphorylation Exacerbates Invasion of Breast Cancer Cells.
Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells: Potential Mechanisms Contributing to Progression of HER2-Positive Breast Cancers.
Emerging therapeutic targets in breast cancer bone metastasis.
Endogenous control of cell cycle progression by autocrine transforming growth factor beta in breast cancer cells.
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens.
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
EphB4 tyrosine kinase stimulation inhibits growth of MDA-MB-231 breast cancer cells in a dose and time dependent manner.
Ephrin?B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis?free survival in breast cancer.
Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion.
Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells.
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Erythropoietin Stimulates Tumor Growth via EphB4.
Estrogen and pure antiestrogen fulvestrant (ICI 182 780) augment cell-matrigel adhesion of MCF-7 breast cancer cells through a novel G protein coupled estrogen receptor (GPR30)-to-calpain signaling axis.
Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
Estrogen receptor alpha phosphorylation and its functional impact in human breast cancer.
Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells.
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Estrogens and PTP1B Function in a Novel Pathway to Regulate Aromatase Enzymatic Activity in Breast Cancer Cells.
Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: signaling partners, hierarchy and physiological significance.
Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells.
Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer.
Evolution of breast cancer therapeutics: Breast tumour kinase's role in breast cancer and hope for breast tumour kinase targeted therapy.
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Exploring Rak tyrosine kinase function in breast cancer.
Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.
Expression of Ephb2 and Ephb4 in breast carcinoma.
Expression of GST-fused kinase domain of human Csk homologous kinase from Pichia pastoris facilitates easy purification.
Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase.
Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness.
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Expression profile of tyrosine kinases in breast cancer.
Extracellular AGR3 regulates breast cancer cells migration via Src signaling.
Extracellular vesicles from young women's breast cancer patients drive increased invasion of non-malignant cells via the Focal Adhesion Kinase pathway: a proteomic approach.
Extracellular Visfatin-Promoted Malignant Behavior in Breast Cancer Is Mediated Through c-Abl and STAT3 Activation.
FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
FAK alters invadopodia and focal adhesion composition and dynamics to regulate breast cancer invasion.
FAK overexpression and p53 mutations are highly correlated in human breast cancer.
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication.
FAK-Copy-Gain Is a Predictive Marker for Sensitivity to FAK Inhibition in Breast Cancer.
Fascin Activates ?-Catenin Signaling and Promotes Breast Cancer Stem Cell Function Mainly Through Focal Adhesion Kinase (FAK): Relation With Disease Progression.
Flavonoid effects relevant to cancer.
Focal adhesion kinase (FAK) deficiency in mononuclear phagocytes alters murine breast tumor progression.
Focal adhesion kinase and protein kinase B cooperate to suppress Doxorubicin-induced apoptosis of breast tumor cells.
Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Focal adhesion kinase N-terminus in breast carcinoma cells induces rounding, detachment and apoptosis.
Focal adhesion kinase regulates the phosphorylation protein tyrosine phosphatase-? at Tyr789 in breast cancer cells.
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasis.
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo.
Functional analysis of Csk and CHK kinases in breast cancer cells.
Functional interaction between the epidermal growth factor receptor and c-Src kinase activity.
Functional involvement of src and focal adhesion kinase in a CD99 splice variant-induced motility of human breast cancer cells.
Ganoderic acid A exerts antitumor activity against MDA-MB-231 human breast cancer cells by inhibiting the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
Gene expression profile by inhibiting Raf-1 protein kinase in breast cancer cells.
Genetic Variability in the microRNA Binding Sites of BMPR1B, TGFBR1, IQGAP1, KRAS, SETD8 and RYR3 and Risk of Breast Cancer in Colombian Women.
Genetic variation in the JAK/STAT/SOCS signaling pathway influences breast cancer-specific mortality through interaction with cigarette smoking and use of aspirin/NSAIDs: the Breast Cancer Health Disparities Study.
Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
Heat shock protein 90? stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells.
HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo.
HER2 regulates Brk/PTK6 stability via upregulating calpastatin, an inhibitor of calpain.
Heregulin and HER2 signaling selectively activates c-Src phosphorylation at tyrosine 215.
High expression of focal adhesion kinase (p125FAK) in node-negative breast cancer is related to overexpression of HER-2/neu and activated Akt kinase but does not predict outcome.
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
High focal adhesion kinase expression in invasive breast carcinomas is associated with an aggressive phenotype.
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Hyaluronan-CD44 interaction promotes c-Src-mediated twist signaling, MicroRNA-10b expression and RhoA/RhoC upregulation leading to Rho-kinase-associated Cytoskeleton Activation and Breast Tumor Cell Invasion.
Hyperphosphorylated cortactin in cancer cells plays an inhibitory role in cell motility.
Hypoglycemia-induced c-Jun phosphorylation is mediated by c-Jun N-terminal kinase 1 and Lyn kinase in drug-resistant human breast carcinoma MCF-7/ADR cells.
Hypoxia-inducible factor-dependent ADAM12 expression mediates breast cancer invasion and metastasis.
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR.
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Identification of STAT3 as a specific substrate of breast tumor kinase.
Identification of TENM4 as a Novel Cancer Stem Cell-Associated Molecule and Potential Target in Triple Negative Breast Cancer.
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Immunohistochemically demonstrable pp60(c-SRC) in human breast-cancer.
Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer.
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
In vitro cytotoxic effect of Trastuzumab in combination with Pertuzumab in breast cancer cells is improved by interleukin-2 activated NK cells.
In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.
Increased expression of miR-551a by c-Fos reduces Focal Adhesion Kinase (FAK) levels and blocks tumorigenesis.
Induction of transforming growth factor-beta receptor type II expression in estrogen receptor-positive breast cancer cells through SP1 activation by 5-aza-2'-deoxycytidine.
Inhibition of a specific N-glycosylation activity results in attenuation of breast carcinoma cell invasiveness-related phenotypes: inhibition of epidermal growth factor-induced dephosphorylation of focal adhesion kinase.
Inhibition of c-ABL sensitizes breast cancer cells to the dual ErbB receptor tyrosine kinase inhibitor lapatinib (GW572016).
Inhibition of focal adhesion kinase by antisense oligonucleotides enhances the sensitivity of breast cancer cells to camptothecins.
Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells.
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Inhibition of SYK kinase does not confer a pro-proliferative or pro-invasive phenotype in breast epithelium or breast cancer cells.
Inhibition of transforming growth factor beta signaling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2.
Inhibitors of growth factor signalling.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.
Interaction between Brk kinase and insulin receptor substrate-4.
Interaction of proliferation cell nuclear antigen (PCNA) with c-Abl in cell proliferation and response to DNA damages in breast cancer.
Interaction of the non-phosphorylated peptide G7-18NATE with Grb7-SH2 domain requires phosphate for enhanced affinity and specificity.
Interactions of STAP-2 with Brk and STAT3 participate in cell growth of human breast cancer cells.
Interleukin-1? activates focal adhesion kinase and Src to induce matrix metalloproteinase-9 production and invasion of MCF-7 breast cancer cells.
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Intramitochondrial Src kinase links mitochondrial dysfunctions and aggressiveness of breast cancer cells.
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Involvement of focal adhesion kinase in inhibition of motility of human breast cancer cells by sphingosine 1-phosphate.
Involvement of Lyn and the Atypical Kinase SgK269/PEAK1 in a Basal Breast Cancer Signaling Pathway.
Involvement of STAP-2 in Brk-mediated phosphorylation and activation of STAT5 in breast cancer cells.
Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells.
Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Is telomerase reactivation associated with the down-regulation of TGF beta receptor-II expression in human breast cancer?
Is there an association with phosphorylation and dephosphorylation of Src kinase at tyrosine 530 and breast cancer patient disease-specific survival.
JAK2, STAT3 and SOCS3 gene expression in women with and without breast cancer.
Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression.
Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor ? positive breast cancer.
Lack of interaction between ErbB2 and insulin receptor substrate signaling in breast cancer.
Leptin induces upregulation of sphingosine kinase 1 in oestrogen receptor-negative breast cancer via Src family kinase-mediated, janus kinase 2-independent pathway.
LINC00520 is induced by Src, STAT3, and PI3K and plays a functional role in breast cancer.
Lipid raft specific knockdown of SRC family kinase activity inhibits cell adhesion and cell cycle progression of breast cancer cells.
Logic-based analysis of gene expression data predicts association between TNF, TGFB1 and EGF pathways in basal-like breast cancer.
Long non-coding RNA (lncRNA) transcriptional landscape in breast cancer identifies LINC01614 as non-favorable prognostic biomarker regulated by TGF? and focal adhesion kinase (FAK) signaling.
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Low expression of BMPRIB indicates poor prognosis of breast cancer and is insensitive to taxane-anthracycline chemotherapy.
Low expression of PTK6/Brk predicts poor prognosis in patients with laryngeal squamous cell carcinoma.
Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.
Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism.
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK.
Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.
Metabolic oxidative stress activates signal transduction and gene expression during glucose deprivation in human tumor cells.
Microparticles Mediate the Intercellular Regulation of microRNA-503 and Proline-Rich Tyrosine Kinase 2 to Alter the Migration and Invasion Capacity of Breast Cancer Cells.
MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway.
MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2?16 mediated breast tumorigenesis and reverse trastuzumab resistance.
miR-101 promotes breast cancer cell apoptosis by targeting Janus kinase 2.
miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells.
Mislocalization of cell-cell adhesion complexes in tamoxifen-resistant breast cancer cells with elevated c-Src tyrosine kinase activity.
Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines.
Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients.
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Molecular characterization of human breast tumor vascular cells.
Molecular oncology: current trends in diagnostics.
Monitoring Src status after dasatinib treatment in HER2+ breast cancer with 89Zr-trastuzumab PET imaging.
MUC16 induced rapid G2/M transition via interactions with JAK2 for increased proliferation and anti-apoptosis in breast cancer cells.
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Myoferlin Depletion Elevates Focal Adhesion Kinase and Paxillin Phosphorylation and Enhances Cell-Matrix Adhesion in Breast Cancer Cells.
N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells.
N-cadherin mediates the migration of bone marrow-derived mesenchymal stem cells toward breast tumor cells.
Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis.
Novel endocrine therapies in breast cancer.
Novel estrogen receptor-alpha binding sites and estradiol target genes identified by chromatin immunoprecipitation cloning in breast cancer.
Nuclear p120-catenin contributes to anoikis resistance of Lobular Breast Cancer through Kaiso-dependent Wnt11 expression.
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Oleic acid induces ERK1/2 activation and AP-1 DNA binding activity through a mechanism involving Src kinase and EGFR transactivation in breast cancer cells.
Oleic acid promotes migration on MDA-MB-231 breast cancer cells through an arachidonic acid-dependent pathway.
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone.
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.
Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts.
Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells.
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.
Overcoming resistance to fulvestrant (ICI182,780) by Downregulating the c-ABL Proto-Oncogene in breast cancer.
Overcoming Resistance to Targeted Therapies in Cancer.
Overexpression of PTK6 (breast tumor kinase) protein--a prognostic factor for long-term breast cancer survival--is not due to gene amplification.
Overexpression of RhoA-GTP induces activation of the Epidermal Growth Factor Receptor, dephosphorylation of focal adhesion kinase and increased motility in breast cancer cells.
p130Cas interacts with estrogen receptor alpha and modulates non-genomic estrogen signaling in breast cancer cells.
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Paradoxes of the EphB4 receptor in cancer.
PARP regulates TGF-beta receptor type II expression in estrogen receptor-positive breast cancer cell lines.
Parthenolide Covalently Targets and Inhibits Focal Adhesion Kinase in Breast Cancer Cells.
Partial agonistic effect of cetuximab on epidermal growth factor receptor and Src kinase activation in triple?negative breast cancer cell lines.
PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells.
PEAK1 Acts as a Molecular Switch to Regulate Context-Dependent TGF? Responses in Breast Cancer.
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
Peripheral T lymphocytes from women with breast cancer exhibit abnormal protein expression of several signaling molecules.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Phosphoproteomic Analysis Identifies Focal Adhesion Kinase 2 (FAK2) as a Potential Therapeutic Target for Tamoxifen Resistance in Breast Cancer.
Phosphorylation of focal adhesion kinase promotes extravasation of breast cancer cells.
Physical Intimacy of Breast Cancer Cells with Mesenchymal Stem Cells Elicits Trastuzumab Resistance through Src Activation.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Polymorphisms associated with oral clefts as potential susceptibility markers for oral and breast cancer.
Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer.
Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin.
Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.
Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase.
Progesterone receptor enhances breast cancer cell motility and invasion via extranuclear activation of focal adhesion kinase.
Progesterone receptor isoforms PRA and PRB differentially contribute to breast cancer cell migration through interaction with focal adhesion kinase complexes.
Prognostic and clinical significance of focal adhesion kinase expression in breast cancer: A systematic review and meta-analysis.
Prognostic Significance of Focal Adhesion Kinase in Node-Negative Breast Cancer.
Prognostic value of ephrin B receptors in breast cancer: An online survival analysis using the microarray data of 3,554 patients.
Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy.
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Prognostic versus predictive value of biomarkers in oncology.
Prolactin stimulates the JAK2 and focal adhesion kinase pathways in human breast carcinoma T47-D cells.
Protein kinases in human breast cancer.
Protein tyrosine kinase 6 mediates TNF?-induced endothelial barrier dysfunction.
Protein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestine.
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Protein-tyrosine Phosphatase and Kinase Specificity in Regulation of SRC and Breast Tumor Kinase.
PTK6/BRK is expressed in the normal mammary gland and activated at the plasma membrane in breast tumors.
PTPL1/PTPN13 regulates breast cancer cell aggressiveness through direct inactivation of Src kinase.
Putting the BRK on breast cancer: From molecular target to therapeutics.
Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells.
PYK2 integrates growth factor and cytokine receptors signaling and potentiates breast cancer invasion via a positive feedback loop.
PYK2 promotes HER2-positive breast cancer invasion.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Quantitative proteomics and transcriptomics addressing the estrogen receptor subtype-mediated effects in T47D breast cancer cells exposed to the phytoestrogen genistein.
Radiation promotes malignant phenotypes through SRC in breast cancer cells.
RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion.
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness.
Reactivation of Syk gene by AZA suppresses metastasis but not proliferation of breast cancer cells.
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Reciprocal regulation of Abl and receptor tyrosine kinases.
Reconstruction of Different Modes of WNT Dependent Protein Networks from Time Series Protein Quantification.
Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells.
Reduced expression of the murine HLA-G homolog Qa-2 is associated with malignancy, epithelial-mesenchymal transition and stemness in breast cancer cells.
Regulated association of protein kinase B/Akt with breast tumor kinase.
Regulation of focal adhesion kinase activation, breast cancer cell motility, and amoeboid invasion by the RhoA guanine nucleotide exchange factor Net1.
Relative levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206 as potential molecular markers to evaluate grade, receptor status and molecular type in breast cancer.
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Requirement of ER? and basal activities of EGFR and Src kinase in Cd-induced activation of MAPK/ERK pathway in human breast cancer MCF-7 cells.
Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type II receptor in human breast cancer cells.
Retinoic acid increases tyrosine phosphorylation of focal adhesion kinase and paxillin in MCF-7 human breast cancer cells.
Role of breast tumour kinase in the in vitro differentiation of HaCaT cells.
Role of c-Myb during prolactin-induced signal transducer and activator of transcription 5a signaling in breast cancer cells.
Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
Role of LOXs and COX-2 on FAK activation and cell migration induced by linoleic acid in MDA-MB-231 breast cancer cells.
Role of microRNA-150-5p/SRCIN1 axis in the progression of breast cancer.
Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Role of the Brk SH3 domain in substrate recognition.
RRR-alpha-tocopheryl succinate enhances TGF-beta 1, -beta 2, and -beta 3 and TGF-beta R-II expression by human MDA-MB-435 breast cancer cells.
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1? pathways in breast cancer.
Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells.
Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
SHPS-1: a budding molecule against cancer dissemination.
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Signaling pathway of globo-series glycosphingolipids and ?1,3-galactosyltransferase V (?3GalT5) in breast cancer.
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain.
Somatic acquisition and signaling of TGFBR1*6A in cancer.
Sortilin is associated with breast cancer aggressiveness and contributes to tumor cell adhesion and invasion.
Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
Specific induction of pp125 focal adhesion kinase in human breast cancer.
Spleen tyrosine kinase (SYK) inhibitor PRT062607 protects against ovariectomy-induced bone loss and breast cancer-induced bone destruction.
Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survival.
Sporadic mutations and expression analysis of spleen tyrosine kinase gene in breast cancer: a preliminary report.
SRC as a therapeutic target in breast cancer.
Src family kinases mediate epidermal growth factor receptor signaling from lipid rafts in breast cancer cells.
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Src inhibitors in breast cancer therapy.
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
Src kinase regulates metalloproteinase-9 secretion induced by type IV collagen in MCF-7 human breast cancer cells.
Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer.
Src phosphorylates Tyr284 in TGF-beta type II receptor and regulates TGF-beta stimulation of p38 MAPK during breast cancer cell proliferation and invasion.
SRC promotes lipogenesis: implications for obesity and breast cancer.
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation.
Star-related lipid transfer protein 10 (STARD10): a novel key player in alcohol-induced breast cancer progression.
Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer.
STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner.
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
SWIM domain protein ZSWIM4 is required for JAK2 inhibition resistance in breast cancer.
Syk, a protein-tyrosine kinase, suppresses the cell motility and nuclear factor kappa B-mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3'-kinase activity in breast cancer cells.
Syndecan-1 modulates ?-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation.
Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor?positive, human epidermal growth factor receptor 2?positive breast cancer cells.
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Synthesis, Src Kinase Inhibitory and Anticancer Activities of 1-Substituted 3-(N-Alkyl-N-phenylamino)propane-2-ols.
TAD1822-7 induces ROS-mediated apoptosis of HER2 positive breast cancer by decreasing E-cadherin in an EphB4 dependent manner.
TAE226-induced apoptosis in breast cancer cells with overexpressed Src or EGFR.
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
Targeting focal adhesion kinase in ER+/HER2+ breast cancer improves trastuzumab response.
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib.
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells.
TGF-? stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
TGF-beta induces formation of F-actin cores and matrix degradation in human breast cancer cells via distinct signaling pathways.
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development.
TGF? isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications.
TGFB1 and TGFBR1 polymorphisms and breast cancer risk in the Nurses' Health Study.
TGFBR1 polymorphism and risk of breast cancer in Iranian women.
TGFBR1 Signaling and Breast Cancer.
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
The Alternative Splice Variant of Protein Tyrosine Kinase 6 Negatively Regulates Growth and Enhances PTK6-Mediated Inhibition of ?-Catenin.
The associated pyrazolopyrimidines PP1 and PP2 inhibit protein tyrosine kinase 6 activity and suppress breast cancer cell proliferation.
The c-Yes 3'-UTR contains adenine/uridine-rich elements that bind AUF1 and HuR involved in mRNA decay in breast cancer cells.
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer [Retraction].
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.
The Concentration of Microvesicles Isolated from Peripheral Blood in Breast Cancer Patients is Elevated.
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways.
The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
The lysyl oxidase pro-peptide attenuates fibronectin-mediated activation of focal adhesion kinase and p130Cas in breast cancer cells.
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study.
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.
The RNA binding protein Sam68 is acetylated in tumor cell lines, and its acetylation correlates with enhanced RNA binding activity.
The role of EphB4 and IGF-IR expression in breast cancer cells.
The role of insulin receptor substrate-1 in transformation by v-src.
The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells.
The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer.
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
The Syk Kinase Promotes Mammary Epithelial Integrity and Inhibits Breast Cancer Invasion by Stabilizing the E-Cadherin/Catenin Complex.
The Syk tyrosine kinase localizes to the centrosomes and negatively affects mitotic progression.
The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.
The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.
Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019.
TNF?/IFN? Mediated Intestinal Epithelial Barrier Dysfunction Is Attenuated by MicroRNA-93 Downregulation of PTK6 in Mouse Colonic Epithelial Cells.
Tracing the footprints of the breast cancer oncogene BRK - Past till present.
TRAF3 in T Cells Restrains Negative Regulators of LAT to Promote TCR/CD28 Signaling.
Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression.
Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.
TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.
Tyrosine kinase p56lck regulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkappaBalpha following hypoxia/reoxygenation.
Tyrosine kinase, p56lck-induced cell motility, and urokinase-type plasminogen activator secretion involve activation of epidermal growth factor receptor/extracellular signal regulated kinase pathways.
Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells.
Tyrosine phosphorylation of sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression.
Tyrosine Phosphorylation Profiling Reveals the Signaling Network Characteristics of Basal Breast Cancer Cells.
Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation.
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Viewing the Eph receptors with a focus on breast cancer heterogeneity.
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
WNT11 is a direct target of early growth response protein 1.
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
[Construction of the eukaryotic expression vector of human syk and its effect on MHC-I expression of human breast cancer cells.]
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
[Effect of Janus kinase inhibitor AG490 on invasion and metastasis of human breast cancer cells]
[Effect of SRC Kinase on Adriamycin Resistance and Invasion and Metastasis in Human Breast Cancer Cells].
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
[Focal adhesion kinase expression and angiogenesis in breast carcinoma]
[Hereditary breast carcinomas pathologist's perspective].
[Janus kinase 3 facilitates the migration of breast cancer cells by store-operated calcium channel].
[Molecular Targeted Therapy and Laboratory Tests].
[PP2 enhances intercellular communication of gap junction in breast cancer Hs578T cells].
[Spleen tyrosine kinase (L) suppresses breast cancer development by downregulating the expression of cyclin D1, ID1, B-myb and Fra1]
Brucellosis
Activation of bovine neutrophils by Brucella spp.
Budd-Chiari Syndrome
Association of factor V Leiden, Janus kinase 2, prothrombin, and MTHFR mutations with primary Budd-Chiari syndrome in Egyptian patients.
Budd-Chiari syndrome.
Janus Kinase 2 Mutation-Associated Budd-Chiari Syndrome Presenting as a Tumor.
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.
Pseudocirrhosis in Chronic Budd Chiari Syndrome With Janus Tyrosine Kinase 2 (JAK2) Mutation.
Burkitt Lymphoma
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
Antitumor activity of new pyrazolo[3,4-d]pyrimidine SRC kinase inhibitors in Burkitt lymphoma cell lines and its enhancement by WEE1 inhibition.
c-Ha-ras1 is not deleted in aniridia-Wilms' tumour association.
Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
Cell cycle-dependent modulation of alpha-interferon-inducible gene expression and activation of signaling components in Daudi cells.
Expression of p56lck in B-cell neoplasias.
Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
In defense of the somatic mutation theory of cancer.
Purification and characterization of proteins with associated tyrosine protein kinase activity from human B lymphocytes.
Rearrangements of c-myc and c-abl genes in tumour cells in Burkitt's lymphoma.
Resistance to TGF-beta1 correlates with a reduction of TGF-beta type II receptor expression in Burkitt's lymphoma and Epstein-Barr virus-transformed B lymphoblastoid cell lines.
Some questions on the significance of chromosome alterations in leukemias and lymphomas: a review.
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
Bursitis
Genetic variants involved in extracellular matrix homeostasis play a role in the susceptibility to frozen shoulder: a case-control study.
Candidiasis
Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects.
Candidiasis, Chronic Mucocutaneous
Mendelian traits causing susceptibility to mucocutaneous fungal infections in human subjects.
Carcinogenesis
"Masked" Ph1-chromosome in chronic myelogenous leukaemia (CML).
17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
A common phosphotyrosine signature for the Bcr-Abl kinase.
A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population.
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
A mutation at the major phosphotyrosine in pp60v-src alters oncogenic potential.
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
A requirement for SOCS-1 and SOCS-3 phosphorylation in Bcr-Abl-induced tumorigenesis.
A Swiss 3T3 variant cell line resistant to the effects of tumor promoters cannot be transformed by src.
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Abelson kinase's intrinsically disordered region plays essential roles in protein function and protein stability.
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
Acacetin and pinostrobin as a promising inhibitor of cancer-associated protein kinases.
Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors.
Activation of abl family kinases in solid tumors.
Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src.
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice.
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
ADAM9 as a potential target molecule in cancer.
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
AGO2 phosphorylation by c-Src kinase promotes tumorigenesis.
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1.
Analysis of microsatellite instability and loss of heterozygosity in uterine endometrial adenocarcinoma.
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
BCR-ABL oncogenic transformation of NIH 3T3 fibroblasts requires the IL-3 receptor.
Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice.
Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
c-Abl in oxidative stress, aging and cancer.
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
c-Abl: activation and nuclear targets.
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression.
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1.
Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Comparative genomics on Wnt5a and Wnt5b genes.
Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer.
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy.
Csk-binding protein (Cbp) negatively regulates epidermal growth factor-induced cell transformation by controlling Src activation.
Cucurbitacin B inhibits cell proliferation and induces apoptosis in human osteosarcoma cells via modulation of the JAK2/STAT3 and MAPK pathways.
CXCR7 promotes melanoma tumorigenesis via Src kinase signaling.
Cyclin-dependent kinase 1-mediated phosphorylation of YES links mitotic arrest and apoptosis during antitubulin chemotherapy.
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Decreased expression of JAK1 associated with immune infiltration and poor prognosis in lung adenocarcinoma.
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Dehydrocrenatidine is a novel janus kinase inhibitor.
Development of TGF-beta resistance during malignant progression.
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Differential regulation of cell motility and invasion by FAK.
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Discovery and evaluation of triple inhibitors of VEGFR-2, TIE-2 and EphB4 as anti-angiogenic and anti-cancer agents.
Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
Disruption of postnatal folliculogenesis and development of ovarian tumor in a mouse model with aberrant transforming growth factor beta signaling.
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Dominant effects of the bcr-abl oncogene on Drosophila morphogenesis.
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
Effect of ets-related transcription factor (ERT) on transforming growth factor (TGF)-beta type II receptor gene expression in human cancer cell lines.
Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Emerging Roles of Wnt Ligands in Human Colorectal Cancer.
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Enhancement of tyrosyl phosphorylation and protein expression of eps8 by v-Src.
EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways.
Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis.
Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Examination of the role of CSF-1 independence in myc retrovirus induced monocyte tumorigenesis.
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Expression of c-Ki-ras, c-Ha-ras, and c-myc in specific cell types during hepatocarcinogenesis.
Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Expression of STAT3 and Bcl-6 oncoprotein in sodium arsenite-treated SV-40 immortalized human uroepithelial cells.
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Flavonoids as Protein Kinase Inhibitors for Cancer Chemoprevention: Direct Binding and Molecular Modeling.
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Focal Adhesion Kinase Expression in Ameloblastoma: A Preliminary Observational Study.
Focal Adhesion Kinase Fine Tunes Multifaced Signals toward Breast Cancer Progression.
Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling.
Focal adhesion kinase overexpression and its impact on human osteosarcoma.
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
From tumorigenesis to microenvironment and immunoregulation: the many faces of focal adhesion kinase and challenges associated with targeting this elusive protein.
From xeroderma pigmentosum to the biological clock contributions of Dirk Bootsma to human genetics.
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.
Genetic engineering to study testicular tumorigenesis.
Genomic amplification upregulates estrogen-related receptor alpha and its depletion inhibits oral squamous cell carcinoma tumors in vivo.
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Hepatitis C virus NS5A protein interacts with and negatively regulates the non-receptor protein tyrosine kinase Syk.
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
High expression of long non-coding RNA H19 is required for efficient tumorigenesis induced by Bcr-Abl oncogene.
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Imaging focal adhesion kinase activation in breast cancer-promoting cell proliferation and carcinogenesis, but not migration, invasion, or metastatic predilection.
Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Important players in carcinogenesis as potential targets in cancer therapy: an update.
In vitro phosphorylation of caveolin-rich membrane domains: identification of an associated serine kinase activity as a casein kinase II-like enzyme.
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
Increased expression of focal adhesion kinase correlates with cellular proliferation and apoptosis during 4-nitroquinoline-1-oxide-induced rat tongue carcinogenesis.
Increased expression of miR-551a by c-Fos reduces Focal Adhesion Kinase (FAK) levels and blocks tumorigenesis.
Increased immunoreactivity and protein tyrosine kinase activity of the protooncogene pp60c-src in preneoplastic lesions in rat pancreas.
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis.
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130.
Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
Liver tyrosine kinase activation during early stages of chemical hepatocarcinogenesis.
Liver-specific expressions of HBx and src in the p53 mutant trigger hepatocarcinogenesis in zebrafish.
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Lymph node metastasis is mediated by suppressor of cytokine signaling-3 in gastric cancer.
Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis.
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
Mapping of hereditary mixed polyposis syndrome (HMPS) to chromosome 10q23 by genomewide high-density single nucleotide polymorphism (SNP) scan and identification of BMPR1A loss of function.
mDia1 targets v-Src to the cell periphery and facilitates cell transformation, tumorigenesis, and invasion.
Mdm2 phosphorylation by Akt regulates the p53 response to oxidative stress to promote cell proliferation and tumorigenesis.
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Microsatellite alteration at chromosome 11 in primary human nasopharyngeal carcinoma in Taiwan.
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
Microsatellite instability(MSI) in non-small cell lung cancer(NSCLC) is highly associated with transforming growth factor-beta type II receptor(TGF-beta RII) frameshift mutation.
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
MiR-203 regulates JAK-STAT pathway in affecting pancreatic cancer cells proliferation and apoptosis by targeting SOCS3.
MiR-221 inhibits proliferation of pancreatic cancer cells via down regulation of SOCS3.
MiR-340 affects gastric cancer cell proliferation, cycle, and apoptosis through regulating SOCS3/JAK-STAT signaling pathway.
miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
MLKL inhibits intestinal tumorigenesis by suppressing STAT3 signaling pathway.
Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandins production during colon carcinogenesis in male F344 rats.
Molecular cloning and characterization of human WNT11.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice.
Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis.
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Myristoylation of Src kinase mediates Src induced and high fat diet accelerated prostate tumor progression in mice.
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Novel insights into c-Src.
Over-Expression of Ephb4 Is Associated with Carcinogenesis of Gastric Cancer.
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Overexpression of cellular Src in fibroblasts enhances endocytic internalization of epidermal growth factor receptor.
p53 regulates FAK expression in human tumor cells.
Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Paradoxes of the EphB4 receptor in cancer.
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer.
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Phosphorylation of Dok1 by Abl family kinases inhibits CrkI transforming activity.
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Preclinical efficacy for a novel tyrosine kinase inhibitor, ArQule 531 against acute myeloid leukemia.
Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.
Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients.
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Protein tyrosine kinase 6 regulates mammary gland tumorigenesis in mouse models.
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors.
Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.
Quantitative modeling of chronic myeloid leukemia: insights from radiobiology.
RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Redox Circuitries Driving Src Regulation.
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma.
Role of cyclooxygenase 2 in protein kinase C beta II-mediated colon carcinogenesis.
Role of erbB3 receptors in cancer therapeutic resistance.
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Role of Pyk2 in Human Cancers.
Role of SRC kinases in Neu-induced tumorigenesis: challenging the paradigm using Csk homologous kinase transgenic mice.
Roles of Src family kinase, Ras, and mTOR signaling in intestinal epithelial homeostasis and tumorigenesis.
Selective elimination of cancer cells by the adenovirus E4orf4 protein in a Drosophila cancer model: a new paradigm for cancer therapy.
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes.
Src SUMOylation Inhibits Tumor Growth Via Decreasing FAK Y925 Phosphorylation.
SSeCKS/Gravin/AKAP12 attenuates expression of proliferative and angiogenic genes during suppression of v-Src-induced oncogenesis.
STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor.
Structural and biophysical characterization of the EphB4*ephrinB2 protein-protein interaction and receptor specificity.
Structure and chromosomal localization of the human gene of the phosphotyrosyl phosphatase activator (PTPA) of protein phosphatase 2A.
Structure and regulation of the c-Fes protein-tyrosine kinase.
Structure, regulation, signaling, and targeting of abl kinases in cancer.
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Suppression of protein tyrosine phosphatase N23 predisposes to breast tumorigenesis via activation of FYN kinase.
Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis.
Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.
Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Targeting the JAK/STAT Signaling Pathway Using Phytocompounds for Cancer Prevention and Therapy.
TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition.
TGF-beta signaling is disrupted in endometrioid-type endometrial carcinomas.
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
The calpain system and cancer.
The contrasting oncogenic and tumor suppressor roles of FES.
The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication.
The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC).
The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis.
The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia.
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
The genomic structure of the gene encoding the human transforming growth factor beta type II receptor (TGF-beta RII).
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
The nonreceptor tyrosine kinase c-Src attenuates SCF(?-TrCP) E3-ligase activity abrogating Taz proteasomal degradation.
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
The receptor-like protein tyrosine phosphatase alpha: a role in cell proliferation and oncogenesis.
The Role of Focal Adhesion Kinase in Lung Cancer.
The Role of STAT3 in Thyroid Cancer.
The Src Family Kinase Inhibitors PP2 and PP1 block TGF-beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-beta Receptors.
The SRC-family tyrosine kinase HCK shapes the landscape of SKAP2 interactome.
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes.
Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-beta signaling and metastasis.
Therapy-related chronic myeloid leukemia: an epidemiological, clinical and pathogenetic appraisal.
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Thymic tumorigenesis induced by overexpression of p56lck.
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2.
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Transforming growth factor-beta receptor type 2 mutations and microsatellite instability in sporadic colorectal adenomas and carcinomas.
Transforming Growth Factor-beta Receptors: Role in Physiology and Disease.
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis.
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
Tumour induction by activated abl involves tyrosine phosphorylation of the product of the cbl oncogene.
Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DNA mismatch repair.
Tyrosine phosphorylation of growth factor receptor-bound protein-7 by focal adhesion kinase in the regulation of cell migration, proliferation, and tumorigenesis.
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Vitamin D Receptor Protects Against Dysbiosis and Tumorigenesis via the JAK/STAT Pathway in Intestine.
While at Rome miRNA and TRAIL do whatever BCR-ABL commands to do.
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
[Effect of spleen tyrosine kinase expression re-activation by inhibition of DNA methylation on oncogenesis growth of gastric cancer]
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
[Human mismatch repair genes and HNPCC]
[Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
[The characteristics of focal adhesion kinase (FAK) and its role in carcinogenesis]
Carcinoid Tumor
Focal Adhesion Kinase, a Downstream Mediator of Raf-1 Signaling, Suppresses Cellular Adhesion, Migration, and Neuroendocrine Markers in BON Carcinoid Cells.
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Carcinoma
15-Deoxy-?12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
3-substitued indoles: one-pot synthesis and evaluation of anticancer and Src kinase inhibitory activities.
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.
A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells.
A differential effect of the Walker 256 carcinoma on the tyrosine protein kinase activity of liver plasma membrane domains.
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
A Luminacin D Analog HL142 Inhibits Ovarian Tumor Growth and Metastasis by Reversing EMT and Attenuating the TGF? and FAK Pathways.
A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
A role for focal adhesion kinase in hyluronan-dependent MMP-2 secretion in a human small-cell lung carcinoma cell line, QG90.
A transmembrane-anchored chimeric focal adhesion kinase is constitutively activated and phosphorylated at tyrosine residues identical to pp125FAK.
A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas.
Abl kinases are required for invadopodia formation and chemokine-induced invasion.
Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer.
Actin disruption inhibits bombesin stimulation of focal adhesion kinase (pp125FAK) in prostate carcinoma.
Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR/S6 signaling pathway in an ERK1/2-independent manner.
Activation of pp60c-src protein kinase activity in human colon carcinoma.
Activation of Src mediates acquired cisplatin resistance in human lung carcinoma cells.
Activation of Src tyrosine kinase in esophageal carcinoma cells in different regulatory environments and corresponding occurrence mechanism.
Activation of the focal adhesion kinase signal transduction pathway in cervical carcinoma cell lines and human genital epithelial cells immortalized with human papillomavirus type 18.
Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis.
Activation of the protein-tyrosine kinase associated with the bombesin receptor complex in small cell lung carcinomas.
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Adhesion systems in normal breast and in invasive breast carcinoma.
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells.
Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Alterations of the cytoskeletal organization in tumor cell lines by a cardiotonic drug, vesnarinone, through protein tyrosine phosphorylation.
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
Amplification of N-myc oncogene in human melanoma cells.
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma.
An intronic variant of the TGFBR1 gene is associated with carcinomas of the kidney and bladder.
Androgen deprivation modulates gene expression profile along prostate cancer progression.
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Ascorbate up-regulates MLH1 (Mut L homologue-1) and p73: implications for the cellular response to DNA damage.
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
B lymphocytes repress hepatic tumorigenesis but not development in Hras12V transgenic mice.
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer.
Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma.
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
c-Abl expression in oral squamous cell carcinomas.
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
c-Src kinase activity is required for hepatocyte growth factor-induced motility and anchorage-independent growth of mammary carcinoma cells.
c-Yes tyrosine kinase activity in human colon carcinoma.
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling.
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Caveolin-1 phosphorylation in human squamous and epidermoid carcinoma cells: dependence on ErbB1 expression and Src activation.
Cell directional migration and oriented division on three-dimensional laser-induced periodic surface structures on polystyrene.
Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis.
Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck.
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Chrysin serves as a novel inhibitor of DGK?/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC).
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.
Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Clinical significance of focal adhesion kinase in resectable pancreatic cancer.
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Coexpression of ephrin-Bs and their receptors in colon carcinoma.
Comparative analysis of a panel of biomarkers related to protein phosphatase 2A between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Correction: Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy.
Correction: Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043.
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.
Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion.
DDR2 overexpression in oral squamous cell carcinoma is associated to lymph node metastasis.
Decreased expression of focal adhesion kinase is associated with a poor prognosis in extrahepatic bile duct carcinoma.
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Decreased Stability of Transforming Growth Factor beta Type II Receptor mRNA in RER+ Human Colon Carcinoma Cells
Decreased stability of transforming growth factor beta type II receptor mRNA in RER+ human colon carcinoma cells.
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion.
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Differential pp60c-src activity in well and poorly differentiated human colon carcinomas and cell lines.
Differentiation of normal and cancer cells induced by sulfhydryl reduction: biochemical and molecular mechanisms.
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus.
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Disruption of Ca2+-dependent cell-matrix adhesion enhances c-Src kinase activity, but causes dissociation of the c-Src/FAK complex and dephosphorylation of tyrosine-577 of FAK in carcinoma cells.
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma.
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Down-Regulation of miR-2053 Inhibits the Development and Progression of Esophageal Carcinoma by Targeting Fyn-Related Kinase (FRK).
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Dual regulation of Myc by Abl.
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Early events in the antiproliferative action of tumor necrosis factor are similar to the early events in epidermal growth factor growth stimulation.
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
EGF-R signaling through Fyn kinase disrupts the function of integrin alpha6beta4 at hemidesmosomes: role in epithelial cell migration and carcinoma invasion.
EGFR-dependent tyrosine phosphorylation of integrin ?4 is not required for downstream signaling events in cancer cell lines.
Elevated c-Src and c-Yes expression in malignant skin cancers.
Elevated expression of pp60c-src in low grade human bladder carcinoma.
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Enhanced tumorigenesis and reduced transforming growth factor-beta type II receptor in lung tumors from mice with reduced gene dosage of transforming growth factor-beta1.
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Eps8 controls Src- and FAK-dependent phenotypes in squamous carcinoma cells.
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues. High levels of serum activin A in women with endometrial and cervical carcinoma.
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms.
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Expression of EphB4 in head and neck squamous cell carcinoma.
Expression of focal adhesion kinase and alpha5 and beta1 integrins in carcinomas and its clinical significance.
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Expression of focal adhesion kinase in small-cell lung carcinoma.
Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.
Expression of p73 and c-Abl proteins in human ovarian carcinomas.
Expression of paxillin and FAK mRNA and the related clinical significance in esophageal carcinoma.
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Expression of the gene coding for the light chain of calpactin I (annexin II) in cell lines DiFi, HT-29, and WI-38.
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma.
Expression of Wnt11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance.
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Extensive alteration in the expression profiles of TGFB pathway signaling components and TP53 is observed along the gastric dysplasia-carcinoma sequence.
Extracellular engagement of ADAM12 induces clusters of invadopodia with localized ectodomain shedding activity.
Features of multiple self-healing squamous epithelioma and Loeys-Dietz syndrome in a patient with a novel TGFBR1 variant.
First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Focal adhesion kinase as a marker of malignant phenotype in breast and cervical carcinomas.
Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids.
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Fusobacteria modulate oral carcinogenesis and promote cancer progression.
Gastric carcinomas with microsatellite instability: clinical features and mutations to the TGF-beta type II receptor, IGFII receptor, and BAX genes.
Gastrin-stimulated G?13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells.
Genetic alterations involved in the development of gallbladder carcinomas from Greek patients.
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor.
Growth factor regulation of integrin-mediated cell motility.
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Hepatic silicosis, cirrhosis, and liver tumors in mice and hamsters: studies of transforming growth factor beta expression.
Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells.
HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Histochemical staining of protein-tyrosine phosphatase activity in primary human mammary carcinoma: relationship with established prognostic indicators.
HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.
Human pancreatic tumor cells are sensitized to ionizing radiation by knockdown of caveolin-1.
Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling.
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Immunohistochemical expression of TGF beta (TGF-?), TGF beta receptor 1 (TGFBR1), and Ki67 in intestinal variant of gastric adenocarcinomas.
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.
In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G.
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Inhibition of cell growth and upregulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the SRC/ABL inhibitor dasatinib.
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.
Inhibition of focal adhesion kinase induces apoptosis in human gastric carcinoma cells (SGC-7901).
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Inhibition of protein FAK enhances 5-FU chemosensitivity to gastric carcinoma via p53 signaling pathways.
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Inhibition of tumor growth and angiogenesis by soluble EphB4.
Integrin alpha2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway.
Interleukin-6 upregulates SOX18 expression in osteosarcoma.
Interleukin4R? (IL4R?) and IL13R?1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
Involvement of c-Src in carcinoma cell motility and metastasis.
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Ionizing radiation modules of the expression and tyrosine phosphorylation of the focal adhesion-associated proteins focal adhesion kinase (FAK) and its substrates p130cas and paxillin in A549 human lung carcinoma cells in vitro.
Isolation of v-fms and its human cellular homolog.
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth.
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance.
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Localization of transforming growth factor-beta1 and type II receptor in developing normal human prostate and carcinoma tissues.
Loss of desmoglein-2 promotes gallbladder carcinoma progression and resistance to EGFR-targeted therapy through Src kinase activation.
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks.
Mechanisms responsible for signaling and functional defects.
Microsatellite instability in the adenoma-carcinoma sequence of the stomach.
Microsatellite instability-associated mutations associate preferentially with the intestinal type of primary gastric carcinomas in a high-risk population.
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma.
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling.
Molecular cloning and characterization of human WNT11.
Morphology of ras-transformed cells becomes apparently normal again with tyrosine kinase inhibitors without a decrease in the ras-GTP complex.
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage.
Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway.
Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9.
Multiple Self-Healing Squamous Epithelioma (MSSE): Rare Variants in an Adjacent Region of Chromosome 9q22.3 to Known TGFBR1 Mutations Suggest a Digenic or Multilocus Etiology.
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
N- and C-terminal isoforms of Arg quantified by real-time PCR are specifically expressed in human normal and neoplastic cells, in neoplastic cell lines, and in HL-60 cell differentiation.
New drugs in thyroid cancer.
Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Oncogenic transformation of human mammary epithelial cells by autocrine human growth hormone.
One-pot regioselective synthesis of tetrahydroindazolones and evaluation of their antiproliferative and Src kinase inhibitory activities.
Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma.
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.
p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.
p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Pleiotrophin exerts its migration and invasion effect through the neuropilin-1 pathway.
Ponicidin induces apoptosis via JAK2 and STAT3 signaling pathways in gastric carcinoma.
pp60c-src activation in human colon carcinoma.
Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization.
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis.
Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway.
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation.
Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells.
Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.
Regulation of the PH-domain-containing tyrosine kinase Etk by focal adhesion kinase through the FERM domain.
Regulation of the Src tyrosine kinase and Syp tyrosine phosphatase by their cellular association.
Regulation of vascular endothelial growth factor expression in human colon carcinoma cells by activity of src kinase.
Relationship between grade of microsatellite instability and target genes of mismatch repair pathways in sporadic colorectal carcinoma.
Repression of transforming growth factor-beta receptor type I promoter expression by Sp1 deficiency.
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Retraction: Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Reverse signaling through membrane-bound interleukin-15.
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice.
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK.
Signal transduction through extracellular signal-regulated kinase-like pp57 blocked in differentiated colon carcinoma cells having low levels of c-src kinase.
Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma.
SNU cell lines and their application for cancer research.
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase.
Src inhibitors are promising therapy molecules for human cervical carcinomas.
SRC is dephosphorylated at tyrosine 530 in human colon carcinomas.
Src kinase contributes to the metastatic spread of carcinoma cells.
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Src Plays a Key Role in ADAM28 Expression in v-src-Transformed Epithelial Cells and Human Carcinoma Cells.
Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Taiwan cobra cardiotoxin III inhibits Src kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma Ca9-22 cells.
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
Targeting Src in Mucinous Ovarian Carcinoma.
TGF-? Signal Transduction in Pancreatic Carcinoma Cells is Sensitive to Inhibition by the Src Tyrosine Kinase Inhibitor AZM475271.
TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma.
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites.
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells.
The role of protein tyrosine phosphorylation in integrin-mediated gene induction in monocytes.
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer.
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Transforming growth factor beta regulates cell-cell adhesion through extracellular matrix remodeling and activation of focal adhesion kinase in human colon carcinoma Moser cells.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Transinactivation of the epidermal growth factor receptor tyrosine kinase and focal adhesion kinase phosphorylation by dietary flavonoids: effect on invasive potential of human carcinoma cells.
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Tyrosine protein kinase activity of human hyperplastic prostate and carcinoma cell lines PC3 and DU145.
Unique Mechanism by Which TGFBR1 Variants Cause 2 Distinct System Diseases?- Loeys-Dietz Syndrome and Multiple Self-Healing Squamous Epithelioma.
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis.
Wnt/?-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
Zeylenone inhibits proliferation and promotes apoptosis in ovarian carcinoma cells via Janus kinase 2 / signal transducers and activators of transcription 3 pathways.
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
[BMP7 Signaling via BMPR1A, BMPR1B Inhibits the Proliferation of Lung Large Carcinoma NCI-H460 Cell.]
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
[Effect of focal adhesion kinase on biological characteristics of Tca8113 tongue squamous cell carcinoma]
[Effect of genistein on proliferation of renal cell carcinoma cell line GRC-1 and its influence to p27 expression]
[Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line].
[Effects of genistein on the expressions of cell apoptosis-related proteins in salivary adenoid cystic carcinoma cell line SACC-83]
[Effects of genistein on the expressions of cell cycle proteins in salivary adenoid cystic carcinoma cell line SACC-83.]
[Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]
[Expression and clinical significance of focal adhesion kinase in oral squamous cell carcinoma]
[Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma].
[Expression of focal adhesion kinase in laryngeal carcinoma]
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
[Expression of proline-rich tyrosine kinase-2 (Pyk2) in gastric carcinoma and its significance]
[Functional properties of the WNT11 new isoform, expressed in colon carcinoma cell line HT29].
[Gene expression profiles of protein kinases and phosphatases obtained by hybridization with cDNA arrays: molecular portrait of human prostate carcinoma]
[Hereditary breast carcinomas pathologist's perspective].
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
[Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells]
[Proteomic identification and comparison of differentiation-related proteins in gastric carcinoma cell lines]
[The endothelial podosome]
[The expression and significance of integrin beta1 and focal adhesion kinase and its clinical value in laryngeal carcinoma]
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
[Tyrosine kinases of the Src family, enzymes with multiple functions: from the growth of fibroblasts to the migration of epithelial cells]
Carcinoma in Situ
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinoma, Adenoid Cystic
Expression and clinical significance of FAK, ILK, and PTEN in salivary adenoid cystic carcinoma.
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
[Effects of genistein on the expressions of cell apoptosis-related proteins in salivary adenoid cystic carcinoma cell line SACC-83]
[Effects of genistein on the expressions of cell cycle proteins in salivary adenoid cystic carcinoma cell line SACC-83.]
[Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
Carcinoma, Basal Cell
Elevated c-Src and c-Yes expression in malignant skin cancers.
In situ analysis of transforming growth factors-beta (TGF-beta 1, TGF-beta 2, TGF-beta 3) and TGF-beta type II receptor expression in basal cell carcinomas.
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Carcinoma, Ductal
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinoma, Ehrlich Tumor
A tyrosine-specific protein kinase from Ehrlich ascites tumor cells.
Carcinoma, Embryonal
Changes in c-onc expression during embryonal carcinoma cell differentiation.
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Complexes of gamma-tubulin with nonreceptor protein tyrosine kinases Src and Fyn in differentiating P19 embryonal carcinoma cells.
Differential expression of BMP receptors in early mouse development.
Differential expression of inhibin subunits and follistatin, but not of activin receptor type II, during early murine embryonic development.
Expression of c-src and c-abl in embryonal carcinoma cells and adult mouse tissues.
Regulation of microtubule nucleation from membranes by complexes of membrane-bound gamma-tubulin with Fyn kinase and phosphoinositide 3-kinase.
Syk protein-tyrosine kinase is involved in neuron-like differentiation of embryonal carcinoma P19 cells.
The effects of v-src expression on the differentiation of embryonal carcinoma cells.
Carcinoma, Endometrioid
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Carcinoma, Hepatocellular
ABL1, Overexpressed in Hepatocellular Carcinomas, Regulates Expression of NOTCH1 and Promotes Development of Liver Tumors in Mice.
Abrogation of constitutive STAT3 activity sensitizes human hepatoma cells to TRAIL-mediated apoptosis.
Activation of c-Yes in hepatocellular carcinoma: A preliminary study.
Alterations of the transforming growth factor-beta signaling pathway in hepatocellular carcinomas induced endogenously and exogenously in rats.
Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population.
Auranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3.
c-src tyrosine kinase is associated with the asialoglycoprotein receptor in human hepatoma cells.
Changes in cell ultrastructure and inhibition of JAK1/STAT3 signaling pathway in CBRH-7919 cells with astaxanthin.
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Cloning, mapping, and characterization of the human sorbin and SH3 domain containing 1 (SORBS1) gene: a protein associated with c-Abl during insulin signaling in the hepatoma cell line Hep3B.
Correction: Zheng, L., et al. PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways. Polymers 2018, 10, 1043.
Corrigendum to: miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-? signaling pathway via targeting TGFBR1.
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.
Current understanding of tyrosine kinase BMX in inflammation and its inhibitors.
Cyclic phosphatidic acid inhibits RhoA-mediated autophosphorylation of FAK at Tyr-397 and subsequent tumor-cell invasion.
Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src.
Distinct pathways of genomic progression to benign and malignant tumors of the liver.
Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Enhanced expression of the protein kinase substrate p36 in human hepatocellular carcinoma.
Expression and prognostic significance of focal adhesion kinase in hepatocellular carcinoma.
Expression of Src and FAK in Hepatocellular Carcinoma and the Effect of Src Inhibitors on Hepatocellular Carcinoma In Vitro.
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Expression of Variant Isoforms of the Tyrosine Kinase SYK Determines the Prognosis of Hepatocellular Carcinoma.
Focal Adhesion Kinase (FAK) Over-Expression and Prognostic Implication in Pediatric Hepatocellular Carcinoma.
Focal adhesion kinase activation limits efficacy of Dasatinib in c-Myc driven hepatocellular carcinoma.
Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.
Focal Adhesion Kinase and ?-Catenin Cooperate to Induce Hepatocellular Carcinoma.
Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2.
Focal adhesion kinase is overexpressed in hepatocellular carcinoma and can be served as an independent prognostic factor.
Focal adhesion kinase: important to prostaglandin E2-mediated adhesion, migration and invasion in hepatocellular carcinoma cells.
Focal Adhesion Kinase: Insight into Molecular Roles and Functions in Hepatocellular Carcinoma.
Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma.
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Functions and therapeutic value of focal adhesion kinase signaling during hepatocellular carcinoma development and progression.
Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
Glycosaminoglycans and their synthetic mimetics inhibit RANTES-induced migration and invasion of human hepatoma cells.
Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA.
Hepatitis B virus large surface antigen promotes liver carcinogenesis by activating the Src/PI3K/Akt pathway.
Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.
High expression of Janus kinase 2 in background normal liver tissue of resected hepatocellular carcinoma is associated with worse prognosis.
Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations.
Identification of a human cDNA encoding a novel protein kinase with two repeats of the LIM/double zinc finger motif.
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Identification of p62, a phosphotyrosine independent ligand of p56lck kinase, as a major component of intracytoplasmic hyaline bodies in hepatocellular carcinoma.
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
In silico identification of oncogenic potential of fyn-related kinase in hepatocellular carcinoma.
Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells.
Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
Jianpijiedu fang improves survival of hepatocarcinoma mice by affecting phosphatase and tensin homolog, phosphoinositide 3-kinase, and focal adhesion kinase.
Krüppel?like factor expression and correlation with FAK, MMP?9 and E?cadherin expression in hepatocellular carcinoma.
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-? RII.
Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea.
miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4.
miR-4458 inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing the TGF-? signaling pathway via targeting TGFBR1.
MR-1 modulates proliferation and migration of human hepatoma HepG2 cells through myosin light chains-2 (MLC2)/focal adhesion kinase (FAK)/Akt signaling pathway.
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Overexpression of Abl2 predicts poor prognosis in hepatocellular carcinomas and is associated with cancer cell migration and invasion.
Overexpression of HAb18G/CD147 promotes invasion and metastasis via alpha3beta1 integrin mediated FAK-paxillin and FAK-PI3K-Ca(2+) pathways.
PBN11-8, a Cytotoxic Polypeptide Purified from Marine Bacillus, Suppresses Invasion and Migration of Human Hepatocellular Carcinoma Cells by Targeting Focal Adhesion Kinase Pathways.
Pharmacological activation of AMPK suppresses inflammatory response evoked by IL-6 signalling in mouse liver and in human hepatocytes.
Prolactin Promotes Hepatocellular Carcinoma through Janus Kinase 2.
Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.
Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
Prostaglandin E2 receptor EP1-mediated phosphorylation of focal adhesion kinase enhances cell adhesion and migration in hepatocellular carcinoma cells.
Protein kinase C-mediated tyrosine phosphorylation of paxillin and focal adhesion kinase requires cytoskeletal integrity and is uncoupled to mitogen-activated protein kinase activation in human hepatoma cells.
Reduced C-terminal Src kinase (Csk) activities in hepatocellular carcinoma.
Regulation of JAK2 protein expression by chronic, pulsatile GH administration in vivo: a possible mechanism for ligand enhancement of signal transduction.
Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma.
Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3?/Wnt/?-catenin signaling.
Staurosporine inhibits a tyrosine protein kinase in human hepatoma cell membranes.
Suppression of in vivo tumorigenicity of rat hepatoma cell line KDH-8 cells by soluble TGF-beta receptor type II.
Targeting interleukin-1 receptor-associated kinase 1 for human hepatocellular carcinoma.
The ectodomain of matriptase-2 plays an important nonproteolytic role in suppressing hepcidin expression in mice.
The effect of Bruton's tyrosine kinase (BTK) inhibitors on collagen-induced platelet aggregation, BTK, and tyrosine kinase expressed in hepatocellular carcinoma (TEC).
The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma.
The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
Transforming growth factor beta 1 selectively increases gene expression of the serine/threonine kinase receptor 1 (SKR1) in human hepatoma cell lines.
Transforming growth factor-beta1 stimulated protein kinase B serine-473 and focal adhesion kinase tyrosine phosphorylation dependent on cell adhesion in human hepatocellular carcinoma SMMC-7721 cells.
Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase.
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Tyrosine Kinase SYK is a Potential Therapeutic Target for Liver Fibrosis.
Tyrosine protein kinase in preneoplastic and neoplastic rat liver.
Upregulation of Focal Adhesion Kinase by 14-3-3? via NF?B Activation in Hepatocellular Carcinoma.
[Focal adhesion kinase mRNA overexpression in hepatocellular carcinoma HCC) and correlation thereof with prognosis of HCC]
[Influence of focal adhesion kinase (FAK) on the biological behaviors of human hepatocellular carcinoma cells]
[Inhibitory effects of antisense focal adhesion kinase oligodeoxynucleotides on the invasion of Bel 7402 hepatocellular carcinoma cells]
[Liver phosphotyrosine protein phosphatase and tyrosine protein kinase in chemical hepatocarcinogenesis]
[RNA interference targeting focal adhesion kinase inhibited the growth of human hepatocellular carcinoma sk-hep-1].
Carcinoma, Intraductal, Noninfiltrating
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
Focal adhesion kinase and Wnt signaling regulate human ductal carcinoma in situ stem cell activity and response to radiotherapy.
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Carcinoma, Lewis Lung
Development of a metastatic fluorescent Lewis Lung carcinoma mouse model: identification of mRNAs and microRNAs involved in tumor invasion.
Carcinoma, Medullary
Renal medullary carcinoma and ABL gene amplification.
Carcinoma, Merkel Cell
A case of Merkel cell carcinoma development under treatment with a Janus kinase inhibitor.
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Carcinoma, Non-Small-Cell Lung
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells.
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.
Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Effect of spleen tyrosine kinase on nonsmall cell lung cancer.
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance.
FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis.
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer.
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p.
Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225-3p/ErbB2 signal.
MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway.
miR-769-5p suppressed cell proliferation, migration and invasion by targeting TGFBR1 in non-small cell lung carcinoma.
New drugs in thyroid cancer.
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
SOCS3 expression is inversely correlated with Pyk2 in non-small cell lung cancer and exogenous SOCS3 inhibits proliferation and invasion of A549 cells.
Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Targeting CXCR4 and FAK reverses doxorubicin resistance and suppresses invasion in non-small cell lung carcinoma.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Up-regulation of focal adhesion kinase in non-small cell lung cancer.
Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
[Association between Ephb4 gene polymorphism and non-small cell lung cancer]
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
[Molecular Targeted Therapy and Laboratory Tests].
[Relationship between multi-slice spiral CT pulmonary perfusion imaging and the expression of EphB4 and ephrinB2 in non-small cell lung cancer].
Carcinoma, Ovarian Epithelial
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Ambivalent role of pFAK-Y397 in serous ovarian cancer--a study of the OVCAD consortium.
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Correlation between SNPs of PIK3CA, ERBB2 3'UTR, and their interactions with environmental factors and the risk of epithelial ovarian cancer.
Expression and clinical significance of focal adhesion kinase and adrenomedullin in epithelial ovarian cancer.
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.
Carcinoma, Pancreatic Ductal
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
Carcinoma, Papillary
Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.
The trk family of oncogenes and neurotrophin receptors.
Carcinoma, Renal Cell
15-Deoxy-?12,14-prostaglandin J2 Inhibits Cell Migration on Renal Cell Carcinoma via Down-Regulation of Focal Adhesion Kinase Signaling.
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Circ_0015756 promotes proliferation, invasion and migration by microRNA-7-dependent inhibition of FAK in hepatocellular carcinoma.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Downregulation of the c-Fes protein-tyrosine kinase inhibits the proliferation of human renal carcinoma cells.
Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
Interleukin4R? (IL4R?) and IL13R?1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.
Kinomic profiling identifies focal adhesion kinase 1 as a therapeutic target in advanced clear cell renal cell carcinoma.
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
Molecular cloning and characterization of human WNT11.
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Over-expression of mir-124 inhibits MMP-9 expression and decreases invasion of renal cell carcinoma cells.
Phosphorylated Signal Transducer and Activator of Transcription 1 is a potential predictor of interferon response in patients with advanced renal cell carcinoma.
RB1CC1 functions as a tumor-suppressing gene in renal cell carcinoma via suppression of PYK2 activity and disruption of TAZ-mediated PDL1 transcription activation.
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy.
Restoration of expression of transforming growth factor-beta type II receptor in murine renal cell carcinoma (renca) cells by 5-Aza-2'-deoxycytidine.
Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.
[Effect of genistein on proliferation of renal cell carcinoma cell line GRC-1 and its influence to p27 expression]
Carcinoma, Small Cell
A tyrosine protein kinase activated by bombesin in normal fibroblasts and small cell carcinomas.
Carcinoma, Squamous Cell
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
A case of aggressive squamous cell carcinoma with lymphovascular invasion during treatment with the Janus kinase inhibitor tofacitinib.
Aggressive squamous cell carcinoma in a patient on the Janus kinase inhibitor ruxolitinib.
An altered fibronectin matrix induces anoikis of human squamous cell carcinoma cells by suppressing integrin alpha v levels and phosphorylation of FAK and ERK.
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Carbon Ion Irradiation Enhances the Anti-tumor Efficiency in Tongue Squamous Cell Carcinoma via Modulating the FAK Signaling.
Chemokine receptor 7 via proline-rich tyrosine kinase-2 upregulates the chemotaxis and migration ability of squamous cell carcinoma of the head and neck.
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Correlation of constitutive activation of raf-1 with morphological transformation and abrogation of tyrosine phosphorylation of distinct sets of proteins in human squamous carcinoma cells.
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Elevated c-Src and c-Yes expression in malignant skin cancers.
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
Expression of EphB4 in head and neck squamous cell carcinoma.
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Inhibition of Raf-1 protein kinase by antisense phosphorothioate oligodeoxyribonucleotide is associated with sensitization of human laryngeal squamous carcinoma cells to gamma radiation.
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Modulation of epidermal growth factor receptor interaction with the detergent-insoluble cytoskeleton and its effects on receptor tyrosine kinase activity.
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
p70S6K is regulated by focal adhesion kinase and is required for Src-selective autophagy.
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Protein kinase C inhibition of the epidermal growth factor receptor tyrosine protein kinase activity is independent of the oligomeric state of the receptor.
Role of epidermal growth factor-stimulated protein kinase in control of proliferation of A431 cells.
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Squamous cell carcinoma cell aggregates escape suspension-induced, p53-mediated anoikis: fibronectin and integrin alphav mediate survival signals through focal adhesion kinase.
Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Wnt/?-catenin signalling induces MLL to create epigenetic changes in salivary gland tumours.
[Effect of focal adhesion kinase on biological characteristics of Tca8113 tongue squamous cell carcinoma]
[Expression and clinical significance of proline-rich tyrosine kinase 2 and phospho-protein kinase B in tongue squamous cell carcinoma].
Carcinoma, Transitional Cell
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
Carcinosarcoma
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Cardiac Tamponade
Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia.
Cardiomegaly
Cardiotoxicity of Novel Targeted Hematological Therapies.
Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling.
Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy.
Focal adhesion kinase signaling in cardiac hypertrophy and failure.
Inactivation of focal adhesion kinase in cardiomyocytes promotes eccentric cardiac hypertrophy and fibrosis in mice.
Inhibitory molecules in signal transduction pathways of cardiac hypertrophy.
Loss of Bmx nonreceptor tyrosine kinase prevents pressure overload-induced cardiac hypertrophy.
Mechanisms of blood pressure variability-induced cardiac hypertrophy and dysfunction in mice with impaired baroreflex.
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Pressure overload-induced cardiac hypertrophy response requires janus kinase 2-histone deacetylase 2 signaling.
Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy.
Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy.
Structure of focal adhesion kinase in healthy heart versus pathological cardiac hypertrophy: A modeling and simulation study.
Targeting focal adhesion kinase with small interfering RNA prevents and reverses load-induced cardiac hypertrophy in mice.
[Expression of focal adhesion kinase in cardiac myocytes of hypertrophic ventricle]
[Phosphorylation and nuclear translocation of serine 722 and serine 910 of focal adhesion kinase in hypertrophic cardiac myocytes of left ventricle of spontaneously hypertensive rats]
Cardiomyopathies
Elevated expression of C3G protein in the peri-infarct myocardium of rats.
Impaired angiotensin II-extracellular signal-regulated kinase signaling in failing human ventricular myocytes.
Increased expression of Dock180 protein in the noninfarcted myocardium in rats.
Unsolved medical issues and new targets for further research in viral myocarditis and dilated cardiomyopathy.
Cardiomyopathy, Dilated
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Inhibition of osteopontin reduce the cardiac myofibrosis in dilated cardiomyopathy via focal adhesion kinase mediated signaling pathway.
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
[Content of myosin-activating protein kinases in myocardium of patients with dilated cardiomyopathy and in the animal heart]
Cardiomyopathy, Hypertrophic
Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes.
Cardiotoxicity
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Focal adhesion kinase antagonizes doxorubicin cardiotoxicity via p21(Cip1.).
Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase.
MiR-15b-5p is Involved in Doxorubicin-Induced Cardiotoxicity via Inhibiting Bmpr1a Signal in H9c2 Cardiomyocyte.
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Cardiovascular Diseases
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
A familial congenital heart disease with a possible multigenic origin involving a mutation in BMPR1A.
Multiple Facial Milia in Patients With Loeys-Dietz Syndrome.
Pathophysiology of the chronic kidney disease-mineral bone disorder.
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Carotid Artery Diseases
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
Cataract
Coordinate signaling by Src and p38 kinases in the induction of cortical cataracts.
Extracellular matrix and integrin signaling in lens development and cataract.
Mechanism of Src kinase induction of cortical cataract following exposure to stress: destabilization of cell-cell junctions.
Role of transforming growth factor-beta in transdifferentiation and fibrosis of lens epithelial cells.
Celiac Disease
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Interleukin 15-Dependent T Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease.
Tofacitinib, a Janus Kinase Inhibitor Demonstrates Efficacy in an IL-15 Transgenic Mouse Model that Recapitulates Pathologic Manifestations of Celiac Disease.
Cell Transformation, Neoplastic
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
Cerebellar Ataxia
The c-Abl inhibitor, nilotinib, as a potential therapeutic agent for chronic cerebellar ataxia.
Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia.
Cerebral Hemorrhage
Hydrogen Inhalation Ameliorated Mast Cell-Mediated Brain Injury After Intracerebral Hemorrhage in Mice.
Levetiracetam Reduces Early Inflammatory Response After Experimental Intracerebral Hemorrhage by Regulating the Janus Kinase 2 (JAK2)-Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway.
Src kinase inhibition decreases thrombin-induced injury and cell cycle re-entry in striatal neurons.
SRC kinase inhibition improves acute outcomes after experimental intracerebral hemorrhage.
The dual role of SRC kinases in intracerebral hemorrhage.
Tyrosine kinase Fyn promotes apoptosis after intracerebral hemorrhage in rats by activating Drp1 signaling.
Cerebral Infarction
Activation of the Non-receptor Tyrosine Kinase cSrc in Macrophage-rich Atherosclerotic Plaques of Human Carotid Arteries.
CHARGE Syndrome
Targeted next?generation sequencing for research and diagnostics in congenital heart disease, and cleft lip and/or palate.
Chemical and Drug Induced Liver Injury
Protective effect of Chushizi (Fructus Broussonetiae) on acetaminophen-induced rat hepatitis by inhibiting the Toll-like receptor 3/c-Jun N-terminal kinase/c-jun/c-fos/janus protein tyrosine kinase/activators of transcription 3 pathway.
Cherubism
Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
[Molecular and Cellular Pathogenesis of Cherubism].
Cholangiocarcinoma
A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1.
Cucurbitacin B Diminishes Metastatic Behavior of Cholangiocarcinoma Cells by Suppressing Focal Adhesion Kinase.
Cucurbitacin B induces mitochondrial-mediated apoptosis pathway in cholangiocarcinoma cells via suppressing focal adhesion kinase signaling.
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1.
Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells.
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Cholecystitis
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Cholera
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Induction of B(1)-kinin receptors in vascular smooth muscle cells: cellular mechanisms of map kinase activation.
Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
[Synthesis, Cloning and Expression of a Multiple Epitope Antigen of BCR-ABL Fusion Gene]
Choline Deficiency
Dietary choline deficiency and excess induced intestinal inflammation and alteration of intestinal tight junction protein transcription potentially by modulating NF-?B, STAT and p38 MAPK signaling molecules in juvenile Jian carp.
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Chondrosarcoma
Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I.
Inhibition of Src by microRNA-23b increases the cisplatin sensitivity of chondrosarcoma cells.
Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells.
Suppressed invasive and migratory behaviors of SW1353 chondrosarcoma cells through the regulation of Src, Rac1 GTPase, and MMP13.
The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines.
Chorea
Chorea, Pruritus and Polycythemia: Looking for Clues.
Chorioamnionitis
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
Choriocarcinoma
Expression of a fms-related oncogene in carcinogen-induced neoplastic epithelial cells.
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Gal-1 silenced trophoblast tumor cells (BeWo) show decreased syncytium formation and different miRNA production compared to non-target silenced BeWo cells.
Is galectin-1 a trigger for trophoblast cell fusion?: the MAP-Kinase pathway and syncytium formation in trophoblast tumor cells BeWo.
Optimized logic rules reveal interferon-?-induced modes regulated by histone deacetylases and protein tyrosine phosphatases.
Choroidal Neovascularization
Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Focal adhesion kinase signaling pathway participates in the formation of choroidal neovascularization and regulates the proliferation and migration of choroidal microvascular endothelial cells by acting through HIF-1 and VEGF expression in RPE cells.
Inhibition of choroidal neovascularization by anti-EphB4 monoclonal antibody.
Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization.
Chronic Kidney Disease-Mineral and Bone Disorder
Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Pathophysiology of the chronic kidney disease-mineral bone disorder.
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Chronic Periodontitis
CD24 activates the NLRP3 inflammasome through c-Src kinase activity in a model of the lining epithelium of inflamed periodontal tissues.
Chronic Urticaria
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.
Cleft Lip
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Cleft Palate
ACTIVIN SUBUNIT AND RECEPTOR EXPRESSION IN NORMAL AND CLEFT HUMAN FETAL PALATE TISSUES.
Activin subunit and receptor expression in normal and cleft human fetal palate tissues.
Altered BMP-Smad4 signaling causes complete cleft palate by disturbing osteogenesis in palatal mesenchyme.
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Clubfoot
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Cockayne Syndrome
Cockayne syndrome protein B interacts with and is phosphorylated by c-Abl tyrosine kinase.
Colitis
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1?-mediated colitis.
Butyric Acid Increases the Therapeutic Effect of EHLJ7 on Ulcerative Colitis by Inhibiting JAK2/STAT3/SOCS1 Signaling Pathway.
E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-?B activation.
Estrogen receptor ? alleviates inflammatory lesions in a rat model of inflammatory bowel disease via down-regulating P2X7R expression in macrophages.
Intestinal Epithelial Cell Tyrosine Kinase 2 Transduces IL-22 Signals To Protect from Acute Colitis.
MFG-E8 attenuates intestinal inflammation in murine experimental colitis by modulating osteopontin-dependent alphavbeta3 integrin signaling.
New treatment options for inflammatory bowel diseases.
Nitrotyrosylation of Ca2+ channels prevents c-Src kinase regulation of colonic smooth muscle contractility in experimental colitis.
Novel Pentapeptide Derived from Chicken by-Product Ameliorates DSS-Induced Colitis by Enhancing Intestinal Barrier Function via AhR-Induced Src Inactivation.
Oxazolone-induced over-expression of focal adhesion kinase in colonic epithelial cells of colitis mouse model.
P014. Selective Janus Kinase 1 inhibitor targets monocytes and tissue macrophages during DSS colitis.
Role of Csk in intestinal epithelial barrier function and protection against colitis.
Role of Janus kinase 3 in mucosal differentiation and predisposition to colitis.
T cells that cannot respond to TGF-beta escape control by CD4(+)CD25(+) regulatory T cells.
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD.
The Src kinase Fyn is protective in acute chemical-induced colitis and promotes recovery from disease.
The Syk Inhibitor Fostamatinib Decreases the Severity of Colonic Mucosal Damage in a Rodent Model of Colitis.
Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis.
Ulcerative Colitis.
[Mechanism of sophocarpine in treating experimental colitis in mice].
Colitis, Ulcerative
A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice.
Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug Exposure and Support Dosing Recommendations for Potential Drug-Drug Interactions or in Special Populations: An Example Using Tofacitinib.
c-src tyrosine kinase activity: a marker of dysplasia in ulcerative colitis.
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Combination Therapy With Tofacitinib Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis as Induction Therapy for Refractory Ulcerative Colitis.
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis.
Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Direct and Indirect Effects of Tofacitinib on Treatment Satisfaction in Patients with Ulcerative Colitis.
Efficacy and Safety of Extended Induction With Tofacitinib for the Treatment of Ulcerative Colitis.
Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.
Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.
Expression of receptor interacting protein 3 and mixed lineage kinase domain-like protein-key proteins in necroptosis is upregulated in ulcerative colitis.
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
GSK2586184, a JAK1 selective inhibitor, in two patients with ulcerative colitis.
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.
JAK inhibition in inflammatory bowel disease.
JAK inhibitors: Novel developments in management of ulcerative colitis.
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
JAK2 rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn's Disease: A Meta-analysis.
Maintenance of Remission With Tofacitinib Therapy in Patients With Ulcerative Colitis.
Medical therapy versus surgery in moderate-to-severe ulcerative colitis.
New drug therapies on the horizon for IBD.
Novel Therapeutic Options for People with Ulcerative Colitis: An Update on Recent Developments with Janus Kinase (JAK) Inhibitors.
Off-label studies on tofacitinib in dermatology: a review.
Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial.
Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
Phase 1 Dose-Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Japanese Healthy Volunteers.
Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review.
Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Randomized trial of tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.
Real-world clinical and endoscopic outcomes after one year tofacitinib treatment in ulcerative colitis.
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience.
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.
Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Schisandrin B prevents ulcerative colitis and colitis-associated-cancer by activating focal adhesion kinase and influence on gut microbiota in an in vivo and in vitro model.
Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.
Tofacitinib as Induction and Maintenance Therapy in Japanese Patients with Active Ulcerative Colitis.
Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation.
Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
Tofacitinib for the treatment of tumor necrosis factor-? inhibitor refractory esophageal Crohn's disease: a case report.
Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.
Tofacitinib in Patients with Ulcerative Colitis: Health-Related Quality of Life in Phase 3 Randomised Controlled Induction and Maintenance Studies.
Tofacitinib in Patients with Ulcerative Colitis: Inflammatory Bowel Disease Questionnaire Items in Phase 3 Randomized Controlled Induction Studies.
Tofacitinib induction and maintenance therapy in East Asian patients with active ulcerative colitis: subgroup analyses from three phase 3 multinational studies.
Tofacitinib Treatment Is Associated With Modest and Reversible Increases in Serum Lipids in Patients With Ulcerative Colitis.
Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data.
Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far?
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Tofacitinib, the First Oral Janus Kinase Inhibitor Approved for Adult Ulcerative Colitis.
Tofacitinib-Associated Cerebral Venous Sinus Thrombosis.
Update on Janus kinase antagonists in inflammatory bowel disease.
Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis.
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib].
[JAK inhibitors: Perspectives in internal medicine].
Colonic Neoplasms
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
A family with two consecutive nonsense mutations in BMPR1A causing juvenile polyposis.
A role for epidermal growth factor receptor, c-Src and focal adhesion kinase in an in vitro model for the progression of colon cancer.
Acquisition of cell adhesion and induction of focal adhesion kinase of human colon cancer Colo 201 cells by retinoic acid-induced differentiation.
Activating SRC mutation in a subset of advanced human colon cancers.
Activation of focal adhesion kinase through an interaction with ?4 integrin contributes to tumorigenicity of colon cancer.
Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion.
Adhesion, actin cytoskeleton organisation and the spreading of colon adenocarcinoma cells induced by EGF are mediated by alpha2beta1 integrin low clustering through focal adhesion kinase.
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
Allele-specific expression of TGFBR1 in colon cancer patients.
Alpha-actinin-1 phosphorylation modulates pressure-induced colon cancer cell adhesion through regulation of focal adhesion kinase-Src interaction.
Analysis of signaling protein kinases in human colon or colorectal carcinomas.
Bone morphogenetic protein signaling and growth suppression in colon cancer.
Butyrate regulates the expression of c-Src and focal adhesion kinase and inhibits cell invasion of human colon cancer cells.
CD44 regulates cell migration in human colon cancer cells via Lyn kinase and AKT phosphorylation.
Clinical and molecular characterization of individuals with recurrent genomic disorder at 10q22.3q23.2.
Colon cancer cell adhesion in response to Src kinase activation and actin-cytoskeleton by non-laminar shear stress.
Combination of an SRC kinase inhibitor with a novel pharmacological antagonist of the urokinase receptor diminishes in vitro colon cancer invasiveness.
Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells.
Cross talk between receptor guanylyl cyclase C and c-src tyrosine kinase regulates colon cancer cell cytostasis.
Dasatinib reduces 5-Fu-triggered apoptosis in colon carcinoma by directly modulating Src-dependent caspase-9 phosphorylation.
Decreased CHK protein levels are associated with Src activation in colon cancer cells.
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Development of a Rapid-Onset, Acid-Labile Linkage Polyplex-Mixed Micellar System for Anticancer Therapy.
Dihydroartemisinin increases apoptosis of colon cancer cells through targeting Janus kinase 2/signal transducer and activator of transcription 3 signaling.
Dual inhibition of MET and SRC kinase activity as a combined targeting strategy for colon cancer.
Early adhesion induces interaction of FAK and Fyn in lipid domains and activates raft-dependent Akt signaling in SW480 colon cancer cells.
Effect of chemopreventive agents on intermediate biomarkers during different stages of azoxymethane-induced colon carcinogenesis.
Effect of ets-related transcription factor (ERT) on transforming growth factor (TGF)-beta type II receptor gene expression in human cancer cell lines.
Effectiveness of Scutellaria barbata water extract on inhibiting colon tumor growth and metastasis in tumor-bearing mice.
Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
Epithelial-mesenchymal transition and metastasis of colon cancer cells induced by the FAK pathway in cancer-associated fibroblasts.
Eps8 facilitates cellular growth and motility of colon cancer cells by increasing the expression and activity of focal adhesion kinase.
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407.
Expression of kinase-defective mutants of c-Src in human metastatic colon cancer cells decreases Bcl-xL and increases oxaliplatin- and Fas-induced apoptosis.
Expression of matrix macromolecules and functional properties of EGF-responsive colon cancer cells are inhibited by panitumumab.
Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Fibronectin promotes invasiveness and focal adhesion kinase tyrosine phosphorylation of human colon cancer cell.
Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients.
Focal adhesion kinase is not required for Src-induced formation of invadopodia in KM12C colon cancer cells and can interfere with their assembly.
Focal adhesion kinase mediates defects in the force-dependent reinforcement of initial integrin-cytoskeleton linkages in metastatic colon cancer cell lines.
Fraxetin inhibits the growth of colon adenocarcinoma cells via the Janus kinase 2/signal transducer and activator of transcription 3 signalling pathway.
Gastrin-releasing peptide mediates its morphogenic properties in human colon cancer by upregulating intracellular adhesion protein-1 (ICAM-1) via focal adhesion kinase.
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Induction of colonic epithelial cell apoptosis by p47-dependent oxidants.
Induction of the differentiated phenotype in human colon cancer cell is associated with the attenuation of subcellular tyrosine phosphorylation.
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Inhibition of c-Yes induces differentiation of HT-29 human colon cancer stem cells through midbody elongation.
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Lack of activating c-SRC mutations at codon 531 in rectal cancer.
Lemur tyrosine kinase 2 acts as a positive regulator of NF-?B activation and colon cancer cell proliferation.
Leptin promotes motility and invasiveness in human colon cancer cells by activating multiple signal-transduction pathways.
Lunasin potentiates the effect of oxaliplatin preventing outgrowth of colon cancer metastasis, binds to ?5?1 integrin and suppresses FAK/ERK/NF-?B signaling.
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
MicroRNA-27b suppresses tumor progression by regulating ARFGEF1 and focal adhesion signaling.
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
MicroRNA?7 suppresses human colon cancer invasion and proliferation by targeting the expression of focal adhesion kinase.
miR-424-5p reduces 5-fluorouracil resistance possibly by inhibiting Src/focal adhesion kinase signalling-mediated epithelial-mesenchymal transition in colon cancer cells.
Overexpression of the csk gene suppresses tumor metastasis in vivo.
p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation.
Possible involvement of Wnt11 in colorectal cancer progression.
Pressure stimulates breast cancer cell adhesion independently of cell cycle and apoptosis regulatory protein (CARP)-1 regulation of focal adhesion kinase.
Prognostic significance and correlation with survival of bcl-2 and TGF-beta RII in colon cancer.
Progression of familial adenomatous polyposis (FAP) colonic cells after transfer of the src or polyoma middle T oncogenes: cooperation between src and HGF/Met in invasion.
PTP1B Contributes to the Oncogenic Properties of Colon Cancer Cells through Src Activation.
Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells.
Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer.
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human colon carcinoma xenograft in nude mice.
Signal Transducers and Activators of Transcription 3 Activation Is Involved in Nuclear Accumulation of {beta}-Catenin in Colorectal Cancer.
Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Src activity alters alpha3 integrin expression in colon tumor cells.
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Src kinase pathway is involved in NFAT5-mediated S100A4 induction by hyperosmotic stress in colon cancer cells.
SRC transcriptional activation in a subset of human colon cancer cell lines.
Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background.
Src tyrosine kinase phosphorylation of nuclear receptor HNF4? correlates with isoform-specific loss of HNF4? in human colon cancer.
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.
Syndecan-2 cytoplasmic domain upregulates Matrix Metalloproteinase-7 expression via Protein KinaseC? mediated FAK/ERK signaling pathway in colon cancer.
Synthesis of 3-phenylpyrazolopyrimidine-1,2,3-triazole conjugates and evaluation of their Src kinase inhibitory and anticancer activities.
Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells Following DNA Damage.
The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and ?-secretase, enhances cell proliferation and migration in colon cancer cells.
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
The role of Src family kinases in the normal and neoplastic gastrointestinal tract.
The role of the cytoskeleton in differentially regulating pressure-mediated effects on malignant colonocyte focal adhesion signaling and cell adhesion.
Thrombin-dependent modulation of ?1-integrin-mediated signaling up-regulates prolidase and HIF-1? through p-FAK in colorectal cancer cells.
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
Transcriptional signature induced by a C-terminal c-Src mutant in a human breast cell line.
Ubiquitin-dependent degradation of active Src.
[A study of gastrin-focal adhesion kinase signal pathway in human colon cancer cells.]
[Effect of JAK2/STAT3/vimentin signaling pathway on proliferation and migration of human colon cancer cells.]
[Influence of Pyk2 on hepatic metastasis and ultrastructure of human colonic cancer cells].
Colorectal Neoplasms
A cell-based screen for inhibitors of protein folding and degradation.
A genetic variant located in the miR-532-5p-binding site of TGFBR1 is associated with the colorectal cancer risk.
A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.
A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients.
A Novel Netrin-1-Derived Peptide Enhances Protection against Neuronal Death and Mitigates of Intracerebral Hemorrhage in Mice.
aCGH local copy number aberrations associated with overall copy number genomic instability in colorectal cancer: coordinate involvement of the regions including BCR and ABL.
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis.
Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.
Analyses of the APC and TGF-beta type II receptor genes, and microsatellite instability in mucosal colorectal carcinomas.
Analysis of SRC oncogenic signaling in colorectal cancer by stable isotope labeling with heavy amino acids in mouse xenografts.
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.
Association of a let-7 miRNA binding region of TGFBR1 with hereditary mismatch repair proficient colorectal cancer (MSS HNPCC).
Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.
AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway.
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
BMPR1A mutations in early-onset colorectal cancer with mismatch repair proficiency.
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
Chemoprevention of colorectal cancer by targeting Janus kinase 3 with a rationally designed small molecule inhibitor.
Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through ?5?1 Integrin.
Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
Combination Antitumor Effect of Sorafenib via Calcium-Dependent Deactivation of Focal Adhesion Kinase Targeting Colorectal Cancer Cells.
Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.
Cotargeting BET proteins overcomes resistance arising from PI3K/mTOR blockade-induced protumorigenic senescence in colorectal cancer.
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
Debate about TGFBR1 and the susceptibility to colorectal cancer.
Demonstration that mutation of the type II transforming growth factor beta receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells.
Detection of Deregulated Pathways to Lymphatic Metastasis in Oral Squamous Cell Carcinoma.
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Dual inhibition of ?V integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer.
Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.
EPHB4 and Survival of Colorectal Cancer Patients.
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.
Expression and Y435-phosphorylation of Abelson interactor 1 (Abi1) promotes tumour cell adhesion, extracellular matrix degradation and invasion by colorectal carcinoma cells.
Expression of C-terminal src kinase in human colorectal cancer cell lines.
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Focal adhesion kinase functions as an akt downstream target in migration of colorectal cancer cells.
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.
Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
Genetic variants in IL-6/JAK/STAT3 pathway and the risk of CRC.
Genetic variants in the TGF?-signaling pathway influence expression of miRNAs in colon and rectal normal mucosa and tumor tissue.
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer.
Growth inhibition due to complementation of transforming growth factor-beta receptor type II-defect by human chromosome 3 transfer in human colorectal carcinoma cells.
Hamartomatous polyposis in a middle-aged female with rare colonic adenomatous spread.
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Increased Bcl-xL expression mediates v-Src-induced resistance to anoikis in intestinal epithelial cells.
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
Inhibiting focal adhesion kinase: A potential target for enhancing therapeutic efficacy in colorectal cancer therapy.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Investigation into Enhancing Capecitabine Efficacy in Colorectal Cancer by Inhibiting Focal Adhesion Kinase Signaling.
Iterative microarray and RNA interference-based interrogation of the SRC-induced invasive phenotype.
KSR1 and EPHB4 Regulate Myc and PGC1? To Promote Survival of Human Colon Tumors.
Lack of activating c-SRC mutations at codon 531 in rectal cancer.
Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.
Lack of mutation at codon 531 of SRC in advanced colorectal cancers from Italian patients.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2.
Mutational analysis of TGF-beta type II receptor, Smad2, Smad3, Smad4, Smad6 and Smad7 genes in colorectal cancer.
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Mutations in hMSH6 alone are not sufficient to cause the microsatellite instability in colorectal cancer cell lines.
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
Netrin-1 Preserves Blood-Brain Barrier Integrity Through Deleted in Colorectal Cancer/Focal Adhesion Kinase/RhoA Signaling Pathway Following Subarachnoid Hemorrhage in Rats.
No association between germline allele-specific expression of TGFBR1 and colorectal cancer risk in Caucasian and Ashkenazi populations.
Noncanonical TGF? Pathway Relieves the Blockade of IL1?/TGF?-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
Notch signaling promotes serrated neoplasia pathway in colorectal cancer through epigenetic modification of EPHB2 and EPHB4.
Nuclear expression of phosphorylated focal adhesion kinase is associated with poor prognosis in human colorectal cancer.
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells.
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Optimization of the diagnosis of inherited colorectal cancer using NGS and capture of exonic and intronic sequences of panel genes.
Overcoming Resistance to Targeted Therapies in Cancer.
Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation.
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Possible involvement of Wnt11 in colorectal cancer progression.
Precise localization of the human gene encoding cell adhesion kinase beta (CAK beta/PYK2) to chromosome 8 at p21.1 by fluorescence in situ hybridization.
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Quantitative phosphoproteomics reveals a cluster of tyrosine kinases that mediates SRC invasive activity in advanced colon carcinoma cells.
Rapid tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130Cas by gastrin in human colon cancer cells.
Reduced C-terminal Src kinase activity is correlated inversely with pp60(c-src) activity in colorectal carcinoma.
Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis.
Role of Bruton's Tyrosine Kinase in Stage III Colorectal Cancer.
Ropivacaine inhibits the proliferation and migration of colorectal cancer cells through ITGB1.
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.
Screening of BMPR1a for pathogenic mutations in familial colorectal cancer type X families from Newfoundland.
Should a single nucleotide variant in TGFBR1 modify colorectal cancer screening recommendations?
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling.
SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC.
Somatic acquisition and signaling of TGFBR1*6A in cancer.
SRC activates TAZ for intestinal tumorigenesis and regeneration.
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Synergistically Anti-metastatic Effect of 5-Flourouracil on Colorectal Cancer Cells via Calcium-mediated Focal Adhesion Kinase Proteolysis.
Tgf-beta signaling alterations and colon cancer.
TGFBR1 and cancer susceptibility.
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
TGFBR1 intralocus epistatic interaction as a risk factor for colorectal cancer.
TGFBR1 variants TGFBR1(*)6A and Int7G24A are not associated with an increased familial colorectal cancer risk.
TGFBR1*6A is a potential modifier of migration and invasion in colorectal cancer cells.
The association of polymorphisms on TGFBR1 and colorectal cancer risk: a meta-analysis.
The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas.
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene.
Ursolic Acid Induces Apoptosis in Colorectal Cancer Cells Partially via Upregulation of MicroRNA-4500 and Inhibition of JAK2/STAT3 Phosphorylation.
Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.
[Expression of proline-rich tyrosine kinase-2 in human primary colorectal carcinoma and its prognostic implication]
[Mutations of hMSH2 gene and hMLH1 gene in human colovectal carcinomas]
[Spleen tyrosine kinase inhibits proliferation and promotes apoptosis of colorectal cancer cells in vitro via regulating Fra-1].
Colorectal Neoplasms, Hereditary Nonpolyposis
BMPR1A mutations in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
Co-occurrence of Lynch syndrome and juvenile polyposis syndrome confirmed by multigene panel testing.
Genetic testing by cancer site: stomach.
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Mutational analysis of the transforming growth factor beta receptor type II gene in hereditary nonpolyposis colorectal cancer and early-onset colorectal cancer patients.
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.
Two divergent signaling pathways for TGF-beta separated by a mutation of its type II receptor gene.
Common Variable Immunodeficiency
Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.
Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects.
Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Communicable Diseases
Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
Confusion
Disruption of anchoring junctions in the testes of experimental varicocele rats.
Congenital Abnormalities
Compound mutations in Bmpr1a and Tak1 synergize facial deformities via increased cell death.
Ectodermal Wnt controls nasal pit morphogenesis through modulation of the BMP/FGF/JNK signaling axis.
Integration of comprehensive 3D microCT and signaling analysis reveals differential regulatory mechanisms of craniofacial bone development.
Modulation of noncanonical TGF-? signaling prevents cleft palate in Tgfbr2 mutant mice.
Conjunctivitis, Allergic
Quercetin as a Lyn kinase inhibitor inhibits IgE-mediated allergic conjunctivitis.
Connective Tissue Diseases
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Contracture
Apelin-induced cardioprotection against ischaemia/reperfusion injury: roles of epidermal growth factor and Src.
Reversal of TET-mediated 5-hmC loss in hypoxic fibroblasts by ascorbic acid.
Coronary Disease
The Expression and Clinical Significance of Spleen Tyrosine Kinase in Patients with Coronary Heart Disease.
Coronary Occlusion
Demonstration of selective protein kinase C-dependent activation of Src and Lck tyrosine kinases during ischemic preconditioning in conscious rabbits.
Coronavirus Infections
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.
COVID-19
Additional baricitinib loading dose improves clinical outcome in COVID-19.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
Baricitinib and dexamethasone for hospitalized patients with COVID-19.
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Bruton's Tyrosine Kinase: A Promising Target for the Treatment of COVID-19.
BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors.
Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19.
Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.
COVID-19 revisiting inflammatory pathways of arthritis.
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.
JAK inhibitors dampen activation of interferon-activated transcriptomes and the SARS-CoV-2 receptor ACE2 in human renal proximal tubules.
JAK out of the Box; The Rationale behind Janus Kinase Inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations.
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
Janus kinase inhibitor baricitinib is not an ideal option for management of COVID-19.
Janus Kinase Inhibitors and Coronavirus Disease (COVID)-19: Rationale, Clinical Evidence and Safety Issues.
Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials.
Janus Kinase inhibitors for the treatment of hospitalized patients with COVID-19.
Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19.
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Perceptions and Behaviors of Patients with Inflammatory Bowel Disease during the COVID-19 Crisis.
Pharmacological and non-pharmacological efforts at prevention, mitigation, and treatment for COVID-19.
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.
Regulation of the ACE2 locus in human airways cells.
Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19.
Reply: Potential role of Janus kinase inhibitors in COVID-19.
Role of monoclonal antibody drugs in the treatment of COVID-19.
Selective targeting of the inactive state of hematopoietic cell kinase (Hck) with a stable curcumin derivative.
Single-Cell Transcriptome Analysis Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis of Severe COVID-19.
Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease.
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation.
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19.
The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
Treating Leukemia in the Time of COVID-19.
Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals.
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
[Potential therapeutic drugs for novel coronavirus pneumonia].
Craniosynostoses
BmpR1A is a major type 1 BMP receptor for BMP-Smad signaling during skull development.
BMPR1A maintains skeletal stem cell properties in craniofacial development and craniosynostosis.
Genetics of craniosynostosis: genes, syndromes, mutations and genotype-phenotype correlations.
Crohn Disease
A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn's Disease.
Clinical Confirmation that the Selective JAK1 Inhibitor Filgotinib (GLPG0634) has a Low Liability for Drug-drug Interactions.
Cross-disorder analysis of schizophrenia and 19 immune-mediated diseases identifies shared genetic risk.
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor.
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.
JAK2 rs10758669 Polymorphisms and Susceptibility to Ulcerative Colitis and Crohn's Disease: A Meta-analysis.
Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn's Disease.
Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn's Disease Intestinal Mucosa: Analysis From the CELEST Study.
Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population.
Tofacitinib for the treatment of tumor necrosis factor-? inhibitor refractory esophageal Crohn's disease: a case report.
UniPR1331: Small Eph/Ephrin Antagonist Beneficial in Intestinal Inflammation by Interfering with Type-B Signaling.
Update on Janus kinase antagonists in inflammatory bowel disease.
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Cryptococcosis
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
Cryptorchidism
Genetic studies of MIS signalling in sexual development.
Cystadenoma
Platelets are associated with xenograft tumor growth and the clinical malignancy of ovarian cancer through an angiogenesis-dependent mechanism.
Cystic Fibrosis
In silico prediction and validation of potential therapeutic genes in pancreatic ?-cells associated with type 2 diabetes.
PhenCode: connecting ENCODE data with mutations and phenotype.
The tyrosine kinase p60c-src regulates the fast gate of the cystic fibrosis transmembrane conductance regulator chloride channel.
Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis.
Cystitis
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Cysts
Csk differentially regulates Src64 during distinct morphological events in Drosophila germ cells.
Effects of src kinase and TGFbeta1 on the differentiation and morphogenesis of MDCK cells grown in three-dimensional collagen and Matrigel environments.
Expression of TGFBR1, TGFBR2, TGFBR3, ACVR1B and ACVR2B is altered in ovaries of cows with cystic ovarian disease.
Impairment of Wnt11 function leads to kidney tubular abnormalities and secondary glomerular cystogenesis.
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
JAK signaling regulates germline cyst breakdown and primordial follicle formation in mice.
Kif3a controls murine nephron number via GLI3 repressor, cell survival, and gene expression in a lineage-specific manner.
Properties of Transport Mediated by the Human Organic Cation Transporter 2 Studied in a Polarized Three-Dimensional Epithelial Cell Culture Model.
Requirement of focal adhesion kinase in branching tubulogenesis.
Src64 controls a novel actin network required for proper ring canal formation in the Drosophila male germline.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Darier Disease
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Death, Sudden, Cardiac
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death.
Deficiency Diseases
Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement.
Disturbed Transcription of TLRs' Negative Regulators and Cytokines Secretion among TLR4- and 9-Activated PBMCs of Agammaglobulinemic Patients.
Dehydration
A role for c-Abl in c-myc regulation.
Dementia
Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias.
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.
Dementia, Vascular
Association of intronic sequence variant in the gene encoding spleen tyrosine kinase with susceptibility to vascular dementia.
Demyelinating Diseases
Can rheumatologists stop causing demyelinating disease?
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease.
Dengue
An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
GNF-2 Inhibits Dengue Virus by Targeting Abl Kinases and the Viral E Protein.
Identification and characterization of the role of c-terminal Src kinase in dengue virus replication.
Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection.
The small molecules AZD0530 and dasatinib inhibit dengue virus RNA replication via Fyn kinase.
Dermatitis
A pharmacokinetic study of oclacitinib maleate in six cats.
Effects of the Janus Kinase Inhibitor CP-690550 (Tofacitinib) in a Rat Model of Oxazolone-Induced Chronic Dermatitis.
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Remission of Severe Eyelid Dermatitis With a Topical Janus Kinase Inhibitor.
Topically Administered Janus-Kinase Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory Responses in a Model of Allergic Dermatitis.
[Granulomatous rosacea-like dermatitis under therapy with tofacitinib].
Dermatitis, Atopic
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
Application of Janus Kinase Inhibitors in Atopic Dermatitis: An Updated Systematic Review and Meta-Analysis of Clinical Trials.
Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Bridging to a selective Janus kinase 1 inhibitor in severe atopic dermatitis: An instructive case with upadacitinib.
Comparing quality of life outcomes of JAK inhibitors and biological treatments for atopic dermatitis: a systematic review and network meta-analysis.
Comparison of topical tofacitinib and 0.1% hypochlorous acid in a murine atopic dermatitis model.
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study.
Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study.
Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Effects of Delgocitinib Ointment 0.5% on the Normal Mouse Skin and Epidermal Tight Junction Proteins in Comparison With Topical Corticosteroids.
Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.
Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Efficacy and Safety of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis.
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Efficacy and safety of topical Janus kinase and phosphodiesterase inhibitor-4 inhibitors for the treatment of atopic dermatitis: A network meta-analysis.
Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.
Emerging Role of Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
Emerging systemic therapies for atopic dermatitis: oral small molecules and targeted topical agents.
Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
Hand eczema: treatment.
IgE hyperproduction through enhanced tyrosine phosphorylation of Janus kinase 3 in NC/Nga mice, a model for human atopic dermatitis.
Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
JAK inhibitors and infections risk: focus on herpes zoster.
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
Janus kinase inhibitors for the therapy of atopic dermatitis.
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Kinetic-Pharmacodynamic Model of Platelet Time Course in Patients With Moderate-to-Severe Atopic Dermatitis Treated With Oral Janus Kinase 1 Inhibitor Abrocitinib.
Leveraging the nice face of Janus kinase inhibition-ruxolitinib cream in atopic dermatitis.
Long-term Efficacy of Baricitinib in Adults With Moderate to Severe Atopic Dermatitis Who Were Treatment Responders or Partial Responders: An Extension Study of 2 Randomized Clinical Trials.
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis.
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.
Phase 2 clinical study of delgocitinib ointment in pediatric patients with atopic dermatitis.
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials.
Rapid Improvement of Itch Associated With Atopic Dermatitis With Abrocitinib Is Partially Independent of Overall Disease Improvement: Results From Pooled Phase 2b and 3 Monotherapy Studies.
Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.
Safety considerations of systemic Janus kinase inhibitors in atopic dermatitis applications.
Safety of Janus kinase (JAK) inhibitors in the short-term treatment of atopic dermatitis.
Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis.
The effectiveness of Janus kinase inhibitors in treating atopic dermatitis: A systematic review and meta-analysis.
The efficacy of Janus kinase inhibitors in patients with atopic dermatitis: A systematic review and network meta-analysis.
The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
Topical treatment with mastic (resin from Pistacia lentiscus) elicits anti-inflammatory and anti-pruritic responses by modulating keratinocyte activation in a mouse model of allergic dermatitis.
Treatment of atopic dermatitis with biologics and Janus kinase inhibitors.
Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate.
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
[Topical therapy for atopic eczema].
Dermatitis, Contact
Effects of the novel and potent lymphocyte-specific protein tyrosine kinase inhibitor TKM0150 on mixed lymphocyte reaction and contact hypersensitivity in mice.
Dermatofibrosarcoma
Complex t(5;8) involving the CSPG2 and PTK2B genes in a case of dermatofibrosarcoma protuberans without the COL1A1-PDGFB fusion.
Dermatomyositis
Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.
Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib.
Reply: Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis.
Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review.
Unexpected Hair Regrowth in a Patient with Longstanding Alopecia Universalis During Treatment of Recalcitrant Dermatomyositis with the Janus Kinase Inhibitor Ruxolitinib.
[Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment].
Diabetes Complications
Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli.
Diabetes Mellitus
A Link Between Alzheimer's and Type II Diabetes Mellitus? Ca+2 -Mediated Signal Control and Protein Localization.
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.
Effects of sevoflurane pretreatment on renal Src and FAK expression in diabetic rats after renal ischemia/reperfusion injury.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.
The rs2304256 Polymorphism in TYK2 Gene Is Associated with Protection for Type 1 Diabetes Mellitus.
Diabetes Mellitus, Experimental
Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up.
Diabetes Mellitus, Type 1
Association analysis of the lymphocyte-specific protein tyrosine kinase (LCK) gene in type 1 diabetes.
Contribution of PTPN22, CD28, CTLA-4 and ZAP-70 variants to the risk of type 1 diabetes in Tunisians.
LCK rs10914542-G allele associates with type 1 diabetes in children via T cell hyporesponsiveness.
MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory ?-cell damage.
Preclinical evaluation of tyrosine kinase 2 inhibitors for human beta-cell protection in type 1 diabetes.
Subtyping of Type 1 Diabetes as Classified by Anti-GAD Antibody, IgE Levels, and Tyrosine kinase 2 (TYK2) Promoter Variant in the Japanese.
The rs2304256 Polymorphism in TYK2 Gene Is Associated with Protection for Type 1 Diabetes Mellitus.
TYK2 Promoter Variant Is Associated with Impaired Insulin Secretion and Lower Insulin Resistance in Japanese Type 2 Diabetes Patients.
Diabetes Mellitus, Type 2
Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.
Enhancement of mesenteric artery contraction to 5-HT depends on Rho kinase and Src kinase pathways in the ob/ob mouse model of type 2 diabetes.
Glucosylpolyphenols as inhibitors of A?-induced Fyn kinase activation and Tau phosphorylation: synthesis, membrane permeability, and exploratory target assessment within the scope of type 2 diabetes and Alzheimer's disease.
Imatinib and type 2 diabetes.
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Insulin-receptor kinase activity of adipose tissue from morbidly obese humans with and without NIDDM.
MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.
Solution structure of the zinc finger HIT domain in protein FON.
The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.
Vascular proliferation and transforming growth factor-beta expression in pre- and early stage of diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats.
[Effects of aerobic exercise and resveratrol on the expressions of JAK2 and TGF-?1 in renal tissue of type 2 diabetes rats].
Diabetic Angiopathies
Key role of Src kinase in S100B-induced activation of the receptor for advanced glycation end products in vascular smooth muscle cells.
Diabetic Cardiomyopathies
Melatonin therapy for diabetic cardiomyopathy: A mechanism involving Syk-mitochondrial complex I-SERCA pathway.
Diabetic Foot
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Diabetic Nephropathies
Evidence for a role of transforming growth factor (TGF)-beta1 in the induction of postglomerular albuminuria in diabetic nephropathy: amelioration by soluble TGF-beta type II receptor.
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Inhibition of Src Kinase Blocks High Glucose-Induced EGFR Transactivation and Collagen Synthesis in Mesangial Cells and Prevents Diabetic Nephropathy in Mice.
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
miR-136 improves renal fibrosis in diabetic rats by targeting down-regulation of tyrosine kinase SYK and inhibition of TGF-?1/Smad3 signaling pathway.
Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy.
Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease.
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Spleen tyrosine kinase promotes NLR family pyrin domain containing 3 inflammasome?mediated IL?1? secretion via c?Jun N?terminal kinase activation and cell apoptosis during diabetic nephropathy.
Suppressor of Cytokine Signaling-1 Ameliorates Expression of MCP-1 in Diabetic Nephropathy.
Suppressor of Cytokine Signaling-1 Peptidomimetic Limits Progression of Diabetic Nephropathy.
Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-beta1 and fibronectin synthesis in human mesangial cells.
Diabetic Neuropathies
Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.
Diabetic Retinopathy
Silver nanoparticles inhibit VEGF-and IL-1beta-induced vascular permeability via Src dependent pathway in porcine retinal endothelial cells.
Spleen Tyrosine Kinase Mediates Microglial Activation in Mice With Diabetic Retinopathy.
The effect of spleen tyrosine kinase inhibitor R406 on diabetic retinopathy in experimental diabetic rats.
The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease.
Diffuse Intrinsic Pontine Glioma
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Disorders of Sex Development
Synergistic cooperation between the beta-catenin signaling pathway and steroidogenic factor 1 in the activation of the Mullerian inhibiting substance type II receptor.
Diverticulum
Transforming growth factor ? receptor type 1 is essential for female reproductive tract integrity and function.
DNA Repair-Deficiency Disorders
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Down Syndrome
Janus kinase inhibition in Down syndrome: 2 cases of therapeutic benefit for alopecia areata.
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Loss-of-function JAK3 mutations in TMD and AMKL of Down syndrome.
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia.
Drug-Related Side Effects and Adverse Reactions
Immunosuppressive agents in organ transplantation: past, present, and future.
Management of Chronic Myeloid Leukemia in Childhood.
Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database.
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
The treatment of pediatric chronic myelogenous leukemia in the imatinib era.
Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Dry Eye Syndromes
Immunomodulatory effect of the topical ophthalmic Janus kinase inhibitor tofacitinib (CP-690,550) in patients with dry eye disease.
Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Dwarfism
Correlation Analysis Between Expression Levels of Hepatic Growth Hormone Receptor, Janus Kinase 2, Insulin-Like Growth Factor-I Genes and Dwarfism Phenotype in Bama Minipig.
Dwarfism, Pituitary
Update on X-linked hypogammaglobulinemia with isolated growth hormone deficiency.
Dysentery, Bacillary
Cortactin and Crk cooperate to trigger actin polymerization during Shigella invasion of epithelial cells.
Dyskinesias
NR2B antagonist CP-101,606 inhibits NR2B phosphorylation at tyrosine-1472 and its interactions with Fyn in levodopa-induced dyskinesia rat model.
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
Tat-Src reduced NR2B tyrosine phosphorylation and its interaction with NR2B in levodopa-induced dyskinetic rats model.
Dyslipidemias
Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
Inhibition of JAK2 Suppresses Myelopoiesis and Atherosclerosis in Apoe-/- Mice.
Dyspnea
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Ebstein Anomaly
A case of capillary malformation-arteriovenous malformation and Ebstein's anomaly in a child with EphB4 mutation.
Ecthyma
Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature.
Eczema
Hand eczema: treatment.
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
TGF? receptor mutations impose a strong predisposition for human allergic disease.
What's new in atopic eczema? An analysis of systematic reviews published in 2018. Part 1: prevention and topical therapies.
Ehlers-Danlos Syndrome
Aneurysm syndromes caused by mutations in the TGF-beta receptor.
Identification of a novel TGFBR1 mutation in a Loeys-Dietz syndrome type II patient with vascular Ehlers-Danlos syndrome phenotype.
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Embolic Stroke
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Encephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Encephalitis, Japanese
Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism.
Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Encephalomyelitis
C-type lectins and extracellular vesicles in virus-induced NETosis.
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Tofacitinib ameliorates atherosclerosis and reduces foam cell formation in apoE deficient mice.
Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
IL-1 receptor-associated kinase 1 regulates susceptibility to organ-specific autoimmunity.
Inhibition of the BMP Signaling Pathway Ameliorated Established Clinical Symptoms of Experimental Autoimmune Encephalomyelitis.
Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
Endometrial Hyperplasia
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Autophagy in the physiological endometrium and cancer.
Overexpression of erythropoietin-producing hepatocyte receptor B4 and ephrin-B2 is associated with estrogen receptor expression in endometrial adenocarcinoma.
Endometrial Neoplasms
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer.
Autophagy in the physiological endometrium and cancer.
Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway.
Conditional abrogation of transforming growth factor-? receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor.
Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance.
Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src.
Estradiol and Tamoxifen Induce Cell Migration through GPR30 and Activation of Focal Adhesion Kinase (FAK) in Endometrial Cancers with Low or without Nuclear Estrogen Receptor ? (ER?).
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Expression of receptor tyrosine kinase EphB4 and its ligand ephrin-B2 is associated with malignant potential in endometrial cancer.
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Genetic Polymorphisms of TGFB1, TGFBR1, SNAI1 and TWIST1 Are Associated with Endometrial Cancer Susceptibility in Chinese Han Women.
Gonadotropin-releasing hormone (GnRH)-I and GnRH-II induce cell growth inhibition in human endometrial cancer cells: involvement of integrin beta3 and focal adhesion kinase.
Insights into endometrial serous carcinogenesis and progression.
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
LEFTY2 Controls Migration of Human Endometrial Cancer Cells via Focal Adhesion Kinase Activity (FAK) and miRNA-200a.
Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1.
MLH1 enhances the sensitivity of human endometrial carcinoma cells to cisplatin by activating the MLH1/c-Abl apoptosis signaling pathway.
Molecular differences between RER+ and RER- sporadic endometrial carcinomas in a large population-based series.
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Overexpression of enhancer of zeste homolog 2 (EZH2) and focal adhesion kinase (FAK) in high grade endometrial carcinoma.
Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Stress-induced phosphoprotein-1 maintains the stability of JAK2 in cancer cells.
The expression and action of granulocyte macrophage-colony stimulating factor and its interaction with TGF-beta in endometrial carcinoma.
The Src kinase pathway promotes tamoxifen agonist action in Ishikawa endometrial cells through phosphorylation-dependent stabilization of estrogen receptor (alpha) promoter interaction and elevated steroid receptor coactivator 1 activity.
Endometriosis
Activin A, Activin Receptor Type II, Nodal, and Cripto mRNA Are Expressed by Eutopic and Ectopic Endometrium in Women With Ovarian Endometriosis.
Alteration of focal adhesion kinase expression in eutopic endometrium of women with endometriosis.
B lymphocytes inactivation by Ibrutinib limits endometriosis progression in mice.
Comprehensive study of angiogenic factors in women with endometriosis compared to women without endometriosis.
Differential expression of genes in eutopic and ectopic endometrium from patients with ovarian endometriosis.
DNA microarray analysis of gene expression profiles in deep endometriosis using laser capture microdissection.
Enhanced cyclooxygenase-2 expression levels and metalloproteinase 2 and 9 activation by Hexachlorobenzene in human endometrial stromal cells.
Expression of focal adhesion kinase in endometrial stromal cells of women with endometriosis was adjusted by ovarian steroid hormones.
Focal adhesion kinase expression in ovarian endometriosis.
Healthy women and patients with endometriosis show high concentrations of inhibin A, inhibin B, and activin A in peritoneal fluid throughout the menstrual cycle.
Inhibition of erythropoietin-producing hepatoma receptor B4 (EphB4) signaling suppresses the vascularization and growth of endometriotic lesions.
miR-96-5p regulated TGF-?/SMAD signaling pathway and suppressed endometrial cell viability and migration via targeting TGFBR1.
Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis.
Specific Photothermal Ablation Therapy of Endometriosis by Targeting Delivery of Gold Nanospheres.
Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1.
Endotoxemia
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research.
In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.
Roles of MMP-2/-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model.
Small interfering RNA targeting focal adhesion kinase prevents cardiac dysfunction in endotoxemia.
Eosinophilia
Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Epidermodysplasia Verruciformis
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Epilepsy
A non-mitotic role for aurora kinase A as a direct activator of cell migration upon interaction with PLD, FAK and Src.
Altered expression of c-Abl in patients with epilepsy and in a rat model.
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
BDNF selectively regulates GABAA receptor transcription by activation of the JAK/STAT pathway.
Gain control of N-methyl-D-aspartate receptor activity by receptor-like protein tyrosine phosphatase alpha.
Genetic Interaction of H19 and TGFBR1 Polymorphisms with Risk of Epilepsy in a Chinese Population.
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Increased NRG1-ErbB4 signaling in human symptomatic epilepsy.
Recombinant Human Erythropoietin Protects Myocardial Cells from Apoptosis via the Janus-Activated Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway in Rats with Epilepsy.
Epilepsy, Temporal Lobe
Altered expression of c-Abl in patients with epilepsy and in a rat model.
Increased expression of TGF-beta type I receptor in brain tissues of patients with temporal lobe epilepsy.
Epstein-Barr Virus Infections
Chronic active Epstein-Barr virus infection as the initial symptom in a Janus kinase 3 deficiency child: Case report and literature review.
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Erectile Dysfunction
The effects of single versus combined therapy using LIM-kinase 2 inhibitor and type 5 phosphodiesterase inhibitor on erectile function in a rat model of cavernous nerve injury-induced erectile dysfunction.
Erythema
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Unilateral and segmental distribution of facial erythema: is it a real port-wine stain?
Escherichia coli Infections
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Esophageal Achalasia
c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs.
Esophageal Neoplasms
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer.
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
miR-1 suppresses the proliferation and promotes the apoptosis of esophageal carcinoma cells by targeting Src.
Esophageal Squamous Cell Carcinoma
Activation of Src tyrosine kinase in esophageal carcinoma cells in different regulatory environments and corresponding occurrence mechanism.
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
Chrysin serves as a novel inhibitor of DGK?/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC).
Cirsiliol targets tyrosine kinase 2 to inhibit esophageal squamous cell carcinoma growth in vitro and in vivo.
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Down-regulation of EphB4 phosphorylation is necessary for esophageal squamous cell carcinoma tumorigenecity.
Downregulated expression of PTK6 is correlated with poor survival in esophageal squamous cell carcinoma.
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Expression of Wnt11 and Rock2 in esophageal squamous cell carcinoma by activation of the WNT/PCP pathway and its clinical significance.
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Identification of spleen tyrosine kinase as a potential therapeutic target for esophageal squamous cell carcinoma using reverse phase protein arrays.
Inhibition of cell growth and upregulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the SRC/ABL inhibitor dasatinib.
Janus kinase 2 inhibition by Licochalcone B suppresses esophageal squamous cell carcinoma growth.
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
Essential Hypertension
Protein tyrosine kinase 2beta as a candidate gene for hypertension.
Exanthema
Expression of proto-oncogenes in mouse eggs and preimplantation embryos.
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Janus kinase inhibitor significantly improved rash and muscle strength in juvenile dermatomyositis.
Vascular tumors produced by NIH/3T3 cells transfected with human AIDS Kaposi's sarcoma DNA.
Exostoses, Multiple Hereditary
DNA polymorphism analysis of hereditary multiple exostoses in horses.
Eye Abnormalities
Distinct developmental programs require different levels of Bmp signaling during mouse retinal development.
Fabry Disease
Sixty-nine kilobases of contiguous human genomic sequence containing the alpha-galactosidase A and Bruton's tyrosine kinase loci.
Familial Primary Pulmonary Hypertension
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Genetics of pulmonary hypertension: from bench to bedside.
Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension.
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.
Sex Differences in Pulmonary Hypertension.
[Pulmonary arterial hypertension and BMP system abnormality]
Fasciculation
Genetic analysis of the role of Eph receptors in the development of the mammalian nervous system.
Fasciitis
Janus kinase inhibitor tofacitinib is a potential therapeutic option for refractory eosinophilic fasciitis.
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.
Fatty Liver
CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.
Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
MiR-130a-3p attenuates activation and induces apoptosis of hepatic stellate cells in nonalcoholic fibrosing steatohepatitis by directly targeting TGFBR1 and TGFBR2.
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis.
[Effects of puerarin on expressions of leptin receptor mRNA, phosphorylated Janus kinase 2/phosphorylated signal transducers and activators of transcription 3 proteins in the liver of rats with non-alcoholic fatty liver]
Fetal Alcohol Spectrum Disorders
Effect of pre- and postnatal ethanol exposure on protein tyrosine kinase activity and its endogenous substrates in rat cerebral cortex.
Fibroadenoma
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
Fibromatosis, Aggressive
Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.
Fibrosarcoma
A conformationally sensitive GHR [growth hormone (GH) receptor] antibody: impact on GH signaling and GHR proteolysis.
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Alopecia in patients treated with molecularly targeted anticancer therapies.
Alpinia officinarum Stimulates Osteoblast Mineralization and Inhibits Osteoclast Differentiation.
Continuous requirement for pp60-Src and phospho-paxillin during fibronectin matrix assembly by transformed cells.
Down-regulation of collagen XII in transformed mesenchymal cells.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Interferon gamma activation of Raf-1 is Jak1-dependent and p21ras-independent.
Janus kinase 2 enhances the stability of the mature growth hormone receptor.
Karyotype analysis of the acute fibrosarcoma from chickens infected with subgroup J avian leukosis virus associated with v-src oncogene.
Lamivudine Inhibits the Replication of ALV-J Associated Acutely Transforming Virus and its Helper Virus and Tumor Growth In vitro and In vivo.
LIM kinase-2 targeting as a possible anti-metastasis therapy.
Localization of viral transforming sequences within marker chromosomes associated with tumor formation and progression in a murine fibrosarcoma.
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Rescue of avian leukosis subgroup-J-associated acutely transforming viruses carrying different lengths of the v-fps oncogene and analysis of their tumorigenicity.
Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor.
Suppression in transformed avian fibroblasts of a gene (crp) encoding a cysteine-rich protein containing LIM domains.
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Taishan Pinus Massoniana pollen polysaccharide inhibits the replication of acute tumorigenic ALV-J and its associated tumor growth.
Food Hypersensitivity
Remission of food allergy by the Janus kinase inhibitor ruxolitinib in mice.
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Foot Ulcer
Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers.
Foot-and-Mouth Disease
Foot-and-mouth disease virus structural protein VP3 degrades Janus kinase 1 to inhibit IFN-? signal transduction pathways.
Fragile X Syndrome
Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome.
JAKMIP1, a Novel Regulator of Neuronal Translation, Modulates Synaptic Function and Autistic-like Behaviors in Mouse.
Frontotemporal Lobar Degeneration
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Gallbladder Neoplasms
JAK2 tyrosine kinase inhibitor AG490 suppresses cell growth and invasion of gallbladder cancer cells via inhibition of JAK2/STAT3 signaling.
The Novel Selective Pan-TRK Inhibitor ONO-7579 Exhibits Antitumor Efficacy Against Human Gallbladder Cancer
Gastritis
Antral atrophy, intestinal metaplasia, and preneoplastic markers in Mexican children with Helicobacter pylori-positive and Helicobacter pylori-negative gastritis.
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Gastroenteritis
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Gastroesophageal Reflux
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Proinflammatory cytokines and bile acids upregulate ?Np73 protein, an inhibitor of p53 and p73 tumor suppressors.
Gastrointestinal Diseases
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Gastrointestinal Neoplasms
A novel germline BMPR1A variant (c.72_73delGA) in a Japanese family with hereditary mixed polyposis syndrome.
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant.
Translational Research in Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
Gastrointestinal Stromal Tumors
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Effect of St John's wort on imatinib mesylate pharmacokinetics.
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Molecular interactions in imatinib-DPPC liposomes.
Molecular targeted therapy of gastrointestinal stromal tumors.
Molecularly targeted therapy for gastrointestinal cancer.
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™).
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Pulmonary toxicities of tyrosine kinase inhibitors.
Rational therapeutic intervention in cancer: kinases as drug targets.
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Reduced exposure of imatinib after coadministration with acetaminophen in mice.
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.
Role of protein tyrosine kinase inhibitors in cancer therapeutics.
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
The development and application of imatinib.
The safety profile of imatinib in CML and GIST: long-term considerations.
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
[Imatinib--a new perspective in the treatment of tumors]
Gaucher Disease
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
c-Abl activates RIPK3 signaling in Gaucher disease.
gelatinase b deficiency
Hes1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells.
Genetic Diseases, Inborn
A novel Bruton's tyrosine kinase gene (BTK) invariant splice site mutation in a Malaysian family with X-linked agammaglobulinemia.
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Presentation of a case of Bruton type primary agammaglobulinemia in Guinea.
Gestational Trophoblastic Disease
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Glaucoma
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma.
Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma.
Glioblastoma
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
Activation and translocation of c-Src to the cytoskeleton by both platelet-derived growth factor and epidermal growth factor.
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells.
ARHGAP21 modulates FAK activity and impairs glioblastoma cell migration.
Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Constitutive phosphorylation of Janus kinase 2 in the GL15 glioblastoma derived human cell line.
Danthron inhibits the migration and invasion of human brain glioblastoma multiforme cells through the inhibition of mRNA expression of focal adhesion kinase, Rho kinases-1 and metalloproteinase-9.
Design, Synthesis, and Biological Evaluation of Covalent Inhibitors of Focal Adhesion Kinase (FAK) against Human Malignant Glioblastoma.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Differential role of proline-rich tyrosine kinase 2 and focal adhesion kinase in determining glioblastoma migration and proliferation.
Downregulation of Focal Adhesion Kinase (FAK) by cord blood stem cells inhibits angiogenesis in glioblastoma.
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
Dual-Modality Micro-Positron Emission Tomography/Computed Tomography and Near-Infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models.
EphB2 receptor controls proliferation/migration dichotomy of glioblastoma by interacting with focal adhesion kinase.
Expression and functional roles of Smad1 and BMPR-IB in glioma development.
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
FAK signaling in anaplastic astrocytoma and glioblastoma tumors.
Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion.
Girdin, an actin-binding protein, is critical for migration, adhesion, and invasion of human glioblastoma cells.
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Glycogen Synthase Kinase 3? Sustains Invasion of Glioblastoma via the Focal Adhesion Kinase, Rac1, and c-Jun N-Terminal Kinase-Mediated Pathway.
HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells.
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.
Identification of new pyrrolo[2,3-d]pyrimidines as Src tyrosine kinase inhibitors in vitro active against Glioblastoma.
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and Arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate Therapy.
In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation.
Inhibition of migration of human glioblastoma cells by cerivastatin in association with focal adhesion kinase (FAK).
Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells.
Integrin ?v?3 Engagement Regulates Glucose Metabolism and Migration through Focal Adhesion Kinase (FAK) and Protein Arginine Methyltransferase 5 (PRMT5) in Glioblastoma Cells.
L-Thyroxine vs. 3,5,3'-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase.
LKB1 deficiency promotes proliferation and invasion of glioblastoma through activation of mTOR and focal adhesion kinase signaling pathways.
Loss of focal adhesion kinase (FAK) inhibits epidermal growth factor receptor-dependent migration and induces aggregation of nh(2)-terminal FAK in the nuclei of apoptotic glioblastoma cells.
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
Microglia-derived TGF-beta as an important regulator of glioblastoma invasion--an inhibition of TGF-beta-dependent effects by shRNA against human TGF-beta type II receptor.
MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
Molecular genetics of human glioma.
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.
NVP-BEZ235 or JAKi Treatment leads to decreased survival of examined GBM and BBC cells.
Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma.
PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex.
Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.
Polyphenolic Compounds of Crataegus Berry, Leaf, and Flower Extracts Affect Viability and Invasive Potential of Human Glioblastoma Cells.
Proton Therapy and Src Family Kinase Inhibitor Combined Treatments on U87 Human Glioblastoma Multiforme Cell Line.
PTEN suppresses hyaluronic acid-induced matrix metalloproteinase-9 expression in U87MG glioblastoma cells through focal adhesion kinase dephosphorylation.
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells.
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
Reciprocal regulation of Abl and receptor tyrosine kinases.
Reciprocal regulation of Abl kinase by Crk Y251 and Abi1 controls invasive phenotypes in glioblastoma.
Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells.
Silencing microRNA-221/222 cluster suppresses glioblastoma angiogenesis by suppressor of cytokine signaling-3-dependent JAK/STAT pathway.
Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
SRC Family Kinase Inhibition Through a New Pyrazolo[3,4-d]Pyrimidine Derivative as a Feasible Approach for Glioblastoma Treatment.
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
SRC Kinase in Glioblastoma News from an Old Acquaintance.
SRC Tyrosine Kinase Inhibitor and X-rays Combined Effect on Glioblastoma Cell Lines.
The nuclear localization of 3'-phosphoinositide-dependent kinase-1 is dependent on its association with the protein tyrosine phosphatase SHP-1.
The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged.
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
The Role of Hypoxia and SRC Tyrosine Kinase in Glioblastoma Invasiveness and Radioresistance.
The significance of microRNA-184 on JAK2/STAT3 signaling pathway in the formation mechanism of glioblastoma.
Therapeutic potential of AZD1480 for the treatment of human glioblastoma.
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation.
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Glioma
A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872.
A role for activated Cdc42 in glioblastoma multiforme invasion.
A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK.
ABL2/ARG tyrosine kinase mediates SEMA3F-induced RhoA inactivation and cytoskeleton collapse in human glioma cells.
Angiopoietin 2 induces glioma cell invasion by stimulating matrix metalloprotease 2 expression through the alphavbeta1 integrin and focal adhesion kinase signaling pathway.
Antisense oligonucleodes targeting the focal adhesion kinase inhibit proliferation, induce apoptosis and cooperate with cytotoxic drugs in human glioma cells.
Arg kinase mediates CXCL12/CXCR4-induced invadopodia formation and invasion of glioma cells.
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein.
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines.
CircRNA EPHB4 modulates stem properties and proliferation of gliomas via sponging miR-637 and up-regulating SOX10.
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma.
Connexin43 recruits PTEN and Csk to inhibit c-Src activity in glioma cells and astrocytes.
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Effects of nonselective cation channels and PI3K on endothelin-1-induced PYK2 tyrosine phosphorylation in C6 glioma cells.
EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications.
Emodin suppresses hyaluronic acid-induced MMP-9 secretion and invasion of glioma cells.
EphB4 is overexpressed in gliomas and promotes the growth of glioma cells.
EphB4 mediates resistance to antiangiogenic therapy in experimental glioma.
Expression and functional roles of Smad1 and BMPR-IB in glioma development.
Expression of c-src in cultured human neuroblastoma and small-cell lung carcinoma cell lines correlates with neurocrine differentiation.
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival.
Expression of tyrosine kinases FAK and Pyk2 in 331 human astrocytomas.
Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases.
Ganglioside GD3 Enhances Invasiveness of Gliomas by Forming a Complex with Platelet-derived Growth Factor Receptor ? and Yes Kinase.
Geldanamycin induces mitotic catastrophe and subsequent apoptosis in human glioma cells.
Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.
High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF-?B activation and predicts poor prognosis in human glioma.
Hyaluronate activates tyrosine phosphorylation of cellular proteins including focal adhesion kinase via CD44 in human glioma cells.
Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.
Induction of WNT11 by hypoxia and hypoxia-inducible factor-1? regulates cell proliferation, migration and invasion.
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme.
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
Leucine-rich glioma inactivated 3 induces neurite outgrowth through Akt and focal adhesion kinase.
Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Mda-9/syntenin Promotes Human Brain Glioma Migration through Focal Adhesion Kinase (FAK)-JNK and FAK-AKT Signaling.
Microglia Activate Migration of Glioma Cells through a Pyk2 Intracellular Pathway.
Microsatellite instability and mutated type II transforming growth factor-beta receptor gene in gliomas.
miR-656 inhibits glioma tumorigenesis through repression of BMPR1A.
Mutated focal adhesion kinase induces apoptosis in a human glioma cell line, T98G.
Nanofiber-mediated inhibition of focal adhesion kinase sensitizes glioma stemlike cells to epidermal growth factor receptor inhibition.
Neurotrophic Receptor Tyrosine Kinase 2 (NTRK2) Alterations in Low-Grade Gliomas: Report of a Novel Gene Fusion Partner in a Pilocytic Astrocytoma and Review of the Literature.
Over-expression of tetraspanin 8 in malignant glioma regulates tumor cell progression.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Patupilone (epothilone B, EPO906) and imatinib (STI571, Glivec) in combination display enhanced antitumour activity in vivo against experimental rat C6 glioma.
Pharmacologic blockade of FAK autophosphorylation decreases human glioblastoma tumor growth and synergizes with temozolomide.
Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma.
Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment.
Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase.
PTEN gene transfer suppresses the invasive potential of human malignant gliomas by regulating cell invasion-related molecules.
PTEN regulates tumor cell adhesion of colon carcinoma cells under dynamic conditions of fluid flow.
Pyr3 Induces Apoptosis and Inhibits Migration in Human Glioblastoma Cells.
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
RNA interference-mediated silencing of focal adhesion kinase inhibits growth of human malignant glioma xenograft in nude mice.
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
Serine protease inhibitor (SERPIN) B1 suppresses cell migration and invasion in glioma cells.
Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype.
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.
Store-operated Ca 2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation.
Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma.
Tenascin-C promotes microvascular cell migration and phosphorylation of focal adhesion kinase.
The Effect of Chemoradiotherapy with SRC Tyrosine Kinase Inhibitor, PP2 and Temozolomide on Malignant Glioma Cells In Vitro and In Vivo.
The effect of epidermal growth factor receptor variant III on glioma cell migration by stimulating ERK phosphorylation through the focal adhesion kinase signaling pathway.
The inflammatory cytokine IL-22 promotes murine gliomas via proliferation.
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration.
The tyrosine kinase pyk2 promotes migration and invasion of glioma cells.
Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.
Tyrosine 311 is phosphorylated by c-Abl and promotes the apoptotic effect of PKCdelta in glioma cells.
Up-Regulation of Hsa-miR-11181 in Glioblastoma Multiforme as A Regulator of AKT2 and TGFBR1 Signalling.
Glomerulonephritis
A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
An inhibitor of spleen tyrosine kinase suppresses experimental crescentic glomerulonephritis.
Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression.
Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.
Gene transfer and kidney disease.
Increased expression of cell adhesion kinase beta in human and rat crescentic glomerulonephritis.
Myeloid cell-mediated renal injury in rapidly progressive glomerulonephritis depends upon spleen tyrosine kinase.
Suppression of Glomerulonephritis in Lupus-Prone NZB × NZW Mice by RN486, a Selective Inhibitor of Bruton's Tyrosine Kinase.
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
Therapeutic Blockade of Immune Complex-Mediated Glomerulonephritis by Highly Selective Inhibition of Bruton's Tyrosine Kinase.
Glomerulonephritis, IGA
Enhanced Bruton's tyrosine kinase activity in the kidney of patients with IgA nephropathy.
Fostamatinib: First Global Approval.
JAK-STAT Activity in Peripheral Blood Cells and Kidney Tissue in IgA Nephropathy.
Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.
Spleen Tyrosine Kinase Inhibition Ameliorates Tubular Inflammation in IgA Nephropathy.
Spleen Tyrosine Kinase Is Important in the Production of Proinflammatory Cytokines and Cell Proliferation in Human Mesangial Cells following Stimulation with IgA1 Isolated from IgA Nephropathy Patients.
Glomerulonephritis, Membranous
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Glomerulosclerosis, Focal Segmental
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier.
Glucose Intolerance
Absence of Shb impairs insulin secretion by elevated FAK activity in pancreatic islets.
Adipocyte-Specific Deletion of Janus Kinase 2 (JAK2) Leads to Increased Adiposity and Age-Related Glucose Intolerance.
Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.
Glucose Metabolism Disorders
[Relationship between glucose metabolic disorders and expression of insulin receptor in posthepatitic cirrhosis hepatocyte and HBV DNA in pancreatic cells]
Glycogen Storage Disease Type VI
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Heterogenous expression of bcr-abl fusion mRNA in a patient with Philadelphia-chromosome-positive acute lymphoblastic leukaemia.
Goiter
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Graft vs Host Disease
Association with the presence of naive T cells in chronic myeloid leukemia patients after allogeneic human stem cell transplantation and the lower incidence of chronic graft-versus host disease and relapse.
Azole antifungals and new targeted therapies for hematological malignancy.
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease.
Combined Inhibition of c-Abl and PDGF Receptors for Prevention and Treatment of Murine Sclerodermatous Chronic Graft-versus-Host Disease.
Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease.
CP-690550, a Janus kinase inhibitor, suppresses CD4+ T-cell-mediated acute graft-versus-host disease by inhibiting the interferon-? pathway.
Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Efficacy and tolerance of ruxolitinib in refractory sclerodermatous chronic Graft-Versus-Host Disease.
Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
Itacitinib prevents xenogeneic GVHD in humanized mice.
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Janus Kinase Inhibition for Graft-Versus-Host Disease: Current Status and Future Prospects.
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Kinetics of the graft-versus-leukemia response after donor leukocyte infusions for relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation.
Off-label studies on ruxolitinib in dermatology: a review.
Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Recipient and donor JAK2 46/1 haplotypes are associated with acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
Syk and tired of current chronic GVHD therapies.
Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
The role of ibrutinib in COVID-19 hyperinflammation: A case report.
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
[Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia]
Granuloma
Expression of Tie-2, angiopoietin-1, angiopoietin-2, ephrinB2 and EphB4 in pyogenic granuloma of human gingiva implicates their roles in inflammatory angiogenesis.
Granuloma Annulare
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways.
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Granulomatosis with Polyangiitis
Evidence for enhanced Bruton's tyrosine kinase activity in transitional and naïve B cells of patients with granulomatosis with polyangiitis.
Granulomatous Disease, Chronic
Novel immunodeficiency data servers.
Granulosa Cell Tumor
Constitutively active transforming growth factor ? receptor 1 in the mouse ovary promotes tumorigenesis.
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Graves Disease
Tear film proteome in age-related macular degeneration.
Hamartoma
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Mutation analysis of related genes in hamartoma polyp tissue of Peutz-Jeghers syndrome.
Hamartoma Syndrome, Multiple
A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome.
An unexpected Cowden syndrome case found among members of a large familial adenomatous polyposis kindred.
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.
BMP2 exposure results in decreased PTEN protein degradation and increased PTEN levels.
Looking for the hidden mutation: Bannayan-Riley-Ruvalcaba syndrome caused by constitutional and mosaic 10q23 microdeletions involving PTEN and BMPR1A.
Overlap of juvenile polyposis syndrome and cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: implications for treatment and surveillance.
Head and Neck Neoplasms
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
EphB4: A promising target for upper aerodigestive malignancies.
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
Screening and Validation of Molecular Targeted Radiosensitizers.
Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.
Hearing Loss
JAK2/STAT3 inhibition attenuates noise-induced hearing loss.
Heart Arrest
Effects of NaHS and hydroxylamine on the expressions of brain-derived neurotrophic factor and its receptors in rats after cardiac arrest and cardiopulmonary resuscitation.
Regulation of tyrosine protein kinase receptor Trk-B and motor function in rats following cardiac arrest.
[Effects of brain necroptosis and cytokines expression array on brain injury in rats with cardiac arrest].
Heart Defects, Congenital
A familial congenital heart disease with a possible multigenic origin involving a mutation in BMPR1A.
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
AcvR1-mediated BMP signaling in second heart field is required for arterial pole development: Implications for myocardial differentiation and regional identity.
BMPR1A is a candidate gene for congenital heart defects associated with the recurrent 10q22q23 deletion syndrome.
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Wnt11 regulates cardiac chamber development and disease during perinatal maturation.
Heart Diseases
Comparative genomics on Wnt11 gene.
Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Heart Failure
Cardiomyocyte apoptosis triggered by RAFTK/pyk2 via Src kinase is antagonized by paxillin.
CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
Elevated expression of C3G protein in the peri-infarct myocardium of rats.
Expression of bone morphogenetic protein 4 and its receptors in the remodeling heart.
Increased expression of Dock180 protein in the noninfarcted myocardium in rats.
Outflow tract cushions perform a critical valve-like function in the early embryonic heart requiring BMPRIA-mediated signaling in cardiac neural crest.
Paxillin and Focal Adhesion Kinase (FAK) Regulate Cardiac Contractility in the Zebrafish Heart.
PYK2 regulates SERCA2 gene expression in neonatal rat ventricular myocytes.
Src and multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch.
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
The role of Pyk2 in cardiac arrhythmogenesis.
Heart Septal Defects, Atrial
BMPR1A mutation-positive juvenile polyposis syndrome and atrial septal defect: coincidence or association?
Homozygous missense variant in BMPR1A resulting in BMPR signaling disruption and syndromic features.
Hemangioma, Cavernous, Central Nervous System
Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
Hemangiosarcoma
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.
Phosphotyrosine enrichment identifies focal adhesion kinase and other tyrosine kinases for targeting in canine hemangiosarcoma.
Hematologic Diseases
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Benzoquinone, a leukemogenic metabolite of benzene, catalytically inhibits the protein tyrosine phosphatase PTPN2 and alters STAT1 signaling.
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
[Oral molecular targeting agents in hematological malignancy]
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
[Research advances in the role of JAK2 mutations in acute leukemia].
Hematologic Neoplasms
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
A Case of Hypophosphatemia with Increased Urinary Excretion of Phosphorus Associated with Ibrutinib.
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma.
Activated c-Abl tyrosine kinase in malignant solid tumors.
Altered splicing in hematological malignancies reveals a tissue-specific translational block of the Src-family tyrosine kinase fyn brain isoform expression.
Azole antifungals and new targeted therapies for hematological malignancy.
BCR-ABL in chronic myelogenous leukemia--how does it work?
Bruton's tyrosine kinase (BTK) mediates resistance to EGFR inhibition in non-small-cell lung carcinoma.
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia.
Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Depletion of STAT5 blocks TEL-SYK-induced APMF-type leukemia with myelofibrosis and myelodysplasia in mice.
Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Design, synthesis and biological evaluation of novel dithiocarbamate-substituted diphenylaminopyrimidine derivatives as BTK inhibitors.
Detection of BCR-ABL in Hematological Malignancies by RT-PCR.
Differences in gene expression and alterations in cell cycle of acute myeloid leukemia cell lines after treatment with JAK inhibitors.
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Early events in leukemogenesis in P190Bcr-abl transgenic mice.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Focal adhesion kinase as a target in the treatment of hematological malignancies.
Functional aspects of apoptosis in hematopoiesis and consequences of failure.
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.
Hematopoietic cell kinase (HCK) is a potential therapeutic target for dysplastic and leukemic cells due to integration of erythropoietin/PI3K pathway and regulation of erythropoiesis: HCK in erythropoietin/PI3K pathway.
Ibrutinib in CLL/SLL: From bench to bedside (Review).
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
Ibrutinib-Induced Vasculitis in a Patient with Metastatic Colon Cancer Treated in Combination with Cetuximab.
Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells.
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Increased expression of a novel c-abl-related RNA in K562 cells.
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.
JAK1/2 Inhibitors AZD1480 and CYT387 Inhibit Canine B-Cell Lymphoma Growth by Increasing Apoptosis and Disrupting Cell Proliferation.
JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma.
Janus kinase deregulation in leukemia and lymphoma.
Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
Kinases as drug discovery targets in hematologic malignancies.
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
MUC1 in hematological malignancies.
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting.
Novel Association of a Familial TGFBR1 Mutation in Loeys-Dietz Syndrome with Concomitant Hematologic Malignancy.
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies.
Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway.
PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis.
Peripheral T cell lymphoma: new model + new insight.
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes.
Preclinical Studies of PROTACs in Hematological Malignancies.
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country.
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Rearrangement of PDGFR? gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report.
Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.
Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
STAT3 Inhibitors: Finding a Home in Lymphoma and Leukemia.
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
SYK is a critical regulator of FLT3 in acute myeloid leukemia.
Synergistic Interactions between DMAG and Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors in Bcr/abl+ Leukemia Cells Sensitive and Resistant to Imatinib Mesylate.
Systematic review of infectious events with the Bruton tyrosine kinase inhibitor ibrutinib in the treatment of hematologic malignancies.
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages.
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
The Janus Kinase 2 (JAK2) V617F mutation in hematological malignancies in México.
The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Therapeutic effect and mechanism of ibrutinib combined with dexamethasone on multiple myeloma.
Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
[Advancement of peptide vaccines for hematologic malignancies].
[Quality assurance of the molecular diagnostic tests in hematological malignancies]
Hematoma, Subdural, Chronic
Inhibitory Mechanism of the Outer Membrane Growth of Chronic Subdural Hematomas.
Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.
Somatic mutations and the hierarchy of hematopoiesis.
Hemoglobinuria, Paroxysmal
Paroxysmal nocturnal hemoglobinuria induced by the occurrence of BCR-ABL in a PIGA mutant hematopoietic progenitor cell.
Somatic mutations and the hierarchy of hematopoiesis.
Hemophilia A
Prevention of the anti-factor VIII memory B-cell response by inhibition of the Bruton's tyrosine kinase in experimental hemophilia A.
Hepatitis
Expression of oncogenes in human liver disease.
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Hepatitis A
SMAD3 promotes autophagy dysregulation by triggering lysosome depletion in tubular epithelial cells in diabetic nephropathy.
Hepatitis B
Activation of c-myc expression by c-Abl is independent of both the DNA binding function of c-Abl and the c-myc EP site.
Activation of Focal Adhesion Kinase by Hepatitis B Virus HBx Protein: Multiple Functions in Viral Replication.
Association of Bcr-Abl Tyrosine Kinase Inhibitors With Hepatitis B Virus Reactivation Requiring Antiviral Treatment in Taiwan.
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
HBx protein induces EMT through c-Src activation in SMMC-7721 hepatoma cell line.
Hepatitis B virus e antigen physically associates with receptor-interacting serine/threonine protein kinase 2 and regulates IL-6 gene expression.
Hepatitis B virus HBx protein activation of cyclin A-cyclin-dependent kinase 2 complexes and G1 transit via a Src kinase pathway.
Hepatitis B virus promotes ?-catenin-signalling and disassembly of adherens junctions in a Src kinase dependent fashion.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Involvement of endoplasmic reticulum in hepatitis B virus replication.
SNU cell lines and their application for cancer research.
Hepatitis B, Chronic
A deficient translocation of CD3?, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection.
Hepatitis C
Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry.
Association of 49245A>G (rs868) polymorphism in the 3'UTR of donor TGFBR1 gene with course of hepatitis C following orthotopic liver transplantation.
Focal Adhesion Kinase (FAK) Mediates the Induction of Pro-Oncogenic and Fibrogenic Phenotypes in Hepatitis C Virus (HCV)-Infected Cells.
Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli.
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Hepatitis C virus NS5A mediated STAT3 activation requires co-operation of Jak1 kinase.
Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction.
Hepatitis C Virus Particle Assembly Involves Phosphorylation of NS5A by the c-Abl Tyrosine Kinase.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Interaction of Hepatitis C Virus Core Protein with Janus Kinase Is Required for Efficient Production of Infectious Viruses.
Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review.
Phosphorylated Ezrin (Thr567) Regulates Hippo Pathway and Yes-Associated Protein (Yap) in Liver.
Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in Hepatitis C virus replicon.
Structure of the c-Src-SH3 domain in complex with a proline-rich motif of NS5A protein from the hepatitis C virus.
Yeast Endoplasmic Reticulum Sequestration Screening for the Engineering of Proteases from Libraries Expressed in Yeast.
Hepatitis E
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Hepatitis, Alcoholic
The role of Tec kinase signaling pathways in the development of Mallory Denk Bodies in balloon cells in alcoholic hepatitis.
Hepatitis, Autoimmune
Serum level of transforming growth factor-beta1 (TGF-beta1) and the expression of TGF-beta receptor type II in peripheral blood mononuclear cells in patients with autoimmune hepatitis.
Hepatitis, Chronic
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Hepatoblastoma
Inhibition of cell migration by focal adhesion kinase: Time-dependent difference in integrin-induced signaling between endothelial and hepatoblastoma cells.
Nuclear accumulations of p53 and Mdm2 are accompanied by reductions in c-Abl and p300 in zinc-depleted human hepatoblastoma cells.
Hepatomegaly
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm.
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
Hepatopulmonary Syndrome
[Splenic tyrosine kinase promotes pulmonary angiogenesis in rats with hepatopulmonary syndrome].
Hereditary Breast and Ovarian Cancer Syndrome
Genetic testing by cancer site: stomach.
Hernia, Umbilical
BMPR1A-mediated BMP1 signalling is disrupted in the cadmium-induced omphalocele in the chick model.
Hernias, Diaphragmatic, Congenital
Upregulated EFNB2 and EPHB4 promotes lung development in a nitrofen-induced congenital diaphragmatic hernia rat model.
Herpes Simplex
Developing RNase P ribozymes for gene-targeting and antiviral therapy.
Engineering of RNase P ribozyme for gene-targeting applications.
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Herpes Simplex Virus Type 1 Neuronal Infection Perturbs Golgi Apparatus Integrity through Activation of Src Tyrosine Kinase and Dyn-2 GTPase.
Inhibition of herpes simplex virus replication by genistein, an inhibitor of protein-tyrosine kinase.
Inhibitory effect of tyrphostin on the replication of herpes simplex virus type 1.
Microarray analysis of genes with differential expression of m6A methylation in lung cancer.
New erythroxane-type diterpenoids from Fagonia boveana (Hadidi) Hadidi & Graf.
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
The location of v-src in a retrovirus vector determines whether the virus is toxic or transforming.
Variations in transcription-repair coupling in mouse cells.
Herpes Zoster
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
Angiopoietin-like protein 2 promotes the progression of diabetic kidney disease.
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Herpes Zoster in Tofacitinib: Risk is Further Increased with Glucocorticoids but not Methotrexate.
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Update on the Safety Profile of Tofacitinib in Rheumatoid Arthritis from Clinical Trials to Real-World Studies: A Narrative Review.
[Risk profile of disease-modifying antirheumatic drugs: an update from the RABBIT register].
Hidradenitis Suppurativa
A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
In silico Analysis of Gamma-Secretase-Complex Mutations in Hidradenitis Suppurativa Demonstrates Disease-Specific Substrate Recognition and Cleavage Alterations.
HIV Infections
HIV infection in vitro enhances the activity of src-family protein tyrosine kinases.
HIV infection--induced posttranslational modification of T cell signaling molecules associated with disease progression.
HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.
Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology.
Hodgkin Disease
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Richter transformation to Hodgkin lymphoma on Bruton's tyrosine kinase inhibitor therapy.
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs.
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma.
The PTP1B mutant PTP1B?2-4 is a positive regulator of the JAK/STAT signalling pathway in Hodgkin lymphoma.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Huntington Disease
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
Hydatidiform Mole
Expression of TGF-beta signaling proteins in normal placenta and gestational trophoblastic disease.
Hydrocephalus
Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus.
Loss of Fyn tyrosine kinase on the C57BL/6 genetic background causes hydrocephalus with defects in oligodendrocyte development.
Toxic non-resorptive internal hydrocephalus as a result of haemorrhagic ventriculitis during induction chemotherapy of Bcr-Abl positive acute lymphoblastic leukaemia.
Hydrocephalus, Normal Pressure
Expression of TGF-betas and TGF-beta type II receptor in cerebrospinal fluid of patients with idiopathic normal pressure hydrocephalus.
Hydronephrosis
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Hydrops Fetalis
EPHB4 kinase-inactivating mutations cause autosomal dominant lymphatic-related hydrops fetalis.
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Loss of function mutations in EPHB4 are responsible for vein of Galen aneurysmal malformation.
Hyper-IgM Immunodeficiency Syndrome
Absence of memory B cells in patients with common variable immunodeficiency.
Novel immunodeficiency data servers.
Hyperalgesia
Can Src protein tyrosine kinase inhibitors be combined with opioid analgesics? Src and opioid-induced tolerance, hyperalgesia and addiction.
CXCL13/CXCR5 signaling contributes to diabetes-induced tactile allodynia via activating pERK, pSTAT3, pAKT pathways and pro-inflammatory cytokines production in the spinal cord of male mice.
EphrinB2 induces tyrosine phosphorylation of NR2B via Src-family kinases during inflammatory hyperalgesia.
GDNF hyperalgesia is mediated by PLCgamma, MAPK/ERK, PI3K, CDK5 and Src family kinase signaling and dependent on the IB4-binding protein versican.
Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia.
Involvement of a spinal brain-derived neurotrophic factor/full-length TrkB pathway in the development of nerve injury-induced thermal hyperalgesia in mice.
JAK/STAT3 pathway is activated in spinal cord microglia after peripheral nerve injury and contributes to neuropathic pain development in rat.
Janus kinase 2 activation participates in prostaglandin E2-induced hyperalgesia.
Prooxidant-induced c-Src/nuclear factor kappa B-coupled signalling in sensory ganglia mediates cutaneous hyperalgesia.
Role of GPCR (mu-opioid)-receptor tyrosine kinase (epidermal growth factor) crosstalk in opioid-induced hyperalgesic priming (type II).
Transient decrease in nociceptor GRK2 expression produces long-term enhancement in inflammatory pain.
Hypereosinophilic Syndrome
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Ponatinib efficiently kills imatinib-resistant chronic eosinophilic leukemia cells harboring gatekeeper mutant T674I FIP1L1-PDGFR?: roles of Mcl-1 and ?-catenin.
Ruxolitinib found to cause eyelash growth: a case report.
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
The chronic myeloproliferative disorders and mutation of JAK2: Dameshek's 54 year old speculation comes of age.
Hypergammaglobulinemia
[Juvenile myelomonocytic leukemia: A three-case series].
Hyperglycemia
Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli.
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Hyperglycemia and reactive oxygen species mediate apoptosis in aortic endothelial cells through Janus kinase 2.
Hyperglycemia-induced p66shc inhibits insulin-like growth factor I-dependent cell survival via impairment of Src kinase-mediated phosphoinositide-3 kinase/AKT activation in vascular smooth muscle cells.
The Abnormal Architecture of Healed Diabetic Ulcers Is the Result of FAK Degradation by Calpain 1.
The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
Hyperhomocysteinemia
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Hyperinsulinism
Actein ameliorates hepatic steatosis and fibrosis in high fat diet-induced NAFLD by regulation of insulin and leptin resistant.
Decreased erythrocyte insulin binding in hypertensive subjects with hyperinsulinemia.
The renal TGF-beta system in the db/db mouse model of diabetic nephropathy.
Hyperlipidemias
Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease.
Hyperostosis
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Hypersensitivity
(-)-Asarinin inhibits mast cells activation as a Src family kinase inhibitor.
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Acute stress induces visceral hypersensitivity via glucocorticoid receptor-mediated membrane insertion of TRPM8: Involvement of a non-receptor tyrosine kinase Pyk2.
Application of a pharmacogenetic test adoption model to six oncology biomarkers.
BDNF Contributes to Spinal Long-Term Potentiation and Mechanical Hypersensitivity Via Fyn-Mediated Phosphorylation of NMDA Receptor GluN2B Subunit at Tyrosine 1472 in Rats Following Spinal Nerve Ligation.
Delgocitinib: First Approval.
Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study.
Discovery of dual ZAP70 and Syk kinases inhibitors by docking into a rare C-helix-out conformation of Syk.
Effect of reduced EPHB4 expression in thymic epithelial cells on thymocyte development and peripheral T cell function.
Effects of Src-kinase inhibition in cancer-induced bone pain.
Electroacupuncture ameliorates mechanical hypersensitivity by down-regulating spinal Janus kinase 2/signal transducer and activation of transcription 3 and interleukin 6 in rats with spared nerve injury.
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Identification of Type-II Inhibitors Using Kinase Structures.
JTE-852, a novel spleen tyrosine kinase inhibitor, blocks antigen-induced allergic reactions in rats.
Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics.
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Negative regulation of immunoglobulin E-dependent allergic responses by Lyn kinase.
Oclacitinib (APOQUEL(®) ) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.
Potential applications of Bruton's tyrosine kinase inhibitors for the prevention of allergic reactions.
Progressive multifocal leukoencephalopathy in a patient with common variable immunodeficiency and abnormal CD8+ T-cell subset distribution.
RN486, a Selective Bruton's Tyrosine Kinase Inhibitor, Abrogates Immune Hypersensitivity Responses and Arthritis in Rodents.
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
The Possible Importance of ?3 Integrins for Leukemogenesis and Chemoresistance in Acute Myeloid Leukemia.
The role of the tyrosine kinase Lyn in allergy and cancer.
Topical treatment with mastic (resin from Pistacia lentiscus) elicits anti-inflammatory and anti-pruritic responses by modulating keratinocyte activation in a mouse model of allergic dermatitis.
Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex.
Vascular Endothelial Growth Factor A Signaling Promotes Spinal Central Sensitization and Pain-related Behaviors in Female Rats with Bone Cancer.
Hypersensitivity, Immediate
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis.
Hypertelorism
International Registry of Patients Carrying TGFBR1 or TGFBR2 Mutations: Results of the MAC (Montalcino Aortic Consortium).
Hypertension
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
A novel BMPR2 mutation with widely disparate heritable pulmonary arterial hypertension clinical phenotype.
Angiotensin II utilizes JANUS KINASE 2 in hypertension, but not in the physiologic control of blood pressure during low salt intake.
Angiotensin-converting enzyme 2 alleviates pulmonary artery hypertension through inhibition of focal adhesion kinase expression.
Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
BMP signaling in vascular diseases.
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells.
Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
C-src tyrosine kinase gene rs1378942 polymorphism and hypertension in Asians: Review and meta-analysis.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Characteristics of pulmonary arterial hypertension in affected carriers of a mutation located in the cytoplasmic tail of BMPRII.
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.
Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy.
Effects of diabetes and hypertension on glomerular transforming growth factor-beta receptor expression.
Erratum to: BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Expression and distribution of Src in the nucleus of myocytes in cardiac hypertrophy.
Genetics of pulmonary arterial hypertension: current and future implications.
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
Interleukin 6 knockout prevents angiotensin II hypertension: role of renal vasoconstriction and janus kinase 2/signal transducer and activator of transcription 3 activation.
miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity.
Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10.
Protein tyrosine kinase 2beta as a candidate gene for hypertension.
Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Smad signaling in the rat model of monocrotaline pulmonary hypertension.
Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
Soluble form of vascular cell adhesion molecule 1 induces migration and proliferation of vascular smooth muscle cells.
Src Kinases Regulate Glutamatergic Input to Hypothalamic Presympathetic Neurons and Sympathetic Outflow in Hypertension.
Subcellular redistribution of focal adhesion kinase and its related nonkinase in hypertrophic myocardium.
The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
The Dynamic Actin Cytoskeleton in Smooth Muscle.
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
[Expression of focal adhesion kinase in cardiac myocytes of hypertrophic ventricle]
[NF-?B inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
[Phosphorylation and nuclear translocation of serine 722 and serine 910 of focal adhesion kinase in hypertrophic cardiac myocytes of left ventricle of spontaneously hypertensive rats]
[Pulmonary arterial hypertension and BMP system abnormality]
Hypertension, Portal
Screening strategies for pulmonary arterial hypertension.
Hypertension, Pulmonary
Activation of signaling molecules and matrix metalloproteinases in right ventricular myocardium of rats with pulmonary hypertension.
Augmented pulmonary vasoconstrictor reactivity following chronic hypoxia requires Src kinase and EGFR signaling.
Critical Role of the Axonal Guidance Cue EphrinB2 in Lung Growth, Angiogenesis, and Repair.
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Eicosapentaenoic acid ameliorates pulmonary hypertension via inhibition of tyrosine kinase Fyn.
Heme Biosynthesis Modulation via ?-Aminolevulinic Acid Administration Attenuates Chronic Hypoxia-induced Pulmonary Hypertension.
Interleukin-6 Modulates the Expression of the Bone Morphogenic Protein Receptor Type II Through a Novel STAT3-microRNA Cluster 17/92 Pathway.
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension.
Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases.
Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia.
Pathobiology of pulmonary arterial hypertension.
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Pyk2 aggravates hypoxia-induced pulmonary hypertension by activating HIF-1?
RELM-? promotes human pulmonary artery smooth muscle cell proliferation via FAK-stimulated surviving.
Signaling molecules in nonfamilial pulmonary hypertension.
[Biomarker screening of rat pulmonary hypertension model by transcriptome sequencing].
[Pulmonary Hypertension: microRNAs in Pathogenesis, Diagnosis and Therapy.]
Hypertension, Renovascular
Possible interesting link between Janus kinase 2 mutation and renovascular hypertension.
Renovascular hypertension from the BCR-ABL tyrosine kinase inhibitor ponatinib.
Hypertrophy, Left Ventricular
CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling.
PYK2 regulates SERCA2 gene expression in neonatal rat ventricular myocytes.
Hypertrophy, Right Ventricular
Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice.
Hypopharyngeal Neoplasms
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
Hypophosphatemia
[Cancer and electrolytes imbalance]
Hypospadias
Associations of TGFBR1 and TGFBR2 gene polymorphisms with the risk of hypospadias: a case-control study in a Chinese population.
Hypotension
EPHB4 Protein Expression in Vascular Smooth Muscle Cells Regulates Their Contractility, and EPHB4 Deletion Leads to Hypotension in Mice.
NF-?B activation mediates LPS-or zymosan-induced hypotension and inflammation reversed by BAY61-3606, a selective Syk inhibitor, in rat models of septic and non-septic shock.
Hypothyroidism
Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia.
Hypoxia, Brain
Effects of Src kinase inhibition on expression of pro-caspase-2 after brain hypoxia in a piglet animal model.
Effects of Src Kinase Inhibition on Expression of Protein Tyrosine Phosphatase 1B after Brain Hypoxia in a Piglet Animal Model.
Temporal Changes in Caspase-1 and Caspase-8 Activities Following Brain Hypoxia With and Without Src kinase Inhibition in a Piglet Animal Model.
Hypoxia-Ischemia, Brain
Effect of Src Kinase inhibition on Cytochrome c, Smac/DIABLO and Apoptosis Inducing Factor (AIF) Following Cerebral Hypoxia-Ischemia in Newborn Piglets.
Neonatal cerebral hypoxia-ischemia: involvement of FAK-dependent pathway.
Idiopathic Pulmonary Fibrosis
Downregulation of FAK-related non-kinase mediates the migratory phenotype of human fibrotic lung fibroblasts.
Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis.
Nintedanib, a triple tyrosine kinase inhibitor, attenuates renal fibrosis in chronic kidney disease.
Ileitis
ZAP-70 genotype disrupts the relationship between microbiota and host, leading to spondyloarthritis and ileitis in SKG mice.
Ileus
Inhibition of JAK1 mitigates postoperative ileus in mice.
Inhibition of spleen tyrosine kinase as treatment of postoperative ileus.
Immune System Diseases
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Effective, safe, and sustained correction of murine XLA using a UCOE-BTK promoter-based lentiviral vector.
Impaired T cell receptor signaling and development of T cell-mediated autoimmune arthritis.
Small-molecule inhibitors of spleen tyrosine kinase as therapeutic agents for immune disorders: will promise meet expectations?
Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
[The next step in the treatment of immune diseases: jakinibs, inhibitors of the intracellular Janus kinase].
Infarction, Middle Cerebral Artery
Delayed phosphorylation of p38 mitogen-activated protein kinase in the AT1a knock-out mouse striatal neurons during middle cerebral artery occlusion and reperfusion.
Infections
A case of Fabry's disease with congenital agammaglobulinemia.
A de novo transcriptome analysis shows that modulation of the JAK-STAT signaling pathway by salmonid alphavirus subtype 3 favors virus replication in macrophage/dendritic-like TO-cells.
A deficient translocation of CD3?, ZAP-70 and Grb2 to lipid raft, as a hallmark of defective adaptive immune response during chronic hepatitis B infection.
A Dual Role for the Nonreceptor Tyrosine Kinase Pyk2 during the Intracellular Trafficking of Human Papillomavirus 16.
A new retroviral vector, CA1, to identify and select for cells expressing an inserted gene in vitro and in vivo.
A novel focal adhesion kinase from Marsupenaeus japonicus and its response to WSSV infection.
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
A role for c-Abl in c-myc regulation.
Abelson tyrosine kinase facilitates Salmonella enterica serovar Typhimurium entry into epithelial cells.
Abl Tyrosine Kinase Regulates Hepatitis C Virus Entry.
Abnormal peripheral lymphocyte function in c-abl mutant mice.
Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms.
Abrogation of IL-3 dependent growth requires a functional v-src gene product: evidence for an autocrine growth cycle.
Access to nectin favors herpes simplex virus infection at the apical surface of polarized human epithelial cells.
Activated lck tyrosine protein kinase stimulates antigen-independent interleukin-2 production in T cells.
Activation of Abl by Helicobacter pylori: a novel kinase for CagA and crucial mediator of host cell scattering.
Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages.
Altered stem cell (CFU-S) function following infection of hematopoietic cells with a virus carrying V-src.
An immediate-early protein of white spot syndrome virus modulates the phosphorylation of focal adhesion kinase of shrimp.
Angiopoietin/Tie2 signaling transforms capillaries into venules primed for leukocyte trafficking in airway inflammation.
ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells.
Avian influenza viruses inhibit the major cellular signalling integrator c-Abl.
Beta Interferon-Mediated Activation of Signal Transducer and Activator of Transcription Protein 1 Interferes with Rickettsia conorii Replication in Human Endothelial Cells.
Bone marrow B lymphocyte development in c-abl-deficient mice.
c-SRC protein tyrosine kinase regulates early HIV-1 infection post-entry.
Caveolin-1 associated adenovirus entry into human corneal cells.
CD36 and Fyn Kinase Mediate Malaria-Induced Lung Endothelial Barrier Dysfunction in Mice Infected with Plasmodium berghei.
CD46 is phosphorylated at tyrosine 354 upon infection of epithelial cells by Neisseria gonorrhoeae.
Cerebral aspergillosis in a patient on ibrutinib therapy-A predisposition not to overlook.
Changes in the level of apoptosis-related proteins in Jurkat cells infected with HIV-1 versus HIV-2.
Characteristics of Chikungunya virus infection in patients with established rheumatoid arthritis.
Chicken myeloid stem cells infected by retroviruses carrying the v-fps oncogene do not require exogenous growth factors to differentiate in vitro.
Chlamydial Infection of Monocytes Stimulates IL-1beta Secretion Through Activation of the NLRP3 Inflammasome.
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Correlation Between PAI-1 Gene 4G/5G Polymorphism and the Risk of Thrombosis in Ph Chromosome-Negative Myeloproliferative Neoplasms.
Debilitating progressive encephalitis in a patient with BTK deficiency.
Decoding Susceptibility to Respiratory Viral Infections and Asthma Inception in Children.
Dectin-1 Activation during Leishmania amazonensis Phagocytosis Prompts Syk-Dependent Reactive Oxygen Species Production To Trigger Inflammasome Assembly and Restriction of Parasite Replication.
Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.
Delayed diagnosis of X-linked agammaglobulinaemia in a boy with recurrent meningitis.
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Dissection of signaling pathways and cloning of new signal transducers in tyrosine kinase-induced pathways by genetic selection.
Disseminated Bacille Calmette-Guérin infection in a patient with severe combined immunodeficiency caused by JAK3 gene mutation.
Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib.
Down regulation by p60v-src of genes specifically expressed and developmentally regulated in postmitotic quail neuroretina cells.
Down-modulation of the ZAP-70 protein tyrosine kinase in macaque T lymphocytes infected with SIVsmmPBj14.
Dual microRNA Screens Reveal That the Immune-Responsive miR-181 Promotes Henipavirus Entry and Cell-Cell Fusion.
Dysregulation of focal adhesion kinase upon Toxoplasma gondii infection facilitates parasite translocation across polarised primary brain endothelial cell monolayers.
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Effect of infection with murine recombinant retroviruses containing the v-src oncogene on interleukin 2- and interleukin 3-dependent growth states.
Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.
Effects of colony-stimulating factors on leukemia progenitor cells and oncogene expression.
Endothelial Cell Proteomic Response to Rickettsia conorii Infection Reveals Activation of the Janus Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT)-Inferferon Stimulated Gene (ISG)15 Pathway and Reprogramming Plasma Membrane Integrin/Cadherin Signaling.
Enteropathogenic Escherichia coli induces modification of the focal adhesions of infected host cells.
Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.
Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
EVALUATION OF EXPERIMENTAL INFECTION WITH L. (L.) AMAZONENSIS IN X-LINKED IMMUNODEFICIENT MICE.
Express path analysis identifies a tyrosine kinase Src-centric network regulating divergent host responses to Mycobacterium tuberculosis infection.
Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells.
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Expression of p56lck in B-cell neoplasias.
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Expression of v-src in embryonic neural retina alters cell adhesion, inhibits histogenesis, and prevents induction of glutamine synthetase.
Extracellular pressure stimulates macrophage phagocytosis by inhibiting a pathway involving FAK and ERK.
Fatal disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's tyrosine kinase.
Focal adhesion kinase activation is required for TNF-?-induced production of matrix metalloproteinase-2 and proinflammatory cytokines in cultured human periodontal ligament fibroblasts.
Focal adhesion kinase is critical for entry of Kaposi's sarcoma-associated herpesvirus into target cells.
Focal adhesion kinase plays a pivotal role in herpes simplex virus entry.
Gamma interferon-induced interferon regulatory factor 1-dependent antiviral response inhibits vaccinia virus replication in mouse but not human fibroblasts.
Gene expression profiling in AGS cells stimulated with Helicobacter pylori isogenic strains (cagA positive or cagA negative).
Genetics in community-acquired pneumonia.
Genome-Wide Gene Expression Analysis Identifies the Proto-oncogene Tyrosine-Protein Kinase Src as a Crucial Virulence Determinant of Infectious Laryngotracheitis Virus in Chicken Cells.
HECT E3 Ubiquitin Ligase Nedd4 Is Required for Antifungal Innate Immunity.
Helicobacter canis bacteraemia in a rheumatoid arthritis patient treated with tofacitinib: case report and literature review.
Helicobacter pylori CagA Induces Cortactin Y-470 Phosphorylation-Dependent Gastric Epithelial Cell Scattering via Abl, Vav2 and Rac1 Activation.
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Helicobacter pylori infection interferes with epithelial Stat6-mediated interleukin-4 signal transduction independent of cagA, cagE, or VacA.
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling.
Herpes simplex virus triggers activation of calcium-signaling pathways.
Herpes Simplex Virus Type 1 Neuronal Infection Perturbs Golgi Apparatus Integrity through Activation of Src Tyrosine Kinase and Dyn-2 GTPase.
HIV-1 down-regulates CD4 costimulation of TCR/CD3-directed tyrosine phosphorylation through CD4/p56lck dissociation.
HIV-1 infection is facilitated in T cells by decreasing p56lck protein tyrosine kinase activity.
Host Src controls gallid alpha herpesvirus 1 intercellular spread in a cellular fatty acid metabolism-dependent manner.
Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.
Human herpesvirus 7 induces the down-regulation of CD4 antigen in lymphoid T cells without affecting p56lck levels.
Human metapneumovirus inhibits IFN-? signaling by downregulating Jak1 and Tyk2 cellular levels.
Hydroquinone regulates hemeoxygenase-1 expression via modulation of Src kinase activity through thiolation of cysteine residues.
Hyper-IgE syndrome.
Hypoxia Decreases Invasin-Mediated Yersinia enterocolitica Internalization into Caco-2 Cells.
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
IFN-alpha beta secreted during infection is necessary but not sufficient for negative feedback regulation of IFN-alpha beta signaling by Mycobacterium tuberculosis.
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
In vivo administration of a JAK3 inhibitor to chronically siv infected rhesus macaques leads to NK cell depletion associated with transient modest increase in viral loads.
In vivo tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity.
Incipient Diabetes Mellitus and Nascent Thyroid Disease Presenting as Beard Alopecia Areata: Case Report and Treatment Review of Alopecia Areata of the Beard.
Increased Src kinase level results in increased protein tyrosine phosphorylation in scrapie-infected neuronal cell lines.
Induction of cyclophilin A by influenza A virus infection facilitates group A Streptococcus coinfection.
Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Infections in baricitinib clinical trials for patients with active rheumatoid arthritis.
Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Integrin alpha3beta1 (CD 49c/29) is a cellular receptor for Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) entry into the target cells.
Intracellular invasion by Orientia tsutsugamushi is mediated by integrin signaling and actin cytoskeleton rearrangements.
Ixodes scapularis JAK-STAT Pathway Regulates Tick Antimicrobial Peptides, Thereby Controlling the Agent of Human Granulocytic Anaplasmosis.
JAK3 restrains inflammatory responses and protects against periodontal disease through Wnt3a signaling.
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
JNK regulates MCP-1 expression in adenovirus type 19-infected human corneal fibroblasts.
Kaposi's sarcoma-associated herpesvirus induces the phosphatidylinositol 3-kinase-PKC-zeta-MEK-ERK signaling pathway in target cells early during infection: implications for infectivity.
Kinase activity profiling of Gram-negative pneumonia.
Laminin acts via focal adhesion kinase/phosphatidylinositol-3' kinase/protein kinase B to down-regulate beta1-adrenergic receptor signalling in cat atrial myocytes.
Leishmania donovani amastigotes impair gamma interferon-induced STAT1alpha nuclear translocation by blocking the interaction between STAT1alpha and importin-alpha5.
Leishmania donovani Exploits Tollip, a Multitasking Protein, To Impair TLR/IL-1R Signaling for Its Survival in the Host.
lncRNA AK085865 Promotes Macrophage M2 Polarization in CVB3-Induced VM by Regulating ILF2-ILF3 Complex-Mediated miRNA-192 Biogenesis.
Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis.
Management of patients with chronic lymphocytic leukemia during the SARS-CoV-2 pandemic.
Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.
Mice lacking protein tyrosine kinase fyn develop a T helper-type 1 response and resistLeishmania major infection.
Microarray analysis of genes with differential expression of m6A methylation in lung cancer.
Modulation of enzymatic activity of Src-family kinases in bovine T cells transformed by Theileria parva.
Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.
Morphological transformation, tumorigenicity and src-specific cytotoxic T-lymphocyte-mediated tumor immunity induced by murine 3T3 cells expressing src oncogenes encoding novel non-myristylated N-terminal domains.
Mutation of a site of tyrosine phosphorylation in the lymphocyte-specific tyrosine protein kinase, p56lck, reveals its oncogenic potential in fibroblasts.
Myeloid-derived tissue-type plasminogen activator promotes macrophage motility through FAK, Rac1, and NF-?B pathways.
MYO1F regulates antifungal immunity by regulating acetylation of microtubules.
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways.
Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism.
Network pharmacology of JAK inhibitors.
NLRP3 inflammasome activation by Paracoccidioides brasiliensis.
Nonmuscle Myosin Heavy Chain IIA Recognizes Sialic Acids on Sialylated RNA Viruses To Suppress Proinflammatory Responses via the DAP12-Syk Pathway.
Nonreceptor Tyrosine Kinase c-Abl- and Arg-Mediated IRF3 Phosphorylation Regulates Innate Immune Responses by Promoting Type I IFN Production.
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Pathogenic prions deviate PrP(C) signaling in neuronal cells and impair A-beta clearance.
Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
PID in Disguise: Molecular Diagnosis of IRAK-4 Deficiency in an Adult Previously Misdiagnosed With Autosomal Dominant Hyper IgE Syndrome.
Population context determines cell-to-cell variability in endocytosis and virus infection.
Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout mice.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Profound differences in potassium current properties of normal and Rous sarcoma virus-transformed chicken embryo fibroblasts.
Protein kinase A-mediated inhibition of gamma interferon-induced tyrosine phosphorylation of Janus kinases and latent cytoplasmic transcription factors in human monocytes by Ehrlichia chaffeensis.
Quercetin Prevents Escherichia coli O157:H7 Adhesion to Epithelial Cells via Suppressing Focal Adhesions.
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines.
Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review.
Requirement for Abl kinases in T cell receptor signaling.
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Role of Abl kinase and the Wave2 signaling complex in HIV-1 entry at a post-hemifusion step.
Role of B cells in host defense against primary Coxiella burnetii infection.
Role of Herpes Simplex Virus VP11/12 Tyrosine-Based Motifs in Binding and Activation of the Src Family Kinase Lck and Recruitment of p85, Grb2, and Shc.
Schistosoma mansoni FES Tyrosine Kinase Involvement in the Mammalian Schistosomiasis Outcome and Miracidia Infection Capability in Biomphalaria glabrata.
Selective immortalization of murine macrophages from fresh bone marrow by a raf/myc recombinant murine retrovirus.
Serine phosphorylation of cortactin controls focal adhesion kinase activity and cell scattering induced by Helicobacter pylori.
Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts.
Some findings of FADD knockdown in inhibition of HIV-1 replication in Jurkat cells and PBMCs.
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
Spleen tyrosine kinase from Nile tilapia (Oreochromis niloticus): Molecular characterization, expression pattern upon bacterial infection and the potential role in BCR signaling and inflammatory response.
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
Src-dependent Tyrosine Phosphorylation of Non-muscle Myosin Heavy Chain-IIA Restricts Listeria monocytogenes Cellular Infection.
State and role of SRC family kinases in replication of herpes simplex virus 1.
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Taohong siwu decoction attenuates myocardial fibrosis by inhibiting fibrosis proliferation and collagen deposition via TGFBR1 signaling pathway.
Testosterone-induced persistent susceptibility to Plasmodium chabaudi malaria: long-term changes of lincRNA and mRNA expression in the spleen.
TGF-beta 1 signaling controls retinal pericyte contractile protein expression.
The Amino-Terminal Part of the Needle-Tip Translocator LcrV of Yersinia pseudotuberculosis Is Required for Early Targeting of YopH and In vivo Virulence.
The c-Src and Pyk2 protein tyrosine kinases play protective roles in early HIV-1 infection of CD4+ T cell lines.
The gammac-cytokine regulated transcription factor, STAT5, increases HIV-1 production in primary CD4 T cells.
The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.
The Interplay of Notch Signaling and STAT3 in TLR-Activated Human Primary Monocytes.
The non-receptor tyrosine kinase Tec controls assembly and activity of the noncanonical caspase-8 inflammasome.
The pathogenic E. coli type III effector EspZ interacts with host CD98 and facilitates host cell prosurvival signalling.
The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor.
The relationship of modulation of major histocompatibility complex class I antigens to retrovirus transformation in rat cell lines.
The role of p56lck in the development of gamma delta T cells and their function during an infection by Listeria monocytogenes.
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
The v-src oncogene may not be responsible for the increased radioresistance of hematopoietic progenitor cells expressing v-src.
TLR2/CXCR4 coassociation facilitates Chlamydia pneumoniae infection-induced atherosclerosis.
Toxoplasma gondii inhibits mast cell degranulation by suppressing phospholipase C?-mediated Ca(2+) mobilization.
Transcriptional downregulation of the retina-specific QR1 gene by pp60v-src and identification of a novel v-src-responsive unit.
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Transgenes encoding both type I and type IV c-abl proteins rescue the lethality of c-abl mutant mice.
Transient myelodysplastic syndrome in X-linked agammaglobulinemia with a novel Btk mutation.
Tuberculosis, hepatitis B and herpes zoster in tofacitinib-treated patients with rheumatoid arthritis.
Tumor Suppressor Analysis in CML.
Two sequential layers of antibody-mediated control of Legionella pneumophila infection.
Type II interferon signaling in the brain during a viral infection with age-dependent pathogenesis.
Usage of heparan sulfate, integrins, and FAK in HPV16 infection.
X-linked agammaglobulinemia - first case with Bruton tyrosine kinase mutation from Pakistan.
Yellow Fever Virus, but Not Zika Virus or Dengue Virus, Inhibits T-Cell Receptor-Mediated T-Cell Function by an RNA-Based Mechanism.
ZAP-70 positive cells in treated and untreated HIV-1 infected patients.
ZAP-70, CTLA-4 and proximal T cell receptor signaling in cows infected with Mycobacterium avium subsp. paratuberculosis.
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
[Risk Factors of Leukemia-free Survival in Ph
[Severe Hepatitis E virus infection in a patient with rheumatoid arthritis treated with baricitinib].
Infertility
BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency.
Determination of c-Abl tyrosine kinase and mTERT catalytic subunit of telomerase expression level during prenatal-postnatal mouse ovary-testis development.
Genetic studies of MIS signalling in sexual development.
Ptk2b deletion improves mice folliculogenesis and fecundity via inhibiting follicle loss mediated by Erk pathway.
Successful Planned Pregnancy through Vitrified-Warmed Embryo Transfer in a Woman with Chronic Myeloid Leukemia: Case Report and Literature Review.
Infertility, Male
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Inflammatory Bowel Diseases
Advances in the Development of Janus Kinase Inhibitors in Inflammatory Bowel Disease: Future Prospects.
Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey.
CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease.
Clinical Pharmacology of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Corrigendum: The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Enhancer of zeste homolog 2 contributes to apoptosis by inactivating janus kinase 2/ signal transducer and activator of transcription signaling in inflammatory bowel disease.
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases.
Intestinally-restricted Janus Kinase inhibition: a potential approach to maximize the therapeutic index in inflammatory bowel disease therapy.
JAK inhibitors and infections risk: focus on herpes zoster.
JAK-STAT inhibitors for the treatment of immunomediated diseases.
Janus Kinase Inhibition With Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment.
Janus kinase inhibitors for the treatment of inflammatory bowel diseases: developments from phase I and phase II clinical trials.
Kinase inhibitors in the treatment of immune-mediated disease.
Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.
Optimizing Immunization Strategies in Patients with IBD.
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Reduced migration of fibroblasts in inflammatory bowel disease: role of inflammatory mediators and focal adhesion kinase.
Regulation of Janus Kinase 2 by an Inflammatory Bowel Disease Causal Non-coding Single Nucleotide Polymorphism.
Role of Csk in intestinal epithelial barrier function and protection against colitis.
Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients.
Safety of Janus Kinase Inhibitors in Patients with Inflammatory Bowel Diseases or Other Immune-mediated Diseases: a Systematic Review and Meta-Analysis.
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Spondyloarthritis: new insights into clinical aspects, translational immunology and therapeutics.
Strong Evidence of a Combination Polymorphism of the Tyrosine Kinase 2 Gene and the Signal Transducer and Activator of Transcription 3 Gene as a DNA-Based Biomarker for Susceptibility to Crohn's Disease in the Japanese Population.
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease.
The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.
Tofacitinib Therapy in Children and Young Adults With Pediatric-onset Medically Refractory Inflammatory Bowel Disease.
Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis.
Update on Janus kinase antagonists in inflammatory bowel disease.
Vaccination in Patients with Inflammatory Bowel Diseases.
Vaccinations in Adult Patients with Inflammatory Bowel Diseases in the West.
Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19?
[Biologics and Janus kinase inhibitor for inflammatory bowel disease -understanding the clinical guideline for IBD].
Inflammatory Breast Neoplasms
The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
Influenza in Birds
Avian influenza viruses inhibit the major cellular signalling integrator c-Abl.
Hemagglutinin from the H5N1 Virus Activates Janus Kinase 3 to Dysregulate Innate Immunity.
Nonstructural Protein 1 (NS1)-Mediated Inhibition of c-Abl Results in Acute Lung Injury and Priming for Bacterial Coninfections: Insights Into 1918 H1N1 Pandemic?
The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection.
Influenza, Human
CLEC5A-Mediated Enhancement of the Inflammatory Response in Myeloid Cells Contributes to Influenza Virus Pathogenicity In Vivo.
Entropy Hotspots for the Binding of Intrinsically Disordered Ligands to a Receptor Domain.
Focal adhesion kinase (FAK) regulates polymerase activity of multiple influenza A virus subtypes.
In Vitro and In Vivo Antiviral Activity of Gingerenone A on Influenza A Virus Is Mediated by Targeting Janus Kinase 2.
Inhibiting Bruton's Tyrosine Kinase Rescues Mice from Lethal Influenza Induced Acute Lung Injury.
Novel Roles of Focal Adhesion Kinase in Cytoplasmic Entry and Replication of Influenza A Viruses.
Optimization of the Isolation and Amplification of RNA From Formalin-fixed, Paraffin-embedded Tissue: The Armed Forces Institute of Pathology Experience and Literature Review.
Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages.
Sphingosine 1-phosphate-metabolizing enzymes control influenza virus propagation and viral cytopathogenicity.
Structure and Dynamics of Membrane Proteins and Membrane Associated Proteins with Native Bicelles from Eukaryotic Tissues.
Insulin Resistance
Adipocyte-specific deficiency of Janus kinase (JAK) 2 in mice impairs lipolysis and increases body weight, and leads to insulin resistance with ageing.
c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice.
Decreased erythrocyte insulin binding in hypertensive subjects with hyperinsulinemia.
Effects of imatinib on vascular insulin sensitivity and free fatty acid transport in early weight gain.
Focal Adhesion Kinase contributes to insulin-induced actin reorganization into a mesh harboring Glucose transporter-4 in insulin resistant skeletal muscle cells.
Focal adhesion kinase negatively regulates neuronal insulin resistance.
Focal adhesion kinase regulates insulin resistance in skeletal muscle.
Immunofluorescent visualisation of focal adhesion kinase in human skeletal muscle and its associated microvasculature.
Impact of fasting on growth hormone signaling and action in muscle and fat.
In vivo inhibition of focal adhesion kinase causes insulin resistance.
Insulin-Like Growth Factor Binding Protein 1 Could Improve Glucose Regulation and Insulin Sensitivity Through Its RGD Domain.
Leptin down-regulates insulin action through phosphorylation of serine-318 in insulin receptor substrate 1.
Loss of BMP receptor type 1A in murine adipose tissue attenuates age-related onset of insulin resistance.
Novel phosphorylation of PPAR? ameliorates obesity-induced adipose tissue inflammation and improves insulin sensitivity.
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?
Upregulation of IL-4 signaling contributes to aerobic exercise-induced insulin sensitivity.
Insulinoma
C-Abl inhibitor imatinib enhances insulin production by ? cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
Intellectual Disability
Abl2/Arg controls dendritic spine and dendrite arbor stability via distinct cytoskeletal control pathways.
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
[Genetic testing and prenatal diagnosis for a family with 10q22.3q23.2 microdeletion].
Intervertebral Disc Degeneration
Wnt11 overexpression promote adipose-derived stem cells differentiating to the nucleus pulposus-like phenotype.
Intervertebral Disc Displacement
Impact of Wnt signals on human intervertebral disc cell regeneration.
Intestinal Diseases
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies.
Intestinal Polyposis
BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling.
Intracranial Aneurysm
The transforming growth factor-? receptor genes and the risk of intracranial aneurysms.
Intracranial Arteriovenous Malformations
Ephrin B2 and EphB4 selectively mark arterial and venous vessels in cerebral arteriovenous malformation.
Intracranial Hemorrhages
Assessing the association of common genetic variants in EPHB4 and RASA1 with phenotype severity in familial cerebral cavernous malformation.
EPHB4 gene polymorphisms and risk of intracranial hemorrhage in patients with brain arteriovenous malformations.
Invasive Fungal Infections
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Invasive fungal infections in patients treated with Bruton's tyrosine kinase inhibitors.
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Invasive Pulmonary Aspergillosis
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Iron Deficiencies
The Role of Advanced Practitioners in Optimizing Clinical Management and Support of Patients With Polycythemia Vera.
Ischemic Stroke
A Truncated Fragment of Src Protein Kinase Generated by Calpain-Mediated Cleavage is A Mediator of Neuronal Death in Excitotoxicity.
Activin A improves the neurological outcome after ischemic stroke in mice by promoting oligodendroglial ACVR1B-mediated white matter remyelination.
Correction to: Pyruvate Kinase M2 Increases Angiogenesis, Neurogenesis, and Functional Recovery Mediated by Upregulation of STAT3 and Focal Adhesion Kinase Activities after Ischemic Stroke in Adult Mice.
Dectin-1/Syk signaling triggers neuroinflammation after ischemic stroke in mice.
Discovery of novel 2-anilinopyrazolo[1,5-a]pyrimidine derivatives as c-Src kinase inhibitors for the treatment of acute ischemic stroke.
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation.
miR-129-2-3p directly targets SYK gene and associates with the risk of ischaemic stroke in a Chinese population.
Overexpression of EphB4 promotes neurogenesis, but inhibits neuroinflammation in mice with acute ischemic stroke.
Perlecan, a modular instructive proteoglycan with diverse functional properties.
Protective effects of angiopoietin-like 4 on cerebrovascular and functional damages in ischaemic stroke.
Pyruvate Kinase M2 Increases Angiogenesis, Neurogenesis, and Functional Recovery Mediated by Upregulation of STAT3 and Focal Adhesion Kinase Activities After Ischemic Stroke in Adult Mice.
Selective Inhibition of Janus Kinase 3 Has No Impact on Infarct Size or Neurobehavioral Outcomes in Permanent Ischemic Stroke in Mice.
Jacobsen Distal 11q Deletion Syndrome
Janus kinase 3 missense mutation in a child with Jacobsen syndrome.
Job Syndrome
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
Hyper-IgE syndrome, 2021 update.
Hyper-IgE syndrome.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
The Hyper-IgE Syndromes: Lessons in Nature, From Bench to Bedside.
The hyperimmunoglobulin E syndrome--clinical manifestation diversity in primary immune deficiency.
Joint Diseases
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
The osteoclast: a potential therapeutic target of bone and joint destruction in rheumatoid arthritis.
Keloid
A Role for Neuregulin-1 in Promoting Keloid Fibroblast Migration via ErbB2-mediated Signaling.
Increased transcriptional response to mechanical strain in keloid fibroblasts due to increased focal adhesion complex formation.
Mechanical coupling of cytoskeletal elasticity and force generation is crucial for understanding the migrating nature of keloid fibroblasts.
Upregulated periostin promotes angiogenesis in keloids through activation of the ERK 1/2 and focal adhesion kinase pathways, as well as the upregulated expression of VEGF and angiopoietin?1.
Keratitis
Correlation between matrix metalloproteinase expression and activation of the focal adhesion kinase signaling pathway in herpes stromal keratitis.
Keratosis
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Keratosis, Actinic
Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis.
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ?-tubulin explains KXO1's low clinical toxicity.
Tirbanibulin Ointment 1% as a Novel Treatment for Actinic Keratosis: Phase 1 and 2 Results.
Tirbanibulin: First Approval.
Kidney Diseases
Inhibition of spleen tyrosine kinase suppresses skin and kidney disease in lupus prone mice.
MicroRNA-140-5p Mediates Renal Fibrosis Through TGF-?1/Smad Signaling Pathway by Directly Targeting TGFBR1.
Kidney Failure, Chronic
Pharmacokinetics of tofacitinib, a Janus Kinase inhibitor, in PATIENTS with impaired renal function and end stage renal disease.
Prevalence of the Janus Kinase 2 V617F Mutation in Patients with End-Stage Renal Disease.
Kidney Neoplasms
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Expression and prognostic significance of Src family members in renal clear cell carcinoma.
Expression of bone morphogenetic protein-7, its receptors and Smad1/5/8 in normal human kidney and renal cell cancer.
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Klinefelter Syndrome
Chronic myeloid leukemia in patient with the Klinefelter syndrome.
Laryngeal Neoplasms
Basement membrane protein ladinin-1 and the MIF-CD44-?1 integrin signaling axis are implicated in laryngeal cancer metastasis.
Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp2.
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Immunohistochemical Expression of Cortactin and Focal Adhesion Kinase Predicts Recurrence Risk and Laryngeal Cancer Risk Beyond Histologic Grading.
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Laryngomalacia
Homozygous missense variant in BMPR1A resulting in BMPR signaling disruption and syndromic features.
Latent Tuberculosis
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Leiomyoma
Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta.
Gonadotropin releasing hormone analogue therapy alters signal transduction pathways involving mitogen-activated protein and focal adhesion kinases in leiomyoma.
Literature Review on the Role of Uterine Fibroids in Endometrial Function.
microRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells.
Paracrine activation of WNT/?-catenin pathway in uterine leiomyoma stem cells promotes tumor growth.
Wnt/?-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
Lens Diseases
The effects of c-Src kinase on EMT signaling pathway in human lens epithelial cells associated with lens diseases.
Lentivirus Infections
IGHG1 functions as an oncogene in tongue squamous cell carcinoma via JAK1/STAT5 signaling.
Leprosy
Disruption of HLA-DR raft, deregulations of Lck-ZAP-70-Cbl-b cross-talk and miR181a towards T cell hyporesponsiveness in leprosy.
Leukemia
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
3rd generation ABL kinase inhibitor and Philadelphia chromosome positive leukemia.
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
9;22 translocation and bcr rearrangements in chronic myelocytic leukemia patients among atomic bomb survivors.
A 77-kDa protein associates with pp125FAK in mast cells and becomes tyrosine-phosphorylated by high affinity IgE receptor aggregation.
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins.
A coiled-coil tetramerization domain of BCR-ABL is essential for the interactions of SH2-containing signal transduction molecules.
A comparative analysis of FISH, RT-PCR, and cytogenetics for the diagnosis of bcr-abl-positive leukemias.
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
A myristoyl/phosphotyrosine switch regulates c-Abl.
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
A Philadelphia chromosome positive acute lymphoblastic leukemia of donor origin after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
A Study on the Expression of BCR-ABL Transcript in Mixed Phenotype Acute Leukemia (MPAL) Cases Using the Reverse Transcriptase Polymerase Reaction Assay (RT-PCR) and its Correlation with Hematological Remission Status Post Initial Induction Therapy.
A transgenic mouse model of human T cell leukemia virus type 1-associated diseases.
Abelson kinase regulates epithelial morphogenesis in Drosophila.
Abelson murine leukemia virus induces platelet-derived growth factor-independent fibroblast growth: correlation with kinase activity and dissociation from full morphologic transformation.
Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
ABL kinase inhibitory and antiproliferative activity of novel picolinamide based benzothiazoles.
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Abl tyrosine protein kinase.
Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-abl transforming activity.
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Abl: the prototype of oncogenic fusion proteins.
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.
Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.
Accumulation of p60lck in HTLV-I-transformed T cell lines detected by an anti-lck monoclonal antibody, MOL 171.
Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-?B signaling.
Acquisition of the Ph chromosome and BCR-ABL fusion product in AML-M2 and t(8;21) leukemia: cytogenetic and FISH evidence for a late event.
Activated abl oncogenes and apoptosis: differing responses of transformed myeloid progenitor cell lines.
Activation of abl family kinases in solid tumors.
Activation of c-Abl kinase activity and transformation by a chemical inducer of dimerization.
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes.
Activation of phosphatidylinositol-3-kinase in Jurkat T cells depends on the presence of the p56lck tyrosine kinase.
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
Activation of tyrosine kinases in cancer.
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL: in vitro and in vivo studies.
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
Activity of the multitargeted kinase inhibitor, AT9283, in imatinib-resistant BCR-ABL-positive leukemic cells.
Acute leukemia.
Acute lymphoblastic leukemia in children.
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Acute myeloblastic leukemia with active tyrosine protein kinase.
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog.
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl.
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Adhesion structures in leukemia cells and their regulation by Src family kinases.
Advances in Immunotherapy of Chronic Myeloid Leukemia CML.
Aggregation of the high-affinity IgE receptor and enhanced activity of p53/56lyn protein-tyrosine kinase.
Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway.
AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells.
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.
Alterations in expression of p56lck during myeloid differentiation of LSTRA cells.
Alterations in Janus kinase (JAK)-signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy.
Altered protein kinase activities of lymphoid cells transformed by Abelson and Moloney leukemia viruses.
Ameliorating effect of Kalpaamruthaa on altered energy metabolism in BCR-ABL(+) cell line induced leukemic mouse model.
AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications.
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
An aging mouse model of human chronic myeloid leukemia.
An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.
An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial.
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy.
Anti-ganglioside monoclonal antibody AA4 selectively inhibits IgE-induced signal transduction pathways in rat basophilic leukemia cells.
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation.
Anti-leukemic effects of gallic acid on human leukemia K562 cells: Downregulation of COX-2, inhibition of BCR/ABL kinase and NF-?B inactivation.
Antiapoptotic effect of c-fes protooncogene during granulocytic differentiation.
Antibody recognition of the tumor-specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome-positive leukemias.
Antileukemic Activity and Molecular Docking Study of a Polyphenolic Extract from Coriander Seeds.
Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Antitumor activity of erbstatin, a tyrosine protein kinase inhibitor.
Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells.
Apoptosis in blood diseases. Review new data.
Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia.
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Application of flow cytometry in pediatric hematology-oncology.
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks.
Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era.
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.
Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
Association of Janus kinase 2 (JAK2) polymorphisms with acute leukemia susceptibility.
Association of p93c-fes tyrosine protein kinase with granulocytic/monocytic differentiation and resistance to differentiating agents in HL-60 leukemia cells.
Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family.
ASXL1 mutations in Chinese patients with essential thrombocythemia.
Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Aurora kinases as anticancer drug targets.
Autoantibodies to Abl and Bcr proteins.
Automated analysis of lipid drug-response markers by combined fast and high-resolution whole cell MALDI mass spectrometry biotyping.
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Azole antifungals and new targeted therapies for hematological malignancy.
Bcr - Abl-mediated resistance to apoptosis is independent of PI 3-kinase activity.
BCR binds to the xeroderma pigmentosum group B protein.
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
BCR sequences essential for transformation by the BCR-ABL oncogene bind to the ABL SH2 regulatory domain in a non-phosphotyrosine-dependent manner.
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
BCR-ABL induces neurite-like structures and BCR lacking the SH2-binding domain induces cell rounding in PC12 cells.
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
bcr-abl mRNA lacking abl exon a2 detected by polymerase chain reaction in a chronic myelogeneous leukemia patient.
bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of ?-catenin and STAT1 in chronic myeloid leukemia cells.
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
BCR-ABL rearrangement and HLA antigens: a possible link to leukemia pathogenesis and immunotherapy.
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
bcr-abl RNA in patients with chronic myelogenous leukemia.
BCR-ABL translocation in a dog with chronic monocytic leukemia.
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.
BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Bcr-Abl-mediated resistance to apoptosis is independent of constant tyrosine-kinase activity.
BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features.
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase.
Betulin, a Newly Characterized Compound in Acacia auriculiformis Bark, Is a Multi-Target Protein Kinase Inhibitor.
Biological effects of T315I-mutated BCR-ABL in an embryonic stem cell-derived hematopoiesis model.
Biological therapy for pediatric malignancy: current perspectives.
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells.
Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells.
Bone marrow mesenchymal stem cells from infants with MLL-AF4+ acute leukemia harbor and express the MLL-AF4 fusion gene.
Bosutinib : a review of preclinical and clinical studies in chronic myelogenous leukemia.
Breakpoint Cluster Region-Mediated Inflammation Is Dependent on Casein Kinase II.
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
c-Abl antagonizes the YAP oncogenic function.
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.
c-Abl mediates endothelial apoptosis induced by inhibition of integrins alphavbeta3 and alphavbeta5 and by disruption of actin.
c-Abl tyrosine kinase promotes adipocyte differentiation by targeting PPAR-gamma 2.
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.
CaMKII ?, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
cDNA array analysis identifies thymic LCK as upregulated in moderate murine zinc deficiency before T-lymphocyte population changes.
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
Chaperone-rich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia.
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors.
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase.
Characterization of the Abelson murine leukemia virus-encoded tyrosine-specific protein kinase.
Characterization of two novel sublines established from a human megakaryoblastic leukemia cell line transfected with p210(BCR-ABL).
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Childhood chronic myeloid leukemia with monocytosis.
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Chromosomal localization of the human genes for lipocortin I and lipocortin II.
Chromosome marker and enhanced expression of c-Ha-ras in a DMBA-induced erythroleukemia cell line (D5A1).
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Chronic Myeloid Leukemia (CML) Mouse Model in Translational Research.
Chronic myeloid leukemia as an immunological target.
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Chronic myeloid leukemia-from the Philadelphia chromosome to specific target drugs: A literature review.
Chronic myeloid leukemia-still a few questions.
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Chronic neutrophilic leukemia: case report documenting the absence of bcr-abl rearrangement.
Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors.
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia.
Clinical applications of BCR-ABL molecular testing in acute leukemia.
Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult.
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Clinical peptide vaccination trials for leukemia patients.
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Clinical significance of BCR-ABL fusion gene subtypes in chronic myelogenous and acute lymphoblastic leukemias.
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Clonal evolution with +11q 13, t(1;7) and t(1;4) at relapse in a patient with Ph positive acute lymphocytic leukemia (ALL) treated with single agent front line imatinib followed by dasatinib.
Cloning and characterization of the human homolog of mouse Jak2.
Cloning of the cDNA for the deleted syk kinase homologous to ZAP-70 from human basophilic leukemia cell line (KU812).
CML mouse model in translational research.
Coadministration of UCN-01 with MEK1/2 inhibitors potently induces apoptosis in BCR/ABL+ leukemia cells sensitive and resistant to ST1571.
Coexistence of PML-RAR? and BCR-ABL in acute promyelocytic leukemia.
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells.
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia.
Comparison of a multiplex reverse transcriptase-polymerase chain reaction for BCR-ABL to fluorescence in situ hybridization, Southern blotting, and conventional cytogenetics in the monitoring of patients with Ph1-positive leukemias.
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Complex chromosomal translocations in the Philadelphia chromosome leukemias. Serial translocations or a concerted genomic rearrangement?
Complex phosphorylation dynamics control the composition of the Syk interactome in B cells.
Conformational disturbance in Abl kinase upon mutation and deregulation.
Conformational flexibility, binding energy, role of salt bridge and alanine-mutagenesis for c-Abl kinase complex.
Conjugate DNAzymes.
Consistent involvement of the bcr gene by 9;22 breakpoints in pediatric acute leukemias.
Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Constitutive NF-kappab/Rel activation in philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.
Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Critical role of Ser-520 phosphorylation for membrane recruitment and activation of the ZAP-70 tyrosine kinase in T cells.
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell.
Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Current CML therapy: progress and dilemma.
Current status of vaccination therapy for leukemias.
Cyclic AMP negatively controls c-myc transcription and G1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4.
Cytogenetic characterization of a BCR-ABL transduced mouse cell line.
Cytogenetic study of 75 erythroleukemias.
Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins.
Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia.
Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.
Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells.
Deletion of the ABL SH3 domain reactivates de-oligomerized BCR-ABL for growth factor independence.
Denbinobin-mediated anticancer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity.
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Depletion of ?-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Design, synthesis and biological activities of Nilotinib derivates as antitumor agents.
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
Detection of bcr-abl fusion in chronic myelogeneous leukemia by in situ hybridization.
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Detection of minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view.
Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR).
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Detection of twelve nucleotides insertion in the BCR-ABL kinase domain in an imatinib-resistant but dasatinib-sensitive patient with bi-phenotypic acute leukemia.
Detection of tyrosine protein kinase substrates in fresh leukemia cells and normal blood cells using an immunoblotting technique.
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
Development and application of a rapid molecular method for detection of fusion genes in pediatric leukemia.
Different molecular consequences of the 1;19 chromosomal translocation in childhood B-cell precursor acute lymphoblastic leukemia.
Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Differentiation stage specificity of tyrosine phosphorylation in response to granulocyte macrophage colony stimulating factor (GM-CSF).
Direct interaction of Jak1 and v-Abl is required for v-Abl-induced activation of STATs and proliferation.
Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Discovery of Janus Kinase 2 (JAK2) and Histone Deacetylase (HDAC) Dual Inhibitors as a Novel Strategy for the Combinational Treatment of Leukemia and Invasive Fungal Infections.
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Disease modifying agents of myeloproliferative neoplasms: a review.
Disruption of R867 and Y613 interaction plays key roles in JAK2 R867Q mutation caused acute leukemia.
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias.
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
Down-regulation of bcr-abl and bcl-x(L) expression in a leukemia cell line and its doxorubicin-resistant variant by topoisomerase II inhibitors.
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Downregulation of miR-217 correlates with resistance of ph(+) leukemia cells to ABL tyrosine kinase inhibitors.
Driver mutations in primary myelofibrosis and their implications.
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells.
Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases.
Dynamic regulatory features of the protein tyrosine kinases.
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.
Early events in leukemogenesis in P190Bcr-abl transgenic mice.
Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.
Effect of Bcr sequences on the cellular function of the Bcr-Abl oncoprotein.
Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
Effect of EPH-ephrin signaling on the growth of human leukemia cells.
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Effects of imatinib on bone marrow engraftment in syngeneic mice.
Effects of leukemia inhibitory receptor gene mutations on human hypothalamo-pituitary-adrenal function.
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells.
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells.
Electrochemical Branched-DNA Assay for Polymerase Chain Reaction-Free Detection and Quantification of Oncogenes in Messenger RNA.
Elevated expression of a subset of interferon inducible genes in primary bone marrow cells expressing p185 Bcr-Abl versus p210 Bcr-Abl by DNA microarray analysis.
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Elevation of c-abl-mRNA in human leukemic B lymphoblasts.
Emerging drugs for chronic myeloid leukemia.
Engagement of the CD19 receptor on human B-lineage leukemia cells activates LCK tyrosine kinase and facilitates radiation-induced apoptosis.
Engineering 3-alkyltriazenes to block bcr-abl kinase: a novel strategy for the therapy of advanced bcr-abl expressing leukemias.
Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.
Engineering the substrate specificity of the Abl tyrosine kinase.
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations.
Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Evidence for involvement of two isoforms of Syk protein-tyrosine kinase in signal transduction through the high affinity IgE receptor on rat basophilic leukemia cells.
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.
Expression analysis of Akirin-2, NF?B-p65 and ?-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Expression of BCR - ABL in M1 myeloid leukemia cells induces differentiation without arresting proliferation.
Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
Expression of cellular oncogenes in primary cells from human acute leukemias.
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Expression of the c-fes proto-oncogene in granulocyte-macrophage colony-stimulating factor-dependent acute myelogenous leukemia cells grown autonomously.
Expression of the human T-cell-specific tyrosine kinase YT16 (lck) message in leukemic T-cell lines.
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
FGF2-FGFR1 signaling regulates release of Leukemia-Protective exosomes from bone marrow stromal cells.
Fibroblast and hematopoietic cell transformation by the fms oncogene (CSF-1 receptor).
Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia.
Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells.
Flotillin-1 regulates IgE receptor-mediated signaling in rat basophilic leukemia (RBL-2H3) cells.
Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients.
Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials.
FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Friend Spleen Focus-Forming Virus Activates the Tyrosine Kinase sf-Stk and the Transcription Factor PU.1 to Cause a Multi-Stage Erythroleukemia in Mice.
From genes to therapy: the case of Philadelphia chromosome-positive leukemias.
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
Gene expression profiling of CD34(+) cells from patients with myeloproliferative neoplasms.
Generation and characterization of transforming variants of the lck tyrosine protein kinase.
Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo.
Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples.
Generation of recombinant murine retroviral genomes containing the v-src oncogene: isolation of a virus inducing hemangiosarcomas in the brain.
Genetic abnormalities and drug resistance in acute lymphoblastic leukemia.
Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML.
Genetic stability of human embryonic stem cells: A first-step toward the development of potential hESC-based systems for modeling childhood leukemia.
Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR.
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.
Glivec and CML: a lucky date.
Global phosphoproteomics reveals crosstalk between bcr-abl and negative feedback mechanisms controlling SRC signaling.
Growth hormone regulation of SIRP and SHP-2 tyrosyl phosphorylation and association.
Growth of chronic myeloid leukemia cells is inhibited by infection with Ad-SH2-HA adenovirus that disrupts Grb2-Bcr-Abl complexes.
Growth, differentiation, and malignant transformation of pre-B cells mediated by inducible activation of v-Abl oncogene.
HDAC Inhibitors potentiate the activity of the Bcr/Abl Kinase Inhibitor KW-2449 in imatinib-sensitive and -resistant Bcr/Abl+ leukemia cells in vitro and in vivo.
Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors.
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2.
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A.
High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukemia virus.
High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinase domain of the chimerical bcr-abl gene.
High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma.
Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
Highly specific characterization of tyrosine phosphoproteins in tumor cells based on monoclonal antibodies defined by conjugated phosphotyramine.
Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death.
HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells.
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
Huai Qi Huang-induced Apoptosis via Down-regulating PRKCH and Inhibiting RAF/MEK/ERK Pathway in Ph+ Leukemia Cells.
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Human leukemia K562 cells: relationship between hemin-mediated erythroid induction, cell proliferation and expression of c-abl and c-myc oncogenes.
Hybrid compounds as new Bcr/Abl inhibitors.
Hybridization protection assay: a rapid, sensitive, and specific method for detection of Philadelphia chromosome-positive leukemias.
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Hypothesis: upfront use of ABL kinase inhibitor combination, either simultaneously or sequentially, in high-risk Ph+ leukemias?
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line.
Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.
Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Identification of Natural inhibitors of Bcr-Abl for the treatment of Chronic Myeloid Leukemia.
Identification of Phosphate-Containing Compounds as New Inhibitors of 14-3-3/c-Abl Protein-Protein Interaction.
Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells.
Ikaros antagonizes DNA binding by STAT5 in pre-B cells.
Imatinib and leptomycin B are effective in overcoming imatinib-resistance due to Bcr-Abl amplification and clonal evolution but not due to Bcr-Abl kinase domain mutation.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia.
Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor.
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
In defense of the somatic mutation theory of cancer.
In vitro Anti-leukaemia Activity of Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs).
In vitro JAK kinase activity and inhibition assays.
In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor.
Increased tyrosine protein kinase activity in hairy cell and monocytic leukemias.
Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Induction of Chronic Myeloid Leukemia in Mice.
Induction of differentiation of human leukemia cells with a structurally altered c-abl (bcr/abl) gene by herbimycin A, an inhibitor of tyrosine kinase activity.
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Induction of hyperphosphorylation and activation of the p56lck protein tyrosine kinase by phenylarsine oxide, a phosphotyrosine phosphatase inhibitor.
Inhibition of Bcr-Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4-d]pyrimidines in Human Leukemia Cells.
Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.
Inhibition of c-Jun N-terminal kinase by SP600125: a cDNA microarray analysis.
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells.
Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model.
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells.
Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells.
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.
Integrated microfluidic and imaging platform for a kinase activity radioassay to analyze minute patient cancer samples.
Integrin VLA-5 and FAK are Good Targets to Improve Treatment Response in the Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.
Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines.
Intracerebral hemorrhage as a rare complication of imatinib in a Philadelphia chromosome positive acute lymphoblastic leukemia pediatric patient.
Intramolecular interactions of the regulatory domains of the Bcr-Abl kinase reveal a novel control mechanism.
Introducing crucial protein panel of gastric adenocarcinoma disease.
Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Isolated central nervous system relapse in two patients with BCR-ABL-positive acute leukemia while receiving a next-generation tyrosine kinase inhibitor.
Isolation and characterization of flat revertant cell lines from A-MuLV-transformed fibroblasts.
JAK-STAT signaling pathway mediates astrogliosis in brains of scrapie-infected mice.
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
JAK2, CALR, and MPL Mutations in Egyptian Patients With Classic Philadelphia-negative Myeloproliferative Neoplasms.
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Janus kinase 3 inhibitor WHI-P131/JANEX-1 prevents graft-versus-host disease but spares the graft-versus-leukemia function of the bone marrow allografts in a murine bone marrow transplantation model.
Janus kinase deregulation in leukemia and lymphoma.
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation.
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kinase-Addiction and Bi-Phasic Sensitivity-Resistance of Bcr-Abl-and Raf-1-Expressing Cells to Imatinib and Geldanamycin.
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
KLF4 suppresses transformation of pre-B cells by ABL oncogenes.
Leukemia inhibitory factor regulates trophoblast giant cell differentiation via Janus kinase 1-signal transducer and activator of transcription 3-suppressor of cytokine signaling 3 pathway.
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Leukemia Stem Cells in Chronic Myeloid Leukemia.
Leukemia stem cells: the root of chronic myeloid leukemia.
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Leukemia-associated fusion proteins, dek-can and bcr-abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes.
Light microscopic detection of BCR-ABL transcripts after in-cell RT-PCR: fusion gene expression might correlate with clinical evolution of chronic myeloid leukemia.
Limitin: An interferon-like cytokine that preferentially influences B-lymphocyte precursors.
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis.
Liposomal Nanoparticles of a Spleen Tyrosine Kinase P-Site Inhibitor Amplify the Potency of Low Dose Total Body Irradiation Against Aggressive B-Precursor Leukemia and Yield Superior Survival Outcomes in Mice.
LLL-3, a STAT3 inhibitor, represses BCR-ABL-positive cell proliferation, activates apoptosis and improves the effects of Imatinib mesylate.
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.
Loss function of Bcr mutation causes gastrointestinal dysmotility and brain developmental defects.
Loss of c-abl facilitates anchorage-independent growth of p53- and RB- deficient primary mouse embryonic fibroblasts.
Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Loss of Gadd45b accelerates BCR-ABL-driven CML.
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.
Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.
Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells.
Mechanism of shortened bones in mucopolysaccharidosis VII.
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias.
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Mice homozygous for the ablm1 mutation show poor viability and depletion of selected B and T cell populations.
MicroRNA miR-125b causes leukemia.
MicroRNA-34a-mediated death of acute myeloid leukemia stem cells through apoptosis induction and exosome shedding inhibition via histone deacetylase 2 targeting.
miR-451a induced apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells by targeting IL-6R.
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Modeling Philadelphia chromosome positive leukemias.
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Modulation of p210(BCR-ABL) activity in transduced primary human hematopoietic cells controls lineage programming.
Molecular and cellular bases of chronic myeloid leukemia.
Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Molecular diagnostics of hematologic malignancies.
Molecular monitoring of Tunisian patients with chronic myeloid leukemia.
Molecular pathogenesis of chronic myeloid leukemia: implications for new therapeutic strategies.
Molecular pathophysiology of chronic myelogenous leukemia.
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Molecular signatures of chronic myeloid leukemia stem cells.
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Morin inhibits Fyn kinase in mast cells and IgE-mediated type I hypersensitivity response in vivo.
Multifunctional Abl kinases in health and disease.
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Mutated BCR-ABL Generates Immunogenic T Cell Epitopes In CML Patients.
Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.
Myeloid differentiation associated tyrosine protein kinase activity in WEHI-3B murine monomyelocytic leukemia cells.
Myeloproliferative Neoplasms: A Contemporary Review.
Myeloproliferative neoplasms: A decade of discoveries and treatment advances.
N- and C-terminal isoforms of Arg quantified by real-time PCR are specifically expressed in human normal and neoplastic cells, in neoplastic cell lines, and in HL-60 cell differentiation.
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl.
Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.
New 2,6,9-trisubstituted purine derivatives as Bcr-Abl and Btk inhibitors and as promising agents against leukemia.
New dosing schedules of dasatinib for CML and adverse event management.
New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time.
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling.
Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia.
Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias.
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases.
Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.
Novel Combination Treatments Targeting Chronic Myeloid Leukemia Stem Cells.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
Novel targeted drug therapies for the treatment of childhood acute leukemia.
Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Nuclear lymphocyte-specific protein tyrosine kinase and its interaction with CR6-interacting factor 1 promote the survival of human leukemic T cells.
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
On systems and control approaches to therapeutic gain.
On the cellular uptake and membrane effect of the multifunctional peptide, TatLK15.
Oncogene expression in Rauscher murine leukemia virus induced erythroid, myeloid and lymphoid cell lines.
Oncogenes and cancer: clinical applications.
Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.
Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain.
Osteopontin is upregulated by BCR-ABL.
Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism.
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells.
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
p190(BCR-ABL) rearrangement as a secondary change in a case of acute myelo-monocytic leukemia with inv(16)(p13q22).
p210(BCR-ABL) reprograms transformed and normal human megakaryocytic progenitor cells into erythroid cells and suppresses FLI-1 transcription.
p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines.
p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia.
Pak1 gene functioned differentially in different BCR-ABL subtypes in leukemiagenesis and treatment response through STAT5 pathway.
Patients with Philadelphia-positive leukemia with BCR-ABL kinase mutations before allogeneic transplantation predominantly relapse with the same mutation.
Patients with Philadelphia-positive leukemia with Y253H or F359V mutation have a high risk of developing new mutations in the setting of dasatinib resistance.
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Pediatric acute lymphoblastic leukemia.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.
Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA.
Phosphorylation of ribosomal protein S6 on serine after microinjection of the Abelson murine leukemia virus tyrosine-specific protein kinase into Xenopus oocytes.
Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro.
PKC-?/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins.
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Polydatin-induced cell apoptosis and cell cycle arrest are potentiated by Janus kinase 2 inhibition in leukemia cells.
Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene.
Potent antiproliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation.
Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase.
Potential therapeutic applications of antisense oligodeoxynucleotides in the treatment of chronic myelogenous leukemia.
Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran.
Pro-survival role of protein kinase C epsilon in Philadelphia chromosome positive acute leukemia.
Proposed Algorithm for the Best Detection of Different bcr-abl Gene Fusion Transcripts in Molecular Diagnostics Laboratories: Experience of a Major Referral Center.
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Proto-oncogene expression and dissection of the myeloid growth to differentiation developmental cascade.
Proto-oncogene expression in human normal bone marrow.
Protooncogene expression and the clinical characteristics of acute nonlymphocytic leukemia: A Leukemia Intergroup pilot study.
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Pulmonary toxicities of tyrosine kinase inhibitors.
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Purification and characterization of a protein-tyrosine kinase encoded by the Abelson murine leukemia virus.
Purification and characterization of p93fes- and p60src-related tyrosine protein kinase activities in differentiated HL-60 leukemia cells.
Purinostat Mesylate is a uniquely potent and selective inhibitor of HDACs for the treatment of BCR-ABL-induced B-cell acute lymphoblastic leukemia.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Quantitative real time-polymerase chain reaction method in Bcr-Abl translocation diagnostics.
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Quinacrine Depletes BCR-ABL and Suppresses Ph-Positive Leukemia Cells.
Rapid automated detection of ABL kinase domain mutations in imatinib-resistant patients.
Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Rearrangement of bcr and c-abl sequences in Ph-positive acute leukemias and Ph-negative CML--an update.
Rearrangement of the c-abl and bcr genes in Ph-negative CML and Ph-positive acute leukemias.
Recombinant murine interleukin-12 elicits potent antileukemic immune responses in a murine model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.
Recurring proviral integration suggests a role for proto-oncogene activation in thymomas induced with Mo-MuLV-rescued BCR/ABL virus.
Regional localization and developmental expression of the BCR gene in rodent brain.
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Regulation of the oncogenic activity of BCR-ABL by a tightly bound substrate protein RIN1.
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.
Reproductive fitness advantage of BCR-ABL expressing leukemia cells.
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells.
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Resistance in the land of molecular cancer therapeutics.
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain.
Retroviral transduction models of Ph+ leukemia: advantages and limitations for modeling human hematological malignancies in mice.
Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-positive cell line.
RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
RNA interference--about the reality to be exploited in cancer therapy.
RNAi-mediated silencing of p190Bcr-Abl inactivates Stat5 and cooperates with imatinib mesylate and 17-allylamino-17-demetoxygeldanamycin in selective killing of p190Bcr-Abl-expressing leukemia cells.
Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.
Role of the BCR-ABL oncogene in human leukemia: fifteenth Richard and Hinda Rosenthal Foundation Award Lecture.
Role of Vitamins A and D in BCR-ABL Arf-/- Acute Lymphoblastic Leukemia.
Roles of C-terminal Src kinase in the initiation and the termination of the high affinity IgE receptor-mediated signaling.
Roots of imatinib resistance: A question of self-renewal?
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
S6K1 determines the metabolic requirements for BCR-ABL survival.
Secondary activation of c-abl may be related to translocation to the nucleolar organizer region in an in vitro cultured rat leukemia cell line (K3D).
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Selective interactions of transforming and normal abl proteins with ATP, tyrosine-copolymer substrates, and tyrphostins.
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Self-renewal of embryonic stem cells through culture on nanopattern polydimethylsiloxane substrate.
Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Serum Inter-?-inhibitor activates the Yes tyrosine kinase and YAP/TEAD transcriptional complex in mouse embryonic stem cells.
Severe hyperlipemia-induced pseudoerythrocytosis - Implication for misdiagnosis and blood transfusion: A case report and literature review.
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways.
Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells.
Significance of the Philadelphia chromosome in acute leukemias: variable correlation with rearrangements involving the c-abl and bcr genes.
Silencing of miR-21 sensitizes CML CD34+ stem/progenitor cells to imatinib-induced apoptosis by blocking PI3K/AKT pathway.
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
Simultaneous occurrence of t(9;22)(q34;q11.2) and t(16;16)(p13;q22) in a patient with chronic myeloid leukemia in blastic phase.
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells.
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
Some lymphoid cell lines transformed by Abelson murine leukemia virus lack a major 36,000-dalton tyrosine protein kinase substrate.
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Specificity of arachidonic acid-induced inhibition of growth and activation of c-jun kinases and p38 mitogen-activated protein kinase in hematopoietic cells.
Specificity of disease induced by M-MuLV chimeric retroviruses containing v-myc or v-src is not determined by the LTR.
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment.
SPR Detection and Discrimination of the Oligonucleotides Related to the Normal and the Hybrid bcr-abl Genes by Two Stringency Control Strategies.
Src activation plays an important key role in lymphomagenesis induced by FGFR1 fusion kinases.
Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.
Src family tyrosine kinase Lyn binds several proteins including paxillin in rat basophilic leukemia cells.
Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.
ST1926, an orally active synthetic retinoid, induces apoptosis in chronic myeloid leukemia cells and prolongs survival in a murine model.
STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells.
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields.
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential.
Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.
Structural and signaling requirements for BCR-ABL-mediated transformation and inhibition of apoptosis.
Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.
Structural modification of c-abl in lymphoma and leukemia.
Structural optimization of diphenylpyrimidine derivatives (DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B leukemia cell lines.
Structure of the Bcr-Abl oncoprotein oligomerization domain.
Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells.
Studying the pathogenesis of BCR-ABL+ leukemia in mice.
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
Suppression of Philadelphia1 leukemia cell growth in mice by BCR-ABL antisense oligodeoxynucleotide.
Suppressor of cytokine signalling 4 (SOCS4): moderator of ovarian primordial follicle activation.
SWATH-Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G-CSFR Signaling.
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
Synthesis, biological evaluation and docking studies of 4-amino substituted 1H-pyrazolo[3,4-d]pyrimidines.
Systemic dasatinib fails to prevent development of central nervous system progression in a patient with BCR-ABL unmutated Philadelphia chromosome-positive leukemia.
Targeted therapies for high-risk acute myeloid leukemia.
Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Targeting of the N-terminal coiled coil oligomerization interface of BCR interferes with the transformation potential of BCR-ABL and increases sensitivity to STI571.
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Targeting Src in endometriosis-associated ovarian cancer.
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
TARGETS AND EFFECTORS OF THE CELLULAR RESPONSE TO AURORA KINASE INHIBITOR MK-0457 (VX-680) IN IMATINIB SENSITIVE AND RESISTANT CHRONIC MYELOGENOUS LEUKEMIA.
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
The amphiphysin-like protein 1 (ALP1) interacts functionally with the cABL tyrosine kinase and may play a role in cytoskeletal regulation.
The anti-apoptotic role of the unfolded protein response in Bcr-Abl-positive leukemia cells.
The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation.
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells.
The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias.
The BCR-ABL tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway.
The BCR-ABL1-negative myeloproliferative neoplasms: a review of JAK inhibitors in the therapeutic armamentarium.
The Capable ABL: What Is Its Biological Function?
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
The combination of Nutlin-3 and Tanshinone IIA promotes synergistic cytotoxicity in acute leukemic cells expressing wild-type p53 by co-regulating MDM2-P53 and the AKT/mTOR pathway.
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domain.
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype.
The effects of c-Abl mutation on developing B cell differentiation and survival.
The emerging role of Bcr-Abl-induced cystoskeletal remodeling in systemic persistence of leukemic stem cells.
The Fab fragment of anti-IgE C?2 domain prevents allergic reactions through interacting with IgE-Fc?RI? complex on rat mast cells.
The fps/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network.
The functional interplay between the t(9;22)-associated fusion proteins BCR/ABL and ABL/BCR in Philadelphia chromosome-positive acute lymphatic leukemia.
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.
The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia.
The in vivo evaluation of active-site TOR inhibitors in models of BCR-ABL+ leukemia.
The involvement of Bcr in leukemias with the Philadelphia chromosome.
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
The mouse c-abl locus: molecular cloning and characterization.
The multi-tyrosine kinase inhibitor TKI258, alone or in combination with RAD001, is effective for treatment of human leukemia with BCR-ABL translocation in vitro.
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors.
The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance.
The Philadelphia (Ph) chromosome in leukemia. I. A new mechanism due to interstitial deletion and insertion in chronic myelocytic leukemia.
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.
The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
The signaling axis atypical protein kinase C ?/?-Satb2 mediates leukemic transformation of B-cell progenitors.
The significance of detecting WT1 expression in childhood acute leukemias.
The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.
The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.
The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
The Syk kinase as a therapeutic target in leukemia and lymphoma.
The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia.
The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells.
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
The Tyrosine Kinase c-Abl Promotes Homeodomain-interacting Protein Kinase 2 (HIPK2) Accumulation and Activation in Response to DNA Damage.
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
Therapeutic prospect of Syk inhibitors.
Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth.
Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia.
Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice.
Thrombopoietin acts synergistically with LIF to maintain an undifferentiated state of embryonic stem cells homozygous for a Shp-2 deletion mutation.
Thy-1 glycoprotein and src-like protein-tyrosine kinase p53/p56lyn are associated in large detergent-resistant complexes in rat basophilic leukemia cells.
TNF? activates MAPK and Jak-Stat pathways to promote mouse Müller cell proliferation.
Tocotrienol-rich fraction from annatto ameliorates expression of lysyl oxidase in human osteoblastic MG-63 cells.
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Transcriptional activation of lck by retrovirus promoter insertion between two lymphoid-specific promoters.
Transformation by v-Myb.
Transformation of T-lymphoid cells by Abelson murine leukemia virus.
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes.
Treating Leukemia in the Time of COVID-19.
Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Treatment of Philadelphia-chromosome-positive human leukemia in SCID mouse model with herbimycin A, bcr-abl tyrosine kinase activity inhibitor.
Trichostatin A down-regulates ZAP-70, LAT and SLP-76 content in Jurkat T cells.
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
Tyrosine kinase inhibitor induced isolated pericardial effusion.
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Tyrosine phosphorylation of P160 BCR by P210 BCR-ABL.
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Unperturbed immune function despite mutation of C-terminal tyrosines in Syk previously implicated in signaling and activity regulation.
Use of the «BCR/ABL - multitest» kit in the algorithm of laboratory diagnostics of oncohematological diseases: economic aspects.
Using Bcr-Abl to examine mechanisms by which abl kinase regulates morphogenesis in Drosophila.
v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
What is the contribution of molecular studies to the diagnosis of BCR-ABL-positive disease in adult acute leukemia?
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
YAP promotes myogenic differentiation via the MEK5-ERK5 pathway.
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
[A Modified Protocol for Rapid Establishing Mouse Model with Ph+ Positive Acute Lymphoblastic Leukemia].
[Acute lymphoblastic leukemias with aberrations of BCR-ABL genes]
[Amplification and rearrangement of proto-oncogene c-abl in human leukemia cells]
[An alternative Abl-kinase inhibitor overcomes imatinib resistance mutations of Bcr-Abl oncogenes]
[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.]
[c-abl gene and bcr-abl fused gene in Ph1-positive leukemias]
[Classical and molecular cytogenetic abnormalities in 124 pediatric patients with acute lymphoblastic leukemia]
[Clinical Analysis of 12 Cases of Acute Myeloid Leukemia with Ph Chromosome and BCR-ABL Positive].
[Clinical and laboratorial analysis for 15 adult cases of mixed phenotypic acute leukemia with Ph chromosome and/or positive BCR-ABL].
[Detection of BCR-ABL gene sequences using RT-PCR in patients with leukemia in the IX region. Chile]
[Detection of phosphotyrosine in bcr-abl-positive cells with PY20 antibody and its clinical applications]
[Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction]
[Effect of methylation inhibitor on EphB4 gene expression, proliferation and apoptosis in CEM cells].
[Effect of Stably Down-regulating FMI Expression of K562 Cells on Sensitivity of K562 cells to Imatinib Mesylate].
[Expression and Clinical Significance of Focal Adhesion Kinase in Patients with Acute Leukemia].
[Expression of c-fes gene in leukemia cells and its clinical significance]
[Expression of the Wilms' Tumor Gene WT1 and Detection of Minimal Residual Disease in Acute Leukemia]
[Hematological malignancies]
[Hematopoietic stem cells and hematopoietic neoplasias]
[Identification bcr-abl fusion gene in leukemia cells with oligonucleotide microarray]
[Juvenile myelomonocytic leukemia: A three-case series].
[Mechanism underlying tumorigenesis induced by Bcr-Abl oncogene and A-MuLV virus].
[Molecular detection of the BCR-ABL gen by RT-PCR in Costa Rican children with leukemia]
[Molecular diagnosis of leukemia and lymphoma]
[Pilot treatment for 13 BCR-ABL positive leukemia patients with T315I mutation].
[Quality assurance of the molecular diagnostic tests in hematological malignancies]
[Research on the molecular basis of neoplasms: malignant melanoma as an example]
[Resistance mechanism of ST1571 and its prevention research--review.]
[Results of clinical studies on a selective inhibitor of ABL tyrosine kinase (STI571) in patients with Ph(+) leukemia]
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
[Synergistic inhibitory effect of STI571 in combination with arsenic trioxide on a multidrug-resistant leukemia cell line expressing bcr-abl.]
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
[The reverse effect on drug-resistance against tyrosine kinase inhibitor STI571 in mdr1 and bcr-abl positive leukemic cells]
[The role of EGF receptor-dependent e3B1/Abi1 protein as a tumor suppressor protein in malignant tumors]
[Therapeutic Effect of Focal Adhesion Kinase Gene Silence on Leukemia.]
[Using real-time polymerase chain reaction to quantitate bcr-abl mRNA]
Leukemia, B-Cell
Apoptotic effect of PP2 a Src tyrosine kinase inhibitor, in murine B cell leukemia.
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Janus Kinase Mutations in Mice Lacking PU.1 and Spi-B Drive B Cell Leukemia through Reactive Oxygen Species-Induced DNA Damage.
ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
Leukemia, Basophilic, Acute
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Leukemia, Biphenotypic, Acute
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia.
[Biphenotypic Acute Leukemia with BCR-ABL mRNA Transcript b3a2 Type: A Case Report with Review of the Literature.]
Leukemia, Erythroblastic, Acute
?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
A case of acute erythroleukemia with concurrence of BCR-ABL and FLT3-TKD (D835E) mutation.
A natural-like synthetic small molecule impairs bcr-abl signaling cascades and induces megakaryocyte differentiation in erythroleukemia cells.
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Erythropoietin induces tyrosine phosphorylation and kinase activity of the c-fps/fes proto-oncogene product in human erythropoietin-responsive cells.
Friend Spleen Focus-Forming Virus Activates the Tyrosine Kinase sf-Stk and the Transcription Factor PU.1 to Cause a Multi-Stage Erythroleukemia in Mice.
Increased ERK phosphorylation and caveolin-1 expression on K562 human chronic myelogenous leukemia cells by jacalin, a dietary plant lectin.
Methylation status of RASSF1A in patients with chronic myeloid leukemia.
Mutation of the Lyn tyrosine kinase delays the progression of Friend virus induced erythroleukemia without affecting susceptibility.
NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
Protooncogene expression in normal, preleukemic, and leukemic murine erythroid cells and its relationship to differentiation and proliferation.
Sustained mitogenic effect on K562 human chronic myelogenous leukemia cells by dietary lectin, jacalin.
v-abl activates embryonic globin gene expression in mouse erythroleukemia cells.
Leukemia, Feline
Colony stimulating factor-1 induced growth stimulation of v-fms transformed fibroblasts.
Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene.
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Nucleotide sequence of the feline retroviral oncogene v-fms shows unexpected homology with oncogenes encoding tyrosine-specific protein kinases.
The amino-terminal domain of the v-fms oncogene product includes a functional signal peptide that directs synthesis of a transforming glycoprotein in the absence of feline leukemia virus gag sequences.
Leukemia, Hairy Cell
Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia.
No Loose Ends: A Review of the Pharmacotherapy of Hairy Cell and Hairy Cell Leukemia Variant.
Leukemia, Large Granular Lymphocytic
Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway.
Leukemia, Lymphocytic, Chronic, B-Cell
A case of chronic lymphocytic leukemia complicated by autoimmune hemolytic anemia due to ibrutinib treatment.
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era.
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).
A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia.
A single-tube multiplex method for monitoring mutations in cysteine 481 of Bruton Tyrosine Kinase (BTK) gene in chronic lymphocytic leukemia patients treated with ibrutinib.
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
Activation of the B-cell receptor successively activates NF-?B and STAT3 in chronic lymphocytic leukemia cells.
Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Activity of the janus kinase inhibitor Ruxolitinib in chronic lymphocytic leukemia: results of a phase II trial.
Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia.
Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia.
An improved flow cytometric method using FACS Lysing Solution for measurement of ZAP-70 expression in B-cell chronic lymphocytic leukemia.
An optimized whole blood method for flow cytometric measurement of ZAP-70 protein expression in chronic lymphocytic leukemia.
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib.
Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells.
Approaches for relapsed CLL after chemotherapy-free frontline regimens.
ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia.
Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70).
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Bruton tyrosine kinase inhibitors for the frontline treatment of chronic lymphocytic leukemia.
Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: Beyond Ibrutinib.
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia.
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
BTK Inhibitors, Irrespective of ITK Inhibition, Increase Efficacy of a CD19/CD3 Bispecific Antibody in CLL.
BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.
c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
c-Abl regulates Mcl-1 gene expression in chronic lymphocytic leukemia cells.
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
Changing landscape of frontline therapy in chronic lymphocytic leukemia.
Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
Chromatin mapping and single-cell immune profiling define the temporal dynamics of ibrutinib response in CLL.
Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis.
Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Chronic lymphocytic leukemia modeled in mouse by targeted miR-29 expression.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Clinical implications of ZAP-70 expressionin chronic lymphocytic leukemia.
Clinical prognostic biomarkers in chronic lymphocytic leukemia and diffuse large B-cell lymphoma.
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia.
Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia.
Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.
Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL.
Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.
Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia.
Combined BTK and PI3K? Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.
Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL.
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia.
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Comparative analysis of ZAP-70 expression and Ig VH mutational status in B-cell chronic lymphocytic leukemia.
Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Comparison of Bcl-2, CD38 and ZAP-70 Expression in Chronic Lymphocytic Leukemia.
Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Comparison of ZAP-70/Syk mRNA levels with immunoglobulin heavy-chain gene mutation status and disease progression in chronic lymphocytic leukemia.
Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Correlation between ZAP-70, phospho-ZAP-70, and phospho-Syk expression in leukemic cells from patients with CLL.
Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia.
Cortactin, another player in the Lyn signaling pathway, is overexpressed and alternatively spliced in leukemic cells from patients with B-cell Chronic Lymphocytic Leukemia.
Current Treatment of Chronic Lymphocytic Leukemia.
CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia.
CXCR4- and BCR-triggered integrin activation in B-cell chronic lymphocytic leukemia cells depends on JAK2-activated Bruton's tyrosine kinase.
Cytomegalovirus Proctitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: A Case Report.
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia.
Decrease in total protein level of Bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes.
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia.
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Detection methods of ZAP-70 in chronic lymphocytic leukemia.
Detection of ZAP-70 in patients with chronic lymphocytic leukemia.
Development and characterization of prototypes for in vitro and in vivo mouse models of ibrutinib-resistant CLL.
Differential expression and function of CD27 in chronic lymphocytic leukemia cells expressing ZAP-70.
Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70.
Discordance of ZAP-70 in patients with chronic lymphocytic leukemia.
Discordant results of flow cytometric ZAP-70 expression status in B-CLL samples if different gating strategies are applied.
Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients.
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines.
Effect of ibrutinib on humoral dysfunction in patients with chronic lymphocytic leukemia: A single-center experience.
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells.
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Efficacy of Ibrutinib-Based Regimen in Chronic Lymphocytic Leukemia: A Systematic Review.
Elevated IL-17A and IL-22 regulate expression of inducible CD38 and Zap-70 in chronic lymphocytic leukemia.
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study.
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process.
Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Expression feature of CD3, Fc?RI?, and Zap-70 in patients with chronic lymphocytic leukemia.
Expression of BTK/p-BTK is different between CD5+ and CD5- B lymphocytes from Autoimmune Hemolytic Anemia/Evans syndromes.
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Expression of the T-cell-specific tyrosine kinase Lck in normal B-1 cells and in chronic lymphocytic leukemia B cells.
Expression of ZAP-70 in patients with chronic lymphocytic leukemia may change significantly during the course of the disease.
Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia.
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia.
Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: a methodological approach.
Final analysis from RESONATE: up to 6?years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?
Flow Cytometric Analysis of ZAP-70 Protein Expression for B-Cell Chronic Lymphocytic Leukemia Prognostication: Usefulness and Limitations.
Flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia: correlation with immunocytochemistry and Western blot analysis.
Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia.
Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Gene expression profiling in malignant lymphomas.
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC? subversion induces an upregulation of PKC?II expression in B lymphocytes.
Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia.
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker?
Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient.
Hodgkin's disease variant of Richter's syndrome clonally related to chronic lymphocytic leukemia arises in ZAP-70 negative mutated CLL.
How I Manage CLL with Venetoclax-Based Treatments.
How I manage ibrutinib-refractory chronic lymphocytic leukemia.
Hydroa Vacciniforme-Like Lymphoproliferative Disorder in an Adult Patient With Chronic Lymphocytic Leukemia.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Ibrutinib does not prevent kidney fibrosis following acute and chronic injury.
Ibrutinib dose modifications in the management of CLL.
Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
Ibrutinib for treatment of chronic lymphocytic leukemia.
Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia.
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects.
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5?years on.
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium.
Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia.
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review.
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin ?IIb?3 in mice and humans.
Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes.
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Ibrutinib-induced acute kidney injury via interstitial nephritis.
Ibrutinib-naïve chronic lymphocytic leukemia lacks Bruton tyrosine kinase mutations associated with treatment resistance.
Ibrutinib: A New Frontier in the Treatment of Chronic Lymphocytic Leukemia by Bruton's Tyrosine Kinase Inhibition.
Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.
Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Imbruvica (Ibrutinib), First-in-Class Bruton's Tyrosine Kinase Inhibitor, Receives Expanded Indications for Patients with Relapsed Chronic Lymphocytic Leukemia.
Immune impacts of Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia patients: are we closer to a holy grail?
Immune Therapy for Chronic Lymphocytic Leukemia: Allogeneic Transplant, Chimeric Antigen Receptor T-cell Therapy, and Beyond.
Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
Improved flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia using experimentally optimized isotypic control antibodies.
In Human Visualization of Ibrutinib-Induced CLL Compartment Shift.
In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.
Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia.
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.
Invasive Fungal Infection Complicating Treatment With Ibrutinib.
JAK2 tyrosine kinase mediates integrin activation induced by CXCL12 in B-cell chronic lymphocytic leukemia.
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status.
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse.
Lycorine sensitizes CD40 ligand-protected chronic lymphocytic leukemia cells to bezafibrate- and medroxyprogesterone acetate-induced apoptosis but dasatanib does not overcome reported CD40-mediated drug resistance.
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.
Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
Managing toxicities of Bruton tyrosine kinase inhibitors.
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia.
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.
miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression.
Modification of immunocytochemical ZAP-70 assay for potential clinical application in B-cell chronic lymphocytic leukemia.
Modulation of CD44 Activity by A6-Peptide.
Molecular basis of aggressive disease in chronic lymphocytic leukemia patients with 11q deletion and trisomy 12 chromosomal abnormalities.
Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review.
Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia.
Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method.
Non-catalytic Bruton's tyrosine kinase activates PLC?2 variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.
Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance.
Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Optimization of flow cytometric measurement of ZAP-70 in chronic lymphocytic leukemia.
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation.
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib.
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition.
Outcomes of Reduced Frequency Dosing of Ibrutinib in Chronic Lymphocytic Leukemia Patients Following Complete or Partial Remission: A Pilot Study.
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia.
p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy.
p65 activity and ZAP-70 status predict the sensitivity of chronic lymphocytic leukemia cells to the selective IkappaB kinase inhibitor BMS-345541.
p66Shc deficiency in the E?-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape.
Paraneoplastic Pemphigus Associated with B-cell Chronic Lymphocytic Leukemia Treated with Ibrutinib and Rituximab.
Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy.
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses.
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Phase 1b Study of Tirabrutinib in Combination With Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Pitfalls and limitations of ZAP-70 detection in chronic lymphocytic leukemia.
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study.
Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients.
Profound Sinoatrial Arrest Associated with Ibrutinib.
Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells.
Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia.
Prognostic value of lipoprotein lipase expression among egyptian B-chronic lymphocytic leukemia patients.
Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells.
Quantification of ZAP-70 expression in chronic lymphocytic leukemia: T/B-cell ratio of mean fluorescence intensity provides stronger prognostic value than percentage of positive cells.
Quantification of ZAP-70 mRNA by real-time PCR is a prognostic factor in chronic lymphocytic leukemia.
Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.
Quantitative flow cytometry of ZAP-70 levels in chronic lymphocytic leukemia using molecules of equivalent soluble fluorochrome.
Real--world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: Data from 95 consecutive patients treated in a compassionate use program.
Reconstitution of humoral immunity and decreased risk of infections in patients with chronic lymphocytic leukemia treated with Bruton tyrosine kinase inhibitors.
Recruitment of PKC-betaII to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70.
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.
Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Response of renal cell carcinoma to ibrutinib, a bruton tyrosine kinase inhibitor, in a patient treated for chronic lymphocytic leukemia.
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Role of spleen tyrosine kinase in the pathogenesis of chronic lymphocytic leukemia.
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia.
Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Significant change in ZAP-70 expression during the course of chronic lymphocytic leukemia.
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
SLP76 integrates into the B-Cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with aggressive disease course.
Smudge cell percentage as a surrogate marker for ZAP-70 expression in patients with chronic lymphocytic leukemia.
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.
Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia.
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.
Steroid effects on ZAP-70 and SYK in relation to apoptosis in poor prognosis chronic lymphocytic leukemia.
Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment.
T-cell ZAP-70 overexpression in chronic lymphocytic leukemia (CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Targeted drugs in concert with chemo: opposites attract.
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Targeting BTK in CLL: Beyond Ibrutinib.
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome.
TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia.
The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia.
The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia.
The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment.
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
The gene expression response of chronic lymphocytic leukemia cells to IL-4 is specific, depends on ZAP-70 status and is differentially affected by an NF?B inhibitor.
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
The Phospholipase C-?2 Mutants R665W and L845F Identified in Ibrutinib-Resistant Chronic Lymphocytic Leukemia Patients are Hypersensitive to the Rho GTPase Rac2.
THE PROGNOSTIC SIGNIFICANCE OF COMBAIND EXPRESSION OF ZAP-70 AND CD38 IN CHRONIC LYMPHOCYTIC LEUKEMIA.
The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia.
The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma.
The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
The structure, regulation, and function of ZAP-70.
The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.
Three years of ibrutinib in CLL.
Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents.
Treating CLL with Bruton Tyrosine Kinase Inhibitors: The Role of the Outpatient Oncology Nurse.
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
US Food and Drug Administration approvals for Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukemia: Potential inefficiencies in trial design and evidence generation.
Using high-sensitivity sequencing for the detection of mutations in BTK and PLC?2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors.
Using the geometric mean fluorescence intensity index method to measure ZAP-70 expression in patients with chronic lymphocytic leukemia.
Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review.
Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia.
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton's tyrosine kinase.
Zanubrutinib (BGB-3111), a Second-Generation Selective Covalent Inhibitor of Bruton's Tyrosine Kinase and Its Utility in Treating Chronic Lymphocytic Leukemia.
ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value.
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.
ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
ZAP-70 enhances IgM signaling independent of its kinase activity in chronic lymphocytic leukemia.
ZAP-70 enhances migration of malignant B lymphocytes towards CCL21 by inducing CCR7 expression via IgM-ERK1/2 activation.
ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia.
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.
ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia.
ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL).
ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study.
ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia.
ZAP-70 in B cell malignancies.
ZAP-70 in chronic lymphocytic leukemia.
ZAP-70 in chronic lymphocytic leukemia: A meta-analysis.
ZAP-70 intron1 DNA methylation status: determination by pyrosequencing in B chronic lymphocytic leukemia.
ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia.
ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype.
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
ZAP-70 methylation and expression status in chronic lymphocytic leukemia.
ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia.
ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia.
Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?
ZAP-70 promotes the infiltration of malignant B-lymphocytes into the bone marrow by enhancing signaling and migration after CXCR4 stimulation.
ZAP-70 protein expression and CD38 positivity in B-cell chronic lymphocytic leukemia.
ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.
ZAP-70 staining in chronic lymphocytic leukemia.
ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
ZAP-70, IgVh, and cytogenetics for assessing prognosis in chronic lymphocytic leukemia.
[Abnormality of serum immunoglobulin in peripheral blood of patients with chronic lymphocytic leukemia.]
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
[Immunohistochemical detection of ZAP-70 protein and its importance in the diagnostics of B-CLL]
[Molecular diagnosis of and molecular targeting therapy for leukemia]
[Prognostic significance of telomere length in patients with chronic lymphocytic leukemia]
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
[ZAP-70 expression in 24 patients with B cell chronic lymphocytic leukemia]
[ZAP-70 in B-cell chronic lymphocytic leukemia: clinical significance and methods of detection]
Leukemia, Lymphoid
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias.
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment.
HS1, a Lyn kinase substrate, is abnormally expressed in B-chronic lymphocytic leukemia and correlates with response to fludarabine-based regimen.
Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus.
Kinases as drug discovery targets in hematologic malignancies.
Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia.
No evidence for genomic imprinting of the human BCR gene.
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk.
Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia.
ZAP-70 Protein Expression in B-cell Chronic Lymphoid Leukemia: a Single Center Experience from Pakistan.
[Expression of c-fes gene in leukemia cells and its clinical significance]
[Expression of CLLU1 in patients with chronic lymphocytic leukemia and its prognostic significance]
[Large granular lymphocytic leukemia]
[Molecular targeted therapy in lymphoid leukemias].
Leukemia, Megakaryoblastic, Acute
Association between Lyn protein tyrosine kinase (p53/56lyn) and the beta subunit of the granulocyte-macrophage colony-stimulating factor (GM-CSF) receptors in a GM-CSF-dependent human megakaryocytic leukemia cell line (M-07e).
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Janus kinase mutations in the development of acute megakaryoblastic leukemia in children with and without Down's syndrome.
Leukemia, Monocytic, Acute
[Molecular diagnosis of leukemia and lymphoma]
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
"Home-brew" FISH assay shows higher efficiency than BCR-ABL dual color, dual fusion probe in detecting microdeletions and complex rearrangements associated with t(9;22) in chronic myeloid leukemia.
(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.
1,3-Butadiene metabolite 1,2,3,4 diepoxybutane induces DNA adducts and micronuclei but not t(9;22) translocations in human cells.
14-3-3 LIGAND PREVENTS NUCLEAR IMPORT OF C-ABL PROTEIN IN CHRONIC MYELOID LEUKEMIA.
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
5'-OH-5-nitro-Indirubin oxime (AGM130), an Indirubin derivative, induces apoptosis of Imatinib-resistant chronic myeloid leukemia cells.
7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.
?12-prostaglandin J3, an omega-3 fatty acid-derived metabolite, selectively ablates leukemia stem cells in mice.
A 41-kilodalton protein is a potential substrate for the p210bcr-abl protein-tyrosine kinase in chronic myelogenous leukemia cells.
A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations.
A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation.
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
A Bcr/Abl kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges.
A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
A Bead-Based Activity Screen for Small-Molecule Inhibitors of Signal Transduction in Chronic Myelogenous Leukemia Cells.
A cascade screening approach for the identification of Bcr-Abl myristate pocket binders active against wild type and T315I mutant.
A Case of Childhood Blastic Phase Chronic Myeloid Leukemia With Minor BCR-ABL.
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
A case of chronic myeloid leukemia with minor bcr-abl transcript following fluorouracil therapy for esophageal carcinoma.
A case of inflammatory nonscarring alopecia associated with the tyrosine kinase inhibitor nilotinib.
A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report.
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.
A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
A common phosphotyrosine signature for the Bcr-Abl kinase.
A comparison of normal and leukemic stem cell biology in Chronic Myeloid Leukemia.
A complex three-way translocation with deletion of the TP53 gene in a blast crisis chronic myeloid leukemia patient.
A comprehensive analysis of breakpoint cluster region-abelson fusion oncogene splice variants in chronic myeloid leukemia and their correlation with disease biology.
A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells.
A computational approach to analyze the mechanism of action of the kinase inhibitor bafetinib.
A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients.
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response.
A historical overview of protein kinases and their targeted small molecule inhibitors.
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects.
A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells.
A Multiple Reaction Monitoring (MRM) Method to Detect Bcr-Abl Kinase Activity in CML Using a Peptide Biosensor.
A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
A new diagnostic kit, ODK-1201, for the quantitation of low major BCR-ABL mRNA level in chronic myeloid leukemia: correlation of quantitation with major BCR-ABL mRNA kits.
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
A NEW NON-PEPTIDIC INHIBITOR OF THE 14-3-3 DOCKING SITE INDUCES APOPTOTIC CELL DEATH IN CHRONIC MYELOID LEUKEMIA SENSITIVE OR RESISTANT TO IMATINIB.
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance.
A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo.
A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia.
A novel BCR-ABL fusion transcript (e18a2) in a child with chronic myeloid leukemia.
A novel cytogenetic abnormality t(7;8)(p11.2:q11.2) and a four-way Philadelphia translocation in an imatinib mesylate-resistant chronic myeloid leukemia patient.
A novel FRET-based biosensor for the measurement of BCR-ABL activity and its response to drugs in living cells.
A novel fusion circular RNA F-circBA1 derived from the BCR-ABL fusion gene displayed an oncogenic role in chronic myeloid leukemia cells.
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.
A novel insertion mutation of K294RGG within BCR-ABL kinase domain confers imatinib resistance: sequential analysis of the clonal evolution in a patient with chronic myeloid leukemia in blast crisis.
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation.
A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation.
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
A once-daily dasatinib dosing strategy for chronic myeloid leukemia.
A peptide biosensor for detecting intracellular Abl kinase activity using MALDI-TOF MS.
A Ph-negative chronic myeloid leukemia patient with a non-classical BCR-ABL rearrangement characterized by fluorescence in situ hybridization.
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease.
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
A Pipeline for Drug Target Identification and Validation.
A possible correlation between the type of bcr-abl hybrid messenger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia.
A Prognostic and Predictive Study of BCR-ABL Expression Based on Characterization of Fusion Transcripts.
A Rare Case of p190 BCR-ABL Chronic Myeloid Leukemia With a Very Good Response to Tyrosine Kinase Inhibitors.
A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.
A rare e14a3 (b3a3) BCR-ABL fusion transcript in chronic myeloid leukemia: diagnostic challenges in clinical laboratory practice.
A report of early cytogenetic response to imatinib in two patients with chronic myeloid leukemia at accelerated phase and carrying the e19a2 BCR-ABL transcript.
A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.
A research-inspired laboratory sequence investigating acquired drug resistance.
A role for c-Abl in cell senescence and spontaneous immortalization.
A screen to identify drug resistant variants to target-directed anti-cancer agents.
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients.
A Small Molecule Inhibitor, OGP46, Is Effective against Imatinib-Resistant BCR-ABL Mutations via the BCR-ABL/JAK-STAT Pathway.
A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.
A Src-like inactive conformation in the abl tyrosine kinase domain.
A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.
A two-color BCR-ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia.
A Unique Activating Mutation in JAK2 (V617F) Is at the Origin of Polycythemia Vera and Allows a New Classification of Myeloproliferative Diseases.
ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug.
Aberrant BCR-ABL transcript with intronic insertion in a patient with philadelphia chromosome-positive chronic myeloid leukemia: implications for disease progression.
Aberrant DNA Methylation of SOCS1 Gene is Not Associated with Resistance to Imatinib Mesylate among Chronic Myeloid Leukemia Patients.
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
ABL Kinase Domain Mutations in Iranian Chronic Myeloid Leukemia Patients with Resistance to Tyrosine Kinase Inhibitors.
ABL kinase domain mutations in patients with chronic myeloid leukemia in Jordan.
ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors.
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors.
ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance.
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571.
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia.
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec).
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients.
Achieving early molecular response in chronic myeloid leukemia in chronic phase to reduce the risk of progression: clinical relevance of the 3- and 6-month time points.
Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Activated c-Abl tyrosine kinase in malignant solid tumors.
Activation of bcr-abl fusion gene and ras oncogenes in chronic myelogenous leukemia.
Activation of Jak2 in patients with blast crisis chronic myelogenous leukemia: inhibition of Jak2 inactivates Lyn kinase.
Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib.
Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.
Activation of the c-abl oncogene by viral transduction or chromosomal translocation generates altered c-abl proteins with similar in vitro kinase properties.
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand.
Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia.
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia.
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.
ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia.
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells.
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy.
Advances in Immunotherapy of Chronic Myeloid Leukemia CML.
Advances in targeted therapy for chronic myeloid leukemia.
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
AHI-1: a novel signaling protein and potential therapeutic target in human leukemia and brain disorders.
Aleukemic bcr-abl positive granulocytic sarcoma.
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Allogeneic stem cell transplants in chronic myeloid leukemia.
Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation.
Allosteric Inhibition of Bcr-Abl Kinase by High-Affinity Monobody Inhibitors Directed to the SH2-Kinase Interface.
Allosteric inhibition of BCR-ABL.
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Allosterically controllable maxizyme-mediated suppression of progression of leukemia in mice.
Allosterically controlled single-chained maxizymes with extremely high and specific activity.
Altered transcription of the c-abl oncogene in K-562 and other chronic myelogenous leukemia cells.
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
Alternative expression of TCR? related genes in patients with chronic myeloid leukemia.
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
AMP-activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR-ABL protein in CML cells.
Amplification of BCR-ABL and t(3;21) in a patient with blast crisis of chronic myelogenous leukemia.
Amplified C lambda and c-abl genes are on the same marker chromosome in K562 leukemia cells.
An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias.
An activating amino acid substitution in the c-abl oncogene protein fails to produce a local conformational change.
An acute myeloid leukemia M6b blast crisis with giant proerythroblasts in chronic myeloid leukemia.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
An ent-Kaurane Diterpenoid Isolated from Rabdosia excisa Suppresses Bcr-Abl Protein Expression in Vitro and in Vivo and Induces Apoptosis of CML Cells.
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259.
An Integrative Informatics Approach to Explain the Mechanism of Action of Novel N1-(Anthraquinon-2-yl) Amidrazones as BCR/ABL Inhibitors.
An intron promotes the anti-bcr-abl activities of a retrovirally expressed ribozyme in chronic myeloid leukemia cells.
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
An inv(16) in Ph-negative cells of a chronic myelogenous leukemia patient after imatinib treatment.
An ultra-long circulating nanoparticle for reviving a highly selective BCR-ABL inhibitor in long-term effective and safe treatment of chronic myeloid leukemia.
An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature.
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
An update on dual Src/Abl inhibitors.
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Analogs, formulations and derivatives of imatinib: a patent review.
Analysis of ABL kinase domain mutations conferring resistance to tyrosine kinase inhibitors in chronic myeloid leukemia cases from India.
Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-related sequence in human DNA.
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients.
Analysis of Philadelphia chromosome-negative BCR-ABL-positive chronic myelogenous leukemia by hypermetaphase fluorescence in situ hybridization.
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
Analytical Validation of a Highly Sensitive, Multiplexed Chronic Myeloid Leukemia Monitoring System Targeting BCR-ABL1 RNA.
Andrographolide and its potent derivative exhibit anticancer effects against imatinib-resistant chronic myeloid leukemia cells by downregulating the Bcr-Abl oncoprotein.
Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line.
Antibiotic anisomycin selectively targets leukemia cell lines and patient samples through suppressing Wnt/?-catenin signaling.
Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia.
Antibody-based detection of protein phosphorylation status to track the efficacy of novel therapies using nanogram protein quantities from stem cells and cell lines.
Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Anticipated Impact of Generic Imatinib Market Entry on the Costs of Tyrosine Kinase Inhibitors.
Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm.
Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
Antisense inhibition of Bcr-Abl/c-Abl synthesis promotes telomerase activity and upregulates tankyrase in human leukemia cells.
Antisense inhibition of P210 bcr-abl in chronic myeloid leukemia.
Antisense oligodeoxynucleotide combination therapy of primary chronic myelogenous leukemia blast crisis in SCID mice.
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
Appearance of acute leukemia-associated P190BCR-ABL in chronic myelogenous leukemia may correlate with disease progression.
Application of a new protocol for nested PCR to the detection of minimal residual bcr/abl transcripts.
Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia.
Application of FISH to complex chromosomal rearrangements associated with chronic myelogenous leukemia.
Application of multiplexed kinase inhibitor beads to study kinome adaptations in drug-resistant leukemia.
Applying the discovery of the Philadelphia chromosome.
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Assessment of Oxidative Stress in Patients with Chronic Myeloid Leukemia Depending on Associated Comorbidities.
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.
Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study.
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Association between severe toxicity of nilotinib and UGT1A1 polymorphisms in Japanese patients with chronic myelogenous leukemia.
Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.
ATG7 regulates energy metabolism, differentiation and survival of Philadelphia-chromosome-positive cells.
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance.
Aurora A Kinase Inhibitor AKI603 Induces Cellular Senescence in Chronic Myeloid Leukemia Cells Harboring T315I Mutation.
Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: back to the bench.
Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide.
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia.
Backbone NMR resonance assignment of the Abelson kinase domain in complex with imatinib.
Bacterial expression and purification of active hematopoietic cell kinase.
Bag1 directly routes immature BCR-ABL for proteasomal degradation.
Balanced parental contribution to the ABL component of the BCR-ABL gene in chronic myeloid leukemia.
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
BAX/BCL-XL gene expression ratio inversely correlates with disease progression in chronic myeloid leukemia.
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients.
BCR gene expression blocks Bcr-Abl induced pathogenicity in a mouse model.
BCR gene recombines with genomically distinct sites on band 11Q13 in complex BCR-ABL translocations of chronic myeloid leukemia.
bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia.
Bcr-Abl activates AURKA and AURKB in chronic myeloid leukemia cells via AKT signaling.
BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Bcr-Abl and inhibition of apoptosis in chronic myelogenous leukemia cells.
BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored.
BCR-ABL antisense oligodeoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase.
BCR-ABL breakpoint and prognosis in chronic myeloid leukemia.
BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
BCR-ABL down-regulates the DNA repair protein DNA-PKcs.
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
BCR-ABL enhances differentiation of long-term repopulating hematopoietic stem cells.
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance.
BCR-ABL expression in different subpopulations of functionally characterized Ph+ CD34+ cells from patients with chronic myeloid leukemia.
BCR-ABL expression in leukemic progenitors and primitive stem cells of patients with chronic myeloid leukemia.
Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
BCR-ABL fusion genes and laboratory findings in patients with chronic myeloid leukemia in northeast Iran.
Bcr-Abl fusion sequences do not induce immune responses in mice when administered in mouse polyomavirus based virus-like particles.
BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib.
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia.
BCR-ABL Gene Transcript Types of Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia.
BCR-ABL in chronic myelogenous leukemia--how does it work?
BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.
BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia.
Bcr-Abl induced tyrosine phosphorylation of emi1 to stabilize skp2 protein via inhibition of ubiquitination in chronic myeloid leukemia cells.
Bcr-Abl induces autocrine IGF-1 signaling.
BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.
BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
BCR-ABL inhibitors: Updates in the management of patients with chronic-phase chronic myeloid leukemia.
BCR-ABL insufficiency for the transformation of human stem cells into CML.
Bcr-Abl is a "molecular switch" for the decision for growth and differentiation in hematopoietic stem cells.
BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-AblT315I: looking into the future of controlling drug resistance in chronic myeloid leukemia.
BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?
BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.
BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.
Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin.
BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death.
BCR-ABL mediated repression of miR-223 results in the activation of MEF2C and PTBP2 in chronic myeloid leukemia.
BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity.
BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria.
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
BCR-ABL mutants spread resistance to non-mutated cells through a paracrine mechanism.
BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
BCR-ABL mutations in chronic myeloid leukemia - not only detection.
BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival.
BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
BCR-ABL mutations in chronic myeloid leukemia.
BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B.
bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanism in chronic myeloid leukemia.
Bcr-Abl oncogene stimulates Jab1 expression via cooperative interaction of ?-catenin and STAT1 in chronic myeloid leukemia cells.
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Bcr-abl positive blast crisis of chronic myeloid leukemia emerging in a case of metastatic colorectal cancer 3 months after completion of an 8-month course of cetuximab and irinotecan.
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
BCR-ABL promotes neutrophil differentiation in the chronic phase of chronic myeloid leukemia by downregulating c-Jun expression.
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
BCR-ABL protein expression in peripheral blood cells of chronic myelogenous leukemia patients undergoing therapy.
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia.
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling.
Bcr-Abl regulates osteopontin transcription via Ras, PI-3K, aPKC, Raf-1, and MEK.
BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance.
Bcr-Abl regulation of sphingomyelin synthase 1 reveals a novel oncogenic-driven mechanism of protein up-regulation.
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
bcr-abl RNA in patients with chronic myelogenous leukemia.
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.
Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1.
Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor.
BCR-Abl Silencing by Short Interfering RNA: A Potent Approach to Sensitize Chronic Myeloid Leukemia Cells to Tyrosine Kinase Inhibitor Therapy.
Bcr-abl silencing by specific small-interference RNA expression vector as a potential treatment for chronic myeloid leukemia.
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation.
BCR-ABL stimulates mutagenic homologous DNA double-strand break repair via the DNA end processing factor CtIP.
BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription.
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
BCR-ABL transcript variations in chronic phase chronic myelogenous leukemia patients on imatinib first-line: Possible role of the autologous immune system.
BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia.
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
BCR-ABL transcripts are not detected in cord blood or the peripheral blood of the newborn child whose mother developed chronic myeloid leukemia while pregnant.
BCR-ABL translocation in a dog with chronic monocytic leukemia.
BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia.
BCR-ABL tyrosine kinase inhibition induces metabolic vulnerability by preventing the integrated stress response in K562?cells.
BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia.
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
BCR-ABL tyrosine kinase inhibitors promote pathological changes in dilator phenotype in the human microvasculature.
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Bcr-Abl ubiquitination and Usp9x inhibition block kinase signaling and promote CML cell apoptosis.
BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia.
BCR-ABL V280G Mutation, Potential Role in Imatinib Resistance: First Case Report.
Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
BCR-ABL, ABL-BCR, BCR, and ABL genes are all expressed in individual granulocyte-macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia.
BCR-ABL-expressing cells transduced with the HSV-tk gene die by apoptosis upon treatment with ganciclovir.
bcr-abl-Induced cell lines can switch from mast cell to erythroid or myeloid differentiation in vitro.
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
Bcr-Abl-mediated protection from apoptosis downstream of mitochondrial cytochrome c release.
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
Bcr-Abl-mediated suppression of normal hematopoiesis in leukemia.
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Bcr-abl-positive cells secrete angiogenic factors including matrix metalloproteinases and stimulate angiogenesis in vivo in Matrigel implants.
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
BCR-ABL: a multi-faceted promoter of DNA mutation in chronic myelogeneous leukemia.
BCR-ABL: an anti-apoptosis gene in chronic myelogenous leukemia.
BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.
Benchmarking 2D/3D/MD-QSAR Models for Imatinib Derivatives: How Far Can We Predict?
Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias.
beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
beta-Glucuronidase is an optimal normalization control gene for molecular monitoring of chronic myelogenous leukemia.
Betulinic acid induces apoptosis in human chronic myelogenous leukemia (CML) cell line K-562 without altering the levels of Bcr-Abl.
Beyond BRAF in Melanoma.
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
Beyond genomics.
Biodegradable charged polyester-based vectors (BCPVs) as an efficient non-viral transfection nanoagent for gene knockdown of the BCR-ABL hybrid oncogene in a human chronic myeloid leukemia cell line.
Biological therapy for pediatric malignancy: current perspectives.
Biology and treatment of chronic myelogenous leukemia.
Biology and treatment of chronic myeloid leukemia.
Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.
Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.
Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL.
Blockade of the interaction between Bcr-Abl and PTB1B by small molecule SBF-1 to overcome imatinib-resistance of chronic myeloid leukemia cells.
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells.
Bone marrow-derived mesenchymal stromal cells promote resistance to tyrosine kinase inhibitors in chronic myeloid leukemia via the IL-7/JAK1/STAT5 pathway.
Bone metabolism, growth rate and pubertal development in children with chronic myeloid leukemia treated with imatinib during puberty.
Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells.
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
Bosutinib for Chronic Myeloid Leukemia.
Bosutinib in the management of chronic myelogenous leukemia.
Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.
Bosutinib Therapy in Patients With Chronic Myeloid Leukemia: Practical Considerations for Management of Side Effects.
Bosutinib treatment for Philadelphia chromosome-positive leukemias.
Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Bothrops moojeni L-amino acid oxidase induces apoptosis and epigenetic modulation on Bcr-Abl+ cells.
Breakpoints on chromosomes 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Amplification of rearranged c-abl oncogenes in CML blast crisis.
Brefeldin A Induces Apoptosis, Inhibits BCR-ABL Activation, and Triggers BCR-ABL Degradation in Chronic Myeloid Leukemia K562 Cells.
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers.
c-Abl in oxidative stress, aging and cancer.
c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
c-abl Oncogene and chromosome 22 "bcr" juxtaposition in chronic myelogenous leukemia.
c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
c-Abl-dependent Molecular Circuitry Involving Smad5 and Phosphatidylinositol 3-Kinase Regulates Bone Morphogenetic Protein-2-induced Osteogenesis.
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
c-kit ligand stimulates tyrosine phosphorylation of a similar pattern of phosphotyrosyl proteins in primary primitive normal hematopoietic progenitors that are constitutively phosphorylated in comparable primitive progenitors in chronic phase chronic myelogenous leukemia.
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies.
C/EBP? is a critical mediator of IFN-?-induced exhaustion of chronic myeloid leukemia stem cells.
C/EBP? promotes BCR-ABL-mediated myeloid expansion and leukemic stem cell exhaustion.
C3G forms complexes with Bcr-Abl and p38? MAPK at the focal adhesions in chronic myeloid leukemia cells: implication in the regulation of leukemic cell adhesion.
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.
CaMKII ?, a critical regulator of CML stem/progenitor cells, is a target of the natural product berbamine.
Camptothecin acts synergistically with imatinib and overcomes imatinib resistance through Bcr-Abl independence in human K562 cells.
Can clues to the molecular defects in chronic myelogenous leukemia come from genetic studies on the Abelson tyrosine kinase in fruit flies?
Can increased immunogenicity in chronic myeloid leukemia improve outcomes?
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study.
Can we afford to let sleeping dogs lie?
Cantharidin Overcomes Imatinib Resistance by Depleting BCR-ABL in Chronic Myeloid Leukemia.
Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines.
Carboxyamidotriazole inhibits cell growth of imatinib-resistant chronic myeloid leukaemia cells including T315I Bcr-Abl mutant by a redox-mediated mechanism.
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
CBL-B is required for leukemogenesis mediated by BCR-ABL through negative regulation of bone marrow homing.
CCN3 - A key regulator of the hematopoietic compartment.
CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells.
CD-200 induces apoptosis and inhibits Bcr-Abl signaling in imatinib-resistant chronic myeloid leukemia with T315I mutation.
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
CD93 is expressed on chronic myeloid leukemia stem cells and identifies a quiescent population which persists after tyrosine kinase inhibitor therapy.
CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.
Celastrol, a novel HSP90 inhibitor, depletes Bcr-Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
Cell lines and clinical isolates derived from Ph1-positive chronic myelogenous leukemia patients express c-abl proteins with a common structural alteration.
Cell lines and peripheral blood leukocytes derived from individuals with chronic myelogenous leukemia display virtually identical proteins phosphorylated on tyrosine residues.
Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.
Cell-penetrating SH3 domain blocker peptides inhibit proliferation of primary blast cells from CML patients.
Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines.
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance.
Changes in cell adhesivity and cytoskeleton-related proteins during imatinib-induced apoptosis of leukemic JURL-MK1 cells.
Changes in molecular biology of chronic myeloid leukemia in tyrosine kinase inhibitor era.
Changes in the activity of the GPx-1 anti-oxidant selenoenzyme in mononuclear cells following imatinib treatment.
Changes in the proteome associated with the action of Bcr-Abl tyrosine kinase are not related to transcriptional regulation.
Changing the subcellular location of the oncoprotein bcr-abl using rationally designed capture motifs.
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations.
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.
Characteristics of BCR-ABL gene variants in patients of chronic myeloid leukemia.
Characteristics of BCR-ABL kinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance.
Characteristics of BCR-ABL kinase domain point mutations in Chinese imatinib-resistant chronic myeloid leukemia patients.
Characterization and selection of benign stem cells in chronic myeloid leukemia.
Characterization of a myeloid tyrosine phosphatase, Lyp, and its role in the Bcr-Abl signal transduction pathway.
Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements.
Characterization of ABL exon 7 deletion by molecular genetic and bioinformatic methods reveals no association with imatinib resistance in chronic myeloid leukemia.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Characterization of dasatinib and its structural analogs as CYP3A4 mechanism based inactivators and the proposed bio-activation pathways.
Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Characterization of p87C3G, a novel, truncated C3G isoform that is overexpressed in chronic myeloid leukemia and interacts with Bcr-Abl.
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Characterization of the different BCR-ABL transcripts with a single multiplex RT-PCR.
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance.
Charting the molecular network of the drug target Bcr-Abl.
Chemical and enzymatic probing of effector-mediated changes in the conformation of a maxizyme.
Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine.
Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Chemokines as a Conductor of Bone Marrow Microenvironment in Chronic Myeloid Leukemia.
Chemokines in chronic myeloid leukemia.
Chibby drives ? catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells.
Chitosan encapsulated quantum dots platform for leukemia detection.
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC???
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Chromatin nucleoprotein complexes containing tightly bound c-abl, p53 and bcl-2 gene sequences: correlation with progression of chronic myelogenous leukemia.
Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.
Chromosomal approaches to the molecular basis of neoplasia.
Chromosomal in situ hybridization and Southern blot analyses using c-abl, c-sis, or bcr probe in chronic myelogenous leukemia cells with variant Philadelphia translocations.
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Chromosome 22 breakpoints in variant Philadelphia translocations and Philadelphia-negative chronic myeloid leukemia.
Chronic myelogenous leukemia cells convert to myofibroblasts in vitro: Effect of vascular endothelial growth factor on development of the microenvironment.
Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases.
Chronic myelogenous leukemia.
Chronic myelogenous leukemia: amplification of a rearranged c-abl oncogene in both chronic phase and blast crisis.
Chronic myelogenous leukemia: biology and therapy.
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.
Chronic myelogenous leukemia: mechanisms underlying disease progression.
Chronic myelogenous leukemia: treatment and monitoring.
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
Chronic myeloid leukemia cells refractory/resistant to tyrosine kinase inhibitors are genetically unstable and may cause relapse and malignant progression to the terminal disease state.
CHRONIC MYELOID LEUKEMIA EXPECTED RELAPSE'S CLINICAL-LABORATORY INDEXES.
Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.
Chronic myeloid leukemia may be associated with several bcr-abl transcripts including the acute lymphoid leukemia-type 7 kb transcript.
Chronic myeloid leukemia patient with co-occurrence of BCR-ABL junction and JAK2 V617F mutation.
Chronic myeloid leukemia patients sensitive and resistant to imatinib treatment show different metabolic responses.
Chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation are resistant to dasatinib: Is that true for all the patients?
Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript.
Chronic myeloid leukemia presenting with bilateral central retinal vein occlusion and massive retinal infiltrates.
Chronic myeloid leukemia progenitor cells require autophagy when leaving hypoxia-induced quiescence.
Chronic myeloid leukemia stem cells and developing therapies.
Chronic myeloid leukemia stem cells and molecular target therapies for overcoming resistance and disease persistence.
Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.
Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Chronic myeloid leukemia with a rare variant BCR-ABL translocation: t(9;22;21)(q34;q11.2;q11.2).
Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.
Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.
Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
Chronic Myeloid Leukemia With P190 BCR-ABL Translocation and Persistent Moderate Monocytosis: A Case Report.
Chronic myeloid leukemia with p210 BCR-ABL and monocytosis.
Chronic myeloid leukemia with unusual variant Ph translocation (22;22)(q11;q13). Two cases with chimeric BCR-ABL transcripts.
Chronic Myeloid Leukemia--Prognostic Value of Mutations.
Chronic myeloid leukemia.
Chronic myeloid leukemia: Existing therapeutic options and strategies to overcome drug resistance.
Chronic myeloid leukemia: overview of new agents and comparative analysis.
Chronic myeloid leukemia: past, present, future.
Chronic myeloid leukemia: reminiscences and dreams.
Chronic myeloid leukemia: state of the art in 2012.
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy.
CircBA1 derived from BCR-ABL fusion gene inhibits cell proliferation in chronic myeloid leukemia.
Circulating bcr-abl-specific CD8+ T cells in chronic myeloid leukemia patients and healthy subjects.
Circulating myeloid dendritic cell directly isolated from patients with chronic myelogenous leukemia are functional and carry the bcr-abl translocation.
Classification of Patients With Chronic Myeloid Leukemia on Basis of BCR-ABL Transcript Level at 3 Months Fails to Identify Patients With Low Organic Cation Transporter-1 Activity Destined to Have Poor Imatinib Response.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Clinical detection of BCR-abl fusion by in situ hybridization in chronic myelogenous leukemia.
Clinical development of imatinib: an anticancer drug.
Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients.
Clinical experience to date with nilotinib in gastrointestinal stromal tumors.
Clinical outcome in chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation: the experience of the Bone Marrow Transplantation Unit of FUNFARME/BRAZIL using FISH.
Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation.
Clinical outcome of chronic myeloid leukemia imatinib-resistant patients: do BCR-ABL kinase domain mutations affect patient survival? First multicenter Argentinean study.
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemia.
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation.
Clinico-hematological profile in biphenotypic acute leukemia.
Clonal analysis of bcr-abl rearrangement in T lymphocytes from patients with chronic myelogenous leukemia.
Clonal chromosome aberrations in Philadelphia-negative cells from chronic myelocytic leukemia patients treated with imatinib mesylate: report of two cases.
Clonal evolution of AML1-ETO coexisting with BCR-ABL and additional chromosome abnormalities in a blastic transformation of chronic myeloid leukemia.
Clonally unrelated BCR-ABL-negative acute myeloblastic leukemia masquerading as blast crisis after busulphan and interferon therapy for BCR-ABL-positive chronic myeloid leukemia.
Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.
CML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.
Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment.
Co-existence of BCR-ABL and JAK2V617F mutation in resistant chronic myeloid leukemia in the imatinib era: Is there a correlation?
Co-expression of HoxA9 and bcr-abl genes in chronic myeloid leukemia.
Co-occurrence of Myeloproliferative Neoplasms and Solid Tumors Is Attributed to a Synergism Between Cytoreductive Therapy and the Common TERT Polymorphism rs2736100.
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.
Combination of a proteomics approach and reengineering of meso scale network models for prediction of mode-of-action for tyrosine kinase inhibitors.
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy.
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells.
Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition.
Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Combined inhibition of ?-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
Combined inhibition of MDM2 and Bcr-Abl tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model.
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells.
Combined Therapy of ATRA and Imatinib Mesylate Decreases BCR-ABL and ABCB1/MDR1 Expression Through Cellular Differentiation in a Chronic Myeloid Leukemia Model.
Commonly used drugs in hematologic disorders.
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Comparative effect of imatinib and ponatinib on autophagy and miRNome in chronic myeloid leukemia.
Comparative gene expression analysis of a chronic myelogenous leukemia cell line resistant to cyclophosphamide using oligonucleotide arrays and response to tyrosine kinase inhibitors.
Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia.
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Comparison of activities between hammerhead ribozymes and DNA enzymes targeted to L6 BCR-ABL chimeric (b2a2) mRNA.
Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Comparison of bcr-abl protein expression and Philadelphia chromosome analyses in chronic myelogenous leukemia patients.
Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients.
Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
Comparison of the specificities and catalytic activities of hammerhead ribozymes and DNA enzymes with respect to the cleavage of BCR-ABL chimeric L6 (b2a2) mRNA.
Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Competitive polymerase chain reaction as a method to detect the amplification of bcr-abl gene of chronic myeloid leukemia.
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
Complete cytogenetic response to Nilotinib in a chronic myeloid leukemia case with a rare e13a3(b2a3) BCR-ABL fusion transcript: A case report.
Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience.
Complex Variant t(9;22) Chromosome Translocations in Five Cases of Chronic Myeloid Leukemia.
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia.
Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.
Comprehensive validation of a real-time quantitative bcr-abl assay for clinical laboratory use.
Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.
Computational analysis of ABL kinase mutations allows predicting drug sensitivity against selective kinase inhibitors.
Computational and Biological Investigations on Abl1 Tyrosine Kinase: A Review.
Computational Modeling of Stapled Peptides toward a Treatment Strategy for CML and Broader Implications in the Design of Lengthy Peptide Therapeutics.
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.
Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia.
Considering baseline factors and early response rates to optimize therapy for chronic myeloid leukemia in chronic phase.
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia.
Constitutive and specific activation of STAT3 by BCR-ABL in embryonic stem cells.
Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.
Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis.
Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients.
Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Controlling subcellular localization to alter function: Sending oncogenic Bcr-Abl to the nucleus causes apoptosis.
Conventional and fluorescence in situ hybridization analysis of three-way complex BCR-ABL rearrangement in a chronic myeloid leukemia patient.
Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.
Coordinate Modulation of Glycolytic Enzymes and OXPHOS by Imatinib in BCR-ABL Driven Chronic Myelogenous Leukemia Cells.
Correction: MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Correlation between the type of bcr-abl transcripts and blood cell counts in chronic myeloid leukemia - a possible influence of mdr1 gene expression.
Correlation of major cytogenetic response with a pharmacogenetic marker in chronic myeloid leukemia patients treated with imatinib (STI571).
Correlation of p210 BCR-ABL transcript variants with clinical, parameters and disease outcome in 45 chronic myeloid leukemia patients.
Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.
Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Coupled delivery of imatinib mesylate and doxorubicin with nanoscaled polymeric vectors for a sustained downregulation of BCR-ABL in chronic myeloid leukemia.
CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Critical molecular pathways in cancer stem cells of chronic myeloid leukemia.
Critical role of STAT5 activation in transformation mediated by ZNF198-FGFR1.
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.
Crosstalk between BCR-ABL and protease-activated receptor 1 (PAR1) suggests a novel target in chronic myeloid leukemia.
Crosstalk between CML cells with HUVECS and BMSCs through CML derived exosomes.
Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy.
Cryptotanshinone suppresses key onco-proliferative and drugresistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia.
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Curcumin affects components of the chromosomal passenger complex and induces mitotic catastrophe in apoptosis-resistant Bcr-Abl-expressing cells.
Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia.
Current status of agents active against the T315I chronic myeloid leukemia phenotype.
Current status of vaccination therapy for leukemias.
Current therapy of chronic myelogenous leukemia.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
Cytogenetic and molecular genetic aspects of essential thrombocythemia.
Cytogenetic and molecular mechanisms of resistance to imatinib.
Cytogenetic characterisation and proteomic profiling of the Imatinib-resistant cell line KCL22-R.
Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft.
Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia.
Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia.
Cytotoxic T cells overcome BCR-ABL-mediated resistance to apoptosis.
Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.
Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
Dasatinib accelerates valproic acid-induced acute myeloid leukemia cell death by regulation of differentiation capacity.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Dasatinib as the salvage therapy for chronic myeloid leukemia with blast crisis and central nervous system involvement: A case report.
Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation.
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Dasatinib in chronic myeloid leukemia: a review.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Dasatinib Inhibits Procoagulant and Clot Retracting Activities of Human Platelets.
Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia.
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line.
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?
Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Dasatinib.
Dasatinib: a new step in molecular target therapy.
Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
De novo Philadelphia chromosome positive myelodysplastic syndrome: Report of two cases with brief literature review.
Deciphering the internal complexity of living cells with quantitative phase microscopy: a multiscale approach.
Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib.
Decreased calpain activity in chronic myeloid leukemia impairs apoptosis by increasing survivin in myeloid progenitors and xiap1 in differentiating granulocytes.
Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Delayed cytogenetic response with prolonged interferon-alpha treatment in chronic myeloid leukemia patients: quantification of BCR-ABL transcript by competitive reverse transcription-polymerase chain reaction.
Deletion of the 5'ABL region in Philadelphia chromosome positive chronic myeloid leukemia: frequency, origin and prognosis.
Deletion of the derivative chromosome 9 in chronic myeloid leukemia.
Deletion of the RNA-editing enzyme ADAR1 causes regression of established chronic myelogenous leukemia in mice.
Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia.
Delivery of antibody mimics into mammalian cells via anthrax toxin protective antigen.
Delivery of therapeutic shRNA and siRNA by Tat fusion peptide targeting bcr-abl fusion gene in Chronic Myeloid Leukemia cells.
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Denbinobin-mediated anticancer effect in human K562 leukemia cells: role in tubulin polymerization and Bcr-Abl activity.
Dendritic cell vaccination for patients with chronic myelogenous leukemia.
Dendritic cells from CML patients have altered actin organization, reduced antigen processing, and impaired migration.
Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia.
Dendritic-cell-peptide immunization provides immunoprotection against bcr-abl-positive leukemia in mice.
Depletion of ?-catenin by Histone Deacetylase Inhibition Confers Elimination of CML Stem Cells in Combination with Imatinib.
Depletion of pleckstrin homology domain leucine-rich repeat protein phosphatase 1 and 2 by Bcr-Abl promotes chronic myelogenous leukemia cell proliferation through continuous phosphorylation of Akt isoforms.
Depression of oncogenecity by dephosphorylating and degrading BCR-ABL.
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Deregulation of calcium homeostasis in Bcr-Abl-dependent chronic myeloid leukemia.
Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability.
Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia.
Design and synthesis of 3-substituted benzamide derivatives as Bcr-Abl kinase inhibitors.
Design of substrate-based BCR-ABL kinase inhibitors using the cyclotide scaffold.
Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation.
Design, Synthesis, and Biological Evaluation of Betulinic Acid Derivatives as New Antitumor Agents for Leukemia.
Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML).
Detailed mapping of methylcytosine positions at the CpG island surrounding the Pa promoter at the bcr-abl locus in CML patients and in two cell lines, K562 and BV173.
Detection and direct sequence identification of BCR-ABL mRNA in Ph+ chronic myeloid leukemia.
Detection by enzymatic amplification of bcr-abl mRNA in peripheral blood and bone marrow cells of patients with chronic myelogenous leukemia.
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Detection of bcr-abl fusion mRNA in chronic myelogenous leukemia by reverse transcription polymerase chain reaction using nested primers.
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib.
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Detection of BCR-ABL mutations and resistance to imatinib mesylate.
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis.
Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review.
Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients.
Detection of bcr-abl transcript in chronic myelogenous leukemia patients by reverse-transcription-polymerase chain reaction and capillary electrophoresis.
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using an in situ RT-PCR assay.
Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
Detection of bcr/c-abl mRNA in chronic myelogenous leukemia by polymerase chain reaction to identify chromosome translocation.
Detection of c-abl tyrosine kinase activity in vitro permits direct comparison of normal and altered abl gene products.
Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.
Detection of drug-resistant clones in chronic myelogenous leukemia patients during dasatinib and nilotinib treatment.
Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals.
Detection of minimal residual bcr/abl transcripts by a modified polymerase chain reaction.
Detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction.
Detection of molecular variants of BCR-ABL gene in bone marrow and blood of patients with chronic myeloid leukemia by reverse-transcriptase polymerase chain reaction (RT-PCR).
Detection of Philadelphia chromosome-positive cells from glass slide smears using the polymerase chain reaction.
Detection of single nucleotide insertion of BCR/ABL region in imatinib-resistant human myelogenous leukemia SR-1 cells.
Detection of the BCR-ABL fusion gene in natural killer cells in patients with chronic myelogenous leukemia.
Detection of the BCR-ABL gene by interphase fluorescence in situ hybridization (iFISH) in chronic myelogenous leukemia patients after hemopoietic stem cell transplantation: the feasibility of iFISH monitoring of therapeutic response in peripheral blood.
Detection of the breakpoint cluster region-ABL fusion in chronic myeloid leukemia with variant Philadelphia chromosome translocations by in situ hybridization.
Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.
Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization.
Detection of two alternative bcr/abl mRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polymerase chain reaction.
Detection of tyrosine protein kinase substrates in fresh leukemia cells and normal blood cells using an immunoblotting technique.
Determination of the optimal chemotherapy drugs pretreatment time through cultivation of hemopoietic cells in CML-patients treated with tyrosine kinase inhibitors.
Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.
Deubiquitylase USP25 prevents degradation of BCR-ABL protein and ensures proliferation of Ph-positive leukemia cells.
Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Development of a rapid and sensitive one-step reverse transcription-nested polymerase chain reaction in a single tube using the droplet-polymerase chain reaction machine.
Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
Development of an integrated assay for detection of BCR-ABL RNA.
Development of BCR-ABL degradation inducers via the conjugation of an imatinib derivative and a cIAP1 ligand.
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Development, function and clinical significance of plasmacytoid dendritic cells in chronic myeloid leukemia.
Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR.
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Diagnostic utility of oncogenes and their products in human cancer.
Differences and similarities in kinetics of BCR-ABL transcript levels in CML patients treated with imatinib mesylate for chronic or accelerated disease phase.
Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia.
Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Differential effects of tumor promoters on P210bcr-abl expression.
Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid leukemia.
Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Direct and rapid identification of T315I-Mutated BCR-ABL expressing leukemic cells using infrared microspectroscopy.
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein.
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Disappearance of Ph1 chromosome with intensive chemotherapy and detection of minimal residual disease by polymerase chain reaction in a patient with blast crisis of chronic myelogenous leukemia.
Discontinuation of BCR-ABL tyrosine kinase inhibitors in patients with chronic myeloid leukemia: a retrospective study.
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML).
Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
Discovery of 2-Acylaminothiophene-3-Carboxamides as Multitarget Inhibitors for BCR-ABL Kinase and Microtubules.
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
Discovery of 8-cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carbonitrile (7x) as a potent inhibitor of cyclin-dependent kinase 4 (CDK4) and AMPK-related kinase 5 (ARK5).
Discovery of a Candidate Containing an (S)-3,3-Difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1H-inden Scaffold as a Highly Potent Pan-Inhibitor of the BCR-ABL Kinase Including the T315I-Resistant Mutant for the Treatment of Chronic Myeloid Leukemia.
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia.
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Discovery of allosteric BCR-ABL inhibitors from phenotypic screen to clinical candidate.
Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation.
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Disease status in patients with chronic myeloid leukemia is better characterized by BCR-ABL/BCR transcript ratio than by BCR-ABL transcript level, which may suggest a role of normal BCR gene in the disease pathogenesis.
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Disruption of Survivin in K562 cells elevates telomerase activity and protects cells against apoptosis induced by the Bcr-abl kinase inhibitor STI571.
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains.
Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines.
Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Diversity of Long-Lived Intermediates along the Binding Pathway of Imatinib to Abl Kinase Revealed by MD Simulations.
Do endothelial cells belong to the primitive stem leukemic clone in CML? Role of extracellular vesicles.
Docosahexaenoic acid enhances the toxic effect of imatinib on Bcr-Abl expressing HL-60 cells.
Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase?
Does HOXA9 Gene Expression in Egyptian Chronic Myelogenous Leukemia Patients Affect Disease Progression? A Retrospective Cohort Study.
Donor leukocyte infusions in the treatment of chronic myeloid leukemia in relapse post bone marrow transplantation.
Donor-derived b2a2-specific T cells for immunotherapy of patients with chronic myeloid leukemia.
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia.
Double minutes containing amplified bcr-abl fusion gene in a case of chronic myeloid leukemia treated by imatinib.
Double-gradient-denaturing-gradient gel electrophoresis for mutation screening of the BCR-ABL tyrosine kinase domain in chronic myeloid leukemia patients.
Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region.
Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC.
Down-regulation of thanatos-associated protein 11 by BCR-ABL promotes CML cell proliferation through c-Myc expression.
Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs.
Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Dual Drug Targeting of Mutant Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic Myeloid Leukemia and Overcoming Monotherapy Resistance.
Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells.
Dual regulation of Myc by Abl.
Dual Src and Abl inhibitors target wild type Abl and the AblT315I Imatinib-resistant mutant with different mechanisms.
Dual tyrosine kinase inhibitors in chronic myeloid leukemia.
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.
Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy.
Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells.
E1A overcomes the apoptosis block in BCR-ABL+ leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents.
e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia.
Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Ecotropic viral integration site I regulates alpha1, 6-fucosyl transferase expression and blocks erythropoiesis in chronic myeloid leukemia.
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Effect of antisense oligonucleotides on CD34+ cells from chronic myeloid leukemia.
Effect of aprepitant, a moderate CYP3A4 inhibitor, on bosutinib exposure in healthy subjects.
Effect of bosutinib on the absorption of dabigatran etexilate mesylate, a P-glycoprotein substrate, in healthy subjects.
Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells.
Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants.
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Effect of recombinant alpha-interferon on the expression of the bcr-abl fusion gene in human chronic myelogenous human leukemia cell lines.
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells.
Effects of As(2)O(3) on BCR-ABL protein level and signal transduction in CML cells.
Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells.
Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
Effects of herbimycin A derivatives on growth and differentiation of K562 human leukemic cells.
Effects of imatinib on bone marrow engraftment in syngeneic mice.
Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.
Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants.
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors.
Effects of the bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro.
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells.
Effects of transfection of p210bcr-abl and bcr-v-abl into the factor-dependent human leukemia cell line HSM-911.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study.
Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells.
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Efficient disruption of bcr-abl gene by CRISPR RNA-guided FokI nucleases depresses the oncogenesis of chronic myeloid leukemia cells.
Efficient transplantation of BCR-ABL-induced chronic myelogenous leukemia-like syndrome in mice.
Elderly Patients With Chronic Myeloid Leukemia Benefit From a Dasatinib Dose as Low as 20 mg.
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Emergence of BCR-ABL kinase domain mutations associated with newly diagnosed chronic myeloid leukemia: a meta-analysis of clinical trials of tyrosine kinase inhibitors.
Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority.
Emerging drugs for chronic myeloid leukemia.
Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer.
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors.
EML4-ALK Rearrangement and Its Therapeutic Implications in Inflammatory Myofibroblastic Tumors.
Emodin Exerts an Antiapoptotic Effect on Human Chronic Myelocytic Leukemia K562 Cell Lines by Targeting the PTEN/PI3K-AKT Signaling Pathway and Deleting BCR-ABL.
Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase.
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
ENHANCED AND SELECTIVE KILLING OF CHRONIC MYELOGENOUS LEUKEMIA CELLS WITH AN ENGINEERED BCR-ABL BINDING PROTEIN AND IMATINIB.
Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML).
Enhanced SH3/Linker Interaction Overcomes Abl Kinase Activation by Gatekeeper and Myristic Acid Binding Pocket Mutations and Increases Sensitivity to Small Molecule Inhibitors.
Enrichment of normal progenitors in counter-flow centrifugal elutriation (CCE) fractions of fresh chronic myeloid leukemia leukapheresis products.
Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl.
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation.
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation.
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia.
Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.
Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib.
Erratum: BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia.
Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
Essential role for telomerase in chronic myeloid leukemia induced by BCR-ABL in mice.
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
Estimation of the distribution of longitudinal biomarker trajectories prior to disease progression.
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias.
Evaluation of T315I mutation frequency in chronic myeloid leukemia patients after imatinib resistance.
Evaluation of the Cepheid GeneXpert BCR-ABL assay.
Ever-advancing chronic myeloid leukemia treatment.
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Evidence that the phl gene encodes a 160,000-dalton phosphoprotein with associated kinase activity.
Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy.
Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line.
Ex vivo purging with NK-92 prior to autografting for chronic myelogenous leukemia.
Exon 7 Deletion in the bcr-abl Gene Is Frequent in Chronic Myeloid Leukemia Patients and Is Not Correlated with Resistance against Imatinib.
Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells.
Exosomes from mesenchymal stromal cells enhance imatinib-induced apoptosis in human leukemia cells via activation of caspase signaling pathway.
Expanding the diversity of allosteric bcr-abl inhibitors.
Expansion of senescent megakaryocyte-lineage cells maintains CML cell leukemogenesis.
Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.
Explaining why Gleevec is a specific and potent inhibitor of Abl kinase.
Exposing oncogenic dependencies for cancer drug target discovery and validation using RNAi.
Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner.
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells.
Expression of inducible NOS is indispensable for the antiproliferative and proapoptotic effect of imatinib in BCR-ABL positive cells.
Expression of programmed cell death proteins in patients with chronic myeloid leukemia.
Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling.
Expression of the hybrid P210 bcr/abl protein in Philadelphia chromosome positive B-lymphoid cell lines.
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome.
Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction.
Fangchinoline induces G0/G1 arrest by modulating the expression of CDKN1A and CCND2 in K562 human chronic myelogenous leukemia cells.
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression.
First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts.
First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia.
First-line therapy for chronic myeloid leukemia: Past, present, and future.
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
FISH for BCR-ABL on interphases of peripheral blood neutrophils but not of unselected white cells correlates with bone marrow cytogenetics in CML patients treated with imatinib.
Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker.
FLT3 as a therapeutic target in childhood acute leukemia.
FLT3 mutations: biology and treatment.
Fluorescence in situ hybridization characterization of different cryptic BCR-ABL rearrangements in chronic myeloid leukemia.
Fluorescence in situ hybridization monitoring of BCR-ABL-positive neutrophils in chronic-phase chronic myeloid leukemia patients during the primary stage of imatinib mesylate therapy.
Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
Four-channel asymmetric Real-Time PCR hybridization probe assay: A rapid pre-screening method for critical BCR-ABL kinase domain mutations.
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
Frequency of BCR-ABL fusion transcripts in Serbian patients with chronic myeloid leukemia.
Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
Frequency of BCR-ABL gene mutations in Polish patients with chronic myeloid leukemia treated with imatinib: a final report of the MAPTEST study.
Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
From 'Targeted Therapy' to Targeted Therapy.
From dissection of disease pathogenesis to elucidation of mechanisms of targeted therapies: leukemia research in the genomic era.
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
From xeroderma pigmentosum to the biological clock contributions of Dirk Bootsma to human genetics.
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Functional genomics of hTERT gene in leukemic myelopoiesis.
Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells.
Functional phosphoproteomic analysis reveals cold-shock domain protein A to be a Bcr-Abl effector-regulating proliferation and transformation in chronic myeloid leukemia.
Functional screen analysis reveals miR-3142 as central regulator in chemoresistance and proliferation through activation of the PTEN-AKT pathway in CML.
Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis.
Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice.
Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Further evidence for the lack of correlation between the breakpoint site within M-BCR and CML prognosis and for the occasional involvement of p53 in transformation.
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Fusion FISH Imaging: Single-Molecule Detection of Gene Fusion Transcripts In Situ.
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Gadd45a deficiency accelerates BCR-ABL driven chronic myelogenous leukemia.
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors.
Gaining insights into the Bcr-Abl activity-independent mechanisms of resistance to imatinib mesylate in KCL22 cells: A comparative proteomic approach.
Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile.
GCA links TRAF6-ULK1-dependent autophagy activation in resistant chronic myeloid leukemia.
Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Gene expression profile of circulating CD34(+) cells and granulocytes in chronic myeloid leukemia.
Gene expression signatures associated with the in vitro resistance to two tyrosine kinase inhibitors, nilotinib and imatinib.
Gene expression signatures associated with the resistance to imatinib.
Gene therapy for chronic myelogenous leukemia.
Gene-targeted specific inhibition of chronic myeloid leukemia cell growth by BCR-ABL antisense oligodeoxynucleotides.
Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.
Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cells.
Generation of induced pluripotent stem cell line KUMi002-A with normal karyotype from a patient with Philadelphia chromosome-positive chronic myeloid leukemia.
Generation of the induced pluripotent stem cell line KUMi001-A carrying the Philadelphia chromosome from a chronic myeloid leukemia patient.
Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques.
Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer.
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
Genomic targeting and genetic conversion in cancer therapy.
GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.
Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells.
Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics.
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in k562 human chronic myeloid leukemia cells.
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Glucosylceramide synthase inhibitor PDMP sensitizes chronic myeloid leukemia T315I mutant to Bcr-Abl inhibitor and cooperatively induces glycogen synthase kinase-3-regulated apoptosis.
Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing.
Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.
Growth arrest specific 2 is up-regulated in chronic myeloid leukemia cells and required for their growth.
Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays.
Growth factor-mediated terminal differentiation of chronic myeloid leukemia.
Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells.
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells.
Hedgehog pathway activation in chronic myeloid leukemia.
Hematologic and cytogenetic remission by STI571 (Glivec) in a patient relapsing with accelerated phase CML after second allogeneic stem cell transplantation.
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
Hematologic disease induced in BALB/c mice by a bcr-abl retrovirus is influenced by the infection conditions.
Hematological and molecular response evaluation of CML patients on imatinib.
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy.
Hematopoietic stem cells in chronic myeloid leukemia.
Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Heterogeneity in expression of the bcr-abl fusion transcript in CML blast crisis.
Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan.
Heterogeneity of genomic fusion of BCR and ABL in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Heterogeneity of leukemia-initiating capacity of chronic myelogenous leukemia stem cells.
High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears.
High-resolution melt curve analysis: initial screening for mutations in BCR-ABL kinase domain.
Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Histone demethylase RBP2 mediates the blast crisis of chronic myeloid leukemia through an RBP2/PTEN/BCR-ABL cascade.
Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4(+) T lymphocytes.
HLA risk markers for chronic myelogenous leukemia in Eastern Canada.
HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia. The Chronic Leukemia Working Party of the EBMT.
HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates.
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.
Hot off the Press.
How to detect the rare BCR-ABL (e14a3) transcript: A case report and literature review.
HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
HS-438, a new inhibitor of Imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
Hsp90 inhibitors as selective anticancer drugs.
Hsp90 N- and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells.
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Human leukocyte antigens in 295 Chinese patients with chronic myeloid leukemia.
Human leukocyte antigens in Indian patients with chronic myeloid leukemia.
Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate).
Hyperdiploidy associated with a high BCR-ABL transcript level may identify patients at risk of progression in chronic myeloid leukemia.
Hypereosinophilia associated with monosomy 7.
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach.
Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome.
Identification of a rare e8a2 BCR-ABL fusion gene in three novel chronic myeloid leukemia patients treated with imatinib.
Identification of BCR-ABL fusion on chromosome 9 by fluorescence in situ hybridization in two chronic myeloid leukemia cases.
Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening.
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Identification of genes involved in imatinib resistance in CML: a gene-expression profiling approach.
Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission.
Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Identification of Natural inhibitors of Bcr-Abl for the treatment of Chronic Myeloid Leukemia.
Identification of new MHC-restriction elements for presentation of the p210(BCR-ABL) fusion region to human cytotoxic T lymphocytes.
Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening.
Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.
Identification of several genes differentially expressed during progression of chronic myelogenous leukemia.
Identification of side effects associated with intolerance to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.
Identification of TopBP1 as a c-Abl-interacting protein and a repressor for c-Abl expression.
Identifying the Time to Change BCR-ABL Inhibitor Therapy in Patients with Chronic Myeloid Leukemia.
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
Imatinib and its successors--how modern chemistry has changed drug development.
Imatinib and type 2 diabetes.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Imatinib as a paradigm of targeted therapies.
Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
Imatinib co-loaded targeted realgar nanocrystal for synergistic therapy of chronic myeloid leukemia.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
Imatinib failure and response to dasatinib in a patient with chronic myeloid leukemia in blast crisis and a novel, nine-nucleotide BCR-ABL insertion mutation.
Imatinib has the potential to exert its antileukemia effects by down-regulating hERG1 K(+) channels in chronic myelogenous leukemia.
Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.
Imatinib in Chronic Myeloid Leukemia: an Overview.
Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Imatinib induces a cytogenetic response in blast crisis or interferon failure chronic myeloid leukemia patients with e19a2 BCR-ABL transcripts.
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Imatinib mesylate as first-line therapy in patients with chronic myeloid leukemia in accelerated phase and blast phase: a retrospective analysis.
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Imatinib mesylate for the treatment of pulmonary arterial hypertension.
Imatinib mesylate in children and adolescents with cancer.
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.
Imatinib mesylate in the treatment of chronic myelogenous leukemia.
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Imatinib mesylate therapy in patients of chronic myeloid leukemia with Philadelphia chromosome positive: an experience from eastern India.
Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Imatinib resistance and blast transformation of chronic myeloid leukemia associated with a novel tri-nucleotide insertion mutation of BCR-ABL kinase domain at position K294.
Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1alpha-induced metabolic reprograming.
Imatinib resistance in a novel translocation der(17)t(1;17)(q25;p13) with loss of TP53 but without BCR/ABL kinase domain mutation in chronic myelogenous leukemia.
Imatinib resistance in gastrointestinal stromal tumors.
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia.
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up.
Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.
Imatinib use during pregnancy and breast feeding: a case report and review of the literature.
Imatinib-Induced Changes in Protein Expression and ATP-Binding Affinities of Kinases in Chronic Myelocytic Leukemia Cells.
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Imatinib. Novartis.
Immature CML cells implement a BMP autocrine loop to escape TKI treatment.
Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1.
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells.
Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro.
Immunohistochemical characterization of cutaneous drug eruptions by STI571.
Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.
Impact of BCR-ABL mutations on patients with chronic myeloid leukemia.
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia.
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Impact of CYP3A4*18 and CYP3A5*3 Polymorphisms on Imatinib Mesylate Response Among Chronic Myeloid Leukemia Patients in Malaysia.
Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.
Impending Cardiac Tamponade as the Initial Manifestation of BCR-ABL Positive Chronic Myeloid Leukemia.
Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib.
Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia.
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
Importance of early and deeper responses to long-term survival in CML patients: Implications of BCR-ABL testing in management of CML in Indian setting.
Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
Improved FRET Biosensor for the Measurement of BCR-ABL Activity in Chronic Myeloid Leukemia Cells.
Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
In defense of the somatic mutation theory of cancer.
In Search of CML Stem Cells' Deadly Weakness.
In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
In silico drug repurposing of FDA-approved drugs to predict new inhibitors for drug resistant T315I mutant and wild-type BCR-ABL1: A virtual screening and molecular dynamics study.
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib.
In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells.
In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations.
In vivo differentiation of blast-phase chronic granulocytic leukemia. Expression of c-myc and c-abl protooncogenes.
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
In-silico identification of inhibitors against mutated BCR-ABL protein of chronic myeloid leukemia: a virtual screening and molecular dynamics simulation study.
Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin.
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Incidence of Bcr-Abl kinase domain mutations in imatinib refractory chronic myeloid leukemia patients from South India.
Incidence of BCR-ABL transcript variants in patients with chronic myeloid leukemia: Their correlation with presenting features, risk scores and response to treatment with imatinib mesylate.
Incidence of chronic myeloid leukemia and patient survival: results of five French population-based cancer registries 1980-2009.
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage.
Increased expression of a novel c-abl-related RNA in K562 cells.
Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia.
Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Indole-3-carbinol induces apoptosis of chronic myelogenous leukemia cells through suppression of STAT5 and Akt signaling pathways.
Induced dendritic cell differentiation of chronic myeloid leukemia blasts is associated with down-regulation of BCR-ABL.
Inducible SHP-2 activation confers resistance to imatinib in drug-tolerant chronic myeloid leukemia cells.
Induction of apoptosis by a dominant negative H-RAS mutant (116Y) in K562 cells.
Induction of apoptosis by arachidonic acid in chronic myeloid leukemia cells.
Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.
Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase.
Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
Induction of autophagy by imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
Induction of BCR-ABL fusion genes by in vitro X-irradiation.
Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity.
Induction of p53 suppresses chronic myeloid leukemia.
Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.
Influence of BCR-ABL Transcript Type on Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib.
Inhibition of abl oncogene tyrosine kinase induces erythroid differentiation of human myelogenous leukemia K562 cells.
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia.
Inhibition of autophagy augments the anticancer activity of ?-mangostin in chronic myeloid leukemia cells.
Inhibition of bcr-abl and/or c-abl gene expression by small interfering, double-stranded RNAs: cross-talk with cell proliferation factors and other oncogenes.
Inhibition of BCR-ABL expression with antisense oligodeoxynucleotides restores beta1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors.
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
Inhibition of Bcr-Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells.
Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
Inhibition of crosstalk between Bcr-Abl and PKC signaling by PEITC, augments imatinib sensitivity in chronic myelogenous leukemia cells.
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells.
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells.
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Inhibition of protein tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl.
Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Inhibition of USP1, a new partner of Bcr-Abl, results in decrease of Bcr-Abl level in K562 cells.
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia.
Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Initial diagnosis of chronic myelogenous leukemia based on quantification of M-BCR status using droplet digital PCR.
Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro.
Insight into the allosteric inhibition of Abl kinase.
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.
Integrating in vitro sensitivity and dose-response slope is predictive of clinical response to ABL kinase inhibitors in chronic myeloid leukemia.
Integrative analyses for omics data: a Bayesian mixture model to assess the concordance of ChIP-chip and ChIP-seq measurements.
Integrin engagement-induced inhibition of human myelopoiesis is mediated by proline-rich tyrosine kinase 2 gene products.
Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
Interferon alpha and T-cell responses in chronic myeloid leukemia.
Interferon in the treatment of myeloproliferative diseases.
Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth.
Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors.
Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants.
Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL.
Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.
Intramolecular Dynamics within the N-Cap-SH3-SH2 Regulatory Unit of the c-Abl Tyrosine Kinase Reveal Targeting to the Cellular Membrane.
Investigating siRNA delivery to chronic myeloid leukemia K562 cells with lipophilic polymers for therapeutic BCR-ABL down-regulation.
Investigating the cytotoxic and apoptotic effects of sunitinib upon K-562 chronic myelogenous leukemia cell line and assessment of gene profiling.
Investigating the role of the innate immune response in relapse or blast crisis in chronic myeloid leukemia.
Investigation of bcr-abl transcription by Ph-positive chronic myeloid leukemia progenitors.
Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells.
Involvement of MCL1, c-myc, and cyclin D2 protein degradation in ponatinib-induced cytotoxicity against T315I(+) Ph+leukemia cells.
Involvement of Oxidative Stress in Resistance to Tyrosine-Kinase Inhibitors Therapy in Chronic Myeloid Leukemia.
Involvement of ROS in chlorogenic acid-induced apoptosis of Bcr-Abl+ CML cells.
Is going for cure in chronic myeloid leukemia possible and justifiable?
Is going for cure in CML targeting aberrant Glycogen Synthase Kinase 3??
Is it downhill from here? Eliminating leukemic stem cells and curing chronic myeloid leukemia.
Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
Is there horizontal transfer of the oncogene BCR-ABL mediated by extracellular vesicles released by chronic myeloid leukemia cells?: PS203.
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
Isolated central nervous system relapse of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients.
JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.
JAK2V617F Mutation in Chronic Myeloid Leukemia Predicts Early Disease Progression.
Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Janus kinase 2: a critical target in chronic myelogenous leukemia.
Juvenile myelomonocytic leukemia-A comprehensive review and recent advances in management.
K356dup - an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
K356dup--an in-frame insertion in the BCR-ABL gene in an imatinib-resistant chronic myeloid leukemia.
Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia.
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Kinase drug discovery approaches in chronic myeloproliferative disorders.
Kinase inhibitors translate lab discoveries into exciting new cures for cancers.
Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Kinetics of BCR-ABL fusion transcript levels in chronic myeloid leukemia patients treated with STI571 measured by quantitative real-time polymerase chain reaction.
Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation.
Knockout Serum Replacement Promotes Cell Survival by Preventing BIM from Inducing Mitochondrial Cytochrome C Release.
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
Lack of Bcr-Abl point mutations in imatinib chronic myeloid leukemia patients in chronic phase before initiation of treatment is not predictive of response.
Lack of c-kit (CD117) expression in CD30+ lymphomas and lymphomatoid papulosis.
Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia.
Larotrectinib (LOXO-101).
LASP1 is a novel BCR-ABL substrate and a phosphorylation-dependent binding partner of CRKL in chronic myeloid leukemia.
Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
Leukemia stem cells in a genetically defined murine model of blast-crisis CML.
Leukemia Stem Cells in Chronic Myeloid Leukemia.
Leukemia stem cells: the root of chronic myeloid leukemia.
Leukemia: stem cells, maturation arrest, and differentiation therapy.
Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
Leukotriene signaling via ALOX5 and cysteinyl leukotriene receptor 1 is dispensable for in vitro growth of CD34(+)CD38(-) stem and progenitor cells in chronic myeloid leukemia.
Lhx2 expression in hematopoietic progenitor/stem cells in vivo causes a chronic myeloproliferative disorder and altered globin expression.
Light microscopic detection of BCR-ABL transcripts after in-cell RT-PCR: fusion gene expression might correlate with clinical evolution of chronic myeloid leukemia.
Limited synergistic effect of antisense oligonucleotides against bcr-abl and transferrin receptor mRNA in leukemic cells in culture.
Lineage-specific requirement of c-abl function in normal hematopoiesis.
Liposomal delivery of oligodeoxynucleotides.
Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects.
LMWPTP modulates the antioxidant response and autophagy process in human chronic myeloid leukemia cells.
Localization of BCR-ABL to Stress Granules Contributes to Its Oncogenic Function.
Localization of the human c-sis oncogene in Ph1-positive and Ph1-negative chronic myelocytic leukemia by in situ hybridization.
Location of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic myeloid leukemia.
Long circulating lectin conjugated paclitaxel loaded magnetic nanoparticles: a new theranostic avenue for leukemia therapy.
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
Long term outcome of chronic myeloid leukemia patients treated with imatinib: Report from a developing country.
Long-range mapping of the Philadelphia chromosome by pulsed-field gel electrophoresis.
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations.
Long-Term Survival, Vascular Occlusive Events and Efficacy Biomarkers of First-Line Treatment of CML: A Meta-Analysis.
Loss of Egr1, a human del5q gene, accelerates BCR-ABL driven chronic myelogenous leukemia.
Loss of Gadd45b accelerates BCR-ABL-driven CML.
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib.
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.
Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia.
Lyn kinase-dependent regulation of miR181 and myeloid cell leukemia-1 expression: implications for drug resistance in myelogenous leukemia.
Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript.
Management of chronic myeloid leukemia in blast crisis.
Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients.
Maximal entropy inference of oncogenicity from phosphorylation signaling.
MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
Mean residual life regression with functional principal component analysis on longitudinal data for dynamic prediction.
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia.
Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
Mechanisms and impacts of chromosomal translocations in cancers.
Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells.
Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.
Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Mechanisms of drug resistance in kinases.
Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
Mechanisms of resistance to imatinib (STI571) and prospects for combination with conventional chemotherapeutic agents.
Mechanisms of resistance to imatinib mesylate in Bcr-Abl-positive leukemias.
Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
Mechanistic Investigation of Imatinib-Induced Cardiac Toxicity and the Involvement of c-Abl Kinase.
MEK kinase 1 is essential for Bcr-Abl-induced STAT3 and self-renewal activity in embryonic stem cells.
MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant.
Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.
Metabolic characterization of imatinib-resistant BCR-ABL T315I chronic myeloid leukemia cells indicates down-regulation of glycolytic pathway and low ROS production.
Metabolic interactions between flumatinib and the CYP3A4 inhibitors erythromycin, cyclosporine, and voriconazole.
Metal chelator TPEN selectively induces apoptosis in K562 cells through reactive oxygen species signaling mechanism: implications for chronic myeloid leukemia.
Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.
Methylenetetrahydrofolate reductase genotype affects risk of relapse after hematopoietic cell transplantation for chronic myelogenous leukemia.
Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.
Microarray analysis reveals distinct immune signatures in BCR-ABL positive and negative myeloproliferative neoplasms.
Microparticle-based RT-qPCR for highly selective rare mutation detection.
MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?
Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
miR-155 effectively induces apoptosis in K562 Philadelphia positive cell line through upregulation of p27kip1.
MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
Miscreant myeloproliferative disorder stem cells.
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.
Missing Y chromosome in Ph1-negative chronic myeloid leukemia with bcr rearrangement. Evidence for a bcr-abl recombination on chromosome 22 by in situ hybridization.
Mixed myelodysplastic and myeloproliferative syndromes.
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
Modeling the low-LET dose-response of BCR-ABL formation: predicting stem cell numbers from A-bomb data.
Modification of Gene Expression, Proliferation, and Function of OP9 Stroma Cells by Bcr-Abl-Expressing Leukemia Cells.
Modulating autophagy for therapeutic benefit.
Modulating the Growth and Imatinib Sensitivity of Chronic Myeloid Leukemia Stem/Progenitor Cells with Pullulan/MicroRNA Nanoparticles In Vitro.
Molecular abnormalities in chronic myeloid leukemia: deregulation of cell growth and apoptosis.
Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase.
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Molecular and structural characterization of the SH3 domain of AHI-1 in regulation of cellular resistance of BCR-ABL(+) chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Molecular background of a new case of chronic myelogenous leukemia with bcr-abl chimera mRNA lacking the A2 exon.
Molecular biology and treatment of CML.
Molecular biology of chronic myeloid leukemia.
Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.
Molecular characteristics of chronic myelogenous leukemia in blast crisis.
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Molecular cloning of a human immunoglobulin lambda chain variable sequence.
Molecular confirmation of BCR-ABL fusion in a chronic myeloid leukemia with a complex translocation involving chromosomes 9, 15, and 22.
Molecular consequences of the BCR-ABL translocation in chronic myelogenous leukemia.
Molecular demonstration of BCR/ABL fusion in two cases with chronic myeloproliferative disorder carrying variant Philadelphia t(14;22)(q32;q11).
Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
Molecular diagnosis of chronic myeloid leukemia using a 3'bcr probe.
Molecular dynamics investigation on the Asciminib resistance mechanism of I502L and V468F mutations in BCR-ABL.
Molecular imaging of Bcr-Abl phosphokinase in a xenograft model.
Molecular interactions in imatinib-DPPC liposomes.
Molecular interactions of c-ABL mutants in complex with imatinib/nilotinib: a computational study using linear interaction energy (LIE) calculations.
Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission.
Molecular mechanisms of Bcr-Abl-induced oncogenesis.
Molecular mechanisms of cancer.
Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia.
Molecular mechanisms of transformation by the BCR-ABL oncogene.
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications.
Molecular Monitoring of BCR-ABL Fusion Transcripts in Patients with Chronic Myeloid Leukemia During Treatment Using the Endpoint Fluorescence Method.
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Molecular monitoring of BCR-ABL transcripts in patients with chronic myelogenous leukemia: is high sensitivity of clinical value?
Molecular monitoring of chronic myelogenous leukemia: identification of the most suitable internal control gene for real-time quantification of BCR-ABL transcripts.
Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.
Molecular monitoring of Tunisian patients with chronic myeloid leukemia.
Molecular oncology: current trends in diagnostics.
Molecular pathology: future issues.
Molecular Pathways: BCR-ABL.
Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.
Molecular profiling of chronic myeloid leukemia in eastern India.
Molecular quantification of residual disease in chronic myelogenous leukemia after bone marrow transplantation.
Molecular relapse in chronic myelogenous leukemia patients after bone marrow transplantation detected by polymerase chain reaction.
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Molecular research directions in the management of gastrointestinal stromal tumors.
Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Molecular screening and the clinical impacts of BCR-ABL KD mutations in patients with imatinib-resistant chronic myeloid leukemia.
Molecular signatures of chronic myeloid leukemia stem cells.
Molecular studies in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Molecular targets in acute myelogenous leukemia.
Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Molecularly targeted therapy for gastrointestinal cancer.
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Monitoring bcr-abl by polymerase chain reaction in the treatment of chronic myeloid leukemia.
Monitoring BCR-ABL in the treatment of chronic myeloid leukemia by polymerase chain reaction.
Monitoring M-BCR-ABL expression level in CML patients by RQ-PCR: experience of a single Center.
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase - the importance of a major molecular response.
Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP).
Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.
Monitoring response and resistance to treatment in chronic myeloid leukemia.
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Mosaicicm in bcr-abl protein expression in B cells in chronic myelogenous leukemia.
MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
mTOR inhibitor RAD001 (Everolimus) enhances the effects of imatinib in chronic myeloid leukemia by raising the nuclear expression of c-ABL protein.
MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells.
Multicolor monitoring of dysregulated protein kinases in chronic myelogenous leukemia.
Multidomain Targeting of Bcr-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML.
Multidrug resistance in chronic myeloid leukemia: How much can we learn from MDR - CML cell lines?
Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells.
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.
Multiple copies of BCR-ABL fusion gene on two isodicentric Philadelphia chromosomes in an imatinib mesylate-resistant chronic myeloid leukemia patient.
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Mutant BCR-ABL clones in chronic myeloid leukemia.
Mutated BCR-ABL Generates Immunogenic T Cell Epitopes In CML Patients.
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors.
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Mutator phenotype of BCR--ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase beta.
Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
N-acetyl cysteine enhances imatinib-induced apoptosis of Bcr-Abl+ cells by endothelial nitric oxide synthase-mediated production of nitric oxide.
N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity.
NADPH oxidases as therapeutic targets in chronic myelogenous leukemia.
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
Naked antisense double-stranded DNA oligonucleotide efficiently suppresses BCR-ABL positive leukemic cells.
Nanotechnology-enabled medicine.
Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants.
Natural product origins of Hsp90 inhibitors.
Naturally occurring CD4(+) CD25(+) FOXP3(+) T-regulatory cells are increased in chronic myeloid leukemia patients not in complete cytogenetic remission and can be immunosuppressive.
NCCN and ELN: What do the guidelines tell us?
Near haploid blast phase in a chronic myeloid leukemia detected by fluorescence in situ hybridization using a BCR-ABL probe.
Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
Negative regulation of c-abl tyrosine kinase by its variable N-terminal amino acids.
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Neutrophil gelatinase-associated lipocalin expression in chronic myeloid leukemia.
New agents in the treatment of chronic myelogenous leukemia.
New approved dasatinib regimen available for clinical use.
New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.
New drugs in thyroid cancer.
New Genetic Variation in BCR gene of Major B3a2 Breakpoint BCR-ABL Fusion Gene in Patients with Chronic Myelogenous Leukemia in Yogyakarta, Indonesia
New insights into small-molecule inhibitors of Bcr-Abl.
New lanthanum (III) complex--synthesis, characterization, and cytotoxic activity.
New Methodologies in the Molecular Monitoring of CML.
New mutations detected by denaturing high performance liquid chromatography during screening of exon 6 bcr-abl mutations in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
New Oral Anti-Cancer Drugs and Medication Safety.
New strategies in controlling drug resistance in chronic myeloid leukemia.
new Strategies in Controlling drug resistance.
New tyrosine kinase inhibitors in chronic myeloid leukemia.
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
NF-?B suppresses ROS levels in BCR-ABL(+) cells to prevent activation of JNK and cell death.
NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants.
NF-kappaB/RelA transactivation is required for atypical protein kinase C iota-mediated cell survival.
NF?B pathway and microRNA-9 and -21 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines.
Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
Nilotinib (AMN107, Tasigna((R))) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Nilotinib and allogeneic stem cell transplantation in a chronic myeloid leukemia patient with e6a2 and e1a2 BCR-ABL transcripts.
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.
Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions.
Nilotinib based pharmacophore models for BCRABL.
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia.
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson's disease models.
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Nilotinib is associated with a reduced incidence of BCR-ABL mutations versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase.
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.
Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability.
Nilotinib reverses ABCB1/P-glycoprotein-mediated multidrug resistance but increases cardiotoxicity of doxorubicin in a MDR xenograft model.
Nilotinib therapy in chronic myelogenous leukemia.
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option.
Nilotinib-induced liver injury: A case report.
Nilotinib-induced panniculitis in a patient with chronic myelogenous leukemia.
Nilotinib: a novel, selective tyrosine kinase inhibitor.
Nilotinib: a phenylamino-pyrimidine derivative with activity against BCR-ABL, KIT and PDGFR kinases.
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia.
No evidence for genomic imprinting of the human BCR gene.
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.
Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Novel compounds with antiproliferative activity against imatinib-resistant cell lines.
Novel conventional therapies in onco-hemathology.
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients.
Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia.
Novel therapies for chronic myelogenous leukemia.
Novel therapies for patients with chronic myeloid leukemia.
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Novel use of old drug: Anti-rheumatic agent auranofin overcomes imatinib-resistance of chronic myeloid leukemia cells.
NPB001-05 inhibits Bcr-Abl kinase leading to apoptosis of imatinib-resistant cells.
NS-187 (INNO-406), a Bcr-Abl/Lyn Dual Tyrosine Kinase Inhibitor.
Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
NUP98 gene rearrangements and the clonal evolution of chronic myelogenous leukemia.
Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset.
Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia.
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia.
Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia.
On the topology of normal chromatids and on their translocations in myelogenous leukemia.
Oncogenes: present status.
Oncogenic heterogeneous nuclear ribonucleoprotein D-like modulates the growth and imatinib response of human chronic myeloid leukemia CD34+ cells via pre-B-cell leukemia homeobox 1.
Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system.
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses.
Opening the door to the development of novel Abl kinase inhibitors.
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
Optimal management of patients with newly diagnosed chronic phase chronic myeloid leukemia in 2007.
Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
Optimization of methods for the detection of BCR-ABL activity in Philadelphia-positive cells.
Optimized Digital Droplet PCR for BCR-ABL.
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Optimizing therapy of chronic myeloid leukemia.
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules.
Origin of hematopoietic progenitor cells after bone marrow transplantation: analysis by means of a Y-chromosome specific DNA probe.
Oroxyloside A Overcomes Bone Marrow Microenvironment-Mediated Chronic Myelogenous Leukemia Resistance to Imatinib via Suppressing Hedgehog Pathway.
Osteopontin is upregulated by BCR-ABL.
Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.
Ovatodiolide targets chronic myeloid leukemia stem cells by epigenetically upregulating hsa-miR-155, suppressing the BCR-ABL fusion gene and dysregulating the PI3K/AKT/mTOR pathway.
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO-406 in newly established K562 variants with BCR-ABL gene amplification.
Overcoming resistance in chronic myelogenous leukemia.
Overcoming Resistance to Targeted Therapies in Cancer.
Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.
Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism.
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines.
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes.
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.
p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia.
p21(Cip1) confers resistance to imatinib in human chronic myeloid leukemia cells.
p210 bcr-abl confers overexpression of inosine monophosphate dehydrogenase: an intrinsic pathway to drug resistance mediated by oncogene.
p210bcr-abl induces amoeboid motility by recruiting ADF/destrin through RhoA/ROCK1.
p38 MAPK-mediated activation of NF-kappaB by the RhoGEF domain of Bcr.
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells.
p57Kip2 is a downstream effector of BCR-ABL kinase inhibitors in chronic myelogenous leukemia cells.
p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells.
Pathological role of a point mutation (T315I) in BCR-ABL1 protein-A computational insight.
Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors.
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Pediatric malignancies provide unique cancer therapy targets.
Pepsi® or Coke®? Influence of acid on dasatinib absorption.
Peptides derived from the whole sequence of BCR-ABL bind to several class I molecules allowing specific induction of human cytotoxic T lymphocytes.
Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay.
Peripheral Artery Disease and Stroke.
Peripheral blood progenitor cells mobilized early at diagnosis in patients with chronic myelogenous leukemia contain very low amounts of BCR-ABL transcripts.
Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.
Persistence of bcr-able gene expression following bone marrow transplantation for chronic myelogenous leukemia in chronic phase.
Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.
Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Perspectives on the development of a molecularly targeted agent.
PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.
Pharmacologic inhibition of the Bcr-Abl kinase with STI571: a novel, safe, and effective therapy for chronic myeloid leukemia.
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase.
Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.
Pharmacology of imatinib (STI571).
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation.
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors.
Philadelphia chromosome as the sole abnormality and p210 bcr-abl chimeric protein expression in an Epstein-Barr virus-transformed B cell line from a patient with chronic myeloid leukemia.
Philadelphia chromosome-negative chronic myelogenous leukemia without breakpoint cluster region rearrangement: a chronic myeloid leukemia with a distinct clinical course.
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Philadelphia negative BCR-ABL positive chronic myeloid leukemia mimicking juvenile chronic myeloid leukemia in a 2-year-old child.
Philadelphia negative, Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia.
Philadelphia-positive acute leukemia: lineage promiscuity and inconsistently rearranged breakpoint cluster region.
Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region.
Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development.
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia.
Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk(348)) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
Phosphotyrosine phosphatase activity prevents the detection of P210bcr/abl protein in mature cells in chronic myelogenous leukemia even by an immunoblotting technique.
Photocleavable peptide-conjugated magnetic beads for protein kinase assays by MALDI-TOF MS.
Photodynamic treatment (ALA-PDT) suppresses the expression of the oncogenic Bcr-Abl kinase and affects the cytoskeleton organization in K562 cells.
Physiological signals and oncogenesis mediated through Crk family adapter proteins.
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™).
Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line.
PKC-?/Alox5 axis activation promotes Bcr-Abl-independent TKI-resistance in chronic myeloid leukemia.
Plasma and Intracellular Imatinib Concentrations in Patients With Chronic Myeloid Leukemia.
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.
Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy.
Pleural effusions due to dasatinib.
Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
PO-55 - Individual variation in hemostatic alterations caused by tyrosine kinase inhibitors - a way to improve personalized cancer therapy?
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Polycythemia vera masked due to severe iron deficiency anemia.
Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients.
Polymerase chain reaction detection of the BCR-ABL fusion transcript after allogeneic marrow transplantation for chronic myeloid leukemia: results and implications in 346 patients.
Polymorphism of the human c-abl gene: relation to incidence and course of chronic myelogenous leukemia.
Polyphenol tri-vanillic ester 13c inhibits P-JAK2V617F and Bcr-Abl oncokinase expression in correlation with STAT3/STAT5 inactivation and apoptosis induction in human leukemia cells.
Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models.
Ponatinib exerts anti-angiogenic effects in the zebrafish and human umbilical vein endothelial cells via blocking VEGFR signaling pathway.
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Ponatinib is a pan-BCR-ABL kinase inhibitor: MD simulations and SIE study.
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase.
Ponatinib-induced neutrophilic panniculitis.
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
Population-Based Testing and Treatment Characteristics for Chronic Myelogenous Leukemia.
Positive interactions between STAP-1 and BCR-ABL influence chronic myeloid leukemia cell proliferation and survival.
Possible correlation of b3-a2-type bcr-abl messenger RNA defined by semiquantitative RT-PCR to platelet and megakaryocyte counts in Philadelphia-positive chronic myelogenous leukemia.
Possible evidence for acquired genetic activity at both chromosomal breakpoints of the Philadelphia translocation in chronic myeloid leukemia.
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib.
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
Potential role of Wnt/?-catenin signaling in blastic transformation of chronic myeloid leukemia: cross talk between ?-catenin and BCR-ABL.
PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia.
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Practical management of dasatinib for maximum patient benefit.
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors.
Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations.
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia.
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization.
Pregnancy and Accelerated Phase of Myeloid Chronic Leukemia Treated with Imatinib: A Case Report from a Developing Country.
Presence of a new BCR-ABL kinase domain mutation, C330G in an imatinib naive patient with chronic myeloid leukemia: very low prevalence of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from eastern India.
Presence of P210bcrabl is associated with decreased expression of a beta chemokine C10 gene in a P210bcrabl-positive myeloid leukemia cell line.
Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia
Prevention of product carry-over by single tube two-round (ST-2R) PCR: application to BCR-ABL analysis in chronic myelogenous leukemia.
Priapismus as Leukostasis Manifestation in Chronic Myeloid Leukemia.
Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.
Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
Probing of the secondary structure of maxizymes.
Profile of BCR-ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib.
Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia.
Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry.
Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Prognostic Implication of BCR-ABL Fusion Transcript Variants in Chronic Myeloid Leukemia (CML) Treated with Imatinib. A First of Its Kind Study on CML Patients of Kashmir
Prognostic significance of BCR-ABL rearrangement in chronic myeloid leukemia.
Prognostic significance of c-ABL methylation in chronic myelogenous leukemia: still an open question.
Programmed cell death 4 and BCR-ABL fusion gene expression are negatively correlated in chronic myeloid leukemia.
Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia.
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Prolonged preleukemic phase of chronic myelogenous leukemia.
Propofol enhances BCR-ABL TKIs' inhibitory effects in chronic myeloid leukemia through Akt/mTOR suppression.
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells.
Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.
Protein tyrosine kinases: autoregulation and small-molecule inhibition.
Protein tyrosine phosphatase 1B antagonizes signalling by oncoprotein tyrosine kinase p210 bcr-abl in vivo.
Protein tyrosine phosphatase PTP1B suppresses p210 bcr-abl-induced transformation of rat-1 fibroblasts and promotes differentiation of K562 cells.
Proteins phosphorylated on tyrosine as markers of human tumor cell lines.
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells.
Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors.
Proteomics approaches to elucidate oncogenic tyrosine kinase signaling in myeloid malignancies.
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
PTPRG and PTPRC modulate nilotinib response in chronic myeloid leukemia cells.
PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
Pulmonary arterial hypertension in a patient treated with dasatinib: a case report.
Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl.
Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
Pyrrolo-1,5-benzoxazepines induce apoptosis in chronic myelogenous leukemia (CML) cells by bypassing the apoptotic suppressor bcr-abl.
Pyrrolo-1,5-Benzoxazepines Induce Apoptosis in Chronic Myeloid Leukemia (CML) Cells by Bypassing the Apoptotic Suppressor BCR-ABL.
Qualitative and quantitative evaluation of the BCR-ABL fusion gene in chronic myelogenous leukemia by flourescence in situ hybridization and molecular genetic methods.
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Quantification of Bcr-Abl transcripts in chronic myelogenous leukemia (CML) using standardized, internally controlled, competitive differential PCR (CD-PCR).
Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
Quantification of change in phosphorylation of BCR-ABL kinase and its substrates in response to Imatinib treatment in human chronic myelogenous leukemia cells.
Quantifying mutated and unmutated BCR-ABL transcripts confirms suitability of direct sequencing sensitivity in mutation analysis of patients with chronic myeloid leukemia with secondary resistance to tyrosine kinase inhibitors, regardless of ratio values.
Quantitative assessment of the BCR-ABL transcript using the Cepheid Xpert BCR-ABL Monitor assay.
Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Quantitative detection of BCR-ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment.
Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia.
Quantitative evaluation of BCR-ABL amount of transcript post mobilization with G-CSF of peripheral blood stem cells from chronic myeloid leukemia patients in cytogenetic response.
Quantitative intra-individual monitoring of BCR-ABL transcript levels in archival bone marrow trephines of patients with chronic myeloid leukemia.
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment.
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors.
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Quantitative Proteomics Analysis of Leukemia Cells.
Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples.
Quantitative- and Phospho-Proteomic Analysis of the Yeast Response to the Tyrosine Kinase Inhibitor Imatinib to Pharmacoproteomics-Guided Drug Line Extension.
Quantum dots self assembly based interface for blood cancer detection.
RAD 001 (everolimus) prevents mTOR and Akt late re-activation in response to imatinib in chronic myeloid leukemia.
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Radotinib inhibits mitosis entry in acute myeloid leukemia cells via suppression of Aurora kinase A expression.
Rakicidin A effectively induces apoptosis in hypoxia adapted Bcr-Abl positive leukemic cells.
Random aneuploidy in CML patients at diagnosis and under imatinib treatment.
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Rapid and sensitive allele-specific (AS)-RT-PCR assay for detection of T315I mutation in chronic myeloid leukemia patients treated with tyrosine-kinase inhibitors.
Rapid detection of BCR-ABL fusion genes using a novel combined LUX primer, in-cell RT-PCR and flow cytometric method.
Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.
Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.
Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
Rapid quantitative detection of the T315I mutation in patients with chronic myelogenous leukemia.
Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: The threats and challenges in monitoring minimal residual disease (MRD).
Rare frameshift mutation Cys475Tyrfs(*)11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia.
Ras as a therapeutic target in hematologic malignancies.
Rational therapeutic intervention in cancer: kinases as drug targets.
Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase.
Re-arrangements of podosome structures are observed when Hck is activated in myeloid cells.
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.
Real-time analysis of imatinib- and dasatinib-induced effects on chronic myelogenous leukemia cell interaction with fibronectin.
Real-time quantification of different types of bcr-abl transcript in chronic myeloid leukemia.
Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.
Real-time quantitative PCR detection of WT1 and M-BCR-ABL expressions in chronic myeloid leukemia.
Real-time quantitative PCR: a reliable molecular diagnostic and follow-up tool for 'minimal residual disease' assessment in chronic myeloid leukemia.
Rearrangement and amplification of c-abl sequences in the human chronic myelogenous leukemia cell line K-562.
Rearrangement in the breakpoint cluster region and the clinical course in Philadelphia-negative chronic myelogenous leukemia.
Rearrangement of PDGFR? gene in a patient with Ph-negative chronic myeloid leukemia t(5;12)(q33;p13) in imatinib mesylate treatment-free remission: a case report.
Rearrangements of immunoglobulin- and BCR-genes in chronic myeloid leukemia.
Recent advancements in the treatment of chronic myelogenous leukemia.
Recent advances in Bcr-Abl tyrosine kinase inhibitors for overriding T315I mutation.
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Recent developments in the third generation inhibitors of Bcr-Abl for overriding T315I mutation.
Receptor tyrosine kinases as rational targets for prostate cancer treatment: platelet-derived growth factor receptor and imatinib mesylate.
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Recognition of peptides corresponding to the joining region of p210BCR-ABL protein by human T cells.
Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring.
Reconsideration of BCR-ABL protein flow cytometric immunobead assay: how potent to diagnose and monitor chronic myeloid leukemia?
Reduced exposure of imatinib after coadministration with acetaminophen in mice.
Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.
Reduction of Bcr-Abl function leads to erythroid differentiation of K562 cells via downregulation of ERK.
Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation.
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib.
Regulated expression of P210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate.
Regulating Apoptosis by Degradation: The N-End Rule-Mediated Regulation of Apoptotic Proteolytic Fragments in Mammalian Cells.
Regulation of hTERT by BCR-ABL at multiple levels in K562 cells.
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
Regulation of synaptic Rac1 activity, long-term potentiation maintenance, and learning and memory by BCR and ABR Rac GTPase-activating proteins.
Regulation of the Fas apoptotic cell death pathway by Abl.
Regulation of the interferon regulatory factor-8 (IRF-8) tumor suppressor gene by the signal transducer and activator of transcription 5 (STAT5) transcription factor in chronic myeloid leukemia.
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.
Rejoining between 9q+ and Philadelphia chromosomes results in normal-looking chromosomes 9 and 22 in Ph1-negative chronic myelocytic leukemia.
Relationship between elevated levels of the alpha 1 acid glycoprotein in chronic myelogenous leukemia in blast crisis and pharmacological resistance to imatinib (Gleevec) in vitro and in vivo.
Relationship between the type of BCR-ABL rearrangement and bone marrow histopathological features in chronic myeloid leukemia.
Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
Relationship of bcr breakpoint to chronic phase duration, survival, and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase.
Relationship of serum imatinib trough level and response in CML patients: Long term follow-up.
Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia.
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Renal tuberculosis in an imatinib-treated chronic myeloid leukemia.
Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia.
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Reproductive fitness advantage of BCR-ABL expressing leukemia cells.
Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.
Requirement of lipocalin 2 for chronic myeloid leukemia.
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Resistance in the land of molecular cancer therapeutics.
Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
Resistance to imatinib: mechanisms and management.
Resistance to targeted therapy in chronic myelogenous leukemia.
Response assessment of patients with chronic myeloid leukemia receiving imatinib mesylate (Glivec) therapy: experience from a single center in a developing country.
Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
Restoration of energy metabolism in leukemic mice treated by a siddha drug--Semecarpus anacardium Linn. nut milk extract.
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.
Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
Revealing genome-wide mRNA and microRNA expression patterns in leukemic cells highlighted "hsa-miR-2278" as a tumor suppressor for regain of chemotherapeutic imatinib response due to targeting STAT5A.
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.
RNA interference targeting of Bcr-Abl increases chronic myeloid leukemia cell killing by 17-allylamino-17-demethoxygeldanamycin.
RNA quantification using gold nanoprobes - application to cancer diagnostics.
RNA quantification using noble metal nanoprobes: simultaneous identification of several different mRNA targets using color multiplexing and application to cancer diagnostics.
RNA Quantification Using Noble Metal Nanoprobes: Simultaneous Identification of Several Different mRNA Targets Using Color Multiplexing and Application to Chronic Myeloid Leukemia Diagnostics.
Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era.
Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571.
Role of BCR/ABL gene-expression levels in determining the phenotype and imatinib sensitivity of transformed human hematopoietic cells.
Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.
Role of cancer immunology in chronic myelogenous leukemia.
Role of constitutively activated protein tyrosine kinases in malignant myeloproliferative disorders: an update.
Role of Dok-1 and Dok-2 in leukemia suppression.
Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia.
Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells.
Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Role of poly(ADP-ribose) polymerase activity in imatinib mesylate-induced cell death.
Role of protein tyrosine kinase inhibitors in cancer therapeutics.
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
Role of STAT3 in Transformation and Drug Resistance in CML.
Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid rafts.
Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells.
Role of the hybrid Bcr/Abl kinase in the pathogenesis of chronic myeloid leukemia lacking C-Abl and CXCR4 proteins.
Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.
ROLES OF INTERFERON REGULATORY FACTORS IN CHRONIC MYELOID LEUKEMIA.
Roots of imatinib resistance: A question of self-renewal?
Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Ruxolitinib induces autophagy in chronic myeloid leukemia cells.
S100A8 may govern hyper-inflammation in severe COVID-19.
S6K1 determines the metabolic requirements for BCR-ABL survival.
Safranal, a Crocus sativus L constituent suppresses the growth of K-562 cells of chronic myelogenous leukemia. In silico and in vitro study.
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
SEA antagonizes the imatinib-meditated inhibitory effects on T cell activation via the TCR signaling pathway.
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Second case of CML with aberrant BCR-ABL fusion transcript (e8/a2) with insertion of an inverted ABL intron 1b sequence.
Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase.
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure.
Secondary malignancy after imatinib therapy: Eight cases and review of the literature.
Secretion of IL-1? from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.
Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of BCR - ABL tyrosine kinase, CGP 57148.
Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
Selective leukemia cell death by activation of the double-stranded RNA-dependent protein kinase PKR.
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Sensitive and quantitative detection of mutations associated with clinical resistance to STI-571.
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay.
Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates.
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?
Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy.
Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.
Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.
Severe hepatic injury caused by imatinib mesylate administered for the treatment of chronic myeloid leukemia and the efficacy of prednisolone for its management.
Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors.
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
Signal transduction inhibitors (STI571): molecularly targeted therapy.
Signal transduction-based strategies for the treatment of chronic myelogenous leukemia.
Significance of Lymphocyte Count, Monocyte Count, and Lymphocyte-To-Monocyte Ratio in Predicting Molecular Response in Patients with Chronic Myeloid Leukemia: a Single-Centre Experience.
Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Simple multiplex RT-PCR for identifying common fusion BCR-ABL transcript types and evaluation of molecular response of the a2b2 and a2b3 transcripts to Imatinib resistance in north Indian chronic myeloid leukemia patients.
Simplifying procedure for prediction of resistance risk in CML patients - Test of sensitivity to TKI ex vivo.
Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.
Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts.
Single-cell analysis of K562 cells: An imatinib-resistant subpopulation is adherent and has upregulated expression of BCR-ABL mRNA and protein.
Sipa1 deficiency unleashes a host-immune mechanism eradicating chronic myelogenous leukemia-initiating cells.
siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
siRNA-mediated BCR-ABL silencing in primary chronic myeloid leukemia cells using lipopolymers.
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
SIRT1 and LSD1 competitively regulate KU70 functions in DNA repair and mutation acquisition in cancer cells.
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells.
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells.
Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Small GTPase RAB45-mediated p38 activation in apoptosis of chronic myeloid leukemia progenitor cells.
Small-Molecule Screening for Genetic Diseases.
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib.
Somatic mutations and the hierarchy of hematopoiesis.
Some questions on the significance of chromosome alterations in leukemias and lymphomas: a review.
Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia.
Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients.
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Specific human cellular immunity to bcr-abl oncogene-derived peptides.
Specific inhibition of bcr-abl gene expression by small interfering RNA.
Specificity of arachidonic acid-induced inhibition of growth and activation of c-jun kinases and p38 mitogen-activated protein kinase in hematopoietic cells.
Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Spectrum of BCR-ABL Mutations and Treatment Outcomes in Ethiopian Imatinib-Resistant Patients With Chronic Myeloid Leukemia.
Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia.
Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Spotlight on imatinib mesylate in chronic myeloid leukemia.
Src family kinases interfere with dimerization of STAT5A through a phosphotyrosine-SH2 domain interaction.
Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells.
Src family kinases phosphorylate the Bcr-Abl SH3-SH2 region and modulate Bcr-Abl transforming activity.
Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential.
Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia.
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
Stable molecular remission induced by imatinib mesylate (STI571) in a patient with CML lymphoid blast crisis relapsing after allogeneic stem cell transplantation.
STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells.
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
Status of leptin in MBCR-ABL p210 positive chronic myeloid leukemia patients before and after imatinib therapy: a conflicting scenario.
Stem cell persistence in chronic myeloid leukemia.
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
Stem cells in chronic myelogenous leukemia.
Stem-cell driven cancer: "hands-off" regulation of cancer development.
STI-571 (imatinib mesylate) enhances the apoptotic efficacy of pyrrolo-1,5-benzoxazepine-6, a novel microtubule-targeting agent, in both STI-571-sensitive and -resistant Bcr-Abl-positive human chronic myeloid leukemia cells.
STI-571: an anticancer protein-tyrosine kinase inhibitor.
STI571 (Gleevec) as a paradigm for cancer therapy.
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
STI571: a gene product-targeted therapy for leukemia.
STI571: a paradigm of new agents for cancer therapeutics.
STI571: targeting BCR-ABL as therapy for CML.
Strategies for overcoming imatinib resistance in chronic myeloid leukemia.
Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.
Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.
Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template.
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.
Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Structural characterization of the BCR gene product.
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.
Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations.
Structural organization of BCR-ABL gene in chronic phase and blast transformation in chronic myeloid leukemia patients.
Structure and dynamic regulation of abl kinases.
Structure of the ABL2/ARG kinase in complex with dasatinib.
Structure of the Bcr-Abl oncoprotein oligomerization domain.
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
Studies in target-based treatment.
Studying the enhancement of programmed cell death by combined AG1024 and paclitaxel in a model of chronic myelogenous leukemia.
Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.
Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl.
Successful autologous stem cell collection in patients with chronic myeloid leukemia in complete cytogenetic response, with quantitative measurement of BCR-ABL expression in blood, marrow, and apheresis products.
Successful Nilotinib therapy in an imatinib-resistant chronic myeloid leukemia patient displaying an intron-derived insertion/truncation mutation in the BCR-ABL kinase domain.
Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.
Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Successful treatment of T315I BCR-ABL mutated lymphoid blast phase chronic myeloid leukemia with chimeric antigen receptor T cell therapy followed by dasatinib.
Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (microarray study).
Suppression of cell proliferation and the expression of a bcr-abl fusion gene and apoptotic cell death in a new human chronic myelogenous leukemia cell line, KT-1, by interferon-alpha.
SUPPRESSION OF SURVIVIN INDUCED BY A BCR-ABL/JAK2/STAT3 PATHWAY SENSITIZES IMATINIB RESISTANT CML CELLS TO DIFFERENT CYTOTOXIC DRUGS.
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.
Surrogate end points for long-term outcomes in chronic myeloid leukemia.
Survey of early disapearance of BCR/ABL fusion transcript after allogeneic or autologous stem cell transplantation for chronic myelogenous leukemia.
Sustained clinical remission despite suboptimal molecular response to imatinib in e1a2 BCR-ABL chronic myeloid leukemia.
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
Sustained targeting of Bcr-Abl + leukemia cells by synergistic action of dual drug loaded nanoparticles and its implication for leukemia therapy.
SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1? axis.
Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes.
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl.
Synthesis and antileukemic activity of an ursolic acid derivative: A potential co-drug in combination with imatinib.
Synthesis and Characterization of a BODIPY Conjugate of the BCR-ABL Kinase Inhibitor Tasigna (Nilotinib): Evidence for Transport of Tasigna and Its Fluorescent Derivative by ABC Drug Transporters.
Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors.
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
T-cell immunity to the joining region of p210BCR-ABL protein.
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
TAL1 mediates imatinib-induced CML cell apoptosis via the PTEN/PI3K/AKT pathway.
TaqMan reverse transcriptase-polymerase chain reaction coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.
TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.
Target Inhibition of CBP Induced Cell Senescence in BCR-ABL- T315I Mutant Chronic Myeloid Leukemia.
Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
Targeted AID-mediated mutagenesis (TAM) enables efficient genomic diversification in mammalian cells.
Targeted blockage of signal transducer and activator of transcription 5 signaling pathway with decoy oligodeoxynucleotides suppresses leukemic K562 cell growth.
Targeted cancer therapy: promise and reality.
Targeted chemotherapy: chronic myelogenous leukemia as a model.
Targeted Chronic Myeloid Leukemia Therapy: Seeking a Cure.
Targeted chronic myeloid leukemia therapy: Seeking a cure.
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Targeted therapy in chronic myeloid leukemia.
Targeted therapy of chronic myeloid leukemia.
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
Targeting activating transcription factor 3 by Galectin-9 induces apoptosis and overcomes various types of treatment resistance in chronic myelogenous leukemia.
Targeting bcr-abl transcripts with siRNAs in an imatinib-resistant chronic myeloid leukemia patient: challenges and future directions.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death.
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Targeting chronic myeloid leukemia stem cells.
Targeting chronic myeloid leukemia stem cells: can transcriptional program be a druggable target for cancers?
Targeting FEN1 Suppresses the Proliferation of Chronic Myeloid Leukemia Cells Through Regulating Alternative End-Joining Pathways.
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells.
Targeting methyltransferase PRMT5 eliminates leukemia stem cells in chronic myelogenous leukemia.
Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells.
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Targeting of GSK3? promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor.
Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Targeting the mTOR Pathway in Leukemia.
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/??catenin/TCF7/ABC transporter signaling axis.
Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.
Telomere dynamics and genetic instability in disease progression of chronic myeloid leukemia.
Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life.
Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C oncoprotein.
The ABL genes in normal and abnormal cell development.
The ABL oncogene in human leukemias.
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.
The ABL-BCR fusion gene is expressed in chronic myeloid leukemia.
The age incidence of chronic myeloid leukemia can be explained by a one-mutation model.
The allometry of chronic myeloid leukemia.
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage.
The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors.
The ARF tumor suppressor in acute leukemias: insights from mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
The bcr gene is joined to c-abl in Ph1 chromosome negative chronic myelogenous leukemia.
The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells.
The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.
The Bcr-Abl kinase inhibitor INNO-406 induces autophagy and different modes of cell death execution in Bcr-Abl-positive leukemias.
The BCR-ABL oncogene transforms Rat-1 cells and cooperates with v-myc.
The BCR-ABL/NF-?B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis.
The biology of chronic myelogenous leukemia progression: who, what, where, and why?
The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
The biology of signal transduction inhibition: basic science to novel therapies.
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
The c-abl oncogene in chronic myelogenous leukemia.
The c-abl, bcr and C lambda genes are amplified in a cell line but not in the uncultured cells from a patient with chronic myelogenous leukemia.
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
The c-Myc-regulated lncRNA NEAT1 and paraspeckles modulate imatinib-induced apoptosis in CML cells.
The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia.
The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript.
The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene.
The chronic myeloid leukemia stem cell.
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants.
The coiled-coil domain and Tyr177 of bcr are required to induce a murine chronic myelogenous leukemia-like disease by bcr/abl.
The Conformational Control Inhibitor of Tyrosine Kinases DCC-2036 Is Effective for Imatinib-Resistant Cells Expressing T674I FIP1L1-PDGFR?.
The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis.
The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene.
The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
The detection and significance of minimal residual disease in chronic myeloid leukemia.
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
The differences and correlations of BCR-ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia.
The Discovery of Novel BCR-ABL Tyrosine Kinase Inhibitors Using a Pharmacophore Modeling and Virtual Screening Approach.
The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge.
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
The effect of bcr-abl antisense oligonucleotide on DNA synthesis and apoptosis in K562 chronic myeloid leukemia cells.
The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.
The effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL positive) cells sensitive and resistant to imatinib.
The effect of the additional cytogenetic abnormalities on major molecular response and BCR-ABL kinase domain mutations in long-term follow-up chronic myeloid leukemia patients, a cross sectional study.
The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.
The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia.
The fundamental prevalence of chronic myeloid leukemia-generating clonogenic cells in the light of the neutrality theory of evolution.
The genomic breakpoint in a patient with Philadelphia-positive acute leukemia is 5' of the breakpoint cluster region.
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL.
The growth factor independence-1 (Gfi1) is overexpressed in chronic myelogenous leukemia.
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia.
The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
The human cellular abl gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity.
The human leukemia oncogene bcr-abl abrogates the anchorage requirement but not the growth factor requirement for proliferation.
The IL-2/CD25 axis maintains distinct subsets of chronic myeloid leukemia-initiating cells.
The immunogenicity of Bcr-Abl expressing dendritic cells is dependent on the Bcr-Abl kinase activity and dominated by Bcr-Abl regulated antigens.
The impact of RNA stabilization on minimal residual disease assessment in chronic myeloid leukemia.
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
The influence of class II HLA type on the lymphoproliferative response of normal donors to a bcr-abl fusion peptide.
The influence of phosphorothioate oligodeoxynucleotides on various organs in vivo.
The influence of target protein half-life on the effectiveness of antisense oligonucleotide analog-mediated biologic responses.
The involvement of Bcr in leukemias with the Philadelphia chromosome.
The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
The K562 chronic myeloid leukemia cell line undergoes apoptosis in response to interferon-alpha.
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
The MEK1/2 inhibitor U0126 reverses imatinib resistance through down-regulating activation of Lyn/ERK signaling pathway in imatinib-resistant K562R leukemia cells.
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
The multifaceted roles of neutrophil gelatinase associated lipocalin (NGAL) in inflammation and cancer.
The mystery of chromosomal translocations in cancer.
The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.
The PERK-eIF2? phosphorylation arm is a pro-survival pathway of BCR-ABL signaling and confers resistance to imatinib treatment in chronic myeloid leukemia cells.
The Perplexity of Synergistic Duality: Inter-Molecular Mechanisms of Communication in BCR-ABL1.
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
The potentiation of menadione on imatinib by down-regulation of ABCB1 expression.
The preferentially expressed antigen in melanoma (PRAME) inhibits myeloid differentiation in normal hematopoietic and leukemic progenitor cells.
The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
The pro-metastasis tyrosine phosphatase, PRL-3 (PTP4A3), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia.
The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
The quiescent fraction of chronic myeloid leukemic stem cells depends on BMPR1B, Stat3 and BMP4-niche signals to persist in patients in remission.
The regulation of bcr-abl in hypoxia is through the mTOR pathway.
The relationship between the type of bcr-abl hybrid messenger RNA and thrombopoiesis in Philadelphia-positive chronic myelogenous leukemia.
The relationship of bone marrow histology with the molecular pattern in chronic myeloid leukemia.
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
The risk of chronic myeloid leukemia: can the dose-response curve be U-shaped?
The role of Bcr-Abl in chronic myeloid leukemia and stem cell biology.
The role of Fas-associated phosphatase 1 in leukemia stem cell persistence during tyrosine kinase inhibitor treatment of chronic myeloid leukemia.
The role of myc in transformation by BCR-ABL.
The role of natural killer cells in chronic myeloid leukemia.
The role of observational studies in optimizing the clinical management of chronic myeloid leukemia.
The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
The role of TC-PTP (PTPN2) in modulating sensitivity to imatinib and interferon-? in CML cell line, KT-1 cells.
The role of the K247R substitution in the ABL tyrosine kinase domain in sensitivity to imatinib.
The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review.
The second generation of BCR-ABL tyrosine kinase inhibitors.
The sensitivity of chronic myeloid leukemia CD34 cells to Bcr-Abl tyrosine kinase inhibitors is modulated by ceramide levels.
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
The SH2 domain of P210BCR/ABL is not required for the transformation of hematopoietic factor-dependent cells.
The significance of bcr-abl molecular detection in chronic myeloid leukemia patients "late," 18 months or more after transplantation.
The Significance of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
The Src family kinase Hck interacts with Bcr-Abl by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr.
The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.
The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib.
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia.
The transcription factor MITF is a critical regulator of GPNMB expression in dendritic cells.
The transforming growth factor beta 1/SMAD signaling pathway involved in human chronic myeloid leukemia.
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein.
The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia.
The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl.
The use of imatinib (STI571) in chronic myelod leukemia: some practical considerations.
Therapeutic drug management of BCR-ABL tyrosine kinase inhibitor for chronic myeloid leukemia patients.
Therapeutic inhibition of Fc?RIIb signaling targets leukemic stem cells in chronic myeloid leukemia.
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia.
Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
Three-dimensional structure of the Hck SH2 domain in solution.
Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis.
Through the open door: Preferential binding of dasatinib to the active form of BCR-ABL unveiled by in silico experiments.
Time-resolved fluorometric hybridization assays with RNA probes synthesized from polymerase chain reaction-generated DNA templates.
Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments.
Towards a Molecular Understanding of the Link between Imatinib Resistance and Kinase Conformational Dynamics.
Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Transcriptional activation of human LIM-HOX gene hLH-2 in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Transcriptional activation of human LIM-HOX gene, hLH-2, in chronic myelogenous leukemia is due to a cis-acting effect of Bcr-Abl.
Transcriptional activation of Skp2 by BCR-ABL in K562 chronic myeloid leukemia cells.
Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck.
Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation.
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
Translating Trial-Based Molecular Monitoring Into Clinical Practice: Importance of International Standards and Practical Considerations for Community Practitioners.
Translisin recognition site sequences flank translocation breakpoints in a Philadelphia chromosome positive chronic myeloid leukemia patient expressing a novel type of chimeric BCR-ABL transcript (E8-INT-A2)
Translocation (4;15)(p16;q24): a novel reciprocal translocation in a patient with BCR/ABL negative myeloproliferative syndrome progressing to blastic phase.
Translocation of BCR to chromosome 9: a new cytogenetic variant detected by FISH in two Ph-negative, BCR-positive patients with chronic myeloid leukemia.
Translocation of c-abl to "masked" Ph in chronic myeloid leukemia.
Transposition of duplicated chromosomal segment involving fused BCR-ABL gene or ABL oncogene alone in chronic myelocytic leukemia and Ph chromosome-positive acute leukemia with complex karyotypes.
Treatment of chronic myelogenous leukemia.
Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Treatment options for chronic myeloid leukemia.
Treatment options for newly diagnosed patients with chronic myeloid leukemia.
Triptolide down-regulates bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells.
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
Trough plasma concentration of imatinib reflects BCR-ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study.
Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations.
Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells.
Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.
Tyrosine kinase inhibitor Thiotanib targets Bcr-Abl and induces apoptosis and autophagy in human chronic myeloid leukemia cells.
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease.
Tyrosine kinase inhibitors induce alternative spliced BCR-ABLIns35bp variant via inhibition of RNA polymerase II on genomic BCR-ABL.
Tyrosine kinase inhibitors: from rational design to clinical trials.
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.
Tyrosine protein kinase substrates in Philadelphia-positive human chronic granulocytic leukemia derived cell lines (K562 and BV173): detection by using an immunoblotting technique.
Ubp43 regulates BCR-ABL leukemogenesis via the type 1 interferon receptor signaling.
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review.
Understanding the role of mutations in therapeutic decision making for chronic myeloid leukemia.
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL.
Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia.
Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications.
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
Up-regulation of WRN and DNA ligase IIIalpha in chronic myeloid leukemia: consequences for the repair of DNA double-strand breaks.
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib.
Uptake of imatinib-loaded polyelectrolyte complexes by BCR-ABL(+) cells: a long-acting drug-delivery strategy for targeting oncoprotein activity.
Uptake of synthetic Low Density Lipoprotein by leukemic stem cells - a potential stem cell targeted drug delivery strategy.
Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases.
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Use of direct sequencing for detection of mutations in the BCR-ABL kinase domain in Slovak patients with chronic myeloid leukemia.
Use of moving optical gradient fields for analysis of apoptotic cellular responses in a chronic myeloid leukemia cell model.
USP10 modulates the SKP2/Bcr-Abl axis via stabilizing SKP2 in chronic myeloid leukemia.
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.
V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
v-abl activates embryonic globin gene expression in mouse erythroleukemia cells.
v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses.
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.
Validating cancer drug targets through chemical genetics.
Variable expression of the translocated c-abl oncogene in Philadelphia-chromosome-positive B-lymphoid cell lines from chronic myelogenous leukemia patients.
Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia.
Vasospastic angina in a chronic myeloid leukemia patient treated with nilotinib.
VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.
Viral/Nonviral Chimeric Nanoparticles To Synergistically Suppress Leukemia Proliferation via Simultaneous Gene Transduction and Silencing.
Vitamin ? activates expression of ?/EBP alpha transcription factor and G-CSF receptor in leukemic K562 cells.
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
Where are we going with CML research?
Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Whole Exome Sequencing of Chronic Myeloid Leukemia Patients.
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
Wrapping BCR-ABL: it's in the bag.
WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells.
Xanthohumol, a Prenylated Flavonoid from Hops, Induces Caspase-Dependent Degradation of Oncoprotein BCR-ABL in K562 Cells.
XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia.
ZnPcS2P2-based photodynamic therapy induces mitochondria-dependent apoptosis in K562 cells.
[A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
[A comparative study of different intervention regimens for chronic myelogenous leukemia post allogeneic hematopoietic stem cell transplantation.]
[A multicenter study on the validation of conversion factor for the conversion of BCR-ABL (P210) transcript levels to the international scale in chronic myeloid leukemia].
[A new drug in the therapy of chronic myeloid leukemia: ST1571]
[Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy].
[An advance in the treatment of CML]
[An experimental study on bone marrow purging in vitro for patients with chronic myelogenous leukemia]
[Analysis of ABL tyrosine kinase point mutations in imatinib treated chronic myelogenous leukemia patients]
[Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia]
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
[Antileukemic drug--a selective inhibitor of BCR-ABL tyrosine kynase, imatinib(STI571)]
[Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
[Autologous hemopoietic stem cell transplantation in treatment of chronic myelogenous leukemia]
[Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial]
[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]
[Chronic myelogenous leukemia expressing two bcr-abl chimeric mRNA; a case report]
[Chronic myeloid leukemia - update 2020].
[Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy]
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]
[Chronic myeloid leukemia: "Archetype" of the impact of targeted therapies].
[Chronic myeloid leukemia: aiming for treatment free remission].
[Chronic myeloid leukemia].
[Clinical efficacy and side effects of STI571 in treatment of patients with chronic myeloid leukemia]
[Clinical factors that affect the detection of BCR-ABL transcripts after allogenic bone marrow transplantation for chronic myeloid leukemia]
[Clinical significance of analysis of BCR- ABL kinase domain mutation in chronic myeloid leukemia patients].
[Constructing a Competitor of BCR-ABL cDNA by PCR Site-Directed Mutagenesis]
[Correlation between point mutation in ABL kinase and clinical outcome of chronic myeloid leukemia patients].
[Cytogenetic and clinical features of Philadelphia chromosome positive leukemias]
[Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek]
[Cytoplasmic kinase inhibitors].
[Dasatinib treatment based on BCR- ABL mutation detection in imatinib- resistant patients with chronic myeloid leukemia].
[Demonstration of BCR-ABL rearrangement in a patient with apparently Ph-negative chronic myeloid leukemia of 15 years' duration]
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction]
[Detection of ABL kinase domain point mutations in chronic myeloid leukemia patients receiving imatinib treatment]
[Detection of Abl kinase domain point mutations in chronic myeloid leukemia patients with imatinib resistance and its clinical significance].
[Detection of bcr-abl Fusion Gene mRNA Level in K562/A02 Cell Line by Real-time Quantitative RT-PCR.]
[Detection of BCR-ABL gene mutations in chronic myeloid leukemia using biochips].
[Detection of bcr-abl transcripts in "minimal residual disease" in chronic myelogenous leukemia by nested polymerase chain reaction (PCR)]
[Dual-color/dual-fusion interphase fluorescence in situ hybridization probe for monitoring tumor load during imatinib therapy for chronic myeloid leukemia]
[Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].
[Effect of A Novel Tyrosine Kinase Inhibitor HHGV678 on Growth Inhibition of Bcr-Abl Wild Type and IM-resistant Cell Lines In Vitro.]
[Effect of specific siRNA targeting against bcr-abl chimeric gene on chronic myelogenous leukemia cells.]
[Effect of Targeted Activation of Protein Kinase PKR on Proliferation of Leukemia Cell Line K562 and Its Mechanism.]
[Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562]
[Evaluation of impact of baseline ABL kinase domain point mutations on response to nilotinib in imatinib-resistant or-intolerant patients with chronic myeloid leukemia].
[Experimental advance of targeted medicines for chronic myeloid leukemia--review]
[Expression of Bcl-2 protein and the amplification of c-myc gene in patients with chronic myeloid leukemia]
[Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
[Gene rearrangement and radiation carcinogenesis]
[Hematologic and molecular response with dasatinib as second-line treatment in chronic myeloid leukemia (CML) with treatment failure].
[Hematological malignancies]
[Imatinib therapy for patients with chronic myelogenous leukemia]
[Imatinib therapy in chronic myeloid leukemia]
[Imatinib--a new perspective in the treatment of tumors]
[Imatinib-induced pulmonary toxicity]
[Implications of ALK (anaplastic lymphoma kinase) in oncohematology]
[Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia]
[Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients]
[JAK2 positive chronic myeloid leukemia complicated with suspected BCR-ABL variant: one case report].
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]
[Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia]
[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia]
[Mechanisms of recombinant adenovirus-mediated SD-HA fusion protein proliferation inhibition and induced apoptosis of K562 cells].
[microRNA targeted to chronic myeloid leukemia Bcr-Abl oncogene screen using deacetylase inhibitor].
[Molecular analysis of bcr-abl mRNA during long-term follow-up of cases of chronic myelogenous leukemia]
[Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification]
[Molecular diagnosis of leukemia and lymphoma]
[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]
[Molecular Targeted Therapy and Laboratory Tests].
[Monitoring bcr-abl mRNA levels by real-time quantitative RT-PCR in chronic myeloid leukemia patients after hematopoietic stem cell transplantation]
[Monitoring of plasma concentration of imatinib mesylate in patients with chronic myeloid leukemia].
[Monitoring the chronic myeloid leukemia patients between 2008 and 2018; the experience of the Hematology and Bone Marrow Transplantation Unit Târgu-Mure?].
[Novel inhibitors of Bcr-Abl]
[Oncogenes in human leukemia]
[Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report]
[Polymorphism analysis of 5' promotor region of BCR gene]
[Preclinical and clinical profile of imatinib mesilate, a potent protein-tyrosine kinase inhibitor for CML therapy]
[Predictive value of molecular response after treatment with tyrosine kinase inhibitor for 3 months in patients with chronic myeloid leukemia].
[Pro-survival signaling pathways activated by BCR-ABL oncogene in chronic myelogenous leukemia cells: the role of the perk-EIF2? signal path and acetylation of p53].
[Relationship between thymus output function in CML patients and their bcr-abl mRNA levels]
[Research Advance on Molecular Genetics of CML Blast Crisis - Review.]
[Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha]
[RT-PCR use for the diagnostic of chronic myeloid leukaemia]
[Secondary chronic myelogenous leukemia following postoperative TS-1 therapy for advanced gastric cancer].
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
[Signal transduction inhibitor--STI571--a new treatment for chronic myeloid leukemia (CML), which opens a new targeted approach to cancer therapy]
[Signal transduction of BCR-ABL in chronic myelogenous leukemia]
[Significance of BCR-ABL fusion gene detection in CD34 (+) cells of chronic myelogenous leukemia patients].
[Significance of Quantitative Detection of bcr-abl mRNA in Chronic Myeloid Leukemia Patients after Allogeneic Hematopoietic Stem Cell Transplant.]
[Standardization of quantitative detection of BCR-ABL gene expression by RQ-PCR in patients with chronic myeloid leukemia in cooperation with European Leukemia Net].
[State-of-the-art management of CML in 2015 and future prospects].
[Study of adhesion-related molecule beta1-integrin and focal adhesion kinase in chronic myeloid leukemia]
[Ten years of molecular monitoring of chronic myeloid leukemia by quantitative RT-PCR]
[The development history and future perspective of molecularly targeted therapy].
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
[The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging]
[The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia]
[The efficacy analysis of interferon combined with imatinib in chronic myelogenous leukemia patients with ABL kinase domain mutations].
[The influence of peripheral blood sample storage and delivery on the quantitative detection result of BCR-ABL (P210) transcript levels].
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
[The mechanisms of the resistance to molecular targeting agents]
[The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
[The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse]
[Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
[Trisomy of chromosome 8 in Ph-negative cells of the bone marrow in patients with chronic myeloid leukemia treated with inhibitors of BCR-ABL tyrosinkinases]
[Types of bcr-abl and their correlations with the blood count in chronic myeloid leukemia (CML) in Togo].
[Tyrosin kinase inhibitors in oncology].
[Tyrosine kinase inhibitor STI571: new possibility in the treatment of chronic myeloid leukemia]
[Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia].
[Tyrosine kinase inhibitors--solid cancers]
[Use of cytogenetic and molecular biology in the detection of chronic myeloid leukemia]
[Using real-time polymerase chain reaction to quantitate bcr-abl mRNA]
[Variables associated with BCR-ABL kinase domain mutation in TKI-resistant patients with chronic myeloid leukemia].
Leukemia, Myeloid
A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
A novel crosstalk between calcium/calmodulin kinases II and IV regulates cell proliferation in myeloid leukemia cells.
A point mutation in the N-terminal coiled-coil domain releases c-Fes tyrosine kinase activity and survival signaling in myeloid leukemia cells.
Abrogation of the cell death response to oxidative stress by the c-Abl tyrosine kinase inhibitor STI571.
Allium Roseum L. Extract Exerts Potent Suppressive Activities on Chronic Myeloid Leukemia K562 Cell Viability Through the Inhibition of BCR-ABL, PI3K/Akt, and ERK1/2 Pathways and the Abrogation of VEGF Secretion.
Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-kappaB and p53 modulation.
Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib? Evaluation of Saglio G, Kim D-W, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251-9, and Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010;362:2260-70.
Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Azo-PROTAC: Novel Light-Controlled Small-Molecule Tool for Protein Knockdown.
BCR-ABL translocation in a dog with chronic monocytic leukemia.
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies.
Chronic myeloid leukemia-derived exosomes promote tumor growth through an autocrine mechanism.
Colorimetric assessment of BCR-ABL1 transcripts in clinical samples via gold nanoprobes.
Comparative gene expression profile of chronic myeloid leukemia cells innately resistant to imatinib mesylate.
Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells.
Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy.
Effect of the mutation of tyrosine 713 in p93c-fes on its catalytic activity and ability to promote myeloid differentiation in K562 cells.
Effects of hibarimicins and hibarimicin-related compounds produced by Microbispora on v-Src kinase activity and growth and differentiation of human myeloid leukemia HL-60 cells.
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Emerging paradigms in cardiomyopathies associated with cancer therapies.
Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia.
Ephrin type-B receptor 4 is an essential mediator in drug-resistance of acute myeloid leukemia cells to Adriamycin.
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias.
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
FLT3-regulated antigens as targets for leukemia-reactive cytotoxic T lymphocytes.
Focal Adhesion Kinase as a Potential Target in AML and MDS.
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells.
GCKR links the Bcr-Abl oncogene and Ras to the stress-activated protein kinase pathway.
Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the Bcr-Abl oncogene.
Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case.
Identification of the differentiation-associated p93 tyrosine protein kinase of HL-60 leukemia cells as the product of the human c-fes locus and its expression in myelomonocytic cells.
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Inhibition of c-Abl with STI571 attenuates stress-activated protein kinase activation and apoptosis in the cellular response to 1-beta-D-arabinofuranosylcytosine.
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts.
Kinases as drug discovery targets in hematologic malignancies.
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.
Long-lasting memory of cellular immunity in a chronic myeloid leukemia patient maintains molecular response 5 after cessation of dasatinib.
Lysosome Inhibition by Mefloquine Preferentially Enhances the Cytotoxic Effects of Tyrosine Kinase Inhibitors in Blast Phase Chronic Myeloid Leukemia.
Molecular diagnostics of hematologic malignancies.
Mucin 1 promotes radioresistance in hepatocellular carcinoma cells through activation of JAK2/STAT3 signaling.
Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias.
Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases.
Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl+ human myeloid leukemia cells.
Regulation of c-Fes tyrosine kinase and biological activities by N-terminal coiled-coil oligomerization domains.
Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
SFT Thijsen et al. Hypersensitivity of bcr-abl progenitors to hyperthermia in patients with chronic myeloid leukemia. Leukemia 1997; 11: 1762-1768.
Spontaneous resolution of a single lesion of myeloid leukemia cutis in an infant: case report and discussion.
Targeted therapies for high-risk acute myeloid leukemia.
Targeted therapy: The new lease on life for acute promyelocytic leukemia, and beyond.
Targeting RSK2 in myeloid leukemia: right for FLT3 but wrong for BCR-ABL.
The c-Fes protein-tyrosine kinase suppresses cytokine-independent outgrowth of myeloid leukemia cells induced by Bcr-Abl.
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells.
Transcriptional regulation of c-Fes in myeloid leukemia cells.
Transformation of myeloid leukemia cells to cytokine independence by Bcr-Abl is suppressed by kinase-defective Hck.
U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
[Chronic myeloid leukemia with variant e13a3 (b2a3) BCR-ABL1 as an ABL1 tyrosine kinase inhibitor-sensitive subtype].
[Coexistence of p210 BCR-ABL and CBF?-MYH11 fusion genes in myeloid leukemia: two cases report and literatures review].
[Expression of c-fes gene in leukemia cells and its clinical significance]
Leukemia, Myeloid, Acute
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
A Novel Inhibitor of STAT5 Signaling Overcomes Chemotherapy Resistance in Myeloid Leukemia Cells.
A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia.
Abivertinib, a novel BTK inhibitor: Anti-Leukemia effects and synergistic efficacy with homoharringtonine in acute myeloid leukemia.
Abnormal expression of TGF-beta type II receptor isoforms contributes to acute myeloid leukemia.
Acute leukemia in children.
Acute myeloblastic leukemia with active tyrosine protein kinase.
Acute myeloblastic leukemia with associated BCR-ABL translocation in a dog.
Acute Myeloid Leukemia with Concomitant BCR-ABL and NPM1 Mutations.
Azole antifungals and new targeted therapies for hematological malignancy.
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3.
Bruton's tyrosine kinase and RAC1 promote cell survival in MLL-rearranged acute myeloid leukemia.
CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs.
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Clinical Experience With Ibrutinib Alone or in Combination With Either Cytarabine or Azacitidine in Patients With Acute Myeloid Leukemia.
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Correction to "Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms".
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells.
Deletion of chromosome 22 without bcr rearrangement and without juxtaposition of c-abl in a case of acute myeloid leukemia.
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Drug resistance of secondary acute myeloid leukemia with megakaryoblastic features and p190 BCR-ABL rearrangement.
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies.
Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
Elevated expression of the c-fes proto-oncogene in adult human myeloid leukemia cells in the absence of gene amplification.
Enhancement of the TCR? Expression, Polyclonal Expansion, and Activation of T Cells from Patients with AML After IL-2, IL-7, and IL-12 Induction.
Entospletinib in Combination With Induction Chemotherapy in Previously Untreated Acute Myeloid Leukemia: Response and Predictive Significance of HOXA9 and MEIS1 expression.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
Ephrin type-B receptor 4 is an essential mediator in drug-resistance of acute myeloid leukemia cells to Adriamycin.
Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Expression of c-abl in Philadelphia-positive acute myelogenous leukemia.
Expression of focal adhesion kinase in acute myeloid leukemia is associated with enhanced blast migration, increased cellularity, and poor prognosis.
Expression of the c-fes proto-oncogene in granulocyte-macrophage colony-stimulating factor-dependent acute myelogenous leukemia cells grown autonomously.
Expression of the human fes cellular oncogene in renal cell tumors.
Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered wnt signaling.
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
High expression of GTPase regulator associated with the focal adhesion kinase (GRAF) is a favorable prognostic factor in acute myeloid leukemia.
High levels of p-JAK2 are associated with adverse clinical outcome and can be a molecular target in individuals with acute myelogenous leukemia.
Identification and characterization of SET, a nuclear phosphoprotein encoded by the translocation break point in acute undifferentiated leukemia.
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.
In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-Family Kinase C-Helix-out Inhibitor Resistance.
Inhibitors Targeting STAT5 Signaling in Myeloid Leukemias: New Tetrahydroquinoline Derivatives with Improved Antileukemic Potential.
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Leukemia patient-derived lymphoblastoid cell lines exhibit increased induction of leukemia-associated transcripts following high-dose irradiation.
Loss of K607 and E877 interaction is a key reason for JAK2 K607N mutation caused acute myeloid leukemia.
Mechanisms of Resistance to Targeted Therapies in Acute Myeloid Leukemia and Chronic Myeloid Leukemia.
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Midostaurin, a Novel Protein Kinase Inhibitor for the Treatment of Acute Myelogenous Leukemia: Insights from Human Absorption, Metabolism, and Excretion Studies of a BDDCS II Drug.
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Molecular mechanisms of leukemia-associated protein degradation.
Mutated tyrosine kinases as therapeutic targets in myeloid leukemias.
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
New Mutations of the ID1 Gene in Acute Myeloid Leukemia Patients.
Oligomerization of the ABL tyrosine kinase by the Ets protein TEL in human leukemia.
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) treated with imatinib mesylate (IM) A report with IM plasma concentration and bcr-abl transcripts.
Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis.
Philadelphia-positive acute leukemia: lineage promiscuity and inconsistently rearranged breakpoint cluster region.
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
Rearrangement of the breakpoint cluster region and expression of P210 BCR-ABL in a "masked" Philadelphia chromosome-positive acute myeloid leukemia.
Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Simultaneous occurrence of bcr-abl and inv16 in a case of M1 acute myeloid leukemia.
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1.
SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia.
SYK Regulates mTOR Signaling in AML.
Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia.
The (6;9) chromosome translocation, associated with a specific subtype of acute nonlymphocytic leukemia, leads to aberrant transcription of a target gene on 9q34.
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
The Philadelphia chromosome as a secondary abnormality in inv(3)(q21q26) acute myeloid leukemia at diagnosis: confirmation of p190 BCR-ABL mRNA by real-time quantitative polymerase chain reaction.
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.
The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias.
Transient response to imatinib mesylate (STI571) in a patient with the ETV6-ABL t(9;12) translocation.
[Clinical Analysis of 12 Cases of Acute Myeloid Leukemia with Ph Chromosome and BCR-ABL Positive].
[Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease]
[Tyrosine kinase mutation and acute myeloid leukemia with T (8; 21).]
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
Atypical chronic myeloid leukemia BCR-ABL 1 negative: A case report and literature review.
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
Leukemia, Myelomonocytic, Chronic
A case of acute myeloid leukemia with e6a2 BCR-ABL fusion transcript acquired after progressing from chronic myelomonocytic leukemia.
Absence of BCR-ABL rearrangement (with m-bcr breakpoint) in chronic myelomonocytic leukemia.
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Identification of a rare e6a2 BCR-ABL fusion gene during the disease progression of chronic myelomonocytic leukemia: a case report.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
[Juvenile myelomonocytic leukemia: A three-case series].
Leukemia, Myelomonocytic, Juvenile
Childhood chronic myeloid leukemia with monocytosis.
Leukemia, Neutrophilic, Chronic
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Chronic neutrophilic leukemia with an associated V617F JAK2 tyrosine kinase mutation.
Chronic neutrophilic leukemia: case report documenting the absence of bcr-abl rearrangement.
Leukemia, Prolymphocytic, B-Cell
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
Leukemia, Prolymphocytic, T-Cell
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Leukemia, Promyelocytic, Acute
Antiapoptotic effect of c-fes protooncogene during granulocytic differentiation.
As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Autophagy: friend or foe in the treatment of fusion protein-associated leukemias?
Biological therapy for pediatric malignancy: current perspectives.
Chromosomal localization of the human genes for lipocortin I and lipocortin II.
Coexistence of PML-RAR? and BCR-ABL in acute promyelocytic leukemia.
Inhibition of c-fes expression by an antisense oligomer causes apoptosis of HL60 cells induced to granulocytic differentiation.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Rt-PCR method for diagnosis and follow-up of hematological malignancies: first approach in Bangladesh.
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules.
Src family kinase inhibitor PP2 enhances differentiation of acute promyelocytic leukemia cell line induced by combination of all-trans-retinoic acid and arsenic trioxide.
Src Family Kinase Inhibitor PP2 Has Different Effects on All-Trans-Retinoic Acid or Arsenic Trioxide-Induced Differentiation of an Acute Promyelocytic Leukemia Cell Line.
Targeted therapies for high-risk acute myeloid leukemia.
Leukemia, T-Cell
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Accumulation of p60lck in HTLV-I-transformed T cell lines detected by an anti-lck monoclonal antibody, MOL 171.
Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Anemia and survival in childhood acute lymphoblastic leukemia.
Blockade of JAK2 activity suppressed accumulation of ?-catenin in leukemic cells.
Fas signaling and blockade of Bcr-Abl kinase induce apoptotic Hrk protein via DREAM inhibition in human leukemia cells.
Functional uncoupling of the Janus kinase 3-Stat5 pathway in malignant growth of human T cell leukemia virus type 1-transformed human T cells.
Human T-cell leukemia virus type-I-infected T-cell lines scarcely produce p56lck, whether or not they express lck mRNA.
Lymphocyte antigen receptor activation of a focal adhesion kinase-related tyrosine kinase substrate.
Multiplex analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays.
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.
Transrepression of lck gene expression by human T-cell leukemia virus type 1-encoded p40tax.
Leukemia-Lymphoma, Adult T-Cell
Anti-adult T?cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor.
Parameter perturbations in a post-treatment chronic myeloid leukemia model capture the essence of pre-diagnosis A-bomb survivor mysteries.
Leukemic Infiltration
CREB is a critical regulator of normal hematopoiesis and leukemogenesis.
Leukocytosis
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
Chronic myeloid leukaemia with BCR-ABL fusion genes located to both chromosomes 9, cyclic leukocytosis and nodal T-lymphoblastic transformation--durable complete remission following imatinib therapy.
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
Coexistence of chronic neutrophilic leukemia with multiple myeloma.
Combination of DNA-hypomethylating agent and hematopoietic stem cell transplantation in treatment of juvenile myelomonocytic leukemia: A case report.
Concurrent chronic neutrophilic leukemia blast crisis and multiple myeloma: A case report and literature review.
Detection of BCR-ABL Positive Cells in an Asymptomatic Patient: A Case Report and Literature Review.
Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis.
Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey.
MIP-1?/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia.
Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Myeloproliferative disorders. Classification and diagnostic features with special emphasis on chronic myelogenous leukemia and agnogenic myeloid metaplasia.
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia.
[Exacerbation of acute leukemia bearing isolated i(17q) along with proliferation of blasts with high BMI-1 expression]
Leukoencephalopathies
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Lewy Body Disease
Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease.
Li-Fraumeni Syndrome
Genetic testing by cancer site: stomach.
Lipoma
Angiotensin II, focal adhesion kinase, and PRX1 enhance smooth muscle expression of lipoma preferred partner and its newly identified binding partner palladin to promote cell migration.
Identification of Novel Genes in Osteoarthritic Fibroblast-Like Synoviocytes Using Next-Generation Sequencing and Bioinformatics Approaches.
Liposarcoma
BMP2/BMPR1A is linked to tumour progression in dedifferentiated liposarcomas.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
miR-193b-regulated signaling networks serve as tumor suppressors in liposarcoma and promote adipogenesis in adipose-derived stem cells.
Lissencephaly
Genes that regulate neuronal migration in the cerebral cortex.
Liver Cirrhosis
A cAbl-MRTF-A Feedback Loop Contributes to Hepatic Stellate Cell Activation.
Adiponectin Reduces Hepatic Stellate Cell Migration by Promoting Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) Secretion.
Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout.
Dual inhibition of reactive oxygen species and spleen tyrosine kinase as a therapeutic strategy in liver fibrosis.
Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis.
Inhibition of PDGF, TGF-? and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.
Long Noncoding RNA HOTTIP Promotes Mouse Hepatic Stellate Cell Activation via Downregulating miR-148a.
Lyn kinase enhanced hepatic fibrosis by modulating the activation of hepatic stellate cells.
Proline-rich tyrosine kinase 2 mediates transforming growth factor-beta-induced hepatic stellate cell activation and liver fibrosis.
Regulation of activin receptor-interacting protein 2 expression in mouse hepatoma Hepa1-6 cells and its relationship with collagen type IV.
Rilpivirine attenuates liver fibrosis through selective STAT1-mediated apoptosis in hepatic stellate cells.
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis.
[Quantitative analysis of the expression of insulin receptor and tyrosine protein kinase of patients with hepatic cirrhosis]
Liver Diseases
Anti-oxidants do not prevent bile acid-induced cell death in rat hepatocytes.
Chronic myelomonocytic leukemia with p190 BCR-ABL rearrangement mimicking advanced liver disease at presentation.
CircScd1 Promotes Fatty Liver Disease via the Janus Kinase 2/Signal Transducer and Activator of Transcription 5 Pathway.
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Negative Correlation Between Hepatitis C Virus (HCV) and Let-7 MicroRNA Family in Transplanted Livers: The Role of rs868 Single-Nucleotide Polymorphism.
Role of spleen tyrosine kinase in liver diseases.
SYK-3BP2 Pathway Activity in Parenchymal and Myeloid Cells Is a Key Pathogenic Factor in Metabolic Steatohepatitis.
Liver Diseases, Alcoholic
Inhibition of spleen tyrosine kinase activation ameliorates inflammation, cell death, and steatosis in alcoholic liver disease.
Liver Failure
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report.
Liver Failure, Acute
A Src family kinase inhibitor improves survival in experimental acute liver failure associated with elevated cerebral and circulating vascular endothelial growth factor levels.
Liver Neoplasms
c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer.
Downregulation of SRC Kinase Signaling Inhibitor 1 (SRCIN1) Expression By MicroRNA-32 Promotes Proliferation and Epithelial-Mesenchymal Transition in Human Liver Cancer Cells.
Epidermal Growth Factor Activates the Rho GTPase-activating Protein (GAP) Deleted in Liver Cancer 1 via Focal Adhesion Kinase and Protein Phosphatase 2A.
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
HOXA11-AS regulates JAK-STAT pathway by miR-15a-3p/STAT3 axis to promote the growth and metastasis in liver cancer.
IL?6 plays a crucial role in epithelial?mesenchymal transition and pro?metastasis induced by sorafenib in liver cancer.
LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling.
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
MicroRNA-543 suppresses liver cancer growth and induces apoptosis via the JAK2/STAT3 signaling pathway.
miR24-2 Promotes Malignant Progression of Human Liver Cancer Stem Cells by Enhancing Tyrosine Kinase Src Epigenetically.
Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma.
Saffron carotenoids inhibit STAT3 activation and promote apoptotic progression in IL-6-stimulated liver cancer cells.
The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
Transforming Growth Factor-beta Receptors: Role in Physiology and Disease.
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
Loeys-Dietz Syndrome
Absence of TGFBR1 and TGFBR2 mutations in patients with bicuspid aortic valve and aortic dilation.
Activation of TGF-? signaling in an aortic aneurysm in a patient with Loeys-Dietz syndrome caused by a novel loss-of-function variant of TGFBR1.
Analysis of TFGBR1*6A variant in individuals evaluated for Marfan syndrome.
Aneurysm syndromes caused by mutations in the TGF-beta receptor.
Arterial tortuosity in genetic arteriopathies.
Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome.
Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes.
Distinct variants affecting differential splicing of TGFBR1 exon 5 cause either Loeys-Dietz syndrome or multiple self-healing squamous epithelioma.
Duplication of the TGFBR1 gene causes features of Loeys-Dietz syndrome.
Dural ectasia in individuals with Marfan-like features but exclusion of mutations in the genes FBN1, TGFBR1 and TGFBR2.
Dural ectasia in Loeys-Dietz syndrome: Comprehensive study of 30 patients with a TGFBR1 or TGFBR2 mutation.
Ectopia lentis in Loeys-Dietz syndrome type 4.
Evolution of the face in Loeys-Dietz syndrome type II: longitudinal observations from infancy in seven cases.
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Features of multiple self-healing squamous epithelioma and Loeys-Dietz syndrome in a patient with a novel TGFBR1 variant.
First evidence of maternally inherited mosaicism in TGFBR1 and subtle primary myocardial changes in Loeys-Dietz syndrome: a case report.
Generation of three induced pluripotent stem cell lines (MHHi012-A, MHHi013-A, MHHi014-A) from a family with Loeys-Dietz syndrome carrying a heterozygous p.M253I (c.759G>A) mutation in the TGFBR1 gene.
Germline TGF-beta receptor mutations and skeletal fragility: a report on two patients with Loeys-Dietz syndrome.
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Identification of a novel TGFBR1 mutation in a Loeys-Dietz syndrome type II patient with vascular Ehlers-Danlos syndrome phenotype.
Loeys-Dietz syndrome: life threatening aortic dissection diagnosed on routine family screening.
Marfan syndrome type II: there is more to Marfan syndrome than fibrillin 1.
Multiple Facial Milia in Patients With Loeys-Dietz Syndrome.
Multiple Self-Healing Squamous Epithelioma (MSSE): A Digenic Trait Associated with Loss of Function Mutations in TGFBR1 and Variants at a Second Linked Locus on the Long Arm of Chromosome 9.
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Novel Association of a Familial TGFBR1 Mutation in Loeys-Dietz Syndrome with Concomitant Hematologic Malignancy.
Novel pathogenic TGFBR1 and SMAD3 variants identified after cerebrovascular events in adult patients with Loeys-dietz syndrome.
Optimising the mutation screening strategy in Marfan syndrome and identifying genotypes with more severe aortic involvement.
Overexpression of Gremlin-1 in patients with Loeys-Dietz syndrome: implications on pathophysiology and early disease detection.
Pathogenic effect of a TGFBR1 mutation in a family with Loeys-Dietz syndrome.
Pregnancy after aortic root replacement in Loeys-Dietz syndrome: High risk of aortic dissection.
Prevalence of dural ectasia in 63 gene-mutation-positive patients with features of Marfan syndrome type 1 and Loeys-Dietz syndrome and report of 22 novel FBN1 mutations.
Recent progress in genetics of Marfan syndrome and Marfan-associated disorders.
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome in a boy with Loeys-Dietz syndrome.
Severe eczema and Hyper-IgE in Loeys-Dietz-syndrome - contribution to new findings of immune dysregulation in connective tissue disorders.
SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction.
Surgical experience in a patient with Loeys-Dietz syndrome type I.
Surgical Outcome and Histological Differences between Individuals with TGFBR1 and TGFBR2 Mutations in Loeys-Dietz Syndrome.
Testing patterns for genetically triggered aortic and arterial aneurysms and dissections at an academic center.
TGF? receptor mutations impose a strong predisposition for human allergic disease.
TGF? signaling and congenital heart disease: Insights from mouse studies.
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
TGFBR1 mutations associated with Loeys-Dietz syndrome are inactivating.
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
Unique Mechanism by Which TGFBR1 Variants Cause 2 Distinct System Diseases?- Loeys-Dietz Syndrome and Multiple Self-Healing Squamous Epithelioma.
Lordosis
Lordosis facilitation by leptin in ovariectomized, estrogen-primed rats requires simultaneous or sequential activation of several protein kinase pathways.
Lung Diseases
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
DNA Methylation Profiling for the Diagnosis and Prognosis of Patients with Nontuberculous Mycobacterium Lung Disease.
Early-onset pulmonary and cutaneous vasculitis driven by constitutively active SRC-family kinase HCK.
Modelling c-Abl Signalling in Activated Neutrophils: the Anti-inflammatory Effect of Seliciclib.
Lung Diseases, Interstitial
Iacta Alea Est: The Inexorable Advance of Tofacitinib in the Treatment of Dermatomyositis-Associated Rapidly Progressive Interstitial Lung Disease. A Case Report.
[The Diagnosis is Obvious].
Lung Injury
Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity.
c-Abl mediated tyrosine phosphorylation of paxillin regulates LPS-induced endothelial dysfunction and lung injury.
Differential effects of the Src family tyrosine kinases Yes and Fyn on lipopolysaccharide-induced lung injury in ice.
Effect of SOCS3 on lung injury in rats with severe acute pancreatitis through regulating JAK2/STAT3 signaling pathway.
Hydrostatin-SN10 Ameliorates Pancreatitis-Induced Lung Injury by Affecting IL-6-Induced JAK2/STAT3-Associated Inflammation and Oxidative Stress.
Inhibition of BTK protects lungs from trauma-hemorrhagic shock-induced injury in rats.
Loss of immune homeostasis in patients with idiopathic pulmonary arterial hypertension.
Lung Epithelial Cell Focal Adhesion Kinase Signaling Inhibits Lung Injury and Fibrosis.
Neuronal Wiskott-Aldrich syndrome protein regulates TGF-?1-mediated lung vascular permeability.
Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.
Protective effects of SOCS3 overexpression in high glucose?induced lung epithelial cell injury through the JAK2/STAT3 pathway.
Role of Focal Adhesion Kinase in Lung Remodeling of Endotoxemic Rats.
Src Regulates Cigarette Smoke-induced Ceramide Generation via nSMase2 in the Airway Epithelium.
Src tyrosine kinase inhibition prevents pulmonary ischemia-reperfusion-induced acute lung injury.
[Regulation of paxillin tyrosine phosphorylation via inhibition of c-Abl kinase to protect ventilator induce lung injury in vivo in rats].
Lung Neoplasms
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
?-elemene inhibits non-small cell lung cancer cell migration and invasion by inactivating the FAK-Src pathway.
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation.
Activated cdc42-associated kinase is up-regulated in non-small-cell lung cancer and necessary for FGFR-mediated AKT activation.
Activation of focal adhesion kinase in human lung cancer cells involves multiple and potentially parallel signaling events.
Activation of Janus kinase 1 confers poor prognosis in patients with non-small cell lung cancer.
Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells.
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Aflatoxin B1 induces Src phosphorylation and stimulates lung cancer cell migration.
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells.
Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Bombesin and gastrin releasing peptide increase tyrosine phosphorylation of focal adhesion kinase and paxillin in non-small cell lung cancer cells.
Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.
Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
Clinical development of SRC tyrosine kinase inhibitors in lung cancer.
Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer.
Combination of heat shock protein 90 and focal adhesion kinase inhibitors synergistically inhibits the growth of non-small cell lung cancer cells.
Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Cryptotanshinone inhibits lung tumor growth by increasing CD4(+) T cell cytotoxicity through activation of the JAK2/STAT4 pathway.
Cytokines from the tumor microenvironment modulate sirtinol cytotoxicity in A549 lung carcinoma cells.
Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK).
Detection of novel paraja ring finger 2-fer tyrosine kinase mRNA chimeras is associated with poor postoperative prognosis in non-small cell lung cancer.
Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer.
DOK7V1 influences the malignant phenotype of lung cancer cells through PI3K/AKT/mTOR and FAK/paxillin signaling pathways.
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin ?1/FAK Signaling.
Early Candidate Biomarkers of Non-Small Cell Lung Cancer Are Screened and Identified in Premalignant Lung Lesions.
Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line.
Effect of spleen tyrosine kinase on nonsmall cell lung cancer.
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis.
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
EphB4: A promising target for upper aerodigestive malignancies.
Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells.
Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Expression of chicken ovalbumin upstream promoter-transcription factor II enhances invasiveness of human lung carcinoma cells.
Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance.
FER overexpression is associated with poor postoperative prognosis and cancer-cell survival in non-small cell lung cancer.
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.
Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
FOXD3-AS1 suppresses the progression of non-small cell lung cancer by regulating miR-150/SRCIN1axis.
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Heterogeneous transforming growth factor (TGF)-beta unresponsiveness and loss of TGF-beta receptor type II expression caused by histone deacetylation in lung cancer cell lines.
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Inhibition of JAK2/STAT3 signaling pathway protects mice from the DDP-induced acute kidney injury in lung cancer.
Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549.
Involvement of the transcription factor twist in phenotype alteration through epithelial-mesenchymal transition in lung cancer cells.
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
JAK3 inhibitor VI is a mutant specific inhibitor for epidermal growth factor receptor with the gatekeeper mutation T790M.
Larotrectinib (LOXO-101).
Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Ling Zhi-8 reduces lung cancer mobility and metastasis through disruption of focal adhesion and induction of MDM2-mediated Slug degradation.
LncRNA TMPO-AS1 facilitates the proliferation and metastasis of NSCLC cells by up-regulating ERBB2 via sponging miR-204-3p.
Long non-coding RNA DANCR promoted non-small cell lung cancer cells metastasis via modulating of miR-1225-3p/ErbB2 signal.
Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report.
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.
Luteolin attenuates migration and invasion of lung cancer cells via suppressing focal adhesion kinase and non-receptor tyrosine kinase signaling pathway.
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors.
MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma.
MicroRNA-510 Plays Oncogenic Roles in Non-Small Cell Lung Cancer by Directly Targeting SRC Kinase Signaling Inhibitor 1.
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
MicroRNA?208a directly targets Src kinase signaling inhibitor 1 to facilitate cell proliferation and invasion in non?small cell lung cancer.
miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1.
miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells.
MiR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITG?8- JAK2/STAT3 axis.
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
MiR-410 affects the proliferation and apoptosis of lung cancer A549 cells through regulation of SOCS3/JAK-STAT signaling pathway.
Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
NEDD9 promotes lung cancer metastasis through epithelial-mesenchymal transition.
Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines.
Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells.
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.
Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.
Non-receptor tyrosine kinase inhibitors in lung cancer.
Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report.
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner.
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Overcoming Resistance to Targeted Therapies in Cancer.
Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.
Overexpression of type VI collagen in neoplastic lung tissues.
p53 modulates the effect of ribosomal protein S6 kinase1 (S6K1) on cisplatin toxicity in chronic myeloid leukemia cells.
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility.
Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.
Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.
Plumbagin reduces osteopontin-induced invasion through inhibiting the Rho-associated kinase signaling pathway in A549 cells and suppresses osteopontin-induced lung metastasis in BalB/c mice.
Prevalence of Mutations in Discoidin Domain-Containing Receptor Tyrosine Kinase 2 (DDR2) in Squamous Cell Lung Cancers in Korean Patients.
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Proline-rich tyrosine kinase 2 and its phosphorylated form pY881 are novel prognostic markers for non-small-cell lung cancer progression and patients' overall survival.
Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Regulatory interplay between Vav1, Syk and ?-catenin occurs in lung cancer cells.
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
ROS1 protein-tyrosine kinase inhibitors in the treatment of ROS1 fusion protein-driven non-small cell lung cancers.
RRM1-induced metastasis suppression through PTEN-regulated pathways.
Selective antitumor activity of ibrutinib in EGFR-mutant non-small cell lung cancer cells.
Serum starvation regulates E-cadherin upregulation via activation of c-Src in non-small-cell lung cancer A549 cells.
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
SOCS3 expression is inversely correlated with Pyk2 in non-small cell lung cancer and exogenous SOCS3 inhibits proliferation and invasion of A549 cells.
Somatic Mutations and Splicing Variants of Focal Adhesion Kinase in Non-Small Cell Lung Cancer.
Spleen tyrosine kinase SYK(L) interacts with YY1 and coordinately suppresses SNAI2 transcription in lung cancer cells.
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
Src Regulates Cigarette Smoke-induced Ceramide Generation via nSMase2 in the Airway Epithelium.
Stimulation of beta1 integrin down-regulates ICAM-1 expression and ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase.
Strategies to overcome resistance to targeted protein kinase inhibitors in the treatment of cancer.
Syntenin increases the invasiveness of small cell lung cancer cells by activating p38, AKT, focal adhesion kinase and SP1.
Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors.
Targeting focal adhesion kinase overcomes erlotinib resistance in smoke induced lung cancer by altering phosphorylation of epidermal growth factor receptor.
TGFBR1 haplotypes and risk of non-small-cell lung cancer.
The 150 most important questions in cancer research and clinical oncology series: questions 57-66 : Edited by Chinese Journal of Cancer.
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.
The Role of Focal Adhesion Kinase in Lung Cancer.
The Spleen Tyrosine Kinase Inhibitor, Entospletinib (GS-9973) Restores Chemosensitivity in Lung Cancer Cells by Modulating ABCG2-mediated Multidrug Resistance.
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Transient potent BCR-ABL inhibition is sufficient to commit chronic myeloid leukemia cells irreversibly to apoptosis.
Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.
Tyrosine Kinase Inhibitors (TKIs) in Lung Cancer Treatment: A Comprehensive Analysis.
Up-regulation of focal adhesion kinase in non-small cell lung cancer.
Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
Upregulation of Complement Factor H by SOCS-1/3?STAT4 in Lung Cancer.
Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity.
[Association between Ephb4 gene polymorphism and non-small cell lung cancer]
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
[Effect of Src Tyrosine Kinase Inhibition on the Drug-resistance as well as MDR1 and LRP Expression of the Human Cis-platinum-resistant Lung Cancer Cell Line A549/DDP].
[Expression of KAI1, MRP-1, and FAK proteins in lung cancer detected by high-density tissue microarray]
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
[Molecular Targeted Therapy and Laboratory Tests].
[Relationship between multi-slice spiral CT pulmonary perfusion imaging and the expression of EphB4 and ephrinB2 in non-small cell lung cancer].
[SRC kinase inhibitor PP2 inhibits invasion and metastasis of lung cancer A549 cells by upregulating connexin43 expression].
Lupus Erythematosus, Cutaneous
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Filgotinib or Lanraplenib in Moderate to Severe Cutaneous Lupus Erythematosus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study.
Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study.
Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients.
Tyrosine kinase 2 and interferon regulatory factor 5 polymorphisms are associated with discoid and subacute cutaneous lupus erythematosus.
Lupus Erythematosus, Discoid
Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus.
Lupus Erythematosus, Systemic
A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis.
Activation signal transduction by proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Altered recruitment of Lyn, Syk and ZAP-70 into lipid rafts of activated B cells in Systemic Lupus Erythematosus.
Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis.
Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families.
Associations between PXK and TYK2 polymorphisms and systemic lupus erythematosus: a meta-analysis.
B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice.
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Bruton's tyrosine kinase in systemic lupus erythematosus.
c-Jun and Ets2 regulate the expression of spleen tyrosine kinase in T cells.
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
CREM? suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells.
Cutting Edge: Deletion of Ezrin in B Cells of Lyn-Deficient Mice Downregulates Lupus Pathology.
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Dysregulation of p56lck kinase in patients with systemic lupus erythematosus.
Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models.
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Expression and activation of proline-rich tyrosine kinase 2 (PYK2) in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Increased frequency of a unique spleen tyrosine kinase bright memory B cell population in systemic lupus erythematosus.
Interferon-? activates interleukin-1 receptor-associated kinase 1 to induce regulatory T-cell apoptosis in patients with systemic lupus erythematosus.
Lack of association between tyrosine kinase 2 (TYK2) gene polymorphisms and susceptibility to SLE in a Japanese population.
p56lck activity and expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus.
Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.
Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus.
Prevalence of ZAP-70, LAT, SLP-76, and DNA methyltransferase 1 expression in CD4+ T cells of patients with systemic lupus erythematosus.
Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling.
ST6Gal-I restrains CD22-dependent antigen receptor endocytosis and Shp-1 recruitment in normal and pathogenic immune signaling.
The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development.
The Potential Role of Lyn Kinase in Systemic Lupus Erythematosus and Autoimmunity.
Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus.
[Modern disease-modifying antirheumatic drugs].
Lupus Nephritis
A novel potential target of IL-35-regulated JAK/STAT signaling pathway in lupus nephritis.
Characterization of the mechanism of action of lanraplenib, a novel spleen tyrosine kinase inhibitor, in models of lupus nephritis.
Effects of a spleen tyrosine kinase inhibitor on progression of the lupus nephritis in mice.
Increased expression of Bruton's tyrosine kinase in peripheral blood is associated with lupus nephritis.
MicroRNA-183 exerts a protective role in lupus nephritis through blunting the activation of TGF-?/Smad/TLR3 pathway via reducing Tgfbr1.
Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond.
Lymphadenopathy
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules.
Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia.
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Prevalence of ZAP-70 and CD 38 in Indian chronic lymphocytic leukemia patients.
Suppression of autoimmune disease and of massive lymphadenopathy in MRL/Mp-lpr/lpr mice lacking tyrosine kinase Fyn (p59fyn).
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Lymphangioleiomyomatosis
Aberrant SYK Kinase Signaling Is Essential for Tumorigenesis Induced by TSC2 Inactivation.
SRC kinase is a novel therapeutic target in lymphangioleiomyomatosis.
Lymphangioma
Src Tyrosine Kinase Inhibition Suppresses Lymphangiogenesis in vitro and in vivo.
Lymphatic Metastasis
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF?R1/VEGF-D signaling.
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Identification of lymphatic metastasis-associated genes in a metastatic ovarian cancer cell line.
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
Lymphedema
EPHB4 mutation causes adult and adolescent-onset primary lymphedema.
Janus-faced EPHB4-associated disorders: novel pathogenic variants and unreported intrafamilial overlapping phenotypes.
Lymphocytosis
Significance of zeta-associated protein (ZAP-70) and CD38 expression in chronic lymphocytic leukemia.
Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia.
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.
Utility of laboratory tests in B-CLL patients in different clinical stages.
Lymphohistiocytosis, Hemophagocytic
A Novel BTK Gene Mutation in a Child With Atypical X-Linked Agammaglobulinemia and Recurrent Hemophagocytosis: A Case Report.
Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.
Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children.
Lymphoma
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA.
A lymphoma cell line expressing elevated levels of tyrosine protein kinase activity.
A lymphoma protein with an in vitro site of tyrosine phosphorylation homologous to that in pp60src.
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Abl: the prototype of oncogenic fusion proteins.
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Alopecia in patients treated with molecularly targeted anticancer therapies.
Altered protein kinase activities of lymphoid cells transformed by Abelson and Moloney leukemia viruses.
An Epstein-Barr virus transformation-associated membrane protein interacts with src family tyrosine kinases.
Anomalous constitutive Src kinase activity promotes B lymphoma survival and growth.
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice.
Azole antifungals and new targeted therapies for hematological malignancy.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.
BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells.
Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity.
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas.
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
Bruton's tyrosine kinase activity and inositol 1,4,5-trisphosphate production are not altered in DT40 lymphoma B cells exposed to power line frequency magnetic fields.
Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Bruton's Tyrosine Kinase Is Not Essential for B Cell Survival beyond Early Developmental Stages.
BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib.
c-Casitas b-Lineage Lymphoma Downregulation Improves the Ability of Long-term Cultured Mesenchymal Stem Cells for Promoting Angiogenesis and Diabetic Wound Healing.
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cellular depletion of p56lck during thymocyte apoptosis.
Characteristics and outcomes of patients on concurrent direct oral anticoagulants and targeted anticancer therapies-TacDOAC registry: Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy.
Characteristics of TCR?, ZAP-70, and Fc?RI? Gene Expression in Patients with T- and NK/T-Cell Lymphoma.
Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells.
CircRNA?0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR?107.
Cloning of the gene encoding rat JAK2, a protein tyrosine kinase.
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Comparative analyses of differentially induced T-cell receptor-mediated phosphorylation pathways in T lymphoma cells.
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
Correction: Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
Covalently bound myristate in a lymphoma tyrosine protein kinase.
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib.
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Degradation of Bruton's tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas.
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
Differential impact of BTK active site inhibitors on the conformational state of full-length BTK.
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Efficient Preparation of (S)-N-Boc-3-Hydroxylpiperidine Through Bioreduction by a Thermostable Aldo-KetoReductase.
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
Emerging biological insights and novel treatment strategies in primary mediastinal large B-cell lymphoma.
Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development.
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Evolving Strategies for the Treatment of T-Cell Lymphoma: A Systematic Review and Recent Patents.
Expression of CD45 alters phosphorylation of the lck-encoded tyrosine protein kinase in murine lymphoma T-cell lines.
Expression of protein tyrosine kinases in the Ig complex of anti-mu-sensitive and anti-mu-resistant B-cell lymphomas: role of the p55blk kinase in signaling growth arrest and apoptosis.
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Expression pattern of adaptor protein PAG: correlation between secondary lymphatic follicle and histogenetically related malignant lymphomas.
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Genetic evidence for a tyrosine kinase cascade preceding the mitogen-activated protein kinase cascade in vertebrate G protein signaling.
Glivec and CML: a lucky date.
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
High level of tyrosine protein kinase in a murine lymphoma cell line induced by Moloney leukemia virus.
High ZAP-70 expression correlates with worse clinical outcome in mantle cell lymphoma.
Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma.
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Ibrutinib brain distribution: a preclinical study.
Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in syngeneic mouse lymphoma model.
Ibrutinib for the treatment of mantle cell lymphoma.
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Ibrutinib: first global approval.
Identification of a 58,000 daltons phosphoprotein with tyrosine protein kinase activity in a murine lymphoma cell line.
Identification of the tyrosine protein kinase from LSTRA cells by use of site-specific antibodies.
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Immunochemical detection of adenine nucleotide-binding proteins with antibodies to 5'-p-fluorosulfonylbenzoyladenosine.
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
In situ hybridization for the detection of low copy numbers of c-abl oncogene mRNA in lymphoma cells: technical approach and comparison with results with anti-oncoprotein antibodies.
In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas.
Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Insights into the conformational flexibility of Bruton's tyrosine kinase from multiple ligand complex structures.
Interleukin 15-Dependent T Cell-like Innate Intraepithelial Lymphocytes Develop in the Intestine and Transform into Lymphomas in Celiac Disease.
Is the c-Cbl proto-oncogene involved in chronic lymphocytic leukemia?
Is the open mouth mightier than the needle?
Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.
Janus kinase deregulation in leukemia and lymphoma.
Janus Reveals Another Face: The Biologic Rationale for Targeting Janus Kinase 2 in Lymphoma.
Kinase group protooncogenes in non-hodgkins-lymphomas and nonmalignant lymphoid-tissues - analysis of their expression by insitu hybridization assays.
Kinase Inhibitor Indole Derivatives as Anticancer Agents: A Patent Review.
Kinase-independent potentiation of B cell antigen receptor-mediated signal transduction by the protein tyrosine kinase Src.
Kinases as drug discovery targets in hematologic malignancies.
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Larotrectinib (LOXO-101).
Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
Localization of a lymphocyte-specific protein tyrosine kinase gene (lck) at a site of frequent chromosomal abnormalities in human lymphomas.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Lyn tyrosine kinase signals cell cycle arrest but not apoptosis in B-lineage lymphoma cells.
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Membrane-associated signaling in human B-lymphoma lines.
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway.
MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-?b signaling pathway in mantle cell lymphoma.
Molecular basis of targeted chemotherapy: novel concepts with special reference to the treatment of Hodgkin's disease.
Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction.
Molecular diagnostics of hematologic malignancies.
MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.
Multiple combination therapy based on intrathecal pemetrexed in non-small cell lung cancer patients with refractory leptomeningeal metastasis.
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
NF-?B signaling and its relevance to the treatment of mantle cell lymphoma.
Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.
Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
Novel JAK3-Activating Mutations in Extranodal NK/T-cell Lymphoma, Nasal Type.
Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.
Novel Therapeutic Targets in Non-small Cell Lung Cancer.
Oncogene expression in murine splenic T cells and in murine T-cell neoplasms.
Oncogenes: present status.
Oncogenic association of the Cbp/PAG adaptor protein with the Lyn tyrosine kinase in human B-NHL rafts.
Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs).
p110? inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma.
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Pharmacological inhibition of focal adhesion kinase 1 (FAK1) and anaplastic lymphoma kinase (ALK) identified via kinome profile analysis attenuates lipopolysaccharide-induced endothelial inflammatory activation.
Pharmacotherapeutic Management of Pediatric Lymphoma.
Phase 1/2 Study of Tirabrutinib, a Second-Generation Bruton's Tyrosine Kinase Inhibitor, in Relapsed/Refractory Primary Central Nervous System Lymphoma.
Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.
Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes.
Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa bcr-abl protein.
Phosphoinositides are not phosphorylated by the very active tyrosine protein kinase from the murine lymphoma LSTRA.
Phosphorylation of p56lck by external ATP in intact cells.
Phosphorylation of SOCS1 Inhibits the SOCS1-p53 Tumor Suppressor Axis.
Phosphorylation of synthetic peptides by a tyrosine protein kinase from the particulate fraction of a lymphoma cell line.
Phosphorylation of the lymphoid cell kinase p56lck is stimulated by micromolar concentrations of Zn2+.
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Positron emission tomography imaging analysis of G2A as a negative modifier of lymphoid leukemogenesis initiated by the BCR-ABL oncogene.
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Privileged Scaffolds or Promiscuous Binders: A Glance of Pyrrolo[2,1-f][1,2,4]triazines and Related Bridgehead Nitrogen Heterocycles in Medicinal Chemistry.
Production of nitric oxide by differentiated LSTRA cells is associated with expression of macrophage-inducible nitric oxide synthase.
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Profound Sinoatrial Arrest Associated with Ibrutinib.
Prolactin induced tyrosine phosphorylation of p59fyn may mediate phosphatidylinositol 3-kinase activation in Nb2 cells.
Purification of the LSTRA tyrosine protein kinase (p56lck).
Rapid activation of the T-cell tyrosine protein kinase pp56lck by the CD45 phosphotyrosine phosphatase.
Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas.
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas.
Recurring proviral integration suggests a role for proto-oncogene activation in thymomas induced with Mo-MuLV-rescued BCR/ABL virus.
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Restoration of surface IgM-mediated apoptosis in an anti-IgM-resistant variant of WEHI-231 lymphoma cells by HS1, a protein-tyrosine kinase substrate.
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.
Roles for phosphoinositide 3-kinases, Bruton's tyrosine kinase, and Jun kinases in B lymphocyte chemotaxis and homing.
Second-generation inhibitors of Bruton tyrosine kinase.
Secondary mutations as mediators of resistance to targeted therapy in leukemia.
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway.
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Single and combined BTK and PI3K? inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas.
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
Src Kinase and Syk Activation Initiate PI3K Signaling by a Chimeric Latent Membrane Protein 1 in Epstein-Barr Virus (EBV)+ B Cell Lymphomas.
Src kinase inhibitors induce apoptosis and mediate cell cycle arrest in lymphoma cells.
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Stimulation of Bruton's tyrosine kinase (BTK) and inositol 1,4,5-trisphosphate production in leukemia and lymphoma cells exposed to low energy electromagnetic fields.
Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib.
Structural modification of c-abl in lymphoma and leukemia.
Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.
Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma.
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Targeting protein kinase C in mantle cell lymphoma.
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Tec family kinases in inflammation and disease.
Temsirolimus inhibits cell growth in combination with inhibitors of the B-cell receptor pathway.
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
The Magnolia Trial: Zanubrutinib, A Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma.
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
The retarded electrophoretic migration of p56lck induced by vanadate in lymphoma cells correlates with modified kinase activity.
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
The sphingolipid-rich rafts of ALK+ lymphomas downregulate the Lyn-Cbp/PAG signalosome.
The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.
The Syk kinase as a therapeutic target in leukemia and lymphoma.
The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma.
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Translational activation of the lck proto-oncogene.
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.
Tumor promoters cause changes in the state of phosphorylation and apparent molecular weight of a tyrosine protein kinase in T lymphocytes.
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Tumorigenesis and aberrant signaling in transgenic mice expressing the human herpesvirus-8 K1 gene.
Tyrosine phosphorylation in human T lymphoma cells.
Tyrosine protein kinase is involved in anti-IgM-mediated signaling in BAL17 B lymphoma cells.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Use of acalabrutinib in patients with mantle cell lymphoma.
Vesicular stomatitis virus produced from infected LSTRA lymphoma cells bear tyrosine protein kinase activity (p56).
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
X-linked immunodeficient mice exhibit enhanced susceptibility to Cryptococcus neoformans Infection.
Zanubrutinib-induced liver injury: a case report and literature review.
ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
[Clinical significance of ZAP-70 protein expression in chronic lymphocytic leukemia/small lymphocytic lymphoma]
[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Lymphoma, B-Cell
3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
A Moving Target: Inactivating BTK Mutations as Drivers of Follicular Lymphoma.
A novel PTPN1 splice variant upregulates JAK/STAT activity in classical Hodgkin lymphoma cells.
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
Autophagy as a Regulatory Component of Erythropoiesis.
B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Biallelic deletion within 16p13.13 including SOCS-1 in Karpas1106P mediastinal B-cell lymphoma line is associated with delayed degradation of JAK2 protein.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives.
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
Clinical pharmacology and PK/PD translation of the second-generation Bruton's tyrosine kinase inhibitor, zanubrutinib.
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Critical comments for roles of biomarkers in the diagnosis and treatment of cancer.
Cross Talk Between TGF-? and JAK Expressions and Nepherotoxicity Induced by Tetrachloromethane: Role of Phytotherapy.
Current Treatment of Refractory/Relapsed Chronic Lymphocytic Leukemia: A Focus on Novel Drugs.
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.
Differential expression of key regulators of Toll-like receptors in ulcerative colitis and Crohn's disease: a role for Tollip and peroxisome proliferator-activated receptor gamma?
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency.
Discovery of Potent and Selective Tricyclic Inhibitors of Bruton's Tyrosine Kinase with Improved Druglike Properties.
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma.
EGR1 Addiction in Diffuse Large B-cell Lymphoma.
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant Janus kinase 2 activation.
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.
Examination of the Biomark assay as an alternative to Oncotype DX for defining chemotherapy benefit.
Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Expression of protein tyrosine kinases in the Ig complex of anti-mu-sensitive and anti-mu-resistant B-cell lymphomas: role of the p55blk kinase in signaling growth arrest and apoptosis.
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.
High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia.
Ibrutinib and Indolent B-Cell Lymphomas.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
Ibrutinib in B-cell lymphoma: single fighter might be enough?
Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas.
Ibrutinib-Associated Atrial Fibrillation.
Ibrutinib-induced severe liver injury.
Ibrutinib: A Review in Chronic Lymphocytic Leukaemia.
Ibrutinib: first global approval.
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Interdisciplinary approach to the current management of chronic lymphocytic leukemia
Lyn tyrosine kinase signals cell cycle arrest in mouse and human B-cell lymphoma.
Maslinic acid suppresses the growth of human gastric cells by inducing apoptosis via inhibition of the interleukin-6 mediated Janus kinase/signal transducer and activator of transcription 3 signaling pathway.
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
MicroRNA-140 inhibits skeletal muscle glycolysis and atrophy in endotoxin-induced sepsis in mice via the WNT signaling pathway.
MiR-17 Regulates Prostate Cancer Cell Proliferation and Apoptosis Through Inhibiting JAK-STAT3 Signaling Pathway.
Novel Agents in the Treatment of Chronic Lymphocytic Leukemia: A Review About the Future.
Novel and emerging drugs for chronic lymphocytic leukemia.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma.
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma.
Searching for evidence of disease and malignant cell contamination in ovarian tissue stored from hematologic cancer patients.
Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway.
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Targeting phosphatidylinositol 3 kinase-? and -? for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
The oral spleen tyrosine kinase inhibitor fostamatinib attenuates inflammation and atherogenesis in low-density lipoprotein receptor-deficient mice.
The SRC family kinase LYN redirects B cell receptor signaling in human SLP65-deficient B cell lymphoma cells.
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.
Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials.
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma.
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Lymphoma, B-Cell, Marginal Zone
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Lymphoma, Follicular
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
c-yes and bcl-2 genes located on 18q21.3 in a follicular lymphoma cell line carrying a t(14;18) chromosomal translocation.
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Follicular lymphoma-associated BTK mutations are inactivating resulting in augmented AKT activation.
Ibrutinib: first global approval.
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma.
Lymphoma, Large B-Cell, Diffuse
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency.
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
EGR1 Addiction in Diffuse Large B-cell Lymphoma.
Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant Janus kinase 2 activation.
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.
Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Ibrutinib: first global approval.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Responses to the Selective Bruton's Tyrosine Kinase (BTK) Inhibitor Tirabrutinib (ONO/GS-4059) in Diffuse Large B-cell Lymphoma Cell Lines.
Spotlight on Ibrutinib in PCNSL: Adding Another Feather to Its Cap.
STAT3 Expression and Activity are Up-Regulated in Diffuse Large B Cell Lymphoma of Dogs.
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases.
Targeting phosphatidylinositol 3 kinase-? and -? for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
Lymphoma, Large-Cell, Anaplastic
Hyperphosphorylation of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Lymphoma, Mantle-Cell
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma.
A Phase III study of zanubrutinib plus rituximab versus bendamustine plus rituximab in transplant-ineligible, untreated mantle cell lymphoma.
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial.
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma.
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Brexucabtagene autoleucel for the treatment of relapsed/refractory mantle cell lymphoma.
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis.
CAR T Cells for Mantle Cell Lymphoma: Is it Time to Reshuffle the Deck?
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Combinatorial drug screening identifies synergistic co-targeting of Bruton's tyrosine kinase and the proteasome in mantle cell lymphoma.
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib.
Current Role and Emerging Evidence for Bruton Tyrosine Kinase Inhibitors in the Treatment of Mantle Cell Lymphoma.
Cutting Edge: ROR1/CD19 Receptor Complex Promotes Growth of Mantle Cell Lymphoma Cells Independently of the B Cell Receptor-BTK Signaling Pathway.
Design and synthesis of novel substituted benzyl pyrrolopyrimidine derivatives as selective BTK inhibitors for treating mantle cell lymphoma.
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma.
Effects of ibrutinib on proliferation and histamine release in canine neoplastic mast cells.
Efficacy and Safety of Ibrutinib in Indian Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma: Cases from a Named Patient Program.
Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy.
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.
FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma.
Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment.
High ZAP-70 expression correlates with worse clinical outcome in mantle cell lymphoma.
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Ibrutinib for the treatment of mantle cell lymphoma.
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide.
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report.
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Ibrutinib: first global approval.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.
Is the open mouth mightier than the needle?
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Metabolic Detection of Bruton's Tyrosine Kinase Inhibition in Mantle Cell Lymphoma Cells.
Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma.
miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf-?b signaling pathway in mantle cell lymphoma.
New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?
NF-?B signaling and its relevance to the treatment of mantle cell lymphoma.
Novel Bruton tyrosine kinase inhibitor acalabrutinib quantification by validated LC-MS/MS method: An application to pharmacokinetic study in Sprague Dawley rats.
p110? inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma.
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma.
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Profound Sinoatrial Arrest Associated with Ibrutinib.
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Simple determination of plasma ibrutinib concentration using high-performance liquid chromatography.
Stable isotope-labelled intravenous microdose for absolute bioavailability and effect of grapefruit juice on ibrutinib in healthy adults.
Sudden ventricular fibrillation and death during ibrutinib therapy-A case report.
Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Targeting protein kinase C in mantle cell lymphoma.
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma.
Transcriptional programming drives Ibrutinib-resistance evolution in mantle cell lymphoma.
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Use of acalabrutinib in patients with mantle cell lymphoma.
What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?
Zanubrutinib-induced liver injury: a case report and literature review.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
[New European Approvals: Brexucabtagene autoleucel for refractory mantle cell lymphoma after Bruton tyrosine kinase (BTK) inhibitor].
Lymphoma, Non-Hodgkin
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
B-cell receptor pathway modulators in NHL.
Bruton's tyrosine kinase (Btk) is a useful marker for Hodgkin and B cell non-Hodgkin lymphoma.
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Decreased expression of TGF-beta type 2 receptor in primary B-cell lymphomas of the stomach.
Discovery of a highly potent and selective Bruton's tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma.
Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
Modeling pharmacological inhibition of mast cell degranulation as a therapy for insulinoma.
New lanthanum (III) complex--synthesis, characterization, and cytotoxic activity.
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Targeting of BMI-1 expression by the novel small molecule PTC596 in mantle cell lymphoma.
Lymphoma, Primary Effusion
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Lymphoma, T-Cell
A lymphocyte-specific protein-tyrosine kinase gene is rearranged and overexpressed in the murine T cell lymphoma LSTRA.
Characteristics of TCR?, ZAP-70, and Fc?RI? Gene Expression in Patients with T- and NK/T-Cell Lymphoma.
Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase.
FER and FES tyrosine kinase fusions in follicular T-cell lymphoma.
GCN5 regulates the activation of PI3K/Akt survival pathway in B cells exposed to oxidative stress via controlling gene expressions of Syk and Btk.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells.
Neoplastic transformation induced by an activated lymphocyte-specific protein tyrosine kinase (pp56lck).
RIBP, a novel Rlk/Txk- and itk-binding adaptor protein that regulates T cell activation.
Son of sevenless binds to the SH3 domain of src-type tyrosine kinase.
TEC family kinases in health and disease - loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.
Tumor promoters cause changes in the state of phosphorylation and apparent molecular weight of a tyrosine protein kinase in T lymphocytes.
Lymphoma, T-Cell, Cutaneous
Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl.
Lymphoma, T-Cell, Peripheral
Disturbed expression of the T-cell receptor/CD3 complex and associated signaling molecules in CD30+ T-cell lymphoproliferations.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Lymphomatoid Granulomatosis
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
Lymphopenia
Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia.
Dietary zinc deficiency and expression of T lymphocyte signal transduction proteins.
Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene.
Requirement for Abl kinases in T cell receptor signaling.
Studies of patients' thymi aid in the discovery and characterization of immunodeficiency in humans.
The c-Abl tyrosine kinase is regulated downstream of the B cell antigen receptor and interacts with CD19.
The expression of the non-receptor tyrosine kinases Arg and c-abl is differently modulated in B lymphoid cells at different stages of differentiation.
Lymphoproliferative Disorders
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Association of cytogenetic abnormalities with detection of BCR-ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL).
CRL3IBTK Regulates the Tumor Suppressor Pdcd4 through Ubiquitylation Coupled to Proteasomal Degradation.
Cutaneous Eruptions from Ibrutinib Resembling EGFR Inhibitor-Induced Dermatologic Adverse Events.
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia.
Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.
Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
Ibrutinib, a Bruton's tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil activation test reactivity.
Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies.
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL).
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
Increased Susceptibility for Atrial and Ventricular Cardiac Arrhythmias in Mice Treated With a Single High Dose of Ibrutinib.
Infectious Complications of Tyrosine Kinase Inhibitors in Hematological Malignancies.
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders.
Management of Ibrutinib Toxicities: a Practical Guide.
Novel immunodeficiency data servers.
Oncogene expression in T-cell lymphoproliferative disorders.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Macular Degeneration
Shared genetic variants for polypoidal choroidal vasculopathy and typical neovascular age-related macular degeneration in East Asians.
Macular Edema
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Malaria
CD36 and Fyn Kinase Mediate Malaria-Induced Lung Endothelial Barrier Dysfunction in Mice Infected with Plasmodium berghei.
Malnutrition
Dietary zinc deficiency and expression of T lymphocyte signal transduction proteins.
[Role of the cytokine-3 signaling suppressor protein (SOCS 3) in growth hormone resistance induced by malnutrition]
Malocclusion
Potential interactions among single nucleotide polymorphisms in bone- and cartilage-related genes in skeletal malocclusions.
Marfan Syndrome
A single heterozygous nucleotide substitution displays two different altered mechanisms in the FBN1 gene of five Italian marfan patients.
Case-matched Comparison of Cardiovascular Outcome in Loeys-Dietz Syndrome versus Marfan Syndrome.
Comprehensive genetic analysis of relevant four genes in 49 patients with Marfan syndrome or Marfan-related phenotypes.
Dural ectasia in individuals with Marfan-like features but exclusion of mutations in the genes FBN1, TGFBR1 and TGFBR2.
FBN1, TGFBR1, and the Marfan-craniosynostosis/mental retardation disorders revisited.
Fibroblast autofluorescence in connective tissue disorders: a future tool for clinical and differential diagnosis?
Gene panel sequencing in heritable thoracic aortic disorders and related entities ¿ results of comprehensive testing in a cohort of 264 patients.
Genetics of Thoracic Aortic Aneurysms.
Identification of 23 TGFBR2 and 6 TGFBR1 gene mutations and genotype-phenotype investigations in 457 patients with Marfan syndrome type I and II, Loeys-Dietz syndrome and related disorders.
Marfan syndrome type II: there is more to Marfan syndrome than fibrillin 1.
Marfan syndrome: clinical diagnosis and management.
May TGFBR1 act also as low penetrance allele in Marfan syndrome?
Molecular analysis for diagnosis of Marfan syndrome and Marfan-associated disorders.
Mutation of ACTA2 gene as an important cause of familial and nonfamilial nonsyndromatic thoracic aortic aneurysm and/or dissection (TAAD).
Role of TGFBR1 and TGFBR2 genetic variants in Marfan syndrome.
SMAD4 mutation segregating in a family with juvenile polyposis, aortopathy, and mitral valve dysfunction.
TGFBR1 and TGFBR2 mutations in patients with features of Marfan syndrome and Loeys-Dietz syndrome.
Three-generation family with novel contiguous gene deletion on chromosome 2p22 associated with thoracic aortic aneurysm syndrome.
WES/WGS Reporting of Mutations from Cardiovascular "Actionable" Genes in Clinical Practice: A Key Role for UMD Knowledgebases in the era of Big Databases.
[Interactions between fibrillin-1 and tgf-beta: consequences and human pathology]
Massive Hepatic Necrosis
The vagus nerve attenuates fulminant hepatitis by activating the Src kinase in Kuppfer cells.
Mastitis
Three Novel Players: PTK2B, SYK, and TNFRSF21 Were Identified to Be Involved in the Regulation of Bovine Mastitis Susceptibility via GWAS and Post-transcriptional Analysis.
Mastocytosis, Systemic
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Measles
The measles virus phosphoprotein interacts with the linker domain of STAT1.
Medulloblastoma
Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.
Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
Downregulation of microRNA-431 by human interferon-? inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6.
EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion.
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis.
New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Megalencephaly
A new case with 10q23 interstitial deletion encompassing both PTEN and BMPR1A narrows the genetic region deleted in juvenile polyposis syndrome.
Melanoma
A Pipeline for Drug Target Identification and Validation.
A Targeted Quantitative Proteomic Method Revealed a Substantial Reprogramming of Kinome during Melanoma Metastasis.
A therapeutic trial of human melanomas with combined small interfering RNAs targeting adaptor molecules p130Cas and paxillin activated under expression of ganglioside GD3.
Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
Actin-binding protein, espin: a novel metastatic regulator for melanoma.
Activation of p21-activated kinase 1 is required for lysophosphatidic acid-induced focal adhesion kinase phosphorylation and cell motility in human melanoma A2058 cells.
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.
Amplification of N-myc oncogene in human melanoma cells.
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Anoikis induction and metastasis suppression by a new integrin ?v?3 inhibitor in human melanoma cell line M21.
Apigenin Attenuates Melanoma Cell Migration by Inducing Anoikis through Integrin and Focal Adhesion Kinase Inhibition.
Approach to the Triple Negative Breast Cancer in New Drugs Area.
Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
Barium promotes anchorage-independent growth and invasion of human HaCaT keratinocytes via activation of c-SRC kinase.
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
c-Abl Kinase Is a Regulator of ?v?3 Integrin Mediated Melanoma A375 Cell Migration.
CD147-targeting siRNA inhibits cell-matrix adhesion of human malignant melanoma cells by phosphorylating focal adhesion kinase.
Cell Hierarchy, Metabolic Flexibity and Systems Approaches to Cancer Treatment.
Changes in the levels of integrin and focal adhesion kinase (FAK) in human melanoma cells following 532 nm laser treatment.
Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Circ_0002770, acting as a competitive endogenous RNA, promotes proliferation and invasion by targeting miR-331-3p in melanoma.
Collisionally induced fragmentation of [M-H](-) species of resveratrol and piceatannol investigated by deuterium labelling and accurate mass measurements.
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.
Comparison of cellular protooncogene activation and transformation-related activity of human melanocytes and metastatic melanoma.
Conservation of structure and expression of the c-yes and fyn genes in lower vertebrates.
Cooperation between thrombospondin-1 type 1 repeat peptides and alpha(v)beta(3) integrin ligands to promote melanoma cell spreading and focal adhesion kinase phosphorylation.
CXCR7 promotes melanoma tumorigenesis via Src kinase signaling.
Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.
Development of a Bifunctional Andrographolide-Based Chemical Probe for Pharmacological Study.
Differential loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions.
Doxycycline inhibits leukemic cell migration via inhibition of matrix metalloproteinases and phosphorylation of focal adhesion kinase.
Doxycycline inhibits the adhesion and migration of melanoma cells by inhibiting the expression and phosphorylation of focal adhesion kinase (FAK).
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Dual Inhibition of MAPK and JAK2/STAT3 Pathways Is Critical for the Treatment of BRAF Mutant Melanoma.
Echistatin induces decrease of pp125FAK phosphorylation, disassembly of actin cytoskeleton and focal adhesions, and detachment of fibronectin-adherent melanoma cells.
Echistatin inhibits pp125FAK autophosphorylation, paxillin phosphorylation and pp125FAK-paxillin interaction in fibronectin-adherent melanoma cells.
Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.
Effect of piceatannol against malignant melanoma in vivo and in vitro.
Effect of SOCS1 silencing on proliferation and apoptosis of melanoma cells: An in vivo and in vitro study.
Effect of synthetic sialyl 2-->1 sphingosine and other glycosylsphingosines on the structure and function of the "glycosphingolipid signaling domain (GSD)" in mouse melanoma B16 cells.
Elevated c-Src and c-Yes expression in malignant skin cancers.
Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma.
Endothelin-B Receptor Blockade Inhibits Molecular Effectors of Melanoma Cell Progression.
EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
EphB4 Promotes Site-Specific Metastatic Tumor Cell Dissemination by Interacting with Endothelial Cell-Expressed EphrinB2.
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro.
Exploring major signaling cascades in melanomagenesis: a rationale route for targetted skin cancer therapy.
Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
FK506 positively regulates the migratory potential of melanocyte-derived cells by enhancing syndecan-2 expression.
Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4.
Focal adhesion kinase (p125FAK) expression correlates with motility of human melanoma cell lines.
Focal adhesion kinase as an immunotherapeutic target.
Focal adhesion kinase as well as p130Cas and paxillin is crucially involved in the enhanced malignant properties under expression of ganglioside GD3 in melanoma cells.
Focal adhesion kinase promotes the aggressive melanoma phenotype.
Focal adhesion kinase signaling and the aggressive melanoma phenotype.
Focal adhesion kinase-dependent apoptosis of melanoma induced by tyrosine and phenylalanine deficiency.
Functional activation of SRC family kinase yes is essential for the enhanced malignant properties of human melanoma cells expressing ganglioside GD3.
Geraniin-mediated apoptosis by cleavage of focal adhesion kinase through up-regulation of Fas ligand expression in human melanoma cells.
Glucose-6-phosphate dehydrogenase and NADPH oxidase 4 control STAT3 activity in melanoma cells through a pathway involving reactive oxygen species, c-SRC and SHP2.
GNG2 inhibits invasion of human malignant melanoma cells with decreased FAK activity.
Heparin plays a key regulatory role via a p53/FAK-dependent signaling in melanoma cell adhesion and migration.
Identification of prognostic mRNAs in metastatic cutaneous melanoma.
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene.
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.
Inhibition of mTORC1 by SU6656, the Selective Src Kinase Inhibitor, Is Not Accompanied by Activation of Akt/PKB Signalling in Melanoma Cells.
Inhibition of tumor growth and angiogenesis by soluble EphB4.
Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Insulin receptor internalization defect in an insulin-resistant mouse melanoma cell line.
Interaction of Xiphophorus and murine Fyn with Focal Adhesion Kinase.
Irradiated riboflavin diminishes the aggressiveness of melanoma in vitro and in vivo.
Irradiation affects cellular properties and Eph receptor expression in human melanoma cells.
Isolation of a cDNA encoding a tyrosine kinase expressed in murine skin.
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells.
Knockdown of STAT3 targets a subpopulation of invasive melanoma stem-like cells.
Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Lipid rafts couple store-operated Ca2+ entry to constitutive activation of PKB/Akt in a Ca2+/calmodulin-, Src- and PP2A-mediated pathway and promote melanoma tumor growth.
Loss of Ambra1 promotes melanoma growth and invasion.
Lyn Kinase Promotes the Proliferation of Malignant Melanoma Cells through Inhibition of Apoptosis and Autophagy via the PI3K/Akt Signaling Pathway.
Mapping of tyrosine kinase gene family members in a Xiphophorus melanoma model.
mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src.
mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB.
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Melanoma cell spreading on fibronectin induced by 12(S)-HETE involves both protein kinase C- and protein tyrosine kinase-dependent focal adhesion formation and tyrosine phosphorylation of focal adhesion kinase (pp125FAK).
Metastatic Melanoma Cells Evade Immune Detection by Silencing STAT1.
Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis.
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
Nestin depletion induces melanoma matrix metalloproteinases and invasion.
New Oral Anti-Cancer Drugs and Medication Safety.
Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.
Osteonectin downregulates E-cadherin, induces Osteopontin and Focal adhesion kinase activity stimulating an invasive melanoma phenotype.
Overcoming Resistance to Targeted Therapies in Cancer.
Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.
Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing.
Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Plasminogen activator inhibitor-1 regulates infiltration of macrophages into melanoma via phosphorylation of FAK-Tyr?²?.
Polyethylenimine-complexed Plasmid Particles Targeting Focal Adhesion Kinase Function as Melanoma Tumor Therapeutics.
pp125FAK in human melanocytes and melanoma: expression and phosphorylation.
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Predictive biomarkers for dasatinib treatment in melanoma.
Reconstitution of membranes simulating "glycosignaling domain" and their susceptibility to lyso-GM3.
Role of zyxin in differential cell spreading and proliferation of melanoma cells and melanocytes.
Roles of activated Src and Stat3 signaling in melanoma tumor cell growth.
Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.
Selective Killing of Melanoma Cells With Non-Thermal Atmospheric Pressure Plasma and p-FAK Antibody Conjugated Gold Nanoparticles.
SERINE-910 Phosphorylated Focal Adhesion Kinase Expression Predicts Better Overall and Disease-free Survival in Melanoma.
Silencing of microRNA-27a facilitates autophagy and apoptosis of melanoma cells through the activation of the SYK-dependent mTOR signaling pathway.
Soft matrices downregulate FAK activity to promote growth of tumor-repopulating cells.
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma.
Src Family Tyrosine Kinase Signaling Regulates FilGAP through Association with RBM10.
Src kinase induces tumor formation in the c-SRC C57BL/6 mouse.
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells.
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand.
The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.
The focal adhesion kinase (P125FAK) is constitutively active in human malignant melanoma.
The oncogenic epidermal growth factor receptor variant xiphophorus melanoma receptor kinase induces motility in melanocytes by modulation of focal adhesions.
Triptolide-Mediated Apoptosis by Suppression of Focal Adhesion Kinase through Extrinsic and Intrinsic Pathways in Human Melanoma Cells.
VE-cadherin promotes vasculogenic mimicry by modulating kaiso-dependent gene expression.
[Construction of stable focal adhesion kinase knockdown cell line and preliminary study of its properties].
Melanoma, Experimental
Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein-tyrosine kinase activity.
EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
Inhibiting focal adhesion kinase (FAK) blocks IL-4 induced VCAM-1 expression and eosinophil recruitment in vitro and in vivo.
PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
Memory Disorders
Identification of novel inhibitor targeting Fyn kinase using molecular docking analysis.
Increased Src Family Kinase Activity Disrupts Excitatory Synaptic Transmission and Impairs Remote Fear Memory in Forebrain Shp2-Deficient Mice.
Inhibition of Src family kinases improves cognitive function after intraventricular hemorrhage or intraventricular thrombin.
Voluntary exercise rescues sevoflurane-induced memory impairment in aged male mice.
Meningioma
Advances in multidisciplinary therapy for meningiomas.
Curcumin Inhibits HGF-Induced EMT by Regulating c-MET-Dependent PI3K/Akt/mTOR Signaling Pathways in Meningioma.
Meningitis
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Meningoencephalitis
Expression of platelet-derived growth factor receptor-?/ß, vascular endothelial growth factor receptor-2, c-Abl, and c-Kit in canine granulomatous meningoencephalitis and necrotizing encephalitis.
Fatal Progressive Meningoencephalitis Diagnosed in Two Members of a Family With X-Linked Agammaglobulinemia.
Mesenteric Ischemia
The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
Mesothelioma
Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.
EphB4 as a therapeutic target in mesothelioma.
EphB4: A promising target for upper aerodigestive malignancies.
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA.
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Up-regulation of EphB4 in mesothelioma and its biological significance.
Mesothelioma, Malignant
Correction: Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.
E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in Merlin-negative malignant mesothelioma cells.
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Human malignant mesothelioma cell growth: activation of janus kinase 2 and signal transducer and activator of transcription 1alpha for inhibition by interferon-gamma.
Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.
Metabolic Diseases
PTP1B: A simple enzyme for a complex world.
Metabolic Syndrome
Role of Janus Kinase 3 in Predisposition to Obesity-associated Metabolic Syndrome.
Metrorrhagia
Expression of c-kit gene products in known cellular targets of W mutations in normal and W mutant mice--evidence for an impaired c-kit kinase in mutant mice.
The dominant W42 spotting phenotype results from a missense mutation in the c-kit receptor kinase.
Microcephaly
Duplication of 10q22.3-q23.3 encompassing BMPR1A and NGR3 associated with congenital heart disease, microcephaly, and mild intellectual disability.
Mitral Valve Prolapse
Screening of TGFBR1, TGFBR2, and FLNA in familial mitral valve prolapse.
Molluscum Contagiosum
A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
Case of disseminated molluscum contagiosum caused by ruxolitinib, a Janus kinase 1 and 2 inhibitor.
Mouth Neoplasms
Augmentation of T-cell immune responses and signal transduction proteins in oral cancer patients: potential for IL-2-mediated immunotherapy.
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Expression of Fyn kinase modulates EMT in oral cancer cells.
Focal adhesion kinase expression in oral cancers.
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation.
Insights From Studies With Oral Cleft Genes Suggest Associations between WNT-pathway Genes and Risk of Oral Cancer.
Polymorphisms associated with oral clefts as potential susceptibility markers for oral and breast cancer.
Prognostic implication of the loss of TGFBR2 expression in oral carcinoma.
Prognostic value of transforming growth factor beta receptor 1 polymorphisms in patients with oral cancer.
Movement Disorders
Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations.
Nilotinib Fails to Prevent Synucleinopathy and Cell Loss in a Mouse Model of Multiple System Atrophy.
Mucocutaneous Lymph Node Syndrome
Non-receptor type, proline-rich protein tyrosine kinase 2 (Pyk2) is a possible therapeutic target for Kawasaki disease.
Multiple Endocrine Neoplasia
A complex endocrine conundrum.
Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Multiple Endocrine Neoplasia Type 2a
Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Multiple Myeloma
A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity.
A novel dual inhibitor of microtubule and Bruton's tyrosine kinase inhibits survival of multiple myeloma and osteoclastogenesis.
A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases.
A phase 2 study of ibrutinib in combination with bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma.
A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with agents targeting the BH3-binding pocket of Bcl-2.
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Activation of c-Abl Kinase Potentiates the Anti-myeloma Drug Lenalidomide by Promoting DDA1 Protein Recruitment to the CRL4 Ubiquitin Ligase.
An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature.
Antitumorigenic effect of plumbagin by induction of SH2-containing protein tyrosine phosphatase 1 in human gastric cancer cells.
As4S4 Exhibits Good Killing Effect on Multiple Myeloma Cells Via Repressing SOCS1 Methylation-Mediated JAK2/STAT3 Signaling Pathway.
Asiatic acid, a triterpene, inhibits cell proliferation through regulating the expression of focal adhesion kinase in multiple myeloma cells.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma.
Bruton's Tyrosine Kinase Targeting in Multiple Myeloma.
Bruton's tyrosine kinase: potential target in human multiple myeloma.
Circular RNA Protein Tyrosine Kinase 2 Promotes Cell Proliferation, Migration and Suppresses Apoptosis via Activating MicroRNA-638 Mediated MEK/ERK, WNT/?-Catenin Signaling Pathways in Multiple Myeloma.
Covalent Cysteine Targeting of Bruton's Tyrosine Kinase (BTK) Family by Withaferin-A Reduces Survival of Glucocorticoid-Resistant Multiple Myeloma MM1 Cells.
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
Dexamethasone-induced apoptotic mechanisms in myeloma cells investigated by analysis of mutant glucocorticoid receptors.
Expression levels of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) and focal adhesion kinase in patients with multiple myeloma and their relationship to clinical stage and extramedullary infiltration.
From CLL to Multiple Myeloma - Spleen Tyrosine Kinase (SYK) influences multiple myeloma cell survival and migration.
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Ibrutinib is not an effective drug in primografts of TCF3-PBX1.
Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-?B and STAT3.
Ibrutinib: first global approval.
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells.
Janus kinase 2 (JAK2) inhibitors in the treatment of multiple myeloma: modulating the myeloma immune microenvironment.
Multiple Myeloma. Advances in disease biology: therapeutic implications.
Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells.
P190 BCR/ABL transcript in a case of Philadelphia-positive multiple myeloma.
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
Signalling molecules and cytokine production in T cells of multiple myeloma-increased abnormalities with advancing stage.
SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma.
STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivo.
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway.
The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
The novel ?2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.
The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia.
The role of phosphatase and tensin homolog deleted on chromosome 10 and focal adhesion kinase in aggressive multiple myeloma.
Therapeutic effect and mechanism of ibrutinib combined with dexamethasone on multiple myeloma.
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
Multiple Pulmonary Nodules
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
Multiple Sclerosis
Balancing Potential Benefits and Risks of Bruton Tyrosine Kinase Inhibitor Therapies in Multiple Sclerosis During the COVID-19 Pandemic.
Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis.
Bruton's tyrosine kinase inhibitors: a promising emerging treatment option for multiple sclerosis.
CNS demyelination during tofacitinib therapy: First report.
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants.
Expression of Bone Morphogenetic Proteins in Multiple Sclerosis Lesions.
Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures.
Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis.
Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation.
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility.
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Multiple System Atrophy
A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor.
Mumps
STAT3 ubiquitylation and degradation by mumps virus suppress cytokine and oncogene signaling.
Murine Acquired Immunodeficiency Syndrome
Altered brain fyn kinase in a murine acquired immunodeficiency syndrome.
Analysis of antigen receptor signaling in B cells from mice with a retrovirus-induced acquired immunodeficiency syndrome.
Reciprocal regulation of protein tyrosine kinases p56lck and p59fyn, and altered tyrosine phosphorylation in murine AIDS.
The murine AIDS virus Gag precursor protein binds to the SH3 domain of c-Abl.
The xid mutation plays an important role in delayed development of murine acquired immunodeficiency syndrome.
Muscle Cramp
Cathelicidin Modulates Vascular Smooth Muscle Cell Phenotypic Switching through ROS/IL-6 Pathway.
Muscle Hypotonia
Progressive aortic root and pulmonary artery aneurysms in a neonate with Loeys-Dietz syndrome type 1B.
Muscle Weakness
Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Janus Kinase Inhibition Prevents Cancer- and Myocardial Infarction-Mediated Diaphragm Muscle Weakness in Mice.
Muscular Atrophy
Inhibition of IL-6/JAK/STAT3 pathway rescues denervation-induced skeletal muscle atrophy.
Inhibition of Janus kinase signaling during controlled mechanical ventilation prevents ventilation-induced diaphragm dysfunction.
Muscular Atrophy, Spinal
Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy.
Muscular Dystrophies
[Personalized medicine based on genomic information: the present status in terms of clinical application]
Muscular Dystrophy, Duchenne
TRPC1 binds to caveolin-3 and is regulated by Src kinase - role in Duchenne muscular dystrophy.
Myasthenia Gravis
Exogenous IL-9 Ameliorates Experimental Autoimmune Myasthenia Gravis Symptoms in Rats.
Mycobacterium Infections
Mycobacterium Intracellulare Infection Associated with TYK2 Deficiency: A Case Report and Review of the Literature.
Mycoses
Aberrant type 1 immunity drives susceptibility to mucosal fungal infections.
Beta-glucan triggers spondyloarthropathy and Crohn's-like ileitis in SKG mice.
Dectin-1 is required for human dendritic cells to initiate immune response to Candida albicans through Syk activation.
Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection.
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.
Neurologic Complications in Patients With Cancer.
Recombinant human granulocyte macrophage-colony stimulating factor expressed in yeast (sargramostim): A potential ally to combat serious infections.
Risk of infection associated with targeted therapies for solid organ and hematological malignancies.
Spleen Tyrosine Kinase Is a Critical Regulator of Neutrophil Responses to Candida Species.
Mycosis Fungoides
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Myelodysplastic Syndromes
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Aberrant methylation of GTPase regulator associated with the focal adhesion kinase (GRAF) promoter is an adverse prognostic factor in myelodysplastic syndrome.
Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia.
Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
Activity of Fgr protein-tyrosine kinase is reduced in neutrophils of patients with myelodysplastic syndromes and chronic myelogenous leukemia.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Early detection of relapse and evaluation of treatment for mixed chimerism using fluorescence in situ hybridization following allogeneic hematopoietic cell transplant for hematological malignancies.
Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair.
Heat Shock Protein 90 is overexpressed in high-risk myelodysplastic syndromes and associated with higher expression and activation of Focal Adhesion Kinase.
Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Impaired Expression of Focal Adhesion Kinase in Mesenchymal Stromal Cells from Low-Risk Myelodysplastic Syndrome Patients.
Microsatellite instability is an early genetic event in myelodysplastic syndrome but is infrequent and not associated with TGF-beta receptor type II gene mutation.
Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
Mutation in TET2 in myeloid cancers.
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.
Phase II pilot study of oral dasatinib in patients with higher-risk myelodysplastic syndrome (MDS) who failed conventional therapy.
Progression from myelodysplastic syndrome to acute lymphoblastic leukaemia with Philadelphia chromosome and p190 BCR-ABL transcript.
PTK2 and PTPN11 expression in myelodysplastic syndromes.
Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications.
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
The implication of 'unknown significance' variants in next-generation sequencing in diagnosis and donor selection for allogenic haematopoietic stem cell transplantation. Report of a case of myelodysplastic syndrome with a polymorphism in the tyrosine kinase 2 (TYK2) gene.
[Granulocyte abnormal chromatin clumping syndrome: report of a new case and review of the literature]
Myeloproliferative Disorders
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
A tetra-primer polymerase chain reaction approach for the detection of JAK2 V617F mutation.
A UHPLC-MS/MS bioanalytical assay for the determination of BMS-911543, a JAK2 inhibitor, in human plasma.
Absence of FTL3 mutations in patients with JAK2V617F mutation negative essential thrombocythemia.
Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.
Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
Allosteric inhibitors of Bcr-abl-dependent cell proliferation.
Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders.
Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera.
Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.
Association of XRCC1 gene polymorphisms with chronic myeloid leukemia in the population of Andhra Pradesh, India.
AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
B cell lymphoproliferation and organ-directed self-recognition to explain autoimmunity: Back to the past.
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
Bcr-Abl has a greater intrinsic capacity than v-Abl to induce the neoplastic expansion of myeloid cells.
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia.
Bcr-Abl-mediated redox regulation of the PI3K/AKT pathway.
BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair.
Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.
Chronic Myeloid Leukemia in a Patient with Hepatitis B Virus Infection: A Case Report.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Clinical implications of JAK2 mutations in myeloproliferative disorders.
Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia.
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders.
Construction of Quantitative Structure Activity Relationship (QSAR) Models to Predict Potency of Structurally Diversed Janus Kinase 2 Inhibitors.
Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia.
Current therapy of chronic myelogenous leukemia.
Deletion of exon b3 of the BCR gene in CML: easy breakpoint mapping by a two-round PCR.
Description of a novel Janus kinase 3 P132A mutation in acute megakaryoblastic leukemia and demonstration of previously reported Janus kinase 3 mutations in normal subjects.
Detection of acquired Janus kinase 2 V617F mutation in myeloproliferative disorders by fluorescence melting curve analysis.
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Detection of Janus Kinase 2 gene single point mutation in real samples with electrochemical DNA biosensor.
Detection of the JAK2V617F mutation in patients with slightly elevated platelets or hemoglobin without a secondary cause.
Detection of the single hotspot mutation in the JH2 pseudokinase domain of Janus kinase 2 in bone marrow trephine biopsies derived from chronic myeloproliferative disorders.
Development of a Predictive Pharmacophore Model and a 3D-QSAR Study for an in silico Screening of New Potent Bcr-Abl Kinase Inhibitors.
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Diagnostic usefulness of the Janus kinase 2 mutation in non BCR/ABL myeloproliferative disorders.
Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.
Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.
Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
Dissecting the role of aberrant DNA methylation in human leukaemia.
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
Effective Downregulation of BCR-ABL Tumorigenicity by RNA Targeted CRISPR-Cas13a.
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation.
Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders.
Erosion of the chronic myeloid leukaemia stem cell pool by PPAR? agonists.
Essential thrombocythemia: scientific advances and current practice.
Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Exosome-mediated crosstalk between chronic myelogenous leukemia cells and human bone marrow stromal cells triggers an Interleukin 8-dependent survival of leukemia cells.
Expression analysis of Akirin-2, NF?B-p65 and ?-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Follow-up of childhood chronic myelogenous leukemia with monitoring the BCR-ABL fusion gene expression in peripheral blood.
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes.
Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia.
Hematopoietic stem cells in chronic myeloid leukemia.
Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Imatinib effect on growth and signal transduction in polycythemia vera.
Imatinib mesylate--gold standards and silver linings.
Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1.
In Search of CML Stem Cells' Deadly Weakness.
Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders.
Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Inhibition of protein tyrosine phosphatase 1B (PTP1B) mediates ubiquitination and degradation of Bcr-Abl.
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
Isolated blast crisis relapse in the central nervous system of a patient treating for a chronic myelogenous leukemia.
JAK the trigger.
JAK1/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression.
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
JAK2 in myeloproliferative disorders is not just another kinase.
JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials.
JAK2 V617F "Indeterminate" Results by MutaScreen Can Be Easily Resolved Using MutaQuant Kits.
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders.
Janus kinase 2 inhibitors in myeloproliferative disorders.
Janus kinase 2 mutations in cases with BCR-ABL-negative chronic myeloproliferative disorders from Turkey.
Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: Clinical implications.
Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.
Kinases as drug discovery targets in hematologic malignancies.
L-amino acid oxidase isolated from Bothrops pirajai induces apoptosis in BCR-ABL-positive cells and potentiates imatinib mesylate effect.
Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.
Leukemia Stem Cells in Chronic Myeloid Leukemia.
Leukemia stem cells: the root of chronic myeloid leukemia.
Low frequency of V617F mutation in JAK2 gene in Indian patients with hepatic venous outflow obstruction and extrahepatic portal venous obstruction.
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.
miR-155 effectively induces apoptosis in K562 Philadelphia positive cell line through upregulation of p27kip1.
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Mutation in TET2 in myeloid cancers.
Myeloproliferative disorders with coexisting BCR-ABL translocation and JAK2(V617F) mutation.
New insights into the pathogenesis and drug treatment of myelofibrosis.
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
NF?B pathway and microRNA-9 and -21 are involved in sensitivity to the pterocarpanquinone LQB-118 in different CML cell lines.
Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia.
p19INK4d inhibits proliferation and enhances imatinib efficacy through BCR-ABL signaling pathway in chronic myeloid leukemia.
p27 deregulation by Skp2 overexpression induced by the JAK2V617 mutation.
Pathogenesis of myelofibrosis with myeloid metaplasia.
Pharmacophore filtering and 3D-QSAR in the discovery of new JAK2 inhibitors.
Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
PPAR-gamma in overcoming kinase resistance in chronic myeloid leukemia.
Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment.
Prevalence and clinical outcomes of the 46/1 haplotype, Janus kinase 2 mutations, and ten-eleven translocation 2 mutations in Budd-Chiari syndrome and their impact on thrombotic complications post liver transplantation.
Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.
Reciprocal translocation between chromosomes 8 and 9 in atypical chronic myeloid leukaemia.
Recommendations for the management of adult chronic myeloid leukaemia in South Africa.
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment.
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
ROLES OF INTERFERON REGULATORY FACTORS IN CHRONIC MYELOID LEUKEMIA.
Routine fluorescence in situ hybridization analysis for detection of BCR-ABL rearrangement in myeloproliferative disorders.
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines.
Shooting the messenger: Targeting signal transduction pathways in leukemia and related disorders.
Simultaneous occurrence of the JAK2V617F mutation and BCR-ABL gene rearrangement in patients with chronic myeloproliferative disorders.
siRNA-cell-penetrating peptides complexes as a combinatorial therapy against chronic myeloid leukemia using BV173 cell line as model.
Sirtuin1 and Chronic Myeloid Leukemia: a Comprehensive Glance at Drug Resistance.
SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling.
SOCS2: inhibitor of JAK2V617F-mediated signal transduction.
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Stem cell factor and chronic myeloid leukemia CD34+ cells.
Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells.
Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients.
Studies of some mechanisms of drug resistance in chronic myeloid leukemia (CML).
SWATH-MS based quantitative proteomics analysis reveals that curcumin alters the metabolic enzyme profile of CML cells by affecting the activity of miR-22/IPO7/HIF-1? axis.
Targeting chronic myeloid leukemia stem cells.
Targeting Survival Pathways in Chronic Myeloid Leukaemia Stem Cells.
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
The impact of JAK2 non-receptor tyrosine kinase mutation on the mobilization of hematopoietic stem cells into peripheral blood of patients with Philadelphia chromosome-negative myeloproliferative disorders.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patients.
The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders.
The NH(2)-terminal coiled-coil domain and tyrosine 177 play important roles in induction of a myeloproliferative disease in mice by Bcr-Abl.
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
The roles of DNA epigenetics and clinical significance in Chronic Myeloid Leukemia: a review.
The SH2 domain of bcr-Abl is not required to induce a murine myeloproliferative disease; however, SH2 signaling influences disease latency and phenotype.
The Src homology-2 protein Shb modulates focal adhesion kinase signaling in a BCR-ABL myeloproliferative disorder causing accelerated progression of disease.
Thrombopoietin in normal and neoplastic stem cell development.
Transcriptional targets of Drosophila JAK/STAT pathway signalling as effectors of haematopoietic tumour formation.
Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Trisomy 13 in a Philadelphia negative chromosome and BCR-ABL negative myeloproliferative disorder.
Tyrosine Kinase Inhibitors in Pulmonary Vascular Disease.
Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders.
Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
Unraveling survivin expression in chronic myeloid leukemia: Molecular interactions and clinical implications.
Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Vascular liver disorders (I): diagnosis, treatment and prognosis of Budd-Chiari syndrome.
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
[Chronic myeloid leukemia--resistance to imatinib mesylate (Glivec)--literature review and personal experience]
[Experimental advance of targeted medicines for chronic myeloid leukemia--review]
[JAK2(V617F) mutation in Korean patients with essential thrombocythemia]
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
[Molecular remission of chronic myeloid leukaemia in a patient with hepatitis and a second kidney transplant]
[Monitoring the chronic myeloid leukemia patients between 2008 and 2018; the experience of the Hematology and Bone Marrow Transplantation Unit Târgu-Mure?].
[RT-PCR use for the diagnostic of chronic myeloid leukaemia]
[Utility of the bone marrow biopsy in the diagnosis of essential thrombocytemia.]
Myocardial Infarction
c-Src Kinase Inhibition Reduces Arrhythmia Inducibility and Connexin43 Dysregulation After Myocardial Infarction.
Cardiac-Specific Deletion of SOCS-3 Prevents Development of Left Ventricular Remodeling After Acute Myocardial Infarction.
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Quercetin protects against experimentally-induced myocardial infarction in rats by an antioxidant potential and concomitant activation of signal transducer and activator of transcription 3.
Role of the JAK-STAT pathway in myocardial injury.
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
Tyrosine phosphorylation of eNOS regulates myocardial survival after an ischaemic insult: role of PYK2.
Update on the Pathophysiological Role of Intracellular Signaling Pathways in Atherosclerotic Plaques and Ischemic Myocardium.
Wnt11 Gene Therapy with Adeno-associated Virus 9 Improves Recovery from Myocardial Infarction by Modulating the Inflammatory Response.
Myocardial Ischemia
Characterization of novel lncRNAs in upper thoracic spinal cords of rats with myocardial ischemia-reperfusion injuries.
MiR-27 alleviates myocardial cell damage induced by hypoxia/reoxygenation via targeting TGFBR1 and inhibiting NF-?B pathway.
Role of STAT3 in ischemic preconditioning.
Statin rosuvastatin inhibits apoptosis of human coronary artery endothelial cells through upregulation of the JAK2/STAT3 signaling pathway.
Myocarditis
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis.
Induction of autoimmunity in the absence of CD28 costimulation.
lncRNA AK085865 Promotes Macrophage M2 Polarization in CVB3-Induced VM by Regulating ILF2-ILF3 Complex-Mediated miRNA-192 Biogenesis.
Role of the JAK-STAT pathway in myocardial injury.
The role of transgenic knockout models in defining the pathogenesis of viral heart disease.
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Wnt11 gene therapy with adeno-associated virus 9 improves the survival of mice with myocarditis induced by coxsackievirus B3 through the suppression of the inflammatory reaction.
[Tanshinone attenuates myocardial injury via activating JAK2/STAT1 pathway in a murine model of viral myocarditis].
Myopathies, Structural, Congenital
Differential Muscle Hypertrophy Is Associated with Satellite Cell Numbers and Akt Pathway Activation Following Activin Type IIB Receptor Inhibition in Mtm1 p.R69C Mice.
Myopia
Association of Myopia and Genetic Variants of TGFB2-AS1 and TGFBR1 in the TGF-? Signaling Pathway: A Longitudinal Study in Chinese School-Aged Children.
Myositis
Association of Dermatomyositis Sine Dermatitis With Anti-Nuclear Matrix Protein 2 Autoantibodies.
Myositis Ossificans
Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Myxoma
Myxoma virus induces extensive CD4 downregulation and dissociation of p56lck in infected rabbit CD4+ T lymphocytes.
Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2.
Treatment of an Alveolar Rhabdomyosarcoma Allograft with Recombinant Myxoma Virus and Oclacitinib.
Nasal Polyps
[The profile of expression of transforming growth factor beta1 and TGFbetaRI, TGFbetaRII and TGFbetaRIII genes in nasal polyps]
Nasopharyngeal Carcinoma
5-aza-CdR induces the demethylation of Syk promoter in nasopharyngeal carcinoma cell.
Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma.
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Parallel genome-wide RNAi screens identify lymphocyte-specific protein tyrosine kinase (LCK) as a targetable vulnerability of cell proliferation and chemoresistance in nasopharyngeal carcinoma.
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis.
Tyrosine kinase Etk/BMX protects nasopharyngeal carcinoma cells from apoptosis induced by radiation.
Nasopharyngitis
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Necrobiosis Lipoidica
Successful treatment of ulcerative necrobiosis lipoidica with janus kinase inhibitor.
Treatment of necrobiosis lipoidica with combination Janus kinase inhibition and intralesional corticosteroid.
Neoplasm Metastasis
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
?-elemene inhibits non-small cell lung cancer cell migration and invasion by inactivating the FAK-Src pathway.
A BALB/c 3T3-transformed cell line suitable for transfection assay of metastasis-inducing genes.
A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis.
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing.
A radiation-induced murine ovarian granulosa cell tumor line: introduction of v-ras gene potentiates a high metastatic ability.
Abnormal expression of FAK and paxillin correlates with oral cancer invasion and metastasis.
Activated Cdc42 kinase regulates Dock localization in male germ cells during Drosophila spermatogenesis.
Activation of abl family kinases in solid tumors.
Activation of Src by c-Met overexpression mediates metastatic properties of colorectal carcinoma cells.
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.
Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase.
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.
An ultrasensitive high-throughput electrochemiluminescence immunoassay for the Cdc42-associated protein tyrosine kinase ACK1.
Analysis of multiple physical parameters for mechanical phenotyping of living cells.
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Ascending the PEAK1 toward targeting TGF? during cancer progression: Recent advances and future perspectives.
Ascochlorin Suppresses MMP-2-Mediated Migration and Invasion by Targeting FAK and JAK-STAT Signaling Cascades.
Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study.
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
ATP7A delivers copper to the lysyl oxidase family of enzymes and promotes tumorigenesis and metastasis.
Backbone assignment of the tyrosine kinase Src catalytic domain in complex with imatinib.
Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells.
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer.
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.
Carbon Ion Therapy Inhibits Esophageal Squamous Cell Carcinoma Metastasis by Upregulating STAT3 Through the JAK2/STAT3 Signaling Pathway.
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.
CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase.
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity.
Cdc42-interacting protein 4 is a Src substrate that regulates invadopodia and invasiveness of breast tumors by promoting MT1-MMP endocytosis.
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Circular RNA circ_0000372 contributes to the proliferation, migration and invasion of colorectal cancer by elevating IL6 expression via sponging miR-495.
Clinical significance of focal adhesion kinase (FAK) in cervical cancer progression and metastasis.
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.
Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Comparative genomics on Wnt5a and Wnt5b genes.
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene.
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Curcumin Suppresses Metastasis via Sp-1, FAK Inhibition, and E-Cadherin Upregulation in Colorectal Cancer.
Cyclin G2 Inhibits Oral Squamous Cell Carcinoma Growth and Metastasis by Binding to IGFBP3 and Regulating the FAK-SRC-STAT Signaling Pathway.
Cytoplasmic c-Abl provides a molecular 'Rheostat' controlling carcinoma cell survival and invasion.
Cytotoxic effects of the anthraquinone derivatives 1'-deoxyrhodoptilometrin and (S)-(-)-rhodoptilometrin isolated from the marine echinoderm Comanthus sp.
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation.
Dasatinib prevents skeletal metastasis of osteotropic MDA-MB-231 cells in a xenograft mouse model.
Daurinol blocks breast and lung cancer metastasis and development by inhibition of focal adhesion kinase (FAK).
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Dependency of colorectal cancer on a TGF-?-driven program in stromal cells for metastasis initiation.
Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis.
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR.
Development of a High-Throughput Fluorescence Polarization Assay to Detect Inhibitors of the FAK-Paxillin Interaction.
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Diallyl trisulfide inhibits cell migration and invasion of human melanoma a375 cells via inhibiting integrin/facal adhesion kinase pathway.
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Differential roles of Src in transforming growth factor-ß regulation of growth arrest, epithelial-to-mesenchymal transition and cell migration in pancreatic ductal adenocarcinoma cells.
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.
Discovery of 4-anilino ?-carbolines as novel Brk inhibitors.
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking.
Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Downregulation of microRNA-4324 promotes the EMT of esophageal squamous-cell carcinoma cells via upregulating FAK.
DSTYK Promotes Metastasis and Chemoresistance via EMT in Colorectal Cancer.
Ductal adenocarcinoma of the pancreas usually retained SMAD4 and p53 protein status as well as expression of epithelial-to-mesenchymal transition markers and cell cycle regulators at the stage of liver metastasis.
Dynamics of p14ARF and Focal Adhesion Kinase-Mediated Autophagy in Cancer.
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2.
Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis.
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development.
Endosomes: Emerging Platforms for Integrin-Mediated FAK Signalling.
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis.
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Estrogen promotes reversible epithelial-to-mesenchymal-like transition and collective motility in MCF-7 breast cancer cells.
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
Evaluation of FAK and Src Expression in Human Benign and Malignant Thyroid Lesions.
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma.
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Expression of focal adhesion kinase (p125 FAK) and proline-rich tyrosine kinase 2 (PYK2/CAKb) in cerebral metastases, correlation with VEGF-R-, ecNOS III-labelling and morphometric data.
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Expression of focal adhesion kinase in small-cell lung carcinoma.
Expression of pY397 FAK promotes the development of non-small cell lung cancer.
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
FAK alternative splice mRNA variants expression pattern in colorectal cancer.
FAK AND P53 Protein Interactions.
FAK and paxillin, two potential targets in pancreatic cancer.
FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR?/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.
FAK signaling in cancer-associated fibroblasts promotes breast cancer cell migration and metastasis by exosomal miRNAs-mediated intercellular communication.
FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer.
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4.
Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues.
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Focal adhesion kinase (pp125FAK) expression, activation and association with paxillin and p50CSK in human metastatic prostate carcinoma.
Focal adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer.
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Focal Adhesion Kinase as a Potential Target in AML and MDS.
Focal adhesion kinase as an immunotherapeutic target.
Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells.
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Focal adhesion kinase regulates syndecan-2-mediated tumorigenic activity of HT1080 fibrosarcoma cells.
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.
Focal adhesion kinase: A prominent determinant in breast cancer initiation, progression and metastasis.
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Function and mechanism of neurotensin (NTS) and its receptor 1 (NTSR1) in occurrence and development of tumors.
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Fyn Requires HnRNPA2B1 and Sam68 to Synergistically Regulate Apoptosis in Pancreatic Cancer.
G9a Promotes Invasion and Metastasis of Non-Small Cell Lung Cancer through Enhancing Focal Adhesion Kinase Activation via NF-?B Signaling Pathway.
Gene Expression Profiling Identifies Important Genes Affected by R2 Compound Disrupting FAK and P53 Complex.
Genomic characterization of liver metastases from colorectal cancer patients.
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.
Heparan Sulfate-Instructed Self-Assembly Selectively Inhibits Cancer Cell Migration.
HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.
High expression of FER tyrosine kinase predicts poor prognosis in clear cell renal cell carcinoma.
High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
Human breast cancer cell metastasis is attenuated by lysyl oxidase inhibitors through down-regulation of focal adhesion kinase and the paxillin-signaling pathway.
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation.
Identification of potential small-molecule protein-protein inhibitors of cancer metastasis by 3D epitope-based computational screening.
Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells.
IGF-I Induces Epithelial-to-Mesenchymal Transition via the IGF-IR-Src-MicroRNA-30a-E-Cadherin Pathway in Nasopharyngeal Carcinoma Cells.
IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.
IL?6 plays a crucial role in epithelial?mesenchymal transition and pro?metastasis induced by sorafenib in liver cancer.
In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.
In Vitro Phosphorylation of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase by Src Kinase.
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Induction of membrane ruffling by growth factors in morphologically TPA-resistant Balb/c3T3 TR4 cells.
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Inhibitory effect of aloe-emodin on metastasis potential in HO-8910PM cell line.
Inhibitory effects of syk transfection on lung cancer cell invasion.
Insights into endometrial serous carcinogenesis and progression.
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Involvement of c-Src in carcinoma cell motility and metastasis.
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Involvement of syk and VEGF-C in invasion of lung adenocarcinoma A549 cells.
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma.
Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Knockdown of FAK inhibits the invasion and metastasis of Tca?8113 cells in vitro.
Knockdown of proteolipid protein 2 or focal adhesion kinase with an artificial microRNA reduces growth and metastasis of B16BL6 melanoma cells.
LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia.
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases.
Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells.
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.
Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src.
Metastatic Thymoma Harboring a Deleterious BRCA2 Mutation Derives Durable Clinical Benefit from Olaparib.
Methionine deprivation suppresses triple-negative breast cancer metastasis in vitro and in vivo.
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer.
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
MiR-199a-5p Inhibits the Growth and Metastasis of Colorectal Cancer Cells by Targeting ROCK1.
MiR-26a-5p potentiates metastasis of human lung cancer cells by regulating ITG?8- JAK2/STAT3 axis.
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain.
Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.
Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer.
Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling.
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Mutation of Y925F in focal adhesion kinase (FAK) suppresses melanoma cell proliferation and metastasis.
Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells.
MYCN, neuroblastoma and focal adhesion kinase (FAK).
Nanomechanical Property Maps of Breast Cancer Cells As Determined by Multiharmonic Atomic Force Microscopy Reveal Syk-Dependent Changes in Microtubule Stability Mediated by MAP1B.
New insights on Fak and Fak inhibitors.
Non-coding RNA 886 promotes renal cell carcinoma growth and metastasis through the Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis.
Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.
Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner.
Novel long non-coding RNA LINC02323 promotes epithelial-mesenchymal transition and metastasis via sponging miR-1343-3p in lung adenocarcinoma.
Osthole suppresses the migratory ability of human glioblastoma multiforme cells via inhibition of focal adhesion kinase-mediated matrix metalloproteinase-13 expression.
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Overexpression of focal adhesion kinase (p125FAK) in human colorectal carcinoma liver metastases: independence from c-src or c-yes activation.
Overexpression of focal adhesion kinase correlates with increased lymph node metastasis and poor prognosis in non-small-cell lung cancer.
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Overexpression of normal c-Src in poorly metastatic human colon cancer cells enhances primary tumor growth but not metastatic potential.
Overexpression of the csk gene suppresses tumor metastasis in vivo.
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.
Parathyroid hormone-related protein and bone metastases.
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Pathways of metastasis suppression in bladder cancer.
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer.
Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes.
Phosphorylation of focal adhesion kinase tyrosine 397 critically mediates gastrin-releasing peptide's morphogenic properties.
Possible involvement of bone morphogenetic protein 2 in heterotopic ossification in metastatic lesion from urothelial carcinoma of bladder.
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis.
Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients.
Rational design of a ligand-controlled protein conformational switch.
Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
Recognition of LD motifs by the focal adhesion targeting domains of focal adhesion kinase and proline-rich tyrosine kinase 2-beta: Insights from molecular dynamics simulations.
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells.
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Reduced expression of focal adhesion kinase in liver metastases compared with matched primary human colorectal adenocarcinomas.
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis.
Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells.
Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer.
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Role of Pyk2 in Human Cancers.
Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
RRM1-induced metastasis suppression through PTEN-regulated pathways.
Sequence variation in the src gene product affects metastasis formation: the central, but not exclusive, role of the tumor immune response.
Serum spleen tyrosine kinase and vascular endothelial growth factor-C levels predict lymph node metastasis of oesophageal squamous cell carcinoma.
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer.
Smad7 induces hepatic metastasis in colorectal cancer.
Somatic acquisition and signaling of TGFBR1*6A in cancer.
Specific induction of pp125 focal adhesion kinase in human breast cancer.
Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells.
Src activity alters alpha3 integrin expression in colon tumor cells.
Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation.
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Src inhibitors in breast cancer therapy.
Src kinase activation by nitric oxide promotes resistance to anoikis in tumour cell lines.
Src kinase contributes to the metastatic spread of carcinoma cells.
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Src signaling pathways in prostate cancer.
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Src-family kinase inhibitors block early steps of caveolin-1-enhanced lung metastasis by melanoma cells.
Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds.
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
Study of cytokine signaling: the quest for immunomodulatory drugs interacting with cytokine production and activity.
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Suppression of MMP-9 and FAK expression by pomolic acid via blocking of NF-?B/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells.
SYK allelic loss and the role of Syk-regulated genes in breast cancer survival.
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.
Targeting FER Kinase Inhibits Melanoma Growth and Metastasis.
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Targeting p70S6K Prevented Lung Metastasis in a Breast Cancer Xenograft Model.
Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Targeting the Metastasis Suppressor, N-Myc Downstream Regulated Gene-1, with Novel Di-2-Pyridylketone Thiosemicarbazones: Suppression of Tumor Cell Migration and Cell-Collagen Adhesion by Inhibiting Focal Adhesion Kinase/Paxillin Signaling.
TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis.
TGF-Beta Suppresses VEGFA-Mediated Angiogenesis in Colon Cancer Metastasis.
The Activation of MEK/ERK Signaling Pathway by Bone Morphogenetic Protein 4 to Increase Hepatocellular Carcinoma Cell Proliferation and Migration.
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance.
The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337.
The NF-?B Pathway and Cancer Stem Cells.
The Role of Focal Adhesion Kinase in Lung Cancer.
The Src Family Kinase Inhibitors PP2 and PP1 block TGF-beta1-Mediated Cellular Responses by Direct and Differential Inhibition of Type I and Type II TGF-beta Receptors.
The SRC-induced mesenchymal state in late-stage colon cancer cells.
The TGF-? Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.
The tumor suppressor activity of SOCS-1.
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box.
Transcriptional and Post-Translational Control Mechanisms for EphB4 Expression in Physiology and Cancer Disease.
Translational Control of C-terminal Src Kinase (Csk) Expression by PRL3 Phosphatase.
TrkB Inhibits the BMP Signaling-Mediated Growth Inhibition of Cancer Cells.
Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-?B transactivation in LNCaP cells.
Tumor suppressive protein gene associated with retinoid-interferon-induced mortality (GRIM)-19 inhibits src-induced oncogenic transformation at multiple levels.
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Tyrosine kinase src inhibitors: potential therapeutic applications.
Tyrosine nitration of c-SRC tyrosine kinase in human pancreatic ductal adenocarcinoma.
Up-regulation of focal adhesion kinase in non-small cell lung cancer.
Upregulation of TCTP is associated with cholangiocarcinoma progression and metastasis.
Uveal melanoma: laboratory advances and new frontiers in patient care.
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
Visualizing and manipulating focal adhesion kinase regulation in live cells.
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
Wnt-11 as a Potential Prognostic Biomarker and Therapeutic Target in Colorectal Cancer.
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Wnt5a and Wnt11 regulate mammalian anterior-posterior axis elongation.
ZAP-70 tyrosine kinase is required for LFA-1-dependent T cell migration.
[Effect of Janus kinase inhibitor AG490 on invasion and metastasis of human breast cancer cells]
[Effect of SRC Kinase on Adriamycin Resistance and Invasion and Metastasis in Human Breast Cancer Cells].
[Effect of Src tyrosine kinase inhibition on secretion of MMP-2 and MMP-9 by non-small cell lung cancer cells].
[Expression of deleted in liver cancer 1 and phosphorelated focal adhesion kinase in breast cancer].
[Expression of focal adhesion kinase in lymphatic endothelial cells of metastasis]
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]
[Expressions of EphB4 and HIF-1? in human lung cancer and their significances.]
[Influence of Pyk2 on hepatic metastasis and ultrastructure of human colonic cancer cells].
[Inhibitory effect of full-length spleen tyrosine kinase on invasion and metastasis of human laryngeal squamous cells].
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
[Novel non-tumorigenic cell variants showing potentially different susceptibility to v-src induced metastasis]
[SRC kinase inhibitor PP2 inhibits invasion and metastasis of lung cancer A549 cells by upregulating connexin43 expression].
Neoplasm Micrometastasis
TGF-? stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.
Neoplasm, Residual
A potential graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from the French Bone Marrow Transplantation Society.
Acute Myeloid Leukemia with Philadelphia Chromosome, Near-tetraploidy, and 5q Deletion.
An assessment of chimeric transcript detection in CML patients after bone marrow transplantation.
Association of cytogenetic abnormalities with detection of BCR-ABL fusion transcripts in children with T-lineage lymphoproliferative diseases (T-ALL and T-NHL).
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
Can we afford to let sleeping dogs lie?
Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chronic myelogenous leukemia--progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture.
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia.
Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Comparison of FISH and quantitative RT-PCR for the diagnosis and follow-up of BCR-ABL-positive leukemias.
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.
Cytogenetic and molecular monitoring of residual disease in chronic myeloid leukaemia.
Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.
Detection and quantification of the abelson tyrosine kinase domains of the BCR-ABL gene translocation in chronic myeloid leukaemia using genomic quantitative real-time polymerase chain reaction.
Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation.
Development of Recombinant Immunotoxins for Hairy Cell Leukemia.
Different impact of BCR-ABL transcripts on allogeneic hematopoietic cell transplantation from different graft sources for Ph?+?ALL with minimal residual disease.
Different suppression of Ph1 positive hemopoiesis induced by intensive chemotherapy in lymphoid and myeloid blast crisis of CML.
Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
Donor leukocyte infusions.
Efficacy and safety of autologous peripheral blood stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia: A study protocol for a multicenter exploratory prospective study (Auto-Ph17 study).
Estimations of BCR-ABL/ABL transcripts by quantitative PCR in chronic myeloid leukaemia after allogeneic bone marrow transplantation and donor lymphocyte infusion.
Evaluation of the Cepheid GeneXpert BCR-ABL assay.
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia.
Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
Manifold-assisted reverse transcription-PCR with real-time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients.
Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia.
Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse.
Molecular measurement of minimal residual disease in Philadelphia-positive acute lymphoblastic leukaemia.
Molecular Monitoring of BCR-ABL Transcripts after Allogeneic Stem Cell Transplantation for Chronic Myeloid Leukemia.
Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
Monitoring twenty-six chronic myeloid leukemia patients by BCR-ABL mRNA level in bone marrow:a single hospital experience.
Monitoring your patients with chronic myeloid leukemia.
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.
Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Predictors of relapse and overall survival in Philadelphia chromosome-positive acute lymphoblastic leukemia after transplantation.
Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia.
Quantitative determination of the hybrid Bcr-Abl RNA in patients with chronic myelogenous leukaemia under interferon therapy.
Rare e14a3 (b3a3) BCR-ABL fusion in chronic myeloid leukemia in India: The threats and challenges in monitoring minimal residual disease (MRD).
Retreatment with purine analogs in patients with chronic lymphocytic leukemia.
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: implications for defining sensitivity in minimal residual disease.
Role of STAT3 in Transformation and Drug Resistance in CML.
Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment.
Successful treatment with allogeneic stem cell transplantation followed by DLI and TKIs for e6a2 BCR-ABL-positive acute myeloid leukaemia: A case report and literature review.
The molecular pathology of chronic myelogenous leukaemia.
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.
[Complex molecular monitoring of chronic myeloid leukemia]
[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction]
[Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction]
[Expression of the Wilms' Tumor Gene WT1 and Detection of Minimal Residual Disease in Acute Leukemia]
[Molecular basis of chronic myelogenous leukemia and significance of diagnostic methods based on BCR-ABL gene amplification]
Neoplasms
(+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase activation in the min/+ mouse.
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents.
17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.
2-methoxyestradiol alters cell motility, migration, and adhesion.
3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
3-Deoxy-2?,16-dihydroxynagilactone E, a natural compound from Podocarpus nagi, preferentially inhibits JAK2/STAT3 signaling by allosterically interacting with the regulatory domain of JAK2 and induces apoptosis of cancer cells.
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
4-Aryl-4H-Chromene-3-Carbonitrile Derivatives: Evaluation of Src Kinase Inhibitory and Anticancer Activities.
?-Catenin haploinsufficiency promotes mammary tumorigenesis in an ErbB2-positive basal breast cancer model.
?-catenin-activated autocrine PDGF/Src signaling is a therapeutic target in pancreatic cancer.
?1 integrin- and JNK-dependent tumor growth upon hypofractionated radiation.
?3?1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.
A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.
A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours.
A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA.
A causal Bayesian network model of disease progression mechanisms in chronic myeloid leukemia.
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells.
A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation.
A clinical transcriptome approach to patient stratification and therapy selection in acute myeloid leukemia.
A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation.
A complex endocrine conundrum.
A comprehensive, multi-scale dynamical model of ErbB receptor signal transduction in human mammary epithelial cells.
A constitutively active Lck kinase promotes cell proliferation and resistance to apoptosis through signal transducer and activator of transcription 5b activation.
A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
A dominant negative mutation of transforming growth factor-beta receptor type II gene in microsatellite stable oesophageal carcinoma.
A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients.
A drug targeting 5-lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F-positive polycythemia vera in vitro.
A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
A Fast and Clean BTK Inhibitor.
A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors.
A Fyn romance: tumor cell Fyn kinase suppresses the immune microenvironment.
A gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of Syk.
A genetic screen for modifiers of the lats tumor suppressor gene identifies C-terminal Src kinase as a regulator of cell proliferation in Drosophila.
A growth-suppressive function for the c-fes protein-tyrosine kinase in colorectal cancer.
A haplotype of TGFBR1 is predominantly found in non-small cell lung cancer patients displaying TGFBR1 allelic-specific expression.
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
A Highly Sensitive Quantitative Real-Time PCR Assay for Determination of Mutant JAK2 Exon 12 Allele Burden.
A History of Cancer Research: Tyrosine Kinases.
A mesenchymal-like subpopulation in non-neuroendocrine SCLC contributes to metastasis.
A molecular case report: functional assay of tyrosine kinase inhibitors in cells from a patient's primary renal cell carcinoma.
A Multiscale Simulation Approach to Modeling Drug-Protein Binding Kinetics.
A New Class of Orthosteric uPAR•uPA Small-Molecule Antagonists Are Allosteric Inhibitors of the uPAR•Vitronectin Interaction.
A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient.
A New Strategy for Glioblastoma Treatment: In Vitro and In Vivo Preclinical Characterization of Si306, a Pyrazolo[3,4-d]Pyrimidine Dual Src/P-Glycoprotein Inhibitor.
A Nimbolide-Based Kinase Degrader Preferentially Degrades Oncogenic BCR-ABL.
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.
A non-covalent inhibitor XMU-MP-3 overrides ibrutinib-resistant BtkC481S mutation in B-cell malignancies.
A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling.
A novel BLK-induced tumor model.
A novel BMX variant promotes tumor cell growth and migration in lung adenocarcinoma.
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia.
A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
A novel function of p38-regulated/activated kinase in endothelial cell migration and tumor angiogenesis.
A novel human gene closely related to the abl proto-oncogene.
A novel lncRNA TCLlnc1 promotes peripheral T cell lymphoma progression through acting as a modular scaffold of HNRNPD and YBX1 complexes.
A novel mouse model of testicular granulosa cell tumors.
A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathways.
A novel quantitative kinase assay using bacterial surface display and flow cytometry.
A novel role of the glial fate determinant glial cells missing in hematopoiesis.
A novel SMAD4 gene mutation in seminoma germ cell tumors.
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
A novel Src kinase inhibitor reduces tumour formation in a skin carcinogenesis model.
A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration.
A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts.
A Patient With BCR-ABL and JAK2 V617F Double-Positive Myeloproliferative Neoplasm With Overlapping Clinical Phenotypes.
A Peptide-Based Biosensor Assay To Detect Intracellular Syk Kinase Activation and Inhibition.
A pharmacodynamic model of Bcr-Abl signalling in chronic myeloid leukaemia.
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors.
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.
A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours.
A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors.
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
A Phenotypic Screen for Small-Molecule Inhibitors of Constitutively Active Mutant Thrombopoietin Receptor Implicated in Myeloproliferative Neoplasms.
A phosphotyrosine-dependent protein interaction screen reveals a role for phosphorylation of caveolin-1 on tyrosine 14: recruitment of C-terminal Src kinase.
A Pipeline for Drug Target Identification and Validation.
A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing.
A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo.
A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.
A rapid and sensitive method for EphB4 identification as a diagnostic and therapeutic biomarker in invasive breast cancer.
A rationally designed photo-chemo core-shell nanomedicine for inhibiting the migration of metastatic breast cancer cells followed by photodynamic killing.
A redox-silent analogue of tocotrienol inhibits hypoxic adaptation of lung cancer cells.
A regulatory SH2 domain-targeting protein binder effectively inhibits the activity of Bruton's tyrosine kinase and its drug-resistant variants.
A research-inspired laboratory sequence investigating acquired drug resistance.
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
A Review: Phytochemicals Targeting JAK/STAT Signaling and IDO Expression in Cancer.
A robust ratio metric method for analysis of Zap-70 expression in chronic lymphocytic leukemia (CLL).
A role for c-Abl in cell senescence and spontaneous immortalization.
A role for focal adhesion kinase signaling in tumor necrosis factor-alpha-dependent matrix metalloproteinase-9 production in a cholangiocarcinoma cell line, CCKS1.
A Role of Agrin in Maintaining the Stability of Vascular Endothelial Growth Factor Receptor-2 during Tumor Angiogenesis.
A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo.
A small molecule Focal Adhesion Kinase (FAK) inhibitor, targeting Y397 site: 1-(2-Hydroxyethyl) -3, 5, 7-triaza-1-azoniatricyclo [3.3.1.13,7]decane; bromide effectively inhibits FAK autophosphorylation activity and decreases cancer cell viability, clonogenicity and tumor growth in vivo.
A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
A Small-Molecule Inhibitor, 5'-O-Tritylthymidine, Targets FAK And Mdm-2 Interaction, And Blocks Breast And Colon Tumorigenesis In Vivo.
A solid-phase Bcr-Abl kinase assay in 96-well hydrogel plates.
A Study of the Focal Adhesion Kinase Inhibitor GSK2256098 in Patients with Recurrent Glioblastoma with Evaluation of Tumor Penetration of [11C]GSK2256098.
A Swiss 3T3 variant cell line resistant to the effects of tumor promoters cannot be transformed by src.
A Synthetic Curcuminoid Analog, (2E,6E)-2,6-bis(2-(trifluoromethyl)benzylidene)cyclohexanone, Ameliorates Impaired Wound Healing in Streptozotocin-Induced Diabetic Mice by Increasing miR-146a.
A transformation-competent recombinant between v-src and Rous-associated virus RAV-1.
A tropomyosin receptor kinase family protein, NTRK2 is a potential predictive biomarker for lung adenocarcinoma.
A tyrosine-specific protein kinase from Ehrlich ascites tumor cells.
A Virtual Screening approach for the Identificationof High affinity small molecules targeting BCR-ABL1 inhibitors for the treatment of Chronic Myeloid Leukemia.
A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer.
A46, a benzothiophene-derived compound, suppresses Jak2-mediated pathologic cell growth.
A6 peptide activates CD44 adhesive activity, induces FAK and MEK phosphorylation, and inhibits the migration and metastasis of CD44-expressing cells.
AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer.
Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia.
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.
Aberrant Methylation of Suppressor of Cytokine Signaling 1 (SOCS1) Gene as a Biomarker for Early Prediction and Diagnosis of Bladder Cancer.
Aberrant transforming growth factor-beta signaling in azoxymethane-induced mouse colon tumors.
Aberration hubs in protein interaction networks highlight actionable targets in cancer.
Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity.
ABL Genomic Editing Sufficiently Abolishes Oncogenesis of Human Chronic Myeloid Leukemia Cells In Vitro and In Vivo.
Abl interconnects oncogenic Met and p53 core pathways in cancer cells.
ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Abl kinases are required for invadopodia formation and chemokine-induced invasion.
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
Abl2/Abl-related Gene Stabilizes Actin Filaments, Stimulates Actin Branching by Actin-related Protein 2/3 Complex, and Promotes Actin Filament Severing by Cofilin.
Abl: the prototype of oncogenic fusion proteins.
Abnormal expression of FAK and paxillin correlates with oral cancer invasion and metastasis.
Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia.
Abnormal Uterine Bleeding Is Associated With Increased BMP7 Expression in Human Endometrium.
Abnormalities in expression of genes, mRNA, and proteins of transforming growth factor-beta receptor type I and type II in human pituitary adenomas.
Absence of alternative splicing in bcr-abl mRNA in chronic myeloid leukemia cell lines.
Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients.
Absence of JAK2V617F mutation in patients with beta-thalassemia major and thrombocytosis due to splenectomy.
Absence of progesterone receptor membrane component 1 reduces migration and metastasis of breast cancer.
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Absence of the hybrid bcr-abl mRNA in Ph1-positive B lymphoblastoid cell lines established from a patient with chronic myelogenous leukemia.
AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.
Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells.
ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial.
Acetylcholinesterase and butyrylcholinesterase genes coamplify in primary ovarian carcinomas.
Ack promotes tissue growth via phosphorylation and suppression of the Hippo pathway component Expanded.
ACK1 is dispensable for development, skin tumor formation, and breast cancer cell proliferation.
ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers.
Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and ?1-integrin signaling pathway in tumor cells.
Actin-binding protein, espin: a novel metastatic regulator for melanoma.
Activated Abl kinase inhibits oncogenic transforming growth factor-{beta} signaling and tumorigenesis in mammary tumors.
Activated c-Abl tyrosine kinase in malignant solid tumors.
Activated c-SRC in ductal carcinoma in situ correlates with high tumour grade, high proliferation and HER2 positivity.
Activated Cdc42 kinase regulates Dock localization in male germ cells during Drosophila spermatogenesis.
Activated SRC oncogene phosphorylates R-ras and suppresses integrin activity.
Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.
Activating CBL mutations are associated with a distinct MDS/MPN phenotype.
Activating JAK2 mutants reveal cytokine receptor coupling differences that impact outcomes in myeloproliferative neoplasm.
Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers.
Activation of a Drosophila Janus kinase (JAK) causes hematopoietic neoplasia and developmental defects.
Activation of abl family kinases in solid tumors.
Activation of bcr-abl fusion gene and ras oncogenes in chronic myelogenous leukemia.
Activation of beta-catenin-TCF-mediated transcription by non-receptor tyrosine kinase v-Src.
Activation of c-Abl tyrosine kinase requires caspase activation and is not involved in JNK/SAPK activation during apoptosis of human monocytic leukemia U937 cells.
Activation of c-Src/HER1/STAT5b and HER1/ERK1/2 Signaling Pathways and Cell Migration by Hexachlorobenzene in MDA-MB-231 Human Breast Cancer Cell Line.
Activation of dickkopf-1 and focal adhesion kinase pathway by tumour necrosis factor ? induces enhanced migration of fibroblast-like synoviocytes in rheumatoid arthritis.
Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.
Activation of Focal Adhesion Kinase in Detached Human Epidermal Cancer Cells and Their Long-term Survival Might be Associated with Cell Surface Expression of Laminin-5.
Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells.
Activation of MAPK signalling results in resistance to saracatinib (AZD0530) in ovarian cancer.
Activation of NF-kappaB by fluid shear stress, but not TNF-alpha, requires focal adhesion kinase in osteoblasts.
Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium.
Activation of spleen tyrosine kinase is required for TNF-?-induced endothelin-1 upregulation in human aortic endothelial cells.
Activation of Src family kinases in Neu-induced mammary tumors correlates with their association with distinct sets of tyrosine phosphorylated proteins in vivo.
Activation of Src in human breast tumor cell lines: elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530.
Activation of STAT transcription factors by herpesvirus Saimiri Tip-484 requires p56lck.
Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice.
Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype.
Activation of the integrin effector kinase focal adhesion kinase in cancer cells is regulated by crosstalk between protein kinase Calpha and the PDZ adapter protein mda-9/Syntenin.
Activation of the Lutropin/Choriogonadotropin Receptor in MA-10 Cells Leads to the Tyrosine Phosphorylation of the Focal Adhesion Kinase by a Pathway that Involves Src Family Kinases.
Activation of the receptor protein tyrosine kinase EphB4 in endometrial hyperplasia and endometrial carcinoma.
Activation of the TGF-beta/Smad signaling pathway in focal segmental glomerulosclerosis.
Activation status of the JAK/STAT3 pathway in mantle cell lymphoma.
Activators of protein kinase C induce dissociation of CD4, but not CD8, from p56lck.
Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition.
Active recombinant human tyrosine kinase c-Yes: expression in baculovirus system, purification, comparison to c-Src, and inhibition by a c-Src inhibitor.
Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
Activity-Based Protein Profiling Reveals Potential Dasatinib Targets in Gastric Cancer.
ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments.
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance.
ADAM9 as a potential target molecule in cancer.
Adaptation to TKI treatment reactivates ERK signaling in tyrosine kinase-driven leukemias and other malignancies.
Adapter protein Shc regulates Janus kinase 3 phosphorylation.
Adaptors for disorders of the brain? The cancer signaling proteins NEDD9, CASS4, and PTK2B in Alzheimer's disease.
Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma.
Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo.
Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
Adenovirus-mediated transfer of FRNK augments drug-induced cytotoxicity in cultured SCCHN cells.
Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase.
Administration of a plasmid that expresses SDF-1? affects the oncogenic potential of mouse bcr-abl-transformed cells.
Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.
Adult reproductive functions after early postnatal inhibition by imatinib of the two receptor tyrosine kinases, c-kit and PDGFR, in the rat testis.
Advanced Glycated apoA-IV Loses Its Ability to Prevent the LPS-Induced Reduction in Cholesterol Efflux-Related Gene Expression in Macrophages.
Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment.
Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia.
Advances in understanding and management of polycythemia vera.
Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl.
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
AG490 reverses phenotypic alteration of dendritic cells by bladder cancer cells.
Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival.
Aggressive juvenile polyposis in children with chromosome 10q23 deletion.
Akt directly regulates focal adhesion kinase through association and serine phosphorylation: implication for pressure-induced colon cancer metastasis.
AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.
AKT2, a member of the protein kinase B family, is activated by growth factors, v-Ha-ras, and v-src through phosphatidylinositol 3-kinase in human ovarian epithelial cancer cells.
Alantolactone Inhibits Cell Proliferation by Interrupting the Interaction between Cripto-1 and Activin Receptor Type II A in Activin Signaling Pathway.
Aleukemic bcr-abl positive granulocytic sarcoma.
Allelic expression imbalance of JAK2 V617F mutation in BCR-ABL negative myeloproliferative neoplasms.
Allo-skin graft rejection, tumor rejection and natural killer activity in mice lacking p56lck.
alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo.
Alterations in expression of p56lck during myeloid differentiation of LSTRA cells.
Alterations in focal adhesion kinase activity and associated proteins during malignant conversion of mouse keratinocytes.
Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells.
Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells.
Altered mammary epithelial development, pattern formation and involution in transgenic mice expressing the EphB4 receptor tyrosine kinase.
Altered p-JAK1 expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma.
Altered regulation of cyclin G in human breast cancer and its specific localization at replication foci in response to DNA damage in p53+/+ cells.
Altered regulation of Src tyrosine kinase by transforming growth factor beta1 in a human hepatoma cell line.
Alternagin-C binding to ?2?1 integrin controls matrix metalloprotease-9 and matrix metalloprotease-2 in breast tumor cells and endothelial cells.
Alternate RASSF1 Transcripts Control SRC Activity, E-Cadherin Contacts, and YAP-Mediated Invasion.
Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer.
Alternative splicing of spleen tyrosine kinase differentially regulates colorectal cancer progression.
American Chemical Society - 240th national meeting - chemistry for preventing and combating disease: part 2.
Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein.
Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms.
Amplification of c-myc oncogene and absence of c-Ha-ras point mutation in human bone sarcoma.
Amplification of the c-yes oncogene in canine mammary tumors.
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase.
An alternative pathway for expression of p56lck from type I promoter transcripts in colon carcinoma.
An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.
An Association Study of Polymorphisms in JAK3 Gene with Lung Cancer in the Korean Population.
An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion.
An EGFR/Src-dependent ?4 integrin/FAK complex contributes to malignancy of breast cancer.
An enzyme-linked immunosorbent assay for the determination of src-family tyrosine kinase activity in breast cancer.
An evaluation of focal adhesion kinase in breast cancer by tissue microarrays.
An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.
An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression.
An overview of cell DNA issues.
An overview of translocation-related oncogenesis in the chronic myeloid leukaemias.
An update on dual Src/Abl inhibitors.
Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Analysis of genetic defects in patients with the common variable immunodeficiency phenotype in a single Taiwanese tertiary care hospital.
Analysis of loss of heterozygosity in lymphoma and leukaemia arising in F1 hybrid mice locates a common region of chromosome 4 loss.
Analysis of microsatellite instability, TGF-beta type II receptor gene mutations and hMSH2 and hMLH1 allele losses in pancreaticobiliary maljunction-associated biliary tract tumors.
Analysis of pp60c-src protein kinase activity in human tumor cell lines and tissues.
Analysis of protein tyrosine kinases expression in the melanoma metastases of patients treated with Imatinib Mesylate (STI571, Gleevec).
Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer.
Analysis of the biologic properties of p230 Bcr-Abl reveals unique and overlapping properties with the oncogenic p185 and p210 Bcr-Abl tyrosine kinases.
Analysis of the cellular functions of PTEN using catalytic domain and C-terminal mutations: differential effects of C-terminal deletion on signalling pathways downstream of phosphoinositide 3-kinase.
Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fc? Receptor (Fc?R) Function.
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
Analyzing time-series microarray data reveals key genes in spinal cord injury.
Androgen receptor regulates SRC expression through microRNA-203.
Andrographolide downregulates the v-Src and Bcr-Abl oncoproteins and induces Hsp90 cleavage in the ROS-dependent suppression of cancer malignancy.
Anti-angiogenic activity of thienopyridine derivative LCB03-0110 by targeting VEGFR-2 and JAK/STAT3 Signalling.
Anti-cancer effects of F16: A novel vascular endothelial growth factor receptor-specific inhibitor.
Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach.
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Anti-invasive effects of CXCR4 and FAK inhibitors in non-small cell lung carcinomas with mutually inactivated p53 and PTEN tumor suppressors.
Anti-neoplastic effect of ?-hydroxyisovalerylshikonin on a human choriocarcinoma cell line.
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4.
Antiangiogenic and antitumor effects of SRC inhibition in ovarian carcinoma.
Antibody neutralization of cell-surface gC1qR/HABP1/SF2-p32 prevents lamellipodia formation and tumorigenesis.
Antimetastatic Potential of Amide-linked Local Anesthetics: Inhibition of Lung Adenocarcinoma Cell Migration and Inflammatory Src Signaling Independent of Sodium Channel Blockade.
Antiproliferative activity of new 1-aryl-4-amino-1H-pyrazolo[3,4-d]pyrimidine derivatives toward the human epidermoid carcinoma A431 cell line.
Antiproliferative effect of sulindac in colonic neoplasia prevention: role of COOH-terminal Src kinase.
Antisense anticancer oligonucleotide therapeutics.
Antisense strategy in hematological malignancies.
Antisense therapeutics in oncology: current status.
Antitumor activity of antibody against cytotoxic T lymphocyte epitope peptide of lymphocyte-specific protein tyrosine kinase.
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptor.
Antitumor activity of NPB001-05, an orally active inhibitor of Bcr-Abl tyrosine kinase.
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment.
Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.
Antitumor effects of circ-EPHB4 in hepatocellular carcinoma via inhibition of HIF-1?.
Antitumor efficacy of arsenic/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors.
Antroquinonol Targets FAK-Signaling Pathway Suppressed Cell Migration, Invasion, and Tumor Growth of C6 Glioma.
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes.
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Aphidicolin-induced proliferative arrest of murine mast cells: morphological and biochemical changes are not accompanied by alterations in cytokine gene induction.
Apoptin-induced apoptosis: a review.
Apoptosis and tumourigenesis.
Apoptosis-inducing effects of two anthraquinones from Hedyotis diffusa WILLD.
Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms.
Application of flow cytometry in pediatric hematology-oncology.
Application Of Kinase Inhibitors For Anti-Aging Intervention.
Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia.
Artocarpin Targets Focal Adhesion Kinase-Dependent Epithelial to Mesenchymal Transition and Suppresses Migratory-Associated Integrins in Lung Cancer Cells.
Ascending the PEAK1 toward targeting TGF? during cancer progression: Recent advances and future perspectives.
Ascorbate/menadione-induced oxidative stress kills cancer cells that express normal or mutated forms of the oncogenic protein Bcr-Abl. An in vitro and in vivo mechanistic study.
Assessment of EGFR and ERBB2 (HER2) in Gastric and Gastroesophageal Carcinomas: EGFR Amplification is Associated With a Worse Prognosis in Early Stage and Well to Moderately Differentiated Carcinoma.
Association between focal adhesion kinase and matrix metalloproteinase-9 expression in prostate adenocarcinoma and their influence on the progression of prostatic adenocarcinoma.
Association between Int7G24A rs334354 polymorphism and cancer risk: a meta-analysis of case-control studies.
Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.
Association between TGFBR1 Polymorphisms and Cancer Risk: A Meta-Analysis of 35 Case-Control Studies.
Association of autoimmune thyroiditis and celiac disease with Juvenile Polyposis due to 10q23.1q23.31 deletion: Potential role of PI3K/Akt pathway dysregulation.
Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
Association of BDNF and BMPR1A with clinicopathologic parameters in benign and malignant gallbladder lesions.
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
Association of herpesvirus saimiri tip with lipid raft is essential for downregulation of T-cell receptor and CD4 coreceptor.
Association of mast cells and bone marrow reticulin fibrosis in patients with bcr-abl negative chronic myeloproliferative neoplasms.
Association of SYK Genetic Variations with Breast Cancer Pathogenesis.
Association of the upregulated expression of focal adhesion kinase with poor prognosis and tumor dissemination in hypopharyngeal cancer.
Associations between immune-suppressive and stimulating drugs and novel COVID-19-a systematic review of current evidence.
Associations between polymorphisms in the SYK promoter and susceptibility to sporadic colorectal cancer in a Southern Han Chinese population - a short report.
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry.
Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells.
Attenuation of eph receptor kinase activation in cancer cells by coexpressed ephrin ligands.
Attenuation of SRC Kinase Activity Augments PARP Inhibitor-mediated Synthetic Lethality in BRCA2-altered Prostate Tumors.
Attenuation of the expression of the focal adhesion kinase induces apoptosis in tumor cells.
Austrian recommendations for the management of essential thrombocythemia.
Automated tracking of tumor-stroma morphology in microtissues identifies functional targets within the tumor microenvironment for therapeutic intervention.
Autophagy in the physiological endometrium and cancer.
Autophagy inhibition by TSSC4 (tumor suppressing subtransferable candidate 4) contributes to sustainable cancer cell growth.
Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis.
Autophagy-independent induction of LC3B through oxidative stress reveals its non-canonical role in anoikis of ovarian cancer cells.
Autophosphorylation-independent and dependent functions of Focal Adhesion Kinase during development.
Axial spondyloarthritis: emerging drug targets.
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
B-cell receptor signaling in diffuse large B-cell lymphoma.
B7 homologue 3 as a prognostic biomarker and potential therapeutic target in gastrointestinal tumors.
B7h Triggering Inhibits the Migration of Tumor Cell Lines.
Baicalin Ameliorates Collagen-Induced Arthritis Through the Suppression of Janus Kinase 1 (JAK1)/Signal Transducer and Activator of Transcription 3 (STAT3) Signaling in Mice.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.
Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.
BAY 61-3606, CDKi, and sodium butyrate treatments alter gene expression in human vestibular schwannomas and cause cell death in vitro.
BCAR3 regulates Src/p130 Cas association, Src kinase activity, and breast cancer adhesion signaling.
BCL-2 stimulates Apoptin-induced apoptosis.
BCL6 regulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.
Bcr (breakpoint cluster region) protein binds to PDZ-domains of scaffold protein PDZK1 and vesicle coat protein Mint3.
BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
BCR-ABL and JAK2V617F Mutation Co-existence, Rare or Just Unexplored.
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Bcr-Abl dependent post-transcriptional activation of NME2 expression is a specific and common feature of chronic myeloid leukemia.
BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP.
BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia.
BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).
Bcr-Abl regulates protein kinase Ciota (PKCiota) transcription via an Elk1 site in the PKCiota promoter.
Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor.
BCR-ABL Testing by Polymerase Chain Reaction in Patients With Neutrophilia: The William Beaumont Hospital Experience and the Case for Rational Laboratory Test Requests.
Bcr-Abl upregulates cytosolic p21WAF-1/CIP-1 by a phosphoinositide-3-kinase (PI3K)-independent pathway.
Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.
bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.
BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents.
BCR-ABL-mediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.
BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
Beta-arrestins operate an on/off control switch for focal adhesion kinase activity.
Beta-hydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells.
Beta1,4-N-acetylgalactosaminyltransferase III enhances malignant phenotypes of colon cancer cells.
Beta2 integrin-dependent phosphorylation of protein-tyrosine kinase Pyk2 stimulated by tumor necrosis factor alpha and fMLP in human neutrophils adherent to fibrinogen.
Bi-directional regulation between tyrosine kinase Etk/BMX and tumor suppressor p53 in response to DNA damage.
Bimolecular Fluorescence Complementation Demonstrates That the c-Fes Protein-Tyrosine Kinase Forms Constitutive Oligomers in Living Cells.
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors.
Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state.
Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors.
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.
Bioinformatics-based study to detect chemical compounds that show potential as treatments for pulmonary thromboembolism.
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis.
Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature.
Biological consequences of a point mutation at codon 969 of the FMS gene.
Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.
Biology of chronic myelogenous leukemia.
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.
Bis-imide granulatimide analogues as potent Checkpoint 1 kinase inhibitors.
Blast-phase myeloproliferative neoplasms: risk factors and treatment approaches.
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.
Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.
Blockade of Lyn kinase upregulates both canonical and non-canonical TLR-3 pathways in THP-1 monocytes exposed to human cytomegalovirus.
Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo.
Blocking hypoxia-induced autophagy in tumors restores cytotoxic T cell activity and promotes regression.
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Bombesin stimulation of p125 focal adhesion kinase tyrosine phosphorylation. Role of protein kinase C, Ca2+ mobilization, and the actin cytoskeleton.
Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours.
Bone sialoprotein-?v?3 integrin axis promotes breast cancer metastasis to the bone.
Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B.
Bosutinib, an SRC inhibitor, induces caspase-independent cell death associated with permeabilization of lysosomal membranes in melanoma cells.
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma.
BRAF as therapeutic target in melanoma.
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Branebrutinib (BMS-986195), a Bruton's Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents.
Breakpoint cluster region-c-abl oncogene 1, non-receptor tyrosine kinase signaling: current patterns of the versatile regulator revisited.
Breakthrough in Degradation of BCR-ABL Fusion Protein for the Treatment of Cancer.
Breast Cancer Malignant Processes are Regulated by Pax-5 Through the Disruption of FAK Signaling Pathways.
Breast cancer metastasis driven by ErbB2 and 14-3-3xi: A division of labor.
Breast Cancer Special Feature: Mammary epithelial-specific disruption of c-Src impairs cell cycle progression and tumorigenesis.
Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm™.
Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.
Breast tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and promote breast carcinoma growth, migration, and invasion.
Breast tumor kinase/protein tyrosine kinase 6 (Brk/PTK6) activity in normal and neoplastic biliary epithelia.
Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.
Bruton tyrosine kinase (BTK) and its role in B-cell malignancy.
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.
Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.
Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)?-Suppressed Migration and Invasion of Prostate Cancer.
Bruton's Tyrosine Kinase (BTK) Inhibitor RN486 Overcomes ABCB1-Mediated Multidrug Resistance in Cancer Cells.
Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018).
Bruton's Tyrosine Kinase and Its Isoforms in Cancer.
Bruton's tyrosine kinase as a new therapeutic target.
Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells.
Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer.
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib.
Bruton's Tyrosine Kinase Inhibitors for the Treatment of Autoimmune Diseases and Cancers.
Bruton's Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3.
Bruton's tyrosine kinase inhibitors in B-cell non-Hodgkin's lymphomas.
Bruton's Tyrosine Kinase inhibitors: approaches to potent and selective inhibition, preclinical and clinical evaluation for inflammatory diseases and B cell malignancies.
Bruton's tyrosine kinase is required for lipopolysaccharide-induced tumor necrosis factor alpha production.
Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.
Bruton's tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies.
Bruton's tyrosine kinase: potential target in human multiple myeloma.
BTK inhibitors synergize with 5-FU to treat drug-resistant TP53-null colon cancers.
BTK signaling drives CD1dhiCD5+ regulatory B-cell differentiation to promote pancreatic carcinogenesis.
BTK: a two-faced effector in cancer and tumour suppression.
c-Abl and Arg induce cathepsin-mediated lysosomal degradation of the NM23-H1 metastasis suppressor in invasive cancer.
c-abl and YWHAZ gene expression in gastric cancer.
c-Abl expression in chronic lymphocytic leukemia cells: clinical and therapeutic implications.
c-Abl expression in oral squamous cell carcinomas.
c-Abl in oxidative stress, aging and cancer.
C-Abl inhibitor imatinib enhances insulin production by ? cells: c-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2.
c-Abl is required for development and optimal cell proliferation in the context of p53 deficiency.
c-Abl Kinase Is a Regulator of ?v?3 Integrin Mediated Melanoma A375 Cell Migration.
c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells.
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity.
c-Abl tyrosine kinase and inhibition by the cancer drug imatinib (Gleevec/STI-571).
c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors.
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
c-ABL tyrosine kinase modulates p53-dependent p21 induction and ensuing cell fate decision in response to DNA damage.
c-Cbl targets active Src for autophagy.
c-Ha-ras1 is not deleted in aniridia-Wilms' tumour association.
C-JUN promotes BCR-ABL induced lymphoid leukemia by inhibiting methylation of the 5' region of Cdk6.
C-kit expression in pediatric solid tumors: a comparative immunohistochemical study.
C-kit immunoreactivity in endometrial adenocarcinomas and its clinicopathologic significance.
c-Ski overexpression promotes tumor growth and angiogenesis through inhibition of transforming growth factor-beta signaling in diffuse-type gastric carcinoma.
c-Src activation promotes nasopharyngeal carcinoma metastasis by inducing the epithelial-mesenchymal transition via PI3K/Akt signaling pathway: a new and promising target for NPC.
C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.
c-Src and cooperating partners in human cancer.
c-Src and EGFR Inhibition in Molecular Cancer Therapy: What Else Can We Improve?
c-Src Antisense Complexed with PAMAM Denderimes Decreases of c-Src Expression and EGFR-Dependent Downstream Genes in the Human HT-29 Colon Cancer Cell Line.
c-Src binds to the cancer drug imatinib with an inactive Abl/c-Kit conformation and a distributed thermodynamic penalty.
c-Src binds to the cancer drug Ruxolitinib with an active conformation.
c-Src drives intestinal regeneration and transformation.
c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer.
c-Src mediates mitogenic signals and associates with cytoskeletal proteins upon vascular endothelial growth factor stimulation in Kaposi's sarcoma cells.
c-Src promotes tumor progression through downregulation of microRNA-129-1-3p.
c-Src regulates constitutive and EGF-mediated VEGF expression in pancreatic tumor cells through activation of phosphatidyl inositol-3 kinase and p38 MAPK.
C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis.
c-Src-induced activation of ceramide metabolism impairs membrane microdomains and promotes malignant progression by facilitating the translocation of c-Src to focal adhesions.
c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function.
C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor.
C-terminal Src kinase controls development and maintenance of mouse squamous epithelia.
c-Yes enhances tumor migration and invasion via PI3K/AKT pathway in epithelial ovarian cancer.
c-Yes Tyrosine Kinase Is a Potent Suppressor of ES Cell Differentiation and Antagonizes the Actions of Its Closest Phylogenetic Relative, c-Src.
CADM1 enhances intestinal barrier function in a rat model of mild inflammatory bowel disease by inhibiting the STAT3 signaling pathway.
Caenorhabditis elegans ABL-1 antagonizes p53-mediated germline apoptosis after ionizing irradiation.
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Calpain activity is generally elevated during transformation but has oncogene-specific biological functions.
CALR gene mutational profile in myeloproliferative neoplasms with non-mutated JAK2 in Moroccan patients: A case series and germline in-frame deletion.
CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report.
Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations.
Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion.
Can kinomics and proteomics bridge the gap between pediatric cancers and newly designed kinase inhibitors?
Cancer biomarkers for targeted therapy.
Cancer cells escape from oncogene addiction: Understanding the mechanisms behind treatment failure for more effective targeting.
Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors.
Cancer prevention and therapy through the modulation of the tumor microenvironment.
Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK)
Cancer/testis antigen cancer-associated gene (CAGE) promotes motility of cancer cells through activation of focal adhesion kinase (FAK).
Cancer: Belt and braces for BCR-ABL.
Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review).
Cantharidin treatment inhibits hepatocellular carcinoma development by regulating the JAK2/STAT3 and PI3K/Akt pathways in an EphB4-dependent manner.
Cardiac and neurological abnormalities in v-fps transgenic mice.
Cardiac side effects of bruton tyrosine kinase (BTK) inhibitors.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Cardiovascular Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
Caspase-dependent cleavage of c-Abl contributes to apoptosis.
Caveolin-1 Y14 phosphorylation suppresses tumor growth while promoting invasion.
CCN3 suppresses mitogenic signalling and reinstates growth control mechanisms in Chronic Myeloid Leukaemia.
CD151 enhances cell motility and metastasis of cancer cells in the presence of focal adhesion kinase.
CD4(+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner.
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.
CD44-mediated oncogenic signaling and cytoskeleton activation during mammary tumor progression.
CD8 T-cell induction against vascular endothelial growth factor receptor 2 by Salmonella for vaccination purposes against a murine melanoma.
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity.
Cdc42-interacting protein 4 is a Src substrate that regulates invadopodia and invasiveness of breast tumors by promoting MT1-MMP endocytosis.
Cell budding from pre-invasive tumors: Intrinsic precursor of invasive breast lesions?
Cell Death Induced by the Jak2 Inhibitor, G6, Correlates with Cleavage of Vimentin Filaments.
Cell Invasion of Highly Metastatic MTLn3 Cancer Cells Is Dependent on Phospholipase D2 (PLD2) and Janus Kinase 3 (JAK3).
Cell migration towards CXCL12 in leukemic cells compared to breast cancer cells.
Cell protein cross-linking by erbstatin and related compounds.
Cell type-specific tumor induction in neural transplants by retrovirus-mediated oncogene transfer.
Cell-cell dissociation upon epithelial cell scattering requires a step mediated by the proteasome.
Cellular processes of v-Src transformation revealed by gene profiling of primary cells--implications for human cancer.
Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src.
Centrosomal targeting of Syk kinase is controlled by its catalytic activity and depends on microtubules and the dynein motor.
Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis.
Changes in expression, and/or mutations in TGF-beta receptors (TGF-beta RI and TGF-beta RII) and Smad 4 in human ovarian tumors.
Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion.
Characteristics of trials and regulatory pathways leading to US approval of innovative vs. non-innovative oncology drugs.
Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
Characterization of in vitro metabolism of focal adhesion kinase inhibitors by LC/MS/MS.
Characterization of in vivo resistance to osimertinib and JNJ-61186372, an EGFR/Met bi-specific antibody, reveals unique and consensus mechanisms of resistance.
Characterization of JAK2 V617F (1849 G > T) Mutation in Cervical Cancer Related to Human Papillomavirus and Sexually Transmitted Infections.
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Characterization of the avian GLUT1 glucose transporter: differential regulation of GLUT1 and GLUT3 in chicken embryo fibroblasts.
Characterization of the binding of a novel antitumor drug ibrutinib with human serum albumin: Insights from spectroscopic, calorimetric and docking studies.
Characterization of transforming viruses rescued from a hamster tumour cell line harbouring the v-src gene flanked by long terminal repeats.
Chemical genetic transcriptional fingerprinting for selectivity profiling of kinase inhibitors.
Chemical Structure Characteristics and Bioactivity of Small Molecule FAK Inhibitors.
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Chemoproteomic profiling of an Ibrutinib analogue reveals its unexpected role in DNA damage repair.
CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
Chromosomal aberrations in squamous cell carcinomas of the upper aerodigestive tract: biologic insights and clinical opportunities.
Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Chromosomal localization and characterization of c-abl in the t(6;9) of acute nonlymphocytic leukemia.
Chromosome rearrangements in canine fibrosarcomas.
Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Chronic lymphocytic leukemia: novel prognostic factors and their relevance for risk-adapted therapeutic strategies.
Chronic myelogenous leukemia stem cells: What's new?
Chronic myeloid leukemia blast crisis arises from progenitors.
Chronic myeloid leukemia stem cells.
Chronic myeloid leukemia.
Chronic myeloproliferative neoplasm with concurrent BCR-ABL translocation and JAK2 mutation.
Chronic versus acute myelogenous leukemia: a question of self-renewal.
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Circular RNA circMTO1 acts as an antitumor factor in rectal cancer cell lines by downregulation of miR-19b-3p.
CircularRNA-9119 protects hepatocellular carcinoma cells from apoptosis by intercepting miR-26a/JAK1/STAT3 signaling.
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
CKAP2 Promotes Ovarian Cancer Proliferation and Tumorigenesis Through the FAK-ERK Pathway.
Class I and III HDACs and loss of active chromatin features contribute to epigenetic silencing of CDX1 and EPHB tumor suppressor genes in colorectal cancer.
Cleavage of focal adhesion kinase by different proteases during SRC-regulated transformation and apoptosis. Distinct roles for calpain and caspases.
CLEC4M overexpression inhibits progression and is associated with a favorable prognosis in hepatocellular carcinoma.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations.
Clinical applications of BCR-ABL molecular testing in acute leukemia.
Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas.
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Clinical implications of EphB4 receptor expression in pancreatic cancer.
Clinical implications of JAK2 mutations in myeloproliferative disorders.
Clinical Importance and Potential Use of Small Molecule Inhibitors of Focal Adhesion Kinase.
Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Clinical Potential of Targeting Bruton's Tyrosine Kinase.
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.
Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma.
Clinical Significance of EphB4 and EphB6 Expression in Human Malignant and Benign Thyroid Lesions.
Clinical significance of focal adhesion kinase in resectable pancreatic cancer.
Clinical significance of high focal adhesion kinase gene copy number and overexpression in invasive breast cancer.
Clinical significance of SCCRO (DCUN1D1) in prostate cancer and its proliferation-inhibiting effect on Lncap cells.
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Clinical Targeting of Mutated and Wild-type Protein Tyrosine Kinases in Cancer.
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.
Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNF?-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.
Clinicopathologic Characterization of Breast Carcinomas in Patients with Non-BRCA Germline Mutations: Results from a Single Institution's High Risk Population.
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome.
Cloning and genomic organization of the human transforming growth factor-beta type I receptor gene.
Cloning, molecular characterization, and expression analysis of the signal transducer and activator of transcription 3 (STAT3) gene from grass carp (Ctenopharyngodon idellus).
Co-expression modules of NF1, PTEN and sprouty enable distinction of adult diffuse gliomas according to pathway activities of receptor tyrosine kinases.
Co-operative effect of c-Src and ezrin in deregulation of cell-cell contacts and scattering of mammary carcinoma cells.
Co-operative effect of c-Src tyrosine kinase and Stat3 in activation of hepatocyte growth factor expression in mammary carcinoma cells.
Co-overexpression of AXL and c-ABL predicts a poor prognosis in esophageal adenocarcinoma and promotes cancer cell survival.
Co-treatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplasm cells.
Codelivery of HIF-1? siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Coelomic Fluid of Lumbricus rubellus Synergistically Enhances Cytotoxic Effect of 5-Fluorouracil through Modulation of Focal Adhesion Kinase and p21 in HT-29 Cancer Cell Line.
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm.
Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.
Coexpression of an unusual form of the EWS-WT1 fusion transcript and interleukin 2/15 receptor betamRNA in a desmoplastic small round cell tumour.
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Coexpression of transcripts encoding EPHB receptor protein tyrosine kinases and their ephrin-B ligands in human small cell lung carcinoma.
Collagen triple helix repeat containing 1 promotes endometrial cancer cell migration by activating the focal adhesion kinase signaling pathway.
Colorectal cancers in patients with the (9A/6A) polymorphism of TGFBR1 exhibit lesser inter-(simple sequence repeat) PCR genomic instability and present clinically at greater age.
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia.
Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death.
Combination therapies against chronic myeloid leukemia: short-term versus long-term strategies.
Combination treatment of Src inhibitor Saracatinib with GMI, a Ganoderma microsporum immunomodulatory protein, induce synthetic lethality via autophagy and apoptosis in lung cancer cells.
Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia.
Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells.
Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation.
Combined inhibition of Janus kinase 1/2 for the treatment of JAK2V617F-driven neoplasms: selective effects on mutant cells and improvements in measures of disease severity.
Combining a QSAR Approach and Structural Analysis to Derive an SAR Map of Lyn Kinase Inhibition.
Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Combining the ABL1 kinase inhibitor ponatinib and the histone deacetylase inhibitor vorinostat: a potential treatment for BCR-ABL-positive leukemia.
Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia".
Commentary on Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT McKenzie S, Sakamoto S, Kyprianou N, Division of Urology, Department of Surgery, Markey Cancer Center, University of Kentucky College of Medicine, Lexington, KY.
Comparative effectiveness and safety of non-tumour necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumour necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.
Comparative Efficacy (DAS28 Remission) of Targeted Immune Modulators for Rheumatoid Arthritis: A Network Meta-Analysis.
Comparison of bone marrow and peripheral blood ZAP-70 status examined by flow cytometric immunophenotyping in patients with chronic lymphocytic leukemia.
Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions.
Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase.
Comparison of the effects of differentially sulphated bovine kidney- and porcine intestine-derived heparan sulphate on breast carcinoma cellular behaviour.
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Comparison of tyrosine phosphorylation of proteins by membrane fractions from mouse liver, Ehrlich ascites tumor and MH134 hepatoma.
Compensatory function of Pyk2 in the promotion of FAK-null mammary cancer stem cell tumorigenicity and metastatic activity.
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
Comprehensive analysis of genomic alterations detected by next-generation sequencing-based tissue and circulating tumor DNA assays in Chinese patients with non-small cell lung cancer.
Comprehensive Analysis of the Immune Implication of ACK1 Gene in Non-small Cell Lung Cancer.
Comprehensive screening of genes resistant to an anticancer drug in esophageal squamous cell carcinoma.
Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients.
Concomitant detection of BCR-ABL translocation and JAK2 V617F mutation in five patients with myeloproliferative neoplasm at diagnosis.
Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.
Concordant Promoter Methylation of Transforming Growth Factor-Beta Receptor Types I and II Occurs Early in Esophageal Squamous Cell Carcinoma.
Conditional ablation of TYK2 in immunity to viral infection and tumor surveillance.
Conditional deletion of the focal adhesion kinase FAK alters remodeling of the blood-brain barrier in glioma.
Conservation of structure and expression of the c-yes and fyn genes in lower vertebrates.
Constitutive activation of breast tumor kinase accelerates cell migration and tumor growth in vivo.
Constitutive activation of extracellular signal-regulated kinase and p38 mitogen-activated protein kinase in B-cell lymphoproliferative disorders.
Constitutive Activation of Interleukin-13/STAT6 Contributes to Kaposi's Sarcoma-Associated Herpesvirus-Related Primary Effusion Lymphoma Cell Proliferation and Survival.
Constitutive activation of JAK2 in mammary epithelium elevates Stat5 signalling, promotes alveologenesis and resistance to cell death, and contributes to tumourigenesis.
Constitutive expression of mature transforming growth factor beta1 in the liver accelerates hepatocarcinogenesis in transgenic mice.
Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptor expression and growth of leukemic Sezary cells.
Constitutively active transforming growth factor ? receptor 1 in the mouse ovary promotes tumorigenesis.
Construction and expression of a recombinant DNA gene encoding a polyomavirus middle-size tumor antigen with the carboxyl terminus of the vesicular stomatitis virus glycoprotein G.
Construction of an IMiD-based azide library as a kit for PROTAC research.
Control of mammary tumor differentiation by SKI-606 (bosutinib).
Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal Cancer.
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Cool-1 functions as an essential regulatory node for EGFreceptor- and Src-mediated cell growth.
Cooperation between c-Met and focal adhesion kinase family members in medulloblastoma and implications for therapy.
Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F.
Coordinate suppression of Sdpr and Fhl1 expression in tumors of the breast, kidney, and prostate.
Coordination of signalling networks and tumorigenic properties by ABL in glioblastoma cells.
Cordycepin Suppresses Endothelial Cell Proliferation, Migration, Angiogenesis, and Tumor Growth by Regulating Focal Adhesion Kinase and p53.
Core Element Cloning, Cis-Element Mapping and Serum Regulation of the Human EphB4 Promoter: A Novel TATA-Less Inr/MTE/DPE-Like Regulated Gene.
Correction to: Role of Bruton's tyrosine kinase in B cells and malignancies.
Correction: ABL kinase inhibition sensitizes primary lung adenocarcinomas to chemotherapy by promoting tumor cell differentiation.
Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437.
Correction: deletion of the endothelial bmx tyrosine kinase decreases tumor angiogenesis and growth.
Correlation between 99mTc-(V)-DMSA uptake and constitutive level of phosphorylated focal adhesion kinase in an in vitro model of cancer cell lines.
Correlation between BCR-ABL expression and tumor burden is restricted to the transition from minor to major cytogenetic response in interferon treated CML patients.
Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Correlation of V-src gene amplification with the tumorigenic phenotype in a Syrian hamster embryo cell line.
Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Correlations between the expression, phosphotyrosine content and enzymatic activity of focal adhesion kinase, pp125FAK, in tumor and nontransformed cells.
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with laryngeal premalignancy.
Cortactin and focal adhesion kinase as predictors of cancer risk in patients with premalignant oral epithelial lesions.
Cortactin in tumor invasiveness.
Cortactin promotes cell migration and invasion through upregulation of the dedicator of cytokinesis 1 expression in human colorectal cancer.
Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells.
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology.
CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
Critical role for the receptor tyrosine kinase EPHB4 in esophageal cancers.
Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma.
Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice.
Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
CRKL plays a pivotal role in tumorigenesis of head and neck squamous cell carcinoma through the regulation of cell adhesion.
CRKL regulates alternative splicing of cancer-related genes in cervical cancer samples and HeLa cell.
Cross Talk Between TGF-? and JAK Expressions and Nepherotoxicity Induced by Tetrachloromethane: Role of Phytotherapy.
Cross talk between the TM4SF5/focal adhesion kinase and the interleukin-6/STAT3 pathways promotes immune escape of human liver cancer cells.
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas.
Crosstalk between CML cells with HUVECS and BMSCs through CML derived exosomes.
CSK-homologous kinase (CHK/MATK) is a potential colorectal cancer tumour suppressor gene epigenetically silenced by promoter methylation.
Cucurbitacin IIa: a novel class of anti-cancer drug inducing non-reversible actin aggregation and inhibiting survivin independent of JAK2/STAT3 phosphorylation.
CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling.
CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway.
Current CML therapy: progress and dilemma.
Current concepts in the management of rheumatoid arthritis.
Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Current status of vaccination therapy for leukemias.
Cx43 and Associated Cell Signaling Pathways Regulate Tunneling Nanotubes in Breast Cancer Cells.
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone.
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas.
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.
Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia.
Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor.
Cytoplasmic retention of protein tyrosine kinase 6 promotes growth of prostate tumor cells.
Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells.
DAPT suppresses proliferation and migration of hepatocellular carcinoma by regulating the extracellular matrix and inhibiting the Hes1/PTEN/AKT/mTOR signaling pathway.
Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Dasatinib inhibits mammary tumour development in a genetically engineered mouse model.
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity.
Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia.
Dasatinib, a small molecule inhibitor of the Src kinase, reduces the growth and activates apoptosis in pre-neoplastic Barrett's esophagus cell lines: evidence for a noninvasive treatment of high-grade dysplasia.
Dasatinib-induced autophagy is enhanced in combination with temozolomide in glioma.
Dasatinib?+?Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Data-driven modeling of SRC control on the mitochondrial pathway of apoptosis: implication for anticancer therapy optimization.
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.
DDR2 upregulation confers ferroptosis susceptibility of recurrent breast tumors through the Hippo pathway.
De Novo proteome analysis of genetically modified tumor cells by a metabolic labeling/azide-alkyne cycloaddition approach.
Deciphering Mode of Action of Functionally Important Regions in the Intrinsically Disordered Paxillin (Residues 1-313) Using Its Interaction with FAT (Focal Adhesion Targeting Domain of Focal Adhesion Kinase).
Declining lymphoid progenitor fitness promotes aging-associated leukemogenesis.
Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells overexpressing the early growth response-1 protein.
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Decreased transforming growth factor beta type II receptor expression in intestinal adenomas from Min/+ mice is associated with increased cyclin D1 and cyclin-dependent kinase 4 expression.
Defective apical extrusion signaling contributes to aggressive tumor hallmarks.
Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2.
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma.
Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches.
Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Degradation of endothelial cell matrix collagen is correlated with induction of stromelysin by an activated ras oncogene.
Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Dehydrocrenatidine is a novel janus kinase inhibitor.
Deletion of Adipose Triglyceride Lipase Links Triacylglycerol Accumulation to a More-Aggressive Phenotype in A549 Lung Carcinoma Cells.
Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis.
Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth.
Delineating the molecular mechanisms of tamoxifen's oncolytic actions in estrogen receptor-negative cancers.
Denbinobin suppresses breast cancer metastasis through the inhibition of Src-mediated signaling pathways.
Depletion of Csk preferentially reduces the protein level of LynA in a Cbl-dependent manner in cancer cells.
Depression promotes prostate cancer invasion and metastasis via a sympathetic-cAMP-FAK signaling pathway.
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Deregulated Expression of SRC, LYN and CKB Kinases by DNA Methylation and Its Potential Role in Gastric Cancer Invasiveness and Metastasis.
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Design and evaluation of a real-time activity probe for focal adhesion kinase.
Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor.
Design and screening of FAK, CDK 4/6 dual inhibitors by pharmacophore model, molecular docking, and molecular dynamics simulation.
Design, synthesis and biological evaluation of novel acrylamide analogues as inhibitors of BCR-ABL kinase.
Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4.
Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2.
Design, synthesis, and biological evaluation of F-18-labelled 2, 4-diaminopyrimidine-type FAK-targeted inhibitors as potential tumour imaging agents.
Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.
Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.
Design, synthesis, and evaluation of novel imidazo[1,2-a][1,3,5]triazines and their derivatives as focal adhesion kinase inhibitors with antitumor activity.
Design, Synthesis, Biological Evaluation, and Molecular Docking of 2,4-Diaminopyrimidine Derivatives Targeting Focal Adhesion Kinase as Tumor Radiotracers.
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.
Detection of a rare BCR-ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS).
Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Detection of multiple tumor suppressor genes for Syrian hamster fibrosarcomas by somatic cell hybridization.
Detection of mutations in JAK2 exons 12-15 by Sanger sequencing.
Detection of resistance to imatinib by metabolic profiling: clinical and drug development implications.
Development and characterization of DP-153, a nontumorigenic prostatic cell line that undergoes malignant transformation by expression of dominant-negative transforming growth factor beta receptor type II.
Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice.
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.
Development of a Bifunctional Andrographolide-Based Chemical Probe for Pharmacological Study.
Development of a Fragment-Based Screening Assay for the Focal Adhesion Targeting Domain Using SPR and NMR.
Development of a High-Throughput Fluorescence Polarization Assay to Detect Inhibitors of the FAK-Paxillin Interaction.
Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein.
Development of a Selective Labeling Probe for Bruton's Tyrosine Kinase Quantification in Live Cells.
Development of a Trispecific Antibody Designed to Simultaneously and Efficiently Target Three Different Antigens on Tumor Cells.
Development of Focal Adhesion Kinase Inhibitors in Cancer Therapy.
Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
Development of TGF-beta resistance during malignant progression.
Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.
Development of transgenic mice that inducibly express an active form of c-Src in the epidermis.
Developmental Therapeutics in Myeloproliferative Neoplasms.
Diagnosis and Individualized Treatment of Secondary Central Nervous System Lymphoma: A Case Report.
Diagnosis and Management of Rheumatoid Arthritis: A Review.
Diagnostic utility of oncogenes and their products in human cancer.
Diallyl trisulfide inhibits cell migration and invasion of human melanoma a375 cells via inhibiting integrin/facal adhesion kinase pathway.
Dietary choline deficiency and excess induced intestinal inflammation and alteration of intestinal tight junction protein transcription potentially by modulating NF-?B, STAT and p38 MAPK signaling molecules in juvenile Jian carp.
Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
Differences and similarities in ibrutinib and acalabrutinib effects on platelet functions.
Differences in the JAK2 and MPL mutation status in the cell lineages of the bcr/abl-negative chronic myeloproliferative neoplasm subtypes.
Differential effect of imatinib and synergism of combination treatment with chemotherapeutic agents in malignant glioma cells.
Differential effect of the focal adhesion kinase Y397F mutant on v-Src-stimulated cell invasion and tumor growth.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Differential expression of Janus kinase 3 (JAK3), matrix metalloproteinase 13 (MMP13), heat shock protein 60 (HSP60), and mouse double minute 2 (MDM2) in human colorectal cancer progression using human cancer cDNA microarrays.
Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array.
Differential protein expression and oncogenic gene network link tyrosine kinase ephrin B4 receptor to aggressive gastric and gastroesophageal junction cancers.
Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model.
Differential response to retinoic acid of Syrian hamster embryo fibroblasts expressing v-src or v-Ha-ras oncogenes.
Differential spheroid formation by oral cancer cells.
Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Digenic/multilocus aetiology of multiple self-healing squamous epithelioma (Ferguson-Smith disease): TGFBR1 and a second linked locus.
Diminished in vitro tyrosine kinase activity of the EGF receptor of senescent human fibroblasts.
Dioscin reduces lipopolysaccharide-induced inflammatory liver injury via regulating TLR4/MyD88 signal pathway.
Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor.
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Direct interaction of the N-terminal domain of focal adhesion kinase with the N-terminal transactivation domain of p53.
Direct Interactions with the Integrin ?1 Cytoplasmic Tail Activate the Abl2/Arg Kinase.
Direct tumorigenic conversion of human gallbladder carcinoma cells by v-src but not by activated c-H-ras oncogene.
Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics.
Discovery and biological evaluation of N-(3-(7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-4-methyl-2-oxo-2H-pyrimido[4,5-d][1,3]oxazin-1(4H)-yl)phenyl)acrylamide as potent Bruton's tyrosine kinase inhibitors.
Discovery and biological evaluation of N5-substituted 6,7-dioxo-6,7-dihydropteridine derivatives as potent Bruton's tyrosine kinase inhibitors.
Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML).
Discovery of 14-3-3 Protein-Protein Interaction Inhibitors that Sensitize Multidrug-Resistant Cancer Cells to Doxorubicin and the Akt Inhibitor GSK690693.
Discovery of 4-anilino ?-carbolines as novel Brk inhibitors.
Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.
Discovery of a Pyrimidothiazolodiazepinone as a Potent and Selective Focal Adhesion Kinase (FAK) Inhibitor.
Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
Discovery of a small molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFR{alpha}, Kit, and Src kinases.
Discovery of Affinity-Based Probes for Btk Occupancy Assays.
Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton.
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancer.
Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and N-Substituted Benzamides as Potential FAK Inhibitors and Anticancer Agents.
Discovery of Novel Bruton's Tyrosine Kinase Inhibitors Using a Hybrid Protocol of Virtual Screening Approaches Based on SVM Model, Pharmacophore and Molecular Docking.
Discovery of novel BTK PROTACs for B-Cell lymphomas.
Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives.
Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Discovery of potent and highly selective covalent inhibitors of Bruton's tyrosine kinase bearing triazine scaffold.
Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.
Discovery of SIAIS178 as an effective BCR-ABL degrader by recruiting von Hippel-Lindau (VHL) E3 Ubiquitin Ligase.
Discovery of Tricyclic Pyranochromenone as Novel Bruton's Tyrosine Kinase Inhibitors with in Vivo Antirheumatic Activity.
Disease expression in juvenile polyposis syndrome: a retrospective survey on a cohort of 221 European patients and comparison with a literature-derived cohort of 473 SMAD4/BMPR1A pathogenic variant carriers.
Disease modifying agents of myeloproliferative neoplasms: a review.
Disrupting the intramolecular interaction between proto-oncogene c-Src SH3 domain and its self-binding peptide PPII with rationally designed peptide ligands.
Disrupting the scaffold to improve focal adhesion kinase-targeted cancer therapeutics.
Disruption of Ca2+-dependent cell-matrix adhesion enhances c-Src kinase activity, but causes dissociation of the c-Src/FAK complex and dephosphorylation of tyrosine-577 of FAK in carcinoma cells.
Disruption of focal adhesion kinase and p53 interaction with small molecule compound R2 reactivated p53 and blocked tumor growth.
Disruption of focal adhesion kinase slows transendothelial migration of AU-565 breast cancer cells.
Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib - Findings from an Investigator-Initiated Phase II Study.
Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation.
Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation.
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis.
Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.
Distinct roles of cellular Lck and p80 proteins in herpesvirus saimiri Tip function on lipid rafts.
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.
Diterpenoids and Triterpenoids From Frankincense Are Excellent Anti-psoriatic Agents: An in silico Approach.
Diversity of Long-Lived Intermediates along the Binding Pathway of Imatinib to Abl Kinase Revealed by MD Simulations.
DNA copy number aberrations in small-cell lung cancer reveal activation of the focal adhesion pathway.
DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis.
DNA damage response: The emerging role of c-Abl as a regulatory switch?
DNA vaccination against v-src oncogene-induced tumours in congenic chickens.
Do structural changes of T cell receptor complex occur in tumor-bearing state?
Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice.
Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models.
Dose-dependent effects of Bcr-Abl in cell line models of different stages of chronic myeloid leukemia.
Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer cells to FAK autophosphorylation inhibitor Y15.
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Down-regulation of focal adhesion kinase, pp125FAK, in endothelial cell retraction during tumor cell invasion.
Down-regulation of JAK1 by RNA interference inhibits growth of the lung cancer cell line A549 and interferes with the PI3K/mTOR pathway.
Down-regulation of the tumor suppressor gene C-terminal Src kinase: an early event during premalignant colonic epithelial hyperproliferation.
Downregulation of drs mRNA expression is associated with the progression of adult T-cell leukemia/lymphoma.
Downregulation of drs tumor suppressor gene in highly malignant human pulmonary neuroendocrine tumors.
Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer.
Downregulation of microRNA-4324 promotes the EMT of esophageal squamous-cell carcinoma cells via upregulating FAK.
Downregulation of microRNAs directs the EMT and invasive potential of anaplastic thyroid carcinomas.
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
Dramatic and durable efficacy of imatinib in an advanced angiosarcoma without detectable KIT and PDGFRA mutations.
Drosophila linker histone H1 coordinates STAT-dependent organization of heterochromatin and suppresses tumorigenesis caused by hyperactive JAK-STAT signaling.
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Drug interactions with Bruton's tyrosine kinase inhibitors: clinical implications and management.
Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
Drug-Related Cutaneous Adverse Events in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Literature Review.
Druggable signaling proteins.
Dsi-1, a region with frequent proviral insertions in Moloney murine leukemia virus-induced rat thymomas.
Dual focal adhesion kinase/Pyk2 inhibitor has positive effects on bone tumors: implications for bone metastases.
Dual Inhibiton of Bruton's Tyrosine Kinase and Phosphoinositide-3-Kinase p110? as a Therapeutic Approach to Treat non-Hodgkin's B cell Malignancies.
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Dual-Modality Micro-Positron Emission Tomography/Computed Tomography and Near-Infrared Fluorescence Imaging of EphB4 in Orthotopic Glioblastoma Xenograft Models.
Dynamic changes in the gene expression profile during rat oral carcinogenesis induced by 4?nitroquinoline 1?oxide.
Dynamic Regulation of Caveolin-1 Phosphorylation and Caveolae Formation by Mammalian Target of Rapamycin Complex 2 in Bladder Cancer Cells.
Dynamics of chronic myeloid leukaemia.
Dynamics of p14ARF and Focal Adhesion Kinase-Mediated Autophagy in Cancer.
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Dysregulated activation of c-Src in gestational trophoblastic disease contributes to its aggressive progression.
Dysregulation of miR-3607 predicts prognosis of hepatocellular carcinoma and regulates tumor cell proliferation, migration and invasion.
Dysregulation of the protein tyrosine kinase LCK in lymphoproliferative disorders and in other neoplasias.
E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin ?v?6 and maintained through TGF? signalling.
Early-onset colorectal cancer: A distinct entity with unique genetic features.
ECM Remodeling in Breast Cancer with Different Grade: Contribution of 2D-DIGE Proteomics.
Ectopic expression of protein-tyrosine kinase Bcr-Abl suppresses tumor necrosis factor (TNF)-induced NF-kappa B activation and IkappaBalpha phosphorylation. Relationship with down-regulation of TNF receptors.
Edaravone mitigates hemorrhagic cystitis by modulating Nrf2, TLR-4/NF-?B, and JAK1/STAT3 signaling in cyclophosphamide-intoxicated rats.
Editorial: Survival Signaling through Focal Adhesion Kinase in Tumors.
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.
Effect of celecoxib on protein expression of FAK and Cx43 in DMBA induced rat tongue carcinoma cells.
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants.
Effect of focal adhesion kinase (FAK) downregulation with FAK antisense oligonucleotides and 5-fluorouracil on the viability of melanoma cell lines.
Effect of HSP90AB1 and CC domain interaction on Bcr-Abl protein cytoplasm localization and function in chronic myeloid leukemia cells.
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2 : A Prospective Cohort Study.
Effect of Janus Kinase 3 on the Peptide Transporters PEPT1 and PEPT2.
Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Effect of targeting janus kinase 3 on the development of intestinal tumors in the adenomatous polyposis coli(min) mouse model of familial adenomatous polyposis.
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen.
Effective Photothermal Chemotherapy Using Doxorubicin-Loaded Gold Nanospheres That Target EphB4 Receptors in Tumors.
Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Effectiveness of Scutellaria barbata water extract on inhibiting colon tumor growth and metastasis in tumor-bearing mice.
Effects of AG490 and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in TRAIL-resistant prostate cancer cells in vitro.
Effects of Alcohol on Postoperative Adhesion Formation in Ischemic Myocardium and Pericardium.
Effects of EphB4 receptor expression on colorectal cancer cells, tumor growth, vascularization and composition.
Effects of Glycyrrhetic Acid on Human Chronic Myelogenous Leukemia Cells.
Effects of ibrutinib on in vitro platelet aggregation in blood samples from healthy donors and donors with platelet dysfunction.
Effects of Jak2 Type 1 Inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 Mutation-Positive and Bcr-Abl-Positive Cell Lines.
Effects of novel Btk and Syk inhibitors on platelet functions alone and in combination in vitro and in vivo.
Effects of Pimozide Derivatives on pSTAT5 in K562 Cells.
Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Effects of tyrosine kinase inhibitors on the proliferation of human breast cancer cell lines and proteins important in the ras signaling pathway.
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
Efficacy of focal adhesion kinase inhibition in non-small cell lung cancer with oncogenically activated MAPK pathways.
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype.
Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review.
Efficient NQO1 Substrates are Potent and Selective Anticancer Agents.
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
EGF regulates tyrosine phosphorylation and membrane-translocation of the scaffold protein Tks5.
EGFR signaling pathway occupies an important position in cancer-related downstream signaling pathways of Pyk2.
EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation.
EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.
eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Elevated activity and expression of Src-family kinases in human breast carcinoma tissue versus matched non-tumor tissue.
Elevated c-Src and c-Yes expression in malignant skin cancers.
Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells.
Elevated focal adhesion kinase expression facilitates oral tumor cell invasion.
Elevated Src kinase activity attenuates Tamoxifen response in vitro and is associated with poor prognosis clinically.
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Elucidation of protein interactions necessary for the maintenance of the BCR-ABL signaling complex.
Emergence of MPLW515 mutation in a patient with CALR deletion: Evidence of secondary acquisition of MPL mutation in the CALR clone.
Emerging drugs for myelofibrosis.
Emerging Role of Migration and Invasion Enhancer 1 (MIEN1) in Cancer Progression and Metastasis.
Emerging roles of focal adhesion kinase in cancer.
Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy.
Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.
Emerging therapeutic targets in breast cancer bone metastasis.
Endogenous c-src as a determinant of the tumorigenicity of src oncogenes.
Endogenous Control Mechanisms of FAK and PYK2 and Their Relevance to Cancer Development.
Endosomes: Emerging Platforms for Integrin-Mediated FAK Signalling.
Endothelial focal adhesion kinase mediates cancer cell homing to discrete regions of the lungs via E-selectin up-regulation.
Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy.
Energetic dissection of Gleevec's selectivity toward human tyrosine kinases.
Enforced SOCS1 and SOCS3 expression attenuates Lck-mediated cellular transformation.
Engagement of the inhibitory receptor CD158a interrupts TCR signaling, preventing dynamic membrane reorganization in CTL/tumor cell interaction.
Engineering of RNase P ribozyme for gene-targeting applications.
Enhanced constitutive invasion activity in human nontumorigenic keratinocytes exposed to a low level of barium for a long time.
Enhanced expression of cholecystokinin-2 receptor promotes the progression of colon cancer through activation of focal adhesion kinase.
Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer.
Enhanced Risk for Specific Somatic Myeloproliferative Neoplastic Mutations in Patients with Stroke.
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
Environmental, lifestyle, and familial/ethnic factors associated with myeloproliferative neoplasms.
Enzymatic and immunohistochemical evaluation of tyrosine phosphorylation in breast cancer specimens.
EPHB4 and Survival of Colorectal Cancer Patients.
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
EphB4 cellular kinase activity assayed using an enzymatic protein interaction system.
EphB4 controls blood vascular morphogenesis during postnatal angiogenesis.
EphB4 expression and biological significance in prostate cancer.
EphB4 expression in pterygium is associated with microvessel density.
EphB4 gene polymorphism and protein expression in non-small-cell lung cancer.
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.
EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model.
EPHB4 is a therapeutic target in AML and promotes leukemia cell survival via AKT.
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
EphB4 localises to the nucleus of prostate cancer cells.
EphB4 mediates resistance to antiangiogenic therapy in experimental glioma.
EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis.
EphB4 promotes or suppresses Ras/MEK/ERK pathway in a context-dependent manner: Implications for EphB4 as a cancer target.
EphB4 Promotes Site-Specific Metastatic Tumor Cell Dissemination by Interacting with Endothelial Cell-Expressed EphrinB2.
EphB4 promotes the proliferation, invasion, and angiogenesis of human colorectal cancer.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
EphB4-targeted imaging with antibody h131, h131-F(ab')2 and h131-Fab.
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
EphB4: A promising target for upper aerodigestive malignancies.
Ephrin type-B receptor 4 affinity chromatography: An effective and rapid method studying the active compounds targeting Ephrin type-B receptor 4.
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor.
Ephrin?B2 inhibits cell proliferation and motility in vitro and predicts longer metastasis?free survival in breast cancer.
EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results.
Epidermal growth factor and its receptor.
Epidermal growth factor receptor potentiates MCM7-mediated DNA replication through tyrosine phosphorylation of Lyn kinase in human cancers.
Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase.
Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Epigenetic dysregulation of secreted frizzled-related proteins in myeloproliferative neoplasms complements the JAK2V617F-mutation.
Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma.
Epimorphin promotes human hepatocellular carcinoma invasion and metastasis through activation of focal adhesion kinase/extracellular signal-regulated kinase/matrix metalloproteinase-9 axis.
Epithelial BMP signaling is required for proper specification of epithelial cell lineages and gastric endocrine cells.
Epithelial Hic-5/ARA55 expression contributes to prostate tumorigenesis and castrate responsiveness.
Epithelial Membrane Protein-2 (EMP2) Activates Src and is a Novel Therapeutic Target for GBM.
ER maleate is a novel anticancer agent in oral cancer: Implications for cancer therapy.
Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) Promotes ATG12-Dependent Autophagy Contributing to Treatment Resistance of Breast Cancer Cells.
Erb?B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53?responsive microRNA?3184?5p in cervical cancer cells.
ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
ERBB2 FISH and Chromosome Microarray Testing of Gastroesophageal Adenocarcinomas at a Single Institution.
ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
ErbB2, EphrinB1, Src kinase and PTPN13 signaling complex regulates MAP kinase signaling in human cancers.
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Erythropoietin Stimulates Tumor Growth via EphB4.
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).
Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Essential role of Stat3 in PI3K-induced oncogenic transformation.
Essential roles of BMPR-IA signaling in differentiation and growth of hair follicles and in skin tumorigenesis.
Establishing the role of tyrosine kinase 2 in cancer.
Establishment and characterization of seven human renal cell carcinoma cell lines.
Establishment of a lymphoblastoid cell line, SD-1, expressing the p190 bcr-abl chimaeric protein.
Establishment of PI3K inhibitor-resistant cancer cell lines and the therapeutic strategies for overcoming the resistance.
Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors.
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: role in endothelial cell migration and angiogenesis.
Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway.
Evaluation of BAT-26 as an indicator of microsatellite instability in gallbladder carcinomas.
Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery.
Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer.
Evaluation of FAK and Src Expression in Human Benign and Malignant Thyroid Lesions.
Evaluation of the Clinical Significance of Focal Adhesion Kinase and Src Expression in Human Pancreatic Ductal Adenocarcinoma.
Evaluation of the cocarcinogenic effect of wounding in Rous sarcoma virus tumorigenesis.
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
Evaluation of WO2011134971, chiral 1,6-napthyridine Syk kinase inhibitors.
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Evidence for BCR-ABL-dependent dysfunctions of iNKT cells from chronic myeloid leukemia patients.
Evidence for interaction of the NLRP3 inflammasome and Bruton's tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta.
Evidence for Janus kinase (JAK) inhibitors for the prevention of major morbid events in patients with myeloproliferative neoplasms (MPNs).
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers.
Evidence that there exist four classes of RNA tumor viruses which encode proteins with associated tyrosine protein kinase activities.
Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Evolving therapies and FAK inhibitors for the treatment of cancer.
Ex vivo activation of tumor-draining lymph node T cells reverses defects in signal transduction molecules.
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.
Exosomes of Mesenchymal Stem Cells as a Proper Vehicle for Transfecting miR-145 into the Breast Cancer Cell Line and Its Effect on Metastasis.
Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future.
Experimental metastasis of oncogene-transformed NIH 3T3 cells in chick embryo.
Experimental non-ATP-competitive therapies for chronic myelogenous leukemia.
Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations.
Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.
Exposure-Response Analysis of Acalabrutinib and its Active Metabolite, ACP-5862, in Patients With B-Cell Malignancies.
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma.
Expression and methylation status of the Syk gene in cervical carcinoma.
Expression and mutation of SMAD4 in poorly differentiated carcinoma and signet-ring cell carcinoma of the colorectum.
Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer.
Expression and prognostic significance of EFNB2 and EphB4 genes in patients with oesophageal squamous cell carcinoma.
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Expression of a phosphorylated substrate domain of p130Cas promotes PyMT-induced c-Src-dependent murine breast cancer progression.
Expression of a truncated first exon BCR sequence in chronic myelogenous leukemia cells blocks cell growth and induces cell death.
Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry.
Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification.
Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative.
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Expression of bone morphogenetic protein-6 and bone morphogenetic protein receptors in myoepithelial cells of canine mammary gland tumors.
Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
Expression of c-yes oncogene product in various animal tissues and spontaneous canine tumours.
Expression of EMT inducers integrin-linked kinase (ILK) and ZEB1 in phyllodes breast tumors is associated with aggressive phenotype.
Expression of Ephb2 and Ephb4 in breast carcinoma.
Expression of EphB4 in head and neck squamous cell carcinoma.
Expression of EphrinB2 and EphB4 in glioma tissues correlated to the progression of glioma and the prognosis of glioblastoma patients.
Expression of etk/bmx tyrosine kinase in intrahepatic cholangiocarcinoma.
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in human gliomas is associated with unfavorable overall survival.
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Expression of focal adhesion kinase gene and invasive cancer.
Expression of focal adhesion kinase in patients with endometrial cancer: a clinicopathologic study.
Expression of focal adhesion kinase in small-cell lung carcinoma.
Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG.
Expression of Functional Sphingosine-1 Phosphate Receptor-1 Is Reduced by B Cell Receptor Signaling and Increased by Inhibition of PI3 Kinase ? but Not SYK or BTK in Chronic Lymphocytic Leukemia Cells.
Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors.
Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Expression of p56lck in B-cell neoplasias.
Expression of p73 and c-Abl proteins in human ovarian carcinomas.
Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease.
Expression of putative tumor suppressor gene spleen tyrosine kinase in esophageal squamous cell carcinoma.
Expression of pY397 FAK promotes the development of non-small cell lung cancer.
Expression of sialidase Neu2 in leukemic K562 cells induces apoptosis by impairing Bcr-Abl/Src kinases signaling.
Expression of Syk in invasive breast cancer: correlation to proliferation and invasiveness.
Expression of the adaptor protein Tks5 in human cancer: Prognostic potential.
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Expression of the human fes cellular oncogene in renal cell tumors.
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Expression of the signal transducer and activator of transcription factor 3 and Janus kinase 3 in colorectal carcinomas, colonic adenomas and ulcerative colitis.
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system.
Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma.
Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors.
Expression of Wnt11 and Rock2 protein with clinical characteristics of esophageal squamous cell carcinoma in Kazakh and Han patients.
Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status.
Expression, purification, and bioactivity of GST-fused v-Src from a bacterial expression system.
Extramedullary blast crisis of chronic myeloid leukemia after allogeneic hematopoietic stem cell transplantation mimicking aggressive, translocation t(14;18)-positive B-cell lymphoma.
Ezrin is key regulator of Src-induced malignant phenotype in three-dimensional environment.
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
FAK alternative splice mRNA variants expression pattern in colorectal cancer.
Fak and Has Inhibtion Synergistically Decrease Colon Cancer Cell Viability and Affect Expression Of Critical Genes.
FAK and Nanog Cross Talk with p53 in Cancer Stem Cells.
FAK and paxillin, two potential targets in pancreatic cancer.
FAK auto-phosphorylation site tyrosine 397 is required for development but dispensable for normal skin homeostasis.
FAK deletion promotes p53-mediated induction of p21, DNA-damage responses and radio-resistance in advanced squamous cancer cells.
FAK displacement from focal adhesions: a promising strategy to target processes implicated in cancer progression and metastasis.
FAK family kinases: The Yin and Yang of cancer cell invasiveness.
FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy.
FAK in cancer: mechanistic findings and clinical applications.
FAK Inhibition Abrogates the Malignant Phenotype in Aggressive Pediatric Renal Tumors.
FAK Inhibition Decreases Hepatoblastoma Survival Both In Vitro and In Vivo.
FAK Inhibition Induces Glioblastoma Cell Senescence-Like State through p62 and p27.
FAK inhibition radiosensitizes pancreatic ductal adenocarcinoma cells in vitro.
FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
FAK is involved in invasion and metastasis of hepatocellular carcinoma.
FAK overexpression and p53 mutations are highly correlated in human breast cancer.
FAK regulates biological processes important for the pathogenesis of cancer.
FAK regulates cardiomyocyte survival following ischemia/reperfusion.
FAK regulates E-cadherin expression via p-SrcY416/p-ERK1/2/p-Stat3Y705 and PPAR?/miR-125b/Stat3 signaling pathway in B16F10 melanoma cells.
FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs.
FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal.
FAK signaling in human cancer as a target for therapeutics.
FAK signaling in neoplastic disorders: a linkage between inflammation and cancer.
FAK signalling controls insulin sensitivity through regulation of adipocyte survival.
FAK tyrosine phosphorylation is regulated by AMPK and controls metabolism in human skeletal muscle.
FAK-targeted and combination therapies for the treatment of cancer: an overview of phase I and II clinical trials.
Fc epsilon RI-mediated tyrosine phosphorylation and activation of the 72-kDa protein-tyrosine kinase, PTK72, in RBL-2H3 rat tumor mast cells.
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
FER mediated HGF-independent regulation of HGFR/MET activates RAC1-PAK1 pathway to potentiate metastasis in ovarian cancer.
Fer protein-tyrosine kinase promotes lung adenocarcinoma cell invasion and tumor metastasis.
Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression.
FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.
FES kinase promotes mast cell recruitment to mammary tumors via the stem cell factor/KIT receptor signaling axis.
Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Fibrinogen activates focal adhesion kinase (FAK) promoting colorectal adenocarcinoma growth.
Fibroblasts can express glial fibrillary acidic protein (GFAP) in vivo.
Filamin B Enhances the Invasiveness of Cancer Cells into 3D Collagen Matrices.
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.
First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer.
First report of the safety, tolerability, and pharmacokinetics of the Src kinase inhibitor saracatinib (AZD0530) in Japanese patients with advanced solid tumours.
Fish Oil Alleviates Activation of Hypothalamic-Pituitary-Adrenal Axis Associated with Inhibition of TLR4 and NOD Signaling Pathways in Weaned Piglets after a Lipopolysaccharide Challenge.
Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function.
FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues.
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling.
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Focal Adhesion Kinase Activity and Localization is Critical for TNF-?-Induced Nuclear Factor-?B Activation.
Focal adhesion kinase affects the sensitivity of human hepatocellular carcinoma cell line SMMC-7721 to tumor necrosis factor-alpha/cycloheximide-induced apoptosis by regulating protein kinase B levels.
Focal Adhesion Kinase and ?-Catenin Cooperate to Induce Hepatocellular Carcinoma.
Focal adhesion kinase and cancer.
Focal adhesion kinase and cross-linked signaling in cancer.
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Focal adhesion kinase and p53 signal transduction pathways in cancer.
Focal adhesion kinase and p53 signaling in cancer cells.
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.
Focal adhesion kinase and protein kinase B cooperate to suppress Doxorubicin-induced apoptosis of breast tumor cells.
Focal adhesion kinase and tumour angiogenesis.
Focal adhesion kinase as a cancer therapy target.
Focal Adhesion Kinase as a Potential Target in AML and MDS.
Focal adhesion kinase as a regulator of cell tension in the progression of cancer.
Focal adhesion kinase as an immunotherapeutic target.
Focal adhesion kinase as potential target for cancer therapy (Review).
Focal adhesion kinase autophosphorylation inhibition decreases colon cancer cell growth and enhances the efficacy of chemotherapy.
Focal adhesion kinase contributes to proliferative potential of ErbB2 mammary tumour cells but is dispensable for ErbB2 mammary tumour induction in vivo.
Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples.
Focal adhesion kinase expression in oral cancers.
Focal adhesion kinase in cancer.
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review.
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Focal adhesion kinase is activated in invading fibrosarcoma cells and regulates metastasis.
Focal adhesion kinase is expressed in the angiogenic blood vessels of malignant astrocytic tumors in vivo and promotes capillary tube formation of brain microvascular endothelial cells.
Focal adhesion kinase is overexpressed in thymic epithelial tumors and may serve as an independent prognostic biomarker.
Focal adhesion kinase is required for synovial fibroblast invasion, but not murine inflammatory arthritis.
Focal adhesion kinase negatively regulates neuronal insulin resistance.
Focal adhesion kinase overexpression and its impact on human osteosarcoma.
Focal adhesion kinase overexpression in endometrial neoplasia.
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Focal adhesion kinase promotes progression and predicts poor clinical outcomes in patients with osteosarcoma.
Focal Adhesion Kinase Regulates Expression of Thioredoxin-interacting Protein (TXNIP) in Cancer Cells.
Focal adhesion kinase regulates metastatic adhesion of carcinoma cells within liver sinusoids.
Focal Adhesion Kinase regulates the DNA damage response and its inhibition radiosensitizes mutant KRAS lung cancer.
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Focal adhesion kinase signaling and the aggressive melanoma phenotype.
Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered wnt signaling.
Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein.
Focal adhesion kinase-An emerging viable target in cancer and development of focal adhesion kinase inhibitors.
Focal Adhesion Kinase-Dependent Role of the Soluble Form of Neurotensin Receptor-3/Sortilin in Colorectal Cancer Cell Dissociation.
Focal adhesion kinase-promoted tumor glucose metabolism is associated with a shift of mitochondrial respiration to glycolysis.
Focal adhesion kinase-regulated signaling events in human cancer.
Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness.
Focal adhesion kinase: a potential target in cancer therapy.
Focal adhesion kinase: Insight into its roles and therapeutic potential in oesophageal cancer.
Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
Focal adhesion kinases in head and neck squamous cell carcinoma.
Folic acid inhibits COLO-205 colon cancer cell proliferation through activating the FR?/c-SRC/ERK1/2/NF?B/TP53 pathway: in vitro and in vivo studies.
Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice.
Food Processing, Dysbiosis, Gastrointestinal Inflammatory Diseases, and Antiangiogenic Functional Foods or Beverages.
Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.
Frameshift mutations at coding mononucleotide repeat microsatellites in endometrial carcinoma with microsatellite instability.
Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties.
Frequent development of murine T-cell lymphomas with TcR alpha/beta+, CD4-/8- phenotype after implantation of human inflammatory breast cancer cells in BALB/c nude mice.
Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers.
FRK inhibits breast cancer cell migration and invasion by suppressing epithelial-mesenchymal transition.
FRK Inhibits Migration and Invasion of Human Glioma Cells by Promoting N-cadherin/?-catenin Complex Formation.
FRK plays an oncogenic role in non-small cell lung cancer by enhancing the stemness phenotype via induction of metabolic reprogramming.
FRK suppresses human glioma growth by inhibiting ITGB1/FAK signaling.
FRK suppresses the proliferation of human glioma cells by inhibiting cyclin D1 nuclear accumulation.
From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms.
From Rous sarcoma virus to plasminogen activator, src oncogene and cancer management.
Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Fullerene derivative prevents cellular transformation induced by JAK2 V617F mutant through inhibiting c-Jun N-terminal kinase pathway.
Function and mechanism of neurotensin (NTS) and its receptor 1 (NTSR1) in occurrence and development of tumors.
Function of focal adhesion kinase scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition and mammary cancer stem cell activities in vivo.
Function of RNH-1/14-3-3 beta gene in cellular differentiation and proliferation.
Function-dependent cooperation between oncogene activation and nonrandom chromosome change during tumorigenic conversion of Syrian hamster cells.
Functional and prognostic role of ZAP-70 in chronic lymphocytic leukaemia.
Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
Functional Consequences of Mutations in Myeloproliferative Neoplasms.
Functional dissection of transformation by c-Src and v-Src.
Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas.
Functional imaging in combination with mutation status aids prediction of response to inhibiting B-cell receptor signaling in lymphoma.
Functional interplay between NIK and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Functional interplay of SP family members and nuclear factor Y is essential for transcriptional activation of the human Calreticulin gene.
Functional role of wogonin in anti-angiogenesis.
Functions and clinical significance of KLRG1 in the development of lung adenocarcinoma and immunotherapy.
Furanodiene, a natural small molecule suppresses metastatic breast cancer cell migration and invasion in vitro.
Fusion proteins in head and neck neoplasms: Clinical implications, genetics, and future directions for targeting.
Future directions of bone-targeted therapy for metastatic breast cancer.
FYN expression potentiates FLT3-ITD induced STAT5 signaling in acute myeloid leukemia.
Fyn kinase in brain diseases and cancer: the search for inhibitors.
Fyn kinase is a direct molecular target of delphinidin for the inhibition of cyclooxygenase-2 expression induced by tumor necrosis factor-alpha.
Fyn Requires HnRNPA2B1 and Sam68 to Synergistically Regulate Apoptosis in Pancreatic Cancer.
Fyn-phosphorylated PIKE-A binds and inhibits AMPK signaling, blocking its tumor suppressive activity.
G2A is an oncogenic G protein-coupled receptor.
Gadd45a transcriptional induction elicited by the Aurora kinase inhibitor MK-0457 in Bcr-Abl-expressing cells is driven by Oct-1 transcription factor.
Galectin-3 Overrides PTRF/Cavin-1 Reduction of PC3 Prostate Cancer Cell Migration.
Gamma linolenic acid inhibits tyrosine phosphorylation of focal adhesion kinase and paxillin and tumour cell matrix interaction.
Gastrin-releasing peptide is a mitogen and a morphogen in murine colon cancer.
Gastrin-stimulated G?13 Activation of Rgnef Protein (ArhGEF28) in DLD-1 Colon Carcinoma Cells.
GATA-1: A potential novel biomarker for the differentiation of essential thrombocythemia and myelofibrosis.
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Geldanamycin-induced cytotoxicity in human colon-cancer cell lines: evidence against the involvement of c-Src or DT-diaphorase.
Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative.
Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triplenegative breast cancers.
Gene expression of transforming growth factor-beta 1 and its type II receptor in giant cell tumors of bone. Possible involvement in osteoclast-like cell migration.
Gene expression profile of herpesvirus-infected T cells obtained using immunomicroarrays: induction of proinflammatory mechanisms.
Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab.
Generation of a poor prognostic chronic lymphocytic leukemia-like disease model: PKC? subversion induces an upregulation of PKC?II expression in B lymphocytes.
Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies.
Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.
Genetic alterations are frequent in APC but rare in the TGF-beta type II receptor gene in cancer in adenomas of the colon.
Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Genetic and clinical features of human pancreatic ductal adenocarcinomas with widespread microsatellite instability.
Genetic and epigenetic alterations of myeloproliferative disorders.
Genetic disruption of Abl nuclear import reduces renal apoptosis in a mouse model of cisplatin-induced nephrotoxicity.
Genetic engineering to study testicular tumorigenesis.
Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma.
Genetic landscape of metastatic and recurrent head and neck squamous cell carcinoma.
Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia.
Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study.
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
Genome-wide association study identifies new loci associated with noise-induced tinnitus in Chinese populations.
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Genomic characterization of liver metastases from colorectal cancer patients.
Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53.
Genotype-defined cancer risk in juvenile polyposis syndrome.
Geranylgeraniol Suppresses the Expression of IRAK1 and TRAF6 to Inhibit NF?B Activation in Lipopolysaccharide-Induced Inflammatory Responses in Human Macrophage-Like Cells.
Germline and germline mosaic PTEN mutations associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriovenous malformations and lipomatosis.
Germline and somatic JAK2 mutations and susceptibility to chronic myeloproliferative neoplasms.
Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes.
GHRH antagonist inhibits focal adhesion kinase (FAK) and decreases expression of vascular endothelial growth factor (VEGF) in human lung cancer cells in vitro.
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
Glivec and CML: a lucky date.
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
Global impact of oncogenic Src on a phosphotyrosine proteome.
Global proteome quantification for discovering imatinib-induced perturbation of multiple biological pathways in k562 human chronic myeloid leukemia cells.
Glucose Drives Growth Factor-Independent Esophageal Cancer Proliferation via Phosphohistidine-Focal Adhesion Kinase Signaling.
Glycine-extended gastrin activates two independent tyrosine-kinases in upstream of p85/p110 phosphatidylinositol 3-kinase in human colonic tumour cells.
GM1 controlled lateral segregation of tyrosine kinase Lck predispose T-cells to cell-derived galectin-1-induced apoptosis.
GPRC5A: An Emerging Biomarker in Human Cancer.
Granulosa Cell-Expressed BMPR1A and BMPR1B Have Unique Functions in Regulating Fertility but Act Redundantly to Suppress Ovarian Tumor Development.
Grb7 and Hax1 may colocalize partially to mitochondria in EGF-treated SKBR3 cells and their interaction can affect Caspase3 cleavage of Hax1.
Grb7 SH2 domain structure and interactions with a cyclic peptide inhibitor of cancer cell migration and proliferation.
GTPase regulator associated with the focal adhesion kinase (GRAF) transcript was down-regulated in patients with myeloid malignancies.
GTPase-activating protein Rasal1 associates with ZAP-70 of the TCR and negatively regulates T-cell tumor immunity.
Guar gum fiber increases suppressor of cytokine signaling-1 expression via toll-like receptor 2 and dectin-1 pathways, regulating inflammatory response in small intestinal epithelial cells.
Guidelines for the management of myeloproliferative neoplasms.
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Haematological cancer: Nilotinib reduces emergence of BCR-ABL mutations in CML.
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
Head and neck cancer cell radiosensitization upon dual targeting of c-Abl and beta1-integrin.
Heat Shock Protein 27 Phosphorylation Regulates Tumor Cell Migration under Shear Stress.
Heat shock protein 90? stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells.
Hedgehog pathway activation in chronic myeloid leukemia.
Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis.
Helicobacter pylori-controlled c-Abl localization promotes cell migration and limits apoptosis.
Heme oxygenase-1 protects rat liver against warm ischemia/reperfusion injury via TLR2/TLR4-triggered signaling pathways.
Hepatocyte growth factor induces tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and enhances cell-matrix interactions.
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
Herpes simplex virus type 1 VP22-mediated intercellular delivery of PTEN increases the antitumor activity of PTEN in esophageal squamous cell carcinoma cells in vitro and in vivo.
Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
Heterogeneous addiction to TGF? signalling in recessive dystrophic epidermolysis bullosa associated cutaneous squamous cell carcinoma.
Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis.
Hi-JAKi-ng Synovial Fibroblasts in Inflammatory Arthritis With JAK Inhibitors.
HIF-1?-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion.
High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs.
High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer.
High FAK combined with low JWA expression: clinical prognostic and predictive role for adjuvant fluorouracil-leucovorin-oxaliplatin treatment in resectable gastric cancer patients.
High focal adhesion kinase expression in breast carcinoma is associated with lymphovascular invasion and triple-negative phenotype.
High intestinal and systemic levels of interleukin-23/T-helper 17 pathway in Chinese patients with inflammatory bowel disease.
High mRNA expression of splice variant SYK short correlates with hepatic disease progression in chemonaive lymph node negative colon cancer patients.
High rate of morphological reversion in tumor cell line H-19 associated with permanent transcriptional suppression of the LTR, v-src, LTR provirus.
High resolution crystal structure of the FAK FERM domain reveals new insights on the Druggability of tyrosine 397 and the Src SH3 binding site.
High tumor grade in salivary gland mucoepidermoid carcinomas and loss of expression of transforming growth factor beta receptor type II.
High-Throughput Functional Evaluation of Variants of Unknown Significance in ERBB2.
High-throughput RNAi screening for novel modulators of vimentin expression identifies MTHFD2 as a regulator of breast cancer cell migration and invasion.
Highly parallel identification of essential genes in cancer cells.
Highly specific characterization of tyrosine phosphoproteins in tumor cells based on monoclonal antibodies defined by conjugated phosphotyramine.
Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
HLX affects cell cycle and proliferation in AML cells via the JAK/STAT signaling pathway.
HMGB1 promotes HCC progression partly by downregulating p21 via ERK/c-Myc pathway and upregulating MMP-2.
HO-3867, a synthetic compound, inhibits the migration and invasion of ovarian carcinoma cells through downregulation of fatty acid synthase and focal adhesion kinase.
hob1+, the fission yeast homolog of Bin1, is dispensable for endocytosis or actin organization, but required for the response to starvation or genotoxic stress.
Hodgkin's disease associated with chronic myeloid leukemia. Determination of bcr-abl rearrangement in paraffin-embedded tumors using the polymerase chain reaction.
Homoharringtonine suppresses tumor proliferation and migration by regulating EphB4-mediated ?-catenin loss in hepatocellular carcinoma.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
How the Discovery of the CD4/CD8-p56lck Complexes Changed Immunology and Immunotherapy.
How to effectively treat acute leukemia patients bearing MLL-rearrangements ?
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents.
Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development.
Hsp90 rescues PTK6 from proteasomal degradation in breast cancer cells.
Human Dendritic Cells Mitigate NK-Cell Dysfunction Mediated by Nonselective JAK1/2 Blockade.
Human homologue of the Drosophila discs large tumor suppressor binds to p56lck tyrosine kinase and Shaker type Kv1.3 potassium channel in T lymphocytes.
Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK.
Human trk oncogenes activated by point mutation, in-frame deletion, and duplication of the tyrosine kinase domain.
Humanized anti-EphB4 antibodies for the treatment of carcinomas and vasculogenesis-related diseases.
Hybrid compounds as new Bcr/Abl inhibitors.
Hypereosinophilia, JAK2V617F, and Budd-Chiari syndrome: who is responsible for what?
Hypomethylation-mediated H19 overexpression increases the risk of disease evolution through the association with BCR-ABL transcript in chronic myeloid leukemia.
Hypoxia-Induced Caveolin-1 Expression Promotes Migration and Invasion of Tumor Cells.
I-FISH control of CGH-detected gain of DNA sequence copy number in oral squamous cell carcinomas (OSCC).
Ibrutinib and Indolent B-Cell Lymphomas.
Ibrutinib and novel BTK inhibitors in clinical development.
Ibrutinib as a Bruton Kinase Inhibitor in the Management of Chronic Lymphocytic Leukemia: A New Agent With Great Promise.
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN Study.
Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes.
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT study.
Ibrutinib exerts potent antifibrotic and antitumor activities in mouse models of pancreatic adenocarcinoma.
Ibrutinib for the treatment of chronic lymphocytic leukemia.
Ibrutinib in B-cell Lymphomas.
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Ibrutinib in PCNSL: The Curious Cases of Clinical Responses and Aspergillosis.
Ibrutinib inactivates BMX-STAT3 in glioma stem cells to impair malignant growth and radioresistance.
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Ibrutinib inhibition of Bruton protein-tyrosine kinase (BTK) in the treatment of B cell neoplasms.
Ibrutinib inhibits B-cell receptor and NF-?B signaling and reduces tumor proliferation in tissue-resident cells of patients with chronic lymphocytic leukemia.
Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes.
Ibrutinib presents antitumor activity in skin cancer and induces autophagy.
Ibrutinib Suppresses Early Megakaryopoiesis but Enhances Proplatelet Formation.
Ibrutinib synergizes with poly(ADP-ribose) glycohydrolase inhibitors to induce cell death in AML cells via a BTK-independent mechanism.
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection.
Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients.
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions.
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease.
Ibrutinib treatment inhibits breast cancer progression and metastasis by inducing conversion of myeloid-derived suppressor cells to dendritic cells.
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumoral activity and induces autophagy in glioblastoma.
Ibrutinib-induced acute kidney injury via interstitial nephritis.
Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
Ibrutinib: a new targeted therapy for hematologic cancers.
Ibrutinib: a paradigm shift in management of CLL.
Ibrutinib: first global approval.
Icariin enhance mild hypothermia-induced neuroprotection via inhibiting the activation of NF-?B in experimental ischemic stroke.
ICV vs. VMH injection of leptin: comparative effects on hypothalamic gene expression.
Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential.
Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Identification and characterization of tyrosine kinase activity associated with mitochondrial outer membrane in sarcoma 180 cells.
Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value.
Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Identification of a novel EphB4 phosphodegron regulated by the autocrine IGFII/IRA axis in malignant mesothelioma.
Identification of Akt1 as a potent therapeutic target for oral squamous cell carcinoma.
Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
Identification of Avian leukosis virus subgroup J associated acutely transforming viruses carrying the v-src oncogene in layer chickens.
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis.
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Identification of cis-acting promoter elements that support expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) in v-src transformed Madin-Darby canine kidney cells.
Identification of concurrent germ-line mutations in hMSH2 and/or hMLH1 in Japanese hereditary nonpolyposis colorectal cancer kindreds.
Identification of expressed genes linked to malignancy of human colorectal carcinoma by parametric clustering of quantitative expression data.
Identification of FAK substrate peptides via colorimetric screening of a one-bead one-peptide combinatorial library.
Identification of immune-activating metabolite for enhancing T cell therapy of cancer.
Identification of key candidate targets and pathways for the targeted treatment of leukemia stem cells of chronic myelogenous leukemia using bioinformatics analysis.
Identification of key genes implicated in the suppressive function of human FOXP3+CD25+CD4+ regulatory T cells through the analysis of time?series data.
Identification of key microRNAs associated with diffuse large B-cell lymphoma by analyzing serum microRNA expressions.
Identification of lymphocyte cell-specific protein-tyrosine kinase (LCK) as a driver for invasion and migration of oral cancer by tumor heterogeneity exploitation.
Identification of methyl violet 2B as a novel blocker of focal adhesion kinase signaling pathway in cancer cells.
Identification of New Fyn Kinase Inhibitors Using a FLAP-Based Approach.
Identification of novel SNPs in SYK gene of breast cancer patients: computational analysis of SNPs in the 5'UTR.
Identification of potential biomarkers for measuring inhibition of Src kinase activity in colon cancer cells following treatment with dasatinib.
Identification of potential small-molecule protein-protein inhibitors of cancer metastasis by 3D epitope-based computational screening.
Identification of potential therapeutic target genes, key miRNAs and mechanisms in acute myeloid leukemia based on bioinformatics analysis.
Identification of protein-tyrosine phosphatase 1B as the major tyrosine phosphatase activity capable of dephosphorylating and activating c-Src in several human breast cancer cell lines.
Identification of pY654-?-catenin as a critical co-factor in hypoxia-inducible factor-1? signaling and tumor responses to hypoxia.
Identification of small molecules that disrupt signaling between ABL and its positive regulator RIN1.
Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior.
Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFN? That Induce PD-L1 Expression in Head and Neck Cancer.
Identification of the Direct Substrates of the ABL Kinase via Kinase Assay Linked Phosphoproteomics with Multiple Drug Treatments.
Identification of the JAK-STAT pathway in canine splenic hemangiosarcoma, thyroid carcinoma, mast cell tumor, and anal sac adenocarcinoma.
Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.
Identification of two regions in the p140Cap adaptor protein that retain the ability to suppress tumor cell properties.
IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells.
IL-33 and ST2 mediate FAK-dependent antitumor immune evasion through transcriptional networks.
IL-6 and ovarian cancer: inflammatory cytokines in promotion of metastasis.
IL-6 attenuates trimethyltin-induced cognitive dysfunction via activation of JAK2/STAT3, M1 mAChR and ERK signaling network.
Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.
Imatinib inhibits VEGF-independent angiogenesis by targeting neuropilin 1-dependent ABL1 activation in endothelial cells.
Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies.
Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro.
Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Imatinib mesylate (STI571) for myeloid malignancies other than CML.
Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells.
Imatinib mesylate enhances therapeutic effects of gemcitabine in human malignant mesothelioma xenografts.
Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia.
Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
Imatinib mesylate.
Imatinib Promotes Osteoblast Differentiation by Inhibiting PDGFR Signaling and Inhibits Osteoclastogenesis by Both Direct and Stromal Cell-Dependent Mechanisms.
Imatinib resistance in gastrointestinal stromal tumors.
Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-?B and HSP27/p38/AKT pathways and by inhibiting ABCB1.
Imatinib upregulates compensatory integrin signaling in a mouse model of gastrointestinal stromal tumor and is more effective when combined with dasatinib.
Imatinib-induced hyperbilirubinemia with UGT1A1 (*28) promoter polymorphism: first case series in patients with gastrointestinal stromal tumor.
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Imatinib: as adjuvant therapy for gastrointestinal stromal tumour.
Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.
Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
Imidazo[1,2-a]pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.
Immune cells in the tumor microenvironment. Mechanisms responsible for functional and signaling defects.
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.
Immune-based resistance to the formation of v-src-induced distal tumors.
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Immunohistochemical analysis of c-yes and c-erbB-2 oncogene products and p53 tumor suppressor protein in canine mammary tumors.
Immunohistochemical Analysis of PDGFR-?, PDGFR-? and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.
Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia.
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma.
Immunohistochemical Expression of Cortactin and Focal Adhesion Kinase Predicts Recurrence Risk and Laryngeal Cancer Risk Beyond Histologic Grading.
Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea.
Immunomodulatory Drugs in the Management of SARS-CoV-2.
Immunoprofiling of Drosophila Hemocytes by Single-cell Mass Cytometry.
Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Immunotherapy for myeloproliferative neoplasms (MPN).
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases.
Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).
Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.
Impact of the SRC inhibitor dasatinib on the metastatic phenotype of human prostate cancer cells.
Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor model.
Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells.
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Improvement of Stability and Efficacy of C16Y Therapeutic Peptide via Molecular Self-Assembly into Tumor-Responsive Nanoformulation.
In search of a function for the E3B1/Abi2/Argbp1/NESH family (Review).
In silico investigation of potential SRC kinase ligands from traditional Chinese medicine.
In situ photoactivation of a caged phosphotyrosine peptide derived from focal adhesion kinase temporarily halts lamellar extension of single migrating tumor cells.
In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues.
In vitro and in vivo characterization of SGI-1252, a small molecule inhibitor of JAK2.
In vitro efficacy of the anticancer drug imatinib on Echinococcus multilocularis larvae.
In Vitro Evolution Reveals a Single Mutation as Sole Source of Src-Family Kinase C-Helix-out Inhibitor Resistance.
In vitro metabolism of ibrutinib in rat, dog and human hepatocytes by using liquid chromatography combined with diode array detector and Q-Exactive Orbitrap tandem mass spectrometry.
In Vitro Phosphorylation of the Focal Adhesion Targeting Domain of Focal Adhesion Kinase by Src Kinase.
In vivo evidence supporting a metastasis suppressor role for Stard13 (Dlc2) in ErbB2 (Neu) oncogene induced mouse mammary tumors.
In vivo imaging of bcr-abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.
In vivo inhibition by a site-specific catalytic RNA subunit of RNase P designed against the BCR-ABL oncogenic products: a novel approach for cancer treatment.
In vivo small-animal PET/CT of EphB4 receptors using 64Cu-labeled peptide.
In vivo toxicity, metabolism and pharmacokinetic properties of FAK inhibitor 14 or Y15 (1, 2, 4, 5-benzenetetramine tetrahydrochloride).
In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers.
In-vitro antiproliferative activities and kinase inhibitory potencies of meridianin derivatives.
INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.
INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.
Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.
Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.
Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.
Increased Expression and Activation of FAK in Small-Cell Lung Cancer Compared to Non-Small-Cell Lung Cancer.
Increased expression of microRNA-146a decreases myocardial ischaemia/reperfusion injury.
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma.
Increased expression of the src proto-oncogene in hairy cell leukemia and a subgroup of B-cell lymphomas.
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Increased PTPRA expression leads to poor prognosis through c-Src activation and G1 phase progression in squamous cell lung cancer.
Increases in c-Yes expression level and activity promote motility but not proliferation of human colorectal carcinoma cells.
Increasing tumor uptake of anticancer drugs with imatinib.
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Induction of a diffuse mesothelioma in chickens by intraperitoneal inoculation of v-src DNA.
Induction of Antitumor Immunity Ex Vivo Using Dendritic Cells Transduced With Fowl Pox Vector Expressing MUC1, CEA, and a Triad of Costimulatory Molecules (rF-PANVAC).
Induction of apoptosis by tumor suppressor genes and oncogenes.
Induction of CML-specific immune response through cross-presentation triggered by CTP-mediated BCR-ABL-derived peptides.
Induction of growth alterations in factor-dependent hematopoietic progenitor cell lines by cocultivation with irradiated bone marrow stromal cell lines.
Induction of mammary epithelial hyperplasias and mammary tumors in transgenic mice expressing a murine mammary tumor virus/activated c-src fusion gene.
Induction of WNT11 by hypoxia and hypoxia-inducible factor-1? regulates cell proliferation, migration and invasion.
Industasis, a promotion of tumor formation by nontumorigenic stray cells.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.
Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Influence of Cancer-Associated Endometrial Stromal Cells on Hormone-Driven Endometrial Tumor Growth.
Influence of controlled release of resveratrol from electrospun fibers in combination with siRNA on leukemia cells.
Influence of the transduced 3'UTR of the c-src oncogene on tumour growth induced by the v-src gene of avian sarcoma virus PR2257.
Infrequent detection of germline allele-specific expression of TGFBR1 in lymphoblasts and tissues of colon cancer patients.
ING1b-inducible microRNA203 inhibits cell proliferation.
Inhibin subunit gene expression in ovarian cancer.
Inhibin-activin receptor subunit gene expression in ovarian tumors.
Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.
Inhibiting FAK-Paxillin Interaction Reduces Migration and Invadopodia-Mediated Matrix Degradation in Metastatic Melanoma Cells.
Inhibiting focal adhesion kinase (FAK) blocks IL-4 induced VCAM-1 expression and eosinophil recruitment in vitro and in vivo.
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.
Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation to GPVI.
Inhibition of c-Abl kinase activity renders cancer cells highly sensitive to mitoxantrone.
Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.
Inhibition of c-Yes induces differentiation of HT-29 human colon cancer stem cells through midbody elongation.
Inhibition of DNA methyltransferase activity upregulates Fyn tyrosine kinase expression in Hut-78 T-lymphoma cells.
Inhibition of effector B cells by ibrutinib in systemic sclerosis.
Inhibition of endothelial FAK activity prevents tumor metastasis by enhancing barrier function.
Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Inhibition of FAK signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo.
Inhibition of FAK Signaling Elicits Lamin A/C-Associated Nuclear Deformity and Cellular Senescence.
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
Inhibition of focal adhesion kinase as a potential therapeutic strategy for imatinib-resistant gastrointestinal stromal tumor.
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells.
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
Inhibition of Hematopoietic Cell Kinase Activity Suppresses Myeloid Cell-Mediated Colon Cancer Progression.
Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Inhibition of Lck: evidence for a novel natural Src family kinase inhibitor.
Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
Inhibition of oncogene product enzyme activity as an approach to cancer chemoprevention. Tyrosine-specific protein kinase inhibition by purpurogallin from Quercus sp. nutgall.
Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.
Inhibition of p21 and Akt Potentiates SU6656-Induced Caspase-Independent Cell Death in FRO Anaplastic Thyroid Carcinoma Cells.
Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors.
Inhibition of Src activation reverses pulmonary vascular remodeling in experimental pulmonary arterial hypertension via Akt/mTOR/HIF-1 signaling pathway.
Inhibition of Src impairs the growth of met-addicted gastric tumors.
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
INHIBITION OF SRC WITH AZD0530 REVEALS THE SRC-FOCAL ADHESION KINASE COMPLEX AS A NOVEL THERAPEUTIC TARGET IN PAPILLARY AND ANAPLASTIC THYROID CANCERS.
Inhibition of TGF-? signaling in tumor cells by small molecule Src family kinase inhibitors.
Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance.
Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.
Inhibition of the SRC Kinase HCK Impairs STAT3-Dependent Gastric Tumor Growth in Mice.
Inhibition of Transforming Growth Factor-? (TGF-?) Signaling by Scutellaria baicalensis and Fritillaria cirrhosa Extracts in Endometrial Cancer.
Inhibition of transforming growth factor-beta-mediated immunosuppression in tumor-draining lymph nodes augments antitumor responses by various immunologic cell types.
Inhibition of tumor growth and angiogenesis by soluble EphB4.
Inhibition of tyrosine protein kinases by halomethyl ketones.
Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53.
Inhibition of vascular endothelial growth factor (VEGF)-165 and semaphorin 3A-mediated cellular invasion and tumor growth by the VEGF signaling inhibitor ZD4190 in human colon cancer cells and xenografts.
Inhibitors of anchorage-independent growth affect the growth of transformed cells on poly(2-hydroxyethyl methacrylate)-coated surfaces.
Inhibitors of Bruton's Tyrosine Kinase (Btk) May Treat Inflammation, Immunological Disorders, and Cancer.
Inhibitors of growth factor signalling.
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.
Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances.
Inhibitory effect of isomorellin on cholangiocarcinoma cells via suppression of NF-?B translocation, the phosphorylated p38 MAPK pathway and MMP-2 and uPA expression.
Inhibitory effects of syk transfection on lung cancer cell invasion.
Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program.
Instability of v-src sequences in nonhuman primate tumors cultured in vitro.
Insulin-like growth factor-I signaling in human neuroblastoma cells.
Int7G24A polymorphism (rs334354) and cancer risk.
Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies.
Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia.
Integrative identification of Epstein-Barr virus-associated mutations and epigenetic alterations in gastric cancer.
Integrin signaling and mammary cell function.
Integrin-associated CD151 is a suppressor of prostate cancer progression.
Integrin-linked kinase: a multi-functional regulator modulating extracellular pressure-stimulated cancer cell adhesion through focal adhesion kinase and AKT.
Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1.
Interferon alpha and T-cell responses in chronic myeloid leukemia.
Interleukin 3- receptor targeted exosomes inhibit in vitro and in vivo Chronic Myelogenous Leukemia cell growth.
Interleukin-1 receptor-associated kinase 1 correlates with metastasis and invasion in endometrial carcinoma.
Interleukin-10 activation of the interleukin-10E1 pathway and tissue inhibitor of metalloproteinase-1 expression is enhanced by proteasome inhibitors in primary prostate tumor lines.
Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth.
Interplay between epidermal growth factor receptor and Janus kinase 3 regulates polychlorinated biphenyl-induced matrix metalloproteinase-3 expression and transendothelial migration of tumor cells.
Interpretation of network meta-analyses of the efficacy of rheumatoid arthritis drugs.
Intestinal immune responses of Jian carp against Aeromonas hydrophila depressed by choline deficiency: Varied change patterns of mRNA levels of cytokines, tight junction proteins and related signaling molecules among three intestinal segments.
Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth.
Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway.
Intratumor Heterogeneity Correlates With Reduced Immune Activity and Worse Survival in Melanoma Patients.
Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.
Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors.
Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Introducing crucial protein panel of gastric adenocarcinoma disease.
Invasive Fungal Infection Complicating Treatment With Ibrutinib.
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Invasive Stratified Mucin-producing Carcinoma (ISMC) of the Uterine Cervix: Clinicopathological and Molecular Characteristics With Special Emphasis on the First Description of Consistent Programmed Death-ligand 1 (PD-L1) Over-expression.
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
Investigations of FAK inhibitors: a combination of 3D-QSAR, docking, and molecular dynamics simulations studies.
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.
Involvement of neutral endopeptidase in neoplastic progression.
Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease.
Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin.
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Is AMN-107 a step forward from imatinib in the treatment of chronic myeloid leukaemia?
Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients?
Is Low Positive JAK2 V617F Mutation Test Result Clinically Significant?: Multi-Institutional Study.
Ischaemic conditioning strategies reduce ischaemia/reperfusion-induced organ injury.
Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.
Isolation and characterization of a novel mitogenic regulatory gene, 322, which is transcriptionally suppressed in cells transformed by src and ras.
Isolation and characterization of adult mammary stem cells from breast cancer-adjacent tissues.
Isolation and properties of gene-modified mouse bcr-abl-transformed cells expressing various immunostimulatory factors.
JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
JAK-Mutant Myeloproliferative Neoplasms.
Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation.
JAK2 V617F -Mediated Clonal Hematopoiesis Accelerates Pathological Remodeling in Murine Heart Failure.
JAK2 46/1 haplotype predisposes to splanchnic vein thrombosis-associated BCR-ABL negative classic myeloproliferative neoplasms.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
JAK2 in the Diagnosis and Treatment of Lymphoid Malignancies: A Review of the Literature.
JAK2 inhibition for the treatment of hematologic and solid malignancies.
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
Jak2 mutation expands the thrombophilic panel in children.
JAK2 mutations and clinical practice in myeloproliferative neoplasms.
JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.
Jak2 tyrosine kinase and cancer: how good cells get HiJAKed.
JAK2 V617F in myeloid disorders: molecular diagnostic techniques and their clinical utility: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology.
JAK2 V617F Mutation in Adult T Cell Leukemia-Lymphoma.
JAK2 V617F Mutation Status of 232 Patients Diagnosed With Chronic Myeloproliferative Neoplasms.
JAK2, CALR, and MPL Mutation Profiles in BCR-ABL Negative Myeloproliferative Neoplasms, a Referral Center Experience in the Middle East.
JAK2, MPL, and CALR mutations in Chinese Han patients with essential thrombocythemia.
JAK2-mutated Langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib.
JAK2V617F drives Mcl-1 expression and sensitizes hematologic cell lines to dual inhibition of JAK2 and Bcl-xL.
JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN?.
JAK2V617F influences epigenomic changes in myeloproliferative neoplasms.
JAK2V617F mutation is associated with special alleles in essential thrombocythemia.
JAK2V617F Mutation Is Not Associated with Thrombosis in Behcet Syndrome.
JAK2V617F mutations in myeloid malignancies: single center experience.
JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.
JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms.
JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.
Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression.
Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Janus Kinase 2 Mutation-Associated Budd-Chiari Syndrome Presenting as a Tumor.
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
Janus kinase deregulation in leukemia and lymphoma.
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Janus kinase inhibitors for the treatment of myeloproliferative neoplasms.
Janus kinase inhibitors: A therapeutic strategy for cancer and autoimmune diseases.
Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms.
Janus kinase inhibitors: jackpot or potluck?
Janus kinase mutations.
Jieduquyuziyin Prescription Suppresses Inflammatory Activity of MRL/lpr Mice and Their Bone Marrow-Derived Macrophages via Inhibiting Expression of IRAK1-NF-?B Signaling Pathway.
JunD/AP-1 Antagonizes the Induction of DAPK1 To Promote the Survival of v-Src-Transformed Cells.
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
Keratin 19, a Cancer Stem Cell Marker in Human Hepatocellular Carcinoma.
Killing tumor cells through their surface beta(2)-microglobulin or major histocompatibility complex class I molecules.
Kinase domain mutants of Bcr enhance Bcr-Abl oncogenic effects.
Kinase inhibitors translate lab discoveries into exciting new cures for cancers.
Kinetic assay for characterization of spleen tyrosine kinase activity and inhibition with recombinant kinase and crude cell lysates.
Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.
Kinome profiling in pediatric brain tumors as a new approach for target discovery.
Kit and PDGFR-alpha activities are necessary for Notch4/Int3-induced tumorigenesis.
Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
Knockdown of FAK inhibits the invasion and metastasis of Tca?8113 cells in vitro.
Knockout of LASP1 in CXCR4 expressing CML cells promotes cell persistence, proliferation and TKI resistance.
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
KSR1 and EPHB4 Regulate Myc and PGC1? To Promote Survival of Human Colon Tumors.
l-Amino acid oxidase isolated from Calloselasma rhodostoma snake venom induces cytotoxicity and apoptosis in JAK2V617F-positive cell lines.
L1CAM stimulates glioma cell motility and proliferation through the fibroblast growth factor receptor.
Lack of an association between the TGFBR1*6A variant and colorectal cancer risk.
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.
Larotrectinib (LOXO-101).
Last findings on dual inhibitors of abl and SRC tyrosine-kinases.
Late polycythemic transformation in JAK2-mutated essential thrombocythemia patients-Characteristics along with a validation of 2016 WHO criteria.
LCK as a Potential Therapeutic Target for Acute Rejection after Kidney Transplantation: A Bioinformatics Clue.
LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme.
Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CML.
Leukemoid reaction in a patient with adenocarcinoma of the lung: a case report.
Licochalcone D directly targets JAK2 to induced apoptosis in human oral squamous cell carcinoma.
LIF-independent JAK signalling to chromatin in embryonic stem cells uncovered from an adult stem cell disease.
Ligand-Dependent and Ligand-Independent Effects of Ephrin-B2-EphB4 Signaling in Melanoma Metastatic Spine Disease.
Ligand-dependent EphB4 activation serves as an anchoring signal in glioma cells.
Ligand-independent anti-oncogenic activity of the alpha subunit of the type I interferon receptor.
LIM kinase-2 targeting as a possible anti-metastasis therapy.
Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Lineage-specific control of superantigen-induced cell death by the protein tyrosine kinase p56(lck).
Lipocalin 2 is required for BCR-ABL-induced tumorigenesis.
Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis.
Liver Protects Metastatic Prostate Cancer From Induced Death by Activating E-cadherin Signaling.
LncRNA ROR1?AS1 high expression and its prognostic significance in liver cancer.
Long non-coding RNA ABHD11-AS1 promotes colorectal cancer progression and invasion through targeting the integrin subunit alpha 5/focal adhesion kinase/phosphoinositide 3 kinase/Akt signaling pathway.
Long noncoding RNA ABHD11-AS1 promote cells proliferation and invasion of colorectal cancer via regulating the miR-1254-WNT11 pathway.
Long persistent bcr-abl positive transcript detected by polymerase chain reaction after marrow transplant for chronic myelogenous leukemia without clinical relapse: a study of 64 patients.
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.
Loss of cellular adhesion to matrix induces p53-independent expression of PTEN tumor suppressor.
Loss of EphB4 receptor tyrosine kinase protein expression during carcinogenesis of the human breast.
Loss of expression of human spectrin src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma.
Loss of heterozygosity on 10q and mutational status of PTEN and BMPR1A in colorectal primary tumours and metastases.
Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth.
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells.
Loss of TGF-beta or Wnt5a results in an increase in Wnt/beta-catenin activity and redirects mammary tumour phenotype.
Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice.
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.
Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation.
Lung cancer deficient in the tumor suppressor GATA4 is sensitive to TGFBR1 inhibition.
Lymphocyte activation provokes modification of a lymphocyte-specific protein tyrosine kinase (p56lck).
Lymphocyte-specific protein tyrosine kinase (Lck) interacts with CR6-interacting factor 1 (CRIF1) in mitochondria to repress oxidative phosphorylation.
Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase.
Lyn deficiency leads to increased microbiota-dependent intestinal inflammation and susceptibility to enteric pathogens.
Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells.
LYN Kinase in the Tumor Microenvironment Is Essential for the Progression of Chronic Lymphocytic Leukemia.
Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.
Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor.
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
Lysyl oxidase is essential for hypoxia-induced metastasis.
Lysyl oxidase-like 2 (LOXL2) from stromal fibroblasts stimulates the progression of gastric cancer.
Machine Learning Models Based on Molecular Fingerprints and an Extreme Gradient Boosting Method Lead to the Discovery of JAK2 Inhibitors.
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Macrophage Syk-PI3K? Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression.
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Major histocompatibility (B) complex control of responses against Rous sarcomas.
Major histocompatibility (B) complex control of the growth pattern of v-src DNA-induced primary tumors.
Malignancy and Janus Kinase Inhibition.
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3.
Mammalian target of rapamycin.
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells.
Mammary epithelial-specific disruption of focal adhesion kinase retards tumor formation and metastasis in a transgenic mouse model of human breast cancer.
Mammary epithelial-specific disruption of the focal adhesion kinase blocks mammary tumor progression.
Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation.
Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity.
MAN2A1-FER Fusion Gene Is Expressed by Human Liver and Other Tumor Types and Has Oncogenic Activity in Mice.
Managing Osteoporosis and Joint Damage in Patients with Rheumatoid Arthritis: An Overview.
Managing resistance in chronic myeloid leukemia.
Mangiferin ameliorates Porphyromonas gingivalis-induced experimental periodontitis by inhibiting phosphorylation of nuclear factor-?B and Janus kinase 1-signal transducer and activator of transcription signaling pathways.
Mapping of tyrosine kinase gene family members in a Xiphophorus melanoma model.
Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway.
Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT.
Massive hepatomegaly and involvement by Janus Kinase 2-positive myeloproliferative neoplasm.
mda-9/Syntenin promotes metastasis in human melanoma cells by activating c-Src.
mda-9/Syntenin regulates the metastatic phenotype in human melanoma cells by activating nuclear factor-kappaB.
Measles virus P protein suppresses Toll-like receptor signal through up-regulation of ubiquitin-modifying enzyme A20.
Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges.
Mechanism of covalent binding of ibrutinib to Bruton's tyrosine kinase revealed by QM/MM calculations.
Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1.
Mechanisms in the chemoprevention of colon cancer: modulation of protein kinase C, tyrosine protein kinase and diacylglycerol kinase activities by 1,4-phenylenebis-(methylene)selenocyanate and impact of low-fat diet.
Mechanisms of CAS substrate domain tyrosine phosphorylation by FAK and Src.
Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma.
Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression.
Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.
Meeting the Challenge of Identifying New Treatments for Type 2-low Neutrophilic Asthma.
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Melatonin attenuates apoptotic liver damage in fulminant hepatic failure induced by the rabbit hemorrhagic disease virus.
Membranal tyrosine protein kinase activity (but not cAMP-dependent protein kinase activity) is associated with growth of rat mammary tumors.
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Merlin neutralizes the inhibitory effect of Mdm2 on p53.
Metabolic convergence on lipogenesis in RAS, BCR-ABL, and MYC-driven lymphoid malignancies.
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Metabolic stress regulates cytoskeletal dynamics and metastasis of cancer cells.
Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
Metastasis--an alternative hypothesis.
Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes.
Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review).
Metformin inhibits SUV39H1-mediated migration of prostate cancer cells.
Metformin one in a million efficient medicines for rheumatoid arthritis complications: inflammation, Osteoblastogenesis, Cardiovascular disease, Malignancies.
Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Methylation status of SOCS1 and SOCS3 in BCR-ABL negative and JAK2V617F negative chronic myeloproliferative neoplasms.
Methylation status of the SOCS3 gene in human malignant melanomas.
Methylseleninic acid overcomes programmed death-ligand 1-mediated resistance of prostate cancer and lung cancer.
Microarray analysis reveals distinct immune signatures in BCR-ABL positive and negative myeloproliferative neoplasms.
Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia.
microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia.
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
MicroRNA-137-mediated Src oncogenic signaling promotes cancer progression.
MicroRNA-140-5p suppresses tumor growth and metastasis by targeting TGFBR1 and FGF9 in hepatocellular carcinoma.
MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma.
MicroRNA-590-5p regulates proliferation and invasion in human hepatocellular carcinoma cells by targeting TGF-? RII.
MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling.
MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1.
MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways.
MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression.
MicroRNAs 130a/b are regulated by BCR-ABL and downregulate expression of CCN3 in CML.
Microsatellite instability and mutations of E2F-4 in hepatocellular carcinoma from Korea.
Migration of renal carcinoma cells is dependent on protein kinase Cdelta via beta1 integrin and focal adhesion kinase.
miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway.
MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells.
MiR-138 and MiR-135 Directly Target Focal Adhesion Kinase, Inhibit Cell Invasion, and Increase Sensitivity to Chemotherapy in Cancer Cells.
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
miR-146a Polymorphism Influences Levels of miR-146a, IRAK-1, and TRAF-6 in Young Patients with Coronary Artery Disease.
miR-151a induces partial EMT by regulating E-cadherin in NSCLC cells.
miR-19 promotes the proliferation of clear cell renal cell carcinoma by targeting the FRK-PTEN axis.
MiR-199a-5p Inhibits the Growth and Metastasis of Colorectal Cancer Cells by Targeting ROCK1.
miR-203 suppresses the proliferation and migration and promotes the apoptosis of lung cancer cells by targeting SRC.
miR-216a may inhibit pancreatic tumor growth by targeting JAK2.
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.
MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
miR-3607-3p suppresses non-small cell lung cancer (NSCLC) by targeting TGFBR1 and CCNE2.
miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX.
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
miRNAs as Biomarkers in Chronic Myelogenous Leukemia.
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.
Mitigation of cocaine-mediated mitochondrial damage, defective mitophagy and microglial activation by superoxide dismutase mimetics.
Mitochondrial dysfunction as an early event in the process of apoptosis induced by woodfordin I in human leukemia K562 cells.
Mitogen-stimulated tyrosine phosphorylation of a 42-kD cellular protein: evidence for a protein kinase-C requirement.
Mitoxantrone Targets The ATP-Binding Site Of FAK, Binds The FAK Kinase Domain And Decreases FAK, Pyk-2, C-Src, And IGF-1R, Pyk-2 In Vitro Kinase Activities.
Mlkl knockout mice demonstrate the indispensable role of Mlkl in necroptosis.
Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Modulation of Intracellular Calcium Levels by Calcium Lactate Affects Colon Cancer Cell Motility through Calcium-Dependent Calpain.
Modulation of Janus kinase 2 by cisplatin in cancer cells.
Modulation of Janus kinase 2 by p53 in ovarian cancer cells.
Molecular and biological properties of hamster tumor cell lines transformed with B77 virus: expression of v-src does not correlate with metastatic potential.
Molecular approaches to brain tumour invasion.
Molecular basis of T cell dysfunction in cancer is influenced by the paracrine secretion of tumor-derived IL-2.
Molecular biology of chronic myeloid leukemia.
Molecular biology of MIS and its receptors.
Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.
Molecular characterization as a target for cancer therapy in relation to orphan status disorders (Review).
Molecular characterization of c-Abl/c-Src kinase inhibitors targeted against murine tumour progenitor cells that express stem cell markers.
Molecular cloning and characterization of a cDNA clone for a protein specifically expressed in embryo as well as in a chemically induced pancreatic B cell tumor of rat.
Molecular cloning and characterization of human WNT11.
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms.
Molecular diagnostics of hematologic malignancies.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Molecular events implicated in brain tumor angiogenesis and invasion.
Molecular interactions in imatinib-DPPC liposomes.
Molecular markers for novel therapies in neuroendocrine (carcinoid) tumors.
Molecular mechanisms of cell proliferation induced by low power laser irradiation.
Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice.
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.
Molecular mutation characteristics of mismatch and homologous recombination repair genes in gastrointestinal cancer.
Molecular oncology: current trends in diagnostics.
Molecular targeted therapy of gastrointestinal stromal tumors.
Molecular targets for tumour progression in gastrointestinal stromal tumours.
Molecularly targeted therapy for gastrointestinal cancer.
Molecularly targeted treatment for dermatofibrosarcoma protuberans.
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
Monosodium Urate and Tumor Necrosis Factor-? Increase Apoptosis in Human Chondrocyte Cultures.
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
Moving Beyond VEGF for Anti-angiogenesis Strategies in Gynecologic Cancer.
MPT0B098, a Microtubule Inhibitor, Suppresses JAK2/STAT3 Signaling Pathway through Modulation of SOCS3 Stability in Oral Squamous Cell Carcinoma.
MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.
MT1-MMP promotes cell growth and ERK activation through c-Src and paxillin in three-dimensional collagen matrix.
mTOR inhibitors reduce enteropathy, intestinal bleeding and colectomy rate in patients with juvenile polyposis of infancy with PTEN-BMPR1A deletion.
Mtss1 is a critical epigenetically regulated tumor suppressor in CML.
MTT assays cannot be utilized to study the effects of STI571/Gleevec on the viability of solid tumor cell lines.
Mullerian inhibiting substance suppresses tumor growth in the C3(1)T antigen transgenic mouse mammary carcinoma model.
Multi-layered proteogenomic analysis unravels cancer metastasis directed by MMP-2 and focal adhesion kinase signaling.
Multi-targeted therapy by curcumin: how spicy is it?
Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Multicentric sporadic gastrointestinal stromal tumors (GISTs) of the stomach with distinct clonal origin: differential diagnosis to familial and syndromal GIST variants and peritoneal metastasis.
Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared?
Multifunctional Abl kinases in health and disease.
Multigene Panel Testing Increases the Number of Loci Associated with Gastric Cancer Predisposition.
Multiple kinase cascades mediate prolactin signals to activating protein-1 in breast cancer cells.
Multiple self-healing squamous epithelioma is caused by a disease-specific spectrum of mutations in TGFBR1.
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Multiplexed tyrosine kinase activity detection in cancer cells using a hydrogel immobilized substrate.
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer.
Muscle-bone interactions: From experimental models to the clinic? A critical update.
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Mutational analysis of activin/transforming growth factor-beta type I and type II receptor kinases in human pituitary tumors.
Mutational Profiles Reveal an Aberrant TGF-?-CEA Regulated Pathway in Colon Adenomas.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Mutations in G protein ? subunits promote transformation and kinase inhibitor resistance.
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Mutations of the transforming growth factor-beta type II receptor gene and genomic instability in hereditary nonpolyposis colorectal cancer.
Mutations of the transforming growth factor-beta type II receptor gene are strongly related to sporadic proximal colon carcinomas with microsatellite instability.
MYCN, neuroblastoma and focal adhesion kinase (FAK).
Mycophenolic acid regulates spleen tyrosine kinase to repress tumour necrosis factor-alpha-induced monocyte chemotatic protein-1 production in cultured human aortic endothelial cells.
Myeloid-derived suppressor cells express Bruton's tyrosine kinase and can be depleted in tumor bearing hosts by ibrutinib treatment.
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Myeloproliferative Neoplasms: A Contemporary Review.
Myeloproliferative neoplasms: new translational therapies.
Myoferlin Depletion Elevates Focal Adhesion Kinase and Paxillin Phosphorylation and Enhances Cell-Matrix Adhesion in Breast Cancer Cells.
Myosin Light Chain Kinase Signaling in Endothelial Barrier Dysfunction.
Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix.
Myristoylation of Src kinase mediates Src induced and high fat diet accelerated prostate tumor progression in mice.
N-(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
N-acetyl-l-cysteine fosters inactivation and transfer to endolysosomes of c-Src.
N-MYC regulates focal adhesion kinase expression in human neuroblastoma.
Na/K-ATPase Y260 Phosphorylation-mediated Src Regulation in Control of Aerobic Glycolysis and Tumor Growth.
NADPH oxidases regulate cell growth and migration in myeloid cells transformed by oncogenic tyrosine kinases.
Nanomechanical Property Maps of Breast Cancer Cells As Determined by Multiharmonic Atomic Force Microscopy Reveal Syk-Dependent Changes in Microtubule Stability Mediated by MAP1B.
Nanotechnology-enabled medicine.
Near infrared light mediated photochemotherapy for efficiently treating deep orthotopic tumors guided by ultrasound imaging.
Negative regulation of PYK2/related adhesion focal tyrosine kinase signal transduction by hematopoietic tyrosine phosphatase SHPTP1.
Neoplastic transformation of normal and carcinogen-induced preneoplastic Syrian hamster embryo cells by the v-src oncogene.
Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer.
Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease.
Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1.
New advances in the pathogenesis and therapy of essential thrombocythemia.
New agents in follicular lymphoma.
New concepts regarding focal adhesion kinase promotion of cell migration and proliferation.
New drugs in thyroid cancer.
New findings of kinase switching in gastrointestinal stromal tumor under imatinib using phosphoproteomic analysis.
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
New insights into the role of dietary spermine on inflammation, immune function and related-signalling molecules in the thymus and spleen of piglets.
New insights on Fak and Fak inhibitors.
New molecular markers in resistant B-CLL.
New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies.
New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.
New roles for B cell receptor associated kinases: when the B cell is not the target.
New strategies in controlling drug resistance in chronic myeloid leukemia.
New targets for Ph+ leukaemia therapy.
New Treatment Opportunities in Phosphatase and Tensin Homolog (PTEN)-Deficient Tumors: Focus on PTEN/Focal Adhesion Kinase Pathway.
Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines.
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Nifuroxazide suppresses UUO-induced renal fibrosis in rats via inhibiting STAT-3/NF-?B signaling, oxidative stress and inflammation.
Nilotinib significantly induces apoptosis in imatinib resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts.
No complementation between TP53 or RB-1 and v-src in astrocytomas of GFAP-v-src transgenic mice.
Nobiletin Inhibits Angiogenesis by Regulating Src/FAK/STAT3-Mediated Signaling through PXN in ER? Breast Cancer Cells.
Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.
Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes I?B? mediated p53 nuclear exclusion.
Non-Covalent BTK Inhibitors-The New BTKids on the Block for B-Cell Malignancies.
Non-denaturing solubilization of inclusion bodies.
Noncanonical TGF? Pathway Relieves the Blockade of IL1?/TGF?-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
Noncanonical Wnt11 inhibits hepatocellular carcinoma cell proliferation and migration.
Nonclinical Safety Assessment of Zanubrutinib: A Novel Irreversible BTK Inhibitor.
Noninvasive imaging of alphaVbeta3 function as a predictor of the antimigratory and antiproliferative effects of dasatinib.
Normal development, oncogenesis and programmed cell death.
Notch signaling promotes serrated neoplasia pathway in colorectal cancer through epigenetic modification of EPHB2 and EPHB4.
Novel Bioluminescent Activatable Reporter for Src Tyrosine Kinase Activity in Living Mice.
Novel biomarker candidates for the diagnosis of ovarian clear cell carcinoma.
Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
Novel e8a2 BCR/ABL Fusion Transcript in Case of a Myeloproliferative Neoplasm.
Novel EphB4 monoclonal antibodies modulate angiogenesis and inhibit tumor growth.
Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer.
Novel focal adhesion kinase 1 inhibitor sensitizes lung cancer cells to radiation in a p53-independent manner.
Novel FRET-Based Src Biosensor Reveals Mechanisms of Src Activation and Its Dynamics in Focal Adhesions.
Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms.
Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors.
Novel insights into c-Src.
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.
Novel SYK gene variations and changes in binding sites of miRs in breast cancer patients.
Novel treatment strategies for myeloproliferative neoplasms.
Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one.
NOX5-L can stimulate proliferation and apoptosis depending on its levels and cellular context, determining cancer cell susceptibility to cisplatin.
NPV-BSK805, an Antineoplastic Jak2 Inhibitor Effective in Myeloproliferative Disorders, Causes Adiposity in Mice by Interfering With the Action of Leptin.
Nuclear export of proteins and drug resistance in cancer.
Nuclear expression of Lyn, a Src family kinase member, is associated with poor prognosis in renal cancer patients.
Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.
Nuclear localization of lymphocyte-specific protein tyrosine kinase (Lck) and its role in regulating LIM domain only 2 (Lmo2) gene.
Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression.
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
Nucleotide sequence analysis of c-raf-1 cDNA and promoter from a radiation-resistant human squamous carcinoma cell line: deletion within exon 17.
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
Occult myeloproliferative neoplasms: not so occult any more.
Off-Target Effects of BCR-ABL and JAK2 Inhibitors.
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells.
Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility.
Oncogene regulation of tumor suppressor genes in tumorigenesis.
Oncogene withdrawal engages the immune system to induce sustained cancer regression.
Oncogene-blocking therapies: new insights from conditional mouse tumor models.
Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice.
Oncogene-dependent survival of highly transformed cancer cells under conditions of extreme centrifugal force - implications for studies on extracellular vesicles.
Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1.
Oncogenic Drivers in Myeloproliferative Neoplasms: From JAK2 to Calreticulin Mutations.
Oncogenic Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance Mechanism to FAK-kinase Inhibitors.
Oncogenic roles of carbonic anhydrase 8 in human osteosarcoma cells.
Oncogenic signaling by tyrosine kinases of the SRC family in advanced colorectal cancer.
Oncogenic signaling: new insights and controversies from chronic myeloid leukemia.
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
Oncogenic Src requires a wild-type counterpart to regulate invadopodia maturation.
Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways.
Opposite expression pattern of Src kinase Lyn in acute and chronic haematological malignancies.
Optimisation of the RT-PCR detection of immunomagnetically enriched carcinoma cells.
Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
Optimization, pharmacophore modeling and 3D-QSAR studies of sipholanes as breast cancer migration and proliferation inhibitors.
Optimized Near-IR Fluorescent Agents for in Vivo Imaging of Btk Expression.
Optimizing Immunization Strategies in Patients with IBD.
Optimizing Platelet GPVI Inhibition versus Haemostatic Impairment by the Btk Inhibitors Ibrutinib, Acalabrutinib, ONO/GS-4059, BGB-3111 and Evobrutinib.
Oral administration of FAK inhibitor TAE226 inhibits the progression of peritoneal dissemination of colorectal cancer.
Orelabrutinib: First Approval.
Organization and post-transcriptional processing of focal adhesion kinase gene.
Oridonin Triggers Chaperon-mediated Proteasomal Degradation of BCR-ABL in Leukemia.
Osteopontin increases breast cancer cell sensitivity to specific signaling pathway inhibitors in preclinical models.
Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms.
Osthole suppresses the migratory ability of human glioblastoma multiforme cells via inhibition of focal adhesion kinase-mediated matrix metalloproteinase-13 expression.
Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States.
Over expression of CDK4 and MDM2 in a patient with recurrent ALK-negative mediastinal inflammatory myofibroblastic tumor: A case report.
Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1.
Over-Expression of Ephb4 Is Associated with Carcinogenesis of Gastric Cancer.
Overexpressed focal adhesion kinase predicts a higher incidence of extrahepatic metastasis and worse survival in hepatocellular carcinoma.
Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database.
Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection.
Overexpression of a constitutively active form of c-src in skin epidermis increases sensitivity to tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.
Overexpression of c-Abl predicts unfavorable outcome in epithelial ovarian cancer.
Overexpression of CTHRC1 in hepatocellular carcinoma promotes tumor invasion and predicts poor prognosis.
Overexpression of endoplasmic reticulum protein 29 regulates mesenchymal-epithelial transition and suppresses xenograft tumor growth of invasive breast cancer cells.
Overexpression of EphB4 in the mammary epithelium shifts the differentiation pathway of progenitor cells and promotes branching activity and vascularization.
Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Overexpression of ephrinB2 and EphB4 in tumor advancement of uterine endometrial cancers.
Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.
Overexpression of focal adhesion kinase in primary colorectal carcinomas and colorectal liver metastases: immunohistochemistry and real-time PCR analyses.
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Overexpression of PTK6 predicts poor prognosis in bladder cancer patients.
Overexpression of Receptor Tyrosine Kinase EphB4 Triggers Tumor Growth and Hypoxia in A375 Melanoma Xenografts: Insights from Multitracer Small Animal Imaging Experiments.
Overexpression of the csk gene suppresses tumor metastasis in vivo.
Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors.
Overexpression of tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) in metastatic MDCK cells transformed by v-src.
Overlap of juvenile polyposis syndrome and cowden syndrome due to de novo chromosome 10 deletion involving BMPR1A and PTEN: implications for treatment and surveillance.
Overriding imatinib resistance with a novel ABL kinase inhibitor.
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson's Disease.
Oxidized LDL induces vimentin secretion by macrophages and contributes to atherosclerotic inflammation.
P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
p110? inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma.
p130Cas substrate domain signaling promotes migration, invasion, and survival of estrogen receptor-negative breast cancer cells.
p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation.
p140Cap protein suppresses tumour cell properties, regulating Csk and Src kinase activity.
p185neu is phosphorylated on tyrosine in human primary breast tumors which overexpress neu/erbB-2.
p190RhoGEF (Rgnef) promotes colon carcinoma tumor progression via interaction with focal adhesion kinase.
P210 Bcr-Abl interacts with the interleukin 3 receptor beta(c) subunit and constitutively induces its tyrosine phosphorylation.
p53 regulates FAK expression in human tumor cells.
p53-Dependent repression of focal adhesion kinase in response to estradiol in breast cancer cell-lines.
p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Pag, a putative tumor suppressor, interacts with the Myc Box II domain of c-Myc and selectively alters its biological function and target gene expression.
PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma.
Paracrine Fibroblast Growth Factor Initiates Oncogenic Synergy with Epithelial FGFR/Src Transformation in Prostate Tumor Progression.
Paradoxes of the EphB4 receptor in cancer.
Paronychia and Periungual Granulation as a Novel Side Effect of Ibrutinib: A Case Report.
Parsaclisib, a potent and highly selective PI3K? inhibitor, in patients with relapsed or refractory B-cell malignancies.
Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Pathways of metastasis suppression in bladder cancer.
Pax-2 expression in adult renal tumors.
Paxillin-Y118 phosphorylation contributes to the control of Src-induced anchorage-independent growth by FAK and adhesion.
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
PCI29732, a Bruton's Tyrosine Kinase Inhibitor, Enhanced the Efficacy of Conventional Chemotherapeutic Agents in ABCG2-Overexpressing Cancer Cells.
PDCD10-Deficiency Promotes Malignant Behaviors and Tumor Growth via Triggering EphB4 Kinase Activity in Glioblastoma.
PDGFR? reverses EphB4 signaling in alveolar rhabdomyosarcoma.
PDLIM4/RIL-mediated regulation of Src and malignant properties of breast cancer cells.
PEGylation potentiates the effectiveness of an antagonistic peptide that targets the EphB4 receptor with nanomolar affinity.
Peptide and Aptamer Decorated Delivery System for Targeting Delivery of Cas9/sgRNA Plasmid To Mediate Antitumor Genome Editing.
Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts.
Peptidomimetic Src/Pretubulin Inhibitor KX-01 Alone and in Combination with Paclitaxel Suppresses Growth, Metastasis in Human ER/PR/HER2-Negative Tumor Xenografts.
Perfusion bioreactor enabled fluid-derived shear stress conditions for novel bone metastatic prostate cancer testbed.
Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth.
Persistence of transcriptionally silent BCR-ABL rearrangements in chronic myeloid leukemia patients in sustained complete cytogenetic remission.
Persistent cutaneous hyperpigmentation after tyrosine kinase inhibition with imatinib for GIST.
Persistent inhibition of ABL tyrosine kinase causes enhanced apoptotic response to TRAIL and disrupts the pro-apoptotic effect of chloroquine.
PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies.
PF573,228 inhibits vascular tumor cell growth, migration as well as angiogenesis, induces apoptosis and abrogates PRAS40 and S6RP phosphorylation.
pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma.
Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells.
PH006, a novel and selective Src kinase inhibitor, suppresses human breast cancer growth and metastasis in vitro and in vivo.
Pharmacokinetics and Disposition of Momelotinib Revealed a Disproportionate Human Metabolite-Resolution for Clinical Development.
Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Phase 1 study of the PI3K? inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer.
Phase 2 study of gandotinib (LY2784544) in patients with myeloproliferative neoplasms.
Phase 2 study of ibrutinib in classic and variant hairy cell leukemia.
Phase I Study of BI 853520, an Inhibitor of Focal Adhesion Kinase, in Patients with Advanced or Metastatic Nonhematologic Malignancies.
Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors.
Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies.
Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies.
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
Phase II trial of imatinib mesylate in patients with metastatic melanoma.
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
PHD3 regulates differentiation, tumour growth and angiogenesis in pancreatic cancer.
Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia.
Phenotypic Differences in Juvenile Polyposis Syndrome With or Without a Disease-causing SMAD4/BMPR1A Variant.
Phenotypic Screening for Inhibitors of a Mutant Thrombopoietin Receptor.
Philadelphia chromosome positive B-cell type malignant lymphoma expressing an aberrant 190 kDa bcr-abl protein.
Philadelphia-negative chronic myeloproliferative neoplasms.
Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes.
Phosphodiesterase 4 inhibitors have wide-ranging activity in B-cell malignancies.
Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion.
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion.
Phosphorylation impact on Spleen Tyrosine kinase conformation by Surface Enhanced Raman Spectroscopy.
Phosphorylation of connexin43 induced by Src: regulation of gap junctional communication between transformed cells.
Phosphorylation of focal adhesion kinase at Tyr397 in gastric carcinomas and its clinical significance.
Phosphorylation of focal adhesion kinase at tyrosine 861 is crucial for Ras transformation of fibroblasts.
Phosphorylation of FOXP3 by LCK downregulates MMP9 expression and represses cell invasion.
Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression.
Phosphorylation of RACK1 on tyrosine 52 by c-Abl is required for IGF-I-mediated regulation of focal adhesion kinase (FAK).
Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation.
Phosphorylation of the Mdm2 oncoprotein by the c-Abl tyrosine kinase regulates p53 tumor suppression and the radiosensitivity of mice.
Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers.
Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.
PI3K? inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3K? and BTK inhibitors.
Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation.
Pin1 links the activities of c-Abl and p300 in regulating p73 function.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™).
Placebo and nocebo responses in randomized controlled trials of non-tumor necrosis factor biologics and Janus kinase inhibitors in patients with active rheumatoid arthritis showing insufficient response to tumor necrosis factor inhibitors: A meta-analysis.
Plant natural compounds: targeting pathways of autophagy as anti-cancer therapeutic agents.
Plasma exosomes stimulate breast cancer metastasis through surface interactions and activation of FAK signaling.
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors.
Pleckstrin homology domain of p210 BCR-ABL interacts with cardiolipin to regulate its mitochondrial translocation and subsequent mitophagy.
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Polyethylenimine-coated SPION exhibits potential intrinsic anti-metastatic properties inhibiting migration and invasion of pancreatic tumor cells.
Polyethylenimine-complexed Plasmid Particles Targeting Focal Adhesion Kinase Function as Melanoma Tumor Therapeutics.
Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression.
Polyphenols as small molecular inhibitors of signaling cascades in carcinogenesis.
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B-Cell Malignancies.
Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies.
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.
Possible involvement of Wnt11 in colorectal cancer progression.
Possible Role of Interleukin-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity.
Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development.
Potential anti-osteoporotic activity of low-molecular weight hyaluronan by attenuation of osteoclast cell differentiation and function in vitro.
Potential applications of RNA interference technology in the treatment of cancer.
Potential role of the src gene product in inhibition of gap-junctional communication in NIH/3T3 cells.
Potential use of compounds from sea cucumbers as MDM2 and CXCR4 inhibitors to control cancer cell growth.
PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL
pp60c-src activation in human colon carcinoma.
PPAR-delta modulates membrane cholesterol and cytokine signaling in malignant B cells.
Pre-clinical anti-tumor activity of Bruton's Tyrosine Kinase inhibitor in Hodgkin's Lymphoma cellular and subcutaneous tumor model.
Preclinical and Clinical Activity of ATP Mimetic JAK2 Inhibitors.
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia.
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib.
Predicting Kinase Inhibitor Resistance: Physics-Based and Data-Driven Approaches.
Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression.
Preponderance of cells with stem cell characteristics in metastasising mouse mammary tumours induced by deregulated EphB4 and ephrin-B2 expression.
Preservation of NADH ubiquinone-oxidoreductase activity by Src kinase-mediated phosphorylation of NDUFB10.
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
Prevalence of MPL (W515K/L) Mutations in Patients with Negative-JAK2 (V617F) Myeloproliferative Neoplasm in North-East of Iran.
Prevalence of MPL W515L/K mutations in Taiwanese patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Pro-apoptotic effect of the c-Abl tyrosine kinase in the cellular response to 1-beta-D-arabinofuranosylcytosine.
Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis.
Profile of pacritinib and its potential in the treatment of hematologic disorders.
Prognostic significance of c-Met, ?-catenin and FAK in patients with hepatocellular carcinoma following surgery.
Prognostic significance of expression of nm23-H1 and focal adhesion kinase in non-small cell lung cancer.
Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine.
Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
Prognostic value of periostin in early-stage breast cancer treated with conserving surgery and radiotherapy.
Prognostic value of spleen tyrosine kinase in human solid tumors.
Prognostic values and clinical relationship of TYK2 in laryngeal squamous cell cancer.
Prognostic versus predictive value of biomarkers in oncology.
Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Progress in the development of small molecular inhibitors of the Bruton's tyrosine kinase (BTK) as a promising cancer therapy.
Progressive cardiac fibrosis and myocyte injury in v-fps transgenic mice. A model for primary disorders of connective tissue in the heart?
Progressive tumor formation in mice with conditional deletion of TGF-beta signaling in head and neck epithelia is associated with activation of the PI3K/Akt pathway.
Proline-Rich Protein Tyrosine Kinase 2 in Inflammation and Cancer.
Proline-rich tyrosine kinase 2 (Pyk2) promotes cell motility of hepatocellular carcinoma through induction of epithelial to mesenchymal transition.
Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells.
Promoter methylation blocks FES protein-tyrosine kinase gene expression in colorectal cancer.
Promotion of Tumor Invasion by Tumor-Associated Macrophages: The Role of CSF-1-Activated Phosphatidylinositol 3 Kinase and Src Family Kinase Motility Signaling.
Properties of the src kinase purified from Rous sarcoma virus-induced rat tumors.
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Prostaglandins Isolated from the Octocoral Plexaura homomalla: In Silico and In Vitro Studies Against Different Enzymes of Cancer.
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
PROTAC-Mediated Degradation of Bruton's Tyrosine Kinase as a Therapeutic Strategy for Cancer.
PROTAC-Mediated Degradation of Janus Kinase as a Therapeutic Strategy for Cancer and Rheumatoid Arthritis.
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Protective effects of type I and type II interferons toward Rous sarcoma virus-induced tumors in chickens.
Protein analytical assays for diagnosing, monitoring, and choosing treatment for cancer patients.
Protein kinase B/AKT and focal adhesion kinase: two close signaling partners in cancer.
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
Protein tyrosine kinase 6 protects cells from anoikis by directly phosphorylating focal adhesion kinase and activating AKT.
Protein Tyrosine Kinase 6 Regulates UVB-Induced Signaling and Tumorigenesis in Mouse Skin.
Protein tyrosine kinase p56lck is required for ceramide-induced but not tumor necrosis factor-induced activation of NF-kappa B, AP-1, JNK, and apoptosis.
Proteins phosphorylated on tyrosine as markers of human tumor cell lines.
Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells.
Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors.
Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors.
Proteomic analysis of p38alpha mitogen-activated protein kinase-regulated changes in membrane fractions of RAS-transformed fibroblasts.
Proteomic Analysis of Src Family Kinase Phosphorylation States in Cancer Cells Suggests Deregulation of the Unique Domain.
Proviruses selected for high and stable expression of transduced genes accumulate in broadly transcribed genome areas.
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers.
Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naïve patients.
PSPC1: a contextual determinant of tumor progression.
PTEN genomic deletions that characterize aggressive prostate cancer originate close to segmental duplications.
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
PTEN regulation of ERK1/2 signaling in cancer.
PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
PTK6 promotes cancer migration and invasion in pancreatic cancer cells dependent on ERK signaling.
PTK6 promotes hepatocellular carcinoma cell proliferation and invasion.
PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells.
PTP1B: A simple enzyme for a complex world.
PTPN2 phosphatase deletion in T cells promotes anti-tumour immunity and CAR T-cell efficacy in solid tumours.
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis.
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.
Pulmonary toxicities of tyrosine kinase inhibitors.
Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Purification and assay of kinase-active EGF receptor from mammalian cells by immunoaffinity chromatography.
Purification of a tyrosine-specific protein kinase from Rous sarcoma virus-induced rat tumor.
Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src.
Putative bovine B cell lineage tumor in sporadic bovine leukosis.
Putrescine enhances intestinal immune function and regulates intestinal bacteria in weaning piglets.
Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells.
Pyk2 cytonuclear localization: mechanisms and regulation by serine dephosphorylation.
Pyk2 promotes tumor progression in multiple myeloma.
Pyk2 promotes tumor progression in renal cell carcinoma.
Pyk2/ERK 1/2 mediate Sp1- and c-Myc-dependent induction of telomerase activity by epidermal growth factor.
Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Pyrazolo[3,4-d]pyrimidine Tyrosine Kinase Inhibitors Induce Oxidative Stress in Patient-Derived Glioblastoma Cells.
QM, a putative tumor suppressor, regulates proto-oncogene c-yes.
Quantification of BCR-ABL mRNA in plasma/serum of patients with chronic myelogenous leukemia.
Quantitative analysis of the secretome of TGF-beta Signaling-deficient mammary fibroblasts.
Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology.
Quantitative In vivo Imaging of the Effects of Inhibiting Integrin Signaling via Src and FAK on Cancer Cell Movement: Effects on E-cadherin Dynamics.
Quantitative structure-activity relationship study on BTK inhibitors by modified multivariate adaptive regression spline and CoMSIA methods.
Rabaptin-5 and Rabex-5 are neoplastic tumour suppressor genes that interact to modulate Rab5 dynamics in Drosophila melanogaster.
Radiation promotes malignant phenotypes through SRC in breast cancer cells.
Radiosensitivity and oxidative signalling in ataxia telangiectasia: an update.
Radiosynthesis of a Bruton's tyrosine kinase inhibitor, [11 C]Tolebrutinib, via palladium-NiXantphos-mediated carbonylation.
RalA mediates v-Src, v-Ras, and v-Raf regulation of CD44 and fibronectin expression in NIH3T3 fibroblasts.
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.
Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia.
Rapid and nonisotopic SSCP-based analysis of the BAT-26 mononucleotide repeat for identification of the replication error phenotype in human cancers.
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling.
Ras-association domain family 10 acts as a novel tumor suppressor through modulating MMP2 in hepatocarcinoma.
RASSF1A Promoter Methylation Levels Positively Correlate with Estrogen Receptor Expression in Breast Cancer Patients.
Rational design of multitargeted tyrosine kinase inhibitors: a novel approach.
Rational therapeutic intervention in cancer: kinases as drug targets.
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Rb plays a role in survival of Abl-dependent human tumor cells as a downstream effector of Abl tyrosine kinase.
Reactivation of chronic hepatitis B infection related to imatinib mesylate therapy.
Real-time quantitation of bcr-abl transcripts in haematological malignancies.
Rearrangements of c-myc and c-abl genes in tumour cells in Burkitt's lymphoma.
Recent advances in cancer therapeutics.
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Receptor protein tyrosine kinase EphB4 is up-regulated in colon cancer.
Receptor tyrosine kinase EphB4 is a survival factor in breast cancer.
Receptor tyrosine kinases and anticancer therapy.
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide.
Recognition of LD motifs by the focal adhesion targeting domains of focal adhesion kinase and proline-rich tyrosine kinase 2-beta: Insights from molecular dynamics simulations.
Recognition of the Lck tyrosine kinase as a tumor antigen by cytotoxic T lymphocytes of cancer patients with distant metastases.
Recombinant Human Mullerian Inhibiting Substance Inhibits Long-term Growth of MIS Type II Receptor-Directed Transgenic Mouse Ovarian Cancers In vivo.
Recombinant tumor necrosis factor alpha and interleukin 1 alpha increase expression of c-abl protooncogene mRNA in cultured human marrow stromal cells.
Recovery of anoikis in Src-transformed cells and human breast carcinoma cells by restoration of the SIRP ?1/SHP-2 signaling system.
Recruitment of focal adhesion kinase and paxillin to beta1 integrin promotes cancer cell migration via mitogen activated protein kinase activation.
Recurrent chromosomal rearrangements of ROS1, FRK and IL6 activating JAK/STAT pathway in inflammatory hepatocellular adenomas.
Redox Circuitries Driving Src Regulation.
Reduced exposure of imatinib after coadministration with acetaminophen in mice.
Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers.
Reduced expression of focal adhesion kinase in intrahepatic cholangiocarcinoma is associated with poor tumor differentiation.
Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung.
Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein.
Reduction in transforming growth factor-beta type II receptor in mouse lung carcinogenesis.
Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Regulated association of protein kinase B/Akt with breast tumor kinase.
Regulation of androgen receptor activity by tyrosine phosphorylation.
Regulation of Bcr-Abl-induced SAP kinase activity and transformation by the SHPTP1 protein tyrosine phosphatase.
Regulation of cell death by the Abl tyrosine kinase.
Regulation of cell signaling pathways by dietary agents for cancer prevention and treatment.
Regulation of Constitutive Interferon-Stimulated Genes (Isgs) in Tumor Cells Contributes to Enhanced Antitumor Response of Newcastle Disease Virus-Infected Tumor Vaccines.
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer.
Regulation of inflammatory responses in tumor necrosis factor - activated and rheumatoid arthritis synovial macrophages by Janus kinase inhibitors.
Regulation of Large Conductance Voltage-and Ca2+-Activated K+ Channels by the Janus Kinase JAK3.
Regulation of mTORC1 signaling by Src kinase activity is Akt1-independent in RSV-transformed cells.
Regulation of SRC family kinases in human cancers.
Regulation of the actin cytoskeleton in cancer cell migration and invasion.
Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition.
Regulation of TRPM8 channel activity by Src-mediated tyrosine phosphorylation.
Regulatory effects of miR-146a/b on the function of endothelial progenitor cells in acute ischemic stroke in mice.
Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation.
Regulatory molecules in tumor metastasis.
Related fibroblast growth factor receptor genes exist in the human genome.
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
Repair by Src kinase of function-impaired RET with multiple endocrine neoplasia type 2A mutation with substitutions of tyrosines in the COOH-terminal kinase domain for phenylalanine.
Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Repression of Fyn-related kinase in breast cancer cells is associated with promoter site-specific CpG methylation.
Repression of interferon ?-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages.
Repression of the gene encoding the TGF-beta type II receptor is a major target of the EWS-FLI1 oncoprotein.
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
Requirement for focal adhesion kinase in the early phase of mammary adenocarcinoma lung metastasis formation.
Requirement for focal adhesion kinase in tumor cell adhesion.
Requirement of PEA3 for transcriptional activation of FAK gene in tumor metastasis.
Research Progress of the Functional Role of ACK1 in Breast Cancer.
Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation.
Resistance to antineoplastic therapy. The oncogenic tyrosine kinase-Bcl-x(L) axis.
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Response to combined molecular targeting: defining the role of P-STAT3.
Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia".
Restoration of bone morphogenetic protein receptor type II expression leads to a decreased rate of tumor growth in bladder transitional cell carcinoma cell line TSU-Pr1.
Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Restoration of RUNX3 enhances transforming growth factor-beta-dependent p21 expression in a biliary tract cancer cell line.
Restoring mir122 in human stem-like hepatocarcinoma cells, prompts tumor dormancy through smad-independent TGF-? pathway.
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma.
Reversal of tumor malignization and modulation of cell behaviors through genome editing mediated by a multi-functional nanovector.
Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of ?-tubulin explains KXO1's low clinical toxicity.
Rewiring kinase specificity with a synthetic adaptor protein.
Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after imatinib resistance: a potential diagnostic pitfall.
RhoGEFs in cell motility: novel links between Rgnef and focal adhesion kinase.
Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed Patients.
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy.
Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Risk of Major Bleeding with Ibrutinib.
RNA quantification using gold nanoprobes - application to cancer diagnostics.
Role of ABL family kinases in cancer: from leukaemia to solid tumours.
Role of additional novel therapies in myeloproliferative neoplasms.
Role of annexin A6 in cancer.
Role of Bruton's tyrosine kinase in B cells and malignancies.
Role of EFNB2/EPHB4 signaling in spiral artery development during pregnancy: An appraisal.
Role of erbB3 receptors in cancer therapeutic resistance.
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Role of focal adhesion kinase in human cancer: a potential target for drug discovery.
Role of Focal Adhesion Kinase in Small-Cell Lung Cancer and Its Potential as a Therapeutic Target.
Role of Janus kinase 3 in mast cell-mediated innate immunity against gram-negative bacteria.
Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.
Role of protein tyrosine kinase inhibitors in cancer therapeutics.
Role of Pyk2 in Human Cancers.
Role of Radiation-induced TGF-beta Signaling in Cancer Therapy.
Role of Src expression and activation in human cancer.
Role of the non-receptor tyrosine kinase fes in cancer.
Role of transforming growth factor-beta1 in prostate cancer.
Role of tumor necrosis factor-alpha, interleukin-8, and dexamethasone in the focal adhesion kinase expression by human nucleus pulposus cells.
Role of Tyk-2 in Th9 and Th17 cells in allergic asthma.
Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned.
Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
Roles of omental and bone marrow adipocytes in tumor biology.
Roles of Raft-Anchored Adaptor Cbp/PAG1 in Spatial Regulation of c-Src Kinase.
Rosmarinic acid inhibits cell proliferation, migration, and invasion and induces apoptosis in human glioma cells.
Rounding up the Usual Suspects: Assessing Yorkie, AP-1, and Stat Coactivation in Tumorigenesis.
RPTP? phosphatase activity is allosterically regulated by the membrane-distal catalytic domain.
RUNX1T1 is overexpressed in imatinib mesylate-resistant cells.
RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion.
Ruxolitinib for the Treatment of Essential Thrombocythemia.
Ruxolitinib induces apoptosis of human colorectal cancer cells by downregulating the JAK1/2-STAT1-Mcl-1 axis.
Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
S100A9 promotes prostate cancer cell invasion by activating TLR4/NF-?B/integrin ?1/FAK signaling.
S100B Protein Regulates Astrocyte Shape and Migration via Interaction with Src Kinase: IMPLICATIONS FOR ASTROCYTE DEVELOPMENT, ACTIVATION, AND TUMOR GROWTH.
Safety and tolerability of ibrutinib monotherapy in Japanese patients with relapsed/refractory B cell malignancies.
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors.
Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma.
Sanguinarine combats hypoxia-induced activation of EphB4 and HIF-1? pathways in breast cancer.
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
Sarcoma and thyroid disorders: a common etiology?
Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome.
Screening for calreticulin mutations in a cohort of patients suspected of having a myeloproliferative neoplasm.
Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Selective targeting of c-Abl via a cryptic mitochondrial targeting signal activated by cellular redox status in leukemic and breast cancer cells.
Seleno-L-Methionine Suppresses Immunoglobulin E-Mediated Allergic Response in RBL-2H3 Cells.
Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.
Sensitive Detection and Quantification of the JAK2V617F Allele by Real-Time PCR Blocking Wild-Type Amplification by Using a Peptide Nucleic Acid Oligonucleotide.
Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates.
Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes.
Sequential therapy in chronic myelogenous leukemia: where do emerging therapies fit within current treatment regimens?
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Serum levels of FAK and some of its effectors in adult AML: correlation with prognostic factors and survival.
Serum Proteomic Analysis of Cannabis Use Disorder in Male Patients.
Sex hormone-induced mammary carcinogenesis in female Noble rats: expression of TGF-beta1 and its receptors, TGF-alpha, and EGF-R in mammary carcinogenesis.
SHC004-221A1, a novel tyrosine kinase, potently inhibits T315I mutant BCR-ABL in chronic myeloid leukemia.
Short-Chain Fatty Acids Suppress Inflammatory Reactions in Caco-2 Cells and Mouse Colons.
Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment.
Should transplantation still be considered for Ph1-negative myeloproliferative neoplasms in transformation?
Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
SHP2 mediates the localized activation of Fyn downstream of the ?6?4 integrin to promote carcinoma invasion.
SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells.
Signal transducer and activator of transcription 5b: a new target of breast tumor kinase/protein tyrosine kinase 6.
Signal transduction by focal adhesion kinase in cancer.
Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity.
Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases.
Signal transduction pathways in liver and the influence of hepatitis C virus infection on their activities.
Signal transduction therapy of cancer.
Signaling by ABL oncogenes through cyclin D1.
Signaling pathway of globo-series glycosphingolipids and ?1,3-galactosyltransferase V (?3GalT5) in breast cancer.
Significance of ER-Src axis in hormonal therapy resistance.
Silencing of focal adhesion kinase by tumor direct injection of small interfering RNA decreases in vivo tumor growth.
Silencing of lemur tyrosine kinase 2 restricts the proliferation and invasion of hepatocellular carcinoma through modulation of GSK-3?/Wnt/?-catenin signaling.
Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Simultaneous visualization of protumorigenic Src and MT1-MMP activities with fluorescence resonance energy transfer.
Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Sinomenine attenuates cancer-induced bone pain via suppressing microglial JAK2/STAT3 and neuronal CAMKII/CREB cascades in rat models.
siRNA directed against c-Src enhances pancreatic adenocarcinoma cell gemcitabine chemosensitivity.
siRNA Library Screening Identifies a Druggable Immune-Signature Driving Esophageal Adenocarcinoma Cell Growth.
siRNA/lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo.
Site-specific metastasis formation: Chemokines as regulators of tumor cell adhesion, motility and invasion.
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Small G protein signalling modulator 2 (SGSM2) is involved in oestrogen receptor-positive breast cancer metastasis through enhancement of migratory cell adhesion via interaction with E-cadherin.
Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells.
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2.
Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers.
Small Molecule Recognition of c-Src via the Imatinib-Binding Conformation.
Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin.
Small-molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in CML cells overcomes BCR-ABL-independent TKI resistance.
Small-world networks of residue interactions in the Abl kinase complexes with cancer drugs: topology of allosteric communication pathways can determine drug resistance effects.
SOHO State of the Art Updates and Next Questions: Myelofibrosis.
Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia.
Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Solution structure of the human pp60c-src SH2 domain complexed with a phosphorylated tyrosine pentapeptide.
Somatic acquisition and signaling of TGFBR1*6A in cancer.
Somatic alterations in juvenile polyps from BMPR1A and SMAD4 mutation carriers.
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
Somatostatin receptor gene expression in neuroblastoma.
Sophoraflavanone G induces apoptosis of human cancer cells by targeting upstream signals of STATs.
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Soyasaponins reduce inflammation by downregulating MyD88 expression and suppressing the recruitments of TLR4 and MyD88 into lipid rafts.
SP2509, an inhibitor of LSD1, exerts potential antitumor effects by targeting the JAK/STAT3 signaling.
Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression.
Specific down-regulation of annexin II expression in human cells interferes with cell proliferation.
Specific induction of pp125 focal adhesion kinase in human breast cancer.
Specific inhibition of SRC kinase impairs malignant glioma growth in vitro and in vivo.
Specific photothermal therapy to the tumors with high EphB4 receptor expression.
Specific protein 1, c-Abl and ERK1/2 form a regulatory loop.
Specific tumor delivery of paclitaxel using glycolipid-like polymer micelles containing gold nanospheres.
Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms.
Spleen tyrosine kinase (Syk) dependent calcium signals mediate efficient CpG-induced exocytosis of tumor necrosis factor alpha (TNF?) in innate immune cells.
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma.
Spontaneous elicitation of potent antitumor immunity and eradication of established tumors by administration of DNA encoding soluble transforming growth factor-beta II receptor without active antigen-sensitization.
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
Src activity increases and Yes activity decreases during mitosis of human colon carcinoma cells.
Src activity is modulated by oxaliplatin and correlates with outcomes after hepatectomy for metastatic colorectal cancer.
Src and focal adhesion kinase as therapeutic targets in cancer.
Src and podoplanin forge a path to destruction.
Src and STAT3 inhibitors synergize to promote tumor inhibition in renal cell carcinoma.
Src as a Therapeutic Target in Biliary Tract Cancer.
Src as the link between inflammation and cancer.
Src controls castration recurrence of CWR22 prostate cancer xenografts.
Src drives the Warburg effect and therapy resistance by inactivating pyruvate dehydrogenase through tyrosine-289 phosphorylation.
Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells.
Src family kinase activity regulates adhesion, spreading and migration of pancreatic endocrine tumour cells.
Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.
Src family kinase inhibitor Saracatinib (AZD0530) impairs oxaliplatin uptake in colorectal cancer cells and blocks organic cation transporters.
Src family kinase members have a common response to histone deacetylase inhibitors in human colon cancer cells.
Src family kinases phosphorylate protein kinase C delta on tyrosine residues and modify the neoplastic phenotype of skin keratinocytes.
SRC gene expression in human cancer: the role of transcriptional activation.
Src in human carcinogenesis.
SRC in human carcinogenesis.
Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson's Disease Models.
Src Inhibition Blocks c-Myc Translation and Glucose Metabolism to Prevent the Development of Breast Cancer.
Src inhibitors are promising therapy molecules for human cervical carcinomas.
Src inhibitors in breast cancer therapy.
Src inhibitors in early breast cancer: a methodology, feasibility and variability study.
Src Inhibitors Pyrazolo[3,4-d]pyrimidines, Si306 and Pro-Si306, Inhibit Focal Adhesion Kinase and Suppress Human Glioblastoma Invasion In Vitro and In Vivo.
SRC is dephosphorylated at tyrosine 530 in human colon carcinomas.
Src kinase activation by nitric oxide promotes resistance to anoikis in tumour cell lines.
Src kinase activation is mandatory for MDA-9/syntenin-mediated activation of nuclear factor-kappaB.
Src kinase activity coordinates cell adhesion and spreading with activation of mTOR in pancreatic endocrine tumor cells.
Src kinase and pancreatic cancer.
Src kinase function controls progenitor cell pools during regeneration and tumor onset in the Drosophila intestine.
Src kinase induces tumor formation in the c-SRC C57BL/6 mouse.
SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Src kinase inhibitors: promising cancer therapeutics?
Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C ? Pathway in a Subset of Triple-Negative Breast Cancers.
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells.
SRC kinase regulation in progressively invasive cancer.
Src Plays a Key Role in ADAM28 Expression in v-src-Transformed Epithelial Cells and Human Carcinoma Cells.
SRC points the way to biomarkers and chemotherapeutic targets.
Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors.
SRC redox regulation: Again in the frontline.
Src SH3/2 domain-mediated peripheral accumulation of Src and phospho-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition.
SRC Signaling in Cancer and Tumor Microenvironment.
Src signaling links mediators of inflammation to Cx43 gap junction channels in primary and transformed CFTR-expressing airway cells.
SRC transcriptional activation in a subset of human colon cancer cell lines.
Src transformation of colonic epithelial cells: enhanced anchorage-independent growth in an Apc(+/min) background.
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis.
Src tyrosine kinase but not activated Ras augments sensitivity to taxanes through apoptosis in human adenocarcinoma cells.
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.
Src tyrosine kinase mediates stimulation of Raf-1 and mitogen-activated protein kinase by the tumor promoter thapsigargin.
Src tyrosine kinase phosphorylation of nuclear receptor HNF4? correlates with isoform-specific loss of HNF4? in human colon cancer.
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Src-mediated morphology transition of lung cancer cells in three-dimensional organotypic culture.
Src-mediated phosphorylation converts FHL1 from tumor suppressor to tumor promoter.
Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention.
Src-signaling interference impairs the dissemination of blood-borne tumor cells.
src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors.
STAP-2 interacts with and modulates BCR-ABL-mediated tumorigenesis.
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
STAT5 is Expressed in CD34+/CD38- Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms.
Statin Use After Diagnosis of Colon Cancer and Patient Survival.
STATs in NK-Cells: The Good, the Bad, and the Ugly.
Stealthy nanoparticles protect endothelial barrier from leakiness by resisting the absorption of VE-cadherin.
Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation.
Stem-cell driven cancer: "hands-off" regulation of cancer development.
STI-571 must select for drug-resistant cells but 'no cell breathes fire out of its nostrils like a dragon'.
STI571 (Glivec) induces cell death in the gastrointestinal stromal tumor cell line, GIST-T1, via endoplasmic reticulum stress response.
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
STI571: targeting BCR-ABL as therapy for CML.
STING-mediated Syk Signaling Attenuates Tumorigenesis of Colitis?associated Colorectal Cancer Through Enhancing Intestinal Epithelium Pyroptosis.
Store-operated Ca 2+ entry regulates glioma cell migration and invasion via modulation of Pyk2 phosphorylation.
Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds.
Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof.
Structural mechanism for Bruton's tyrosine kinase activation at the cell membrane.
Structural reengineering of imatinib to decrease cardiac risk in cancer therapy.
Structure and dynamic regulation of abl kinases.
Structure-Based Design, Synthesis, and Characterization of the First Irreversible Inhibitor of Focal Adhesion Kinase.
Structure-based modification of carbonyl-diphenylpyrimidines (Car-DPPYs) as a novel focal adhesion kinase (FAK) inhibitor against various stubborn cancer cells.
Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core.
Structure-Function Relationships of Covalent and Non-Covalent BTK Inhibitors.
Structure-guided design of a potent peptide inhibitor targeting the interaction between CRK and ABL kinase.
Studies in target-based treatment.
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
Studies on the inhibitory effects of quercetin on the growth of HL-60 leukemia cells.
Study of angiogenic signaling pathways in hemangioblastoma.
SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Subcellular and Dynamic Coordination between Src Activity and Cell Protrusion in Microenvironment.
Subcellular localization of total and activated Src kinase in African American and Caucasian breast cancer.
Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.
Substances from the medicinal mushroom Daedalea gibbosa inhibit kinase activity of native and T315I mutated Bcr-Abl.
Substitution scanning identifies a novel, catalytically active ibrutinib-resistant BTK cysteine 481 to threonine (C481T) variant.
Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.
Successful Treatment of a Patient with Chronic Myelogenous Leukemia with Concurrent Janus Kinase 2 (JAK2) R795S Mutation and Breakpoint Cluster Region-ABL1 (BCR-ABL1) Fusion: A Case Report and Literature Review.
Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1.
Sudden extramedullary blast crisis of chronic myeloid leukemia manifesting as T-cell lymphoblastic lymphoma.
Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.
Suppression of anoikis by v-Src but not by activated c-H-ras in human gallbladder epithelial cells.
Suppression of human MDA-MB-435S tumor by U6 promoter-driven short hairpin RNAs targeting focal adhesion kinase.
Suppression of liver tumor growth and metastasis by adiponectin in nude mice through inhibition of tumor angiogenesis and downregulation of Rho kinase/IFN-inducible protein 10/matrix metalloproteinase 9 signaling.
Suppression of malignant growth potentials of v-Src-transformed human gallbladder epithelial cells by adenovirus-mediated dominant negative H-Ras.
Suppression of migratory and metastatic pathways via blocking VEGFR1 and VEGFR2.
Suppression of MMP-9 and FAK expression by pomolic acid via blocking of NF-?B/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells.
Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway.
Suppression of Rous sarcoma virus-induced tumor formation by preinfection with viruses encoding src protein with novel N termini.
Suppression of Spleen Tyrosine Kinase (Syk) by Histone Deacetylation Promotes, Whereas BAY61-3606, a Synthetic Syk Inhibitor Abrogates Colonocyte Apoptosis by ERK Activation.
Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.
Suppressor of cytokine signaling 3 inhibits breast tumor kinase activation of STAT3.
Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy.
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts.
Suspected Herpes Zoster-associated Encephalitis during Treatment with Oral Tofacitinib in Alopecia Universalis.
Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction.
SWAP-70 is required for oncogenic transformation by v-Src in mouse embryo fibroblasts.
SY-1530, a highly selective BTK inhibitor, effectively treats B-cell malignancies by blocking B-cell activation.
SYK allelic loss and the role of Syk-regulated genes in breast cancer survival.
SYK Inhibition Blocks Proliferation and Migration of Glioma Cells, and Modifies the Tumor Microenvironment.
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro.
Syk Inhibits the Activity of Protein Kinase A by Phosphorylating Tyrosine 330 of the Catalytic Subunit.
SYK is a target of lymphocyte-derived microparticles in the induction of apoptosis of human retinoblastoma cells.
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric ETV6-RUNX1 B-Acute Lymphoblastic Leukemia Patients.
Synchronous Occurrence of Chronic Myeloid Leukemia and Mantle Cell Lymphoma.
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
Synergistic effect of focal adhesion kinase overexpression and hepatocyte growth factor stimulation on cell transformation.
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Synergy between truncated c-Met (cyto-Met) and c-Myc in liver oncogenesis: importance of TGF-beta signalling in the control of liver homeostasis and transformation.
Synthesis and biological activity of novel organoselenium derivatives targeting multiple kinases and capable of inhibiting cancer progression to metastases.
Synthesis and evaluation of c-Src kinase inhibitory activity of pyridin-2(1H)-one derivatives.
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.
Synthesis of Bioactive Side-Chain Analogues of TAN-2483B.
Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity.
Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor.
Synthesis, radiolabelling and initial biological characterisation of 18F-labelled xanthine derivatives for PET imaging of Eph receptors.
Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers.
Systematic Transcriptome Analysis Reveals the Inhibitory Function of Cinnamaldehyde in Non-Small Cell Lung Cancer.
T cells from late tumor-bearing mice express normal levels of p56lck, p59fyn, ZAP-70, and CD3 zeta despite suppressed cytolytic activity.
T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor.
T-cell expression of Bruton's tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia.
T670X KIT mutations in gastrointestinal stromal tumors: making sense of missense.
TAE226-mediated inhibition of focal adhesion kinase interferes with tumor angiogenesis and vasculogenesis.
TANK-binding kinase 1 and Janus kinase 2 play important roles in the regulation of mitogen-activated protein kinase phosphatase-1 expression after toll-like receptor 4 activation.
Target fishing and docking studies of the novel derivatives of aryl-aminopyridines with potential anticancer activity.
Targeted cancer therapy: promise and reality.
Targeted Chronic Myeloid Leukemia Therapy: Seeking a Cure.
Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy.
Targeted regulationof STAT3 by miR-29a in mediating Taxol resistance of nasopharyngeal carcinoma cell line CNE-1.
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
Targeted treatment and new agents in follicular lymphoma.
Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.
Targeting BRAF-mutant tumours with TGFBR1 inhibitors.
Targeting BRK-Positive Breast Cancers with Small-Molecule Kinase Inhibitors.
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.
Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.
Targeting Bruton's tyrosine kinase for the treatment of B cell associated malignancies and autoimmune diseases: Preclinical and clinical developments of small molecule inhibitors.
Targeting Bruton's tyrosine kinase in B cell malignancies.
Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.
Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.
Targeting BTK Signaling in the Microenvironment of Solid Tumors as a Feasible Cancer Therapy Option.
Targeting BTK through microRNA in chronic lymphocytic leukemia.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia.
Targeting c-Src kinase enhances tamoxifen's inhibitory effect on cell growth by modulating expression of cell cycle and survival proteins.
Targeting cell signaling pathways for drug discovery: an old lock needs a new key.
Targeting chronic myeloid leukemia stem cells: can transcriptional program be a druggable target for cancers?
Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Targeting FAK in human cancer: from finding to first clinical trials.
Targeting FAK scaffold functions inhibits human renal cell carcinoma growth.
Targeting FER Kinase Inhibits Melanoma Growth and Metastasis.
Targeting focal adhesion kinase in cancer cells and the tumor microenvironment.
Targeting focal adhesion kinase in neuroblastoma.
Targeting focal adhesion kinase signaling in tumor growth and metastasis.
Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions.
Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.
Targeting Forward and Reverse EphB4/EFNB2 Signaling by a Peptide with Dual Functions.
Targeting glutamine metabolism and the focal adhesion kinase additively inhibits the mammalian target of the rapamycin pathway in spheroid cancer stem-like properties of ovarian clear cell carcinoma in vitro.
Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.
Targeting heat shock protein 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors.
Targeting JAK3 and BTK Tyrosine Kinases with Rationally-Designed Inhibitors.
Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy.
Targeting Kinases in Fasciola hepatica: Anthelminthic Effects and Tissue Distribution of Selected Kinase Inhibitors.
Targeting Lyn inhibits tumor growth and metastasis in Ewing's sarcoma.
Targeting of erbB3 receptor to overcome resistance in cancer treatment.
Targeting of focal adhesion kinase by flavonoids and small-interfering RNAs reduces tumor cell migration ability.
Targeting of the Alox12-12-HETE in Blast Crisis Chronic Myeloid Leukemia Inhibits Leukemia Stem/Progenitor Cell Function.
Targeting of the protein interaction site between FAK and IGF-1R.
Targeting PDGF receptors in cancer--rationales and proof of concept clinical trials.
Targeting primary human leukaemia cells with RNA interference: Bcr-Abl targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells.
Targeting Protein Tyrosine Kinase 6 Enhances Apoptosis of Colon Cancer Cells Following DNA Damage.
Targeting protein tyrosine kinase 6 in cancer.
Targeting receptor tyrosine kinase EphB4 in cancer therapy.
Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.
Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
Targeting Solid Tumors With BTK Inhibitors.
Targeting Src family kinases in anti-cancer therapies: turning promise into triumph.
Targeting SRC Family Kinases in Mesothelioma: Time to Upgrade.
Targeting SRC family kinases inhibits bevacizumab-induced glioma cell invasion.
Targeting Src in breast cancer.
Targeting Src in endometriosis-associated ovarian cancer.
Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer.
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation.
Targeting the Eph/Ephrin System as Anti-Inflammatory Strategy in IBD.
Targeting the EphB4 receptor for cancer diagnosis and therapy monitoring.
Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions.
Targeting the p53 Pathway.
Targeting the tumor microenvironment with SRC kinase inhibition.
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Targeting thioredoxin reductase by ibrutinib promotes apoptosis of SMMC-7721 cells.
Taxol Induces Brk-dependent Prosurvival Phenotypes in TNBC Cells through an AhR/GR/HIF-driven Signaling Axis.
Tec kinases regulate actin assembly and cytokine expression in LPS-stimulated human neutrophils via JNK activation.
Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.
Temporal blastemal cell gene expression analysis in the kidney reveals new Wnt and related signaling pathway genes to be essential for Wilms' tumor onset.
TFAP2C-mediated upregulation of TGFBR1 promotes lung tumorigenesis and epithelial-mesenchymal transition.
TGF-? activity restoration and phosphodiesterase 4 inhibition as therapeutic options for inflammatory bowel diseases.
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
TGF-beta insensitive dendritic cells: an efficient vaccine for murine prostate cancer.
TGF-beta, c-Cbl, and PDGFR-alpha the in mammary stroma.
TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system.
TGF-beta1 acts as a tumor suppressor of human malignant keratinocytes independently of Smad 4 expression and ligand-induced G(1) arrest.
TGF? isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications.
TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
TGFBR1 and cancer susceptibility.
Tgfbr1 haploinsufficiency is a potent modifier of colorectal cancer development.
TGFBR1(*)6A and Int7G24A variants of transforming growth factor-beta receptor 1 in Swedish familial and sporadic breast cancer.
TGFBR1*6A is not associated with prostate cancer in men of European ancestry.
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
The ankyrin-binding domain of CD44s is involved in regulating hyaluronic acid-mediated functions and prostate tumor cell transformation.
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
The association of transforming growth factor-beta 1 with myometrial invasion of endometrial carcinomas through effects on matrix metalloproteinase.
The benzoquinone ansamycin geldanamycin stimulates proteolytic degradation of focal adhesion kinase.
The biology of chronic myelogenous leukemia:mouse models and cell adhesion.
The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.
The blood-testis barrier and its implications for male contraception.
The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.
The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae.
The c-Abl inhibitor, radotinib induces apoptosis in multiple myeloma cells via mitochondrial-dependent pathway.
The c-Fes protein tyrosine kinase as a potential anti-angiogenic target in cancer.
The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
The C-terminal domain of focal adhesion kinase reduces the tumor cell invasiveness in chondrosarcoma cell lines.
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-? in mammary epithelial cells.
The calpain system and cancer.
The Cardenolide Glycoside Acovenoside A Interferes with Epidermal Growth Factor Receptor Trafficking in Non-Small Cell Lung Cancer Cells.
The cardioprotective effects of urocortin are mediated via activation of the Src tyrosine kinase-STAT3 pathway.
The chicken--a laboratory animal of the class Aves.
The Chromatin Assembly Factor Complex 1 (CAF1) and 5-Azacytidine (5-AzaC) Affect Cell Motility in Src-transformed Human Epithelial Cells.
The coexpression of EphB4 and EphrinB2 is associated with poor prognosis in HER2-positive breast cancer.
The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression.
The contrasting oncogenic and tumor suppressor roles of FES.
The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells.
The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma.
The cooperative complex of Argonaute-2 and microRNA-146a regulates hepatitis B virus replication through flap endonuclease 1.
The Crosstalk between FAK and Wnt Signaling Pathways in Cancer and Its Therapeutic Implication.
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
The development and application of imatinib.
The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
The differential expression of EPHB4 and ephrin B2 in cutaneous squamous cell carcinoma according to the grade of tumor differentiation: a clinicopathological study.
The discovery of novel experimental therapies for inflammatory arthritis.
The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein.
The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers.
The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR.
The effects of ephrinB2 signaling on proliferation and invasion in glioblastoma multiforme.
The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.
The effects of focal adhesion kinase on the motility, proliferation and apoptosis of Caco2 and SMMC-7721 cells.
The effects of inducible overexpression of FAK-related non-kinase (FRNK) on a transformed epithelial cell line.
The embryonic environment strongly attenuates v-src oncogenesis in mesenchymal and epithelial tissues, but not in endothelia.
The Emerging Potential for Network Analysis to Inform Precision Cancer Medicine.
The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target.
The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells.
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
The expression and role of tyrosine kinase ETK/BMX in renal cell carcinoma.
The expression of microRNAs and exposure to environmental contaminants related to human health: a review.
The Expression of Myeloproliferative Neoplasm-Associated Calreticulin Variants Depends on the Functionality of ER-Associated Degradation.
The expressions of EphB4 and ephrinB2 in lung adenocarcinomas: a high level of the EphB4 protein is associated with lymph node metastasis.
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma.
The FAK inhibitor BI 853520 exerts anti-tumor effects in breast cancer.
The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
The Fer tyrosine kinase is important for platelet-derived growth factor-BB-induced signal transducer and activator of transcription 3 (STAT3) protein phosphorylation, colony formation in soft agar, and tumor growth in vivo.
The fingerprints of the host innate immunity on the cells of primary virus-induced tumors.
The focal adhesion kinase inhibitor PF-562,271 impairs primary CD4+ T cell activation.
The focal adhesion kinase suppresses transformation-associated, anchorage-independent apoptosis in human breast cancer cells. Involvement of death receptor-related signaling pathways.
The function of FAK/CCDC80/E-cadherin pathway in the regulation of B16F10 cell migration.
The gene expression patterns of BMPR2, EP300, TGF?2, and TNFAIP3 in B-Lymphoma cells.
The hamster polyomavirus--a brief review of recent knowledge.
The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
The HELIOS trial protocol: a Phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
The Hippo pathway kinase Lats2 prevents DNA damage-induced apoptosis through inhibition of the tyrosine kinase c-Abl.
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4.
The human splice variant ?16HER2 induces rapid tumor onset in a reporter transgenic mouse.
The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
The IGF-II-Insulin Receptor Isoform-A Autocrine Signal in Cancer: Actionable Perspectives.
The impact of oncogenic mutations of the viral Src kinase on the structure and stability of the SH3 domain.
The influence of novel transcriptional regulatory element in intron 14 on the expression of Janus kinase 2 gene in myeloproliferative neoplasms.
The Inhibition of Spinal Astrocytic JAK2-STAT3 Pathway Activation Correlates with the Analgesic Effects of Triptolide in the Rat Neuropathic Pain Model.
The Integrated Analyses of Driver Genes Identify Key Biomarkers in Thyroid Cancer.
The intensification of anticancer activity of LFM-A13 by erythropoietin as a possible option for inhibition of breast cancer.
The Interaction between Cancer Stem Cell Marker CD133 and Src Protein Promotes Focal Adhesion Kinase (FAK) Phosphorylation and Cell Migration.
The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma.
The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer.
The interplay between glioblastoma and microglia cells leads to endothelial cell monolayer dysfunction via the interleukin-6-induced JAK2/STAT3 pathway.
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/?-catenin signaling in human multiple myeloma.
The Jak/STAT pathway is involved in synaptic plasticity.
The Jak/STAT pathway: A focus on pain in rheumatoid arthritis.
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness.
The lipid raft-anchored adaptor protein Cbp controls the oncogenic potential of c-Src.
The lncRNA XIST promotes proliferation, migration and invasion of gastric cancer cells by targeting miR-337.
The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma.
The loss of TGF-beta signaling promotes prostate cancer metastasis.
The LTR, v-src, LTR provirus in H-19 hamster tumor cell line is integrated adjacent to the negative regulatory region.
The majority of myeloid-antigen-positive (My+) childhood B-cell precursor acute lymphoblastic leukaemias express TEL-AML1 fusion transcripts.
The marrow stem cell niche in normal and malignant hematopoiesis.
The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML.
The multi-site docking protein Gab1 is constitutively phosphorylated independent from its recruitment to the plasma membrane in Jak2-V617F-positive cells and mediates proliferation of human erythroleukaemia cells.
The Mutational Features of Aristolochic Acid-Induced Mouse and Human Liver Cancers.
The N-terminal domain of the non-receptor tyrosine kinase ABL confers protein instability and suppresses tumorigenesis.
The new small molecule tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs.
The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase.
The non-receptor tyrosine kinase ACK: regulatory mechanisms, signalling pathways and opportunities for attACKing cancer.
The nonreceptor tyrosine kinase SRMS inhibits autophagy and promotes tumor growth by phosphorylating the scaffolding protein FKBP51.
The Novel Src Kinase Inhibitor M475271 Inhibits VEGF-Induced Vascular Endothelial-Cadherin and beta-Catenin Phosphorylation but Increases Their Association.
The Outgrowth of Micrometastases Is Enabled by the Formation of Filopodium-like Protrusions.
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
The PEAK1-PPP1R12B axis inhibits tumor growth and metastasis by regulating Grb2/PI3K/Akt signalling in colorectal cancer.
The Pharmacogenomics "Side-Effect" of TP53/EGFR in Non-Small Cell Lung Cancer Companied with Atorvastatin Therapy: A Functional Network Analysis.
The phosphorylation connection to cancer (review).
The pp60c-Src inhibitor PP1 is non-competitive against ATP.
The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU.
The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.
The prognostic significance of focal adhesion kinase expression in stage I non-small-cell lung cancer.
The Promising Impact of Ibrutinib, a Bruton's Tyrosine Kinase Inhibitor, for the Management of Lymphoid Malignancies.
The protective effect of rheumatic disease agents in COVID-19.
The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells.
The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts.
The Radiosensitizing Effect of AZD0530 in Glioblastoma and Glioblastoma Stem-Like Cells.
The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis.
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
The regulation of Neuropilin 1 expression by miR-338-3p promotes non-small cell lung cancer via changes in EGFR signaling.
The relation between anti-TGBFR1 immunohistochemical reaction and low Ki67, small tumor size and high estrogen receptor expression in invasive breast cancer.
The relationship between phosphorylation status of focal adhesion kinases, molecular subtypes, tumour microenvironment and survival in patients with primary operable ductal breast cancer.
The road to Src.
The role of Bruton's tyrosine kinase inhibitors in the management of mantle cell lymphoma.
The role of cytokines in the initiation and progression of myelofibrosis.
The role of EphB4 and IGF-IR expression in breast cancer cells.
The role of exogenous Fibrinogen in cardiac surgery: stop bleeding or induce cardiovascular disease.
The role of FAK catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
The role of FAK in tumor metabolism and therapy.
The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder.
The role of focal adhesion kinase in tumor initiation and progression.
The role of ibrutinib in COVID-19 hyperinflammation: A case report.
The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: Therapeutic implications.
The role of miR-146a on NF-?B expression level in human umbilical vein endothelial cells under hyperglycemic condition.
The role of molecular techniques in the clinical management of leukemia. Lessons from the Philadelphia chromosome.
The role of natural killer cells in chronic myeloid leukemia.
The role of proline rich tyrosine kinase 2 (Pyk2) on cisplatin resistance in hepatocellular carcinoma.
The role of RIP3 in cardiomyocyte necrosis induced by mitochondrial damage of myocardial ischemia-reperfusion.
The role of Src family kinases in the normal and neoplastic gastrointestinal tract.
The role of Src in solid tumors.
The Role of STAT3 in Thyroid Cancer.
The role of the CSF-1 receptor gene (C-fms) in cell transformation.
The role of the tyrosine kinase Lyn in allergy and cancer.
The roles of nuclear focal adhesion kinase (FAK) on Cancer: a focused review.
The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors.
The Roles of Tissue Rigidity and Its Underlying Mechanisms in Promoting Tumor Growth.
The root bark of Morus alba L. regulates tumor-associated macrophages by blocking recruitment and M2 polarization of macrophages.
The Safety of baricitinib in patients with rheumatoid arthritis.
The safety profile of imatinib in CML and GIST: long-term considerations.
The secretome of non-tumorigenic mammary cells MCF-10A elicits DNA damage in MCF-7 and MDA-MB-231 breast cancer cells.
The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.
The SH2-containing adapter protein GRB10 interacts with BCR-ABL.
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
The significance of proline-rich tyrosine kinase2 (Pyk2) on hepatocellular carcinoma progression and recurrence.
The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study.
The small peptide OGP(10-14) reduces proliferation and induces differentiation of TPO-primed M07-e cells through RhoA/TGFbeta1/SFK pathway.
The soluble extracellular domain of EphB4 (sEphB4) antagonizes EphB4-EphrinB2 interaction, modulates angiogenesis, and inhibits tumor growth.
The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
The Src family kinase inhibitor dasatinib delays pain-related behaviour and conserves bone in a rat model of cancer-induced bone pain.
The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells.
The Src kinases Hck, Fgr and Lyn activate Arg to facilitate IgG-mediated phagocytosis and Leishmania infection.
The Src signaling pathway: a potential target in melanoma and other malignancies.
The SRC-induced mesenchymal state in late-stage colon cancer cells.
The study of c-Src kinase and pStat3 protein expression in retinoblastoma.
The study of different chromosomal aberrations, CD38 and ZAP-70 in chronic lymphocytic leukemia patients.
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
The TCR Vbeta repertoire usage of T-cells from cord blood induced by chronic myelogenous leukemia associated antigen.
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
The TGF-beta type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression.
The TGFBR1*6A/9A polymorphism is not associated with differential risk of breast cancer.
The therapeutic effect of artesunate on rosacea through the inhibition of the JAK/STAT signaling pathway.
The therapeutic effects of Periploca forrestii Schltr. Stem extracts on collagen-induced arthritis by inhibiting the activation of Src/NF-?B signaling pathway in rats.
The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.
The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
The tumor suppressor DAPK is reciprocally regulated by tyrosine kinase Src and phosphatase LAR.
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-?8 in prostate cancer cells.
The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.
The tyrosine kinase v-Src modifies cytotoxicities of anticancer drugs targeting cell division.
The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity.
The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases.
The unique N-terminal region of SRMS regulates enzymatic activity and phosphorylation of its novel substrate docking protein 1.
The Use of Bruton's Tyrosine Kinase Inhibitors to Treat Allergic Disorders.
The use of cystatin C to inhibit epithelial-mesenchymal transition and morphological transformation stimulated by transforming growth factor-beta.
The v-fms oncogene induces factor independence and tumorigenicity in CSF-1 dependent macrophage cell line.
The v-Src and c-Src tyrosine kinases immunoprecipitated from Rous sarcoma virus-transformed cells display different peptide substrate specificities.
The von Hippel-Lindau Tumor Suppressor Protein Is Destabilized by Src: Implications for Tumor Angiogenesis and Progression.
The Wnt-Driven Mll1 Epigenome Regulates Salivary Gland and Head and Neck Cancer.
Theoretical studies of the role of C-terminal cysteines in the process of S-nitrosylation of human Src kinases.
Therapeutic Advances in Myeloproliferative Neoplasms: The Role of New-Small Molecule Inhibitors.
Therapeutic Drug Monitoring for Current and Investigational Inflammatory Bowel Disease Treatments.
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma.
Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).
Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Therapeutic Potential of TNF? and IL1? Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation.
Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Three-dimensional genome architecture influences partner selection for chromosomal translocations in human disease.
Three-Dimensional Interactions Analysis of the Anticancer Target c-Src Kinase with Its Inhibitors.
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
Thrombospondin-1 suppresses tumorigenesis and angiogenesis in serum- and anchorage-independent NIH 3T3 cells.
Tirabrutinib hydrochloride for B-cell lymphomas.
Tirabrutinib: First Approval.
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Tissue transglutaminase-mediated chemoresistance in cancer cells.
Title Current Status of the Search for Biomarkers for Optimal Therapeutic Drug Selection for Patients with Rheumatoid Arthritis.
Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis.
TNF? contributes for attenuating both Y397 FAK and Y416 Src phosphorylations in osteoblasts.
TNIK Is a Therapeutic Target in Lung Squamous Cell Carcinoma and Regulates FAK Activation through Merlin.
To C or not to C: direct and indirect redox regulation of Src protein tyrosine kinase.
Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
Transactivation of the epidermal growth factor receptor by formylpeptide receptor exacerbates the malignant behavior of human glioblastoma cells.
Transcription of the bone sialoprotein gene is stimulated by v-Src acting through an inverted CCAAT box.
Transcription repressor activity of spleen tyrosine kinase mediates breast tumor suppression.
Transcription suppression of SARI (suppressor of AP-1, regulated by IFN) by BCR-ABL in human leukemia cells.
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Transcriptional and Post-Translational Control Mechanisms for EphB4 Expression in Physiology and Cancer Disease.
Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis.
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Transfer of the interleukin-2 gene into human cancer cells induces specific antitumor recognition and restores the expression of CD3/T-cell receptor associated signal transduction molecules.
Transformation by ras suppresses expression of the neurotrophic growth factor pleiotrophin.
Transformation of epithelial Madin-Darby canine kidney cells with p60(v-src) induces expression of membrane-type 1 matrix metalloproteinase and invasiveness.
Transformation of the intestinal epithelium by the MSI2 RNA-binding protein.
Transformation suppressor activity of a Jun transcription factor lacking its activation domain.
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Transforming growth factor beta depletion is the primary determinant of Smad signaling kinetics.
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis.
Transforming growth factor beta type II receptor gene mutations in adenomas from hereditary nonpolyposis colorectal cancer.
Transforming growth factor-beta 1 and its receptors in human lung cancer and mouse lung carcinogenesis.
Transforming Growth Factor-beta Receptors: Role in Physiology and Disease.
Transforming growth factor-beta signaling helps specify tumor type in DMBA and hormone-induced mammary cancers.
Transforming growth factor-beta1 and prostate cancer.
Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes.
Transient knockdown-mediated deficiency in plectin alters hepatocellular motility in association with activated FAK and Rac1-GTPase.
Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice.
Translational activation of the lck proto-oncogene.
Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death.
Transmission of (LTR, v-src, LTR) without recombination with a helper virus.
Transplantation resistance to a Rous sarcoma virus-induced tumor in mice immunized with v-src protein.
Treating imatinib-resistant leukemia: the next generation targeted therapies.
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Treatment Patterns of Newly Diagnosed Rheumatoid Arthritis Patients from a Commercially Insured Population.
Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis After a Change in Targeted Therapy.
Treatment with Src inhibitor Dasatinib results in elevated metastatic potential in the 4T1 murine mammary carcinoma model.
Triple-negative breast cancer: disease entity or title of convenience?
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
Tubulosine selectively inhibits JAK3 signalling by binding to the ATP-binding site of the kinase of JAK3.
Tumor Angiogenesis Is Differentially Regulated by Phosphorylation of Endothelial Cell Focal Adhesion Kinase Tyrosines-397 and -861.
Tumor cell adhesion under hydrodynamic conditions of fluid flow.
Tumor cell-activated CARD9 signaling contributes to metastasis-associated macrophage polarization.
Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4.
Tumor cells induced by the v-src oncogene are heterogeneous for expression of markers of mesenchyme differentiation.
Tumor growth inhibition by synthetic and expressed siRNA targeting focal adhesion kinase.
Tumor growth suppression by adenovirus-mediated introduction of a cell growth suppressing gene tob in a pancreatic cancer model.
Tumor induction by direct injection of cloned v-src DNA into chickens.
Tumor induction by the LTR, v-src, LTR DNA in four B (MHC) congenic lines of chickens.
Tumor necrosis factor alpha-induced apoptosis requires p73 and c-ABL activation downstream of RB degradation.
Tumor necrosis factor modulates epidermal growth factor receptor phosphorylation and kinase activity in human tumor cells. Correlation with cytotoxicity.
Tumor Necrosis Factor-? (TNF?)-induced Ceramide Generation via Ceramide Synthases Regulates Loss of Focal Adhesion Kinase (FAK) and Programmed Cell Death.
Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase.
Tumor necrosis factor-alpha inhibits osteogenic differentiation of pre-osteoblasts by downregulation of EphB4 signaling via activated nuclear factor-kappaB signaling pathway.
Tumor necrosis factor-alpha mediates pancreatitis responses in acinar cells via protein kinase C and proline-rich tyrosine kinase 2.
Tumor necrosis factor-alpha stimulates focal adhesion kinase activity required for mitogen-activated kinase-associated interleukin 6 expression.
Tumor promoters cause changes in the state of phosphorylation and apparent molecular weight of a tyrosine protein kinase in T lymphocytes.
Tumor prone phenotype of mice deficient in a novel apoptosis-inducing gene, drs.
Tumor protein D52 (isoform 3) contributes to prostate cancer cell growth via targeting nuclear factor-?B transactivation in LNCaP cells.
Tumor rejection antigens on BALB3T3 cells transformed by activated oncogenes.
Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing's sarcoma cells.
Tumor Suppressor Analysis in CML.
Tumor suppressor function of Bruton tyrosine kinase is independent of its catalytic activity.
Tumor suppressor PTEN inhibition of cell invasion, migration, and growth: differential involvement of focal adhesion kinase and p130Cas.
Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathways.
Tumor-associated intronic editing of HNRPLL generates a novel splicing variant linked to cell proliferation.
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Tumour induction in fetal brain transplants exposed to the viral oncogenes polyoma middle T and v-src.
Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer.
Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case.
Two additional protein-tyrosine kinases expressed in human lung: fourth member of the fibroblast growth factor receptor family and an intracellular protein-tyrosine kinase.
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
TYK2 Variants in B-Acute Lymphoblastic Leukaemia.
Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis.
Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene.
Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy.
Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse.
Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia.
Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.
Tyrosine kinase signalling in breast cancer: epidermal growth factor receptor and c-Src interactions in breast cancer.
Tyrosine kinase, aurora kinase and leucine aminopeptidase as attractive drug targets in anticancer therapy - characterisation of their inhibitors.
Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia.
Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells.
Tyrosine protein kinase activity in the DMBA-induced rat mammary tumor: inhibition by quercetin.
Tyrosine protein kinase inhibition and cancer.
Tyrosine-phosphorylated low density lipoprotein receptor-related protein 1 (Lrp1) associates with the adaptor protein SHC in SRC-transformed cells.
Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
Ubiquitination of Src promotes its secretion via small extracellular vesicles.
Ulcerative Colitis.
Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Understanding the cellular roles of Fyn-related kinase (FRK): implications in cancer biology.
Unexpected properties of endostatin-producing mouse BCR-ABL-transformed cells.
Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma.
Up-regulation of EphB4 in mesothelioma and its biological significance.
Up-regulation of miR-124 inhibits invasion and proliferation of prostate cancer cells through mediating JAK-STAT3 signaling pathway.
Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
Update on JAK2 Inhibitors in Myeloproliferative Neoplasm.
Upregulation of focal adhesion kinase (FAK) expression in ductal carcinoma in situ (DCIS) is an early event in breast tumorigenesis.
Upregulation of Focal Adhesion Kinase by 14-3-3? via NF?B Activation in Hepatocellular Carcinoma.
Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration.
Uptake of a cell permeable G7-18NATE construct into cells and binding with the Grb7-SH2 domain.
Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinase Abl transcript in the treatment of chronic myeloid leukaemia.
Use and limitations of imatinib mesylate (Glivec), a selective inhibitor of the tyrosine kinaseAbl transcript in the treatment of chronic myeloid leukaemia.
Use of QSAR Global Models and Molecular Docking for Developing New Inhibitors of c-src Tyrosine Kinase.
Use of various immunotherapies for refractory ulcerative colitis in a person living with HIV: a case report.
Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.
Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study.
Utility of peripheral blood dual color, double fusion fluorescent in situ hybridization for BCR/ABL fusion to assess cytogenetic remission status in chronic myeloid leukemia.
v-abl causes hematopoietic disease distinct from that caused by bcr-abl.
v-fps protein-tyrosine kinase coordinately enhances the malignancy and growth factor responsiveness of pre-neoplastic lung fibroblasts.
v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.
v-src activation of the collagenase-1 (matrix metalloproteinase-1) promoter through PEA3 and STAT: requirement of extracellular signal-regulated kinases and inhibition by retinoic acid receptors.
v-Src causes delocalization of Mklp1, Aurora B, and INCENP from the spindle midzone during cytokinesis failure.
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.
v-src induction of the TIS10/PGS2 prostaglandin synthase gene is mediated by an ATF/CRE transcription response element.
Vaccination with transforming growth factor-beta insensitive dendritic cells suppresses pulmonary metastases of renal carcinoma in mice.
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
Validation of Standards for Quantitative Assessment of JAK2 c.1849G>T (p.V617F) Allele Burden Analysis in Clinical Samples.
Vascular endothelial growth factor receptor-3 and focal adhesion kinase bind and suppress apoptosis in breast cancer cells.
Vascular endothelial growth factor receptors 1,3 and caveolin-1 are implicated in colorectal cancer aggressiveness and prognosis--correlations with epidermal growth factor receptor, CD44v6, focal adhesion kinase, and c-Met.
Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation.
Vascular permeability changes involved in tumor metastasis.
Vasculogenic mimicry: a new prognostic sign of human osteosarcoma.
VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix.
VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms.
Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.
Visualizing and manipulating focal adhesion kinase regulation in live cells.
Water-pipe smoking promotes epithelial-mesenchymal transition and invasion of human breast cancer cells via ERK1/ERK2 pathways.
Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome.
What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?
What Is the Role of JAK2V617F Mutation in Leukemic Transformation of Myeloproliferative Neoplasms?
Whole Genome Resequencing of Arkansas Progressor and Regressor Line Chickens to Identify SNPs Associated with Tumor Regression.
Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/?-catenin signaling pathway mutations.
Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.
Wnt/?-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunities.
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
WNT11 Expression Is Induced by Estrogen-Related Receptor {alpha} and {beta}-Catenin and Acts in an Autocrine Manner to Increase Cancer Cell Migration.
Wnt11 in 2011 - the regulation and function of a non-canonical Wnt.
WNT11 is a direct target of early growth response protein 1.
Wnt5a and Wnt11 regulate mammalian anterior-posterior axis elongation.
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Xiaoyaosan exerts anxiolytic-like effects by down-regulating the TNF-?/JAK2-STAT3 pathway in the rat hippocampus.
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Y-27632, an inhibitor of rho-associated protein kinase, suppresses tumor cell invasion via regulation of focal adhesion and focal adhesion kinase.
Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Zanubrutinib-induced liver injury: a case report and literature review.
Zanubrutinib: First Approval.
ZAP-70 and Syk expression in canine lymphoid cells and preliminary results on leukaemia cases.
ZAP-70 expression and proliferative activity in chronic lymphocytic leukemia.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
ZAP-70 in B cell malignancies.
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies.
Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling.
ZINC4085554 inhibits cancer cell adhesion by interfering with the interaction of Akt1 and FAK.
Zoledronate sensitizes endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained activation of focal adhesion kinase and protein kinase B/Akt.
ZYBT1, a potent, irreversible Bruton's Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer.
[Adjuvant adoptive immunotherapy in patients with stage III and resected stage IV melanoma: a pilot study]
[Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
[Anti-angiogenic effect of interferon on JAK2V617F positive myeloproliferative neoplasms and its anti-angiogenic mechanisms].
[Anti-proliferation effect of genistein on salivary adenoid cystic carcinoma cell line SACC-83 in vitro]
[Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow].
[Biological mechanism of full-length form of spleen tyrosine kinase regulating gene transcription in breast cancer cells]
[Cancer genome analysis through next-generation sequencing].
[Cancer treatment-induced nephrotoxicity: BCR-Abl and VEGF inhibitors.]
[Changes of serum miR-375 and blood target genes in patients with allergic rhinitis before and after treatment and its significance].
[Characteristics and clinical outcome of T315I mutation in Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
[Characteristics of the epidermal growth factor receptors in the epithelium of the gastrointestinal tract of rats and in intestinal tumors induced by 1,2-dimethylhydrazine]
[Complex molecular genetic algorithm in the diagnosis of myeloproliferative neoplasms].
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
[Damage to the transforming growth factor TGF-beta type II receptor gene and microsatellite instability in carcinoma cells of the gastrointestinal tract]
[Detecting protein expression of EphrinB2 ligand and its receptor EphB4 in astrocytoma using confocal laser scanning microscopy]
[Detection of fps tumor antigen with mono-specific anti-fps serum in tumors induced by acute transforming ALV].
[Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
[Differential gene expression in nasopharyngeal carcinoma cell with reduced and normal expression of 6A8 alpha-mannosidase]
[Effect of stopping tyrosine kinase inhibitors during pregnancy on disease status and reproductive outcomes among patients with chronic myeloid leukemia].
[EGFR-targeted therapies: what's new?]
[Establishment of mouse SP2/0 cell line stably expressing bcr-abl fusion gene fragment]
[Expression of focal adhesion kinase in lymphatic endothelial cells of metastasis]
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]
[FAK related non-kinase (FRNK) inhibits migration of a human breast carcinoma cell line MDA-MB-435]
[Focal adhesion kinase and tumors]
[Functions of spleen tyrosine kinase (Syk) gene and its correlation to neoplasms]
[Hereditary nonpolyposis colorectal cancer]
[Human mismatch repair genes and HNPCC]
[Imatinib--a new perspective in the treatment of tumors]
[Induction of unstable mutations in Drosophila melanogaster by microinjection of oncogenic virus DNA into polar embryonic plasm. Malignant effect of oncoviral DNA]
[Influences of bcr-abl Gene Vaccine on Inoculated SP2/0/bcr-abl Tumor Cells in Mice.]
[Inhibitory effect of full-length spleen tyrosine kinase on invasion and metastasis of human laryngeal squamous cells].
[Investigation of the influence of mechanical signals on the structure of CD44/FERM complex via molecular dynamics simulation].
[Involvement of Src kinase in the down-regulation of ultra-rapid delayed rectifier K(+)current induced by tumor necrosis factor-? in cardiomyocytes].
[JAK2-V617F mutation in patients with myeloproliferative neoplasms: association with FLT3-ITD mutation].
[JAK2V617F mutation and BCR-ABL fusion gene positive myeloproliferative neoplasm: two case report].
[Knockdown of Fez family zinc finger protein 1 antisense ribonucleic acid 1 (FEZF1-AS1) inhibits invasion and migration of esophageal squamous cell carcinoma cells by blocking JAK2/STAT3 pathway].
[Mesh structure of two-dimensional tumor microvascular architecture phenotype heterogeneity in non-small cell lung cancer]
[Molecular Targeted Therapy and Laboratory Tests].
[Molecular targeting drugs--present status and future development]
[Mullerian inhibiting substance type II receptor as a potential target for antineoplastic therapy].
[New directions of pharmacotherapy of immune - inflammatory rheumatic diseases].
[New oncological treatment principle with imatinib]
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
[Personalized medicine based on genomic information: the present status in terms of clinical application]
[Polymerase chain reaction (PCR)--a novel tool for the molecular diagnosis of neoplasms]
[Properties of tyrosine-specific protein kinase from rat sarcoma cells]
[Protective effect of Shenfu injection on the endothelium of severe sepsis by inhibiting CD11b+ cell paralysis induced by high mobility group protein B1].
[Regulation of Ruxolitinib on matrix metalloproteinase in JAK2V617F positive myeloroliferative neoplasms cells].
[Research on the molecular basis of neoplasms: malignant melanoma as an example]
[Research progress of myeloproliferative neoplasms].
[Research progress on aurora kinase inhibitor MK-0457 in therapy for some hematological malignancies -- review]
[Role of miR-106b-5p in the regulation of gene profiles in endothelial cells].
[Selective inhibition of tyrosine kinases - a new therapeutic principle in oncology]
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
[SRC kinases in tumor therapy].
[Target antigens for graft-versus-host disease (GVHD) and graft-versus-leukemia/tumor (GVL/T)]
[The characteristics of evaluation of expression of ZAP-70 in tumor cells under b-cell chronic lymphatic leukemia using the flow cytofluorometry technique].
[The distribution of various type of oncogenes products in the tumor tissue of malignant mesothelioma]
[The effect of transfected microRNA-146a on expression of interleukin-1 receptor-associated kinase 1 and tumor necrosis factor receptor-associated factor 6 in alveolar macrophages].
[The expression of tumor suppressor gene PTEN protein and focal adhesion kinase in salivary adenoid cystic carcinoma and its significance.]
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
[The involvement of c-Abl and D40 (AF15q14/CASC5) proteins in the regulation of cell proliferation and cancer]
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
[The minimal residual disease (MRD) in hematological malignancies]
[Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects].
[Tumor antigens presented to T helper lymphocytes--critical components of the cancer vaccine]
[Tyrosine kinase inhibitors--solid cancers]
{beta}1 integrin cytoplasmic tyrosines promote skin tumorigenesis independent of their phosphorylation.
Neoplasms, Germ Cell and Embryonal
A novel SMAD4 gene mutation in seminoma germ cell tumors.
The roles of supernumerical X chromosomes and XIST expression in testicular germ cell tumors.
Neoplasms, Squamous Cell
Expression levels of EPHB4, EFNB2 and caspase-8 are associated with clinicopathological features and progression of esophageal squamous cell cancer.
Inhibition of mTOR reduces anal carcinogenesis in transgenic mouse model.
The expression and prognostic value of protein tyrosine kinase 6 in early-stage cervical squamous cell cancer.
Neoplastic Cells, Circulating
Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages.
Identification of circulating tumour cells in early stage breast cancer patients using multi marker immunobead RT-PCR.
Nephritis
BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Podocyte EphB4 signaling helps recovery from glomerular injury.
Spleen tyrosine kinase promotes acute neutrophil-mediated glomerular injury via activation of JNK and p38 MAPK in rat nephrotoxic serum nephritis.
Nephritis, Hereditary
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Nephritis, Interstitial
Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling.
Nephrolithiasis
The Wnt11 Signaling Pathway in Potential Cellular EMT and Osteochondral Differentiation Progression in Nephrolithiasis Formation.
Nephrosis, Lipoid
Crk1/2-dependent signaling is necessary for podocyte foot process spreading in mouse models of glomerular disease.
Nephrotic Syndrome
Enhanced expression of the cytoskeletal-associated protein, paxillin, in experimental nephrotic syndrome.
Nerve Sheath Neoplasms
Intraosseous intraneural perineurioma derived from the inferior alveolar nerve with an abnormality of chromosome 22 and expression of the BCR-ABL fusion gene: report of a case and review of recent literature.
Nervous System Diseases
GTPase Regulator Associated with Focal Adhesion Kinase 1 (GRAF1) Immunoglobulin-Associated Ataxia and Neuropathy.
Structure of human Fyn kinase domain complexed with staurosporine.
Neuralgia
A Src family kinase maintains latent sensitization in rats, a model of inflammatory and neuropathic pain.
Activation of EphB receptors contributes to primary sensory neuron excitability by facilitating Ca2+ influx directly or through Src kinase-mediated NMDA receptor phosphorylation.
Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain.
Aspirin-triggered Lipoxin A4 attenuates mechanical allodynia in association with inhibiting spinal JAK2/STAT3 signaling in neuropathic pain in rats.
BDNF released during neuropathic pain potentiates NMDA receptors in primary afferent terminals.
Corrigendum: Analgesic effect of AG490, a Janus kinase inhibitor, on oxaliplatin-induced acute neuropathic pain.
Curcumin ameliorates neuropathic pain by down-regulating spinal IL-1? via suppressing astroglial NALP1 inflammasome and JAK2-STAT3 signalling.
Electroacupuncture ameliorates mechanical hypersensitivity by down-regulating spinal Janus kinase 2/signal transducer and activation of transcription 3 and interleukin 6 in rats with spared nerve injury.
Electroacupuncture treatment upregulates ?7nAChR and inhibits JAK2/STAT3 in dorsal root ganglion of rat with spared nerve injury.
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain.
IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain.
Ligustrazine attenuates neuropathic pain by inhibition of JAK/STAT3 pathway in a rat model of chronic constriction injury.
Lyn tyrosine kinase is required for P2X(4) receptor upregulation and neuropathic pain after peripheral nerve injury.
Neurilemmoma
Crizotinib inhibits NF2-associated schwannoma through inhibition of focal adhesion kinase 1.
Neuroacanthocytosis
Defective mitochondrial and lysosomal trafficking in chorea-acanthocytosis is independent of Src-kinase signaling.
Erythrocyte membrane changes of chorea-acanthocytosis are the result of altered Lyn kinase activity.
Neuronal Dysfunction in iPSC-Derived Medium Spiny Neurons from Chorea-Acanthocytosis Patients Is Reversed by Src Kinase Inhibition and F-Actin Stabilization.
Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare Disease.
Therapeutic targeting of Lyn kinase to treat chorea-acanthocytosis.
Neurobehavioral Manifestations
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
[Neurogenetics and Neuroepigenetics].
Neuroblastoma
A MAP kinase-signaling pathway mediates neurite outgrowth on L1 and requires Src-dependent endocytosis.
Aberrantly expressed Bruton's tyrosine kinase preferentially drives metastatic and stem cell-like phenotypes in neuroblastoma cells.
Acrylamide-induced peripheral neuropathy: manifestations, mechanisms, and potential treatment modalities.
An inward rectifier K+ current modulates in neuroblastoma cells the tyrosine phosphorylation of the pp125FAK and associated proteins: role in neuritogenesis.
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells.
Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells.
Bruton's tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma.
Cadmium blocks receptor-mediated Jak/STAT signaling in neurons by oxidative stress.
CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase.
CD146 is a potential immunotarget for neuroblastoma.
Csk homologous kinase inhibits CXCL12-CXCR4 signaling in neuroblastoma.
Degradation and dephosphorylation of focal adhesion kinase during okadaic acid-induced apoptosis in human neuroblastoma cells.
Direct interaction of beta-amyloid with Na,K-ATPase as a putative regulator of the enzyme function.
Discovery of a novel compound: insight into mechanisms for acrylamide-induced axonopathy and colchicine-induced apoptotic neuronal cell death.
Effect of tumor gangliosides on tyrosine phosphorylation of p125FAK in platelet adhesion to collagen.
Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Elevated protein-tyrosine-phosphatase activity in human colon-carcinoma.
Exposure of neuroblastoma cell lines to imatinib results in the upregulation of the CDK inhibitor p27(KIP1) as a consequence of c-Abl inhibition.
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.
FAK is a critical regulator of neuroblastoma liver metastasis.
Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.
Focal adhesion kinase expression in human neuroblastoma: immunohistochemical and real-time PCR analyses.
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Inhibition of focal adhesion kinase and src increases detachment and apoptosis in human neuroblastoma cell lines.
Inhibition of focal adhesion kinase decreases tumor growth in human neuroblastoma.
Inhibition of the focal adhesion kinase and vascular endothelial growth factor receptor-3 interaction leads to decreased survival in human neuroblastoma cell lines.
Inhibitors of protein kinases induce differentiation in human neuroblastoma cell lines.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Interaction of integrin beta1 with cytokeratin 1 in neuroblastoma NMB7 cells.
Interferon-? induces apoptosis in human SH-SY5Y neuroblastoma cells through activation of JAK-STAT signaling and down-regulation of PI3K/Akt pathway.
Iron depletion results in Src kinase inhibition with associated cell cycle arrest in neuroblastoma cells.
K-252a induces tyrosine phosphorylation of the focal adhesion kinase and neurite outgrowth in human neuroblastoma SH-SY5Y cells.
LIMK2 Mediates Resistance to Chemotherapeutic Drugs in Neuroblastoma Cells through Regulation of Drug-Induced Cell Cycle Arrest.
Loss of a FYN-regulated differentiation and growth arrest pathway in advanced stage neuroblastoma.
MYCN, neuroblastoma and focal adhesion kinase (FAK).
N-MYC regulates focal adhesion kinase expression in human neuroblastoma.
Oncogenes: present status.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Src kinase family inhibitor PP2 induces aggregation and detachment of neuroblastoma cells and inhibits cell growth in a PI3 kinase/Akt pathway-independent manner.
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro.
Targeting focal adhesion kinase in neuroblastoma.
TGF?R1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
The human ion channel TRPM2 modulates neuroblastoma cell survival and mitochondrial function through Pyk2, CREB, and MCU activation.
The Interaction Between FAK, MYCN, p53 and Mdm2 in Neuroblastoma.
The Netrin-1-Neogenin-1 signaling axis controls neuroblastoma cell migration via integrin-?1 and focal adhesion kinase activation.
The spin trapping agent PBN stimulates H2 O2 -induced Erk and Src kinase activity in human neuroblastoma cells.
Tyrosine 251 at the C-terminus of neuronal glycoprotein M6a is critical for neurite outgrowth.
Tyrosine phosphorylation of measles virus P-phosphoprotein in persistently infected neuroblastoma cells.
Vmax. activation of pp60c-src tyrosine kinase from neuroblastoma neuro-2A.
[Inhibition of Non-Receptor Tyrosine Kinase JAK2 Reduces Neuroblastoma Cell Growth and Enhances the Action of Doxorubicin].
Neurocytoma
Histogenesis and differentiation potential of central neurocytomas.
Neurodegenerative Diseases
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
c-Abl in Neurodegenerative Disease.
c-Abl Inhibition Activates TFEB and Promotes Cellular Clearance in a Lysosomal Disorder.
Canonical JAK-STAT signaling is pivotal for long-term depression at adult hippocampal temporoammonic-CA1 synapses.
Fyn Kinase Activity and Its Role in Neurodegenerative Disease Pathology: a Potential Universal Target?
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Nilotinib restores memory function by preventing dopaminergic neuron degeneration in a mouse model of Alzheimer's Disease.
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.
Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.
STI571 protects neuronal cells from neurotoxic prion protein fragment-induced apoptosis.
The c-Abl inhibitor in Parkinson disease.
Neuroectodermal Tumors, Primitive, Peripheral
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Neuroendocrine Tumors
Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
Neurofibroma
Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.
Neurofibromatoses
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Neurofibromatosis 1
A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies.
Neurofibromatosis 2
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Neurofibrosarcoma
Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Dissecting the roles of Ephrin-A3 in malignant peripheral nerve sheath tumor by TALENs.
Malignant peripheral nerve sheath tumor cell invasion is facilitated by Src and aberrant CD44 expression.
Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components.
Neuregulin-1beta and neuregulin-1alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death.
Neuroinflammatory Diseases
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
A c-Src Inhibitor Peptide Based on Connexin43 Exerts Neuroprotective Effects through the Inhibition of Glial Hemichannel Activity.
A Role for the Non-Receptor Tyrosine Kinase Abl2/Arg in Experimental Neuroinflammation.
Aspirin-triggered Lipoxin A4 attenuates mechanical allodynia in association with inhibiting spinal JAK2/STAT3 signaling in neuropathic pain in rats.
c-Abl in Neurodegenerative Disease.
c-Abl-p38? signaling pathway mediates dopamine neuron loss in trigeminal neuralgia.
ErbB1-dependent signalling and vesicular trafficking in primary afferent nociceptors associated with hypersensitivity in neuropathic pain.
Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation via JAK2/STAT3 Pathway Inhibition.
Mechanism of Non-receptor Tyrosine Kinase Src Regulating Neuroinflammation Through Phosphatase and Tensin Homology Protein in Microglia.
Neuronal c-Abl activation leads to induction of cell cycle and interferon signaling pathways.
Neuronal c-Abl Overexpression Leads to Neuronal Loss and Neuroinflammation in the Mouse Forebrain.
Overexpression of EphB4 promotes neurogenesis, but inhibits neuroinflammation in mice with acute ischemic stroke.
Oxidative Stress, DNA Damage, and c-Abl Signaling: At the Crossroad in Neurodegenerative Diseases?
Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo.
Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson's Disease Models.
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Tyrosine kinase Fyn promotes apoptosis after intracerebral hemorrhage in rats by activating Drp1 signaling.
Neutropenia
Association of src-kinase Lyn and non-src-kinase Syk with the granulocyte colony-stimulating factor receptor (G-CSFR) is not abrogated in neutrophils from severe congenital neutropenia patients with point mutations in the G-CSFR mRNA.
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Nevus
c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.
Niemann-Pick Disease, Type C
c-Abl links APP-BACE1 interaction promoting APP amyloidogenic processing in Niemann-Pick type C disease.
Nijmegen Breakage Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Reduced expression of SRC family kinases decreases PI3K activity in NBS1-/- lymphoblasts.
Non-alcoholic Fatty Liver Disease
Altered Inflammatory Pathway but Unaffected Liver Fibrosis in Mouse Models of Nonalcoholic Steatohepatitis Involving Interleukin-1 Receptor-Associated Kinase 1 Knockout.
Function of inhibitor of Bruton's tyrosine kinase isoform ? (IBTK?) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.
Non-Radiographic Axial Spondyloarthritis
Non-Radiographic Axial Spondyloarthritis (nr-axSpA): Advances in Classification, Imaging and Therapy.
non-specific protein-tyrosine kinase deficiency
A novel human autoimmune syndrome caused by combined hypomorphic and activating mutations in ZAP-70.
A Patient with Tyrosine Kinase 2 Deficiency without Hyper-IgE Syndrome.
A positive role for c-Abl in Atm and Atr activation in DNA damage response.
An infant with ZAP-70 deficiency with disseminated mycobacterial disease.
BMP type II receptor deficiency confers resistance to growth inhibition by TGF-? in pulmonary artery smooth muscle cells: role of proinflammatory cytokines.
Bruton tyrosine kinase deficiency augments NLRP3 inflammasome activation and causes IL-1?-mediated colitis.
Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction.
Bruton's tyrosine kinase deficiency inhibits autoimmune arthritis but fails to block immune complex-mediated inflammatory arthritis.
c-Abl Deficiency Provides Synaptic Resiliency Against A?-Oligomers.
c-Abl promotes osteoblast expansion by differentially regulating canonical and non-canonical BMP pathways and p16INK4a expression.
c-Abl-Mediated Tyrosine Phosphorylation of the T-bet DNA-Binding Domain Regulates CD4+ T-Cell Differentiation and Allergic Lung Inflammation.
Clinical and Mutation Description of the First Iranian Cohort of Infantile Inflammatory Bowel Disease: The Iranian Primary Immunodeficiency Registry (IPIDR).
Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.
Complete focal adhesion kinase deficiency in the mammary gland causes ductal dilation and aberrant branching morphogenesis through defects in Rho kinase-dependent cell contractility.
Course of IL-2-inducible T-cell kinase deficiency in a family: lymphomatoid granulomatosis, lymphoma and allogeneic bone marrow transplantation in one sibling; and death in the other.
Critical role of Bmpr1a in mandibular condyle growth.
Diffuse large B-cell lymphoma as presenting feature of Zap-70 deficiency.
Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70.
Effects of p56lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line.
Eosinophilic gastroenteritis in a patient with Bruton's tyrosine kinase deficiency.
Fatal Progressive Meningoencephalitis Diagnosed in Two Members of a Family With X-Linked Agammaglobulinemia.
Female agammaglobulinemia due to the Bruton tyrosine kinase deficiency caused by extremely skewed X-chromosome inactivation.
Functions of Fyn kinase in the completion of meiosis in mouse oocytes.
Genotype-phenotype correlation in Bruton's tyrosine kinase deficiency.
Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis.
Herpesvirus saimiri replaces ZAP-70 for CD3- and CD2-mediated T cell activation.
Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity.
Hyperimmunoglobulin E syndrome and tyrosine kinase 2 deficiency.
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
Immunological reconstitution in a patient with ZAP-70 deficiency following transfusion of blood lymphocytes from a previously transplanted sibling without conditioning.
Impaired V(D)J recombination and increased apoptosis among B cell precursors in the bone marrow of c-Abl-deficient mice.
Impairment of Wnt11 function leads to kidney tubular abnormalities and secondary glomerular cystogenesis.
Increased sensitivity to apoptotic stimuli in c-abl-deficient progenitor B-cell lines.
Loss of a quiescent niche but not follicle stem cells in the absence of bone morphogenetic protein signaling.
Loss of BMP signaling through BMPR1A in osteoblasts leads to greater collagen cross-link maturation and material-level mechanical properties in mouse femoral trabecular compartments.
Molecular characterization of Bruton's tyrosine kinase deficiency in 12 Iranian patients with presumed X-linked agammaglobulinemia.
Morpholino-based correction of hypomorphic ZAP70 mutation in an adult with combined immunodeficiency.
Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.
Novel immunodeficiency data servers.
Novel mechanism for Fc{epsilon}RI-mediated signal transducer and activator of transcription 5 (STAT5) tyrosine phosphorylation and the selective influence of STAT5B over mast cell cytokine production.
Novel Mutation of ZAP-70-related Combined Immunodeficiency: First Case from the National Iranian Registry and Review of the Literature.
Patchy deletion of Bmpr1a potentiates proximal pulmonary artery remodeling in mice exposed to chronic hypoxia.
Pleiotropic consequences of Bruton tyrosine kinase deficiency in myeloid lineages lead to poor inflammatory responses.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity.
Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells.
Retrovirus-mediated transduction of primary ZAP-70-deficient human T cells results in the selective growth advantage of gene-corrected cells: implications for gene therapy.
SCID due to ZAP-70 deficiency.
Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency.
Smooth muscle cell-specific Tgfbr1 deficiency attenuates neointimal hyperplasia but promotes an undesired vascular phenotype for injured arteries.
Smooth muscle cell-specific Tgfbr1 deficiency promotes aortic aneurysm formation by stimulating multiple signaling events.
Specific immunoglobulin E responses in ZAP-70-deficient patients are mediated by Syk-dependent T-cell receptor signalling.
Studies of patients' thymi aid in the discovery and characterization of immunodeficiency in humans.
Successful unrelated cord blood transplantation in two children with severe combined immunodeficiency syndrome.
TGF-beta receptor type II deficiency results in defects of yolk sac hematopoiesis and vasculogenesis.
TGF-beta type II receptor deficiency prevents renal injury via decrease in ERK activity in crescentic glomerulonephritis.
The Abl-1 Kinase is Dispensable for NK Cell Inhibitory Signalling and is not Involved in Murine NK Cell Education.
Time-dependent decline of T-cell receptor excision circle levels in ZAP-70 deficiency.
ZAP-70 constitutively regulates gene expression and protein synthesis in chronic lymphocytic leukemia.
ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency.
ZAP-70 Regulates Autoimmune Arthritis via Alterations in T Cell Activation and Apoptosis.
[Primary immunodeficiency secondary to ZAP-70 deficiency]
Obesity
(-)-Epigallocatechin Gallate Regulates CD3-mediated T Cell Receptor Signaling in Leukemia through the Inhibition of ZAP-70 Kinase.
Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity.
Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice.
Combined parental obesity augments single-parent obesity effects on hypothalamus inflammation, leptin signaling (JAK/STAT), hyperphagia, and obesity in the adult mice offspring.
Expression-based network biology identifies alteration in key regulatory pathways of type 2 diabetes and associated risk/complications.
Fgr kinase is required for proinflammatory macrophage activation during diet-induced obesity.
Inhibition of Bruton's TK regulates macrophage NF-?B and NLRP3 inflammasome activation in metabolic inflammation.
Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
JAK2, STAT3 and SOCS3 gene expression in women with and without breast cancer.
Leptin enhances the potency of circulating angiogenic cells via src kinase and integrin (alpha)vbeta5: implications for angiogenesis in human obesity.
Leptin Resistance in the Ovary of Obese Mice is Associated with Profound Changes in the Transcriptome of Cumulus Cells.
MiR-503 inhibits adipogenesis by targeting bone morphogenetic protein receptor 1a.
Sex Differences in Pulmonary Hypertension.
Soluble activin receptor type IIB treatment does not cause fat loss in mice with diet-induced obesity.
Obstetric Labor, Premature
Decrease in SHP-1 enhances myometrium remodeling via FAK activation leading to labor.
Differential expression of transforming growth factor-beta 1 and transforming growth factor-beta receptors in myometrium of women with failed induction of labor, no labor, and preterm labor.
High levels of fetal membrane activin beta A and activin receptor IIB mRNAs and augmented concentration of amniotic fluid activin A in women in term or preterm labor.
Ocular Hypertension
Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma.
Modeling of LIM-Kinase 2 Inhibitory Activity of Pyrrolopyrimidine Analogues: Useful in Treatment of Ocular Hypertension and Glaucoma.
Novel Class of LIM-Kinase 2 Inhibitors for the Treatment of Ocular Hypertension and Associated Glaucoma.
Odontogenic Tumors
MicroRNA profiling reveals dysregulated microRNAs and their target gene regulatory networks in cemento-ossifying fibroma.
Oligodendroglioma
Gliomatosis cerebri: no evidence for a separate brain tumor entity.
PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK).
Oncogene Addiction
Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor ? and bcr-abl oncogene addiction in malignant hematologic cells.
From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Identification of Bisindolylmaleimide IX as a potential agent to treat drug-resistant BCR-ABL positive leukemia.
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Maintenance of adenomatous polyposis coli (APC)-mutant colorectal cancer is dependent on Wnt/beta-catenin signaling.
MEK-dependent negative feedback underlies BCR-ABL-mediated oncogene addiction.
Opportunistic Infections
A Case of Disseminated Cutaneous Mycobacterium chelonae Infection During Treatment With Tofacitinib.
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.
Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib.
Optic Nerve Injuries
MMP Inhibition Preserves Integrin Ligation and FAK Activation to Induce Survival and Regeneration in RGCs Following Optic Nerve Damage.
Osteitis
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
Osteoarthritis
Cerebrospinal fluid of chronic osteoarthritic patients induced interleukin-6 release in human glial cell-line T98G.
Circ_0128846/miR-140-3p/JAK2 Network in Osteoarthritis Development.
Eph and ephrin interactions in bone.
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis.
FAK inhibition protects condylar cartilage under excessive mechanical stress.
Functional analysis of discoidin domain receptor 2 in synovial fibroblasts in rheumatoid arthritis.
Impact of extracellular matrix derived from osteoarthritis subchondral bone osteoblasts on osteocytes: role of integrin?1 and focal adhesion kinase signaling cues.
In vivo bone-specific EphB4 overexpression in mice protects both subchondral bone and cartilage during osteoarthritis.
Ingenuity pathway analysis of human facet joint tissues: Insight into facet joint osteoarthritis.
LncRNA HOTTIP leads to osteoarthritis progression via regulating miR-663a/ Fyn-related kinase axis.
Mechanical Loading Disrupts Focal Adhesion Kinase Activation in Mandibular Fibrochondrocytes During Murine Temporomandibular Joint Osteoarthritis.
Recent advances in the opioid mu receptor based pharmacotherapy for rheumatoid arthritis.
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype.
Tyrosine kinase Fyn promotes osteoarthritis by activating the ?-catenin pathway.
Osteoarthritis, Knee
[Phosphorylated Focal Adhesion Kinase, Phosphinositides 3 Kinase and Aggrecan Genes and Proteins in Cartilage Cells Are Probably Involved in Needle Knife Intervention Induced Improvement of Knee Osteoarthritis in Rabbits].
Osteogenesis Imperfecta
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta.
Soluble activin receptor type IIB decoy receptor differentially impacts murine osteogenesis imperfecta muscle function.
Osteolysis
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone.
Inhibitory Effect of Adenovirus-Mediated siRNA-Targeting BMPR-IB on UHMWPE-Induced Bone Destruction in the Murine Air Pouch Model.
Osteomyelitis
The nonreceptor tyrosine kinase SYK drives caspase-8/NLRP3 inflammasome-mediated autoinflammatory osteomyelitis.
Osteonecrosis
PPARgamma-2 and BMPR2 genes were differentially expressed in peripheral blood of SLE patients with osteonecrosis.
PPARgamma-2 and BMPR2 Genes Were Significantly Differentially Expressed in Peripheral Blood of SLE Patients with Osteonecrosis.
Osteopetrosis
Characterization of unique functionalities in c-Src domains required for osteoclast podosome belt formation.
Cytokines and growth factors in the regulation of bone remodeling.
In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene.
Malignant osteopetrosis: c-src kinase is not reduced in fibroblasts.
Recent developments in the understanding of the pathophysiology of osteopetrosis.
The protein tyrosine kinase p60c-Src is not implicated in the pathogenesis of the human autosomal recessive form of osteopetrosis: a study of 13 children.
Osteoporosis
A soluble activin receptor Type IIA fusion protein (ACE-011) increases bone mass via a dual anabolic-antiresorptive effect in Cynomolgus monkeys.
Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues.
c-Abl, Free Radicals, and Osteoporosis.
Defactinib attenuates osteoarthritis by inhibiting positive feedback loop between H-type vessels and MSCs in subchondral bone.
Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand.
Future Developments in Osteoporosis Therapy.
Genetic studies of bone diseases: evidence for involvement of DNA damage response proteins in bone remodeling.
Muscle-bone interactions: From experimental models to the clinic? A critical update.
Novel bone-targeted Src tyrosine kinase inhibitor drug discovery.
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis.
Simultaneous assay of Src SH3 and SH2 domain binding using different wavelength fluorescence polarization probes.
Specific inhibition of FAK signaling attenuates subchondral bone deterioration and articular cartilage degeneration during osteoarthritis pathogenesis.
Structural Basis of Src Tyrosine Kinase Inhibition with a New Class of Potent and Selective Trisubstituted Purine-based Compounds.
Three-dimensional quantitative structure-activity relationship studies on c-Src inhibitors based on different docking methods.
Tyrosine kinases Btk and Tec regulate osteoclast differentiation by linking RANK and ITAM signals.
Osteosarcoma
2-Hydroxypropyl-?-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells.
Activation of the JAK-STAT signal transduction pathway by oncostatin-M cultured human and mouse osteoblastic cells.
Analyzing time-series microarray data reveals key genes in spinal cord injury.
Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells.
Antitumor effect of focal adhesion kinase inhibitor PF562271 against human osteosarcoma in vitro and in vivo.
Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: The pivotal role of focal adhesion kinase signalling.
Association between TGFBR1*6A and osteosarcoma: A Chinese case-control study.
BMPR1A is necessary for chondrogenesis and osteogenesis, whereas BMPR1B prevents hypertrophic differentiation.
BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells.
CD99 acts as an oncosuppressor in osteosarcoma.
Depression of Focal Adhesion Kinase Induces Apoptosis in Rat Osteosarcoma OSR-6 Cells in a Caspase-Dependent Pathway.
Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.
Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.
Disialyl gangliosides enhance tumor phenotypes with differential modalities.
DNA methylation-mediated downregulation of PTPN3 attenuates to boost TGF-? signaling in osteosarcoma cells.
Downregulation of miR-19a inhibits the proliferation and promotes the apoptosis of osteosarcoma cells by regulating the JAK2/STAT3 pathway.
Erratum: Focal adhesion kinase is involved in the migration of human osteosarcoma cells.
Expression of protooncogenes in murine osteosarcomas.
Focal adhesion kinase is involved in the migration of human osteosarcoma cells.
Focal adhesion kinase overexpression and its impact on human osteosarcoma.
Focal adhesion kinase promotes progression and predicts poor clinical outcomes in patients with osteosarcoma.
Glycogen synthase kinase 3? promotes osteosarcoma invasion and migration via regulating PTEN and phosphorylation of focal adhesion kinase.
Inhibition of autophagy attenuated curcumol-induced apoptosis in MG-63 human osteosarcoma cells via Janus kinase signaling pathway.
Inhibition of focal adhesion kinase induces apoptosis in human osteosarcoma SAOS-2 cells.
Inhibition of Src phosphorylation alters metastatic potential of osteosarcoma in vitro but not in vivo.
Int7G24A variant of transforming growth factor-beta receptor 1 is associated with osteosarcoma susceptibility in a Chinese population.
miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1.
Nuclear IRS-1 and cancer.
Overexpression of CD155 relates to metastasis and invasion in osteosarcoma.
Potential Antimetastatic Effect of Timosaponin AIII against Human Osteosarcoma Cells through Regulating the Integrin/FAK/Cofilin Axis.
Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer.
Recruitment of nuclear factor Y to the inverted CCAAT element (ICE) by c-Jun and E1A stimulates basal transcription of the bone sialoprotein gene in osteosarcoma cells.
Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2.
Tanshinone IIA Inhibits Osteosarcoma Growth through a Src Kinase-Dependent Mechanism.
Targeted MEK inhibition by cobimetinib enhances doxorubicin's efficacy in osteosarcoma models.
The ?5/focal adhesion kinase/glycogen synthase kinase 3? integrin pathway in high-grade osteosarcoma: a protein expression profile predictive of response to neoadjuvant chemotherapy.
The effect of bone morphogenetic protein-7 on the expression of type I inositol 1,4,5-trisphosphate receptor in G-292 osteosarcoma cells and primary osteoblast cultures.
TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy.
WNT5A promotes migration and invasion of human osteosarcoma cells via SRC/ERK/MMP-14 pathway.
[Expression analysis of protein tyrosine kinases of the FAK (focal adhesion kinase) family in osteosarcoma]
Osteosclerosis
Genetic studies of bone diseases: evidence for involvement of DNA damage response proteins in bone remodeling.
Otosclerosis
Signaling by way of type IB and II bone morphogenetic protein receptors regulates bone formation in otospongiosis.
Ovarian Diseases
Expression of TGFBR1, TGFBR2, TGFBR3, ACVR1B and ACVR2B is altered in ovaries of cows with cystic ovarian disease.
Ovarian Hyperstimulation Syndrome
Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Ovarian Neoplasms
8-Benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic Acid (SD-1008), a Novel Janus Kinase 2 Inhibitor, Increases Chemotherapy Sensitivity in Human Ovarian Cancer Cells.
A heterodimeric nuclear protein complex binds two palindromic sequences in the proximal enhancer of the human erbB-2 gene.
A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-?, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort.
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers.
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
Administration of PLGA nanoparticles carrying shRNA against focal adhesion kinase and CD44 results in enhanced antitumor effects against ovarian cancer.
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis.
Analyses of merlin/NF2 connection to FAK inhibitor responsiveness in serous ovarian cancer.
Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase.
Biological significance of focal adhesion kinase in ovarian cancer: role in migration and invasion.
Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronectin in ovarian cancer cells.
Bruton's tyrosine kinase (Btk) inhibitor ibrutinib suppresses stem-like traits in ovarian cancer.
c-Jun N-terminal kinase inhibitor II (SP600125) activates Mullerian inhibiting substance type II receptor-mediated signal transduction.
Caspase 3-mediated focal adhesion kinase processing in human ovarian cancer cells: possible regulation by X-linked inhibitor of apoptosis protein.
CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.
CD166 Promotes the Cancer Stem-like Properties of Primary Epithelial Ovarian Cancer Cells.
CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.
CD44-targeted PLGA nanoparticles incorporating paclitaxel and FAK siRNA overcome chemoresistance in epithelial ovarian cancer.
Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: a potential role in autocrine growth regulation.
Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers.
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma.
Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.
Differential expression of activin/inhibin subunit and activin receptor mRNAs in normal and neoplastic ovarian surface epithelium (OSE).
Differential molecular regulation of processing and membrane expression of Type-I BMP receptors: implications for signaling.
Differential Wnt11 Expression Related to Wnt5a in High- and Low-grade Serous Ovarian Cancer: Implications for Migration, Adhesion and Survival.
ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.
Expression of p73 and c-Abl proteins in human ovarian carcinomas.
FAK-ERK activation in cell/matrix adhesion induced by the loss of apolipoprotein E stimulates the malignant progression of ovarian cancer.
Fibronectin promotes migration and invasion of ovarian cancer cells through up-regulation of FAK-PI3K/Akt pathway.
Focal Adhesion Kinase in Ovarian Cancer: A Potential Therapeutic Target for Platinum and Taxane-Resistant Tumors.
Focal adhesion kinase interacts with the transcriptional coactivator FHL2 and both are overexpressed in epithelial ovarian cancer.
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells.
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy.
Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.
Genetic testing by cancer site: stomach.
Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Granulocyte colony-stimulating factor receptor signalling via Janus kinase 2/signal transducer and activator of transcription 3 in ovarian cancer.
HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.
Hormonal regulation and distinct functions of semaphorin-3B and semaphorin-3F in ovarian cancer.
Host Wnt5a Potentiates Microenvironmental Regulation of Ovarian Cancer Metastasis.
Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Identification of Receptor Tyrosine Kinase, Discoidin Domain Receptor 1 (DDR1), as a Potential Biomarker for Serous Ovarian Cancer.
Influence of c-Src on hypoxic resistance to paclitaxel in human ovarian cancer cells and reversal of FV-429.
Inhibition of focal adhesion kinase (FAK) activity prevents anchorage-independent ovarian carcinoma cell growth and tumor progression.
Inhibition of ovarian tumor cell invasiveness by targeting SYK in the tyrosine kinase signaling pathway.
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules.
Inhibition of the integrin/FAK signaling axis and c-Myc synergistically disrupts ovarian cancer malignancy.
Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell-Mediated Antitumor Immunity By Suppressing PD-L1.
Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome.
Leptin receptor signaling via Janus kinase 2/Signal transducer and activator of transcription 3 impacts on ovarian cancer cell phenotypes.
Lysophosphatidic acid induces ovarian cancer cell dispersal by activating Fyn kinase associated with p120-catenin.
Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via G?i2, Src, and HIF1? signaling nexus.
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Modulation of Janus kinase 2 by p53 in ovarian cancer cells.
Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer.
MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.
Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.
Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK), and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced apoptosis.
Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation.
Proteome-wide Tyrosine Phosphorylation Analysis Reveals Dysregulated Signaling Pathways in Ovarian Tumors.
Proteome-wide tyrosine phosphorylation analysis reveals dysregulated signaling pathways in ovarian tumors.
PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines.
Resistance to bevacizumab in ovarian cancer SKOV3 xenograft due to EphB4 overexpression.
Role of Focal Adhesion Kinase in Regulating YB-1-Mediated Paclitaxel Resistance in Ovarian Cancer.
Selective sensitization of tumors to chemotherapy by marine-derived lipids: A review.
Shikonin induces apoptosis and inhibits migration of ovarian carcinoma cells by inhibiting the phosphorylation of Src and FAK.
SOX2 enhances the migration and invasion of ovarian cancer cells via Src kinase.
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer.
Spleen Tyrosine Kinase Confers Paclitaxel Resistance in Ovarian Cancer.
Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3.
SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
Src tyrosine kinase promotes survival and resistance to chemotherapeutics in a mouse ovarian cancer cell line.
Steroid receptor coactivator-3, a homolog of Taiman that controls cell migration in the Drosophila ovary, regulates migration of human ovarian cancer cells.
Suppression of EphB4 improves the inhibitory effect of mTOR shRNA on the biological behaviors of ovarian cancer cells by down-regulating Akt phosphorylation.
Suppression of urokinase expression and invasion by a soybean Kunitz trypsin inhibitor are mediated through inhibition of Src-dependent signaling pathways.
Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.
Targeting JAK1/STAT3 signaling suppresses tumor progression and metastasis in a peritoneal model of human ovarian cancer.
Targeting Src in Mucinous Ovarian Carcinoma.
The EPH receptor Bs (EPHBs) promoters are unmethylated in colon and ovarian cancers.
The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma.
The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.
The Syk inhibitor R406 is a modulator of P-glycoprotein (ABCB1)-mediated multidrug resistance.
Wnt11 alters integrin and cadherin expression by ovarian cancer spheroids and inhibits tumorigenesis and metastasis.
Overweight
Adipose tissue expression and genetic variants of the bone morphogenetic protein receptor 1A gene (BMPR1A) are associated with human obesity.
Paget Disease, Extramammary
Overexpression of Janus kinase 2 protein in extramammary Paget's disease.
Pancreatic Neoplasms
A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Activation of focal adhesion kinase enhances the adhesion and invasion of pancreatic cancer cells via extracellular signal-regulated kinase-1/2 signaling pathway activation.
Allergen?removed Rhus verniciflua Stokes suppresses invasion and migration of pancreatic cancer cells through downregulation of the JAK/STAT and Src/FAK signaling pathways.
Apigenin Inhibits NNK-Induced Focal Adhesion Kinase Activation in Pancreatic Cancer Cells.
Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer.
Breaking resistance of pancreatic cancer cells to an attenuated vesicular stomatitis virus through a novel activity of IKK inhibitor TPCA-1.
CHK negatively regulates Lyn kinase and suppresses pancreatic cancer cell invasion.
Cholecystokinin receptors in human pancreatic cancer cell lines.
Clinical implications of EphB4 receptor expression in pancreatic cancer.
Clinical significance of focal adhesion kinase in resectable pancreatic cancer.
Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreatic Cancer.
Correction: Alcalá, S., et al. Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells. Int. J. Mol. Sci. 2020, 21, 7437.
Development of resistance to FAK inhibition in pancreatic cancer is linked to stromal depletion.
Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer.
Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
EphB4 regulates the growth and migration of pancreatic cancer cells.
Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma.
Focal adhesion kinase inhibitor PF573228 and death receptor 5 agonist lexatumumab synergistically induce apoptosis in pancreatic carcinoma.
Focal adhesion kinase signaling and function in pancreatic cancer.
Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.
Glycofullerenes as non-receptor tyrosine kinase inhibitors- towards better nanotherapeutics for pancreatic cancer treatment.
Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor.
Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data.
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Inhibition of discoidin domain receptor 1 reduces collagen-mediated tumorigenicity in pancreatic ductal adenocarcinoma.
Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
Inhibition of focal adhesion kinase enhances antitumor response of radiation therapy in pancreatic cancer through CD8+ T cells.
Inhibition of Src reduces gemcitabine-induced cytotoxicity in human pancreatic cancer cell lines.
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice.
Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.
Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness.
Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
Lysophosphatidic Acid Stimulates Activation of Focal Adhesion Kinase and Paxillin and Promotes Cell Motility, via LPA1-3, in Human Pancreatic Cancer.
Mechanism Comparison of Gemcitabine and Dasatinib-Resistant Pancreatic Cancer by Integrating mRNA and miRNA Expression Profiles.
Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2.
miR-202 Diminishes TGFbeta Receptors and Attenuates TGFbeta1-induced EMT in Pancreatic Cancer.
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells.
MUC4-induced nuclear translocation of ?-catenin: A novel mechanism for growth, metastasis and angiogenesis in pancreatic cancer.
New Imidazo[2,1-b][1,3,4]Thiadiazole Derivatives Inhibit FAK Phosphorylation and Potentiate the Antiproliferative Effects of Gemcitabine Through Modulation of the Human Equilibrative Nucleoside Transporter-1 in Peritoneal Mesothelioma.
Nicotine induces inhibitor of differentiation-1 in a Src-dependent pathway promoting metastasis and chemoresistance in pancreatic adenocarcinoma.
Overexpression of PEAK1 contributes to epithelial-mesenchymal transition and tumor metastasis in lung cancer through modulating ERK1/2 and JAK2 signaling.
PAUF promotes adhesiveness of pancreatic cancer cells by modulating focal adhesion kinase.
Periostin promotes invasiveness and resistance of pancreatic cancer cells to hypoxia-induced cell death: role of the beta4 integrin and the PI3k pathway.
Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer.
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.
Rap1 reverses transcriptional repression of TGF-beta type II receptor by a mechanism involving AP-1 in the human pancreatic cancer cell line, UK Pan-1.
Reversion of transcriptional repression of Sp1 by 5 aza-2' deoxycytidine restores TGF-beta type II receptor expression in the pancreatic cancer cell line MIA PaCa-2.
Ror2-Src signaling in metastasis of mouse melanoma cells is inhibited by NRAGE.
Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase III studies.
S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase.
Src kinase and pancreatic cancer.
Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells.
Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
Targeting SRC Kinase Signaling in Pancreatic Cancer Stem Cells.
Targeting the C-terminal focal adhesion kinase scaffold in pancreatic cancer.
Targeting the Yin and the Yang: Combined Inhibition of the Tyrosine Kinase c-Src and the Tyrosine Phosphatase SHP-2 Disrupts Pancreatic Cancer Signaling and Biology In Vitro and Tumor Formation In Vivo.
Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer.
The inhibition of SRC family kinase suppresses pancreatic cancer cell proliferation, migration, and invasion.
The tyrosine kinase c-Src directly mediates growth factor-induced Notch-1 and Furin interaction and Notch-1 activation in pancreatic cancer cells.
Pancreatitis
c-Abl kinase regulates neutrophil extracellular trap formation, inflammation, and tissue damage in severe acute pancreatitis.
Da-Cheng-Qi Decoction Alleviates Intestinal Injury in Rats with Severe Acute Pancreatitis by Inhibiting the JAK2-STAT3 Signaling Pathway.
Da-Huang-Fu-Zi-Tang attenuates liver injury in rats with severe acute pancreatitis.
Effect of SOCS3 on lung injury in rats with severe acute pancreatitis through regulating JAK2/STAT3 signaling pathway.
Effects of Tec Tyrosine Kinase Inhibition on the Inflammatory Response of Severe Acute Pancreatitis-Associated Acute Lung Injury in Mice.
Loss of TGF-beta signaling contributes to autoimmune pancreatitis.
Protective Effect of Alprostadil on Acute Pancreatitis in Rats via Inhibiting Janus Kinase 2 (JAK2)/STAT3 Signal Transduction Pathway.
The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease.
Tumor necrosis factor-alpha mediates pancreatitis responses in acinar cells via protein kinase C and proline-rich tyrosine kinase 2.
Pancytopenia
[CD22 signal abnormalities in the pathogenesis of immune related pancytopenia].
Panniculitis
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Panniculitis in Patients Undergoing Treatment With the Bruton Tyrosine Kinase Inhibitor Ibrutinib for Lymphoid Leukemias.
Self-limiting Ibrutinib-Induced Neutrophilic Panniculitis.
Papilledema
Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits.
Papilloma
Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells.
Decreased focal adhesion kinase suppresses papilloma formation during experimental mouse skin carcinogenesis.
Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.
Modulation of the angiogenesis response through Ha-ras control, placenta growth factor, and angiopoietin expression in mouse skin carcinogenesis.
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
p53 loss of function enhances genomic instability and accelerates clonal evolution of murine myeloid progenitors expressing the p(210)BCR-ABL tyrosine kinase.
p63 drives invasion in keratinocytes expressing HPV16 E6/E7 genes through regulation of Src-FAK signalling.
Sensitization of transformed rat cells to parvovirus MVMp is restricted to specific oncogenes.
Subtraction hybridization identifies a transformation progression-associated gene PEG-3 with sequence homology to a growth arrest and DNA damage-inducible gene.
The c-Ha-ras oncogene induces increased expression of beta-galactoside alpha-2, 6-sialyltransferase in rat fibroblast (FR3T3) cells.
Variable transduction efficiency of murine leukemia retroviral vector on mammalian cells: role of cellular glycosylation.
Paralysis
A novel type 3 secretion system effector, YspI of Yersinia enterocolitica, induces cell paralysis by reducing total focal adhesion kinase.
Paraparesis, Spastic
Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
Paraproteinemias
Ibrutinib in the management of Waldenstrom macroglobulinemia.
Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy.
Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia.
Parasitemia
Syk inhibitors interfere with erythrocyte membrane modification during P falciparum growth and suppress parasite egress.
Testosterone-induced persistent susceptibility to Plasmodium chabaudi malaria: long-term changes of lincRNA and mRNA expression in the spleen.
Paratuberculosis
ZAP-70, CTLA-4 and proximal T cell receptor signaling in cows infected with Mycobacterium avium subsp. paratuberculosis.
Parkinson Disease
?-synuclein aggregates induce c-Abl activation and dopaminergic neuronal loss by a feed-forward redox stress mechanism.
?-Synucleinopathy associated c-Abl activation causes p53-dependent autophagy impairment.
A Bcr-Abl Inhibitor GNF-2 Attenuates Inflammatory Activation of Glia and Chronic Pain.
A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers.
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
C-Abl Inhibition; a novel therapeutic target for Parkinson's disease.
c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson's Disease.
c-Abl phosphorylates ?-synuclein and regulates its degradation: implication for ?-synuclein clearance and contribution to the pathogenesis of Parkinson's disease.
Dopamine D1-dependent trafficking of striatal N-methyl-D-aspartate glutamate receptors requires Fyn protein tyrosine kinase but not DARPP-32.
Effect of kaempferol on IgE-mediated anaphylaxis in C57BL/6 mice and LAD2 cells.
Fyn kinase mediates pro-inflammatory response in a mouse model of endotoxemia: Relevance to translational research.
Fyn Kinase Regulates Microglial Neuroinflammatory Responses in Cell Culture and Animal Models of Parkinson's Disease.
Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.
Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.
Neuroprotective efficacy of a new brain-penetrating C-Abl inhibitor in a murine Parkinson's disease model.
Pivotal Role of Fyn Kinase in Parkinson's Disease and Levodopa-Induced Dyskinesia: a Novel Therapeutic Target?
The c-Abl inhibitor in Parkinson disease.
The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.
The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Parkinsonian Disorders
c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism.
Pemphigoid, Bullous
Treatment of Mucous Membrane Pemphigoid With Janus Kinase Inhibitor Baricitinib.
Pemphigus
A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus.
Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus.
Bruton tyrosine kinase inhibition warrants further study for pemphigus.
Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus.
Focal adhesion kinase is expressed in acantholytic keratinocytes associated with pemphigus vulgaris and pemphigus foliaceus.
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus.
Pharmacological advances in pemphigus.
Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study.
Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.
Periapical Granuloma
JAK2/STAT3 is associated with the inflammatory process in periapical granuloma.
Periapical Periodontitis
The potential effect of Bruton's tyrosine kinase in refractory periapical periodontitis.
[Effects of Bruton's tyrosine kinase on the proliferation and differentiation of osteoclasts].
Perinatal Death
A role for c-Abl in c-myc regulation.
Periodontitis
CD24 activates the NLRP3 inflammasome through c-Src kinase activity in a model of the lining epithelium of inflamed periodontal tissues.
Effects of tofacitinib on the clinical features of periodontitis in patients with rheumatoid arthritis: two case reports.
Mangiferin ameliorates Porphyromonas gingivalis-induced experimental periodontitis by inhibiting phosphorylation of nuclear factor-?B and Janus kinase 1-signal transducer and activator of transcription signaling pathways.
Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
Peripheral Nerve Injuries
Lyn tyrosine kinase is required for P2X(4) receptor upregulation and neuropathic pain after peripheral nerve injury.
Microglial Janus kinase/signal transduction and activator of transcription 3 pathway activity directly impacts astrocyte and spinal neuron characteristics.
Peripheral Nervous System Diseases
Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors.
Peritoneal Fibrosis
Spleen Tyrosine Kinase (SYK) in the Progression of Peritoneal Fibrosis Through Activation of the TGF-?1/Smad3 Signaling Pathway.
The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer.
Peritoneal Neoplasms
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites.
Persistent Infection
Cortactin: A Major Cellular Target of the Gastric Carcinogen Helicobacter pylori.
The Structural Basis for Activation and Inhibition of ZAP-70 Kinase Domain.
Peutz-Jeghers Syndrome
Genetic testing by cancer site: stomach.
Genetic testing in colorectal cancer: who, when, how and why.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Pheochromocytoma
Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor.
HIV-1 Tat induces tyrosine phosphorylation of p125FAK and its association with phosphoinositide 3-kinase in PC12 cells.
Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Neurite extension and protein tyrosine phosphorylation elicited by inducible expression of the v-src oncogene in a PC12 cell line.
Tyrosine 402 phosphorylation of pyk2 is involved in ionomycin-induced neurotransmitter release.
v-src genes stimulate neurite outgrowth in pheochromocytoma (PC12) variants unresponsive to neurotrophic factors.
Pituitary Neoplasms
Study on miRNAs' expression for the invasion of pituitary adenomas.
The expression of integrinbeta1 and FAK in pituitary adenomas and their correlation with invasiveness.
Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.
Pityriasis
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Pityriasis Rubra Pilaris
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Plasmablastic Lymphoma
Activation of Src kinase Lyn by the Kaposi sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis.
Plasmacytoma
BALB/c.CBA/N mice carrying the defective Btk(xid) gene are resistant to pristane-induced plasmacytomagenesis.
Constitutive NF-{kappa}B Activation Confers Interleukin 6 (IL6) Independence and Resistance to Dexamethasone and Janus Kinase Inhibitor INCB018424 in Murine Plasmacytoma Cells.
Genomic instability in B-cells and diversity of recombinations that activate c-myc.
Molecular requirements for rapid plasmacytoma and pre-B lymphoma induction by Abelson murine leukemia virus in myc-transgenic mice.
Pleural Effusion
Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: a case report.
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.
Extramedullary Blast Crisis in a Patient with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Pulmonary toxicities from targeted therapies: a review.
Pneumonia
Additional baricitinib loading dose improves clinical outcome in COVID-19.
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.
c-Abl-Mediated Tyrosine Phosphorylation of PARP1 Is Crucial for Expression of Proinflammatory Genes.
Constitutive activation of the SRC family kinase Hck results in spontaneous pulmonary inflammation and an enhanced innate immune response.
Covid-19 and diabetes mellitus: unveiling the interaction of two pandemics.
Deletion of Src family kinase Lyn aggravates endotoxin-induced lung inflammation.
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family.
Genetic ablation of the src kinase p59fynT exacerbates pulmonary inflammation in an allergic mouse model.
Genetics in community-acquired pneumonia.
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Src kinase inhibition with dasatinib impairs neutrophil function and clearance of Escherichia coli infection in a murine model of acute lung injury.
The effect of siRNA-mediated lymphocyte-specific protein tyrosine kinase (Lck) inhibition on pulmonary inflammation in a mouse model of asthma.
TLR4 activation of TRPC6-dependent calcium signaling mediates endotoxin-induced lung vascular permeability and inflammation.
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia.
Pneumonia, Bacterial
ABL kinase inhibition promotes lung regeneration through expansion of an SCGB1A1+ SPC+ cell population following bacterial pneumonia.
Polycystic Kidney Diseases
Inhibiting Focal Adhesion Kinase Ameliorates Cyst Development in Polycystin-1-Deficient Polycystic Kidney Disease in Animal Model.
Polycystic Kidney, Autosomal Dominant
Apico-basal polarity in polycystic kidney disease epithelia.
Proliferative signaling by ERBB proteins and RAF/MEK/ERK effectors in polycystic kidney disease.
Polycystic Ovary Syndrome
Dysregulated miR-142, -33b, and -423 in granulosa cells target TGFBR1 and SMAD7: a possible role in polycystic ovary syndrome.
Polycythemia
An inhibitor of Janus kinase 2 prevents polycythemia in mice.
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Bumpy road to the diagnosis of polycythaemia vera.
Comparison of diagnostic criteria for polycythaemia vera.
Erythroblast transformation by the friend spleen focus-forming virus is associated with a block in erythropoietin-induced STAT1 phosphorylation and DNA binding and correlates with high expression of the hematopoietic phosphatase SHP-1.
Hemopoietic Cell Kinase amplification with Protein Tyrosine Phosphatase Receptor T depletion leads to polycythemia, aberrant marrow erythoid maturation, and splenomegaly.
Hereditary gene mutations in Korean patients with isolated erythrocytosis.
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
The small molecule inhibitor g6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of jak2-mediated myelofibrosis.
Polycythemia Vera
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
A rare case of large aortopulmonary window with Eisenmenger syndrome and adult survival.
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Advances in understanding and management of polycythemia vera.
Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera.
Anti-inflammatory cytokines hepatocyte growth factor and interleukin-11 are over-expressed in Polycythemia vera and contribute to the growth of clonal erythroblasts independently of JAK2V617F.
Apolipoprotein A1: A new serum marker correlated to JAK2 V617F proportion at diagnosis in patients with polycythemia vera.
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
BCR-ABL1- positive chronic myeloid leukemia with erythrocytosis presenting as polycythemia vera: a case report.
Cerebellar venous thrombosis mimicking a cerebellar tumor due to polycythemia vera: a case report.
Chromosomal abnormalities and molecular markers in myeloproliferative disorders.
Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Detection of Exon 12 and 14 Mutations in Janus Kinase 2 Gene Including a Novel Mutant in V617F Negative Polycythemia Vera Patients from Pakistan.
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Genetic and epigenetic alterations of myeloproliferative disorders.
Guidelines for the management of myeloproliferative neoplasms.
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
Hereditary gene mutations in Korean patients with isolated erythrocytosis.
How Does 2016 WHO Criteria for Polycythemia Vera Contribute to Our Daily Practice? A Single-Center Study from Turkey.
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Imatinib effect on growth and signal transduction in polycythemia vera.
Immunotherapy for myeloproliferative neoplasms (MPN).
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders.
JAK-Mutant Myeloproliferative Neoplasms.
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained.
JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera.
JAK2 V617F/C618R mutation in a patient with polycythemia vera: a case study and review of the literature.
Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor.
Janus kinase inhibitors: jackpot or potluck?
Janus kinase mutations.
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program.
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count.
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.
Myeloproliferative Neoplasms: A Contemporary Review.
Natural killer cells in patients with polycythemia vera.
Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.
New advances in the pathogenesis and therapy of essential thrombocythemia.
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Novel treatment strategies for myeloproliferative neoplasms.
Off-label studies on ruxolitinib in dermatology: a review.
Off-label Studies on the Use of Ruxolitinib in Dermatology.
Polycythaemia Vera among Sudanese Patients with Special Emphasis on JAK2 Mutations
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Polycythemia vera as a presentation of renal angiomyolipoma: a case report.
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals.
Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera.
Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes.
Ruxolitinib for the Treatment of Essential Thrombocythemia.
Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial.
Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Ruxolitinib: a targeted treatment option for patients with polycythemia vera.
Splenectomy normalizes hematocrit in murine polycythemia vera.
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
Subclinical hypercortisolism among polycythemia vera patients.
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
The diagnostic interface between histology and molecular tests in myeloproliferative disorders.
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
The marrow stem cell niche in normal and malignant hematopoiesis.
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
The role of jak2a in zebrafish hematopoiesis.
Thrombopoietin in normal and neoplastic stem cell development.
Two clinical phenotypes in polycythemia vera.
Typical essential thrombocythaemia does not express bcr-abelson fusion transcript.
Unclassifiable non-CML classical myeloproliferative diseases with microcytosis: findings indicating diagnosis of polycythemia vera masked by iron deficiency
Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
[Molecular mechanisms of myeloproliferative diseases and myelodysplastic syndromes]
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
[Research progress of myeloproliferative neoplasms].
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
[Successful treatment with dasatinib for polycythemia vera patient emerging BCR-ABL positive clone during 13 years of treatment].
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
[Vascular complications of essential thrombocythemia]
Polyneuropathies
Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Pre-Eclampsia
Association study of interleukin-1 receptor associated kinase 1 rs3027898 A/C gene polymorphism and preeclampsia in Pakistani population.
EPHB4 Regulates Human Trophoblast Cell Line HTR-8/SVneo Function: Implications for the Role of EPHB4 in Preeclampsia.
EPHB4, a down stream target of IFN-?/STAT1 signal pathway, regulates endothelial activation possibly contributing to the development of preeclampsia.
HOXA9 transcriptionally regulates the EPHB4 receptor to modulate trophoblast migration and invasion.
Human placental microRNAs and preeclampsia.
Induction of TGF-? receptor I expression in a DNA methylation-independent manner mediated by DNMT3A downregulation is involved in early-onset severe preeclampsia.
PP038. Renal ETK/BMX activation decreased in preeclampsia.
PP039. ETK/BMX and renin-angiotensin system (RAS) components are differentially expressed in renal tissue in both normal and preeclamptic pregnancy.
Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta.
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells.
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
A bcr-v-abl oncogene induces lymphomas in transgenic mice.
A case of chronic myelogenous leukemia with e8a2 fusion transcript.
A case of chronic myeloproliferative syndrome followed by precursor T-cell acute lymphoblastic leukemia.
A late-appearing Philadelphia chromosome in acute lymphoblastic leukemia confirmed by expression of BCR-ABL mRNA.
A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia.
A novel variant of the bcr-abl fusion product in Philadelphia chromosome-positive acute lymphoblastic leukemia.
A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.
A rare e14a3 BCR/ABL fusion transcript in acute lymphoblastic leukemia patient treated with CAR-modified T-cell therapy.
A Screening-Based Approach to Circumvent Tumor Microenvironment-Driven Intrinsic Resistance to BCR-ABL+ Inhibitors in Ph+ Acute Lymphoblastic Leukemia.
A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL.
A variant transcript, e1a3, of the minor BCR-ABL fusion gene in acute lymphoblastic leukemia: case report and review of the literature.
Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia.
Aberrant expression of tumor suppressor genes and their association with chimeric oncogenes in pediatric acute lymphoblastic leukemia.
ABL deletion without associated BCR-ABL in precursor B-cell acute lymphoblastic leukemia.
ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.
ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL.
Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.
Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient.
Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins.
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
Acute bilateral retina hemorrhages beneath internal limiting membrane: An unusual ophthalmological case report of acute leukemia during complete clinical remission.
Acute leukemia in children.
Acute leukemia.
Acute Lymphoblastic Leukemia Expressing b3a2 (p210), e1a2 (p190), and Variant e1a2 BCR-ABL Transcripts: A Case Report and Review of the Literature.
Acute lymphoid leukemia molecular phenotype in a patient with benign-phase chronic myelogenous leukemia.
Acute monocytic leukemia with coexpression of minor BCR-ABL1 and PICALM-MLLT10 fusion genes along with overexpression of HOXA9.
Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels.
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Allosteric BCR-ABL inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia: novel opportunities for drug combinations to overcome resistance.
Alternative 5' end of the bcr-abl transcript in chronic myelogenous leukemia.
Alternative forms of the BCR-ABL oncogene have quantitatively different potencies for stimulation of immature lymphoid cells.
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Amplification of BCR-ABL rearrangement in atypical Philadelphia chromosome: a new variant detected by fluorescence in situ hybridization in one case of acute lymphoblastic leukemia.
An unusual case of T-cell acute lymphoblastic leukemia in a patient with BCR-ABL positive chronic myeloid leukemia and Gaucher disease.
Analysis of immunoglobulin, T cell receptor and bcr rearrangements in human malignant lymphoma and Hodgkin's disease.
Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia.
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.
Association of HLA antigens and BCR-ABL transcripts in leukemia patients with the Philadelphia chromosome.
Atypical BCR-ABL mRNA transcripts in adult acute lymphoblastic leukemia.
Augmentation of the antileukemia potency of total-body irradiation (TBI) by a novel P-site inhibitor of spleen tyrosine kinase (SYK).
B-ALL Relapses After Autologous Stem Cell Transplantation Associated With a Shift from e1a2 to e14a2 BCR-ABL Transcripts: A Case Report.
bcr rearrangement and C-abl gene expression in Ph1-positive hybrid acute leukemia with simultaneous proliferation of lymphoid and myeloid blasts.
bcr rearrangement and translocation of the c-abl oncogene in Philadelphia positive acute lymphoblastic leukemia.
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.
BCR-ABL fusion protein detection in peripheral blood and bone marrow samples of adult precursor B-cell acute lymphoblastic leukemia patients using the flow cytometric immunobead assay.
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
bcr-abl oncogene activation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway.
BCR-ABL rearrangement frequencies in chronic myeloid leukemia and acute lymphoblastic leukemia in Ecuador, South America.
BCR-ABL rearrangement in adult T-cell acute lymphoblastic leukemia.
bcr-abl rearrangement in adult T-lineage acute lymphoblastic leukemia.
BCR-ABL translocation as a favorable prognostic factor in elderly acute lymphoblastic leukemia patients in potent tyrosine kinase era.
BCR-ABL Translocation in Pediatric Acute Lymphoblastic Leukemia in Southern India.
BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
BCR-ABL, ETV6-RUNX1 and E2A-PBX1: prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients.
BCR-ABL-independent and RAS / MAPK pathway-dependent form of imatinib resistance in Ph-positive acute lymphoblastic leukemia cell line with activation of EphB4.
bcr-abl-positive T-cell acute lymphoblastic leukemia associated with parvovirus B19 infection.
Bortezomib treatment causes remission in a Ph+ALL patient and reveals FoxO as a theranostic marker.
c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.
C6-unsubstituted pyrazolo[3,4-d]pyrimidines are dual Src/Abl inhibitors effective against imatinib mesylate resistant chronic myeloid leukemia cell lines.
Can clues to the molecular defects in chronic myelogenous leukemia come from genetic studies on the Abelson tyrosine kinase in fruit flies?
CD4(+) T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation.
Cellular expression of antiapoptotic BCL-2 oncoprotein in newly diagnosed childhood acute lymphoblastic leukemia: a Children's Cancer Group Study.
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.
Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China.
Clinical features and outcome of children with first marrow relapse of acute lymphoblastic leukemia expressing BCR-ABL fusion transcripts. BFM Relapse Study Group.
Clinical features and prognostic implications of TCF3-PBX1 and ETV6-RUNX1 in adult acute lymphoblastic leukemia.
Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia.
Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762).
Clonal cytogenetic abnormalities after tyrosine kinase inhibitor therapy in Ph+ all resolution after decitabine therapy.
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia.
Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.
Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
Comparative analysis of interphase FISH and RT-PCR to detect bcr-abl translocation in chronic myelogenous leukemia and related disorders.
Comparison of a pediatric-inspired treatment protocol versusstandard-intensity chemotherapy for young adults with standard-riskBCR-ABL negative acute lymphoblastic leukemia.
Constitutive 53BP1/?H2AX foci are increased in cells of ALL patients dependent on BCR-ABL and TEL-AML1 preleukemic gene fusions.
Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients.
Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia.
Cytogenetics and molecular genetics of childhood leukemia.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.
Dasatinib-Induced Pleural Effusions: A Lymphatic Network Disorder?
Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report.
Dasatinib.
Dasatinib: An Anti-Tumour Agent via Src Inhibition.
Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia.
Design and synthesis of phosphoryl-substituted diphenylpyrimidines (Pho-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors: Targeted treatment of B lymphoblastic leukemia cell lines.
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia.
Detection and Clinical Relevance of BCR-ABL Fusion Gene in Childhood T-lineage Acute Lymphoblastic Leukemia: A Report on 4 Cases.
Detection and significance of bcr-abl mRNA transcripts and fusion proteins in Philadelphia-positive adult acute lymphoblastic leukemia.
Detection of BCR-ABL fusion genes in adult acute lymphoblastic leukemia by the polymerase chain reaction.
Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array.
Detection of BCR-ABL transcripts in acute lymphoblastic leukemia in Indian patients.
Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation.
Detection of chimeric BCR-ABL genes on bone marrow samples and blood smears in chronic myeloid and acute lymphoblastic leukemia by in situ hybridization.
Detection of Philadelphia chromosome-positive acute lymphoblastic leukemia by polymerase chain reaction: possible eradication of minimal residual disease by marrow transplantation.
Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction.
Development of BCR-ABL positive acute lymphoblastic leukemia in donor cells after allogeneic hematopoietic cell transplantation for Philadelphia-positive acute lymphoblastic leukemia.
Diagnostic utility of oncogenes and their products in human cancer.
Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias.
Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics.
Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin.
Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvement.
Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).
Effect of a selective Abl tyrosine kinase inhibitor, STI571, on in vitro growth of BCR-ABL-positive acute lymphoblastic leukemia cells.
Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations: abrogative effect on the transformation of murine hematopoietic cells by transfection of a retroviral vector expressing oncoprotein P210bcr/abl and preferential inhibition on Ph1-positive leukemia cell growth.
Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity.
Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects.
Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
Electrochemical detection of leukemia oncogenes using enzyme-loaded carbon nanotube labels.
Epidemiological study on survival of chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) patients with BCR-ABL T315I mutation.
Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Establishment of the 1st World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA.
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression.
Examining the origin of posttransplant lymphoproliferative disorder in a patient after a second allogeneic hematopoeitic stem cell transplantation for relapsed BCR-ABL positive acute lymphoblastic leukemia.
Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).
Expression of BCR-ABL, E2A-PBX1, and MLL-AF4 fusion transcripts in newly diagnosed children with acute lymphoblastic leukemia: a Children's Cancer Group initiative.
Expression of the ABL-BCR fusion gene in Philadelphia-positive acute lymphoblastic leukemia.
Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity.
Expression patterns of WT-1 and Bcr-Abl measured by TaqMan quantitative real-time RT-PCR during follow-up of leukemia patients with the Ph chromosome.
Failure of CDKN2A/B (INK4A/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL.
Focal adhesion kinase comes into focus for B-cell acute lymphoblastic leukemia treatment.
Frequency and clinical impact of ETV6/RUNX1, AF4-MLL, and BCR/ABL fusion genes on features of acute lymphoblastic leukemia at presentation.
Frequency of BCR-ABL fusion oncogene in Pakistani childhood acute lymphoid leukemia (ALL) patients reflects ethnic differences in molecular genetics of ALL.
Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia.
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Further Analytical, Pharmacokinetic, and Clinical Observations on Low-Dose Ponatinib in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
Further evidence of the involvement of the c-abl oncogene in chronic myelogenous leukemia and acute lymphocytic leukemia.
Fusion of the bcr and the c-abl genes in Ph'-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region.
Fyn is not essential for Bcr-Abl-induced leukemogenesis in mouse bone marrow transplantation models.
Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.
Genetic evaluation of childhood acute lymphoblastic leukemia in Iraq using FTA cards.
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.
Global PROTAC Toolbox for Degrading BCR-ABL Overcomes Drug-Resistant Mutants and Adverse Effects.
GZD824 suppresses the growth of human B cell precursor acute lymphoblastic leukemia cells by inhibiting the SRC kinase and PI3K/AKT pathways.
Haploinsufficiency of the IKZF1 (IKAROS) tumor suppressor gene cooperates with BCR-ABL in a transgenic model of acute lymphoblastic leukemia.
Hemin counteracts the repression of Bcl-2 and NrF2 genes and the cell killing induced by imatinib in human Bcr-Abl(+) CML cells.
Heterogeneity in lineage derivation of Philadelphia-positive acute lymphoblastic leukemia expressing p190BCR-ABL or p210BCR-ABL: determination by analysis of individual colonies with the polymerase chain reaction.
High incidence of a second BCR-ABL fusion in chronic myeloid leukemia revealed by interphase cytogenetic analysis on blood and bone marrow smears.
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
High-risk acute lymphoblastic leukemia cells with bcr-abl and INK4A/ARF mutations retain susceptibility to alloreactive T cells.
How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome.
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Hypermethylation of the spleen tyrosine kinase promoter in T-lineage acute lymphoblastic leukemia.
Identification of a novel p190-derived breakpoint Peptide suitable for Peptide vaccine therapeutic approach in ph+ acute lymphoblastic leukemia patients.
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
Ikaros family zinc-finger 1 mutation is an independent factor for the poor prognosis of adult B-cell acute lymphoblastic leukemia, and allogeneic hematopoietic stem cell transplantation can improve clinical outcomes.
Imatinib treatment alone in Philadelphia-positive acute lymphoblastic leukemia: is it enough?
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform.
Immunologic characterization of the tumor-specific bcr-abl junction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia.
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemia.
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups.
In vitro drug resistance to imatinib and mutation of ABL gene in childhood Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.
In vitro effect of curcumin in combination with chemotherapy drugs in Ph+ acute lymphoblastic leukemia cells.
In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.
Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia.
Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature.
Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-R? mutations.
Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571).
Inhibition of Phosphotyrosine Phosphatase 1B Causes Resistance in BCR-ABL-Positive Leukemia Cells to the ABL Kinase Inhibitor STI571.
Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice.
Interphase FISH for Y chromosome, VNTR polymorphisms, and RT-PCR for BCR-ABL in the monitoring of HLA-matched and mismatched transplants.
JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL.
Keeping PACE with Ph Positive to Ph-Like Detection in B-Lineage Acute Lymphoblastic Leukemia: A Practical and Cost Effective (PACE) Approach in a Resource Constrained Setting.
Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology.
Lack of TEL-AML1 fusion transcript resulting from a cryptic t(12;21) in adult B lineage acute lymphoblastic leukemia in Taiwan.
Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.
Long-term follow-up of minimal residual disease in childhood acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers.
Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
Management of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Mcl-1 downregulation leads to the heightened sensitivity exhibited by BCR-ABL positive ALL to induction of energy and ER-stress.
Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation.
Methodologic and biological variability of quantitative real-time polymerase chain reaction analysis of Bcr-Abl expression in Philadelphia chromosome-positive acute lymphoblastic leukemia.
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.
Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.
Molecular biology of Philadelphia chromosome in chronic granulocytic leukaemia and acute lymphoblastic leukaemia.
Molecular cytogenetics in childhood acute lymphoblastic leukemia: a hospital-based observational study.
Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia.
Molecular diagnostics in the treatment of childhood acute lymphoblastic leukemia.
Molecular diagnostics in the treatment of leukemia.
Molecular mechanisms of Bcr-Abl-induced oncogenesis.
Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1).
Multi-Lineage BCR-ABL Expression in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Associated With Improved Prognosis but No Specific Molecular Features.
Multiplex in-cell reverse transcription-polymerase chain reaction for the simultaneous detection of p210 and p190 BCR-ABL mRNAs in chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia cell lines.
Multiplex PCR of bcr-abl fusion transcripts in Philadelphia positive acute lymphoblastic leukemia.
Multiplex RT-PCR for the detection of common BCR-ABL fusion transcripts in paraffin-embedded tissues from patients with chronic myeloid leukemia and acute lymphoblastic leukemia.
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.
Mutation-specific control of BCR-ABL T315I positive leukemia with a recombinant yeast-based therapeutic vaccine in a murine model.
Nanoscale liposomal formulation of a SYK P-site inhibitor against B-precursor leukemia.
New approved dasatinib regimen available for clinical use.
New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Niemann-Pick disease type C1(NPC1) is involved in resistance against imatinib in the imatinib-resistant Ph+ acute lymphoblastic leukemia cell line SUP-B15/RI.
Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia.
No prognostic significance of immunophenotypic changes at the end of remission induction therapy in children with B-lineage acute lymphoblastic leukemia.
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Novel antibody-based therapies for acute lymphoblastic leukemia.
Novel conventional therapies in onco-hemathology.
Novel role of pleckstrin homology domain of the Bcr-Abl protein: analysis of protein-protein and protein-lipid interactions.
NUP214-ABL1 mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.
Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL.
Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis.
Optimal approach to treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: how to best use all the available tools.
Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Oxidative stress is involved in Dasatinib-induced apoptosis in rat primary hepatocytes.
p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias.
p190 BCR-ABL rearrangement in chronic myeloid leukemia and acute lymphoblastic leukemia.
Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
Pepsi® or Coke®? Influence of acid on dasatinib absorption.
Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation.
Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Is Separated into Two Subgroups Associated with Survival by BCR-ABL Fluorescence in situ Hybridization of Segmented Cell Nuclei: Report from a Single Institution.
Philadelphia negative, BCR-ABL positive adult acute lymphoblastic leukemia (ALL) in 2 of 39 patients with combined cytogenetic and molecular analysis.
Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis.
Phospho-CRKL monitoring for the assessment of BCR-ABL activity in imatinib-resistant chronic myeloid leukemia or Ph+ acute lymphoblastic leukemia patients treated with nilotinib.
Phosphorylation of tyrosine 393 in the kinase domain of Bcr-Abl influences the sensitivity towards imatinib in vivo.
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines.
Pleural effusions due to dasatinib.
Polymerase chain reaction analysis of BCR-ABL sequences in adult Philadelphia chromosome-negative acute lymphoblastic leukemia patients.
Ponatinib in refractory Philadelphia chromosome-positive leukemias.
Ponatinib-induced neutrophilic panniculitis.
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies.
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia.
Practical management of dasatinib for maximum patient benefit.
Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone.
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition.
Predictors of outcome in adults with BCR-ABL negative acute lymphoblastic leukemia treated with a pediatric-based regimen.
Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia.
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Prophylactic post-transplant dasatinib administration in a pediatric patient with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Prospective BCR-ABL analysis by polymerase chain reaction (RT-PCR) in adult acute B-lineage lymphoblastic leukemia: reliability of RT-nested-PCR and comparison to cytogenetic data.
Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors.
Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias.
PTEN is a tumor suppressor in CML stem cells and BCR-ABL-induced leukemias in mice.
Quantification of minimal residual disease in patients with e1a2 BCR-ABL-positive acute lymphoblastic leukemia using a real-time RT-PCR assay.
Quinacrine Depletes BCR-ABL and Suppresses Ph-Positive Leukemia Cells.
Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia.
Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.
Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia.
Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia.
Ribozyme-mediated inhibition of a Philadelphia chromosome-positive acute lymphoblastic leukemia cell line expressing the p190 bcr-abl oncogene.
Role of Vitamins A and D in BCR-ABL Arf-/- Acute Lymphoblastic Leukemia.
Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Serial monitoring of T315I BCR-ABL mutation by Invader assay combined with RT-PCR.
Simple multiplex RT-PCR for identifying common fusion transcripts in childhood acute leukemia.
Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts.
Sole BCR-ABL inhibition is insufficient to eliminate all myeloproliferative disorder cell populations.
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Specific inhibition of bcr-abl gene expression by small interfering RNA.
Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Spotlight on dasatinib in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Src, Akt, NF-?B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia.
Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy.
Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Susceptibility of Ph-positive all to TKI therapy associated with Bcr-Abl rearrangement patterns: a retrospective analysis.
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Synthesis of imatinib, a tyrosine kinase inhibitor, labeled with carbon-14.
T lymphoblastic lymphoma with BCR-ABL negative chronic myeloid leukaemia: a novel association.
T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.
Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Targeting miR-21 sensitizes Ph+ ALL Sup-b15 cells to imatinib-induced apoptosis through upregulation of PTEN.
Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.
Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.
The ABL tyrosine kinase inhibitor STI571 (Glivec) in Philadelphia positive acute lymphoblastic leukemia - promises, pitfalls and possibilities.
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
The BCR-ABL/NF-?B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias.
The development of agents targeting the BCR-ABL tyrosine kinase as Philadelphia chromosome-positive acute lymphoblastic leukemia treatment.
The existence of lymphoid lineage restricted Philadelphia chromosome-positive acute lymphoblastic leukemia with heterogeneous bcr-abl rearrangement.
The Formin mDia1 Regulates Acute Lymphoblastic Leukemia Engraftment, Migration, and Progression in vivo.
The Impact of Pre-transplant Cell-free DNA Levels on Leukemia Relapse and Transplant Related Complications in Allogeneic Hematopoietic Stem Cell Transplant Recipients
The in vitro generation of Ph1+ ALL-specific HLA-A24-restricted cytotoxic T lymphocytes using a synthetic 16 mer minor bcr-abl peptide.
The incidence of submicroscopic deletions in reciprocal translocations is similar in acute myeloid leukemia, BCR-ABL positive acute lymphoblastic leukemia, and chronic myeloid leukemia.
The kinase inhibitor STI571 reverses the Bcr-Abl induced point mutation frequencies observed in pre-leukemic P190(Bcr-Abl) transgenic mice.
The potential for dasatinib in treating chronic lymphocytic leukemia, acute myeloid leukemia, and myeloproliferative neoplasms.
The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease.
The role of Aktand RAFTK in beta1 integrin mediated survival of precursor B-acute lymphoblastic leukemia cells.
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in pregnancy.
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Tumor classification ranking from microarray data.
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.
TYK2-STAT1-BCL2 Pathway Dependence in T-Cell Acute Lymphoblastic Leukemia.
Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial.
Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia.
Uncommon BCR-ABL kinase domain mutations in kinase inhibitor-resistant chronic myelogenous leukemia and Ph+ acute lymphoblastic leukemia show high rates of regression, suggesting weak selective effects.
Undifferentiated immunophenotypes and not expression of BCR-ABL can be associated in adult Mestizo Mexican patients with ALL.
Unexpected heterogeneity of BCR-ABL fusion mRNA detected by polymerase chain reaction in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Unique fusion of bcr and c-abl genes in Philadelphia chromosome positive acute lymphoblastic leukemia.
Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain.
VE-cadherin Regulates Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Sensitivity to Apoptosis.
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.
ZAP-70 and Bcl-2 expression in B lymphoblastic leukemia cells and hematogones.
ZAP-70 as a possible prognostic factor in childhood acute lymphoblastic leukemia.
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL.
ZAP-70 expression in normal pro/pre B cells, mature B cells, and in B-cell acute lymphoblastic leukemia.
ZAP-70 is expressed by normal and malignant human B-cell subsets of different maturational stage.
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia.
ZAP-70 tyrosine kinase is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells.
[A Modified Protocol for Rapid Establishing Mouse Model with Ph+ Positive Acute Lymphoblastic Leukemia].
[Adult acute lymphoblastic leukemia with atypical BCR-ABL transcript e1a3: a case report and literature review].
[Analysis of Clinical Characteristics in De novo Chronic Myelogenous Leukemia Patients with Extramedullary T-Lymphoblastic Blast Crisis].
[Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia]
[Clinical and laboratory characteristics and treatment option for Philadelphia positive acute lymphoblastic leukemia patients with ABL kinase domain mutations].
[Comparison of clinical efficacy between first-generation and second-generation tyrosine kinase inhibitors based regimen in the treatment of patients with BCR-ABL positive acute lymphoblastic leukemia].
[Effects of PCI-32765 and Dasatinib on the Acute Lymphoblastic Leukemic Cells and Their Mechanisms].
[Frequently ABL kinase domain G:C?A:T mutation and uracil DNA glycosylase abnormal expression in TKI-resistant acute lymphoblastic leukemia of Chinese population].
[Hematological malignancies]
[Molecular genetics of acute lymphoblastic leukemia].
[PCR detection of relevant translocations in pediatric acute lymphoblastic leukemia].
[Prognostic significance of Ph-positive acute lymphoblastic leukemia].
[Prolonged molecular response induced by imatinib in Philadelphia positive acute lymphoblastic leukemia A case report and brief review].
[Risk Factors of Leukemia-free Survival in Ph
[Role of molecular genetic investigations in the diagnosis of acute leukemias and in the detection of minimal residual disease]
[The different characteristics of ABL kinase domain mutation in the Chinese Han nationality imatinib resistant Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic myeloid leukemia].
[The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells].
[The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome]
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Acute leukemia: subtype discovery and prediction of outcome by gene expression profiling.
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
Clinical-Grade Peptide-Based Inhibition of CK2 Blocks Viability and Proliferation of T-ALL Cells and Counteracts IL-7 Stimulation and Stromal Support.
Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases.
Detection of occult cerebrospinal fluid involvement during maintenance therapy identifies a group of children with acute lymphoblastic leukemia at high risk for relapse.
FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.
Genome-wide screen reveals WNT11, a non-canonical WNT gene, as a direct target of ETS transcription factor ERG.
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia.
Molecular detection of a late-appearing BCR-ABL gene in a child with T-cell acute lymphoblastic leukemia.
Multidisciplinary analysis of pediatric T-ALL: 9q34 gene fusions.
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia.
Mutations Encountered in Acute Lymphoblastic Leukemia: A Retrospective Study in a Teaching Hospital in Jeddah, Saudi Arabia.
Pediatric acute lymphoblastic leukemia (ALL) gene expression signatures classify an independent cohort of adult ALL patients.
Pediatric acute lymphoblastic leukemia.
Persistence of TEL-AML1 transcript in acute lymphoblastic leukemia in long-term remission.
Prevalence of common fusion transcripts in acute lymphoblastic leukemia: A report of 304 cases.
PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.
Saracatinib impairs maintenance of human T-ALL by targeting the LCK tyrosine kinase in cells displaying high level of lipid rafts.
Simultaneous expression of RBTN-2 and BCR-ABL oncogenes in a T-ALL with a t(11;14)(p13;q11) and a late-appearing Philadelphia chromosome.
Single monochrome real-time RT-PCR assay for identification, quantification, and breakpoint cluster region determination of t(9;22) transcripts.
T-cell blast crisis of chronic myelogenous leukemia presented with coexisting p210 and p190 BCR-ABL transcripts and t(10;11)(q11;p15).
Unique amplification of BCR-ABL1 gene fusion in a case of T-cell acute lymphoblastic leukemia.
VLA-4 Induces Chemoresistance of T Cell Acute Lymphoblastic Leukemia Cells via PYK2-Mediated Drug Efflux.
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.
Prediabetic State
Role of Fyn-mediated NMDA receptor function in prediabetic neuropathy in mice.
Pregnancy, Tubal
Networks of E-cadherin, ?1 integrin, and focal adhesion kinase in the pathogenesis of tubal pregnancy.
Primary Immunodeficiency Diseases
A novel deletion mutation and structural abnormality in the Bruton's tyrosine kinase gene identified in a Chinese patient with X-linked agammaglobulinemia.
Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy.
Bruton's tyrosine kinase: cell biology, sequence conservation, mutation spectrum, siRNA modifications, and expression profiling.
Clinical characteristics and genotype-phenotype correlation in 62 patients with X-linked agammaglobulinemia.
Compound heterozygous TYK2 mutations underlie primary immunodeficiency with T-cell lymphopenia.
Debilitating progressive encephalitis in a patient with BTK deficiency.
Delayed diagnosis of X-linked agammaglobulinaemia in a boy with recurrent meningitis.
Eczema and X-linked agammaglobulinaemia.
Functional analysis of peripheral blood B cells in patients with X-linked agammaglobulinemia.
IL-2-inducible T-cell kinase deficiency with pulmonary manifestations due to disseminated Epstein-Barr virus infection.
IL-2-inducible T-cell kinase deficiency: clinical presentation and therapeutic approach.
Metastatic colorectal cancer and severe hypocalcemia following irinotecan administration in a patient with X-linked agammaglobulinemia: a case report.
Multiple colorectal neoplasms in X-linked agammaglobulinemia.
Novel deletion mutation in Bruton's tyrosine kinase results in X-linked agammaglobulinemia: A case report.
Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK.
Splice-correction strategies for treatment of x-linked agammaglobulinemia.
X-linked agammaglobulinemia combined with juvenile idiopathic arthritis and invasive Klebsiella pneumoniae polyarticular septic arthritis.
X-linked agammaglobulinemia in a 10-year-old boy with a novel non-invariant splice-site mutation in Btk gene.
X-Linked Agammaglobulinemia With Chronic Meningoencephalitis: A Diagnostic Challenge.
[Gene diagnosis of X-linked agammaglobulinemia]
Primary Myelofibrosis
'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies.
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
A case-based discussion of clinical problems in the management of patients treated with ruxolitinib for myelofibrosis.
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis.
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis.
A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF).
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis.
A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers.
A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.
Acquired familial Mediterranean fever associated with a somatic MEFV mutation in a patient with JAK2 associated post-polycythemia myelofibrosis.
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation.
Adding hydroxyurea in combination with ruxolitinib improves clinical responses in hyperproliferative forms of myelofibrosis.
Advances in myelofibrosis: a clinical case approach.
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Allogeneic Hematopoietic Stem-Cell Transplantation in Myelofibrosis: Key Messages for Clinical Practice in the Era of Janus Kinase 1/2 Inhibitors.
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.
An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors.
Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Chromosomal abnormalities and molecular markers in myeloproliferative disorders.
Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene.
Circulating Calreticulin Is Increased in Myelofibrosis: Correlation with Interleukin-6 Plasma Levels, Bone Marrow Fibrosis, and Splenomegaly.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Clearance of the Janus kinase 2 (JAK2) V617F mutation after allogeneic stem cell transplantation in a patient with myelofibrosis with myeloid metaplasia.
Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Clinical potential of pacritinib in the treatment of myelofibrosis.
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies.
Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor.
Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis.
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience.
Current Clinical Investigations in Myelofibrosis.
De novo variant in tyrosine kinase SRC causes thrombocytopenia: case report of a second family.
Definition and management of ruxolitinib treatment failure in myelofibrosis.
Developmental Therapeutics in Myeloproliferative Neoplasms.
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Direct activation of STAT5 by ETV6-LYN fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis.
Discovery of the macrocycle 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a potent Janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) inhibitor for the treatment of myelofibrosis and lymphoma.
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Drug Development Pipeline for Myeloproliferative Neoplasms: Potential Future Impact on Guidelines and Management.
Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.
Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis.
Effects of repeated oral doses of ketoconazole on a sequential ascending single oral dose of fedratinib in healthy subjects.
Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I.
Effects of strong and moderate CYP3A4 inducers on the pharmacokinetics of fedratinib in healthy adult participants.
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis.
Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis.
Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
Emerging drugs for myelofibrosis.
Erythema Nodosum-like Septal Panniculitis Secondary to Lenalidomide Therapy in a Patient With Janus Kinase 2-Positive Myelofibrosis.
Essential thrombocythaemia: challenges and evidence-based management.
Excretion balance and pharmacokinetics following a single oral dose of [14C]-fedratinib in healthy subjects.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-?1 Signaling Pathway.
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis.
Genetic and epigenetic alterations of myeloproliferative disorders.
Guidelines for the management of myeloproliferative neoplasms.
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
Hit the spleen, JAK!
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.
Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
Idiopathic myelofibrosis causing inflammatory central retinal vein occlusion mimicking frosted branch angiitis.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Immunotherapy for myeloproliferative neoplasms (MPN).
Impact of Bone Marrow Pathology on the Clinical Management of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts.
Investigational Janus kinase inhibitors in development for myelofibrosis.
JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
JAK-Mutant Myeloproliferative Neoplasms.
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
JAK2 inhibitors do not affect stem cells present in the spleens of patients with myelofibrosis.
JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
JAK2 V617F as a Marker for Long-Term Disease Progression and Mortality in Polycythemia Vera and its Role in Economic Modeling.
Janus kinase 2 (V617F) mutation status, signal transducer and activator of transcription-3 phosphorylation and impaired neutrophil apoptosis in myelofibrosis with myeloid metaplasia.
Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?
Janus Kinase Inhibitors and Allogeneic Stem Cell Transplantation for Myelofibrosis.
Janus Kinase Inhibitors and Stem Cell Transplantation in Myelofibrosis.
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.
Janus kinase mutations.
Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis.
Janus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosis.
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Long-term Effects of the Janus Kinase 1/2 Inhibitor Ruxolitinib on Pulmonary Hypertension and the Cardiac Function in a Patient with Myelofibrosis.
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes.
Managing Patients With Myelofibrosis in the Era of Janus Kinase Inhibitors.
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms.
Molecular genetics of myelofibrosis and its associated disease phenotypes.
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review.
Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.
Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines.
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
Myelofibrosis-When Do We Select Transplantation or Non-transplantation Therapeutic Options?
Myelofibrosis: clinicopathologic features, prognosis, and management.
Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
Myeloproliferative Neoplasms: A Contemporary Review.
Necessity to screen and treat latent tuberculosis before ruxolitinib treatment-Ruxolitinib-associated disseminated tuberculosis: A case report and literature review.
New advances in the pathogenesis and therapy of essential thrombocythemia.
New Concepts of Treatment for Patients with Myelofibrosis.
New insights into the pathogenesis and drug treatment of myelofibrosis.
Novel Concepts of Treatment for Patients with Myelofibrosis and Related Neoplasms.
Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology.
Novel Therapies for Myelofibrosis.
Off-label studies on ruxolitinib in dermatology: a review.
Off-label Studies on the Use of Ruxolitinib in Dermatology.
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Pacritinib: a new agent for the management of myelofibrosis?
Pathogenetic role of JAK2 V617F mutation in chronic myeloproliferative disorders.
Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment.
Pharmacokinetics and tolerability of fedratinib, an oral, selective Janus kinase 2 inhibitor, in subjects with renal or hepatic impairment.
Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.
Physiologically based pharmacokinetic modeling to assess metabolic drug-drug interaction risks and inform the drug label for fedratinib.
Pneumocystis jiroveci pneumonitis complicating ruxolitinib therapy.
Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation.
Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Primary Myelofibrosis: Update on Definition, Pathogenesis, and Treatment.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis.
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib.
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Role of additional novel therapies in myeloproliferative neoplasms.
Ruxolitinib - better prognostic impact in low-intermediate 1 risk score: evaluation of the 'rete ematologica pugliese' (REP) in primary and secondary myelofibrosis.
Ruxolitinib dose management as a key to long-term treatment success.
Ruxolitinib for myelofibrosis--an update of its clinical effects.
Ruxolitinib for the Treatment of Essential Thrombocythemia.
Ruxolitinib for the treatment of myelofibrosis: its clinical potential.
Ruxolitinib photodegradation mechanisms by theoretical and experimental chemistry.
Ruxolitinib: a new treatment option for myelofibrosis.
Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians.
Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis.
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
SOHO State of the Art Updates and Next Questions: Identifying and Treating "Progression" in Myelofibrosis.
Somatic mutations of calreticulin in myeloproliferative neoplasms.
Stem cell defects in Philadelphia chromosome negative chronic myeloproliferative disorders: a phenotypic and molecular puzzle?
Sustained-release ruxolitinib: Findings from a phase 1 study in healthy subjects and a phase 2 study in patients with myelofibrosis.
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
The marrow stem cell niche in normal and malignant hematopoiesis.
The Mutation Profile Of Calreticulin In Patients With Myeloproliferative Neoplasms And Acute Leukemia.
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.
The V617F JAK2 mutation and the myeloproliferative disorders.
Three-year efficacy, overall survival, and safety of ruxolitinib therapy in patients with myelofibrosis from the COMFORT-I study.
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.
Thrombopoietin in normal and neoplastic stem cell development.
Transcriptome profiling reveals target in primary myelofibrosis together with structural biology study on novel natural inhibitors regarding JAK2.
Transforming growth factor ?-mediated micromechanics modulates disease progression in primary myelofibrosis.
Treating early-stage myelofibrosis.
Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.
Usefulness of Low-Dose Splenic Irradiation prior to Reduced-Intensity Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Elderly Patients with Myelofibrosis.
What is next beyond janus kinase 2 inhibitors for primary myelofibrosis?
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
[Molecular mechanisms of myeloproliferative diseases and myelodysplastic syndromes]
[Pathogenesis of thrombosis in JAK2V617F myeloproliferative neoplasms].
[Research progress of myeloproliferative neoplasms].
[Research Progress on Effect of JAK Inhibitors on Myelofibrosis- Review].
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
[Treatment options and limitations in the management of myelofibrosis].
Primary Ovarian Insufficiency
Association study of anti-Mullerian hormone and anti-Mullerian hormone type II receptor polymorphisms with idiopathic primary ovarian insufficiency.
BMPR1A and BMPR1B Missense Mutations Cause Primary Ovarian Insufficiency.
Prion Diseases
c-Abl Tyrosine Kinase Mediates Neurotoxic Prion Peptide-Induced Neuronal Apoptosis via Regulating Mitochondrial Homeostasis.
Differential expression of transforming growth factor-beta isoforms in human prion diseases.
Increased Src kinase level results in increased protein tyrosine phosphorylation in scrapie-infected neuronal cell lines.
Proctocolitis
Inhibition of JAK/STAT signaling in rheumatologic disorders: the expanding spectrum.
Prostatic Intraepithelial Neoplasia
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-?8 in prostate cancer cells.
Prostatic Neoplasms
?3?1 Integrin Suppresses Prostate Cancer Metastasis via Regulation of the Hippo Pathway.
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy.
A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells.
Activation of intracellular calcium by multiple Wnt ligands and translocation of ?-catenin into the nucleus: a convergent model of Wnt/Ca2+ and Wnt/?-catenin pathways.
Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells.
Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.
Activin receptor signaling regulates prostatic epithelial cell adhesion and viability.
ADAM-mediated amphiregulin shedding and EGFR transactivation.
Analysis of Wnt gene expression in prostate cancer: mutual inhibition by WNT11 and the androgen receptor.
Androgen deprivation modulates gene expression profile along prostate cancer progression.
Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase.
Anti-prostate cancer activity of a nanoformulation of the spleen tyrosine kinase (SYK) inhibitor C61.
Atorvastatin inhibited Rho-associated kinase 1 (ROCK1) and focal adhesion kinase (FAK) mediated adhesion and differentiation of CD133+CD44+ prostate cancer stem cells.
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.
Bioluminescent imaging study: FAK inhibitor, PF-562,271, preclinical study in PC3M-luc-C6 local implant and metastasis xenograft models.
BMX-Mediated Regulation of Multiple Tyrosine Kinases Contributes to Castration Resistance in Prostate Cancer.
Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4.
Bruton's Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)?-Suppressed Migration and Invasion of Prostate Cancer.
Bruton's tyrosine kinase is a potential therapeutic target in prostate cancer.
c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.
C-Src-mediated phosphorylation of ?-catenin increases its protein stability and the ability of inducing nuclear distribution of ?-catenin.
Cancer cells exploit the Eph-ephrin system to promote invasion and metastasis: tales of unwitting partners.
CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines.
Chromosomal deletion, promoter hypermethylation and downregulation of FYN in prostate cancer.
Clinical Targeting of Mutated and Wild-type Protein Tyrosine Kinases in Cancer.
Cloning of human bone morphogenetic protein type IB receptor (BMPR-IB) and its expression in prostate cancer in comparison with other BMPRs.
Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells.
Context-specific protein tyrosine kinase 6 (PTK6) signalling in prostate cancer.
CTA095, a Novel Etk and Src Dual Inhibitor, Induces Apoptosis in Prostate Cancer Cells and Overcomes Resistance to Src Inhibitors.
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone.
Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation.
Decreased c-Abl activity in PC-3 and LNCaP prostate cancer cells overexpressing the early growth response-1 protein.
Determination of the membrane topology of lemur tyrosine kinase 2 (LMTK2) by fluorescence protease protection.
Dietary palmitate cooperates with Src kinase to promote prostate tumor progression.
Differential transformation capacity of Src family kinases during the initiation of prostate cancer.
Downregulation of c-SRC kinase CSK promotes castration resistant prostate cancer and pinpoints a novel disease subclass.
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
Editor's Note: Focal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer.
Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Effects of lysophosphatidic acid on calpain-mediated proteolysis of focal adhesion kinase in human prostate cancer cells.
EphB4 expression and biological significance in prostate cancer.
EPHB4 inhibition activates ER stress to promote immunogenic cell death of prostate cancer cells.
EphB4 localises to the nucleus of prostate cancer cells.
Etk/Bmx, a PH-domain containing tyrosine kinase, protects prostate cancer cells from apoptosis induced by photodynamic therapy or thapsigargin.
Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells.
Evidence for a dual function of EphB4 as tumor promoter and suppressor regulated by the absence or presence of the ephrin-B2 ligand.
Expression of a truncated form of the c-Kit tyrosine kinase receptor and activation of Src kinase in human prostatic cancer.
Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
Focal adhesion kinase and its potential involvement in tumor invasion and metastasis.
Focal adhesion kinase controls aggressive phenotype of androgen-independent prostate cancer.
Focal Adhesion Kinase Controls Prostate Cancer Progression via Intrinsic Kinase and Scaffolding Functions.
Focal adhesion kinase is required for bombesin-induced prostate cancer cell motility.
Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion.
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Genistein-induced apoptosis of prostate cancer cells is preceded by a specific decrease in focal adhesion kinase activity.
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
Global analysis of differentially expressed genes in androgen-independent prostate cancer.
Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells.
Growth regulation of human prostate cancer cells by bone morphogenetic protein-2.
Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells.
High intracellular Zn2+ ions modulate the VHR, ZAP-70 and ERK activities of LNCaP prostate cancer cells.
Identification and characterization of biomarkers and their functions for docetaxel-resistant prostate cancer cells.
Identification of inactivating mutations in the JAK1, SYNJ2, and CLPTM1 genes in prostate cancer cells using inhibition of nonsense-mediated decay and microarray analysis.
In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation.
Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications.
Indirubin derivative E804 inhibits angiogenesis.
Induction of anoikis by doxazosin in prostate cancer cells is associated with activation of caspase-3 and a reduction of focal adhesion kinase.
Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells.
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Intracellular modifiers of integrin alpha 6p production in aggressive prostate and breast cancer cell lines.
Invasive prostate carcinoma driven by c-Src and androgen receptor synergy.
Investigation of the expression of the EphB4 receptor tyrosine kinase in prostate carcinoma.
LCoR acts as a novel androgen receptor corepressor, inhibits prostate cancer growth and is functionally inactivated by the Src kinase.
Lemur Tyrosine Kinase 2, a novel target in prostate cancer therapy.
Long-Chain Acyl-CoA Synthetase 4-Mediated Fatty Acid Metabolism Sustains Androgen Receptor Pathway-Independent Prostate Cancer.
Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells.
Loss of Myeloid BMPR1a Alters Differentiation and Reduces Mouse Prostate Cancer Growth.
Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer.
MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells.
MicroRNA-214 targets PTK6 to inhibit tumorigenic potential and increase drug sensitivity of prostate cancer cells.
MicroRNA-4723 inhibits prostate cancer growth through inactivation of the Abelson family of nonreceptor protein tyrosine kinases.
miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer.
miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT.
miRNA-128 suppresses prostate cancer by inhibiting BMI-1 to inhibit tumor-initiating cells.
Molecular mechanism of prostate cancer cell apoptosis induced by busulfan via adjustment of androgen receptor phosphatization.
Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
Murine, but not human, ephrin-B2 can be efficiently cleaved by the serine protease kallikrein-4: Implications for xenograft models of human prostate cancer.
Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers.
Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase.
Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling.
New experimental markers for early detection of high-risk prostate cancer: role of cell-cell adhesion and cell migration.
Overexpressed gene signature of EPH receptor A/B family in cancer patients-comprehensive analyses from the public high-throughput database.
Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts.
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer.
Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects.
Preclinical Evaluation of the Supercritical Extract of Azadirachta Indica (Neem) Leaves In Vitro and In Vivo on Inhibition of Prostate Cancer Tumor Growth.
Preclinical investigation of ibrutinib, a Bruton's kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes.
Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix.
Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells.
Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis.
Protein tyrosine kinase 6 signaling in prostate cancer.
Reduced tumor growth in vivo and increased c-Abl activity in PC3 prostate cancer cells overexpressing the Shb adapter protein.
Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer.
Role of focal adhesion kinase and phosphatidylinositol 3'-kinase in integrin fibronectin receptor-mediated, matrix metalloproteinase-1-dependent invasion by metastatic prostate cancer cells.
Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines.
Signal transducer and activator of transcription 5A/B in prostate and breast cancers.
SRC family kinase activity is up-regulated in hormone-refractory prostate cancer.
SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer.
Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells.
SRC kinase regulation in progressively invasive cancer.
SRC ONCOGENE INDUCES TROP2 PROTEOLYTIC ACTIVATION VIA CYCLIN D1.
Stat3 promotes metastatic progression of prostate cancer.
STEAP4 regulates focal adhesion kinase activation and CpG motifs within STEAP4 promoter region are frequently methylated in DU145, human androgen-independent prostate cancer cells.
STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death.
Survival analysis of multiple peptide vaccination for the selection of correlated peptides in urological cancers.
SYK is a candidate kinase target for the treatment of advanced prostate cancer.
Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells.
Targeting Tyrosine Kinases and Autophagy in Prostate Cancer.
TGF-?/PI3K/AKT/mTOR/NF-kB pathway. Clinicopathological features in prostate cancer.
The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs.
The conventional transforming growth factor-beta (TGF-beta) receptor type I is not required for TGF-beta 1 signaling in a human prostate cancer cell line, LNCaP.
The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer.
The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth.
The loss of TGF-beta signaling promotes prostate cancer metastasis.
The TGF-? Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.
The tumour-promoting receptor tyrosine kinase, EphB4, regulates expression of integrin-?8 in prostate cancer cells.
Tumor classification ranking from microarray data.
Tyrosine Kinase Etk/BMX Is Up-regulated in Human Prostate Cancer and Its Overexpression Induces Prostate Intraepithelial Neoplasia in Mouse.
Vemurafenib Inhibits Active PTK6 in PTEN-null Prostate Tumor Cells.
Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.
Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity.
ZNF507 affects TGF-? signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state.
Protein Deficiency
Atypical X-linked agammaglobulinemia diagnosed in three adults.
Early-onset colorectal cancer: A distinct entity with unique genetic features.
protein-tyrosine-phosphatase deficiency
Protein Tyrosine Phosphatase 1B Deficiency Ameliorates Murine Experimental Colitis via the Expansion of Myeloid-Derived Suppressor Cells.
SHP-1 deficiency in B-lineage cells is associated with heightened lyn protein expression and increased lyn kinase activity.
Proteinuria
Angiotensin II down-regulates nephrin-Akt signaling and induces podocyte injury: roleof c-Abl.
BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Membranous Nephropathy and Intrarenal Extramedullary Hematopoiesis in a Patient With Myelofibrosis.
Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril.
Pruritus
A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats.
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Janus kinase inhibitor delgocitinib suppresses pruritus and nerve elongation in an atopic dermatitis murine model.
Oclacitinib in feline nonflea-, nonfood-induced hypersensitivity dermatitis: results of a small prospective pilot study of client-owned cats.
Small molecule drugs for the treatment of pruritus in patients with atopic dermatitis.
The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
Pseudarthrosis
Mechanical microenvironments and protein expression associated with formation of different skeletal tissues during bone healing.
Pseudomonas Infections
Spleen Tyrosine Kinase as a Target Therapy for Pseudomonas aeruginosa Infection.
Psoriasis
4,5-bis(4-fluoroanilino)phthalimide: A selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent in vivo antitumor activity.
A randomised Phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis.
Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis.
Application of the Itch Severity Score in patients with moderate-to-severe plaque psoriasis: Clinically important difference and responder analyses.
Assessment of the role of spleen tyrosine kinase and zeta-chain-associated 70-kDa protein (tyrosine) kinase in the pathogenesis of psoriasis.
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials.
Conformational insights into the inhibitory mechanism of phyto-compounds against Src kinase family members implicated in psoriasis.
Considerations for safety in the use of systemic medications for psoriasis and atopic dermatitis during the COVID-19 pandemic.
Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses.
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.
Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study.
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 Trials.
Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, on Clinical Signs of Moderate-to-Severe Plaque Psoriasis in Different Body Regions.
Efficacy of topical tofacitinib, a Janus kinase inhibitor, in the treatment of plaque psoriasis.
Emerging systemic drugs in the treatment of plaque psoriasis.
Emerging therapies in psoriasis: a systematic review.
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.
Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study.
Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors.
Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Immunohistochemical study of janus kinase 1/signal transducer and activator of transcription 3 in psoriasis vulgaris.
Immunosuppressive drugs for patients with psoriasis during the COVID-19 pandemic era. A review.
In the pipeline for psoriasis: upcoming psoriasis treatments.
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
JAK inhibitors and infections risk: focus on herpes zoster.
JAK Inhibitors in Psoriasis: A Promising New Treatment Modality.
JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis.
JAK-STAT inhibitors for the treatment of immunomediated diseases.
JAK/STAT and VEGF/PAK1 signaling as emerging targets for topical treatment of psoriasis: a pilot study.
Janus kinase inhibition as a potential strategy for the treatment of psoriasis: state of the art and future perspectives.
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Janus Kinase Inhibitors: A Review of Their Emerging Applications in Dermatology
Kinase inhibitors in the treatment of immune-mediated disease.
Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis.
Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update.
Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis.
New and emerging therapies in psoriasis.
New jak inhibitors for the treatment of psoriasis and psoriatic arthritis.
New Oral Therapies for Psoriasis: A Comprehensive Review.
Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Novel systemic therapies for the treatment of psoriasis.
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.
Oral tofacitinib for the treatment of adults with moderate to severe chronic plaque psoriasis.
Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Phase 2a Randomised, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study to Evaluate the Efficacy and Safety of ASP015K, a Novel Janus Kinase (JAK) Inhibitor, in Patients with Moderate to Severe Psoriasis.
Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.
Randomized Pilot Clinical Trial of Tofacitinib Solution for Plaque Psoriasis: Challenges of the Intra-Subject Study Design.
Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.
Small Molecules for Psoriasis.
The Effect of Janus Kinase Inhibitors and Phosphodiesterase-4 Inhibitors on Skin and Plasma Cytokine Levels in Patients with Psoriasis.
The JAK inhibitor tofacitinib ameliorates immune?mediated liver injury in mice.
The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development.
The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
Tirbanibulin: First Approval.
Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study.
Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.
Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.
Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study.
Tofacitinib withdrawal and re-treatment in moderate-to-severe chronic plaque psoriasis: a randomised controlled trial.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Tofacitinib: a new oral Janus kinase inhibitor for psoriasis.
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
Tyk2 is a therapeutic target for psoriasis-like skin inflammation.
Tyrosine kinase 2 and Janus kinase?signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
[JAK inhibitors: Perspectives in internal medicine].
Pterygium
EphB4 expression in pterygium is associated with microvessel density.
EphrinB2 and EphB4 expression in pterygia: new insights and preliminary results.
Puberty, Delayed
BMPR1A is a candidate gene for congenital heart defects associated with the recurrent 10q22q23 deletion syndrome.
Pulmonary Alveolar Proteinosis
ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.
Pulmonary Arterial Hypertension
'There and Back Again'-Forward Genetics and Reverse Phenotyping in Pulmonary Arterial Hypertension.
Blockade of JAK2 protects mice against hypoxia-induced pulmonary arterial hypertension by repressing pulmonary arterial smooth muscle cell proliferation.
BMP signaling in vascular diseases.
BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis.
Bone morphogenetic protein receptor type II and inflammation are bringing old concepts into the new pulmonary arterial hypertension world.
Bone morphogenetic protein receptor type II C-terminus interacts with c-Src: implication for a role in pulmonary arterial hypertension.
Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension.
Clinical characteristics and survival of Chinese patients diagnosed with pulmonary arterial hypertension who carry BMPR2 or EIF2KAK4 variants.
Clinical features of pulmonary arterial hypertension in patients receiving dasatinib.
Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension.
Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report.
Defective cellular trafficking of the bone morphogenetic protein receptor type II by mutations underlying familial pulmonary arterial hypertension.
Erratum to: BMP type II receptor as a therapeutic target in pulmonary arterial hypertension.
Genetics of pulmonary arterial hypertension: current and future implications.
miR-181b-5p inhibits endothelial-mesenchymal transition in monocrotaline-induced pulmonary arterial hypertension by targeting endocan and TGFBR1.
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.
Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature.
Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease.
Smooth muscle protein 22alpha-mediated patchy deletion of Bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling.
The BMP Receptor 2 in Pulmonary Arterial Hypertension: When and Where the Animal Model Matches the Patient.
Three novel BMPR2 mutations associated with advanced pulmonary arterial hypertension.
[NF-?B inhibitor improves pulmonary vascular remodeling by reversing LPS-induced down-regulation of BMPRII].
Pulmonary Atelectasis
BMP signaling is essential in neonatal surfactant production during respiratory adaptation.
Pulmonary Disease, Chronic Obstructive
Cigarette smoke activates the proto-oncogene c-src to promote airway inflammation and lung tissue destruction.
Decreased expression of TGF-beta type II receptor in bronchial glands of smokers with COPD.
Effect of Liuweibuqi capsule, a Chinese patent medicine, on the JAK1/STAT3 pathway and MMP9/TIMP1 in a chronic obstructive pulmonary disease rat model.
Hematopoietic cell kinase gene polymorphisms and the risk of chronic obstructive pulmonary disease in a Chinese population.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Lyn regulates epithelial-mesenchymal transition in CS-exposed model through Smad2/3 signaling.
Src Regulates Cigarette Smoke-induced Ceramide Generation via nSMase2 in the Airway Epithelium.
[The Involvement of Src in Airway Inflammation Induced by Repeated Exposure to Lipopolysaccharide in Mice].
Pulmonary Fibrosis
Abrogation of transforming growth factor-?-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Ang-(1-7) treatment attenuates lipopolysaccharide-induced early pulmonary fibrosis.
Antifibrotic Effects of Focal Adhesion Kinase Inhibitor in Bleomycin-Induced Pulmonary Fibrosis in Mice.
Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice.
Fibroblast-enriched endoplasmic reticulum protein TXNDC5 promotes pulmonary fibrosis by augmenting TGF? signaling through TGFBR1 stabilization.
miR-770-5p inhibits the activation of pulmonary fibroblasts and silica-induced pulmonary fibrosis through targeting TGFBR1.
Non-canonical Wnt Signaling Promotes Myofibroblast Differentiation in Pulmonary Fibrosis.
Overexpression of Inhibitor of DNA-Binding 2 Attenuates Pulmonary Fibrosis through Regulation of c-Abl and Twist.
Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis.
Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Therapeutic targeting of SRC kinase in myofibroblast differentiation and pulmonary fibrosis.
Purpura, Thrombocytopenic, Idiopathic
A High Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury during the COVID-19 pandemic.
A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury.
Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats.
Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.
Fostamatinib for the treatment of chronic immune thrombocytopenia.
Fostamatinib for the treatment of immune thrombocytopenia in adults.
Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA.
Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Fostamatinib: A Review in Chronic Immune Thrombocytopenia.
Fostamatinib: First Global Approval.
Increased serum BAFF (B-cell activating factor of the TNF family) level is a peculiar feature associated with familial chronic lymphocytic leukemia.
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Refractory case of ulcerative colitis with idiopathic thrombocytopenic purpura successfully treated by Janus kinase inhibitor tofacitinib: A case report.
Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
Transitioning From Thrombopoietin Agonists to the Novel SYK Inhibitor Fostamatinib: A Multicenter, Real-World Case Series.
Pyoderma Gangrenosum
Idiopathic myelofibrosis and pyoderma gangrenosum involving a mutation of Janus kinase 2 (JAK2V617F), showing poor prognosis.
Pyoderma gangrenosum in association with Janus kinase 2 (JAK2V617F) mutation.
Rabies
Focal adhesion kinase is involved in rabies virus infection through its interaction with viral phosphoprotein P.
Radiation Pneumonitis
Prevention of radiation-induced pneumonitis by recombinant adenovirus-mediated transferring of soluble TGF-beta type II receptor gene.
Rectal Neoplasms
Circular RNA circMTO1 acts as an antitumor factor in rectal cancer cell lines by downregulation of miR-19b-3p.
Focal adhesion kinase: predictor of tumour response and risk factor for recurrence after neoadjuvant chemoradiation in rectal cancer.
Genetic variation in bone morphogenetic protein (BMP) and colon and rectal cancer.
The Prognostic Value of Tyrosine Kinase SRC Expression in Locally Advanced Rectal Cancer.
Rectal Prolapse
c-Abl regulates gastrointestinal muscularis propria homeostasis via ERKs.
Red-Cell Aplasia, Pure
Philadelphia negative, Bcr-Abl positive chronic myeloid leukemia associated with pure red cell aplasia.
Renal Insufficiency
A direct binding site for Grb2 contributes to transformation and leukemogenesis by the Tel-Abl (ETV6-Abl) tyrosine kinase.
Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse.
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571.
The Tel-Abl (ETV6-Abl) tyrosine kinase, product of complex (9;12) translocations in human leukemia, induces distinct myeloproliferative disease in mice.
Renal Insufficiency, Chronic
Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice.
The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Reperfusion Injury
Astragaloside IV Alleviates Cerebral Ischemia-Reperfusion Injury by Activating the Janus Kinase 2 and Signal Transducer and Activator of Transcription 3 Signaling Pathway.
Basal and Src kinase-mediated activation of the EphA2 promoter requires a cAMP-responsive element but is CREB-independent.
Commentary on 'protective effect of focal adhesion kinase against skeletal muscle reperfusion injury after acute limb ischemia'.
Curcumin protects against cerebral ischemia-reperfusion injury by activating JAK2/STAT3 signaling pathway in rats.
Effect of sevoflurane on hepatic ischemia-reperfusion injury in rats via JAK2-STAT3 pathway.
Granulocyte colony-stimulating factor prevents reperfusion injury after heart preservation.
Imatinib Is Protective Against Ischemia-Reperfusion Injury in an Ex Vivo Rabbit Model of Lung Injury.
Increased Bioavailable Berberine Protects Against Myocardial Ischemia Reperfusion Injury Through Attenuation of NF?B and JNK Signaling Pathways.
Intratubular epithelial-mesenchymal transition and tubular atrophy after kidney injury in mice.
Levo-tetrahydropalmatine Attenuates Neuron Apoptosis Induced by Cerebral Ischemia-Reperfusion Injury: Involvement of c-Abl Activation.
Ouabain protects rat hearts against ischemia-reperfusion injury via pathway involving src kinase, mitoKATP, and ROS.
Protective Effect of Focal Adhesion Kinase against Skeletal Muscle Reperfusion Injury after Acute Limb Ischemia.
Proteomics study of oxidative stress and Src kinase inhibition in H9C2 cardiomyocytes: a cell model of heart ischemia-reperfusion injury and treatment.
Re: 'Protective Effect of Focal Adhesion Kinase against Skeletal Muscle Reperfusion Injury after Acute Limb Ischemia'.
Re: 'Protective Effect of Focal Adhesion Kinase against Skeletal Muscle Reperfusion Injury after Acute Limb Ischemia': Exciting Questions about Ischemia Reperfusion Injury.
Role of the Janus kinase 2/signal transducers and activators of transcription 3 pathway in the protective effect of remote ischemia preconditioning against cerebral ischemia-reperfusion injury in rats.
Transcriptional modulation of the T helper 17/interleukin 17 axis ameliorates renal ischemia-reperfusion injury.
[Activation of JAK2/STAT3 pathway by CPU0213 alleviates myocardial ischemia-reperfusion and oxidative stress injury in rats].
Respiratory Distress Syndrome
Keratinocyte growth factor expression is suppressed in early acute lung injury/acute respiratory distress syndrome by smad and c-Abl pathways.
Silencing Bruton's tyrosine kinase in alveolar neutrophils protects mice from LPS/immune complex-induced acute lung injury.
Wnt5a and Wnt11 as acute respiratory distress syndrome biomarkers for SARS-CoV-2 patients.
Respiratory Tract Infections
Clinical, Immunological, and Genetic Features in 49 Patients With ZAP-70 Deficiency: A Systematic Review.
Genetics in community-acquired pneumonia.
Reticuloendotheliosis, Avian
Feed?back loops integrating RELA, SOX18 and FAK mediate the break?down of the lymph?endothelial barrier that is triggered by 12(S)?HETE.
Retinal Degeneration
LIF-dependent JAK3 activation is not essential for retinal degeneration.
Retinal Diseases
Identification and expression analysis of novel Jakmip1 transcripts.
Retinal Dysplasia
Retinal dysplasia in mice lacking p56lck.
Retinal Neovascularization
c-abl is required for the development of hyperoxia-induced retinopathy.
Proline-rich tyrosine kinase 2 via enhancing signal transducer and activator of transcription 3-dependent cJun expression mediates retinal neovascularization.
Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy.
Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularization.
[Variation of expression of Pyk2 in oxygen-induced retinal neovascularization mice model].
Retinoblastoma
A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle.
Abrogation of retinoblastoma protein function by c-Abl through tyrosine kinase-dependent and -independent mechanisms.
An epigenomic mechanism in retinoblastoma: the end of the story?
c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors.
Cell-cell contact promotes specific activity of pp60c-src protein kinase in human retinoblastoma cells.
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis.
Erb-B2 receptor tyrosine kinase 2 knockdown inhibits retinoblastoma progression via Wnt/?-catenin signaling pathway in vitro.
Hepatoprotective Effects of Traditional Chinese Medicine on Liver Fibrosis from Ethanol Administration following Partial Hepatectomy.
Immunohistochemical Analysis of PDGFR-?, PDGFR-? and c-Abl in Retinoblastoma: Potential Therapeutic Targets.
Induction of protein-tyrosine-phosphatase activity by interleukin 6 in M1 myeloblastic cells and analysis of possible counteractions by the BCR-ABL oncogene.
Inhibition of c-Abl tyrosine kinase activity by filamentous actin.
Interaction of BCR-ABL with the retinoblastoma protein in Philadelphia chromosome-positive cell lines.
Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.
Nuclear export of proteins and drug resistance in cancer.
Oncogenes: present status.
Overexpression of Inhibitor of DNA-Binding 2 Attenuates Pulmonary Fibrosis through Regulation of c-Abl and Twist.
Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays.
Pharmacokinetics and Efficacy of the Spleen Tyrosine Kinase Inhibitor R406 after Ocular Delivery for Retinoblastoma.
Progress in Small Molecule Therapeutics for the Treatment of Retinoblastoma.
Regulation of cell death by the Abl tyrosine kinase.
Signal transduction via serine/threonine kinase receptors.
Spleen tyrosine kinase expression and its correlation with necrosis and high-risk histopathologic features in retinoblastoma.
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Targeted therapy of gastroenteropancreatic neuroendocrine tumours: preclinical strategies and future targets.
TGF-{beta} type II Receptor mRNA in Retinoblastoma Cell Lines is induced by Trichostatin A.
The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products.
The study of c-Src kinase and pStat3 protein expression in retinoblastoma.
Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.
v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines.
[Effect of AG490 on JAK2/STAT3 signaling pathway in human retinoblastoma HXO-RB44 cell lines].
Retinopathy of Prematurity
c-abl is required for the development of hyperoxia-induced retinopathy.
Expression of ephrinB2 and its receptors on fibroproliferative membranes in ocular angiogenic diseases.
Retroviridae Infections
Cooperative transforming activities of ras, myc, and src viral oncogenes in nonestablished rat adrenocortical cells.
Rett Syndrome
Unraveling Molecular Pathways Altered in MeCP2-Related Syndromes, in the Search for New Potential Avenues for Therapy.
Rhabdoid Tumor
The tyrosine kinase c-Abl promotes proliferation and is expressed in atypical teratoid and malignant rhabdoid tumors.
Rhabdomyosarcoma
An E2F-dependent late-serum-response promoter in a gene that controls glycolysis.
Development of non-viral, ligand-dependent, EPHB4-specific chimeric antigen receptor T cells for treatment of rhabdomyosarcoma.
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Expression of TGF-beta type I and II receptors in normal and cancerous human endometrium.
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation.
Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells.
Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
Rhabdomyosarcoma, Alveolar
PDGFR? reverses EphB4 signaling in alveolar rhabdomyosarcoma.
Rhabdomyosarcoma, Embryonal
Focal adhesion kinase (FAK) phosphorylation is a key regulator of embryonal rhabdomyosarcoma (ERMS) cell viability and migration.
Rheumatic Diseases
JAK Inhibitors in Rheumatology: Implications for Paediatric Syndromes?
Practical management of patients on Janus kinase inhibitor (JAKi) therapy: Practical fact sheets drawn up by the Rheumatism and Inflammation Club (CRI), a group endorsed by the French Society for Rheumatology (SFR).
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations.
The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors.
Thromboembolic Safety Reporting of Tofacitinib and Baricitinib: An Analysis of the WHO VigiBase.
Uncharted waters: mesenchymal stem cell treatment for pediatric refractory rheumatic diseases; a single center case series.
Rhinitis
Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis.
Rhinitis, Allergic
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.
MicroRNA-let-7e regulates the progression and development of allergic rhinitis by targeting suppressor of cytokine signaling 4 and activating Janus kinase 1/signal transducer and activator of transcription 3 pathway.
Spleen tyrosine kinases: biology, therapeutic targets and drugs.
Src-type tyrosine kinase p56lck is critical for thymic stromal lymphopoietin-induced allergic rhinitis.
TGF? receptor mutations impose a strong predisposition for human allergic disease.
Root Resorption
Intermittent parathyroid hormone promotes cementogenesis via ephrinB2-EPHB4 forward signaling.
Rosacea
Immunohistochemical expression of matrix metalloproteinases in the granulomatous rosacea compared with the non-granulomatous rosacea.
Salmonella Infections
CARD9 negatively regulates NLRP3-induced IL-1? production on Salmonella infection of macrophages.
Sarcoidosis
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.
Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare.
Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera.
Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis.
Tofacitinib Treatment and Molecular Analysis of Cutaneous Sarcoidosis.
Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis.
Treatment of Multiorgan Sarcoidosis With Tofacitinib.
Sarcoidosis, Pulmonary
Effects of broad-spectrum antimycobacterial therapy on chronic pulmonary sarcoidosis.
Tofacitinib as a Steroid-Sparing Therapy in Pulmonary Sarcoidosis, an Open-Label Prospective Proof-of-Concept Study.
Sarcoma
A common cellular pathway for v-mos and v-Ki-ras is not required for v-Ki-ras-induced tumorigenicity in a nonmalignant, v-mos-expressing revertant cell.
A guanine nucleotide-dependent phosphatidylinositol 4,5-diphosphate phospholipase C in cells transformed by the v-fms and v-fes oncogenes.
A highly conserved NTRK3 C-terminal sequence in the ETV6-NTRK3 oncoprotein binds the phosphotyrosine binding domain of insulin receptor substrate-1: an essential interaction for transformation.
A lysine in the ATP-binding site of P130gag-fps is essential for protein-tyrosine kinase activity.
A major site of tyrosine phosphorylation within the SH2 domain of Fujinami sarcoma virus P130gag-fps is not required for protein-tyrosine kinase activity or transforming potential.
A new acute transforming feline retrovirus with fms homology specifies a C-terminally truncated version of the c-fms protein that is different from SM-feline sarcoma virus v-fms protein.
A novel approach to detect resistance mechanisms reveals FGR as a factor mediating HDAC inhibitor SAHA resistance in B-cell lymphoma.
A recessive cellular mutation in v-fes-transformed mink cells restores contact inhibition and anchorage-dependent growth.
Activation of murine c-abl protooncogene: effect of a point mutation on oncogenic activation.
Activation of SRC kinase and phosphorylation of signal transducer and activator of transcription-5 are required for decidual transformation of human endometrial stromal cells.
Analysis of functional domains of the v-fms-encoded protein of Susan McDonough strain feline sarcoma virus by linker insertion mutagenesis.
Antitumor activity of irradiated riboflavin on human renal carcinoma cell line 786-O.
Appropriate glycosylation of the fms gene product is a prerequisite for its transforming potency.
Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib.
c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms.
Calcium-activated chloride channel ANO1 promotes breast cancer progression by activating EGFR and CAMK signaling.
Catalytic and non-catalytic domains of the Fujinami sarcoma virus P130gag-fps protein-tyrosine kinase distinguished by the expression of v-fps polypeptides in Escherichia coli.
Cell surface expression of the McDonough strain of feline sarcoma virus fms gene product (gp 140fms).
Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage.
Chromosomal assignment of the human homologues of feline sarcoma virus and avian myeloblastosis virus onc genes.
Chromosomal sublocalization of human c-myb and c-fes cellular onc genes.
Correlation between CSF-1 responsiveness and expression of (CSF-1 receptor) c-fms in purified murine granulocyte-macrophage progenitor cells (CFU-GM).
Cross talk between Smad, MAPK, and actin in the etiology of pulmonary arterial hypertension.
Cytoplasmic localization of the transforming protein of Fujinami sarcoma virus: salt-sensitive association with subcellular components.
Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Delineation of functional determinants in the transforming protein of Fujinami sarcoma virus.
Detection of fms-oncogene-specific tyrosine kinase activity in human leukemia cells.
Differences in mechanisms of transformation by independent feline sarcoma virus isolates.
Distinct and opposite roles for SH2 and SH3 domains of v-src in embryo survival and hemangiosarcoma formation.
Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation.
Effects of the cFMS kinase inhibitor 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine (GW2580) in normal and arthritic rats.
Electrochemical investigations into kinase-catalyzed transformations of tau protein.
Elevated expression of IRS2 in the progression from neurofibroma to malignant peripheral nerve sheath tumor.
Enzymatic activation of Fujinami sarcoma virus gag-fps transforming proteins by autophosphorylation at tyrosine.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
Epidermal growth factor (EGF) modulation of feline sarcoma virus fms tyrosine kinase activity, internalization, degradation, and transforming potential in an EGF receptor/v-fms chimera.
Epidermal growth factor receptor metabolism and protein kinase activity in human A431 cells infected with Snyder-Theilen feline sarcoma virus or harvey or Kirsten murine sarcoma virus.
Escherichia coli virulence protein NleH1 interaction with the v-Crk sarcoma virus CT10 oncogene-like protein (CRKL) governs NleH1 inhibition of the ribosomal protein S3 (RPS3)/nuclear factor ?B (NF-?B) pathway.
Evidence that there exist four classes of RNA tumor viruses which encode proteins with associated tyrosine protein kinase activities.
Expression of a translocated c-abl gene in hybrids of mouse fibroblasts and chronic myelogenous leukaemia cells.
Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation.
Expression of proto-oncogenes and cytoskeletal actin gene in foreign body-induced murine sarcomas.
Expression of the human monocyte membrane antigen gp55 by murine fibroblasts after DNA-mediated gene transfer.
Expression of V-SRC and chromosome analysis of a newly established cell line from rat sarcoma induced by an avian retroviral strain.
Extracellular pressure stimulates adhesion of sarcoma cells via activation of focal adhesion kinase and Akt.
Fer kinase/FerT and adherens junction dynamics in the testis: an in vitro and in vivo study.
Genetic mapping of the mouse oncogenes c-Ha-ras-1 and c-fes to chromosome 7.
Genomic landscape of ground glass opacities (GGOs) in East Asians.
Hepatitis B virus core protein promotes hepatocarcinogenesis by enhancing Src expression and activating the Src/PI3K/Akt pathway.
Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Identification of FES as a Novel Radiosensitizing Target in Human Cancers.
Identification of SRC as a Potent Drug Target for Asthma, Using an Integrative Approach of Protein Interactome Analysis and In Silico Drug Discovery.
Identification of the binding site for Gqalpha on its effector Bruton's tyrosine kinase.
In vitro transformation of osteoblasts: putative formation of osteosarcoma in vitro.
Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells.
Influence of tyrosine residues Y705 and Y807 on the transforming potency of the v-fms oncogene product of feline sarcoma virus.
Inhibition of the rous sarcoma virus long terminal repeat-driven transcription by in vitro methylation: different sensitivity in permissive chicken cells versus mammalian cells.
INNO-406 inhibits the growth of chronic myeloid leukemia and promotes its apoptosis via targeting PTEN.
Introducing crucial protein panel of gastric adenocarcinoma disease.
Investigation of the role of P130gag-fps in transformation: generation and use of a temperature-sensitive mutant P130gag-fps.
Isolation and characterization of a human locus homologous to the transforming gene (v-fes) of feline sarcoma virus.
Kinase activity profiling of Gram-negative pneumonia.
KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Localization and characterization of phosphorylation sites of the Fujinami avian sarcoma virus and PRCII virus transforming proteins.
Lymphoid and mesenchymal tumors in transgenic mice expressing the v-fps protein-tyrosine kinase.
Malignant transformation of a human fibroblast cell strain by transfection of a v-fes oncogene but not by transfection of a gag-human c-fes construct.
MerTK mediates STAT3-KRAS/SRC-signaling axis for glioma stem cell maintenance.
Metastatic phenotype of murine tumor cells expressing different cooperating oncogenes.
Methylselenol, a selenium metabolite, plays common and different roles in cancerous colon HCT116 cell and noncancerous NCM460 colon cell proliferation.
Modifications of tumor histology by point mutations in the v-fps oncogene: possible role of extracellular matrix.
Molecular Analysis of a Mutated FSH Receptor Detected in a Patient with Spontaneous Ovarian Hyperstimulation Syndrome.
Molecular and cellular mechanisms for differentiation and regeneration of the uterine endometrium.
Molecular cloning and characterization of feline cellular genetic sequences homologous to the oncogene of the McDonough strain of feline sarcoma virus.
Molecular cloning of the feline c-fes proto-oncogene and construction of a chimeric transforming gene.
Monoclonal antibodies specific to transforming polyproteins encoded by independent isolates of feline sarcoma virus.
Mouse platelet-derived growth factor alpha receptor: sequence, tissue-specific expression and correlation with metastatic phenotype.
Mutagenesis of Fujinami sarcoma virus: evidence that tyrosine phosphorylation of P130gag-fps modulates its biological activity.
Nucleic acid sequence and oncogenic properties of the HZ2 feline sarcoma virus v-abl insert.
Nucleotide sequence of v-fps in the PRCII strain of avian sarcoma virus.
Pathological significance and prognostic significance of FES expression in bladder cancer vary according to tumor grade.
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance.
Phosphocaveolin-1 enforces tumor growth and chemoresistance in rhabdomyosarcoma.
Phosphoproteomics identifies driver tyrosine kinases in sarcoma cell lines and tumors.
Photocarcinogenesis and Skin Cancer Prevention Strategies: An Update.
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions.
Preparation of rat monoclonal antibodies to epitopes encoded by the viral oncogene (v-fms) of McDonough feline sarcoma virus.
Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology.
Protein kinase C delta-mediated cytoskeleton remodeling is involved in aloe-emodin-induced photokilling of human lung cancer cells.
Quercetin inhibits migration and invasion of SAS human oral cancer cells through inhibition of NF-?B and matrix metalloproteinase-2/-9 signaling pathways.
Reassessment of the v-fms sequence: threonine phosphorylation of the COOH-terminal domain.
Regression of v-src DNA-induced sarcomas is under host genetic control.
Reimagining high-throughput profiling of reactive cysteines for cell-based screening of large electrophile libraries.
Relationship between c-src tyrosine kinase activity and the control of glucose transporter gene expression.
Resistance to oncogenic transformation in revertant R1 of human ras-transformed NIH 3T3 cells.
Rous sarcoma virus does not induce sarcoma in early chick embryos by lack of the v-src gene expression.
Sarcoma and thyroid disorders: a common etiology?
Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins.
Simultaneous Identification of EGFR,KRAS,ERBB2, and TP53 Mutations in Patients with Non-Small Cell Lung Cancer by Machine Learning-Derived Three-Dimensional Radiomics.
Single amino acid substitution, from Glu1025 to Asp, of the fps oncogenic protein causes temperature sensitivity in transformation and kinase activity.
Snyder-Theilen feline sarcoma virus P85 contains a single phosphotyrosine acceptor site recognized by its associated protein kinase.
Specificity of disease induced by M-MuLV chimeric retroviruses containing v-myc or v-src is not determined by the LTR.
Src: a potential target for the treatment of triple-negative breast cancer.
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus.
Structural alterations in the carboxyl-terminal domain of the BCRABL gene product activate its fibroblastic transforming potential.
Subcellular localization of glycoproteins encoded by the viral oncogene v-fms.
Suppression of Rous sarcoma virus-induced tumor formation by preinfection with viruses encoding src protein with novel N termini.
Syndecan-1 suppresses cell growth and migration via blocking JAK1/STAT3 and Ras/Raf/MEK/ERK pathways in human colorectal carcinoma cells.
Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma.
The amino-terminal domain of the v-fms oncogene product includes a functional signal peptide that directs synthesis of a transforming glycoprotein in the absence of feline leukemia virus gag sequences.
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.
The avian sarcoma virus PRCII lacks 1020 nucleotides of the fps transforming gene.
The importance of Src signaling in sarcoma.
The kinase activity of the v-fms encoded protein has a low pH optimum.
The myristylation signal of p60v-src functionally complements the N-terminal fps-specific region of P130gag-fps.
The Pyrazolo[3,4-d]pyrimidine-Based Kinase Inhibitor NVP-BHG712: Effects of Regioisomers on Tumor Growth, Perfusion, and Hypoxia in EphB4-Positive A375 Melanoma Xenografts.
The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts.
The Role of Lysyl Oxidase in SRC-Dependent Proliferation and Metastasis of Colorectal Cancer.
The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes.
The structure of the human c-fes/fps proto-oncogene.
The transcription factor EGR1 regulates metastatic potential of v-src transformed sarcoma cells.
The Tyr-kinase inhibitor AG879, that blocks the ETK-PAK1 interaction, suppresses the RAS-induced PAK1 activation and malignant transformation.
Three-dimensional contact with type I collagen mediates tyrosine phosphorylation in primary human fibroblasts.
Transformation by the v-fms oncogene product: role of glycosylational processing and cell surface expression.
Transformation of chicken fibroblasts by the v-fms oncogene.
Transformation-defective mutants of Snyder-Theilen feline sarcoma virus lack tyrosine-specific protein kinase activity.
Transforming activity and tissue tropism of hybrid retroviral genomes containing portions of the v-abl and v-src oncogenes.
Transforming genes of avian (v-fps) and mammalian (v-fes) retroviruses correspond to a common cellular locus.
Transforming mechanism of the feline sarcoma virus encoded v-fms oncogene product.
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Tumor immunity generated in the course of regression of v-src-induced sarcomas.
Tumor induction by direct injection of cloned v-src DNA into chickens.
TYK2 in Cancer Metastases: Genomic and Proteomic Discovery.
Tyrosine 807 of the v-Fms oncogene product controls cell morphology and association with p120RasGAP.
Tyrosine protein kinase activity of the HZ4-feline sarcoma virus P80gag-kit-transforming protein.
v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation.
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
Wing web or intravenous inoculation of chickens with v-src DNA induces visceral sarcomas.
Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
[Properties of tyrosine-specific protein kinase from rat sarcoma cells]
Sarcoma 180
Identification and characterization of tyrosine kinase activity associated with mitochondrial outer membrane in sarcoma 180 cells.
Sarcoma, Avian
A cis-acting element in Rous sarcoma virus long terminal repeat required for promoter repression by HeLa nuclear protein p21.
A History of Cancer Research: Tyrosine Kinases.
A human c-src gene resides on the proximal long arm of chromosome 20 (cen----q131).
A mutation in v-src that removes a single conserved residue in the SH-2 domain of pp60v-src restricts transformation in a host-dependent manner.
A noncatalytic domain conserved among cytoplasmic protein-tyrosine kinases modifies the kinase function and transforming activity of Fujinami sarcoma virus P130gag-fps.
A novel group IIA phospholipase A2 interacts with v-Src oncoprotein from RSV-transformed hamster cells.
A sequence homologous to Rous sarcoma virus v-src Is on human chromosome 20.
A tyrosine kinase related to pp60c-src is associated with membranes of Electrophorus electricus electric organ.
Absence of genetic alteration at codon 531 of the human c-src gene in 479 advanced colorectal cancers from Japanese and Caucasian patients.
Activating SRC mutation in a subset of advanced human colon cancers.
Activation of the pp60c-src kinase during differentiation of monomyelocytic cells in vitro.
Amino acid alterations within a highly conserved region of the Rous sarcoma virus src gene product pp60src inactivate tyrosine protein kinase activity.
An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins.
Analysis of cDNAs of the proto-oncogene c-src: heterogeneity in 5' exons and possible mechanism for the genesis of the 3' end of v-src.
Autocrine factor-independent growth of mammalian fibroblasts established in fully synthetic medium: no v-onc requirement in establishment.
Band 3 tyrosine kinase in avian erythrocyte plasma membrane is immunologically related to pp60c-src.
Binding of pp60v-src to membranes: evidence for multiple membrane interactions.
c-myc gene activation as a permanent trait of RSV-infected quail cells.
C-terminal end of v-src protein interacts with peptide coded by gadd7/adapt15-like RNA in two-hybrid system.
Calcium-dependent conformational changes in the 36-kDa subunit of intestinal protein I related to the cellular 36-kDa target of Rous sarcoma virus tyrosine kinase.
Cellular homologue (c-src) of the transforming gene of Rous sarcoma virus: isolation, mapping, and transcriptional analysis of c-src and flanking regions.
Cellular src gene product detected in the freshwater sponge Spongilla lacustris.
Changes in protein phosphorylation in Rous sarcoma virus-transformed chicken embryo cells.
Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease.
cis-Acting RNA packaging locus in the 115-nucleotide direct repeat of Rous sarcoma virus.
Cloning of the proto-oncogene c-src from rat testis.
Comparison of protein phosphorylations in variant A431 cells with different growth responses to epidermal growth factor.
Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: differences in in vitro transformation and in vivo pathogenicity.
Creation and characterization of temperature-sensitive mutants of the lck tyrosine protein kinase.
Critical amino acid substitutions in the Src SH3 domain that convert c-Src to be oncogenic.
Cytokinesis Failure Leading to Chromosome Instability in v-Src-Induced Oncogenesis.
Decrease in coupling of Gs in v-src-transformed NIH-3T3 fibroblasts: possible involvement of tyrosine phosphorylation of Gs by pp60v-src.
Development of cellular resistance to pp60v-src kinase-induced cell death.
Down regulation by p60v-src of genes specifically expressed and developmentally regulated in postmitotic quail neuroretina cells.
Effect of dimerization on signal transduction and biological function of oncogenic Ros, insulin, and insulin-like growth factor I receptors.
Effect of tumor promoters on sarc gene expression in normal and transformed chick embryo fibroblasts.
Effects of herbimycin A and its derivatives on growth and differentiation of Ph1-positive acute lymphoid leukemia cell lines.
Effects of herbimycin A derivatives on growth and differentiation of K562 human leukemic cells.
Effects of v-src oncogene activation on radiation sensitivity in drug-sensitive and in multidrug-resistant rat fibroblasts.
Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis.
Elevated c-yes tyrosine kinase activity in premalignant lesions of the colon.
Elevation of nerve growth factor synthesis by constitutive expression of v-src oncogene in cultured rat fibroblasts.
Emerging Role for SRC family kinases in junction dynamics during spermatogenesis.
Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates.
Evidence that there exist four classes of RNA tumor viruses which encode proteins with associated tyrosine protein kinase activities.
Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells.
Expression of Rous sarcoma virus transforming protein pp60v-src in Saccharomyces cerevisiae cells.
Expression of v-src in embryonic neural retina alters cell adhesion, inhibits histogenesis, and prevents induction of glutamine synthetase.
Frameshift mutations in the v-src gene of avian sarcoma virus act in cis to specifically reduce v-src mRNA levels.
Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes.
Gene expression profiles analysis identifies key genes for acute lung injury in patients with sepsis.
Generation of a recombinant Moloney murine leukemia virus carrying the v-src gene of avian sarcoma virus: transformation in vitro and pathogenesis in vivo.
High-level expression of human c-jun gene causes cellular transformation of chicken embryo fibroblasts.
Human cellular src gene: nucleotide sequence and derived amino acid sequence of the region coding for the carboxy-terminal two-thirds of pp60c-src.
Identification of a ribosomal protein S6 kinase regulated by transformation and growth-promoting stimuli.
Identification of an amino terminal domain required for the transforming activity of the Rous sarcoma virus src protein.
Immune-based resistance to the formation of v-src-induced distal tumors.
Increased activity of c-Src and Csk in fibroblasts transformed by v-src oncogene.
Infection of terminally differentiated myotubes with Rous sarcoma virus: reduced synthesis of env and v-src proteins.
Influence of the transduced 3'UTR of the c-src oncogene on tumour growth induced by the v-src gene of avian sarcoma virus PR2257.
Inhibition of the tyrosine kinase activity of v-src, v-fgr, and v-yes gene products by a monoclonal antibody which binds both amino and carboxy peptide fragments of pp60v-src.
Inhibition of tyrosine protein kinases by halomethyl ketones.
Intracellular localization and processing of pp60v-src proteins expressed by two distinct temperature-sensitive mutants of Rous sarcoma virus.
Kinetics of v-src-induced epithelial-mesenchymal transition in developing glandular stomach.
Lack of activating c-SRC mutations at codon 531 in rectal cancer.
Localization and characterization of phosphorylation sites of the Fujinami avian sarcoma virus and PRCII virus transforming proteins.
Localization of temperature-sensitive transformation mutations and back mutations in the Rous sarcoma virus src gene.
Major histocompatibility (B) complex control of the growth pattern of v-src DNA-induced primary tumors.
Membrane binding of myristylated peptides corresponding to the NH2 terminus of Src.
miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1.
Mitogenesis by v-Src: a need for active oncoprotein both in leaving G0 and in completing G1 phases of the cell cycle.
Modulatory effect of the transmembrane domain of the protein-tyrosine kinase encoded by oncogene ros: biological function and substrate interaction.
Molecular cloning of the PRCII sarcoma viral genome and the chicken proto-oncogene c-fps.
Most of the substrates of oncogenic viral tyrosine protein kinases can be phosphorylated by cellular tyrosine protein kinases in normal cells.
Mutations in v-Src SH3 and catalytic domains that jointly confer temperature-sensitive transformation with minimal temperature-dependent changes in cellular tyrosine phosphorylation.
Myogenin expression is necessary for commitment to differentiation and is closely related to src tyrosine kinase activity in quail myoblasts transformed with Rous sarcoma virus.
N-terminal deletion in the src gene of Rous sarcoma virus results in synthesis of a 45,000-Mr protein with mitogenic activity.
Nature and specificity of lymphokine independence induced by a selectable retroviral vector expressing v-src.
Neoplastic transformation of normal and carcinogen-induced preneoplastic Syrian hamster embryo cells by the v-src oncogene.
Neural nitric oxide synthase participates in pemphigus vulgaris acantholysis through upregulation of Rous sarcoma, mammalian target of rapamycin and focal adhesion kinase.
NSAID-induced apoptosis in Rous sarcoma virus-transformed chicken embryo fibroblasts is dependent on v-src and c-myc and is inhibited by bcl-2.
Nucleotide sequence of avian sarcoma virus UR2 and comparison of its transforming gene with other members of the tyrosine protein kinase oncogene family.
Nucleotide sequence of v-fps in the PRCII strain of avian sarcoma virus.
Overexpression of avian or mouse c-jun in primary chick embryo fibroblasts confers a partially transformed phenotype.
Overexpression of the c-src protein does not induce transformation of NIH 3T3 cells.
Partial purification and characterization of a pp60v-src-related tyrosine kinase from bovine brain.
Partial reversion of conditional transformation correlates with a decrease in the sensitivity of rat cells to killing by the parvovirus minute virus of mice but not in their capacity for virus production: effect of a temperature-sensitive v-src oncogene.
Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations.
Phospholipids stimulate phosphorylation of of vinculin by the tyrosine-specific protein kinase of Rous sarcoma virus.
Phospholipids stimulate phosphorylation of vinculin by the tyrosine-specific protein kinase of Rous sarcoma virus.
Phosphopeptide occupancy and photoaffinity cross-linking of the v-Src SH2 domain attenuates tyrosine kinase activity.
Phosphorylation of a high molecular weight DNA polymerase alpha.
Phosphorylation of p125FAK and paxillin focal adhesion proteins in src-transformed cells with different metastatic capacity.
Phosphorylation of synthetic peptides containing Tyr-Met-X-Met motifs by nonreceptor tyrosine kinases in vitro.
Phosphorylation sites in enolase and lactate dehydrogenase utilized by tyrosine protein kinases in vivo and in vitro.
Polypurine tract adjacent to the U3 region of the Rous sarcoma virus genome provides a cis-acting function.
Potent and specific inhibition of p60v-src protein kinase both in vivo and in vitro by radicicol.
pp60c-src encoded by the proto-oncogene c-src is a product of sensory neurons.
pp60c-src is expressed in human fetal and adult brain.
pp60c-src Kinase is in chick and human embryonic tissues.
pp60src-dependent protein phosphorylation in membranes from Rous sarcoma virus-transformed chicken embryo fibroblasts.
Properties of the src kinase purified from Rous sarcoma virus-induced rat tumors.
Protein kinases and adherens junction dynamics in the seminiferous epithelium of the rat testis.
Purification of a tyrosine-specific protein kinase from Rous sarcoma virus-induced rat tumor.
Purification of the Rous sarcoma virus src kinase by casein-agarose and tyrosine-agarose affinity chromatography.
Ras/MAP kinase pathway is associated with the control of myotube formation but not myofibril assembly in quail myoblasts transformed with Rous sarcoma virus.
Reconstitution of interactions between the Src tyrosine kinases and Ras GTPase-activating protein using a baculovirus expression system.
Role of gag sequence in the biochemical properties and transforming activity of the avian sarcoma virus UR2-encoded gag-ros fusion protein.
Role of Gas1 down-regulation in mitogenic stimulation of quiescent NIH3T3 cells by v-Src.
Role of replaced v-src and env genes in the duck-adapted variant of Rous sarcoma virus.
Rous sarcoma virus does not induce sarcoma in early chick embryos by lack of the v-src gene expression.
Rous sarcoma virus mutant dlPA105 induces different transformed phenotypes in quail embryonic fibroblasts and neuroretina cells.
Salpalpha and Salpbeta, growth-arresting homologs of Sam68.
Screening of agents which convert 'transformed morphology' of Rous sarcoma virus-infected rat kidney cells to 'normal morphology': identification of an active agent as herbimycin and its inhibition of intracellular src kinase.
Slow time-dependent cellular transformation induced at restrictive temperature by ts-src mutants.
Small deletion in v-src SH3 domain of a transformation defective mutant of Rous sarcoma virus restores wild type transforming properties.
Splicing of intervening sequences introduced into an infectious retroviral vector.
Src homology 2 domain deletion mutants of p60v-src do not phosphorylate cellular proteins of 120-150 kDa.
Src protein-tyrosine kinase structure and regulation.
src-specific immunity in inbred chickens bearing v-src DNA- and RSV-induced tumors.
STAT5 Phosphorylation in Malignant Melanoma Is Important for Survival and Is Mediated Through SRC and JAK1 Kinases.
Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60.
Stimulation of mouse osteopontin promoter by v-Src is mediated by a CCAAT box-binding factor.
Structural Thermodynamics of myr-Src(2-19) Binding to Phospholipid Membranes.
Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus.
Substrate specificities of tyrosine-specific protein kinases toward cytoskeletal proteins in vitro.
Synthetic peptide substrates for a tyrosine protein kinase.
The avian sarcoma virus PRCII lacks 1020 nucleotides of the fps transforming gene.
The expression in eukaryotes of a tyrosine kinase which is reactive with pp60v-src antibodies.
The lack of v-src involvement in tumorigenicity of marmoset cells transformed in vitro with Rous sarcoma virus.
The location of v-src in a retrovirus vector determines whether the virus is toxic or transforming.
The many faces of Src: multiple functions of a prototypical tyrosine kinase.
The p60c-src family of protein-tyrosine kinases: structure, regulation, and function.
The product of the v-src-inducible gene nr-13 is a potent anti-apoptotic factor.
The ras-related gene rhoB is an immediate-early gene inducible by v-Fps, epidermal growth factor, and platelet-derived growth factor in rat fibroblasts.
The role of RNA molecules in transduction of the proto-oncogene c-fps.
The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes.
The stimulation of quiescent rat fibroblasts by v-src and v-fps oncogenic protein-tyrosine kinases leads to the induction of a subset of immediate early genes.
The transforming proteins of PRCII virus and Rous sarcoma virus form a complex with the same two cellular phosphoproteins.
The tyrosine kinase v-Src causes mitotic slippage by phosphorylating an inhibitory tyrosine residue of Cdk1.
The tyrosine phosphorylation substrate p36 is developmentally regulated in embryonic avian limb and is induced in cell culture.
The v-Src and c-Src tyrosine kinases immunoprecipitated from Rous sarcoma virus-transformed cells display different peptide substrate specificities.
Three Ca2+-binding proteins from porcine liver and intestine differ immunologically and physicochemically and are distinct in Ca2+ affinities.
Transcriptional downregulation of the retina-specific QR1 gene by pp60v-src and identification of a novel v-src-responsive unit.
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Transformation by viral and cellular oncogenes of a mouse BALB/3T3 cell mutant resistant to transformation by chemical carcinogens.
Transformation of chicken embryo fibroblasts and tumor induction by the middle T antigen of polyomavirus carried in an avian retroviral vector.
Transforming potential and growth stimulating activity of the v-fos and c-fos genes carried by avian retrovirus vectors.
Transforming protein of avian sarcoma virus UR2 is associated with phosphatidylinositol kinase activity: possible role in tumorigenesis.
Transforming proteins of some feline and avian sarcoma viruses are related structurally and functionally.
Transgene expression facilitated by the v-src splice acceptor can impair replication kinetics and lead to genomic instability of Rous sarcoma virus-based vectors.
Transgenic mice and host cell mutants resistant to transformation as model systems for identifying multiple components in oncogenesis.
Transplantation resistance to a Rous sarcoma virus-induced tumor in mice immunized with v-src protein.
tsLA23-NRK cells need pp60v-src protein-tyrosine kinase activity in G2 phase to initiate mitosis in serum-free medium.
Tumor cells induced by the v-src oncogene are heterogeneous for expression of markers of mesenchyme differentiation.
Tumor induction by direct injection of cloned v-src DNA into chickens.
Tumor induction by the LTR, v-src, LTR DNA in four B (MHC) congenic lines of chickens.
Two point mutations in the transmembrane domain of P68gag-ros inactive its transforming activity and cause a delay in membrane association.
Tyrosine phosphorylation of a gap junction protein correlates with inhibition of cell-to-cell communication.
Tyrosine-specific protein kinase activity associated with p105 of avian sarcoma virus PRCII.
Tyrosyl and cyclic AMP-dependent protein kinase activities in BHK cells that express viral pp60src.
Tyrosylprotein kinase and phosphatase activities in membrane vesicles from normal and Rous sarcoma virus-transformed rat cells.
Unstable expression and amplification of a transfected oncogene in confluent and subconfluent cells.
v-Src Causes Chromosome Bridges in a Caffeine-Sensitive Manner by Generating DNA Damage.
v-Src causes delocalization of Mklp1, Aurora B, and INCENP from the spindle midzone during cytokinesis failure.
v-Src enhances phosphorylation at Ser-282 of the Rous sarcoma virus integrase.
v-src induces clonal sarcomas and rapid metastasis following transduction with a replication-defective retrovirus.
v-src mutations outside the carboxyl-coding region are not sufficient to fully activate transformation by pp60c-src in NIH 3T3 cells.
v-src oncogene-specific carboxy-terminal peptide is immunoprotective against Rous sarcoma growth in chickens with MHC class I allele B-F12.
VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd.
Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.
Xiphophorus as an in vivo model for studies on oncogenes.
[New molecular mechanisms of virus-mediated carcinogenesis: oncogenic transformation of cells by retroviral structural protein Envelope]
Sarcoma, Clear Cell
The arylstibonic acid compound NSC13746 disrupts B-ZIP binding to DNA in living cells.
Sarcoma, Ewing
c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
Focal adhesion kinase confers pro-migratory and antiapoptotic properties and is a potential therapeutic target in Ewing sarcoma.
Fusion FISH Imaging: Single-Molecule Detection of Gene Fusion Transcripts In Situ.
High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma.
High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma.
Indistinguishable patterns of protooncogene expression in two distinct but closely related tumors: Ewing's sarcoma and neuroepithelioma.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Matrilin-3 as a putative effector of C-type natriuretic peptide signaling during TGF-? induced chondrogenic differentiation of mesenchymal stem cells.
Newly established Askin tumor cell line and overexpression of focal adhesion kinase in Ewing sarcoma family of tumors cell lines.
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules.
Rapamycin inhibits F-actin reorganization and phosphorylation of focal adhesion proteins.
SRC Family Kinase Inhibition in Ewing Sarcoma Cells Induces p38 MAP Kinase-Mediated Cytotoxicity and Reduces Cell Migration.
TAE226, a dual inhibitor of focal adhesion kinase and insulin-like growth factor-I receptor, is effective for Ewing sarcoma.
Tumor suppressive microRNA-138 inhibits metastatic potential via the targeting of focal adhesion kinase in Ewing's sarcoma cells.
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation.
Sarcoma, Kaposi
Cytokine signaling through the novel tyrosine kinase RAFTK in Kaposi's sarcoma cells.
KSHV LANA inhibits TGF-beta signaling through epigenetic silencing of the TGF-beta type II receptor.
Vascular tumors produced by NIH/3T3 cells transfected with human AIDS Kaposi's sarcoma DNA.
Sarcoma, Myeloid
Aleukemic bcr-abl positive granulocytic sarcoma.
An e6a2 BCR-ABL fusion transcript in a CML patient having an iliac chloroma at initial presentation.
Detection of BCR-ABL transcripts in chronic myeloid leukemia (CML) using a 'real time' quantitative RT-PCR assay.
Sarcoma, Synovial
Clustered organization of Krüppel zinc-finger genes at Xp11.23, flanking a translocation breakpoint at OATL1: a physical map with locus assignments for ZNF21, ZNF41, ZNF81, and ELK1.
EPHB4 tyrosine-kinase receptor expression and biological significance in soft tissue sarcoma.
SRC signaling is crucial in the growth of synovial sarcoma cells.
Sarcopenia
Meeting Report: American Aging Association 40(th) Annual Meeting, Raleigh, North Carolina, June 3-6, 2011.
Muscle-bone interactions: From experimental models to the clinic? A critical update.
Schistosomiasis
Schistosoma mansoni FES Tyrosine Kinase Involvement in the Mammalian Schistosomiasis Outcome and Miracidia Infection Capability in Biomphalaria glabrata.
Scleroderma, Diffuse
Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Scleroderma, Localized
Treatment of generalized deep morphea and eosinophilic fasciitis with the Janus kinase inhibitor tofacitinib.
Scleroderma, Systemic
Attenuation of fibrosis with selective inhibition of c-Abl by siRNA in systemic sclerosis dermal fibroblasts.
c-Abl silencing reduced the inhibitory effects of TGF-?1 on apoptosis in systemic sclerosis dermal fibroblasts.
Challenges in the diagnosis and treatment of disabling pansclerotic morphea of childhood: case-based review.
Imatinib and the treatment of fibrosis: recent trials and tribulations.
Immunomodulating role of the JAKs inhibitor tofacitinib in a mouse model of bleomycin-induced scleroderma.
Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Targeting Src family kinase member Fyn by Saracatinib attenuated liver fibrosis in vitro and in vivo.
Scoliosis
Genetic Risk for Aortic Aneurysm in Adolescent Idiopathic Scoliosis.
Seizures
Altered expression of c-Abl in patients with epilepsy and in a rat model.
Enhanced susceptibility of audiogenic seizures in Fyn-kinase deficient mice.
Focal adhesion molecules regulate astrocyte morphology and glutamate transporters to suppress seizure-like behavior.
Impairment of conditioned freezing to tone, but not to context, in Fyn-transgenic mice: relationship to NMDA receptor subunit 2B function.
Role of the Fyn-PKC? signaling in SE-induced neuroinflammation and epileptogenesis in experimental models of temporal lobe epilepsy.
Seminoma
A novel SMAD4 gene mutation in seminoma germ cell tumors.
Activin receptor subunits in normal and dysfunctional adult human testis.
Human testicular germ cell tumours express inhibin subunits, activin receptors and follistatin mRNAs.
Sepsis
Acquired platelet GPVI receptor dysfunction in critically ill patients with sepsis.
Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice.
Complement regulatory protein CD59 involves c-SRC related tyrosine phosphorylation of the creatine transporter in skeletal muscle during sepsis.
Functional polymorphism in exon 5 and variant haplotype of the interleukin-1 receptor-associated kinase 1 gene are associated with susceptibility to and severity of sepsis in the Chinese population.
In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands.
miR-375 ameliorates sepsis by downregulating miR-21 level via inhibiting JAK2-STAT3 signaling.
Monocyte deactivation in severe human sepsis or following cardiopulmonary bypass.
Pseudomonas aeruginosa sepsis presenting as oral ecthyma gangrenosum in identical twins with Bruton tyrosine kinase gene mutation: Two case reports and review of the literature.
Regulation of RelA/p65 and Endothelial Cell Inflammation by Proline-Rich Tyrosine Kinase 2.
Selective inhibition of interleukin-1 receptor-associated kinase 1 ameliorates lipopolysaccharide-induced sepsis in mice.
Sepsis-induced brain mitochondrial dysfunction is associated with altered mitochondrial Src and PTP1B levels.
Sepsis-Induced Cardiac Mitochondrial Dysfunction Involves Altered Mitochondrial-Localization of Tyrosine Kinase Src and Tyrosine Phosphatase SHP2.
Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis.
The potential value of plasma receptor interacting protein 3 in neonates with culture-positive late-onset sepsis.
Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation and Prolongs Survival.
X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure.
Severe Acute Respiratory Syndrome
Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Severe Combined Immunodeficiency
A case of aberrant CD8 T cell-restricted IL-7 signaling with a Janus kinase 3 defect-associated atypical severe combined immunodeficiency.
A novel mutation of intron 22 in Janus kinase 3-deficient severe combined immunodeficiency.
Absence of ZAP-70 prevents signaling through the antigen receptor on peripheral blood T cells but not on thymocytes.
Advances in the understanding and treatment of human severe combined immunodeficiency.
Atypical immune phenotype in severe combined immunodeficiency patients with novel mutations in IL2RG and JAK3.
Cutaneous granulomas with predominantly CD8(+) lymphocytic infiltrate in a child with severe combined immunodeficiency.
Defective expression of p56lck in an infant with severe combined immunodeficiency.
Dominant-negative zeta-associated protein 70 inhibits T cell antigen receptor signaling.
Herpesvirus saimiri replaces ZAP-70 for CD3- and CD2-mediated T cell activation.
Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase.
Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain.
Hypomorphic Janus kinase 3 mutations result in a spectrum of immune defects, including partial maternal T-cell engraftment.
Identification of four highly conserved regions in DNA-PKcs.
Immunodeficiencies caused by genetic defects in protein kinases.
In vitro correction of JAK3-deficient severe combined immunodeficiency by retroviral-mediated gene transduction.
Insight into the therapeutic aspects of 'Zeta-Chain Associated Protein Kinase 70 kDa' inhibitors: a review.
Intrathymic administration of hematopoietic progenitor cells enhances T cell reconstitution in ZAP-70 severe combined immunodeficiency.
JAK3 inhibition as a new concept for immune suppression.
JAK3 mutations in Italian patients affected by SCID: New molecular aspects of a long-known gene.
Jak3 negatively regulates dendritic-cell cytokine production and survival.
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation.
Leukemia treatment in severe combined immunodeficiency mice by antisense oligodeoxynucleotides targeting cooperating oncogenes.
Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene Targeting.
Novel immunodeficiency data servers.
p27Kip1 and cyclin D1 are necessary for focal adhesion kinase regulation of cell cycle progression in glioblastoma cells propagated in vitro and in vivo in the scid mouse brain.
Persistence of natural killer cells with expansion of a hypofunctional CD56(-)CD16(+)KIR(+)NKG2C(+) subset in a patient with atypical Janus kinase 3-deficient severe combined immunodeficiency.
Reconstitution of lymphoid development and function in ZAP-70-deficient mice following gene transfer into bone marrow cells.
Reconstitution of T cell receptor signaling in ZAP-70-deficient cells by retroviral transduction of the ZAP-70 gene.
Severe combined immunodeficiency due to a defect in the tyrosine kinase ZAP-70.
Severe combined immunodeficiency with absence of peripheral blood CD8+ T cells due to ZAP-70 deficiency.
Spleen tyrosine kinase (Syk) deficiency in childhood pro-B cell acute lymphoblastic leukemia.
Structural and functional basis for JAK3-deficient severe combined immunodeficiency.
The structure, regulation, and function of ZAP-70.
Unexpected and variable phenotypes in a family with JAK3 deficiency.
Virus-specific immunity after gene therapy in a murine model of severe combined immunodeficiency.
ZAP-70 and defects of T-cell receptor signaling.
ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency.
ZAP-70 restoration in mice by in vivo thymic electroporation.
Shock, Septic
Organ-specific and differential requirement of TYK2 and IFNAR1 for LPS-induced iNOS expression in vivo.
Sinus Thrombosis, Intracranial
Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis.
Sinusitis
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family.
Skin Diseases
A case of presumed autoimmune subepidermal blistering dermatosis treated with oclacitinib.
Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Efficacy and Safety of Janus Kinase Inhibitors in Type I Interferon-Mediated Monogenic Autoinflammatory Disorders: A Scoping Review.
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial.
Immunomodulatory in vitro effects of oclacitinib on canine T-cell proliferation and cytokine production.
Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report.
Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
Preclinical Mechanisms of Topical PRN473, a Bruton Tyrosine Kinase Inhibitor, in Immune-Mediated Skin Disease Models.
SHP-1 (PTPN6) keeps the inflammation at bay: limiting IL-1?-mediated neutrophilic dermatoses by preventing Syk kinase activation.
Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
The anti-inflammatory effect of topical tofacitinib on immediate and late-phase cutaneous allergic reactions in dogs: a placebo-controlled pilot study.
Treatment of alopecia universalis with topical Janus kinase inhibitors - a double blind, placebo, and active controlled pilot study.
Skin Neoplasms
Activation of T-cell protein-tyrosine phosphatase suppresses keratinocyte survival and proliferation following UVB irradiation.
Aggressive Skin Cancers Occurring in Patients Treated With the Janus Kinase Inhibitor Ruxolitinib.
Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis.
Elevated c-Src and c-Yes expression in malignant skin cancers.
Janus Kinase Inhibitors and Non-Melanoma Skin Cancer.
Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.
Systemic medications linked to an increased risk for skin malignancy.
Sleep Deprivation
Transcriptional alterations of genes related to fertility decline in male rats induced by chronic sleep restriction.
Small Cell Lung Carcinoma
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines.
Cryptotanshinone inhibits lung tumor growth by increasing CD4(+) T cell cytotoxicity through activation of the JAK2/STAT4 pathway.
Essential role of Pyk2 and Src kinase activation in neuropeptide-induced proliferation of small cell lung cancer cells.
Lack of correlation between growth inhibition by TGF-beta and the percentage of cells expressing type II TGF-beta receptor in human non-small cell lung carcinoma cell lines.
Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Neuropeptides stimulate tyrosine phosphorylation and tyrosine kinase activity in small cell lung cancer cell lines.
Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells.
Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Syntenin increases the invasiveness of small cell lung cancer cells by activating p38, AKT, focal adhesion kinase and SP1.
Therapeutic Potential of Focal Adhesion Kinase Inhibition in Small Cell Lung Cancer.
Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.
Spinal Cord Compression
Ephrin-B2-EphB4 communication mediates tumor-endothelial cell interactions during hematogenous spread to spinal bone in a melanoma metastasis model.
Src family kinase inhibitor PP1 reduces secondary damage after spinal cord compression in rats.
Spinal Cord Injuries
BMPR1a and BMPR1b signaling exert opposing effects on gliosis after spinal cord injury.
Focal adhesion kinase signaling is decreased 56 days following spinal cord injury in rat gastrocnemius.
Lavendustin A enhances axon elongation in VHL gene-transfected neural stem cells.
Mechanisms of autophagy and apoptosis mediated by JAK2 signaling pathway after spinal cord injury of rats.
Src family kinase inhibitor PP1 improves motor function by reducing edema after spinal cord contusion in rats.
STAT3 signaling after traumatic brain injury.
Tamoxifen and Src kinase inhibitors as neuroprotective/neuroregenerative drugs after spinal cord injury.
Spondylarthropathies
Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies.
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Spondylitis, Ankylosing
A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
Association between single nucleotide polymorphisms in prospective genes and susceptibility to ankylosing spondylitis and inflammatory bowel disease in a single centre in Turkey.
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Impact of filgotinib on sacroiliac joint MRI structural lesions at 12 weeks in patients with active ankylosing spondylitis (TORTUGA trial).
Increased BMPR1A Expression Enhances the Adipogenic Differentiation of Mesenchymal Stem Cells in Patients with Ankylosing Spondylitis.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (Covid-19) outcomes: a systematic review and meta-analysis.
Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials.
Nocebo effects of Janus kinase inhibitors in the treatment of active ankylosing spondylitis.
Performance of Janus kinase inhibitors in psoriatic arthritis with axial involvement in indirect comparison with ankylosing spondylitis: a retrospective analysis from pooled data.
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Squamous Cell Carcinoma of Head and Neck
3D cell cultures of human head and neck squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor TAE226.
Aberrant methylation inactivates transforming growth factor Beta receptor I in head and neck squamous cell carcinoma.
Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop.
Actin cytoskeletal mediators of motility and invasion amplified and overexpressed in head and neck cancer.
Activated spleen tyrosine kinase promotes malignant progression of oral squamous cell carcinoma via mTOR/S6 signaling pathway in an ERK1/2-independent manner.
Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Anti-tumor effect of a novel FAK inhibitor TAE226 against human oral squamous cell carcinoma.
AXL Mediates Cetuximab and Radiation Resistance Through Tyrosine 821 and the c-ABL Kinase Pathway in Head and Neck Cancer.
Bone morphogenetic protein-2/4 and bone morphogenetic protein receptor type IA expression in metastatic and nonmetastatic oral squamous cell carcinoma.
c-Abl expression in oral squamous cell carcinomas.
c-Abl Tyrosine Kinase Is Regulated Downstream of the Cytoskeletal Protein Synemin in Head and Neck Squamous Cell Carcinoma Radioresistance and DNA Repair.
Chemopreventive and Chemotherapeutic Actions of mTOR Inhibitor in Genetically Defined Head and Neck Squamous Cell Carcinoma Mouse Model.
Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Current aspects of targeted therapy in head and neck tumors.
DDR2 overexpression in oral squamous cell carcinoma is associated to lymph node metastasis.
Decreased expression of protein tyrosine kinase 6 contributes to tumor progression and metastasis in laryngeal squamous cell carcinoma.
Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway.
Differential expression of the non-receptor tyrosine kinase BRK in oral squamous cell carcinoma and normal oral epithelium.
Disruption of transforming growth factor beta-Smad signaling pathway in head and neck squamous cell carcinoma as evidenced by mutations of SMAD2 and SMAD4.
Downregulation of transforming growth factor beta type II receptor in laryngeal carcinogenesis.
Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Elevated Src family kinase activity stabilizes E-cadherin-based junctions and collective movement of head and neck squamous cell carcinomas.
Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.
EphB4 provides survival advantage to squamous cell carcinoma of the head and neck.
EPHB4 Regulates the Proliferation and Metastasis of Oral Squamous Cell Carcinoma through the HMGB1/NF-?B Signalling Pathway.
Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system.
Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma.
Expression of EphB4 in head and neck squamous cell carcinoma.
Expression of focal adhesion kinase and phosphorylated focal adhesion kinase in squamous cell carcinoma of the larynx.
Expression of the EPHB4 receptor tyrosine kinase in head and neck and renal malignancies--implications for solid tumors and potential for therapeutic inhibition.
Focal Adhesion Kinase (FAK) Overexpression and Phosphorylation in Oral Squamous Cell Carcinoma and their Clinicopathological Significance.
Focal adhesion kinase knockdown in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis via downregulating MCP-1/CCL2 expression.
Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma.
Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Fusobacteria modulate oral carcinogenesis and promote cancer progression.
Genetic alterations in Wnt family of genes and their putative association with head and neck squamous cell carcinoma.
Genome-wide analysis of oral squamous cell carcinomas revealed over expression of ISG15, Nestin and WNT11.
Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells.
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer.
Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions.
In oral squamous cell carcinoma, high FAK expression is correlated with low P53 expression.
Induction of apoptosis of detached oral squamous cell carcinoma cells by safingol. Possible role of Bim, focal adhesion kinase and endonuclease G.
Inhibition of Bruton's tyrosine kinase as a therapeutic strategy for chemoresistant oral squamous cell carcinoma and potential suppression of cancer stemness.
Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.
Inhibition of IKK?/NF-?B signaling pathway to improve Dasatinib efficacy in suppression of cisplatin-resistant head and neck squamous cell carcinoma.
Inhibitory Effect of 1,8-Cineol on ?-Catenin Regulation, WNT11 Expression, and Cellular Progression in HNSCC.
Involvement of focal adhesion kinase in cellular invasion of head and neck squamous cell carcinomas via regulation of MMP-2 expression.
Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma.
JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Metformin sensitizes anticancer effect of dasatinib in head and neck squamous cell carcinoma cells through AMPK-dependent ER stress.
miRNA- and cytokine-associated extracellular vesicles mediate squamous cell carcinomas.
Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of fak gene copy number.
Role of Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma and Its Therapeutic Prospect.
Role of integrin ?1 as a biomarker of stemness in head and neck squamous cell carcinoma.
Saracatinib Impairs Head and Neck Squamous Cell Carcinoma Invasion by Disrupting Invadopodia Function.
SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma.
Soluble form of ephrinB2 inhibits xenograft growth of squamous cell carcinoma of the head and neck.
Spleen tyrosine kinase as a novel candidate tumor suppressor gene for human oral squamous cell carcinoma.
STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro.
Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.
Taiwan cobra cardiotoxin III inhibits Src kinase leading to apoptosis and cell cycle arrest of oral squamous cell carcinoma Ca9-22 cells.
The association between elevated EphB4 expression, smoking status, and advanced-stage disease in patients with head and neck squamous cell carcinoma.
The significance of EphB4 and EphrinB2 expression and survival in head and neck squamous cell carcinoma.
[Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line].
[Expression and clinical significance of focal adhesion kinase in oral squamous cell carcinoma]
[Expression of full-length spleen tyrosine kinase in the oral squamous cell carcinoma and its relationship with tumor invasion and metastasis].
Starvation
Expression of the v-Src oncoprotein in fibroblasts disrupts normal regulation of the CDK inhibitor p27 and inhibits quiescence.
Serum starvation regulates E-cadherin upregulation via activation of c-Src in non-small-cell lung cancer A549 cells.
Subcellular localization determines the protective effects of activated ERK2 against distinct apoptogenic stimuli in myeloid leukemia cells.
The yeast trimeric guanine nucleotide-binding protein alpha subunit, Gpa2p, controls the meiosis-specific kinase Ime2p activity in response to nutrients.
Transcriptional stimulation of the retina-specific QR1 gene upon growth arrest involves a Maf-related protein.
Tyrosine phosphorylation of p145met mediated by EGFR and Src is required for serum-independent survival of human bladder carcinoma cells.
Status Epilepticus
Change in neurotrophins and their receptor mRNAs in the rat forebrain after status epilepticus induced by pilocarpine.
Still's Disease, Adult-Onset
Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease.
Stomach Diseases
Phosphorylation of Helicobacter pylori CagA by c-Abl leads to cell motility.
Stomach Neoplasms
Aberrant JAK/STAT Signaling Suppresses TFF1 and TFF2 through Epigenetic Silencing of GATA6 in Gastric Cancer.
ADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation.
Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
c-abl and YWHAZ gene expression in gastric cancer.
Caveolin 1 expression correlates with poor prognosis and focal adhesion kinase expression in gastric cancer.
CEACAM5 and CEACAM6 are major target genes for Smad3-mediated TGF-beta signaling.
Circular RNA CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and Regulating TGFBR1 Expression.
Clinical significance of nuclear expression of spleen tyrosine kinase (Syk) in gastric cancer.
Conversion therapy for advanced gastric cancer with trastuzumab combined with chemotherapy: A case report.
Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Deregulated bone morphogenetic proteins and their receptors are associated with disease progression of gastric cancer.
Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer.
Development of TGF-beta resistance during malignant progression.
Disease spectrum of gastric cancer susceptibility genes.
Downregulation of microRNA-375, combined with upregulation of its target gene Janus kinase 2, predicts unfavorable prognosis in patients with gastric cancer.
Effects of combining erlotinib and RNA-interfered downregulation of focal adhesion kinase expression on gastric cancer.
Enterolobium contortisiliquum trypsin inhibitor (EcTI), a plant proteinase inhibitor, decreases in vitro cell adhesion and invasion by inhibition of Src protein-focal adhesion kinase (FAK) signaling pathways.
Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
Estimating copy number using next-generation sequencing to determine ERBB2 amplification status.
Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells.
Expression of ASAP1 and FAK in gastric cancer and its clinicopathological significance.
Expression of transforming growth factor beta type II receptor reduces tumorigenicity in human gastric cancer cells.
Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer.
Focal adhesion kinase (FAK) is associated with poor prognosis in urinary bladder carcinoma.
Formation of the IGF1R/CAV1/SRC tri-complex antagonizes TRAIL-induced apoptosis in gastric cancer cells.
Frequent microsatellite instabilities and analyses of the related genes in familial gastric cancers.
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer.
Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta.
Genetic testing by cancer site: stomach.
Genipin induces mitochondrial dysfunction and apoptosis via downregulation of Stat3/mcl-1 pathway in gastric cancer.
High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome.
Identification of protein-tyrosine kinase genes preferentially expressed in embryo stomach and gastric cancer.
Identification of the prelinitis condition in gastric cancer and analysis of TGF-beta, TGF-beta RII and pS2 expression.
IL-6 secreted by cancer-associated fibroblasts promotes epithelial-mesenchymal transition and metastasis of gastric cancer via JAK2/STAT3 signaling pathway.
Inhibition of the JAK2/STAT3 pathway reduces gastric cancer growth in vitro and in vivo.
Integrative genomic analyses of WNT11: transcriptional mechanisms based on canonical WNT signals and GATA transcription factors signaling.
Janus kinase 2 polymorphisms are associated with risk in patients with gastric cancer in a Chinese population.
Knockdown of long non-coding RNA HOXD-AS1 inhibits gastric cancer cell growth via inactivating the JAK2/STAT3 pathway.
Long noncoding RNA BC005927 upregulates EPHB4 and promotes gastric cancer metastasis under hypoxia.
MicroRNA-150-5p and SRC kinase signaling inhibitor 1 involvement in the pathological development of gastric cancer.
Microsatellite instability and mutations of p53 and TGF-beta RII genes in gastric cancer.
miR-135a inhibits tumor metastasis and angiogenesis by targeting FAK pathway.
MiR-135a targets JAK2 and inhibits gastric cancer cell proliferation.
MiR-375 frequently downregulated in gastric cancer inhibits cell proliferation by targeting JAK2.
Molecular cloning and characterization of human WNT11.
Molecular dimensions of gastrointestinal tumors: some thoughts for digestion.
Mutation of the transforming growth factor-beta type II receptor gene is a rare event in human sporadic gastric carcinomas.
Notch1 pathway-mediated microRNA-151-5p promotes gastric cancer progression.
Over-Expression of Ephb4 Is Associated with Carcinogenesis of Gastric Cancer.
Overexpression of EPHB4 Is Associated with Poor Survival of Patients with Gastric Cancer.
Overexpression of Nedd9 is a prognostic marker of human gastric cancer.
PFK15, a Small Molecule Inhibitor of PFKFB3, Induces Cell Cycle Arrest, Apoptosis and Inhibits Invasion in Gastric Cancer.
Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
Polymorphisms of TGFBR1, TLR4 are associated with prognosis of gastric cancer in a Chinese population.
Posttranscriptional deregulation of Src due to aberrant miR34a and miR203 contributes to gastric cancer development.
Protein-tyrosine kinase and protein-serine/threonine kinase expression in human gastric cancer cell lines.
PTEN inhibits the invasion and metastasis of gastric cancer via downregulation of FAK expression.
Research of shRNAmir inhibitory effects towards focal adhesion kinase expression in the treatment of gastric cancer.
Role of TGF-beta 1 and TGF-beta type II receptor in gastric cancer.
Sequence-specific enhancer binding protein is responsible for the differential expression of ERT/ESX/ELF-3/ESE-1/jen gene in human gastric cancer cell lines: Implication for the loss of TGF-beta type II receptor expression.
Snail-regulated MiR-375 inhibits migration and invasion of gastric cancer cells by targeting JAK2.
Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells.
TGFBR1 tagging SNPs and gastric cancer susceptibility: A two-stage case-control study in Chinese population.
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Truncation of the TGF-beta type II receptor gene results in insensitivity to TGF-beta in human gastric cancer cells.
Y-box binding protein-1 and STAT3 independently regulate ATP-binding cassette transporters in the chemoresistance of gastric cancer cells.
[Current management and future prospect of HER-2 mutant non-small cell lung cancer].
[Effect of gastrin on tyrosine phosphorylation of focal adhesion kinase in human gastric cancer cell line SGC7901]
[Effect of spleen tyrosine kinase expression re-activation by inhibition of DNA methylation on oncogenesis growth of gastric cancer]
[Oncogenes in human gastric carcinoma]
Stomach Ulcer
A novel non-PPARgamma insulin sensitizer: MLR-1023 clinicalproof-of-concept in type 2 diabetes mellitus.
Strabismus
Combinatorial activity of Flamingo proteins directs convergence and extension within the early zebrafish embryo via the planar cell polarity pathway.
Planar cell polarity pathway genes and risk for spina bifida.
Stroke
Does Src Kinase Mediated Vasoconstriction Impair Penumbral Reperfusion?
EphrinB2 Activation Enhances Vascular Repair Mechanisms and Reduces Brain Swelling After Mild Cerebral Ischemia.
Ginkgetin aglycone attenuates neuroinflammation and neuronal injury in the rats with ischemic stroke by modulating STAT3/JAK2/SIRT1.
Neuroprotective Profile of Novel Src Kinase Inhibitors in Rodent Models of Cerebral Ischemia.
Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke.
Subarachnoid Hemorrhage
c-Abl Tyrosine Kinase-Mediated Neuronal Apoptosis in Subarachnoid Hemorrhage by Modulating the LRP-1-Dependent Akt/GSK3? Survival Pathway.
Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage.
Macrophage-Inducible C-Type Lectin/Spleen Tyrosine Kinase Signaling Pathway Contributes to Neuroinflammation After Subarachnoid Hemorrhage in Rats.
Superinfection
Differences in Activation of HIV-1 Replication by Superinfection With HIV-1 and HIV-2 in U1 Cells.
The effects of MAPK p38? on AZT resistance against reactivating HIV-1 replication in ACH2 cells.
Syndactyly
BMPs are direct triggers of interdigital programmed cell death.
Synovitis
Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
Rapid remission of refractory synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome in response to the Janus kinase inhibitor tofacitinib: A case report.
SOCS3 participates in cholinergic pathway regulation of synovitis in rheumatoid arthritis.
Syringoma
Next-generation sequencing implicates oncogenic roles for p53 and JAK/STAT signaling in microcystic adnexal carcinomas.
Tachycardia, Ventricular
TGFBR1 Rare Variant Associated With Thoracic Aortic Aneurysm, Double Chamber Left Ventricle, Coronary Anomaly, and Inducible Ventricular Tachycardia.
Takayasu Arteritis
Aortitis: an update.
Genome-wide association study identifies susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu's arteritis.
Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib.
Tauopathies
Distribution of spleen tyrosine kinase and tau phosphorylated at tyrosine 18 in a mouse model of tauopathy and in the human hippocampus.
Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial.
Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy.
Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn.
Studies on the ATP Binding Site of Fyn Kinase for the Identification of New Inhibitors and Their Evaluation as Potential Agents against Tauopathies and Tumors.
The microtubule-associated protein tau is also phosphorylated on tyrosine.
Tyrosine Kinase Inhibition Regulates Early Systemic Immune Changes and Modulates the Neuroimmune Response in ?-Synucleinopathy.
Telangiectasia, Hereditary Hemorrhagic
BMP signaling in vascular diseases.
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.
Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.
Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
Telangiectasis
BMP signaling in vascular diseases.
Hsa-miR-520d-5p promotes survival in human dermal fibroblasts exposed to a lethal dose of UV irradiation.
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis.
Overlapping spectra of SMAD4 mutations in juvenile polyposis (JP) and JP-HHT syndrome.
Phenotype of CM-AVM2 caused by variants in EPHB4: how much overlap with hereditary hemorrhagic telangiectasia (HHT)?
Primary pulmonary hypertension in families with hereditary haemorrhagic telangiectasia.
Testicular Neoplasms
A novel mouse model of testicular granulosa cell tumors.
Down-regulation of FAK and IAPs by laminin during cisplatin-induced apoptosis in testicular germ cell tumors.
Tetanus
Tyrosine phosphorylation modulates the activity of clostridial neurotoxins.
Tyrphostin AG-490 inhibits cytokine-mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen-activated human T cells.
VEGF secretion during hypoxia depends on free radicals-induced Fyn kinase activity in mast cells.
[Synthesis, Cloning and Expression of a Multiple Epitope Antigen of BCR-ABL Fusion Gene]
Tetralogy of Fallot
Wnt11 regulates cardiac chamber development and disease during perinatal maturation.
Thalassemia
A Phase 1 Study of ACE-536, a Regulator of Erythroid Differentiation, in Healthy Volunteers.
Heparanase Level and Procoagulant Activity Are Increased in Thalassemia and Attenuated by Janus Kinase 2 Inhibition.
Mechanisms and Significance of Eryptosis, the Suicidal Death of Erythrocytes.
Thrombasthenia
Clustering of integrin alphaIIb-beta3 differently regulates tyrosine phosphorylation of pp72syk, PLCgamma2 and pp125FAK in concanavalin A-stimulated platelets.
Thrombocythemia, Essential
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia.
A case of essential thrombocythemia and ankylosing spondylitis treated with a combination of anagrelide, disease-modifying antirheumatic drugs, and etanercept.
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.
A novel Janus Kinase 2 mutation involving 14th intron splicing region in a patient with essential thrombocythemia.
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Activated STAT1 and STAT5 transcription factors in extramedullary hematopoietic tissue in a polycythemia vera patient carrying the JAK2 V617F mutation.
Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia.
Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Among a panel of polymorphisms in genes related to oxidative stress, CAT-262 C>T, GPX1 Pro198Leu and GSTP1 Ile105Val influence the risk of developing BCR-ABL negative myeloproliferative neoplasms.
AXL Inhibition Represents a Novel Therapeutic Approach in BCR-ABL Negative Myeloproliferative Neoplasms.
bcr-abl hybrid messenger RNA in a patient with Philadelphia-negative essential thrombocythemia.
Bcr-abl mRNA expression in patients with chronic myeloproliferative disorders--absence of bcr-abl fused clone except chronic myelocytic leukemia.
BCR-ABL rearrangement is not detectable in essential thrombocythemia.
BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance.
CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation.
Calreticulin mutation analysis in non-mutated Janus kinase 2 essential thrombocythemia patients in Chiang Mai University: analysis of three methods and clinical correlations.
Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis.
Chromosomal abnormalities and molecular markers in myeloproliferative disorders.
Chronic Myeloid Leukemia: Atypical Presentation and Diagnostic Pitfall in the Workup of Isolated Thrombocytosis.
Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era.
Clinical applications of molecular haematology: JAK2 in myeloproliferative disorders.
Clinical characteristics and whole exome/transcriptome sequencing of coexisting chronic myeloid leukemia and myelofibrosis.
Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study.
Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Coexistence of breakpoint cluster region-Abelson1 rearrangement and Janus kinase 2 V617F mutation in chronic myeloid leukemia: A case report.
Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia.
Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.
Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease.
Decreased expression of PIAS1 and PIAS3 in essential thrombocythemia patients.
Defining the thrombotic risk in patients with myeloproliferative neoplasms.
Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia.
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry.
Essential Thrombocythemia Due to Janus Kinase 2 Mutation Unmasked After Splenectomy.
Essential thrombocythemia with BCR/ABL rearrangement.
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Essential thrombocythemia: scientific advances and current practice.
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation.
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Genetic and epigenetic alterations of myeloproliferative disorders.
Guidelines for the management of myeloproliferative neoplasms.
Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups.
Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency.
Identification of unipotent megakaryocyte progenitors in human hematopoiesis.
Imatinib and tyrosine kinase inhibition, in the management of BCR-ABL negative myeloproliferative disorders.
Immunotherapy for myeloproliferative neoplasms (MPN).
Implications of Janus Kinase 2 Mutation in Embolic Stroke of Unknown Source.
JAK2 46/1 haplotype is associated with JAK2 V617F-positive myeloproliferative neoplasms in Japanese patients.
JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera.
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
JAK2 Inhibitors for Myelofibrosis: Why Are They Effective in Patients With and Without JAK2V617F Mutation?
Janus kinase (JAK) 2 V617F mutation as the cause of primary thrombocythemia in acromegaly with severe visceromegaly and divergence between growth hormone and insulin-like growth factor-1 concentrations during the follow-up: causal or casual association?
Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.
Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years.
Management of thrombocythemia.
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.
Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm.
miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets.
Molecular analysis of Philadelphia positive essential thrombocythemia.
Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Mutations in myeloproliferative neoplasms - their significance and clinical use.
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.
Myeloproliferative Neoplasms: A Contemporary Review.
New insights into the pathogenesis and treatment of chronic myeloproliferative disorders.
New mutations and pathogenesis of myeloproliferative neoplasms.
Novel strategies for patients with chronic myeloproliferative disorders.
Patients with essential thrombocythemia do not express BCR-ABL transcripts.
Philadelphia chromosome and/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation.
Polycythemia vera and essential thrombocythemia: algorithmic approach.
Presence of calreticulin mutations in JAK2-negative polycythemia vera.
Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Random Mutagenesis Reveals Residues of JAK2 Critical in Evading Inhibition by a Tyrosine Kinase Inhibitor.
Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Ruxolitinib for the Treatment of Essential Thrombocythemia.
Screening of Bcr-Abl transcripts in Philadelphia negative essential thrombocythemia.
Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients.
Simultaneous screening for JAK2 and calreticulin gene mutations in myeloproliferative neoplasms with high resolution melting.
Somatic mutations of calreticulin in myeloproliferative neoplasms.
Src tyrosine kinase preactivation is associated with platelet hypersensitivity in essential thrombocythemia and polycythemia vera.
The allele burden of JAK2 V617F can aid in differential diagnosis of Philadelphia Chromosome-Negative Myeloproliferative Neoplasm.
The association of JAK2(V617F) mutation and leukocytosis with thrombotic events in essential thrombocythemia.
The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes.
The JAK2(V617F) tyrosine kinase mutation in myeloproliferative disorders: Summary of published literature and a perspective.
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
The marrow stem cell niche in normal and malignant hematopoiesis.
The Mutation Profile Of Calreticulin In Patients With Myeloproliferative Neoplasms And Acute Leukemia.
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN.
The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia.
Thrombopoietin in normal and neoplastic stem cell development.
Triple Negative Mutations in Essential Thrombocythemia With bcr-abl Rearrangement: Is There a Such Distinct Disease?
Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.
Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: A common defective stem cell?
[JAK2V617F Mutation in the Patients with Myeloproliferative Disorder and Its Relation with Clinical Characteristics].
[Molecular anomalies in malignant hemopathies]
[Research progress of myeloproliferative neoplasms].
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
[The JAK2 mutation in myeloproliferative disorders: A predictive factor of thrombosis].
Thrombocytopenia
A dominant gain-of-function mutation in universal tyrosine kinase SRC causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies.
Absolute lymphocyte count with extreme hyperleukocytosis does not have a prognostic impact in chronic lymphocytic leukemia.
Acquired amegakaryocytic thrombocytopenia associated with proliferation of gamma/delta TCR T-lymphocytes and a BCR-ABL (p210) fusion transcript.
BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocytopenia patients: clinical presentation.
Cell surface expression of CD25 antigen (surface IL-2 receptor alpha-chain) is not a prognostic marker in chronic lymphocytic leukemia: results of a retrospective study of 281 patients.
De novo variant in tyrosine kinase SRC causes thrombocytopenia: case report of a second family.
Development of severe thrombocytopenia with TAFRO syndrome-like features in a patient with rheumatoid arthritis treated with a Janus kinase inhibitor: A case report.
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Identification of e6a2 bcr-abl fusion in a Philadelphia-positive cml with marked basophilia: implications for treatment strategy.
Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.
Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial.
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.
The thrombopoietin receptor: revisiting the master regulator of platelet production.
Utility of laboratory tests in B-CLL patients in different clinical stages.
Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): Targeting Pathomechanisms with Bruton Tyrosine Kinase Inhibitors.
Thrombocytosis
An Unusual Cause of the Transient Osteoporosis of the Femoral Head: Essential Thrombocytosis.
Austrian recommendations for the management of essential thrombocythemia.
Back to biology: new insights on inheritance in myeloproliferative disorders.
BCR-ABL gene variants.
BCR-ABL oncoprotein is expressed by platelets from CML patients and associated with a special pattern of CrkL phosphorylation.
Calreticulin mutant mice develop essential thrombocythemia that is ameliorated by the JAK inhibitor ruxolitinib.
Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide.
Chronic Myeloid Leukemia: Atypical Presentation and Diagnostic Pitfall in the Workup of Isolated Thrombocytosis.
Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.
Clinical Significance of BCR-ABL Fusion Gene in Chronic Myeloid Leukemia Patients.
Cytogenetic and molecular genetic aspects of essential thrombocythemia.
Diagnosis of the myeloproliferative disorders: resolving phenotypic mimicry.
Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation.
Essential thrombocythemia with the Philadelphia chromosome and BCR-ABL gene rearrangement. An entity distinct from chronic myeloid leukemia and Philadelphia chromosome-negative essential thrombocythemia.
Feasibility of Qualitative Testing of BCR-ABL and JAK2 V617F in Suspected Myeloproliperative Neoplasm (MPN) Using RT-PCR Reversed Dot Blot Hybridization (RT-PCR RDB).
Frequency and characteristics of the JAK2 V617F mutation in 23 cerebral venous sinus thrombosis patients with thrombocytosis.
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.
Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F.
Is Ciprofloxacin in Combination With Beta-lactam Antibiotics a Recipe for Thrombocytosis?: A Case Report of Thrombocytosis in a Patient Receiving Ciprofloxacin and Ceftriaxone.
Jak-2 mutation frequency in patients with thrombocytosis.
JAK-Mutant Myeloproliferative Neoplasms.
Janus kinase mutations.
Mixed myelodysplastic and myeloproliferative syndromes.
Myelodysplastic syndrome without ring sideroblasts and with Janus kinase 2 gene mutation: An unusual case report.
Philadelphia-chromosome positive thrombocythemia in a child.
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
Rapidly relapsing squamous cell carcinoma of the renal pelvis associated with paraneoplastic syndromes of leukocytosis, thrombocytosis and hypercalcemia.
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
Recurrent thrombosis after carotid endarterectomy secondary to activated protein C resistance and essential thrombocytosis: A case report.
Refractory anemia with ring sideroblasts associated with marked thrombocytosis: case report and literature review.
The small molecule inhibitor g6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of jak2-mediated myelofibrosis.
[Exacerbation of acute leukemia bearing isolated i(17q) along with proliferation of blasts with high BMI-1 expression]
[Report of 8 cases of bcr-abl gene positive thrombocytosis and review of the literature.]
[The genetic characteristics of BCR-ABL-negative myeloproliferative neoplasms].
Thromboembolism
Cardiovascular Risk Assessment and Impact of Medications on Cardiovascular Disease in Inflammatory Bowel Disease.
Recurrent refractory arterial thromboembolism associated with the Janus kinase 2 V617F mutation.
The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Thromboembolism and Janus Kinase Inhibitors.
Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Thromboinflammation
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Thrombophilia
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia.
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib as Potential Repurposed Drugs against COVID-19.
Thrombosis
Acute ST-segment elevation myocardial infarction: A rare initial presentation of previously undiagnosed essential thrombocythemia.
Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms.
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?
Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo.
Clinical course of myeloproliferative leukaemia virus oncogene (MPL) mutation-associated familial thrombocytosis: a review of 64 paediatric and adult patients.
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Dynamic interaction between Src and C-terminal Src kinase in integrin alphaIIbbeta3-mediated signaling to the cytoskeleton.
Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients.
Evaluation of The Presence of Hereditary And Acquired Thrombophilias In Brazilian Children And Adolescents With Diagnoses of Portal Vein Thrombosis.
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Genetic Polymorphisms of Hemostatic Factors and Thrombotic Risk in Non BCR-ABL Myeloproliferative Neoplasms: A Pilot Study.
Impaired thrombin-induced platelet activation and thrombus formation in mice lacking the Ca(2+)-dependent tyrosine kinase Pyk2.
Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
JAK2 mutation and acute coronary syndrome complicated with stent thrombosis.
JAK2 V617F: implications for thrombosis in myeloproliferative diseases.
JAK2V617F Mutation Is Not Associated with Thrombosis in Behcet Syndrome.
Low prevalence of JAK2 V617F mutation in patients with thrombosis and normal blood counts: a retrospective impact study.
Mesenteric vein thrombosis caused by secondary polycythaemia from AndroGel.
NLRP3 inflammasome and bruton tyrosine kinase inhibition interferes with upregulated platelet aggregation and in vitro thrombus formation in sickle cell mice.
Novel strategies for patients with chronic myeloproliferative disorders.
Oral Bruton tyrosine kinase inhibitors selectively block atherosclerotic plaque-triggered thrombus formation.
Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics.
Platelet Activation and Thrombus Formation over IgG Immune Complexes Requires Integrin ?IIb?3 and Lyn Kinase.
Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies.
Platelets at the crossroads of thrombosis, inflammation and haemolysis.
Portal vein thrombosis as the first sign of a primary myeloproliferative disorder: diagnostic interest of the V617F JAK-2 mutation. A report of 2 cases.
Refractory Arterial Insufficiency Associated with Janus Kinase 2 Positive Essential Thrombocythaemia.
Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
Resveratrol Improves Endothelial Progenitor Cell Function through miR-138 by Targeting Focal Adhesion Kinase (FAK) and Promotes Thrombus Resolution In Vivo.
Should We Screen for Janus Kinase 2 V617F Mutation in Cerebral Venous Thrombosis?
The evaluation of patients with essential thrombocythemia in terms of risk of thrombosis.
The interaction of SRC kinase with beta3 integrin tails: a potential therapeutic target in thrombosis and cancer.
The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation.
The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study.
The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
[ELABORATION AND TREATMENT DECISION IN INCIDENTAL SPLANCHNIC VEIN THROMBOSIS].
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Thymoma
Additional member of the protein-tyrosine kinase family: the src- and lck-related protooncogene c-tkl.
BCR-ABL and v-abl oncogenes induce distinct patterns of thymic lymphoma involving different lymphocyte subsets.
Characterization of the protein apparently responsible for the elevated tyrosine protein kinase activity in LSTRA cells.
Differential activation of multiple signalling pathways dictates eNOS upregulation by FGF2 but not VEGF in placental artery endothelial cells.
Dynamic protein pathway activation mapping of adipose-derived stem cell differentiation implicates novel regulators of adipocyte differentiation.
Expression of a new tyrosine protein kinase is stimulated by retrovirus promoter insertion.
Expression of cellular oncogenes: unrearranged c-myc gene but altered promoter usage in radiation-induced thymoma.
FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma.
Generation and characterization of transforming variants of the lck tyrosine protein kinase.
Hematopoietic progenitor cells as possible origins of epithelial thymoma in a human T lymphocyte virus type I pX gene transgenic rat model.
Induction of hyperphosphorylation and activation of the p56lck protein tyrosine kinase by phenylarsine oxide, a phosphotyrosine phosphatase inhibitor.
Introducing crucial protein panel of gastric adenocarcinoma disease.
LIFR functions as a metastasis suppressor in hepatocellular carcinoma by negatively regulating phosphoinositide 3-kinase/AKT pathway.
Malignant transformation of thymoma in recipient rats by heterotopic thymus transplantation from HTLV-I transgenic rats.
New function of type I IFN: induction of autophagy.
Physical association of the cytoplasmic domain of CD2 with the tyrosine kinases p56lck and p59fyn.
Restoration of thymic development in an Lck(-/-) thymoma overexpressing ZAP-70.
Therapeutic Inducers of Apoptosis in Ovarian Cancer.
Tissue invasion and metastasis: Molecular, biological and clinical perspectives.
Transcriptional activation of lck by retrovirus promoter insertion between two lymphoid-specific promoters.
Two lck transcripts containing different 5' untranslated regions are present in T cells.
Tyrosine phosphorylation of GAP and GAP-associated proteins in lymphoid and fibroblast cells expressing lck.
[Expression of the p56lck by colon tumors: a marker of their invasive capacity?]
Thymus Neoplasms
Apoptosis-Related (Survivin, Bcl-2), Tumor Suppressor Gene (p53), Proliferation (Ki-67), and Non-Receptor Tyrosine Kinase (Src) Markers Expression and Correlation With Clinicopathologic Variables in 60 Thymic Neoplasms.
Thyroid Cancer, Papillary
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
DDR2 facilitates papillary thyroid carcinoma epithelial mesenchymal transition by activating ERK2/Snail1 pathway.
Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells.
EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.
Germline Bone Morphogenesis Protein Receptor 1A Mutation Causes Colorectal Tumorigenesis in Hereditary Mixed Polyposis Syndrome.
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma.
Overexpression of EphB4, EphrinB2 and EGFR in Papillary Thyroid Carcinoma: A Pilot Study.
Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Thyroid Carcinoma, Anaplastic
Doxorubicin has a synergistic cytotoxicity with cucurbitacin B in anaplastic thyroid carcinoma cells.
Inhibition of ABL tyrosine kinase potentiates radiation-induced terminal growth arrest in anaplastic thyroid cancer cells.
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Thyroid Diseases
Associations of secreted phosphoprotein 1 and B lymphocyte kinase gene polymorphisms with autoimmune thyroid disease.
Thyroid Neoplasms
Cytogenetic and fluorescence in situ hybridization studies in a case of anaplastic thyroid carcinoma.
Direct phosphorylation of proliferative and survival pathway proteins by RET.
Exclusion of c-Abl from the nucleus restrains the p73 tumor suppression function.
FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics.
Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer.
Increased expression of focal adhesion kinase in thyroid cancer: immunohistochemical study.
RET signals through focal adhesion kinase in medullary thyroid cancer cells.
Targeted inhibition of Src kinase with dasatinib blocks thyroid cancer growth and metastasis.
The nuclear factor kappa-B signaling pathway as a therapeutic target against thyroid cancers.
The Role of STAT3 in Thyroid Cancer.
The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.
Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile response to Hepatocyte Growth Factor.
Upregulation of Tyrosine Kinase FYN in Human Thyroid Carcinoma: Role in Modulating Tumor Cell Proliferation, Invasion, and Migration.
Thyroid Nodule
Clinical utility of TGFB1 and its receptors (TGFBR1 and TGFBR2) in thyroid nodules: evaluation based on single nucleotide polymorphisms and mRNA analysis.
Tongue Neoplasms
Focal adhesion kinase serves as a marker of cervical lymph node metastasis and is a potential therapeutic target in tongue cancer.
Toxoplasmosis
Dysregulation of focal adhesion kinase upon Toxoplasma gondii infection facilitates parasite translocation across polarised primary brain endothelial cell monolayers.
Trauma, Nervous System
Long-term treatment with PP2 after spinal cord injury resulted in functional locomotor recovery and increased spared tissue.
Trigeminal Neuralgia
c-Abl-p38? signaling pathway mediates dopamine neuron loss in trigeminal neuralgia.
Triple Negative Breast Neoplasms
ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy.
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast Cancer.
c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression.
CIP4 promotes metastasis in triple-negative breast cancer and is associated with poor patient prognosis.
Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.
Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase.
Down-regulation of cathepsin S and matrix metalloproteinase-9 via Src, a non-receptor tyrosine kinase, suppresses triple-negative breast cancer growth and metastasis.
Dual Src Kinase/Pretubulin Inhibitor KX-01, Sensitizes ER?-negative Breast Cancers to Tamoxifen through ER? Reexpression.
Enhanced immortalization, HUWE1 mutations and other biological drivers of breast invasive carcinoma in Black/African American patients.
Focal adhesion kinase (FAK) activation by estrogens involves GPER in triple-negative breast cancer cells.
IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel.
Mutant p53 dictates the oncogenic activity of c-Abl in triple-negative breast cancers.
PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
Small Non-Coding RNA Profiling Identifies miR-181a-5p as a Mediator of Estrogen Receptor Beta-Induced Inhibition of Cholesterol Biosynthesis in Triple-Negative Breast Cancer.
Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C ? Pathway in a Subset of Triple-Negative Breast Cancers.
Src: a potential target for the treatment of triple-negative breast cancer.
Targeting synthetic lethality between the SRC kinase and the EPHB6 receptor may benefit cancer treatment.
Targeting the Nerve Growth Factor Signaling Impairs the Proliferative and Migratory Phenotype of Triple-Negative Breast Cancer Cells.
The impact of Thr91 mutation on c-Src resistance to UM-164: molecular dynamics study revealed a new opportunity for drug design.
The non-receptor tyrosine kinase TNK2/ACK1 is a novel therapeutic target in triple negative breast cancer.
Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
[Triple-negative breast cancer: molecular characteristics and potential therapeutic approaches].
Trisomy 13 Syndrome
Trisomy 13 in a Philadelphia negative chromosome and BCR-ABL negative myeloproliferative disorder.
Truncus Arteriosus, Persistent
Outflow tract cushions perform a critical valve-like function in the early embryonic heart requiring BMPRIA-mediated signaling in cardiac neural crest.
Tuberculosis
A Case of Disseminated Cutaneous Mycobacterium chelonae Infection During Treatment With Tofacitinib.
Abelson Tyrosine Kinase Controls Phagosomal Acidification Required for Killing of Mycobacterium tuberculosis in Human Macrophages.
c-Abl-TWIST1 Epigenetically Dysregulate Inflammatory Responses during Mycobacterial Infection by Co-Regulating Bone Morphogenesis Protein and miR27a.
Efficacy of Adjunctive Tofacitinib Therapy in Mouse Models of Tuberculosis.
Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling.
Mycobacterium tuberculosis ManLAM inhibits T-cell-receptor signaling by interference with ZAP-70, Lck and LAT phosphorylation.
Risk of tuberculosis reactivation with tofacitinib (CP-690550).
Targeting Drug-Sensitive and -Resistant Strains of Mycobacterium tuberculosis by Inhibition of Src Family Kinases Lowers Disease Burden and Pathology.
The role of Mycobacterium tuberculosis complex species on apoptosis and necroptosis state of macrophages derived from active pulmonary tuberculosis patients.
Tuberculosis, Pulmonary
Differential expression of interleukin-4 (IL-4) and IL-4 delta 2 mRNA, but not transforming growth factor beta (TGF-beta), TGF-beta RII, Foxp3, gamma interferon, T-bet, or GATA-3 mRNA, in patients with fast and slow responses to antituberculosis treatment.
Tuberous Sclerosis
Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth.
Doxycycline reduces the migration of tuberous sclerosis complex-2 null cells - effects on RhoA-GTPase and focal adhesion kinase.
Tumor Lysis Syndrome
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Imatinib-induced tumor lysis syndrome: report of a case and review of the literature.
Uremia
A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia.
Ureteral Obstruction
Activation of Wnt11 by transforming growth factor-? drives mesenchymal gene expression through non-canonical Wnt protein signaling in renal epithelial cells.
Urinary Bladder Neoplasms
Bone marrow mesenchymal stem cells-derived exosomal microRNA-19b-1-5p reduces proliferation and raises apoptosis of bladder cancer cells via targeting ABL2.
circEHBP1 promotes lymphangiogenesis and lymphatic metastasis of bladder cancer via miR-130a-3p/TGF?R1/VEGF-D signaling.
Dasatinib enhances tumor growth in gemcitabine-resistant orthotopic bladder cancer xenografts.
EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival.
Expression and Functions of Formyl Peptide Receptor 1 in Drug-Resistant Bladder Cancer.
Focal adhesion kinases crucially regulate TGF?-induced migration and invasion of bladder cancer cells via Src kinase and E-cadherin.
Identification of novel allosteric binding sites and multi-targeted allosteric inhibitors of receptor and non-receptor tyrosine kinases using a computational approach.
Inhibition of Bruton's Tyrosine Kinase Suppresses Cancer Stemness and Promotes Carboplatin-induced Cytotoxicity Against Bladder Cancer Cells.
Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway.
Int7G24A variant of transforming growth factor-beta receptor type I is associated with invasive breast cancer.
Low Expression of EphB2, EphB3, and EphB4 in Bladder Cancer: Novel Potential Indicators of Muscular Invasion.
Proline-Rich Tyrosine Kinase 2 (Pyk2) Regulates IGF-I-Induced Cell Motility and Invasion of Urothelial Carcinoma Cells.
Promoter analysis of epigenetically controlled genes in bladder cancer.
TGFB1 and TGFBR1 polymorphic variants in relationship to bladder cancer risk and prognosis.
The chromosome 9q genes TGFBR1, TSC1, and ZNF189 are rarely mutated in bladder cancer.
The differential expression of EphB2 and EphB4 receptor kinases in normal bladder and in transitional cell carcinoma of the bladder.
The impact of delay in cryo-fixation on biomarkers of Src tyrosine kinase activity in human breast and bladder cancers.
The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder.
The miR-130 family promotes cell migration and invasion in bladder cancer through FAK and Akt phosphorylation by regulating PTEN.
Tyrosine Kinase ETK/BMX Is Up-Regulated in Bladder Cancer and Predicts Poor Prognosis in Patients with Cystectomy.
Urticaria
?-Linolenic acid attenuates pseudo-allergic reactions by inhibiting Lyn kinase activity.
A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally.
Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study.
[Effect of electroacupuncture on expressions of Lyn and Syk in mast cells of subcutaneous loose connective tissue in rats with urticarial].
[Effect of pre-acupuncture intervention on serum IgE and cutaneous phosphorylated tyrosine-protein kinase expression in rats with urticaria].
Uterine Cervical Neoplasms
Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-?B/Survivin Expression in HeLa Cells.
Cervical Cancer Growth Is Regulated by a c-ABL-PLK1 Signaling Axis.
Clinical significance of focal adhesion kinase (FAK) in cervical cancer progression and metastasis.
Coexpression of EphB4 and ephrinB2 in tumor advancement of uterine cervical cancers.
Differential gene expression in cervical cancer cell lines before and after ionizing radiation.
Down-regulation of phospho-non-receptor Src tyrosine kinases contributes to growth inhibition of cervical cancer cells.
Erb?B2 Receptor Tyrosine Kinase 2 is negatively regulated by the p53?responsive microRNA?3184?5p in cervical cancer cells.
Fibronectin promotes cervical cancer tumorigenesis through activating FAK signaling pathway.
Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa).
Fyn-related kinase expression predicts favorable prognosis in patients with cervical cancer and suppresses malignant progression by regulating migration and invasion.
Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.
MicroRNA-7 inhibits metastasis and invasion through targeting focal adhesion kinase in cervical cancer.
MicroRNA?433 inhibits cell growth and induces apoptosis in human cervical cancer through PI3K/AKT signaling by targeting FAK.
Molecular cloning and characterization of human WNT11.
Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
Redox Regulation of NOX Isoforms on FAK(Y397)/SRC(Y416) Phosphorylation Driven Epithelial-to-Mesenchymal Transition in Malignant Cervical Epithelial Cells.
Src family kinase inhibitor PP2 efficiently inhibits cervical cancer cell proliferation through down-regulating phospho-Src-Y416 and phospho-EGFR-Y1173.
The expression and tyrosine phosphorylation of E-cadherin/catenin adhesion complex, and focal adhesion kinase in invasive cervical carcinomas.
Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study.
Vascular endothelial growth factor C enhances cervical cancer migration and invasion via activation of focal adhesion kinase.
Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome.
[Effects of Src on cervical cancer cells proliferation and apoptosis through ERK signal transduction pathway].
Uterine Neoplasms
PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer.
Uveitis
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis.
Uveitis, Anterior
Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis.
Vaccinia
CHK down-regulates SCF/KL-activated Lyn kinase activity in Mo7e megakaryocytic cells.
CTLs specific for bcr-abl joining region segment peptides fail to lyse leukemia cells expressing p210 bcr-abl protein.
Tyrosine phosphorylation of VHR phosphatase by ZAP-70.
Vaccinia virus growth factor stimulates tyrosine protein kinase activity of A431 cell epidermal growth factor receptors.
Vaccinia virus-mediated high level expression and single step purification of recombinant Jak2 protein.
Varicose Ulcer
Fibroblasts from chronic wounds show altered TGF-beta-signaling and decreased TGF-beta Type II receptor expression.
Varicose Veins
Evaluation of transforming growth factor-beta signaling pathway in the wall of normal and varicose veins.
Vascular Calcification
Activin receptor IIA ligand trap in chronic kidney disease: 1 drug to prevent 2 complications-or even more?
The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology.
Vascular Diseases
Aneurysm syndromes caused by mutations in the TGF-beta receptor.
Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review.
FAK Family Kinases in Vascular Diseases.
Hypertension promotes phosphorylation of focal adhesion kinase and proline-rich tyrosine kinase 2 in rats: implication for the pathogenesis of hypertensive vascular disease.
Pathophysiology of the chronic kidney disease-mineral bone disorder.
Renovascular hypertension associated with JAK2 V617F positive myeloproliferative neoplasms treated with angioplasty: 2 cases and literature review.
Signalling through Src family kinase isoforms is not redundant in models of thrombo-inflammatory vascular disease.
The retinal tyrosine kinome of diabetic Akimba mice highlights potential for specific Src family kinase inhibition in retinal vascular disease.
Vascular Malformations
A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4).
EPHB4 Mutation Implicated in Capillary Malformation-Arteriovenous Malformation Syndrome: A Case Report.
RASA1 mosaic mutations in patients with capillary malformation-arteriovenous malformation.
Vascular System Injuries
Critical role for Syk in responses to vascular injury.
Phosphodiesterase type 4 blockade prevents platelet-mediated neutrophil recruitment at the site of vascular injury.
The role of Rac1 in glycoprotein Ib-IX-mediated signal transduction and integrin activation.
Vasculitis
Levistilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats.
Non-receptor type, proline-rich protein tyrosine kinase 2 (Pyk2) is a possible therapeutic target for Kawasaki disease.
Spleen tyrosine kinase inhibition is an effective treatment for established vasculitis in a pre-clinical model.
[The negative regulatory factor of CAWS (Candida albicans water-soluble fraction) -vasculitis in CBA/J mice as assessed by comparison with Bruton's tyrosine kinase-deficient CBA/N mice].
Vasospasm, Intracranial
Contribution of Src tyrosine kinase to cerebral vasospasm after subarachnoid hemorrhage.
Venous Insufficiency
Mutations in EPHB4 cause human venous valve aplasia.
Venous Thromboembolism
Evidence of jak2 val617phe positive essential thrombocythemia with splanchnic thrombosis during estroprogestinic treatment.
Incidence of Silent Thrombosis in Patients Younger Than 60 Years With Myeloproliferative Neoplasms: Single-Center Egyptian Study.
Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis.
Venous Thrombosis
Diffuse Alveolar Hemorrhage Secondary to Ibrutinib Therapy in a Patient With Refractory Mantle Cell Lymphoma.
Janus kinase (JAK) 2 V617F mutation in Asian Indians with cerebral venous thrombosis and without overt myeloproliferative disorders.
Massive upper gastrointestinal bleeding due to splenoportal axis thrombosis in a patient with a tested JAK2 mutation: A case report and review literature.
Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.
Treatment of gastric varices with partial splenic embolization in a patient with portal vein thrombosis and a myeloproliferative disorder.
Ventilator-Induced Lung Injury
Activation of c-Src tyrosine kinase mediated the degradation of occludin in ventilator-induced lung injury.
Activation of Src-dependent Smad3 signaling mediates the neutrophilic inflammation and oxidative stress in hyperoxia-augmented ventilator-induced lung injury.
Vesicular Stomatitis
Intracellular targeting of pp60src expression: localization of v-src to adhesion plaques is sufficient to transform chicken embryo fibroblasts.
Lentiviral transduction of murine oligodendrocytes in vivo.
Vesicular stomatitis virus produced from infected LSTRA lymphoma cells bear tyrosine protein kinase activity (p56).
Viremia
[Prognostic analysis of allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in complete remission in the era of tyrosine kinase inhibitors].
Virus Diseases
An evolutionary conserved function of the JAK-STAT pathway in anti-dengue defense.
Blocking the PI3K/AKT pathway enhances mammalian reovirus replication by repressing IFN-stimulated genes.
Bruton's tyrosine kinase phosphorylates Toll-like receptor 3 to initiate antiviral response.
Caveolin-1 associated adenovirus entry into human corneal cells.
Characterization of a novel non-receptor tyrosine kinase Src from Litopenaeus vannamei and its response to white spot syndrome virus infection.
Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors.
Expression of Etk/Bmx tyrosine kinase in the tumorigenicity of nasopharyngeal epithelium and its relation with EB virus infection and the apoptosis-related protein Bcl-2.
Focal adhesion kinase is involved in rabies virus infection through its interaction with viral phosphoprotein P.
Hepatitis C virus infection inhibits a Src-kinase regulatory phosphatase and reduces T cell activation in vivo.
Herpes simplex virus triggers activation of calcium-signaling pathways.
Human immunodeficiency virus infection abolishes CD4-dependent activation of ZAP-70 by inhibition of p56lck.
Involvement of fish signal transducer and activator of transcription 3 (STAT3) in nodavirus infection induced cell death.
Japanese encephalitis virus infection stimulates Src tyrosine kinase in neuron/glia.
Major histocompatibility (B) complex control of the growth pattern of v-src DNA-induced primary tumors.
Molecular cloning and functional analysis of three STAT isoforms in red swamp crayfish Procambarus clarkii.
Myxoma virus induces extensive CD4 downregulation and dissociation of p56lck in infected rabbit CD4+ T lymphocytes.
Positive regulatory role of c-Src-mediated TRIM25 tyrosine phosphorylation on RIG-I ubiquitination and RIG-I-mediated antiviral signaling pathway.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Quantitative subcellular proteome and secretome profiling of influenza A virus-infected human primary macrophages.
Role of Itk signaling in the interaction between influenza A virus and T cells.
SARS-CoV-2 (COVID-19) and Chronic Myeloid Leukemia (CML): a Case Report and Review of ABL Kinase Involvement in Viral Infection.
Spleen Tyrosine Kinase (Syk) Mediates IL-1? Induction by Primary Human Monocytes during Antibody-enhanced Dengue Virus Infection.
Suppression of Interferon (IFN)-inducible Genes and IFN-mediated Functional Responses in BCR-ABL-expressing Cells.
The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection.
The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection.
Tumor necrosis factor-alpha production induced by viruses and by lipopolysaccharides in macrophages: similarities and differences.
Use of QSAR Global Models and Molecular Docking for Developing New Inhibitors of c-src Tyrosine Kinase.
Whole Transcriptome Analysis of Aedes albopictus Mosquito Head and Thorax Post-Chikungunya Virus Infection.
Vision Disorders
Leucapheresis for management of retinopathy in chronic myeloid leukaemia.
Vitamin D Deficiency
Role of Vitamins A and D in BCR-ABL Arf-/- Acute Lymphoblastic Leukemia.
Vitamin D Deficiency and Janus kinase 2 V617F Mutation Status in Essential Thrombocythemia and Polycythemia Vera.
Vitiligo
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies.
Association of myalgias with compounded topical Janus kinase inhibitor use in vitiligo.
Clinical Features, Immunopathogenesis, and Therapeutic Strategies in Vitiligo.
Drugs targeting the JAK/STAT pathway for the treatment of immune-mediated inflammatory skin diseases: protocol for a scoping review.
Entangled Conditional Adversarial Autoencoder for de Novo Drug Discovery.
Expression of Janus Kinase 1 in vitiligo & psoriasis before and after narrow band UVB: a case-control study.
Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo.
Janus kinase inhibitor tofacitinib does not facilitate the repigmentation in mouse model of rhododendrol-induced vitiligo.
Janus Kinase Inhibitors in Dermatology: Part 1 - General Considerations and Applications in Vitiligo and Alopecia Areata.
Janus Kinase Inhibitors: A Review of Their Application in the Vitiligo.
Micro - Focused Phototherapy Associated To Janus Kinase Inhibitor: A Promising Valid Therapeutic Option for Patients with Localized Vitiligo.
PF-06651600, a Dual JAK3/TEC Family Kinase Inhibitor.
Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis.
Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.
Role of Janus kinase 1 and signal transducer and activator of transcription 3 in vitiligo.
The Use of Janus Kinase Inhibitors in Vitiligo: A Review of the Literature.
Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib.
Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32-week open label extension study with optional narrow-band ultraviolet B.
Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib.
Vitiligo: an update on systemic treatments.
[Systemic treatment of vitiligo : Balance and current developments].
Vitreoretinopathy, Proliferative
Gene transfer of soluble TGF-beta type II receptor inhibits experimental proliferative vitreoretinopathy.
Soluble EphB4 inhibits PDGF-induced RPE migration in vitro.
von Hippel-Lindau Disease
A complex endocrine conundrum.
Waldenstrom Macroglobulinemia
A case of new-onset cardiomyopathy and ventricular tachycardia in a patient receiving ibrutinib for relapsed mantle cell lymphoma.
A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia.
A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia.
A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY.
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies.
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Bruton Tyrosine Kinase Inhibitors in Waldenstrom Macroglobulinemia: Unprecedented Clinical Activity and Promising Future Directions.
Bruton Tyrosine Kinase Inhibitors: Present and Future.
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Direct and two-step bioorthogonal probes for Bruton's tyrosine kinase based on ibrutinib: a comparative study.
Extended follow-up with the Bruton's tyrosine kinase inhibitor ibrutinib in previously treated Waldenström's macroglobulinemia.
First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia.
Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
How to Sequence Therapies in Waldenström Macroglobulinemia.
Ibrutinib effect in acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia.
Ibrutinib in chronic lymphocytic leukemia and B cell malignancies.
Ibrutinib in the management of Waldenstrom macroglobulinemia.
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience.
Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
Ibrutinib Inhibits Platelet Integrin ?IIb?3 Outside-In Signaling and Thrombus Stability But Not Adhesion to Collagen.
Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Ibrutinib: first global approval.
Macrophage-Mediated Antibody Dependent Effector Function in Aggressive B-Cell Lymphoma Treatment is Enhanced by Ibrutinib via Inhibition of JAK2.
Management of Atrial Fibrillation in Patients on Ibrutinib: A Cleveland Clinic Experience.
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
Profound Sinoatrial Arrest Associated with Ibrutinib.
Resistance to Bruton's Tyrosine Kinase Inhibitors: The Achilles Heel of Their Success Story in Lymphoid Malignancies.
Rituximab and ibrutinib in the treatment of Waldenström's macroglobulinemia.
Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Malignancies.
Severe Hepatotoxicity due to Ibrutinib with a Review of Published Cases.
Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström's Macroglobulinemia.
Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy Against Waldenström's Macroglobulinemia.
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.
Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: three years of follow-up.
Warts
Drosophila C-terminal Src kinase regulates growth via the Hippo signaling pathway.
Expressionof langerhans cell and plasmacytoid dendritic cell markers, and toll-like receptor 7/9 signaling pathway proteins in verruca vulgaris lesions.
Primary immunodeficiency diseases associated with increased susceptibility to viral infections and malignancies.
Wasting Syndrome
Prevention of cachexia-like syndrome development and reduction of tumor progression in inhibin-deficient mice following administration of a chimeric activin receptor type II-murine Fc protein.
The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects.
Werner Syndrome
Identification of proteins in the hamster DNA end-binding complex.
Werner syndrome protein phosphorylation by abl tyrosine kinase regulates its activity and distribution.
Wernicke Encephalopathy
Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters.
Putamina involvement in Wernicke encephalopathy induced by Janus Kinase 2 inhibitor.
The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy.
West Nile Fever
Interaction of West Nile virus with alpha v beta 3 integrin mediates virus entry into cells.
The Src family kinase c-Yes is required for maturation of West Nile virus particles.
Virus-induced Ca2+ influx extends survival of west nile virus-infected cells.
Whooping Cough
Activation of P2Y2 receptors by UTP and ATP stimulates mitogen-activated kinase activity through a pathway that involves related adhesion focal tyrosine kinase and protein kinase C.
Activation of Src family kinase activity by the G protein-coupled thrombin receptor in growth-responsive fibroblasts.
Angiotensin II type 2 receptor-dependent increases in nitric oxide synthase expression in the pulmonary endothelium is mediated via a G alpha i3/Ras/Raf/MAPK pathway.
Antibody binding to cell surface amyloid precursor protein induces neuronal injury by deregulating the phosphorylation of focal adhesion signaling related proteins.
Bradykinin B2 receptors activate Na+/H+ exchange in mIMCD-3 cells via Janus kinase 2 and Ca2+/calmodulin.
Effect of pertussis toxin and herbimycin A on proteinase-activated receptor 2-mediated cyclooxygenase 2 expression in Helicobacter pylori-infected gastric epithelial AGS cells.
Evidence that v-Src-induced phospholipase D activity is mediated by a G protein.
Expression and muscarinic receptor coupling of Lyn kinase in cultured human airway smooth muscle cells.
Fyn kinase-directed activation of SH2 domain-containing protein-tyrosine phosphatase SHP-2 by Gi protein-coupled receptors in Madin-Darby canine kidney cells.
G(i)-mediated Cas tyrosine phosphorylation in vascular endothelial cells stimulated with sphingosine 1-phosphate: possible involvement in cell motility enhancement in cooperation with Rho-mediated pathways.
GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain.
Induction of human neutrophil chemotaxis by Candida albicans-derived beta-1,6-long glycoside side-chain-branched beta-glucan.
Inhibitory phosphorylation of soluble guanylyl cyclase by muscarinic m2 receptors via Gbetagamma-dependent activation of c-Src kinase.
Involvement of G(i) proteins and Src tyrosine kinase in TNFalpha production induced by lipopolysaccharide, group B Streptococci and Staphylococcus aureus.
Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.
Melanin-concentrating hormone receptor 1 activates extracellular signal-regulated kinase and synergizes with G(s)-coupled pathways.
Nitric oxide modulates ?-opioid receptor function in vitro.
P-selectin cross-links PSGL-1 and enhances neutrophil adhesion to fibrinogen and ICAM-1 in a Src kinase-dependent, but GPCR-independent mechanism.
Pertussis toxin activates protein kinase C and a tyrosine protein kinase in the human T cell line Jurkat.
Platelet-activating factor stimulates calcium-dependent activation of protein-tyrosine kinase Syk in a human B cell line.
Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism.
RANTES and MIP-1alpha activate stats in T cells.
Rapid nongenomic E2 effects on p42/p44 MAPK, activator protein-1, and cAMP response element binding protein in rat white adipocytes.
Regulation of endothelin-1- and lysophosphatidic acid-stimulated tyrosine phosphorylation of focal adhesion kinase (pp125fak) in Rat-1 fibroblasts.
Regulation of lysophosphatidic acid-stimulated tyrosine phosphorylation of mitogen-activated protein kinase by protein kinase C- and pertussis toxin-dependent pathways in the endothelial cell line EAhy 926.
Regulation of PI3K/Akt signaling by N-desmethylclozapine through activation of ?-opioid receptor.
Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases.
Role of gelsolin in actin depolymerization of adherent human neutrophils.
Role of phosphatidylinositol 3-kinase in the development of hepatocyte preconditioning.
Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells.
Src kinase mediates angiotensin II-dependent increase in pulmonary endothelial nitric oxide synthase.
Src-dependence and pertussis-toxin sensitivity of urokinase receptor-dependent chemotaxis and cytoskeleton reorganization in rat smooth muscle cells.
sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation.
The thromboxane A2 receptor activates mitogen-activated protein kinase via protein kinase C-dependent Gi coupling and Src-dependent phosphorylation of the epidermal growth factor receptor.
The upstream regulation of p38 mitogen-activated protein kinase phosphorylation by arachidonic acid in rat neutrophils.
Trypsin stimulates integrin alpha(5)beta(1)-dependent adhesion to fibronectin and proliferation of human gastric carcinoma cells through activation of proteinase-activated receptor-2.
Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.
Williams Syndrome
Cloning and biochemical characterization of LIMK-2, a protein kinase containing two LIM domains.
Handedness and corpus callosal morphology in Williams syndrome.
LIM-kinase deleted in Williams syndrome.
Wilms Tumor
Bladder cancer-associated transcript 2 contributes to nephroblastoma progression.
Examination of Stability of Bone Marrow Blood RNA in the PAXgene Tube.
Germline Bone Morphogenesis Protein Receptor 1A Mutation Causes Colorectal Tumorigenesis in Hereditary Mixed Polyposis Syndrome.
Identification of TCR V?11-2-D?1-J?1-1 T cell clone specific for WT1 peptides using high-throughput TCR? gene sequencing.
Investigation of New Therapeutic Targets in Undifferentiated Endometrial Sarcoma.
Long Noncoding RNA DUXAP8 Promotes Pancreatic Carcinoma Cell Migration and Invasion Via Pathway by miR-448/WTAP/Fak Signaling Axis.
Mechanisms of impaired nephrogenesis with fetal growth restriction: altered renal transcription and growth factor expression.
miR-140-5p alleviates the aggressive progression of Wilms' tumor through directly targeting TGFBR1 gene.
Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia.
Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules.
Peptide vaccines for myeloid leukaemias.
The effects of focal adhesion kinase and platelet-derived growth factor receptor beta inhibition in a patient-derived xenograft model of primary and metastatic Wilms tumor.
Transcriptome-Wide High-Throughput m6A Sequencing of Differential m6A Methylation Patterns in the Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes Cell Line MH7A.
Wilms' tumor 1 protein and focal adhesion kinase mediate keratinocyte growth factor signaling in breast cancer cells.
Wiskott-Aldrich Syndrome
An Evolutionarily Conserved Pathway Essential for Orsay Virus Infection of Caenorhabditis elegans.
BCR-ABL1-induced downregulation of WASP in chronic myeloid leukemia involves epigenetic modification and contributes to malignancy.
c-Src and Neural Wiskott-Aldrich Syndrome Protein (N-WASP) Promote Low Oxygen-Induced Accelerated Brain Invasion by Gliomas.
Distinctive roles of Abi1 in regulating actin-associated proteins during human smooth muscle cell migration.
Effects of progesterone and medroxyprogesterone on actin remodeling and neuronal spine formation.
Estrogen receptor-{alpha} promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP.
High shear flow induces migration of adherent human platelets.
Identification of host proteins involved in rickettsial invasion of tick cells.
Identification of novel SH3 domain ligands for the Src family kinase Hck. Wiskott-Aldrich syndrome protein (WASP), WASP-interacting protein (WIP), and ELMO1.
Interaction between Wiskott-Aldrich Syndrome protein (WASP) and the Fyn protein-tyrosine kinase.
Protein-tyrosine kinase and GTPase signals cooperate to phosphorylate and activate Wiskott-Aldrich syndrome protein (WASP)/neuronal WASP.
Regulation of podosome dynamics by WASp phosphorylation: implication in matrix degradation and chemotaxis in macrophages.
Role of the adapter protein Abi1 in actin-associated signaling and smooth muscle contraction.
The identification of Bruton's tyrosine kinase and Wiskott-Aldrich syndrome protein associated proteins and signalling pathways.
X-Linked Combined Immunodeficiency Diseases
Extreme variation in X-linked agammaglobulinemia phenotype in a three-generation family.
Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants.
Posttranscriptional regulation of Bruton's tyrosine kinase expression in antigen receptor-stimulated splenic B cells.
Role of Btk in B cell development and signaling.
The transcription factor Bright associates with Bruton's tyrosine kinase, the defective protein in immunodeficiency disease.
The transcription factor, Bright, and immunoglobulin heavy chain expression.
Xeroderma Pigmentosum
BCR binds to the xeroderma pigmentosum group B protein.
Impact of p210(Bcr-Abl) on ultraviolet C wavelength-induced DNA damage and repair.
The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein.
Zika Virus Infection
Integrin ?v?5 Internalizes Zika Virus during Neural Stem Cells Infection and Provides a Promising Target for Antiviral Therapy.